[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEQoD43Zq-oHJwyU1yyWWlwlB-_yylfuQZCtu9ptMALE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Hoffmann-La Roche",[4],2074,false,208,566,950208,221,249,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Rheumatoid Arthritis",184,{"name":18,"count":19},"Breast Cancer",134,{"name":21,"count":22},"Healthy Volunteer",114,{"name":24,"count":25},"Anemia",89,{"name":27,"count":28},"Hepatitis C, Chronic",79,{"name":30,"count":31},"Colorectal Cancer",70,{"name":33,"count":34},"HIV Infections",61,{"name":36,"count":37},"Diabetes Mellitus Type 2",50,[39,44,49,54,59,64,69,73,78,83],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT02838420","A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","2018-05-31","Alectinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03100149","A Study to Evaluate the Efficacy of Prasinezumab (RO7046015\u002FPRX002) in Participants With Early Parkinson's Disease","2019-11-27","RO7046015",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT02286089","Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration","2021-12-31","OpRegen",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04654468","A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition","2022-02-10","Crovalimab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04576455","A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","2022-02-18","Giredestrant",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04102098","A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","2022-10-21","Atezolizumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":58},"NCT04434092","A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors","2022-11-16",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT03779334","A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy","2023-02-20","Risdiplam",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05119569","A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)","2023-03-29","Fenebrutinib",{"nctId":84,"briefTitle":85,"date":86,"intervention":68},"NCT04661150","A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","2023-05-08",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,371,508,707,852,878,896,2353,3329,3468,3907,4020,4724,4814,5012,5157,5331,5636,5729,5785,5917,5981,6517,6789,6891,6963,7013,7223,7320,7435,7489,7597,7699,7741,7800,7834,7868,8223,8573,8869,9094,9227,9308,9356,9390,9427,9477,9780,9838,9868,9898,9942,9985,10011,10268,10445,10598,10736,10780,10806,10832,10858,10940,10974,11017,11043,11078,11100,11130,11152,11174,11210,11232,11254,11412,11616,11693,11741,11805,11844,11883,11920,11955,11986,12012,12038,12064,12086,12108,12130,12152,12178,12213,12235,12253,12271,12289,12314,12332,12350,12368,12386,12409,12427,12445,12463,12481,12499,12517,12535,12553,12571,12589,12607,12625,12643,12661,12679,12697,12715,12733,12751,12824,12850,12888,12949,13037,13059,13130,13230,13266,13318,13340,13374,13400,13426,13448,13470,13502,13534,13552,13570,13594,13614,13632,13650,13671,13689,13707,13725,13743,13765,13783,13801,13823,13848,13866,13884,13902,13920,13938,13962,13990,14008,14026,14044,14062,14080,14098,14116,14134,14152,14170,14188,14206,14224,14242,14260,14278,14296,14314,14332,14350,14368,14392,14410,14434,14562,14673,14741,14767,14789,14814,14837,14860,14885,14903,14928,14946,14964,14982,15000,15025,15043,15061,15079,15103,15128,15150,15173,15200,15218,15236,15254,15277,15295,15322,15340,15358,15376,15394,15412,15776,15972,16191,16359,16449,16581,16654,16769,16835,16901,16995,17103,17186,17255,17312,17369,17427,17498,17571,17631,17677,17734,17785,17819,17866,17906,17940,17980,18018,18044,18070,18095,18117,18139,18171,18199,18224,18246,18268,18290,18308,18326,18344,18362,18380,18398,18416,18434,18456,18474,18492,18510,18532,18553,18571,18593,18611,18629,18647,18669,18687,18705,18723,18744,18769,18787,18805,18823,18841,18863,18888,18906,18924,18945,18963,18981,18999,19017,19035,19057,19081,19103,19125,19143,19166,19184,19202,19220,19438,19585,19707,19816,19896,19990,20095,20149,20226,20291,20374,20459,20504,20546,20586,20647,20685,20719,20753,20808,20854,20905,20952,20995,21025,21067,21097,21127,21157,21187,21224,21254,21292,21325,21365,21397,21426,21452,21494,21520,21556,21585,21612,21634,21656,21678,21700,21722,21744,21766,21790,21812,21840,21862,21888,21910,21932,21954,21976,21998,22020,22042,22072,22094,22116,22138,22160,22186,22204,22222,22243,22261,22279,22302,22320,22338,22356,22374,22392,22410,22428,22446,22464,22487,22505,22523,22541,22559,22577,22595,22613,22631,22649,22671,22693,22717,22735,22756,22774,22797,22815,22837,22855,22873,22894,22912,22930,22948,22966,22984,23002,23020,23038,23056,23074,23092,23110,23128,23146,23164,23186,23204,23222,23240,23258,23276,23304,23322,23340,23358,23376,23394,23416,23434,23457,23479,23500,23518,23542,23560,23578,23596,23620,23638,23656,23674,23692,23710,23728,23746,23764,23782,23804,23822,23840,23858,23876,23900,23918,23936,23954,23972,23990,24008,24026,24044,24062,24080,24098,24116,24134,24152,24174,24192,24210,24228,24246,24264,24282,24303,24321,24342,24360,24382,24400,24418,24436,24454,24472,24500,24518,24536,24554,24572,24590,24608,24626,24644,24748,24829,24890,24953,25014,25074,25130,25166,25214,25268,25315,25366,25407,25452,25482,25521,25551,25589,25620,25650,25690,25727,25753,25779,25808,25846,25875,25897,25921,25943,25965,25987,26012,26034,26056,26084,26106,26134,26157,26186,26208,26239,26261,26289,26311,26337,26359,26387,26411,26442,26472,26494,26516,26550,26572,26602,26629,26653,26686,26715,26733,26751,26769,26787,26805,26830,26848,26866,26884,26902,26920,26942,26960,26978,26996,27014,27032,27050,27073,27091,27109,27127,27145,27163,27181,27199,27222,27240,27258,27280,27301,27319,27343,27361,27379,27397,27415,27433,27451,27469,27492,27510,27538,27556,27574,27592,27610,27628,27646,27664,27682,27700,27718,27736,27757,27775,27793,27811,27829,27850,27868,27890,27908,27931,27949,27967,27985,28003,28026,28044,28062,28080,28098,28116,28134,28152,28170,28188,28206,28224,28242,28260,28278,28296,28314,28332,28350,28368,28392,28415,28433,28451,28473,28497,28515,28533,28551,28569,28587,28608,28626,28649,28667,28685,28706,28724,28742,28764,28786,28804,28825,28843,28864,28885,28910,28928,28951,28969,28992,29010,29028,29049,29072,29094,29112,29130,29148,29166,29188,29206,29229,29247,29265,29283,29301,29319,29337,29355,29373,29391,29409,29427,29469,29521,29564,29606,29636,29666,29708,29741,29767,29800,29829,29855,29880,29907,29938,29964,29992,30014,30040,30068,30090,30112,30138,30169,30193,30215,30239,30261,30283,30314,30344,30366,30399,30423,30445,30467,30495,30513,30531,30552,30570,30592,30610,30633,30651,30673,30694,30712,30737,30755,30773,30791,30812,30830,30848,30866,30884,30902,30925,30943,30961,30982,31000,31018,31036,31054,31072,31093,31111,31134,31152,31173,31191,31213,31237,31255,31273,31294,31316,31338,31356,31374,31395,31417,31440,31458,31476,31494,31512,31530,31548,31570,31588,31610,31628,31649,31677,31695,31713,31731,31749,31767,31785,31803,31821,31839,31857,31875,31893,31916,31934,31952,31970,31988,32006,32024,32042,32060,32078,32096,32114,32132,32153,32174,32192,32210,32228,32246,32269,32287,32308,32326,32344,32366,32387,32412,32430,32454,32472,32490,32508,32529,32547,32565,32586,32607,32625,32649,32667,32685,32703,32721,32739,32760,32785,32803,32824,32842,32866,32884,32902,32920,32941,32959,32977,32998,33021,33042,33060,33078,33096,33118,33144,33162,33180,33198,33216,33234,33256,33283,33301,33319,33337,33355,33373,33397,33415,33433,33451,33469,33490,33508,33530,33551,33569,33590,33608,33630,33651,33674,33692,33710,33728,33746,33770,33788,33813,33831,33849,33870,33888,33906,33924,33942,33960,33978,33999,34022,34040,34062,34080,34102,34125,34143,34161,34182,34200,34218,34236,34260,34497,34724,34981,35226,35414,35595,35750,35923,36029,36146,36222,36318,36399,36484,36566,36624,36701,36760,36822,36884,36922,36973,37007,37041,37071,37112,37138,37169,37200,37222,37251,37273,37295,37317,37348,37378,37400,37422,37455,37477,37499,37521,37542,37560,37578,37600,37621,37639,37657,37675,37693,37717,37735,37753,37771,37789,37813,37835,37853,37871,37895,37913,37931,37949,37972,37990,38011,38029,38047],{"intervention":96,"totalTrials":97,"cells":98},"Ocrelizumab",25,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":115,"PHASE3":163,"PHASE4":307,"NA":351},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":19,"conditions":111,"interventions":113},"NCT03972306","A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","COMPLETED",[89],"2025-06-03","2019-08-12",[112],"Multiple Sclerosis (MS)",[96,96,114],"rHuPH20",{"trials":116,"activeCount":162,"soonestReadout":142},[117,127,137,149],{"nctId":118,"briefTitle":119,"status":107,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT02723071","A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)",[89,90],"2008-01","2005-05",48,[125],"Non-Hodgkin's Lymphoma",[96],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":136},"NCT02720120","A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","TERMINATED",[89,90],"2013-02","2005-10",175,[15],[96],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT04075266","A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis","ACTIVE_NOT_RECRUITING",[90],"2023-10-05","2029-12-01","2020-01-09",23,[147],"Multiple Sclerosis",[96],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT07282574","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","RECRUITING",[90],"2028-05-30","2030-05-30","2026-03-10",360,[159],"Progressive Multiple Sclerosis",[161,96],"RO7268489",2,{"trials":164,"activeCount":306,"soonestReadout":267},[165,176,185,195,205,214,224,235,244,254,263,275,284,296],{"nctId":166,"briefTitle":167,"status":107,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT01194570","A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis",[91],"2015-07-23","2022-12-31","2011-03-02",735,[174],"Multiple Sclerosis, Primary Progressive",[96],{"nctId":177,"briefTitle":178,"status":107,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT03599245","This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)",[91],"2025-07-17","2018-07-12",1055,[147],[96],{"nctId":186,"briefTitle":187,"status":130,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT03085810","Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)",[91],"2023-04-27","2017-03-24",1225,[193],"Multiple Sclerosis, Relapsing-Remitting",[96],{"nctId":196,"briefTitle":197,"status":107,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":204},"NCT02861014","A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)",[91],"2019-10-25","2020-12-15","2016-09-09",681,[193],[96],{"nctId":206,"briefTitle":207,"status":152,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":213},"NCT06675955","An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment",[91],"2029-12-31","2024-12-13",500,[147],[96],{"nctId":215,"briefTitle":216,"status":140,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT04544449","A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis",[91],"2025-09-17","2027-07-21","2020-10-26",985,[174],[82,96],{"nctId":225,"briefTitle":226,"status":107,"phases":227,"primaryCompletion":228,"completion":170,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT01247324","A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis",[91],"2015-04-02","2011-08-31",821,[232],"Relapsing Multiple Sclerosis",[234,96],"Interferon beta-1a",{"nctId":236,"briefTitle":226,"status":107,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT01412333",[91],"2015-05-12","2022-12-30","2011-09-20",835,[232],[234,96],{"nctId":245,"briefTitle":246,"status":140,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT03523858","A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis",[91],"2026-10-22","2018-05-28",927,[252],"Progressive Multiple Sclerosis (PMS)",[96],{"nctId":255,"briefTitle":256,"status":140,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT05269004","A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis",[91],"2027-12-31","2022-05-03",1300,[147],[96],{"nctId":264,"briefTitle":265,"status":140,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":272},"NCT04544436","A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",[91],"2024-12-19","2028-08-31","2020-11-26",864,[147],[96,96,273,274],"Antihistamine","Methylprednisolone",{"nctId":276,"briefTitle":277,"status":140,"phases":278,"primaryCompletion":279,"completion":280,"start":110,"enrollment":281,"conditions":282,"interventions":283},"NCT04035005","A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",[91],"2025-01-15","2028-01-19",1013,[174],[96],{"nctId":285,"briefTitle":286,"status":140,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":294},"NCT05123703","A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)",[91],"2025-06-09","2029-09-17","2022-05-19",188,[293],"Relapsing-Remitting Multiple Sclerosis",[96,295],"Fingolimod",{"nctId":297,"briefTitle":298,"status":140,"phases":299,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":305},"NCT04548999","A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",[91],"2025-06-30","2027-09-08","2020-12-03",769,[147],[96,96,273,274],8,{"trials":308,"activeCount":350,"soonestReadout":333},[309,320,329,340],{"nctId":310,"briefTitle":311,"status":107,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":319},"NCT04998851","A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab",[92],"2024-03-29","2025-01-13","2021-09-16",26,[147,318],"Clinically Isolated Syndrome",[96],{"nctId":321,"briefTitle":322,"status":107,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":31,"conditions":327,"interventions":328},"NCT04998812","A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy",[92],"2024-04-08","2025-07-14","2022-04-13",[147,318],[96],{"nctId":330,"briefTitle":331,"status":152,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT07483450","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis",[92],"2027-03-12","2027-04-23","2025-07-04",60,[232,338],"Primary Progressive Multiple Sclerosis",[96],{"nctId":341,"briefTitle":342,"status":343,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":101,"conditions":348,"interventions":349},"NCT05208840","A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis","WITHDRAWN",[92],"2025-01-31","2026-01-31","2023-09-15",[147],[96],1,{"trials":352,"activeCount":350,"soonestReadout":366},[353,362],{"nctId":354,"briefTitle":355,"status":107,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT03593590","Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis",[],"2026-01-19","2018-11-12",1710,[147],[96],{"nctId":363,"briefTitle":364,"status":152,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT06780150","A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)",[],"2028-03-31","2024-09-26",842,[147],[96],{"intervention":77,"totalTrials":372,"cells":373},13,{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":429,"PHASE3":475,"PHASE4":488,"NA":506},{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":101},[378,389,399,408,419],{"nctId":379,"briefTitle":380,"status":107,"phases":381,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT03988907","A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants",[89],"2019-09-29","2019-06-18",35,[386],"Spinal Muscular Atrophy",[77,388],"Midazolam",{"nctId":390,"briefTitle":391,"status":107,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":397},"NCT02633709","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers",[89],"2016-08-04","2016-01-07",33,[386],[398,77],"Itraconazole",{"nctId":400,"briefTitle":401,"status":107,"phases":402,"primaryCompletion":403,"completion":403,"start":404,"enrollment":316,"conditions":405,"interventions":407},"NCT03920865","A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function",[89],"2020-01-02","2019-05-16",[406],"Muscular Atrophy, Spinal",[77],{"nctId":409,"briefTitle":410,"status":107,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":416},"NCT04718181","Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants",[89],"2023-01-28","2021-02-01",131,[406],[417,418],"risdiplam","omeprazole",{"nctId":420,"briefTitle":421,"status":107,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":428},"NCT03040635","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants",[89],"2017-10-02","2017-03-22",24,[427],"Healthy Volunteers",[77],{"trials":430,"activeCount":162,"soonestReadout":76},[431,440,450,456,465],{"nctId":432,"briefTitle":433,"status":107,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":439},"NCT03032172","A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy",[90],"2025-02-07","2017-03-03",174,[386],[77],{"nctId":441,"briefTitle":442,"status":107,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":449},"NCT02913482","Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy",[90],"2019-11-14","2023-12-22","2016-12-23",62,[406],[77],{"nctId":74,"briefTitle":75,"status":140,"phases":451,"primaryCompletion":76,"completion":452,"start":453,"enrollment":316,"conditions":454,"interventions":455},[90],"2027-02-28","2019-08-07",[406],[77],{"nctId":457,"briefTitle":458,"status":152,"phases":459,"primaryCompletion":460,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":464},"NCT05808764","A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy",[90],"2026-11-30","2024-04-26",10,[406],[77],{"nctId":466,"briefTitle":467,"status":107,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT02908685","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants",[90],"2019-09-06","2023-10-02","2016-10-19",231,[406],[77],{"trials":476,"activeCount":350,"soonestReadout":481},[477],{"nctId":478,"briefTitle":479,"status":140,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT05115110","A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy",[90,91],"2029-02-27","2022-06-02",259,[485],"Spinal Muscular Atrophy (SMA)",[487,77],"RO7204239",{"trials":489,"activeCount":162,"soonestReadout":366},[490,499],{"nctId":491,"briefTitle":492,"status":152,"phases":493,"primaryCompletion":366,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":498},"NCT05861986","A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy",[92],"2029-03-31","2024-05-30",28,[406],[77],{"nctId":500,"briefTitle":501,"status":152,"phases":502,"primaryCompletion":366,"completion":494,"start":503,"enrollment":496,"conditions":504,"interventions":505},"NCT05861999","A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy",[92],"2024-08-14",[406],[77],{"trials":507,"activeCount":101},[],{"intervention":509,"totalTrials":510,"cells":511},"Faricimab",17,{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":562,"PHASE4":659,"NA":672},{"trials":513,"activeCount":101},[],{"trials":515,"activeCount":101},[],{"trials":517,"activeCount":101},[518,530,542,553],{"nctId":519,"briefTitle":520,"status":107,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},"NCT02484690","A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",[90],"2017-09-26","2015-08-11",273,[526],"Choroidal Neovascularization",[509,528,529],"Ranibizumab","Sham Procedure",{"nctId":531,"briefTitle":532,"status":107,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT03038880","Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration",[90],"2018-01-11","2018-03-29","2017-01-27",76,[539,540],"Neovascularization, Choroidal","Macular Degeneration, Age-Related",[509,528,529],{"nctId":543,"briefTitle":544,"status":107,"phases":545,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":550,"interventions":552},"NCT02699450","A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema",[90],"2017-09-15","2017-12-14","2016-04-27",229,[551],"Diabetic Macular Edema",[509,528],{"nctId":554,"briefTitle":555,"status":107,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":561},"NCT04597918","A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab",[90],"2022-12-22","2020-11-25",99,[551],[509],{"trials":563,"activeCount":350,"soonestReadout":568},[564,575,587,600,610,620,629,639,650],{"nctId":565,"briefTitle":566,"status":140,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},"NCT06176352","A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia",[91],"2025-09-11","2026-05-29","2024-03-06",280,[573],"Choroidal Neovascularization Secondary to Pathologic Myopia",[509,528],{"nctId":576,"briefTitle":577,"status":107,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT03823300","A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)",[91],"2020-10-05","2022-01-07","2019-03-11",658,[584],"Wet Macular Degeneration",[509,586],"Aflibercept",{"nctId":588,"briefTitle":589,"status":107,"phases":590,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":599},"NCT04740931","A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion",[91],"2022-08-09","2023-07-12","2021-03-02",729,[596,597,598],"Macular Edema","Central Retinal Vein Occlusion","Hemiretinal Vein Occlusion",[509,586],{"nctId":601,"briefTitle":602,"status":107,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":609},"NCT03622580","A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)",[91],"2020-10-20","2021-09-03","2018-09-05",940,[551],[586,509],{"nctId":611,"briefTitle":612,"status":107,"phases":613,"primaryCompletion":614,"completion":615,"start":593,"enrollment":616,"conditions":617,"interventions":619},"NCT04740905","A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion",[91],"2022-07-06","2023-06-12",553,[596,618],"Branch Retinal Vein Occlusion",[509,586],{"nctId":621,"briefTitle":622,"status":107,"phases":623,"primaryCompletion":220,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":628},"NCT03823287","A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)",[91],"2022-01-18","2019-02-19",671,[584],[509,586],{"nctId":630,"briefTitle":631,"status":107,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":638},"NCT03622593","A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema",[91],"2020-10-19","2023-05-31","2018-10-09",951,[551],[586,509],{"nctId":640,"briefTitle":641,"status":107,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT04777201","A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration",[91],"2024-09-03","2021-04-19",1036,[647],"Neovascular Age-related Macular Degeneration",[509,649],"Anti-VEGF Therapy",{"nctId":651,"briefTitle":652,"status":107,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT04432831","A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema",[91],"2023-10-11","2020-08-05",1479,[551],[509],{"trials":660,"activeCount":350,"soonestReadout":665},[661],{"nctId":662,"briefTitle":663,"status":140,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT06795048","A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration",[92],"2026-10-15","2027-09-16","2025-03-14",274,[670],"Neovascular Age-related Macular Degeneration (nAMD)",[509],{"trials":673,"activeCount":706,"soonestReadout":700},[674,686,696],{"nctId":675,"briefTitle":676,"status":140,"phases":677,"primaryCompletion":460,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":684},"NCT05476926","A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products",[],"2027-11-30","2022-11-21",6000,[647,551,682,618,597,683],"Retinal Vein Occlusion","Hemi-retinal Vein Occlusion",[509,685],"Port Delivery System with Ranibizumab",{"nctId":687,"briefTitle":688,"status":152,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT06680817","A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)",[],"2027-06-30","2028-06-30","2025-02-05",850,[647,551],[509],{"nctId":697,"briefTitle":698,"status":140,"phases":699,"primaryCompletion":700,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":705},"NCT06439576","Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)",[],"2026-11-15","2027-11-15","2024-05-09",1000,[551,647,682],[509],3,{"intervention":708,"totalTrials":709,"cells":710},"Emicizumab",12,{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":725,"PHASE3":727,"PHASE4":837,"NA":850},{"trials":712,"activeCount":101},[],{"trials":714,"activeCount":101},[715],{"nctId":716,"briefTitle":717,"status":107,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT03380780","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers",[89],"2018-09-18","2018-03-12",16,[427,723],"Hemophilia A",[708],{"trials":726,"activeCount":101},[],{"trials":728,"activeCount":706,"soonestReadout":783},[729,739,748,758,770,779,790,800,810,825],{"nctId":730,"briefTitle":731,"status":107,"phases":732,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":738},"NCT02795767","A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors",[91],"2018-04-30","2020-11-11","2016-07-22",88,[723],[708],{"nctId":740,"briefTitle":741,"status":107,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":123,"conditions":746,"interventions":747},"NCT03020160","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A",[91],"2017-12-15","2022-06-29","2017-01-30",[723],[708],{"nctId":749,"briefTitle":750,"status":107,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT03315455","Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants",[91],"2022-08-03","2025-08-29","2018-04-26",85,[723],[708],{"nctId":759,"briefTitle":760,"status":107,"phases":761,"primaryCompletion":762,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":769},"NCT04158648","A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors",[91],"2021-10-30","2025-12-19","2020-02-10",73,[767,768,723],"Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor","Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor",[708],{"nctId":771,"briefTitle":772,"status":107,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":778},"NCT03191799","A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors",[91],"2020-11-19","2017-09-05",195,[723],[708],{"nctId":780,"briefTitle":781,"status":140,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":789},"NCT04431726","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors",[91],"2023-05-22","2030-05-18","2021-02-04",55,[788],"Severe Hemophilia A",[708],{"nctId":791,"briefTitle":792,"status":152,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":157,"conditions":797,"interventions":798},"NCT07416604","A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A",[91],"2028-02-29","2032-01-29","2026-04-27",[723],[799,708],"NXT007",{"nctId":801,"briefTitle":802,"status":107,"phases":803,"primaryCompletion":546,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":808},"NCT02847637","A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors",[91],"2022-05-12","2016-09-27",152,[723],[708,809],"Factor VIII",{"nctId":811,"briefTitle":812,"status":152,"phases":813,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":820},"NCT06998524","A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease",[91],"2027-04-30","2029-04-30","2025-06-27",75,[819],"Von Willebrand Disease, Type 3",[708,821,822,823,824],"von Willebrand Factor (VWF) Concentrates","Factor VIII (FVIII) Concentrates","von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates","Bypassing Agents",{"nctId":826,"briefTitle":827,"status":107,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":834},"NCT02622321","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors",[91],"2016-10-25","2020-12-01","2015-11-18",113,[723],[708,835,836],"rFVIIa","aPCC",{"trials":838,"activeCount":350,"soonestReadout":843},[839],{"nctId":840,"briefTitle":841,"status":140,"phases":842,"primaryCompletion":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT05181618","A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis",[92],"2026-12-04","2027-05-21","2022-06-20",136,[788,848],"Moderate Hemophilia A",[708],{"trials":851,"activeCount":101},[],{"intervention":853,"totalTrials":350,"cells":854},"Vevye®",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":876},{"trials":856,"activeCount":101},[],{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":350,"soonestReadout":869},[865],{"nctId":866,"briefTitle":867,"status":140,"phases":868,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":874},"NCT07025811","A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment",[92],"2026-07-31","2025-07-09",378,[873],"Dry Eye Disease",[853,875],"Xiidra®",{"trials":877,"activeCount":101},[],{"intervention":875,"totalTrials":350,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":894},{"trials":881,"activeCount":101},[],{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":350,"soonestReadout":869},[890],{"nctId":866,"briefTitle":867,"status":140,"phases":891,"primaryCompletion":869,"completion":869,"start":870,"enrollment":871,"conditions":892,"interventions":893},[92],[873],[853,875],{"trials":895,"activeCount":101},[],{"intervention":68,"totalTrials":897,"cells":898},138,{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":1263,"PHASE3":1797,"PHASE4":2269,"NA":2280},{"trials":900,"activeCount":101},[],{"trials":902,"activeCount":162,"soonestReadout":219},[903,914,925,936,948,958,967,978,995,1005,1020,1030,1041,1052,1064,1075,1086,1097,1109,1118,1127,1143,1152,1168,1179,1188,1198,1209,1224,1233,1243,1252],{"nctId":904,"briefTitle":905,"status":107,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT02814669","Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor",[89],"2019-07-31","2016-09-23",45,[911],"Castrate-Resistant Prostate Cancer",[68,913],"Radium-223 Dichloride",{"nctId":915,"briefTitle":916,"status":107,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":923},"NCT04857138","A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors",[89],"2024-01-18","2021-05-18",80,[922],"Solid Tumors",[924,68],"RO7300490",{"nctId":926,"briefTitle":927,"status":107,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":934},"NCT02892318","A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)",[89],"2019-12-12","2016-10-31",40,[933],"Acute Myeloid Leukemia",[68,935],"Guadecitabine",{"nctId":937,"briefTitle":938,"status":130,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT04404140","A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).",[89],"2022-10-14","2020-07-09",6,[944],"Castration-Resistant Prostatic Cancer",[946,68,947],"Ipatasertib","Docetaxel",{"nctId":949,"briefTitle":950,"status":130,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT04303858","A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and\u002For Metastatic Solid Tumors",[89],"2025-10-02","2020-05-04",189,[922],[957,68],"Eciskafusp Alfa",{"nctId":959,"briefTitle":960,"status":107,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":31,"conditions":964,"interventions":965},"NCT02350673","A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and\u002For Metastatic Solid Tumors",[89],"2019-12-16","2015-06-29",[922],[68,966],"Cergutuzumab Amunaleukin",{"nctId":968,"briefTitle":969,"status":107,"phases":970,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":974,"interventions":976},"NCT02013219","A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)",[89],"2020-02-05","2014-04-03",52,[975],"Non-Small Cell Lung Cancer",[43,68,977],"Erlotinib",{"nctId":979,"briefTitle":980,"status":107,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":987},"NCT04584112","A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",[89],"2023-03-08","2020-09-28",83,[986],"Triple-Negative Breast Cancer",[988,68,989,988,68,989,990,991,992,993,994],"Tiragolumab","Nab-paclitaxel","Carboplatin","Doxorubicin","Cyclophosphamide","Granulocyte colony-stimulating factor","Granulocyte-macrophage colony-stimulating factor",{"nctId":996,"briefTitle":997,"status":130,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT04642365","A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.",[89],"2024-01-04","2021-01-04",49,[922],[1004,68],"RO7296682",{"nctId":1006,"briefTitle":1007,"status":107,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT02174172","A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2019-11-25","2014-08-18",158,[1013],"Solid Cancers",[68,1015,1016,1017,1018,1019],"Bevacizumab","Interferon alfa-2b","Ipilimumab","Obinutuzumab","PEG-interferon alfa-2a",{"nctId":1021,"briefTitle":1022,"status":107,"phases":1023,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT02304393","A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and\u002For Metastatic Solid Tumors",[89],"2019-11-07","2014-12-12",140,[922],[68,1029],"Selicrelumab",{"nctId":1031,"briefTitle":1032,"status":107,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1039},"NCT02220842","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed\u002FRefractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",[89],"2020-01-21","2014-12-18",96,[1038],"Lymphoma",[68,1018,1040],"Tazemetostat",{"nctId":1042,"briefTitle":1043,"status":107,"phases":1044,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1050},"NCT03063762","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and\u002For Metastatic Renal Cell Carcinoma (RCC)",[89],"2021-06-14","2017-03-20",69,[1049],"Renal Cell Carcinoma",[68,1015,1051],"RO6874281",{"nctId":1053,"briefTitle":1054,"status":130,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1062},"NCT03292172","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",[89],"2019-02-26","2017-11-08",36,[1060,1061],"Advanced Ovarian Cancer","Triple Negative Breast Cancer",[68,1063],"RO6870810",{"nctId":1065,"briefTitle":1066,"status":130,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":162,"conditions":1070,"interventions":1072},"NCT04422210","A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).",[89],"2020-11-06","2020-09-22",[1071],"Small Cell Lung Cancer",[1073,68,990,1074],"Venetoclax","Etoposide",{"nctId":1076,"briefTitle":1077,"status":107,"phases":1078,"primaryCompletion":592,"completion":592,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1083},"NCT03695380","A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer",[89],"2019-01-09",77,[1082],"OVARIAN CANCER",[1084,1085,68],"Cobimetinib","Niraparib",{"nctId":1087,"briefTitle":1088,"status":130,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1094},"NCT03866239","A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma",[89],"2024-03-13","2019-05-07",47,[30],[1018,68,1095,1096],"Cibisatamab","Tocilizumab",{"nctId":1098,"briefTitle":1099,"status":107,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT03800836","A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer",[89],"2022-03-16","2018-02-13",139,[18],[946,1106,68,1107,1108],"Paclitaxel","Nab-Paclitaxel","AC",{"nctId":1110,"briefTitle":1111,"status":107,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1117},"NCT02876224","Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors",[89],"2019-06-25","2016-09-30",51,[30],[68,1015,1084],{"nctId":1119,"briefTitle":1120,"status":107,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":11,"conditions":1124,"interventions":1125},"NCT02323191","A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors",[89],"2020-08-21","2015-01-19",[1013],[68,1126],"Emactuzumab",{"nctId":1128,"briefTitle":1129,"status":152,"phases":1130,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT04929223","A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",[89],"2030-08-31","2021-10-22",542,[1135],"Metastatic Colorectal Cancer",[1137,1015,1138,68,988,1139,1140,1141,1142],"Inavolisib","Cetuximab","SY-5609","Divarasib","FOLFOX","FOLFIRI",{"nctId":1144,"briefTitle":1145,"status":107,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":394,"enrollment":1148,"conditions":1149,"interventions":1150},"NCT02650713","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and\u002For Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",[89],"2020-01-13",228,[922],[68,1151],"RO6958688",{"nctId":1153,"briefTitle":1154,"status":107,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1161},"NCT02715531","A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and\u002For Other Treatments in Participants With Solid Tumors",[89],"2021-05-31","2016-04-06",243,[1160],"Solid Tumor",[1162,68,1015,1163,1164,1107,1165,1166,1167],"5-FU","Gemcitabine","Leucovorin","Oxaliplatin","Capecitabine","Cisplatin",{"nctId":1169,"briefTitle":1170,"status":107,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT03101280","A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer",[89],"2020-08-11","2017-04-27",29,[1176],"Gynecologic Neoplasms",[68,1178],"Rucaparib",{"nctId":1180,"briefTitle":1181,"status":140,"phases":1182,"primaryCompletion":219,"completion":219,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1187},"NCT06496568","A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers",[89],"2023-12-11",30,[1186],"PIK3CA-Mutated Cancers",[1137,68],{"nctId":1189,"briefTitle":1190,"status":343,"phases":1191,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":101,"conditions":1195,"interventions":1197},"NCT03369964","A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[89],"2018-12-31","2019-08-31","2018-03-14",[1196],"Lymphoma, Non-Hodgkin",[68,1126,1018],{"nctId":1199,"briefTitle":1200,"status":107,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1207},"NCT02508870","A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes",[89],"2019-06-10","2015-09-30",46,[1206],"Myelodysplastic Syndromes",[68,1208],"Azacitidine",{"nctId":1210,"briefTitle":1211,"status":107,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1220},"NCT02605915","Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer",[89],"2019-11-13","2015-12-31",98,[1217,1218,1219],"HER2-Positive Metastatic Breast Cancer","HER2-Negative Metastatic Breast Cancer","Locally Advanced or Early Breast Cancer",[68,990,947,1221,1222,1223,991,992],"Pertuzumab","Trastuzumab","Trastuzumab emtansine",{"nctId":1225,"briefTitle":1226,"status":130,"phases":1227,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":372,"conditions":1230,"interventions":1231},"NCT03922477","A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and\u002For Refractory Acute Myeloid Leukemia",[89],"2020-11-03","2019-10-08",[933],[68,1232],"Hu5F9-G4",{"nctId":1234,"briefTitle":1235,"status":107,"phases":1236,"primaryCompletion":1237,"completion":1238,"start":393,"enrollment":1239,"conditions":1240,"interventions":1242},"NCT02825940","A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2020-01-14","2022-11-04",120,[1241],"Neoplasms",[68,1163,1167],{"nctId":1244,"briefTitle":1245,"status":107,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":1250,"interventions":1251},"NCT01988896","Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2019-11-04","2013-12-27",153,[922],[68,1084],{"nctId":1253,"briefTitle":1254,"status":107,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT03178851","Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma",[89],"2019-05-29","2020-09-21","2017-06-20",155,[1261],"Malignant Melanoma",[68,1084,68,68],{"trials":1264,"activeCount":1796,"soonestReadout":86},[1265,1276,1290,1299,1307,1325,1335,1345,1360,1369,1379,1388,1399,1409,1425,1435,1446,1460,1469,1480,1489,1503,1516,1529,1543,1552,1561,1578,1587,1600,1609,1619,1629,1638,1647,1654,1665,1675,1686,1698,1709,1717,1729,1738,1759,1774,1787],{"nctId":1266,"briefTitle":1267,"status":107,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT04622228","Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin\u002FCarboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer",[90],"2022-06-21","2024-06-30","2020-12-16",56,[1274],"Carcinoma, Small Cell Lung",[68,1167,990,1074],{"nctId":1277,"briefTitle":1278,"status":107,"phases":1279,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1286},"NCT05116202","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)",[89,90],"2023-09-22","2024-05-28","2022-02-02",110,[1285],"Melanoma",[1287,1017,1288,68,988,1289],"Nivolumab","RO7247669 2100 mg","RO7247669 600 mg",{"nctId":1291,"briefTitle":1292,"status":130,"phases":1293,"primaryCompletion":1294,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1298},"NCT02541604","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors",[89,90],"2019-06-06","2015-11-30",87,[1160],[68],{"nctId":1300,"briefTitle":1301,"status":107,"phases":1302,"primaryCompletion":919,"completion":919,"start":1303,"enrollment":1001,"conditions":1304,"interventions":1306},"NCT03312530","A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma",[89,90],"2017-11-13",[1305],"Multiple Myeloma",[1084,1073,68],{"nctId":1308,"briefTitle":1309,"status":130,"phases":1310,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT03337698","A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)",[89,90],"2025-10-14","2025-11-25","2017-12-27",314,[1316],"Carcinoma, Non-Small-Cell Lung",[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],"CPI-444","Pemetrexed","Linagliptin","Sacituzumab Govitecan","Evolocumab","XL092","Camonsertib",{"nctId":1326,"briefTitle":1327,"status":130,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":306,"conditions":1331,"interventions":1333},"NCT05315713","An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma",[89,90],"2023-07-19","2022-05-10",[1332],"Non-Hodgkin Lymphoma, Follicular Lymphoma",[1334,988,68],"Mosunetuzumab SC",{"nctId":1336,"briefTitle":1337,"status":107,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1344},"NCT02031458","A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[90],"2015-05-28","2019-01-11","2014-01-22",667,[975],[68],{"nctId":1346,"briefTitle":1347,"status":107,"phases":1348,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1355},"NCT02596971","A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],"2018-04-11","2020-05-08","2015-12-22",91,[1354],"Diffuse Large B-Cell Lymphoma, Lymphoma Follicular",[68,1356,992,991,1018,1357,1358,1359],"Bendamustine","Prednisone","Vincristine","Rituximab",{"nctId":1361,"briefTitle":1362,"status":107,"phases":1363,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":709,"conditions":1366,"interventions":1368},"NCT05459129","A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)",[89,90],"2024-08-15","2023-04-12",[1367],"Squamous Cell Carcinoma of the Head and Neck",[68,988,990,1106],{"nctId":1370,"briefTitle":1371,"status":107,"phases":1372,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1378},"NCT01903993","A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"",[90],"2015-11-19","2018-09-06","2013-08-06",287,[975],[947,68],{"nctId":1380,"briefTitle":1381,"status":107,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1009,"enrollment":1385,"conditions":1386,"interventions":1387},"NCT04091217","Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma",[90],"2022-08-31","2023-09-01",43,[1285],[68,1015],{"nctId":1389,"briefTitle":1390,"status":107,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1398},"NCT04677504","A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer",[90],"2022-05-16","2023-08-25","2021-02-23",162,[1397],"Biliary Tract Cancer",[68,1015,1167,1163],{"nctId":1400,"briefTitle":1401,"status":130,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1408},"NCT02322814","A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread",[90],"2018-08-10","2021-09-17","2015-03-12",169,[18],[1084,1106,68,1107],{"nctId":1410,"briefTitle":1411,"status":140,"phases":1412,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT04931342","A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors",[90],"2028-02-28","2021-10-07",176,[1417],"Ovarian Cancer",[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],"Trastuzumab Emtansine","Abemaciclib","Palbociclib","Letrozole","Olaparib","Luteinizing Hormone-Releasing Hormone (LHRH) Agonists",{"nctId":1426,"briefTitle":1427,"status":343,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":101,"conditions":1431,"interventions":1433},"NCT04267237","A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer",[90],"2025-09-30","2021-03-31",[1432],"Non-small Cell Lung Cancer (NSCLC)",[68,1434],"RO7198457",{"nctId":1436,"briefTitle":1437,"status":107,"phases":1438,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":447,"conditions":1442,"interventions":1444},"NCT05908786","A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma",[89,90],"2025-08-27","2025-11-13","2023-12-05",[1443],"Carcinoma, Hepatocellular",[68,1015,988,1445],"Tobemstomig",{"nctId":1447,"briefTitle":1448,"status":152,"phases":1449,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1455},"NCT04802759","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",[89,90],"2029-05-30","2021-06-22",316,[1454],"Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer",[63,1420,946,1137,1456,1457,1458,1459,1421,68],"Ribociclib","Everolimus","Samuraciclib","PH FDC SC",{"nctId":1461,"briefTitle":1462,"status":130,"phases":1463,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":1466,"interventions":1468},"NCT04832854","A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",[90],"2025-03-05","2021-04-23",[1467],"Non-Small Cell Lung Cancer (NSCLC)",[68,988,990,1167,1319,1163,1106],{"nctId":1470,"briefTitle":1471,"status":107,"phases":1472,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":920,"conditions":1476,"interventions":1478},"NCT03625141","A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases",[90],"2021-06-07","2023-04-13","2018-12-13",[1477],"Metastatic Melanoma",[1084,68,1479],"Vemurafenib",{"nctId":1481,"briefTitle":1482,"status":130,"phases":1483,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":931,"conditions":1486,"interventions":1488},"NCT05251948","An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma",[89,90],"2025-09-04","2022-03-01",[1487],"Gastric and Gastroesophageal Junction Carcinoma",[68,1166,1165,988],{"nctId":1490,"briefTitle":1491,"status":130,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":1495,"interventions":1496},"NCT03555149","A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",[89,90],"2022-09-26","2018-09-27",[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],"Regorafenib","Imprime PGG","Isatuximab","Idasanutlin","AB928","LOAd703",{"nctId":1504,"briefTitle":1505,"status":107,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT03193190","A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)",[89,90],"2025-02-27","2017-07-05",341,[1511],"Pancreatic Adenocarcinoma",[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],"Fluorouracil","PEGPH20","BL-8040",{"nctId":1517,"briefTitle":1518,"status":107,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1525},"NCT02291289","A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)",[90],"2019-05-31","2021-03-24","2015-04-17",1044,[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],"FOLFOX induction regimen","Fluoropyrimidine","5-FU\u002FLV",{"nctId":1530,"briefTitle":1531,"status":107,"phases":1532,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":1537,"interventions":1540},"NCT03869190","Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)",[89,90],"2025-10-08","2025-12-22","2019-06-01",272,[1538,1539],"Urothelial Carcinoma","Bladder Cancer",[68,1541,1085,1542,988,1321,1096,1167,1163],"Enfortumab Vedotin","Magrolimab",{"nctId":1544,"briefTitle":1545,"status":107,"phases":1546,"primaryCompletion":1547,"completion":1439,"start":593,"enrollment":1548,"conditions":1549,"interventions":1551},"NCT04665843","A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent\u002FMetastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck",[90],"2023-09-20",123,[1550],"Squamous Cell Carcinoma of Head and Neck",[68,988],{"nctId":1553,"briefTitle":1554,"status":107,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1296,"conditions":1558,"interventions":1559},"NCT03264066","A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors",[90],"2020-06-25","2017-11-23",[922],[1084,68,1560],"Atezolizumab Cohort 7",{"nctId":1562,"briefTitle":1563,"status":152,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1570},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[89,90],"2030-09-30","2018-03-30",792,[1569],"Metastatic Breast Cancer",[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],"SGN-LIV1A","Chemotherapy","Fulvestrant","Trastuzumab Deruxtecan","Empagliflozin","Metformin","Atirmociclib",{"nctId":1579,"briefTitle":1580,"status":140,"phases":1581,"primaryCompletion":1582,"completion":1582,"start":1474,"enrollment":1583,"conditions":1584,"interventions":1586},"NCT05645692","A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer",[90],"2026-12-31",204,[1585],"Urothelial Cancer",[68,1445,988],{"nctId":1588,"briefTitle":1589,"status":107,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1596},"NCT03281369","A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G\u002FGEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",[89,90],"2025-10-09","2017-10-13",214,[1595],"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma",[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],"5-Fluorouracil","Ramucirumab","PEGylated recombinant human hyaluronidase",{"nctId":1601,"briefTitle":1602,"status":130,"phases":1603,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":425,"conditions":1606,"interventions":1607},"NCT02792192","Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants",[89,90],"2020-09-29","2016-06-13",[1539],[68,1608],"Bacille Calmette-Guérin",{"nctId":1610,"briefTitle":1611,"status":107,"phases":1612,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1618},"NCT02108652","A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)",[90],"2016-07-04","2023-02-28","2014-05-31",310,[1539],[68],{"nctId":1620,"briefTitle":1621,"status":343,"phases":1622,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":1626,"interventions":1628},"NCT04611776","A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer",[90],"2025-03-06","2026-01-08","2021-07-01",[1627],"Carcinoma, Non-Small Cell Lung",[68,990,1167,1319,1163,1106],{"nctId":1630,"briefTitle":1631,"status":107,"phases":1632,"primaryCompletion":1633,"completion":1634,"start":1635,"enrollment":145,"conditions":1636,"interventions":1637},"NCT04426825","A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer",[90],"2022-01-19","2023-02-10","2020-09-09",[1316],[68,1015],{"nctId":1639,"briefTitle":1640,"status":343,"phases":1641,"primaryCompletion":1642,"completion":1643,"start":1644,"enrollment":101,"conditions":1645,"interventions":1646},"NCT06331598","A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)",[90],"2028-10-20","2029-09-20","2024-11-30",[922],[68,988],{"nctId":1648,"briefTitle":1649,"status":107,"phases":1650,"primaryCompletion":1613,"completion":1614,"start":1615,"enrollment":1651,"conditions":1652,"interventions":1653},"NCT02951767","A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)",[90],119,[1539],[68],{"nctId":1655,"briefTitle":1656,"status":107,"phases":1657,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1664},"NCT04300647","A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and\u002For Recurrent PD-L1-Positive Cervical Cancer",[90],"2021-12-08","2025-02-24","2020-06-30",172,[1663],"Cervical Cancer",[988,68],{"nctId":1666,"briefTitle":1667,"status":107,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT02924883","A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy",[90],"2017-12-11","2020-02-06","2016-09-26",202,[1569],[68,1223],{"nctId":1676,"briefTitle":1677,"status":107,"phases":1678,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1685},"NCT05171777","A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer",[90],"2023-11-09","2024-10-25","2022-04-04",179,[1684],"Non-small Cell Lung Cancer",[68],{"nctId":1687,"briefTitle":1688,"status":140,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1694},"NCT04589845","Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study",[90],"2032-09-25","2021-01-18",920,[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],"Entrectinib","Belvarafenib","Pralsetinib",{"nctId":1699,"briefTitle":1700,"status":107,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1705,"conditions":1706,"interventions":1708},"NCT04321330","A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma",[90],"2023-07-16","2024-06-03","2020-08-07",34,[1707],"Carcinoma, Thymic",[68],{"nctId":1710,"briefTitle":1711,"status":130,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":425,"conditions":1715,"interventions":1716},"NCT04308785","A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer",[90],"2023-07-25","2021-12-01",[1274],[68,988],{"nctId":1718,"briefTitle":1719,"status":140,"phases":1720,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1728},"NCT05009069","A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer",[90],"2023-11-21","2026-11-10","2022-03-18",58,[1726,1727],"Rectal Neoplasms","Rectal Cancer",[1166,1513,68,988],{"nctId":84,"briefTitle":85,"status":140,"phases":1730,"primaryCompletion":86,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1737},[90],"2026-07-30","2021-03-12",42,[1735,1736],"Gastric Cancer","Gastroesophageal Junction Adenocarcinoma",[68,1222,1166,1165],{"nctId":1739,"briefTitle":1740,"status":152,"phases":1741,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":1746,"interventions":1748},"NCT04524871","A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)",[89,90],"2027-07-30","2027-09-30","2020-11-01",518,[1747],"Advanced Liver Cancers",[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],"Bevacizumab 15 mg\u002Fkg","TPST-1120","Tobemstomig 2100 mg","Bevacizumab 10 mg\u002Fkg","Tobemstomig 600 mg","Tobemstomig 1200 mg","ADG126","IO-108 1800 mg","NKT2152","IO-108 1200 mg",{"nctId":1760,"briefTitle":1761,"status":107,"phases":1762,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1769},"NCT03498521","A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site",[90],"2023-02-14","2024-11-07","2018-07-10",529,[1768],"Cancer of Unknown Primary Site",[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],"Vismodegib","Trastuzumab Subcutaneous","Ivosidenib","Pemigatinib",{"nctId":1775,"briefTitle":1776,"status":140,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":1781,"interventions":1783},"NCT03533283","An Open-Label Phase lB\u002FII Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed\u002FRefractory B-Cell Non-Hodgkin's Lymphoma",[89,90],"2026-10-16","2018-05-08",211,[1782],"Non-Hodgkins Lymphoma",[1784,68,1018,1096,1785,1786],"Glofitamab","Polatuzumab Vedotin","89Zr-Df-IAB22M2C",{"nctId":1788,"briefTitle":1789,"status":130,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1174,"conditions":1793,"interventions":1795},"NCT04933227","A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)",[90],"2023-11-17","2021-08-06",[1794,1735,1736],"Stomach Neoplasms",[68,988,1165,1166],9,{"trials":1798,"activeCount":721,"soonestReadout":67},[1799,1806,1814,1824,1831,1842,1850,1858,1866,1875,1885,1894,1903,1911,1919,1929,1939,1949,1958,1966,1973,1984,1993,2001,2012,2021,2032,2040,2050,2062,2072,2083,2095,2102,2111,2122,2133,2143,2153,2164,2174,2183,2191,2202,2214,2224,2234,2241,2250,2259],{"nctId":65,"briefTitle":66,"status":140,"phases":1800,"primaryCompletion":67,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1805},[91],"2026-05-15","2019-12-31",668,[1443],[68,1015],{"nctId":1807,"briefTitle":1808,"status":107,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":806,"conditions":1812,"interventions":1813},"NCT04487067","A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista",[91],"2024-08-13","2020-08-25",[1443],[68,1015],{"nctId":1815,"briefTitle":1816,"status":130,"phases":1817,"primaryCompletion":1818,"completion":1818,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1822},"NCT03498716","A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline\u002FTaxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer",[91],"2023-08-14","2018-08-02",2199,[1061],[68,1106,1823,992],"Dose-dense Doxorubicin or dose-dense Epirubicin",{"nctId":1825,"briefTitle":1826,"status":140,"phases":1827,"primaryCompletion":690,"completion":690,"start":1714,"enrollment":1001,"conditions":1828,"interventions":1829},"NCT05112965","An Extension Study in Participants Previously Enrolled in a Genentech and\u002For F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)",[91],[1241],[68,1015,1319,1106,1830],"Enzalutamide",{"nctId":1832,"briefTitle":1833,"status":107,"phases":1834,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT03016312","A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",[91],"2019-06-24","2022-12-20","2017-01-10",759,[1840],"Prostatic Neoplasms, Castration-Resistant",[68,1830],{"nctId":1843,"briefTitle":1844,"status":130,"phases":1845,"primaryCompletion":461,"completion":461,"start":1846,"enrollment":1847,"conditions":1848,"interventions":1849},"NCT04732286","A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy",[91],"2021-05-04",100,[1443],[68,1015],{"nctId":1851,"briefTitle":1852,"status":343,"phases":1853,"primaryCompletion":1854,"completion":1855,"start":1340,"enrollment":101,"conditions":1856,"interventions":1857},"NCT03693573","A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma",[91],"2021-08-14","2024-01-31",[1049],[68,1015],{"nctId":1859,"briefTitle":1860,"status":130,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":306,"conditions":1864,"interventions":1865},"NCT02409355","A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)",[91],"2017-12-07","2015-05-07",[975],[68,990,1167,1163],{"nctId":1867,"briefTitle":1868,"status":107,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1874},"NCT04294810","A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer",[91],"2025-12-30","2020-03-04",620,[975],[68,988],{"nctId":1876,"briefTitle":1877,"status":140,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1884},"NCT03148418","A Study in Participants Previously Enrolled in a Genentech- and\u002For F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)",[91],"2030-03-06","2017-09-20",382,[1883],"Cancer",[68,1015],{"nctId":1886,"briefTitle":1887,"status":107,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT03922997","A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],"2022-08-11","2019-07-03",101,[1684],[68],{"nctId":1895,"briefTitle":1896,"status":130,"phases":1897,"primaryCompletion":259,"completion":1898,"start":1899,"enrollment":1900,"conditions":1901,"interventions":1902},"NCT03024996","A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy",[91],"2022-12-08","2017-01-03",778,[1049],[68],{"nctId":1904,"briefTitle":1905,"status":107,"phases":1906,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":16,"conditions":1909,"interventions":1910},"NCT04148911","A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer",[91],"2024-12-15","2019-12-10",[986],[68,1107],{"nctId":1912,"briefTitle":1913,"status":140,"phases":1914,"primaryCompletion":268,"completion":1915,"start":1846,"enrollment":1916,"conditions":1917,"interventions":1918},"NCT04873362","A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",[91],"2034-10-02",1188,[18],[68,1419,1222],{"nctId":1920,"briefTitle":1921,"status":107,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT04256421","A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",[91],"2022-09-06","2025-07-31","2020-02-04",490,[1071],[988,68,990,1074],{"nctId":1930,"briefTitle":1931,"status":107,"phases":1932,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":1937,"interventions":1938},"NCT04194203","A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)",[91],"2023-02-02","2024-06-27","2020-04-09",305,[1316],[68,1015,1106,1319,990],{"nctId":1940,"briefTitle":1941,"status":107,"phases":1942,"primaryCompletion":1943,"completion":1924,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1947},"NCT04513925","A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)",[91],"2025-05-27","2020-08-24",829,[1432],[68,988,1948],"Durvalumab",{"nctId":1950,"briefTitle":1951,"status":107,"phases":1952,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":1955,"interventions":1956},"NCT04619797","A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin\u002FCisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin\u002FCisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer",[90,91],"2024-04-19","2025-11-20",[1432],[988,68,1319,990,1167,1957],"Pembrolizumab",{"nctId":1959,"briefTitle":1960,"status":140,"phases":1961,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":1964,"interventions":1965},"NCT03178552","A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)",[90,91],"2026-10-31","2017-09-22",[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":1967,"briefTitle":1968,"status":130,"phases":1969,"primaryCompletion":1970,"completion":1970,"start":1473,"enrollment":1036,"conditions":1971,"interventions":1972},"NCT04740918","A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)",[91],"2024-06-19",[1569],[1419,68],{"nctId":1974,"briefTitle":1975,"status":140,"phases":1976,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":1981,"interventions":1982},"NCT02486718","Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]",[91],"2024-01-26","2027-08-31","2015-10-31",1280,[975],[68,1167,1983,947,1163,1319],"Vinorelbine",{"nctId":1985,"briefTitle":1986,"status":107,"phases":1987,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":1991,"interventions":1992},"NCT03726879","A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer",[91],"2021-02-05","2023-08-24",454,[18],[68,991,992,1106,1222,1221,1419],{"nctId":1994,"briefTitle":1995,"status":107,"phases":1996,"primaryCompletion":1997,"completion":1997,"start":1998,"enrollment":1272,"conditions":1999,"interventions":2000},"NCT06267001","A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy",[91],"2025-12-16","2024-03-21",[1432],[68,988],{"nctId":2002,"briefTitle":2003,"status":107,"phases":2004,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2010},"NCT03434379","A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma",[91],"2020-08-31","2022-11-17","2018-03-15",558,[1443],[68,1015,2011],"Sorafenib",{"nctId":2013,"briefTitle":2014,"status":140,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":983,"enrollment":2017,"conditions":2018,"interventions":2020},"NCT04543617","A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy",[91],"2027-03-31",760,[2019],"Esophageal Squamous Cell Carcinoma",[988,68],{"nctId":2022,"briefTitle":2023,"status":140,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2030},"NCT04770896","A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab",[91],"2026-06-30","2021-04-26",557,[2029],"Unresectable Hepatocellular Carcinoma",[68,2031,2011],"Lenvatinib",{"nctId":2033,"briefTitle":2034,"status":107,"phases":2035,"primaryCompletion":2036,"completion":2036,"start":110,"enrollment":1259,"conditions":2037,"interventions":2039},"NCT04028050","A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",[91],"2023-07-13",[2038],"Small Cell Lung Carcinoma",[68,990,1074],{"nctId":2041,"briefTitle":2042,"status":140,"phases":2043,"primaryCompletion":2044,"completion":2044,"start":1732,"enrollment":2045,"conditions":2046,"interventions":2048},"NCT04712643","A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma",[91],"2029-02-01",342,[2047],"Hepatocellular Carcinoma",[68,2049],"Becavizumab",{"nctId":2051,"briefTitle":2052,"status":140,"phases":2053,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":2057,"conditions":2058,"interventions":2060},"NCT05091567","A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer",[91],"2024-07-29","2026-08-13","2021-11-18",660,[2059],"Small-Cell Lung Cancer",[68,2061,990,1074],"Lurbinectedin",{"nctId":2063,"briefTitle":2064,"status":130,"phases":2065,"primaryCompletion":2066,"completion":2067,"start":1669,"enrollment":2068,"conditions":2069,"interventions":2071},"NCT03273153","A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",[91],"2019-04-15","2021-02-19",446,[2070],"Advanced BRAFV600 Wild-type Melanoma",[1084,68,1957],{"nctId":2073,"briefTitle":2074,"status":107,"phases":2075,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":2080,"interventions":2082},"NCT04540211","A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma",[91],"2023-02-13","2025-08-28","2020-10-30",461,[2081],"Esophageal Cancer",[68,988,1106,1167],{"nctId":2084,"briefTitle":2085,"status":107,"phases":2086,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2092},"NCT02908672","A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma",[91],"2019-10-11","2024-07-01","2017-01-13",514,[1285],[68,2093,1084,1479,2094],"Atezolizumab Placebo","Vemurafenib Placebo",{"nctId":2096,"briefTitle":2097,"status":107,"phases":2098,"primaryCompletion":1614,"completion":1614,"start":1009,"enrollment":2099,"conditions":2100,"interventions":2101},"NCT04177108","A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer",[91],242,[986],[68,946,1106],{"nctId":2103,"briefTitle":2104,"status":107,"phases":2105,"primaryCompletion":2106,"completion":2106,"start":534,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT03371017","A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer",[91],"2024-10-23",595,[2109],"Triple Negative Breast Neoplasms",[68,1163,1166,990],{"nctId":2112,"briefTitle":2113,"status":107,"phases":2114,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2120},"NCT04471428","Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1\u002FPD-1 Antibody and Platinum-Containing Chemotherapy",[91],"2022-09-28","2025-01-17","2020-10-01",366,[1316],[2121,68,947],"Cabozantinib",{"nctId":2123,"briefTitle":2124,"status":140,"phases":2125,"primaryCompletion":2126,"completion":2127,"start":2128,"enrollment":2129,"conditions":2130,"interventions":2132},"NCT04660344","A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy",[91],"2025-06-15","2026-10-01","2021-05-03",761,[2131],"Muscle-invasive Bladder Cancer",[68],{"nctId":2134,"briefTitle":2135,"status":107,"phases":2136,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2142},"NCT02657434","A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)",[91],"2019-07-18","2022-12-13","2016-04-30",578,[975],[68,990,1167,1319],{"nctId":2144,"briefTitle":2145,"status":140,"phases":2146,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":2149,"interventions":2150},"NCT03768063","A Study in Patients Previously Enrolled in a Genentech and\u002For F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",[91],"2028-07-05","2019-02-28",[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],"FAP IL2V","Sunitinib",{"nctId":2154,"briefTitle":2155,"status":130,"phases":2156,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":2160,"conditions":2161,"interventions":2163},"NCT02450331","A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection",[91],"2019-11-30","2022-06-14","2015-10-05",809,[2162],"Carcinoma, Transitional Cell",[68],{"nctId":2165,"briefTitle":2166,"status":130,"phases":2167,"primaryCompletion":2168,"completion":570,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2173},"NCT03452137","A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[91],"2023-09-27","2018-04-03",406,[2172],"Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)",[68],{"nctId":2175,"briefTitle":2176,"status":107,"phases":2177,"primaryCompletion":1383,"completion":2178,"start":2179,"enrollment":2180,"conditions":2181,"interventions":2182},"NCT02807636","Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma",[91],"2024-02-12","2016-06-30",1213,[1538],[68,990,1163,1167],{"nctId":2184,"briefTitle":2185,"status":140,"phases":2186,"primaryCompletion":2187,"completion":2025,"start":2188,"enrollment":1548,"conditions":2189,"interventions":2190},"NCT04665856","Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer",[91],"2023-08-31","2020-12-21",[2038],[988,68,990,1074],{"nctId":2192,"briefTitle":2193,"status":130,"phases":2194,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":2199,"interventions":2201},"NCT04338269","A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment",[91],"2023-01-03","2025-03-24","2020-07-28",522,[2200],"Carcinoma, Renal Cell",[68,2121],{"nctId":2203,"briefTitle":2204,"status":107,"phases":2205,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2213},"NCT03038100","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2022-02-08","2022-08-12","2017-03-08",1301,[1417,2211,2212],"Fallopian Tube Cancer","Peritoneal Neoplasms",[1106,990,68,1015,2093],{"nctId":2215,"briefTitle":2216,"status":107,"phases":2217,"primaryCompletion":2218,"completion":2219,"start":2220,"enrollment":2221,"conditions":2222,"interventions":2223},"NCT03735121","A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],"2022-04-26","2024-11-11","2018-12-27",438,[975],[68,114],{"nctId":2225,"briefTitle":2226,"status":107,"phases":2227,"primaryCompletion":2228,"completion":2228,"start":2229,"enrollment":2230,"conditions":2231,"interventions":2233},"NCT02928406","A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract",[91],"2022-12-12","2016-11-30",1004,[2232],"Urinary Tract Cancer",[68],{"nctId":2235,"briefTitle":2236,"status":140,"phases":2237,"primaryCompletion":1870,"completion":2238,"start":2158,"enrollment":336,"conditions":2239,"interventions":2240},"NCT05047250","A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer",[91],"2027-08-30",[975],[68],{"nctId":2242,"briefTitle":2243,"status":152,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":2247,"interventions":2248},"NCT05862285","A Rollover Study for Participants Previously Enrolled in a Genentech and\u002For F. Hoffman-La Roche Sponsored Study",[91],"2033-03-01","2023-06-01",[1883],[946,988,68,2249,1015,1695,1137,1140],"Tiragolumab and Atezolizumab",{"nctId":2251,"briefTitle":2252,"status":107,"phases":2253,"primaryCompletion":2254,"completion":1079,"start":2255,"enrollment":191,"conditions":2256,"interventions":2258},"NCT02008227","A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy",[91],"2016-07-07","2014-03-11",[2257],"Non-Squamous Non-Small Cell Lung Cancer",[68,947],{"nctId":2260,"briefTitle":2261,"status":140,"phases":2262,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2266,"conditions":2267,"interventions":2268},"NCT05904886","A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)",[91],"2025-05-08","2026-09-01","2023-09-14",687,[2047],[68,1015,988],{"trials":2270,"activeCount":101},[2271],{"nctId":2272,"briefTitle":2273,"status":107,"phases":2274,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":2277,"conditions":2278,"interventions":2279},"NCT03285763","A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",[92],"2022-04-07","2017-10-25",619,[1316],[68],{"trials":2281,"activeCount":706,"soonestReadout":2025},[2282,2292,2301,2309,2317,2326,2334,2343],{"nctId":2283,"briefTitle":2284,"status":130,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":2289,"conditions":2290,"interventions":2291},"NCT03399643","A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)",[],"2018-08-28","2019-01-28","2017-12-28",22,[1538],[68],{"nctId":2293,"briefTitle":2294,"status":107,"phases":2295,"primaryCompletion":2207,"completion":2207,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2300},"NCT03232593","A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)",[],"2017-11-29",1758,[1538,1627,2038,2299,2047],"Triple Negative Breast Carcinoma",[68],{"nctId":2302,"briefTitle":2303,"status":107,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":832,"conditions":2307,"interventions":2308},"NCT06503250","A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization",[],"2024-11-27","2024-07-19",[2029],[68,1015],{"nctId":2310,"briefTitle":2311,"status":140,"phases":2312,"primaryCompletion":869,"completion":869,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2316},"NCT03782207","A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice",[],"2019-02-07",2756,[1538,975,1071,2047],[68],{"nctId":2318,"briefTitle":2319,"status":107,"phases":2320,"primaryCompletion":2321,"completion":2321,"start":2322,"enrollment":2323,"conditions":2324,"interventions":2325},"NCT03559647","The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy",[],"2023-08-20","2018-05-30",358,[1467],[68],{"nctId":2327,"briefTitle":2328,"status":107,"phases":2329,"primaryCompletion":2330,"completion":2330,"start":2331,"enrollment":372,"conditions":2332,"interventions":2333},"NCT03330886","A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina",[],"2019-03-02","2018-02-09",[1538],[68],{"nctId":2335,"briefTitle":2336,"status":140,"phases":2337,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":2340,"interventions":2341},"NCT04158258","A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America",[],"2020-02-21",2907,[18],[1015,1222,2342,1221,68,1166],"Ado-trastuzumab emtamsine",{"nctId":2344,"briefTitle":2345,"status":152,"phases":2346,"primaryCompletion":2016,"completion":2347,"start":2348,"enrollment":2349,"conditions":2350,"interventions":2352},"NCT07284121","A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice",[],"2028-12-31","2025-07-15",700,[2351],"Lung Cancer, Hepatocellular Carcinoma",[68],{"intervention":1096,"totalTrials":1283,"cells":2354},{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2632,"PHASE3":2762,"PHASE4":3089,"NA":3160},{"trials":2356,"activeCount":101},[],{"trials":2358,"activeCount":2631,"soonestReadout":678},[2359,2369,2383,2395,2404,2413,2422,2434,2445,2456,2469,2478,2486,2497,2501,2510,2518,2527,2536,2545,2556,2566,2580,2588,2597,2605,2613,2623],{"nctId":2360,"briefTitle":2361,"status":107,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},"NCT02165345","Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra\u002FActemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis",[89],"2021-11-24","2014-07-16",82,[2367],"Juvenile Idiopathic Arthritis",[1096],{"nctId":2370,"briefTitle":2371,"status":107,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2380},"NCT04551352","A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas",[89],"2022-07-28","2020-10-28",20,[2377,2378,2379],"Cutaneous Melanoma","Uveal Melanoma","Mucosal Melanoma",[2381,1096,1018,2382],"RO7293583","Adalimumab",{"nctId":2384,"briefTitle":2385,"status":107,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":2390,"interventions":2393},"NCT03467373","A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL",[89],"2024-12-02","2018-03-13",111,[2391,2392],"B-Cell Lymphoma","Non-Hodgkin Lymphoma",[1784,1018,1359,1096,992,991,1358,1357,2394],"Polatuzumab vedotin",{"nctId":2396,"briefTitle":2397,"status":107,"phases":2398,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":1184,"conditions":2402,"interventions":2403},"NCT04657302","A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[89],"2022-10-25","2024-01-12","2021-01-08",[1038],[1018,1784,1096],{"nctId":2405,"briefTitle":2406,"status":107,"phases":2407,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":2409,"interventions":2411},"NCT05364424","A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed\u002FRefractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",[89],"2025-10-15",[2410],"Diffuse Large B-Cell Lymphoma (DLBCL)",[1784,1018,1096,1359,2412,990,1074],"Ifosfamide",{"nctId":2414,"briefTitle":2415,"status":130,"phases":2416,"primaryCompletion":2417,"completion":2417,"start":2418,"enrollment":316,"conditions":2419,"interventions":2420},"NCT03539484","A Study of RO7172508 in Patients With Locally Advanced and\u002For Metastatic CEA-Positive Solid Tumors",[89],"2019-07-22","2018-07-04",[922],[2421,1018,1096],"RO7172508",{"nctId":2423,"briefTitle":2424,"status":152,"phases":2425,"primaryCompletion":2426,"completion":2427,"start":2428,"enrollment":2429,"conditions":2430,"interventions":2432},"NCT05091424","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia",[89],"2028-05-31","2030-02-28","2022-03-07",137,[2431],"Chronic Lymphocytic Leukemia",[2433,1096,1073],"Mosunetuzumab",{"nctId":2435,"briefTitle":2436,"status":107,"phases":2437,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":2440,"conditions":2441,"interventions":2443},"NCT05619744","A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas",[89],"2025-03-04","2023-01-23",41,[1071,2442],"Neuroendocrine Carcinoma",[2444,1096],"RO7616789",{"nctId":2446,"briefTitle":2447,"status":107,"phases":2448,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":786,"conditions":2451,"interventions":2454},"NCT04338685","A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases",[89],"2023-01-09","2020-07-16",[1443,1397,2452,2453],"Secondary Liver Cancer","Liver Metastases",[2455,1096],"RO7119929",{"nctId":2457,"briefTitle":2458,"status":152,"phases":2459,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":2463,"interventions":2464},"NCT05169515","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and\u002For CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma",[89],"2029-09-15","2022-10-26",121,[2392],[2465,2466,2467,2468,1018,1096],"SC Mosunetuzumab","IV Glofitamab","Iberdomide","Golcadomide",{"nctId":2470,"briefTitle":2471,"status":107,"phases":2472,"primaryCompletion":2473,"completion":2473,"start":2474,"enrollment":162,"conditions":2475,"interventions":2477},"NCT05164133","A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19",[89],"2024-03-27","2022-06-10",[2476],"COVID-19",[1096],{"nctId":2479,"briefTitle":2480,"status":152,"phases":2481,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":37,"conditions":2484,"interventions":2485},"NCT06624085","A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[89],"2030-03-31","2025-04-28",[1038],[1784,1096,1018,1163,1165],{"nctId":2487,"briefTitle":2488,"status":130,"phases":2489,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":2492,"conditions":2493,"interventions":2495},"NCT02336048","A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities",[89],"2018-09-21","2015-06-26",38,[2494],"B-Cell Chronic Lymphocytic Leukemia",[2496,1018,1096],"Chlorambucil",{"nctId":1087,"briefTitle":1088,"status":130,"phases":2498,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":2499,"interventions":2500},[89],[30],[1018,68,1095,1096],{"nctId":2502,"briefTitle":2503,"status":107,"phases":2504,"primaryCompletion":2505,"completion":2505,"start":2506,"enrollment":425,"conditions":2507,"interventions":2509},"NCT03923738","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).",[89],"2020-11-12","2019-08-05",[2508],"Giant Cell Arteritis",[1096],{"nctId":2511,"briefTitle":2512,"status":107,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":973,"conditions":2516,"interventions":2517},"NCT01904279","A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)",[89],"2016-05","2013-07",[2367],[1096],{"nctId":2519,"briefTitle":2520,"status":107,"phases":2521,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2526},"NCT02324257","A Study of RO6958688 in Participants With Locally Advanced and\u002For Metastatic Carcinoembryonic Antigen Positive Solid Tumors",[89],"2019-09-03","2014-12-30",149,[922],[1151,1018,1096],{"nctId":2528,"briefTitle":2529,"status":130,"phases":2530,"primaryCompletion":2531,"completion":2531,"start":62,"enrollment":2532,"conditions":2533,"interventions":2534},"NCT05219513","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed\u002FRefractory B-Cell Non-Hodgkin's Lymphoma",[89],"2024-07-17",53,[1196],[2535,1784,1018,1096],"RO7443904",{"nctId":2537,"briefTitle":2538,"status":107,"phases":2539,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":2542,"interventions":2544},"NCT04313608","A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma",[89],"2021-10-26","2020-06-04",[2543],"B-cell Lymphoma",[1784,1163,1165,2433,1018,1096],{"nctId":2546,"briefTitle":2547,"status":130,"phases":2548,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":706,"conditions":2551,"interventions":2553},"NCT05769959","Study of RO7515629 in Participants With HLA-G Positive Solid Tumors",[89],"2024-03-19","2023-06-15",[1049,1684,1511,30,2552],"Ovarian Neoplasms",[2554,2555],"RO7515629","tocilizumab",{"nctId":2557,"briefTitle":2558,"status":107,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT01455701","A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra\u002FActemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)",[89],"2016-07-28","2017-07-13","2012-10-26",11,[2367],[1096],{"nctId":2567,"briefTitle":2568,"status":107,"phases":2569,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT04580121","A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.",[89],"2023-08-09","2020-11-04",59,[933],[2575,2575,1096,2576,2577,2578,2579],"RO7283420","Dasatinib","Dexamethasone","Paracetamol\u002Facetaminophen","Diphenhydramine",{"nctId":2581,"briefTitle":2582,"status":107,"phases":2583,"primaryCompletion":2584,"completion":2584,"start":2585,"enrollment":973,"conditions":2586,"interventions":2587},"NCT01904292","A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis",[89],"2017-06-13","2013-08-15",[2367],[1096],{"nctId":2589,"briefTitle":2590,"status":152,"phases":2591,"primaryCompletion":2592,"completion":2592,"start":2593,"enrollment":2375,"conditions":2594,"interventions":2595},"NCT06934044","A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma",[89],"2028-11-04","2025-05-13",[1305],[2596,1096],"Cevostamab",{"nctId":2598,"briefTitle":2599,"status":107,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":954,"conditions":2603,"interventions":2604},"NCT02678988","A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers",[89],"2016-06","2016-02",[21],[1096],{"nctId":2606,"briefTitle":2607,"status":130,"phases":2608,"primaryCompletion":592,"completion":592,"start":2609,"enrollment":145,"conditions":2610,"interventions":2611},"NCT05129280","A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and\u002For Metastatic MAGE-A4-positive Solid Tumors",[89],"2022-01-25",[922],[2612,1096],"RO7444973",{"nctId":2614,"briefTitle":2615,"status":107,"phases":2616,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2622},"NCT05155345","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus",[89],"2024-12-17","2022-01-11",15,[2621],"Systemic Lupus Erythematosus",[2433,1096],{"nctId":2624,"briefTitle":2625,"status":152,"phases":2626,"primaryCompletion":678,"completion":678,"start":2627,"enrollment":31,"conditions":2628,"interventions":2629},"NCT05835986","A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus",[89],"2023-12-18",[2621],[2630,1096],"RO7507062",5,{"trials":2633,"activeCount":2563,"soonestReadout":2673},[2634,2645,2656,2660,2669,2680,2688,2698,2702,2711,2715,2723,2727,2737,2746,2750,2758],{"nctId":2635,"briefTitle":2636,"status":140,"phases":2637,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2643},"NCT04246086","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma",[89,90],"2030-09-06","2020-08-12",237,[2642],"Follicular Lymphoma",[2433,1096,2644,2433],"Lenalidomide",{"nctId":2646,"briefTitle":2647,"status":107,"phases":2648,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":291,"conditions":2651,"interventions":2653},"NCT03677154","Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly\u002FUnfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",[89,90],"2025-08-07","2019-05-23",[2652],"Diffuse Large B-cell Lymphoma",[2654,2655,1785,1096],"Mosunetuzumab Intravenous","Mosunetuzumab Subcutaneous",{"nctId":1308,"briefTitle":1309,"status":130,"phases":2657,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":2658,"interventions":2659},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":2661,"briefTitle":2662,"status":140,"phases":2663,"primaryCompletion":2016,"completion":2016,"start":2664,"enrollment":2665,"conditions":2666,"interventions":2667},"NCT04077723","A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed\u002FRefractory B-Cell Non-Hodgkin's Lymphoma",[89,90],"2019-08-13",498,[1196],[2668,1018,1784,1096],"Englumafusp alfa",{"nctId":2670,"briefTitle":2671,"status":140,"phases":2672,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":2676,"conditions":2677,"interventions":2679},"NCT03671018","A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",[89,90],"2024-01-30","2025-07-20","2018-09-25",422,[2678],"B-cell Non-Hodgkin Lymphoma",[2433,2433,2394,1096,1359],{"nctId":2681,"briefTitle":2682,"status":107,"phases":2683,"primaryCompletion":2684,"completion":2684,"start":2685,"enrollment":1092,"conditions":2686,"interventions":2687},"NCT01468077","A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra\u002FActemra (Tocilizumab) Treatment",[90],"2013-09","2011-11",[15],[1096],{"nctId":2689,"briefTitle":2690,"status":152,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":2695,"interventions":2697},"NCT05533775","A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed\u002FRefractory Mature B-Cell Non-Hodgkin Lymphoma",[89,90],"2029-11-30","2032-11-30",65,[2696],"Mature B-Cell Non-Hodgkin Lymphoma",[1018,1784,1359,2412,990,1074,1096],{"nctId":1504,"briefTitle":1505,"status":107,"phases":2699,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":2700,"interventions":2701},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":2703,"briefTitle":2704,"status":152,"phases":2705,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":2709,"interventions":2710},"NCT05583617","A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma",[89,90],"2028-07-31","2023-11-14",200,[1305],[2596,2644,1096,2467,2577],{"nctId":1530,"briefTitle":1531,"status":107,"phases":2712,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":2713,"interventions":2714},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"nctId":2716,"briefTitle":2717,"status":140,"phases":2718,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":607,"conditions":2721,"interventions":2722},"NCT03075696","A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed\u002FRefractory B-cell Non-hodgkin's Lymphoma",[89,90],"2029-03-30","2017-02-21",[125],[1784,1018,1096],{"nctId":1562,"briefTitle":1563,"status":152,"phases":2724,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":2725,"interventions":2726},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":2728,"briefTitle":2729,"status":107,"phases":2730,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":2734,"interventions":2735},"NCT03677141","A Phase Ib\u002FII Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma",[89,90],"2023-10-12","2019-03-08",117,[2678],[2433,1785,2736,992,991,1358,1357,1096],"Rituxumab",{"nctId":2738,"briefTitle":2739,"status":140,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":2743,"conditions":2744,"interventions":2745},"NCT05535244","A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed\u002FRefractory Multiple Myeloma",[89,90],"2027-02-26","2022-10-17",90,[1305],[2596,1096],{"nctId":1739,"briefTitle":1740,"status":152,"phases":2747,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":2748,"interventions":2749},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"nctId":2751,"briefTitle":2752,"status":140,"phases":2753,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":2756,"interventions":2757},"NCT04980222","A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma",[90],"2026-09-30","2022-03-22",[1038],[1784,1096,991,1358,1357,1359,992],{"nctId":1775,"briefTitle":1776,"status":140,"phases":2759,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":2760,"interventions":2761},[89,90],[1782],[1784,68,1018,1096,1785,1786],{"trials":2763,"activeCount":706,"soonestReadout":2983},[2764,2773,2780,2788,2796,2804,2812,2826,2833,2843,2851,2860,2871,2882,2892,2901,2910,2919,2927,2936,2943,2951,2959,2969,2979,2987,2995,3002,3010,3018,3025,3037,3047,3060,3071,3080],{"nctId":2765,"briefTitle":2766,"status":107,"phases":2767,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":1204,"conditions":2770,"interventions":2771},"NCT01044498","A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis",[91],"2012-02","2009-12",[15],[1096,2772],"Ortho-Novum® 1\u002F35",{"nctId":2774,"briefTitle":2775,"status":107,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2276,"enrollment":706,"conditions":2778,"interventions":2779},"NCT03202368","An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)",[91],"2019-08-21",[2508],[1096],{"nctId":2781,"briefTitle":2782,"status":107,"phases":2783,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":145,"conditions":2786,"interventions":2787},"NCT01668966","A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra\u002FActemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)",[91],"2016-05-11","2013-12-09",[15],[1096],{"nctId":2789,"briefTitle":2790,"status":107,"phases":2791,"primaryCompletion":2792,"completion":2792,"start":2793,"enrollment":2619,"conditions":2794,"interventions":2795},"NCT01655381","A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra\u002FActemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis",[91],"2015-07","2012-04",[15],[1096],{"nctId":2797,"briefTitle":2798,"status":107,"phases":2799,"primaryCompletion":2800,"completion":2800,"start":2801,"enrollment":1001,"conditions":2802,"interventions":2803},"NCT01664598","An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra\u002FActemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis",[91],"2015-06","2012-05",[15],[1096],{"nctId":2805,"briefTitle":2806,"status":107,"phases":2807,"primaryCompletion":2808,"completion":2808,"start":2809,"enrollment":2563,"conditions":2810,"interventions":2811},"NCT01734993","A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).",[91],"2015-09","2012-10",[15],[1096],{"nctId":2813,"briefTitle":2814,"status":107,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":2818,"interventions":2819},"NCT01941095","A Study of Subcutaneous Tocilizumab as Monotherapy and\u002For in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis",[91],"2016-07-10","2013-11-20",[15],[2820,2821,2822,2823,2824,2825,1096],"Azathioprine","Chloroquine","Hydroxychloroquine","Leflunomide","Methotrexate","Sulfasalazine",{"nctId":2827,"briefTitle":2828,"status":107,"phases":2829,"primaryCompletion":2792,"completion":2792,"start":2830,"enrollment":1847,"conditions":2831,"interventions":2832},"NCT01988012","A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.",[91],"2014-01",[15],[2555],{"nctId":2834,"briefTitle":2835,"status":107,"phases":2836,"primaryCompletion":2837,"completion":2837,"start":2838,"enrollment":2839,"conditions":2840,"interventions":2841},"NCT01987479","A Study on Safety and Efficacy of Tocilizumab (RoActemra\u002FActemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis",[91],"2016-05-26","2014-01-30",150,[15],[2842,1096,2824],"Non-Biologic DMARDs",{"nctId":2844,"briefTitle":2845,"status":107,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2830,"enrollment":1103,"conditions":2848,"interventions":2849},"NCT02001987","A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and\u002For Biologic Therapy",[91],"2015-12",[15],[1096,2824,2850],"csDMARDs",{"nctId":2852,"briefTitle":2853,"status":107,"phases":2854,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":2858,"interventions":2859},"NCT02046616","A Study of Subcutaneous (SC) Tocilizumab (RoActemra\u002FActemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)",[91],"2016-09-13","2014-05-28",133,[15],[1096,2824,2842],{"nctId":2861,"briefTitle":2862,"status":107,"phases":2863,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":2868,"interventions":2869},"NCT01941940","A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and\u002For Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants",[91],"2015-09-09","2016-07-05","2013-09-05",227,[15],[1096,2870],"DMARDs",{"nctId":2872,"briefTitle":2873,"status":107,"phases":2874,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":2878,"conditions":2879,"interventions":2881},"NCT02453256","A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)",[91],"2018-01-15","2019-02-04","2015-11-20",212,[2880],"Systemic Sclerosis",[1096],{"nctId":2883,"briefTitle":2884,"status":107,"phases":2885,"primaryCompletion":2886,"completion":2886,"start":2887,"enrollment":2888,"conditions":2889,"interventions":2890},"NCT03155347","An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy",[91],"2022-08-08","2017-08-02",340,[15],[1096,2891],"MTX",{"nctId":2893,"briefTitle":2894,"status":107,"phases":2895,"primaryCompletion":2896,"completion":2896,"start":2897,"enrollment":2898,"conditions":2899,"interventions":2900},"NCT01855789","A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX",[91],"2016-10-14","2013-11-07",718,[15],[1096,2824],{"nctId":2902,"briefTitle":2903,"status":130,"phases":2904,"primaryCompletion":2905,"completion":2905,"start":2906,"enrollment":832,"conditions":2907,"interventions":2909},"NCT01209689","A Study of Tocilizumab (RoActemra\u002FActemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy",[91],"2011-12","2010-10",[2908],"Spondylitis, Ankylosing",[1096],{"nctId":2911,"briefTitle":2912,"status":107,"phases":2913,"primaryCompletion":2914,"completion":2915,"start":2916,"enrollment":291,"conditions":2917,"interventions":2918},"NCT00988221","A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis",[91],"2011-11-30","2013-01-28","2009-11-30",[2367],[1096],{"nctId":2920,"briefTitle":2921,"status":107,"phases":2922,"primaryCompletion":2801,"completion":2801,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2926},"NCT00721123","A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis",[91],"2005-08",538,[15],[1096],{"nctId":2928,"briefTitle":2929,"status":130,"phases":2930,"primaryCompletion":2931,"completion":2905,"start":2932,"enrollment":2933,"conditions":2934,"interventions":2935},"NCT01209702","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs",[91],"2011-05","2010-09",306,[2908],[2555],{"nctId":2937,"briefTitle":2938,"status":140,"phases":2939,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":2941,"interventions":2942},"NCT04408638","A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[91],270,[2652],[1018,1784,2736,1096,1163,1165],{"nctId":2944,"briefTitle":2945,"status":107,"phases":2946,"primaryCompletion":2947,"completion":2947,"start":2948,"enrollment":1092,"conditions":2949,"interventions":2950},"NCT01772316","A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra\u002FActemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",[91],"2015-05","2012-12",[15],[2555],{"nctId":2952,"briefTitle":2953,"status":107,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":973,"conditions":2957,"interventions":2958},"NCT01951170","An Open-Label Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],"2015-08","2013-11",[15],[1096],{"nctId":2960,"briefTitle":2961,"status":107,"phases":2962,"primaryCompletion":2963,"completion":2964,"start":2965,"enrollment":2277,"conditions":2966,"interventions":2967},"NCT00531817","A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis",[91],"2009-06","2011-03","2007-10",[15],[1096,2968],"Permitted DMARDs",{"nctId":2970,"briefTitle":2971,"status":107,"phases":2972,"primaryCompletion":2973,"completion":2974,"start":2975,"enrollment":2976,"conditions":2977,"interventions":2978},"NCT01007435","A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis",[91],"2012-05-31","2014-01-28","2009-10-31",1162,[15],[1096,2824],{"nctId":2980,"briefTitle":2981,"status":140,"phases":2982,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":2985,"interventions":2986},"NCT05171647","A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",[91],"2025-02-17","2022-04-25",[2392],[2433,2394,1096,1359,1163,1165],{"nctId":2988,"briefTitle":2989,"status":107,"phases":2990,"primaryCompletion":393,"completion":393,"start":2991,"enrollment":1395,"conditions":2992,"interventions":2993},"NCT02046603","A Study of Tocilizumab (RoActemra\u002FActemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent",[91],"2014-03-04",[15],[1096,2870,2994,2824],"Oral Corticosteroids",{"nctId":2996,"briefTitle":2997,"status":107,"phases":2998,"primaryCompletion":2808,"completion":2808,"start":2830,"enrollment":2999,"conditions":3000,"interventions":3001},"NCT02031471","TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra\u002FActemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra\u002FActemra Treatment",[91],57,[15],[2555],{"nctId":3003,"briefTitle":3004,"status":130,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":2492,"conditions":3008,"interventions":3009},"NCT01665430","A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis",[91],"2015-02","2012-07",[15],[1096],{"nctId":3011,"briefTitle":3012,"status":152,"phases":3013,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":3016,"interventions":3017},"NCT06084936","A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed\u002FRefractory Mantle Cell Lymphoma",[91],"2023-10-22",182,[1038],[1018,1784,1359,1356,2644,1096],{"nctId":3019,"briefTitle":3020,"status":107,"phases":3021,"primaryCompletion":2793,"completion":2793,"start":3022,"enrollment":1724,"conditions":3023,"interventions":3024},"NCT00996606","A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs",[91],"2009-10",[15],[2870,1096],{"nctId":3026,"briefTitle":3027,"status":107,"phases":3028,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":3031,"conditions":3032,"interventions":3033},"NCT00720798","An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies",[91],"2013-04","2005-09",2067,[15],[1096,3034,3035,3036],"Disease-modifying anti-rheumatic drugs","Non-steroidal anti-inflammatory drugs","Oral corticosteroids",{"nctId":3038,"briefTitle":3039,"status":107,"phases":3040,"primaryCompletion":3041,"completion":3042,"start":3043,"enrollment":3044,"conditions":3045,"interventions":3046},"NCT00535782","A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis",[91],"2008-09-30","2011-01-31","2007-10-31",132,[15],[1096,2824],{"nctId":3048,"briefTitle":3049,"status":107,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":3055,"interventions":3056},"NCT01791153","An Efficacy and Safety Study of Tocilizumab (RoActemra\u002FActemra) in Participants With Giant Cell Arteritis (GCA)",[91],"2016-04-11","2018-06-04","2013-07-22",251,[2508],[1096,1357,3057,3058,3059,2824],"Tocilizumab Placebo","Prednisone Placebo","Corticosteroids",{"nctId":3061,"briefTitle":3062,"status":107,"phases":3063,"primaryCompletion":413,"completion":3064,"start":3065,"enrollment":3066,"conditions":3067,"interventions":3069},"NCT04409262","A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia",[91],"2021-03-08","2020-06-16",649,[3068],"COVID-19 Pneumonia",[3070,1096],"Remdesivir",{"nctId":3072,"briefTitle":3073,"status":107,"phases":3074,"primaryCompletion":3075,"completion":2197,"start":3076,"enrollment":3077,"conditions":3078,"interventions":3079},"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",[91],"2020-06-24","2020-04-03",452,[3068],[1096],{"nctId":3081,"briefTitle":3082,"status":107,"phases":3083,"primaryCompletion":3084,"completion":3084,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3088},"NCT00754559","A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.",[91],"2009-11","2008-08",286,[15],[1096],{"trials":3090,"activeCount":101},[3091,3099,3108,3118,3126,3133,3142,3150],{"nctId":3092,"briefTitle":3093,"status":107,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":384,"conditions":3097,"interventions":3098},"NCT01734382","A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra\u002FActemra (Tocilizumab)",[92],"2019-10-09","2013-06-10",[2367],[1096],{"nctId":3100,"briefTitle":3101,"status":107,"phases":3102,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":3106,"interventions":3107},"NCT01119859","A Study of Tocilizumab (RoActemra\u002FActemra) Versus Adalimumab in Patients With Rheumatoid Arthritis",[92],"2012-01","2010-05",326,[15],[1096,2382],{"nctId":3109,"briefTitle":3110,"status":107,"phases":3111,"primaryCompletion":3112,"completion":3113,"start":754,"enrollment":447,"conditions":3114,"interventions":3115},"NCT03301883","A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)",[92],"2021-09-04","2022-08-05",[2367],[1096,3116,3117,2891],"NSAIDs","CSs",{"nctId":3119,"briefTitle":3120,"status":107,"phases":3121,"primaryCompletion":3122,"completion":3122,"start":3123,"enrollment":1352,"conditions":3124,"interventions":3125},"NCT02682823","Tocilizumab Real-Life Human Factors (RLHFs) Validation Study",[92],"2016-07-29","2016-03-21",[15],[1096],{"nctId":3127,"briefTitle":3128,"status":107,"phases":3129,"primaryCompletion":2331,"completion":2331,"start":3130,"enrollment":1314,"conditions":3131,"interventions":3132},"NCT02573012","Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants",[92],"2016-03-29",[15],[1357,1096],{"nctId":3134,"briefTitle":3135,"status":107,"phases":3136,"primaryCompletion":3137,"completion":3137,"start":3138,"enrollment":316,"conditions":3139,"interventions":3141},"NCT01715831","A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488",[92],"2016-06-06","2013-01-15",[3140],"Arthritis, Rheumatoid",[2870,1096],{"nctId":3143,"briefTitle":3144,"status":130,"phases":3145,"primaryCompletion":3006,"completion":3006,"start":3146,"enrollment":3147,"conditions":3148,"interventions":3149},"NCT01661140","A Study of RoActemra\u002FActemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage",[92],"2012-09",427,[15],[2824,1096,2824],{"nctId":3151,"briefTitle":3152,"status":107,"phases":3153,"primaryCompletion":3154,"completion":3154,"start":3155,"enrollment":3156,"conditions":3157,"interventions":3158},"NCT01331837","A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors",[92],"2016-03-25","2011-08-02",3080,[15],[3159,1096],"Etanercept",{"trials":3161,"activeCount":101},[3162,3170,3178,3185,3193,3200,3208,3217,3224,3232,3241,3250,3257,3264,3272,3281,3289,3298,3304,3311,3320],{"nctId":3163,"briefTitle":3164,"status":107,"phases":3165,"primaryCompletion":3166,"completion":3166,"start":1214,"enrollment":3167,"conditions":3168,"interventions":3169},"NCT02608112","Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year",[],"2018-07-26",291,[15],[2824,1096],{"nctId":3171,"briefTitle":3172,"status":107,"phases":3173,"primaryCompletion":3174,"completion":3174,"start":3175,"enrollment":1385,"conditions":3176,"interventions":3177},"NCT01670045","A Non-Interventional Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",[],"2014-06","2012-03",[15],[1096],{"nctId":3179,"briefTitle":3180,"status":107,"phases":3181,"primaryCompletion":3182,"completion":3182,"start":2801,"enrollment":37,"conditions":3183,"interventions":3184},"NCT01617005","A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)",[],"2014-09",[15],[1096],{"nctId":3186,"briefTitle":3187,"status":107,"phases":3188,"primaryCompletion":2956,"completion":2956,"start":3189,"enrollment":3190,"conditions":3191,"interventions":3192},"NCT01462162","A Prospective Observational Study of Tocilizumab (RoActemra\u002FActemra) in Participants With Rheumatoid Arthritis",[],"2011-09",122,[15],[1096],{"nctId":3194,"briefTitle":3195,"status":107,"phases":3196,"primaryCompletion":3197,"completion":3197,"start":2768,"enrollment":37,"conditions":3198,"interventions":3199},"NCT01562327","A Non-interventional Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Rheumatoid Arthritis",[],"2014-03",[15],[1096],{"nctId":3201,"briefTitle":3202,"status":107,"phases":3203,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":2708,"conditions":3206,"interventions":3207},"NCT02648035","EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis",[],"2018-12-20","2016-09-22",[15],[1096],{"nctId":3209,"briefTitle":3210,"status":107,"phases":3211,"primaryCompletion":3212,"completion":3212,"start":3213,"enrollment":3214,"conditions":3215,"interventions":3216},"NCT01664104","A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting",[],"2013-12","2012-06",151,[15],[1096],{"nctId":3218,"briefTitle":3219,"status":107,"phases":3220,"primaryCompletion":3221,"completion":3221,"start":2562,"enrollment":721,"conditions":3222,"interventions":3223},"NCT01741688","An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis",[],"2014-03-06",[15],[1096],{"nctId":3225,"briefTitle":3226,"status":107,"phases":3227,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":1283,"conditions":3230,"interventions":3231},"NCT01362062","Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and\u002For Anti-tumor Necrosis Factor (Anti-TNF) Therapy",[],"2015-01-01","2010-10-26",[15],[1096],{"nctId":3233,"briefTitle":3234,"status":107,"phases":3235,"primaryCompletion":3236,"completion":3236,"start":3236,"enrollment":3237,"conditions":3238,"interventions":3239},"NCT02797769","A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)",[],"2016-06-02",48950,[15],[3240,1096],"Other Biologics",{"nctId":3242,"briefTitle":3243,"status":107,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3249},"NCT02234960","Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)",[],"2016-07","2014-08",102,[15],[1096],{"nctId":3251,"briefTitle":3252,"status":107,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":1979,"enrollment":1026,"conditions":3255,"interventions":3256},"NCT02552940","An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice",[],"2017-10-23",[15],[1096],{"nctId":3258,"briefTitle":3259,"status":107,"phases":3260,"primaryCompletion":3182,"completion":3182,"start":3103,"enrollment":3261,"conditions":3262,"interventions":3263},"NCT01474291","An Observational Study of RoActemra\u002FActemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice",[],608,[15],[1096],{"nctId":3265,"briefTitle":3266,"status":107,"phases":3267,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":336,"conditions":3270,"interventions":3271},"NCT02534311","A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)",[],"2015-12-01","2015-10-13",[15],[1096],{"nctId":3273,"briefTitle":3274,"status":107,"phases":3275,"primaryCompletion":3276,"completion":3276,"start":3277,"enrollment":3278,"conditions":3279,"interventions":3280},"NCT02402686","Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)",[],"2018-12-17","2015-05-20",353,[15],[1096],{"nctId":3282,"briefTitle":3283,"status":107,"phases":3284,"primaryCompletion":1025,"completion":1025,"start":3285,"enrollment":3286,"conditions":3287,"interventions":3288},"NCT01705730","A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra\u002FActemra (Tocilizumab) in Monotherapy",[],"2012-07-31",71,[15],[2555],{"nctId":3290,"briefTitle":3291,"status":107,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":3295,"conditions":3296,"interventions":3297},"NCT03112213","Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment",[],"2018-07-17","2017-01-12",135,[15],[1096,3116],{"nctId":3299,"briefTitle":3300,"status":107,"phases":3301,"primaryCompletion":3197,"completion":3197,"start":2801,"enrollment":16,"conditions":3302,"interventions":3303},"NCT01579006","Observational Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Rheumatoid Arthritis",[],[15],[1096],{"nctId":3305,"briefTitle":3306,"status":107,"phases":3307,"primaryCompletion":3175,"completion":3175,"start":3308,"enrollment":693,"conditions":3309,"interventions":3310},"NCT02809833","Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine",[],"2009-01",[15],[1096],{"nctId":3312,"briefTitle":3313,"status":107,"phases":3314,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":1891,"conditions":3317,"interventions":3318},"NCT03291457","A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice",[],"2019-12-04","2017-03-30",[15],[1096,3319],"Glucocorticoid Agent",{"nctId":3321,"briefTitle":3322,"status":107,"phases":3323,"primaryCompletion":3324,"completion":3324,"start":3325,"enrollment":3326,"conditions":3327,"interventions":3328},"NCT02721004","Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis",[],"2014-12","2009-03",592,[15],[1096],{"intervention":1137,"totalTrials":510,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3343,"PHASE3":3406,"PHASE4":3455,"NA":3457},{"trials":3332,"activeCount":101},[],{"trials":3334,"activeCount":162,"soonestReadout":219},[3335,3339],{"nctId":1128,"briefTitle":1129,"status":152,"phases":3336,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":3337,"interventions":3338},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"nctId":1180,"briefTitle":1181,"status":140,"phases":3340,"primaryCompletion":219,"completion":219,"start":1183,"enrollment":1184,"conditions":3341,"interventions":3342},[89],[1186],[1137,68],{"trials":3344,"activeCount":306,"soonestReadout":3349},[3345,3354,3358,3362,3372,3381,3385,3393,3397],{"nctId":3346,"briefTitle":3347,"status":152,"phases":3348,"primaryCompletion":3349,"completion":3350,"start":3351,"enrollment":336,"conditions":3352,"interventions":3353},"NCT07054190","A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer",[90],"2027-07-31","2027-09-28","2025-09-09",[18],[1137,1456,1422],{"nctId":1410,"briefTitle":1411,"status":140,"phases":3355,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":3356,"interventions":3357},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1447,"briefTitle":1448,"status":152,"phases":3359,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":3360,"interventions":3361},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":3363,"briefTitle":3364,"status":152,"phases":3365,"primaryCompletion":366,"completion":3366,"start":3367,"enrollment":1847,"conditions":3368,"interventions":3370},"NCT07287150","A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer",[90],"2029-07-30","2026-03-11",[3369],"Metastatic Castration-Resistant Prostate Cancer",[1137,1830,3371,947],"Abiraterone",{"nctId":3373,"briefTitle":3374,"status":152,"phases":3375,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":920,"conditions":3379,"interventions":3380},"NCT07405801","A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer",[90],"2028-12-19","2030-02-26","2026-04-07",[18],[1137,1456,1573],{"nctId":1562,"briefTitle":1563,"status":152,"phases":3382,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":3383,"interventions":3384},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":3386,"briefTitle":3387,"status":152,"phases":3388,"primaryCompletion":3389,"completion":3389,"start":3390,"enrollment":920,"conditions":3391,"interventions":3392},"NCT07368998","To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer",[90],"2031-10-31","2026-02-18",[18],[1137,1573],{"nctId":1687,"briefTitle":1688,"status":140,"phases":3394,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":3395,"interventions":3396},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"nctId":3398,"briefTitle":3399,"status":343,"phases":3400,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":101,"conditions":3404,"interventions":3405},"NCT07323576","A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer",[90],"2029-03-01","2031-03-31","2026-02-01",[30],[1137,1015,1141,1142],{"trials":3407,"activeCount":2631,"soonestReadout":3412},[3408,3417,3429,3439,3451],{"nctId":3409,"briefTitle":3410,"status":140,"phases":3411,"primaryCompletion":3412,"completion":701,"start":3413,"enrollment":3414,"conditions":3415,"interventions":3416},"NCT04191499","A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",[90,91],"2023-09-29","2020-01-29",325,[18],[1137,1421,1573],{"nctId":3418,"briefTitle":3419,"status":152,"phases":3420,"primaryCompletion":1582,"completion":3421,"start":3422,"enrollment":3423,"conditions":3424,"interventions":3425},"NCT05894239","A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",[91],"2032-12-28","2023-09-08",230,[1569],[1137,3426,3427,3428],"Phesgo","Taxane-based Chemotherapy","Optional Endocrine Therapy of Investigator's Choice",{"nctId":3430,"briefTitle":3431,"status":152,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":3435,"conditions":3436,"interventions":3437},"NCT06790693","A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4\u002F6 Inhibitor and Letrozole vs Placebo + CDK4\u002F6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",[91],"2032-05-30","2025-04-09",450,[18],[1137,3438,1422],"CDK4\u002F6i",{"nctId":3440,"briefTitle":3441,"status":140,"phases":3442,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3447},"NCT05646862","A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4\u002F6i and Endocrine Combination Therapy",[91],"2026-11-13","2023-06-07",420,[18],[1137,1573,3448,3449,3450,388],"Alpelisib","Bupropion","Omeprazole",{"nctId":2242,"briefTitle":2243,"status":152,"phases":3452,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":3453,"interventions":3454},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"trials":3456,"activeCount":101},[],{"trials":3458,"activeCount":350,"soonestReadout":2347},[3459],{"nctId":3460,"briefTitle":3461,"status":152,"phases":3462,"primaryCompletion":2347,"completion":3463,"start":3464,"enrollment":211,"conditions":3465,"interventions":3467},"NCT07347600","A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer",[],"2029-09-09","2026-01-21",[3466,1569],"Locally Advanced Breast Cancer",[1137,1421,1573],{"intervention":1018,"totalTrials":1724,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3578,"PHASE3":3730,"PHASE4":3860,"NA":3872},{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":162,"soonestReadout":2460},[3474,3483,3487,3491,3501,3505,3509,3513,3517,3521,3525,3534,3538,3542,3546,3550,3554,3558,3565,3569],{"nctId":3475,"briefTitle":3476,"status":107,"phases":3477,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":3480,"interventions":3481},"NCT00825149","A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma",[89],"2015-11","2009-02",[125],[1356,992,991,3482,1018,1357,1358],"Fludarabine",{"nctId":2370,"briefTitle":2371,"status":107,"phases":3484,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":3485,"interventions":3486},[89],[2377,2378,2379],[2381,1096,1018,2382],{"nctId":2384,"briefTitle":2385,"status":107,"phases":3488,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":3489,"interventions":3490},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":3492,"briefTitle":3493,"status":107,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":3497,"conditions":3498,"interventions":3499},"NCT02453087","A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",[89],"2019-07-12","2015-08-04",66,[125],[3500,1359,1018],"DCDS0780A",{"nctId":2396,"briefTitle":2397,"status":107,"phases":3502,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":1184,"conditions":3503,"interventions":3504},[89],[1038],[1018,1784,1096],{"nctId":2405,"briefTitle":2406,"status":107,"phases":3506,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":3507,"interventions":3508},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"nctId":2414,"briefTitle":2415,"status":130,"phases":3510,"primaryCompletion":2417,"completion":2417,"start":2418,"enrollment":316,"conditions":3511,"interventions":3512},[89],[922],[2421,1018,1096],{"nctId":1006,"briefTitle":1007,"status":107,"phases":3514,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":3515,"interventions":3516},[89],[1013],[68,1015,1016,1017,1018,1019],{"nctId":2457,"briefTitle":2458,"status":152,"phases":3518,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":3519,"interventions":3520},[89],[2392],[2465,2466,2467,2468,1018,1096],{"nctId":1031,"briefTitle":1032,"status":107,"phases":3522,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":3523,"interventions":3524},[89],[1038],[68,1018,1040],{"nctId":3526,"briefTitle":3527,"status":107,"phases":3528,"primaryCompletion":3529,"completion":3529,"start":1373,"enrollment":425,"conditions":3530,"interventions":3532},"NCT02586051","A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation",[89],"2018-11-26",[3531],"Kidney Failure, Chronic",[1018,3533],"Intravenous Immunoglobulin",{"nctId":2479,"briefTitle":2480,"status":152,"phases":3535,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":37,"conditions":3536,"interventions":3537},[89],[1038],[1784,1096,1018,1163,1165],{"nctId":2487,"briefTitle":2488,"status":130,"phases":3539,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":2492,"conditions":3540,"interventions":3541},[89],[2494],[2496,1018,1096],{"nctId":1087,"briefTitle":1088,"status":130,"phases":3543,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":3544,"interventions":3545},[89],[30],[1018,68,1095,1096],{"nctId":2519,"briefTitle":2520,"status":107,"phases":3547,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":3548,"interventions":3549},[89],[922],[1151,1018,1096],{"nctId":2528,"briefTitle":2529,"status":130,"phases":3551,"primaryCompletion":2531,"completion":2531,"start":62,"enrollment":2532,"conditions":3552,"interventions":3553},[89],[1196],[2535,1784,1018,1096],{"nctId":2537,"briefTitle":2538,"status":107,"phases":3555,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":3556,"interventions":3557},[89],[2543],[1784,1163,1165,2433,1018,1096],{"nctId":3559,"briefTitle":3560,"status":107,"phases":3561,"primaryCompletion":3324,"completion":3324,"start":3146,"enrollment":123,"conditions":3562,"interventions":3564},"NCT01680991","A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease",[89],[3563],"Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma",[1018],{"nctId":1189,"briefTitle":1190,"status":343,"phases":3566,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":101,"conditions":3567,"interventions":3568},[89],[1196],[68,1126,1018],{"nctId":3570,"briefTitle":3571,"status":107,"phases":3572,"primaryCompletion":2219,"completion":2219,"start":3573,"enrollment":3574,"conditions":3575,"interventions":3576},"NCT04826003","Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment",[89],"2021-07-14",54,[1135],[3577,1095,1018],"RO7122290",{"trials":3579,"activeCount":942,"soonestReadout":1778},[3580,3588,3600,3610,3614,3618,3627,3637,3646,3655,3659,3670,3678,3688,3695,3699,3710,3718,3726],{"nctId":3581,"briefTitle":3582,"status":107,"phases":3583,"primaryCompletion":3584,"completion":3584,"start":3585,"enrollment":2857,"conditions":3586,"interventions":3587},"NCT02611323","A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],"2022-08-04","2016-03-09",[125],[1018,1359,1785,1073],{"nctId":3589,"briefTitle":3590,"status":107,"phases":3591,"primaryCompletion":3592,"completion":3593,"start":3594,"enrollment":3595,"conditions":3596,"interventions":3598},"NCT02550652","A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)",[90],"2019-01-15","2023-08-02","2015-11-13",126,[3597],"Lupus Nephritis",[3599,1018,274,1357],"Mycophenolate Mofetil\u002FMycophenolic Acid",{"nctId":3601,"briefTitle":3602,"status":107,"phases":3603,"primaryCompletion":3604,"completion":3605,"start":1214,"enrollment":2492,"conditions":3606,"interventions":3608},"NCT02631577","A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma",[89,90],"2018-10-23","2020-10-07",[3607],"Lymphoma, Follicular",[3609,2644,1018],"Atezolizumab (MPDL3280A) [TECENTRIQ]",{"nctId":2661,"briefTitle":2662,"status":140,"phases":3611,"primaryCompletion":2016,"completion":2016,"start":2664,"enrollment":2665,"conditions":3612,"interventions":3613},[89,90],[1196],[2668,1018,1784,1096],{"nctId":1346,"briefTitle":1347,"status":107,"phases":3615,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":3616,"interventions":3617},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":3619,"briefTitle":3620,"status":107,"phases":3621,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":3624,"conditions":3625,"interventions":3626},"NCT02257567","A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",[89,90],"2021-10-21","2014-10-15",331,[1038],[1356,1018,2394,1359,2394],{"nctId":3628,"briefTitle":3629,"status":107,"phases":3630,"primaryCompletion":3631,"completion":3632,"start":3633,"enrollment":1058,"conditions":3634,"interventions":3635},"NCT02729896","A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],"2018-09-03","2019-10-07","2016-11-09",[1038],[3636,1018,1785,1359],"Atezolizumab [TECENTRIQ]",{"nctId":3638,"briefTitle":3639,"status":130,"phases":3640,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":1174,"conditions":3643,"interventions":3645},"NCT03135262","A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R\u002FR) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R\u002FR Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],"2020-04-30","2017-06-15",[2642,3644],"Lymphoma, Large B-Cell, Diffuse",[1500,1018,1073,1359],{"nctId":3647,"briefTitle":3648,"status":107,"phases":3649,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":22,"conditions":3652,"interventions":3654},"NCT02600897","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",[89,90],"2021-12-15","2016-03-24",[3653],"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[2644,1018,1785,1359],{"nctId":2689,"briefTitle":2690,"status":152,"phases":3656,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":3657,"interventions":3658},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"nctId":3660,"briefTitle":3661,"status":107,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":3665,"conditions":3666,"interventions":3667},"NCT02071225","A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia",[90],"2018-11-19","2014-04-09",72,[2431],[3668,3669],"bendamustine","obinutuzumab",{"nctId":3671,"briefTitle":3672,"status":107,"phases":3673,"primaryCompletion":3189,"completion":3674,"start":121,"enrollment":134,"conditions":3675,"interventions":3676},"NCT00576758","GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma",[90],"2013-03",[125],[3669,3677],"rituximab",{"nctId":3679,"briefTitle":3680,"status":107,"phases":3681,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":3686,"interventions":3687},"NCT02055820","A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL",[89,90],"2017-06-28","2019-06-28","2013-11-17",267,[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":3689,"briefTitle":3690,"status":107,"phases":3691,"primaryCompletion":2956,"completion":2956,"start":3692,"enrollment":19,"conditions":3693,"interventions":3694},"NCT00517530","A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)",[89,90],"2007-09",[1038],[1018],{"nctId":2716,"briefTitle":2717,"status":140,"phases":3696,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":607,"conditions":3697,"interventions":3698},[89,90],[125],[1784,1018,1096],{"nctId":3700,"briefTitle":3701,"status":152,"phases":3702,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":3705,"interventions":3706},"NCT05039619","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",[90],"2028-06-15","2030-06-14",[3597],[1018,3707,3708,3709,274,1357],"Mycophenolate Mofetil","Acetaminophen\u002Fparacetamol","Diphenhydramine hydrochloride",{"nctId":3711,"briefTitle":3712,"status":130,"phases":3713,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":97,"conditions":3716,"interventions":3717},"NCT02624986","A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed\u002FRefractory (R\u002FR) Follicular Lymphoma (FL) and in Combination With Rituximab in R\u002FR Diffuse Large B-Cell Lymphoma (DLBCL) Participants",[89,90],"2019-05-20","2015-12-23",[125],[1500,1018,1359],{"nctId":3719,"briefTitle":3720,"status":152,"phases":3721,"primaryCompletion":3722,"completion":2719,"start":1464,"enrollment":1847,"conditions":3723,"interventions":3725},"NCT06806033","A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed\u002FRefractory Aggressive B-Cell Non-Hodgkin's Lymphoma",[90],"2027-01-31",[3724],"B-Cell Non-Hodgkins Lymphoma",[1018,1784,1163,1165],{"nctId":1775,"briefTitle":1776,"status":140,"phases":3727,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":3728,"interventions":3729},[89,90],[1782],[1784,68,1018,1096,1785,1786],{"trials":3731,"activeCount":942,"soonestReadout":1364},[3732,3744,3756,3765,3776,3786,3794,3798,3808,3817,3828,3832,3840,3850],{"nctId":3733,"briefTitle":3734,"status":107,"phases":3735,"primaryCompletion":3736,"completion":3737,"start":3738,"enrollment":3739,"conditions":3740,"interventions":3742},"NCT02053610","CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)",[91],"2013-08-31","2017-08-23","2009-12-31",787,[3741],"Lymphocytic Leukemia, Chronic",[3669,3677,3743],"chlorambucil",{"nctId":3745,"briefTitle":3746,"status":140,"phases":3747,"primaryCompletion":1534,"completion":3748,"start":3749,"enrollment":3750,"conditions":3751,"interventions":3753},"NCT04629248","A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy",[91],"2027-12-21","2021-06-25",142,[3752],"Primary Membranous Nephropathy",[1018,3754,274,3755,2579],"Tacrolimus","Acetaminophen",{"nctId":3757,"briefTitle":3758,"status":107,"phases":3759,"primaryCompletion":3760,"completion":1439,"start":3761,"enrollment":3762,"conditions":3763,"interventions":3764},"NCT02242942","Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia",[91],"2018-08-17","2014-12-31",445,[3741],[2496,1073,1018],{"nctId":3766,"briefTitle":3767,"status":140,"phases":3768,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":3770,"interventions":3772},"NCT05627557","A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome",[91],"2026-09-04",[3771],"Childhood Idiopathic Nephrotic Syndrome",[1018,3773,1357,274,3774,3775],"MMF","Acetaminophen\u002F Paracetamol","Diphenhydramine Hydrochloride",{"nctId":3777,"briefTitle":3778,"status":107,"phases":3779,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":3784,"interventions":3785},"NCT01332968","A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)",[91],"2016-02-01","2021-07-30","2011-07-06",1401,[125],[1018,992,991,1358,1357,1356,1359],{"nctId":3787,"briefTitle":3788,"status":107,"phases":3789,"primaryCompletion":3790,"completion":3737,"start":3791,"enrollment":3739,"conditions":3792,"interventions":3793},"NCT01010061","CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)",[91],"2012-07-01","2009-12-21",[3741],[3669,3677,3743],{"nctId":2937,"briefTitle":2938,"status":140,"phases":3795,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":3796,"interventions":3797},[91],[2652],[1018,1784,2736,1096,1163,1165],{"nctId":3799,"briefTitle":3800,"status":107,"phases":3801,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":3805,"interventions":3807},"NCT04285567","A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)\u002F Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation",[91],"2025-03-19","2020-05-28",166,[3806],"Chronic Lymphocytic Leukemia (CLL)",[1018,1073,3482,992,1359,1356],{"nctId":3809,"briefTitle":3810,"status":140,"phases":3811,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3816},"NCT04221477","A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN\u002FRPS 2003 Class III or IV Lupus Nephritis",[91],"2031-03-02","2020-08-10",271,[3597],[1018,3773,1357,274,3755,2579],{"nctId":3818,"briefTitle":3819,"status":130,"phases":3820,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":3825,"interventions":3827},"NCT01287741","A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)",[91],"2016-04-29","2018-01-31","2011-07-26",1418,[3826],"Diffuse Large B-Cell Lymphoma",[1359,1018,992,991,1358,1357],{"nctId":3011,"briefTitle":3012,"status":152,"phases":3829,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":3830,"interventions":3831},[91],[1038],[1018,1784,1359,1356,2644,1096],{"nctId":3833,"briefTitle":3834,"status":107,"phases":3835,"primaryCompletion":3836,"completion":3737,"start":3837,"enrollment":3739,"conditions":3838,"interventions":3839},"NCT01998880","CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)",[91],"2012-08-01","2009-12-22",[3741],[3669,3677,3743],{"nctId":3841,"briefTitle":3842,"status":107,"phases":3843,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":3847,"conditions":3848,"interventions":3849},"NCT01905943","A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia",[91],"2016-12-29","2018-10-08","2013-11-04",979,[2431],[1356,2496,992,3482,1018],{"nctId":3851,"briefTitle":3852,"status":140,"phases":3853,"primaryCompletion":3854,"completion":3855,"start":2540,"enrollment":3856,"conditions":3857,"interventions":3858},"NCT04963296","A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus",[91],"2025-09-15","2028-03-13",303,[2621],[1018,3859,3709,274],"Acetaminophen\u002FParacetamol",{"trials":3861,"activeCount":101},[3862],{"nctId":3863,"briefTitle":3864,"status":107,"phases":3865,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":3868,"interventions":3870},"NCT03817853","An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma",[92],"2020-08-04","2023-01-25",[3869],"Advanced Follicular Lymphoma",[1018,1356,992,991,3871,1358],"Prednisone\u002FPrednisolone\u002FMethylprednisolone",{"trials":3873,"activeCount":101},[3874,3883,3891,3899],{"nctId":3875,"briefTitle":3876,"status":107,"phases":3877,"primaryCompletion":3878,"completion":3878,"start":3879,"enrollment":3880,"conditions":3881,"interventions":3882},"NCT04034056","Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)",[],"2024-04-22","2019-09-02",299,[2642],[1018],{"nctId":3884,"briefTitle":3885,"status":107,"phases":3886,"primaryCompletion":3887,"completion":3887,"start":3888,"enrollment":37,"conditions":3889,"interventions":3890},"NCT02915224","A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities",[],"2021-06-08","2016-11-23",[2431],[2496,1018],{"nctId":3892,"briefTitle":3893,"status":107,"phases":3894,"primaryCompletion":3895,"completion":3895,"start":3896,"enrollment":786,"conditions":3897,"interventions":3898},"NCT03374137","Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia",[],"2022-11-10","2018-03-09",[2431,2642],[3669],{"nctId":3900,"briefTitle":3901,"status":107,"phases":3902,"primaryCompletion":3903,"completion":3903,"start":3904,"enrollment":162,"conditions":3905,"interventions":3906},"NCT03059251","Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina",[],"2019-03-30","2017-08-31",[2431],[1018],{"intervention":3908,"totalTrials":2563,"cells":3909},"Afimkibart",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3914,"PHASE3":3961,"PHASE4":4016,"NA":4018},{"trials":3911,"activeCount":101},[],{"trials":3913,"activeCount":101},[],{"trials":3915,"activeCount":2631,"soonestReadout":3920},[3916,3927,3933,3943,3952],{"nctId":3917,"briefTitle":3918,"status":140,"phases":3919,"primaryCompletion":3920,"completion":3921,"start":3922,"enrollment":3923,"conditions":3924,"interventions":3926},"NCT06863961","A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis",[90],"2026-07-22","2027-02-03","2025-04-01",160,[3925],"Atopic Dermatitis",[3908],{"nctId":3928,"briefTitle":3929,"status":152,"phases":3930,"primaryCompletion":2245,"completion":2245,"start":1624,"enrollment":1239,"conditions":3931,"interventions":3932},"NCT07223697","A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis",[90],[3925],[3908],{"nctId":3934,"briefTitle":3935,"status":140,"phases":3936,"primaryCompletion":3937,"completion":3937,"start":3938,"enrollment":3939,"conditions":3940,"interventions":3942},"NCT05910528","Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease",[90],"2030-12-31","2023-07-24",21,[3941],"Crohns Disease",[3908],{"nctId":3944,"briefTitle":3945,"status":152,"phases":3946,"primaryCompletion":3947,"completion":3948,"start":3949,"enrollment":3923,"conditions":3950,"interventions":3951},"NCT07137598","A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and\u002For Janus Kinase (JAK Inhibitors)",[90],"2027-04-19","2027-10-08","2025-12-05",[15],[3908],{"nctId":3953,"briefTitle":3954,"status":3955,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":1239,"conditions":3959,"interventions":3960},"NCT07620392","An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis","NOT_YET_RECRUITING",[90],"2032-06-05","2026-06-05",[15],[3908],{"trials":3962,"activeCount":942,"soonestReadout":3984},[3963,3971,3980,3990,3999,4008],{"nctId":3964,"briefTitle":3965,"status":152,"phases":3966,"primaryCompletion":2482,"completion":3402,"start":3967,"enrollment":1847,"conditions":3968,"interventions":3970},"NCT07158242","A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis",[91],"2026-04-15",[3969],"Moderately to Severely Active Ulcerative Colitis",[3908],{"nctId":3972,"briefTitle":3973,"status":152,"phases":3974,"primaryCompletion":3975,"completion":3976,"start":569,"enrollment":1847,"conditions":3977,"interventions":3979},"NCT07298421","A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease",[91],"2030-05-31","2031-05-30",[3978],"Moderately to Severely Active Crohns Disease",[3908],{"nctId":3981,"briefTitle":3982,"status":152,"phases":3983,"primaryCompletion":3984,"completion":3985,"start":3986,"enrollment":3987,"conditions":3988,"interventions":3989},"NCT06588855","A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis",[91],"2027-01-30","2031-01-30","2024-12-11",350,[3969],[3908],{"nctId":3991,"briefTitle":3992,"status":152,"phases":3993,"primaryCompletion":2347,"completion":3994,"start":3995,"enrollment":3996,"conditions":3997,"interventions":3998},"NCT06819878","A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease",[91],"2033-12-31","2025-03-17",600,[3978],[3908],{"nctId":4000,"briefTitle":4001,"status":152,"phases":4002,"primaryCompletion":2347,"completion":4003,"start":4004,"enrollment":4005,"conditions":4006,"interventions":4007},"NCT06819891","A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease",[91],"2033-04-30","2025-05-12",425,[3978],[3908],{"nctId":4009,"briefTitle":4010,"status":140,"phases":4011,"primaryCompletion":3984,"completion":3985,"start":4012,"enrollment":4013,"conditions":4014,"interventions":4015},"NCT06589986","A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",[91],"2024-09-17",400,[3969],[3908],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[],{"intervention":1015,"totalTrials":4021,"cells":4022},95,{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4058,"PHASE3":4335,"PHASE4":4549,"NA":4612},{"trials":4024,"activeCount":101},[],{"trials":4026,"activeCount":350,"soonestReadout":1131},[4027,4038,4042,4046,4050,4054],{"nctId":4028,"briefTitle":4029,"status":107,"phases":4030,"primaryCompletion":4031,"completion":4031,"start":4032,"enrollment":4033,"conditions":4034,"interventions":4036},"NCT02665416","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors",[89],"2019-10-30","2016-01-25",94,[4035],"Advanced\u002FMetastatic Solid Tumors",[1029,4037,1015],"Vanucizumab",{"nctId":1006,"briefTitle":1007,"status":107,"phases":4039,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":4040,"interventions":4041},[89],[1013],[68,1015,1016,1017,1018,1019],{"nctId":1042,"briefTitle":1043,"status":107,"phases":4043,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":1047,"conditions":4044,"interventions":4045},[89],[1049],[68,1015,1051],{"nctId":1110,"briefTitle":1111,"status":107,"phases":4047,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":4048,"interventions":4049},[89],[30],[68,1015,1084],{"nctId":1128,"briefTitle":1129,"status":152,"phases":4051,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":4052,"interventions":4053},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"nctId":1153,"briefTitle":1154,"status":107,"phases":4055,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":4056,"interventions":4057},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"trials":4059,"activeCount":162,"soonestReadout":1413},[4060,4073,4082,4091,4105,4109,4116,4123,4132,4145,4149,4153,4163,4167,4176,4186,4190,4194,4202,4210,4220,4224,4228,4236,4245,4252,4259,4263,4273,4277,4285,4293,4301,4310,4318,4327,4331],{"nctId":4061,"briefTitle":4062,"status":107,"phases":4063,"primaryCompletion":2089,"completion":4064,"start":4065,"enrollment":4066,"conditions":4067,"interventions":4069},"NCT01860638","A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma",[90],"2017-05-05","2013-08-19",296,[4068],"Glioblastoma",[1015,4070,4071,4072],"Lomustine","Temozolomide","SOC Agent",{"nctId":4074,"briefTitle":4075,"status":107,"phases":4076,"primaryCompletion":3285,"completion":4077,"start":4078,"enrollment":4079,"conditions":4080,"interventions":4081},"NCT00937560","A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer",[90],"2013-07-01","2009-06-25",190,[1417],[1015,1106,990],{"nctId":4083,"briefTitle":4084,"status":107,"phases":4085,"primaryCompletion":2792,"completion":2792,"start":4086,"enrollment":1272,"conditions":4087,"interventions":4088},"NCT00559845","A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer",[90],"2008-02",[18],[4089,4090,992,1106,1015],"5-fluorouracil","Epidoxorubicin",{"nctId":4092,"briefTitle":4093,"status":130,"phases":4094,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":4097,"interventions":4099},"NCT01765582","Sequential and Concurrent FOLFOXIRI\u002FBevacizumab Regimens Versus FOLFOX\u002FBevacizumab in First-Line Metastatic Colorectal Cancer",[90],"2016-03-14","2013-01-23",[4098],"Colorectal Neoplasms",[4089,4100,4101,4102,4103,4104],"bevacizumab","capecitabine","irinotecan","folinic acid","oxaliplatin",{"nctId":1308,"briefTitle":1309,"status":130,"phases":4106,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":4107,"interventions":4108},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":4110,"briefTitle":4111,"status":107,"phases":4112,"primaryCompletion":3325,"completion":3325,"start":4113,"enrollment":162,"conditions":4114,"interventions":4115},"NCT00754650","A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia",[90],"2008-09",[3741],[1015],{"nctId":4117,"briefTitle":4118,"status":107,"phases":4119,"primaryCompletion":2931,"completion":2931,"start":4086,"enrollment":1184,"conditions":4120,"interventions":4122},"NCT00576199","A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer",[90],[4121],"Liver Cancer",[1015],{"nctId":4124,"briefTitle":4125,"status":107,"phases":4126,"primaryCompletion":2856,"completion":4127,"start":4128,"enrollment":1080,"conditions":4129,"interventions":4130},"NCT01383707","A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer",[90],"2016-05-18","2011-08-12",[30],[1597,1015,4131,1165],"Levofolinic acid",{"nctId":4133,"briefTitle":4134,"status":107,"phases":4135,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":4138,"interventions":4140},"NCT03280563","A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",[89,90],"2017-12-22",144,[4139],"Breast Neoplasms",[4141,1015,4142,4143,1573,946,4144,1420],"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody","Entinostat","Exemestane","Tamoxifen",{"nctId":1380,"briefTitle":1381,"status":107,"phases":4146,"primaryCompletion":1383,"completion":1384,"start":1009,"enrollment":1385,"conditions":4147,"interventions":4148},[90],[1285],[68,1015],{"nctId":1389,"briefTitle":1390,"status":107,"phases":4150,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":4151,"interventions":4152},[90],[1397],[68,1015,1167,1163],{"nctId":4154,"briefTitle":4155,"status":107,"phases":4156,"primaryCompletion":4157,"completion":3413,"start":4158,"enrollment":4159,"conditions":4160,"interventions":4162},"NCT01390948","A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma",[90],"2016-02-05","2011-10-18",124,[4161],"High Grade Glioma",[1015,4071],{"nctId":1410,"briefTitle":1411,"status":140,"phases":4164,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":4165,"interventions":4166},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":4168,"briefTitle":4169,"status":107,"phases":4170,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":806,"conditions":4173,"interventions":4174},"NCT01142778","A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer",[90],"2017-12-13","2010-05-19",[18],[1015,947,1222,4175],"Hormonal Therapy",{"nctId":4177,"briefTitle":4178,"status":107,"phases":4179,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":4182,"interventions":4183},"NCT00773695","A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer",[90],"2022-11-09","2008-11-07",[18],[4184,1015,4185,1597,992,1106,947],"Aromatase Inhibitor","Epirubicine",{"nctId":1436,"briefTitle":1437,"status":107,"phases":4187,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":447,"conditions":4188,"interventions":4189},[89,90],[1443],[68,1015,988,1445],{"nctId":1490,"briefTitle":1491,"status":130,"phases":4191,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":4192,"interventions":4193},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"nctId":4195,"briefTitle":4196,"status":107,"phases":4197,"primaryCompletion":2932,"completion":2932,"start":4198,"enrollment":1115,"conditions":4199,"interventions":4200},"NCT00605722","A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.",[90],"2008-03",[4121],[4100,4201],"erlotinib",{"nctId":4203,"briefTitle":4204,"status":107,"phases":4205,"primaryCompletion":4206,"completion":4206,"start":121,"enrollment":4159,"conditions":4207,"interventions":4208},"NCT00531960","A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.",[90],"2010-01",[975],[977,1015,4209],"Standard platinum-based chemotherapy",{"nctId":4211,"briefTitle":4212,"status":107,"phases":4213,"primaryCompletion":4214,"completion":4215,"start":4216,"enrollment":1936,"conditions":4217,"interventions":4218},"NCT01984242","A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma",[90],"2016-10-17","2019-01-08","2014-01-08",[1049],[4219,1015,2152],"Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody",{"nctId":1504,"briefTitle":1505,"status":107,"phases":4221,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":4222,"interventions":4223},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1517,"briefTitle":1518,"status":107,"phases":4225,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":4226,"interventions":4227},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":4229,"briefTitle":4230,"status":107,"phases":4231,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":931,"conditions":4234,"interventions":4235},"NCT01201265","A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer",[90],"2015-04","2011-02",[18],[1015,990,1163],{"nctId":4237,"briefTitle":4238,"status":107,"phases":4239,"primaryCompletion":4240,"completion":4240,"start":4241,"enrollment":3295,"conditions":4242,"interventions":4243},"NCT01632228","A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma",[90],"2016-01-21","2012-06-29",[4068],[1015,4244],"Onartuzumab",{"nctId":4246,"briefTitle":4247,"status":107,"phases":4248,"primaryCompletion":2905,"completion":4249,"start":3308,"enrollment":2743,"conditions":4250,"interventions":4251},"NCT00846027","A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer",[90],"2013-01",[18],[1015,1106,1163],{"nctId":4253,"briefTitle":4254,"status":107,"phases":4255,"primaryCompletion":1192,"completion":3592,"start":4256,"enrollment":806,"conditions":4257,"interventions":4258},"NCT02467907","Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer",[90],"2015-07-28",[1663],[1015,990,1106],{"nctId":1562,"briefTitle":1563,"status":152,"phases":4260,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":4261,"interventions":4262},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":4264,"briefTitle":4265,"status":130,"phases":4266,"primaryCompletion":3122,"completion":4267,"start":4268,"enrollment":4269,"conditions":4270,"interventions":4271},"NCT02141295","A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer",[90],"2017-02-01","2014-06-30",197,[30],[1162,1015,4272,1165,4037],"Folinic acid",{"nctId":1630,"briefTitle":1631,"status":107,"phases":4274,"primaryCompletion":1633,"completion":1634,"start":1635,"enrollment":145,"conditions":4275,"interventions":4276},[90],[1316],[68,1015],{"nctId":4278,"briefTitle":4279,"status":130,"phases":4280,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":462,"conditions":4283,"interventions":4284},"NCT02079519","A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma",[90],"2008-05","2006-05",[1305],[1015],{"nctId":4286,"briefTitle":4287,"status":107,"phases":4288,"primaryCompletion":2973,"completion":2973,"start":4289,"enrollment":931,"conditions":4290,"interventions":4291},"NCT01164007","A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable\u002FMetastatic Melanoma",[90],"2006-06-30",[1261],[1015,4292],"Dacarbazine",{"nctId":4294,"briefTitle":4295,"status":107,"phases":4296,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":559,"conditions":4299,"interventions":4300},"NCT01739218","A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC\u002FIV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable",[90],"2016-08-17","2013-02-01",[1417],[990,1106,1015],{"nctId":4302,"briefTitle":4303,"status":107,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1352,"conditions":4307,"interventions":4308},"NCT00865189","A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer",[90],"2016-03-23","2007-10-23",[1727],[1015,1165,4309,4089],"Folinic Acid",{"nctId":4311,"briefTitle":4312,"status":107,"phases":4313,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":37,"conditions":4316,"interventions":4317},"NCT00661778","A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer",[90],"2011-07","2007-07",[1684],[1015,1167,947],{"nctId":4319,"briefTitle":4320,"status":107,"phases":4321,"primaryCompletion":4322,"start":4323,"enrollment":4324,"conditions":4325,"interventions":4326},"NCT00118755","A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer",[90],"2009-04","2005-07",435,[30],[4101,1165,4100,4101,1165,4100],{"nctId":1760,"briefTitle":1761,"status":107,"phases":4328,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":4329,"interventions":4330},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"nctId":3398,"briefTitle":3399,"status":343,"phases":4332,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":101,"conditions":4333,"interventions":4334},[90],[30],[1137,1015,1141,1142],{"trials":4336,"activeCount":4548,"soonestReadout":67},[4337,4343,4347,4351,4361,4365,4369,4373,4379,4383,4392,4401,4405,4415,4419,4429,4437,4441,4450,4459,4469,4478,4484,4493,4505,4509,4518,4522,4532,4540,4544],{"nctId":4338,"briefTitle":4339,"status":107,"phases":4340,"primaryCompletion":2931,"completion":3246,"start":3325,"enrollment":1672,"conditions":4341,"interventions":4342},"NCT00887822","A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer",[91],[1735],[1015,1166,1167],{"nctId":65,"briefTitle":66,"status":140,"phases":4344,"primaryCompletion":67,"completion":1801,"start":1802,"enrollment":1803,"conditions":4345,"interventions":4346},[91],[1443],[68,1015],{"nctId":1807,"briefTitle":1808,"status":107,"phases":4348,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":806,"conditions":4349,"interventions":4350},[91],[1443],[68,1015],{"nctId":4352,"briefTitle":4353,"status":107,"phases":4354,"primaryCompletion":4355,"completion":4356,"start":4357,"enrollment":4358,"conditions":4359,"interventions":4360},"NCT01364012","A Study of Bevacizumab Versus Placebo in Combination With Carboplatin\u002FPaclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy",[91],"2013-01-27","2017-08-17","2011-05-23",276,[975],[1015,990,1106],{"nctId":1825,"briefTitle":1826,"status":140,"phases":4362,"primaryCompletion":690,"completion":690,"start":1714,"enrollment":1001,"conditions":4363,"interventions":4364},[91],[1241],[68,1015,1319,1106,1830],{"nctId":1843,"briefTitle":1844,"status":130,"phases":4366,"primaryCompletion":461,"completion":461,"start":1846,"enrollment":1847,"conditions":4367,"interventions":4368},[91],[1443],[68,1015],{"nctId":1851,"briefTitle":1852,"status":343,"phases":4370,"primaryCompletion":1854,"completion":1855,"start":1340,"enrollment":101,"conditions":4371,"interventions":4372},[91],[1049],[68,1015],{"nctId":4374,"briefTitle":4375,"status":107,"phases":4376,"primaryCompletion":3674,"completion":3674,"start":4315,"enrollment":571,"conditions":4377,"interventions":4378},"NCT00484939","A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer",[91],[30],[1015,1166],{"nctId":1876,"briefTitle":1877,"status":140,"phases":4380,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":4381,"interventions":4382},[91],[1883],[68,1015],{"nctId":4384,"briefTitle":4385,"status":107,"phases":4386,"primaryCompletion":4387,"completion":4387,"start":4388,"enrollment":4389,"conditions":4390,"interventions":4391},"NCT01351415","A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)",[91],"2016-06-25","2011-06-25",485,[2257],[1015,947,977,1319],{"nctId":4393,"briefTitle":4394,"status":107,"phases":4395,"primaryCompletion":4396,"completion":2864,"start":4397,"enrollment":4398,"conditions":4399,"interventions":4400},"NCT00943826","A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma",[91],"2013-02-28","2009-06-29",921,[4068],[1015,4071],{"nctId":1930,"briefTitle":1931,"status":107,"phases":4402,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":4403,"interventions":4404},[91],[1316],[68,1015,1106,1319,990],{"nctId":4406,"briefTitle":4407,"status":107,"phases":4408,"primaryCompletion":4409,"completion":3213,"start":4410,"enrollment":4411,"conditions":4412,"interventions":4413},"NCT00112918","Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer",[91],"2010-06","2004-12",3451,[30],[1015,1166,1597,4414,1165],"Leucovorin calcium",{"nctId":1959,"briefTitle":1960,"status":140,"phases":4416,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":4417,"interventions":4418},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":4420,"briefTitle":4421,"status":107,"phases":4422,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":1847,"conditions":4426,"interventions":4428},"NCT03635489","A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[91],"2021-05-26","2023-05-11","2018-08-15",[1417,2211,4427],"Primary Peritoneal Cancer",[1106,1015,990],{"nctId":4430,"briefTitle":4431,"status":107,"phases":4432,"primaryCompletion":4433,"completion":4433,"start":4434,"enrollment":709,"conditions":4435,"interventions":4436},"NCT02488330","An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study",[91],"2018-06-29","2015-08-27",[1160],[4244,1015,977],{"nctId":2002,"briefTitle":2003,"status":107,"phases":4438,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":4439,"interventions":4440},[91],[1443],[68,1015,2011],{"nctId":4442,"briefTitle":4443,"status":107,"phases":4444,"primaryCompletion":4445,"completion":4445,"start":4446,"enrollment":4447,"conditions":4448,"interventions":4449},"NCT00700102","A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.",[91],"2013-05","2006-02",820,[30],[1572,1015],{"nctId":4451,"briefTitle":4452,"status":107,"phases":4453,"primaryCompletion":2965,"completion":4454,"start":4455,"enrollment":4456,"conditions":4457,"interventions":4458},"NCT00333775","A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer",[91],"2013-10","2006-03",736,[18],[947,1015],{"nctId":4460,"briefTitle":4461,"status":107,"phases":4462,"primaryCompletion":4463,"completion":4464,"start":3277,"enrollment":4465,"conditions":4466,"interventions":4467},"NCT02420821","A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)",[91],"2020-02-14","2021-12-13",915,[1049],[4468,1015,2152],"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",{"nctId":4470,"briefTitle":4471,"status":107,"phases":4472,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":4475,"conditions":4476,"interventions":4477},"NCT01239732","A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer",[91],"2015-03","2010-12",1021,[1417],[1106,1015,990],{"nctId":4479,"briefTitle":4480,"status":107,"phases":4481,"primaryCompletion":2801,"completion":2801,"start":4198,"enrollment":1548,"conditions":4482,"interventions":4483},"NCT00623805","A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer",[91],[30],[1015,1166,1165],{"nctId":4485,"briefTitle":4486,"status":107,"phases":4487,"primaryCompletion":4488,"completion":4488,"start":4282,"enrollment":4489,"conditions":4490,"interventions":4491},"NCT01169558","A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.",[91],"2009-07",168,[30],[1015,4492],"Fluoropyrimidine-based Chemotherapy",{"nctId":4494,"briefTitle":4495,"status":107,"phases":4496,"primaryCompletion":4497,"completion":4497,"start":4498,"enrollment":4499,"conditions":4500,"interventions":4501},"NCT00976911","AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer",[91],"2014-07-09","2009-10-29",361,[1417],[1015,4502,4503,4504],"liposomal doxorubicin","paclitaxel","topotecan",{"nctId":2144,"briefTitle":2145,"status":140,"phases":4506,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":4507,"interventions":4508},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":4510,"briefTitle":4511,"status":107,"phases":4512,"primaryCompletion":2768,"completion":3174,"start":4513,"enrollment":4514,"conditions":4515,"interventions":4516},"NCT00528567","BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer",[91],"2007-12",2591,[18],[1015,4517],"Standard adjuvant chemotherapy",{"nctId":2203,"briefTitle":2204,"status":107,"phases":4519,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":4520,"interventions":4521},[91],[1417,2211,2212],[1106,990,68,1015,2093],{"nctId":4523,"briefTitle":4524,"status":107,"phases":4525,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":4529,"conditions":4530,"interventions":4531},"NCT02366143","A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",[91],"2019-09-13","2020-12-07","2015-03-31",1202,[1316],[4468,1015,990,1106],{"nctId":4533,"briefTitle":4534,"status":130,"phases":4535,"primaryCompletion":2914,"completion":2914,"start":4536,"enrollment":3739,"conditions":4537,"interventions":4538},"NCT00486759","A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma",[91],"2007-07-26",[2543],[1015,1359,4539],"CHOP",{"nctId":2242,"briefTitle":2243,"status":152,"phases":4541,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":4542,"interventions":4543},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"nctId":2260,"briefTitle":2261,"status":140,"phases":4545,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2266,"conditions":4546,"interventions":4547},[91],[2047],[68,1015,988],7,{"trials":4550,"activeCount":101},[4551,4558,4567,4578,4585,4593,4602],{"nctId":4552,"briefTitle":4553,"status":107,"phases":4554,"primaryCompletion":2847,"completion":2847,"start":4555,"enrollment":1001,"conditions":4556,"interventions":4557},"NCT01094184","A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer",[92],"2010-03",[18],[1015,1106,947],{"nctId":4559,"briefTitle":4560,"status":107,"phases":4561,"primaryCompletion":4562,"completion":4562,"start":4563,"enrollment":4564,"conditions":4565,"interventions":4566},"NCT00121836","A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer",[92],"2008-12","2005-06",109,[18],[1166,1015],{"nctId":4568,"briefTitle":4569,"status":107,"phases":4570,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":4574,"interventions":4575},"NCT01588990","A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer",[92],"2016-09-15","2012-06-26",128,[4098],[1165,1166,1015,1164,4576,4577],"5-Fluouracil","Irinotecan",{"nctId":4579,"briefTitle":4580,"status":107,"phases":4581,"primaryCompletion":2965,"completion":4582,"start":122,"enrollment":931,"conditions":4583,"interventions":4584},"NCT02582970","A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum",[92],"2008-04",[30],[1597,1015,4577,1165],{"nctId":4586,"briefTitle":4587,"status":107,"phases":4588,"primaryCompletion":4589,"completion":4589,"start":4590,"enrollment":4021,"conditions":4591,"interventions":4592},"NCT01588184","An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche\u002FGenentech Sponsored Study",[92],"2019-09-27","2012-07-13",[1241],[1015],{"nctId":4594,"briefTitle":4595,"status":107,"phases":4596,"primaryCompletion":4597,"completion":4597,"start":4598,"enrollment":1847,"conditions":4599,"interventions":4601},"NCT01932125","An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced\u002FMetastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",[92],"2025-06-18","2018-12-05",[2552,2212,4600],"Fallopian Tube Neoplasms",[1015],{"nctId":4603,"briefTitle":4604,"status":107,"phases":4605,"primaryCompletion":4606,"completion":4607,"start":4608,"enrollment":37,"conditions":4609,"interventions":4610},"NCT01695772","A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer",[92],"2015-04-04","2016-05-12","2012-10-16",[30],[4611,4100],"5-FU based doublet chemotherapy",{"trials":4613,"activeCount":350,"soonestReadout":2025},[4614,4622,4631,4640,4644,4652,4659,4665,4678,4686,4695,4704,4708,4717],{"nctId":4615,"briefTitle":4616,"status":107,"phases":4617,"primaryCompletion":4618,"completion":4618,"start":4619,"enrollment":537,"conditions":4620,"interventions":4621},"NCT02393898","BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older",[],"2019-06-14","2015-04-23",[1417],[1015,990,1106],{"nctId":4623,"briefTitle":4624,"status":107,"phases":4625,"primaryCompletion":4626,"completion":4626,"start":4627,"enrollment":4628,"conditions":4629,"interventions":4630},"NCT01775644","An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)",[],"2019-05-10","2012-12-14",3003,[30],[1015],{"nctId":4632,"briefTitle":4633,"status":107,"phases":4634,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4637,"conditions":4638,"interventions":4639},"NCT01712347","An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer",[],"2016-07-01","2012-10-11",351,[30],[1015,1572],{"nctId":2302,"briefTitle":2303,"status":107,"phases":4641,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":832,"conditions":4642,"interventions":4643},[],[2029],[68,1015],{"nctId":4645,"briefTitle":4646,"status":107,"phases":4647,"primaryCompletion":4648,"completion":4648,"start":4649,"enrollment":2389,"conditions":4650,"interventions":4651},"NCT02613208","A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer",[],"2018-12-03","2015-12-09",[18],[1015,1106],{"nctId":4653,"briefTitle":4654,"status":107,"phases":4655,"primaryCompletion":4454,"completion":4454,"start":3692,"enrollment":4656,"conditions":4657,"interventions":4658},"NCT02596958","Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants",[],996,[2257],[1015],{"nctId":4660,"briefTitle":4661,"status":107,"phases":4662,"primaryCompletion":3007,"completion":3007,"start":4206,"enrollment":496,"conditions":4663,"interventions":4664},"NCT01215123","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer",[],[18],[1015],{"nctId":4666,"briefTitle":4667,"status":107,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":4672,"interventions":4673},"NCT01506167","An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)",[],"2017-03-10","2012-07-06",719,[30],[1015,4674,4675,1166,4676,4677],"Capecitabine\u002FOxaliplatin","Fluorouracil\u002FFolinic Acid\u002FOxaliplatin","Fluorouracil\u002FFolinic Acid\u002FIrinotecan","Fluorouracil +\u002F- Folinic Acid",{"nctId":4679,"briefTitle":4680,"status":107,"phases":4681,"primaryCompletion":4682,"completion":4682,"start":4314,"enrollment":4683,"conditions":4684,"interventions":4685},"NCT01399190","An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer",[],"2014-02",68,[30],[1015,1166,1165],{"nctId":4687,"briefTitle":4688,"status":107,"phases":4689,"primaryCompletion":3182,"completion":3182,"start":121,"enrollment":4690,"conditions":4691,"interventions":4693},"NCT02627144","Bevacizumab in Metastatic Renal Cancer",[],365,[4692],"Renal Cell Cancer",[1015,4694],"Interferon alpha-2a",{"nctId":4696,"briefTitle":4697,"status":107,"phases":4698,"primaryCompletion":4699,"completion":4699,"start":4700,"enrollment":4701,"conditions":4702,"interventions":4703},"NCT01343901","An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases",[],"2015-06-30","2010-09-30",210,[30],[1015],{"nctId":2335,"briefTitle":2336,"status":140,"phases":4705,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":4706,"interventions":4707},[],[18],[1015,1222,2342,1221,68,1166],{"nctId":4709,"briefTitle":4710,"status":107,"phases":4711,"primaryCompletion":3822,"completion":3822,"start":4712,"enrollment":4713,"conditions":4714,"interventions":4716},"NCT02093000","A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma",[],"2014-11-30",201,[4715],"Lung Adenocarcinoma",[1015],{"nctId":4718,"briefTitle":4719,"status":107,"phases":4720,"primaryCompletion":3836,"completion":3836,"start":4721,"enrollment":2839,"conditions":4722,"interventions":4723},"NCT03170284","Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer",[],"2008-06-17",[1316],[1015],{"intervention":1784,"totalTrials":721,"cells":4725},{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4754,"PHASE3":4780,"PHASE4":4801,"NA":4803},{"trials":4727,"activeCount":101},[],{"trials":4729,"activeCount":350,"soonestReadout":2482},[4730,4734,4738,4742,4746,4750],{"nctId":2384,"briefTitle":2385,"status":107,"phases":4731,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":4732,"interventions":4733},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":2396,"briefTitle":2397,"status":107,"phases":4735,"primaryCompletion":2399,"completion":2400,"start":2401,"enrollment":1184,"conditions":4736,"interventions":4737},[89],[1038],[1018,1784,1096],{"nctId":2405,"briefTitle":2406,"status":107,"phases":4739,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":4740,"interventions":4741},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"nctId":2479,"briefTitle":2480,"status":152,"phases":4743,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":37,"conditions":4744,"interventions":4745},[89],[1038],[1784,1096,1018,1163,1165],{"nctId":2528,"briefTitle":2529,"status":130,"phases":4747,"primaryCompletion":2531,"completion":2531,"start":62,"enrollment":2532,"conditions":4748,"interventions":4749},[89],[1196],[2535,1784,1018,1096],{"nctId":2537,"briefTitle":2538,"status":107,"phases":4751,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":4752,"interventions":4753},[89],[2543],[1784,1163,1165,2433,1018,1096],{"trials":4755,"activeCount":942,"soonestReadout":2754},[4756,4760,4764,4768,4772,4776],{"nctId":2661,"briefTitle":2662,"status":140,"phases":4757,"primaryCompletion":2016,"completion":2016,"start":2664,"enrollment":2665,"conditions":4758,"interventions":4759},[89,90],[1196],[2668,1018,1784,1096],{"nctId":2689,"briefTitle":2690,"status":152,"phases":4761,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":4762,"interventions":4763},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"nctId":2716,"briefTitle":2717,"status":140,"phases":4765,"primaryCompletion":2719,"completion":2719,"start":2720,"enrollment":607,"conditions":4766,"interventions":4767},[89,90],[125],[1784,1018,1096],{"nctId":3719,"briefTitle":3720,"status":152,"phases":4769,"primaryCompletion":3722,"completion":2719,"start":1464,"enrollment":1847,"conditions":4770,"interventions":4771},[90],[3724],[1018,1784,1163,1165],{"nctId":2751,"briefTitle":2752,"status":140,"phases":4773,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":4774,"interventions":4775},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"nctId":1775,"briefTitle":1776,"status":140,"phases":4777,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":4778,"interventions":4779},[89,90],[1782],[1784,68,1018,1096,1785,1786],{"trials":4781,"activeCount":706,"soonestReadout":1978},[4782,4793,4797],{"nctId":4783,"briefTitle":4784,"status":140,"phases":4785,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":4790,"interventions":4792},"NCT06047080","An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",[91],"2027-10-01","2030-10-30","2023-09-18",1130,[4791],"Large B-Cell Lymphoma",[1784,2394,1359,992,991,1357],{"nctId":2937,"briefTitle":2938,"status":140,"phases":4794,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":4795,"interventions":4796},[91],[2652],[1018,1784,2736,1096,1163,1165],{"nctId":3011,"briefTitle":3012,"status":152,"phases":4798,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":4799,"interventions":4800},[91],[1038],[1018,1784,1359,1356,2644,1096],{"trials":4802,"activeCount":101},[],{"trials":4804,"activeCount":350,"soonestReadout":4809},[4805],{"nctId":4806,"briefTitle":4807,"status":152,"phases":4808,"primaryCompletion":4809,"completion":4809,"start":4810,"enrollment":4811,"conditions":4812,"interventions":4813},"NCT07200375","An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma",[],"2029-09-29","2025-09-29",300,[3826],[1784],{"intervention":43,"totalTrials":2289,"cells":4815},{"EARLY_PHASE1":4816,"PHASE1":4818,"PHASE2":4847,"PHASE3":4931,"PHASE4":4981,"NA":4983},{"trials":4817,"activeCount":101},[],{"trials":4819,"activeCount":101},[4820,4827,4836,4840],{"nctId":4821,"briefTitle":4822,"status":107,"phases":4823,"primaryCompletion":3197,"completion":3197,"start":3212,"enrollment":145,"conditions":4824,"interventions":4825},"NCT01984229","A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers",[89],[21],[43,4826],"Posaconazole",{"nctId":4828,"briefTitle":4829,"status":107,"phases":4830,"primaryCompletion":4831,"completion":4831,"start":4832,"enrollment":496,"conditions":4833,"interventions":4835},"NCT02621047","Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib",[89],"2016-12-08","2015-12-04",[4834],"Hepatic Impairment",[43],{"nctId":968,"briefTitle":969,"status":107,"phases":4837,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":4838,"interventions":4839},[89],[975],[43,68,977],{"nctId":4841,"briefTitle":4842,"status":107,"phases":4843,"primaryCompletion":3197,"completion":3197,"start":3212,"enrollment":1733,"conditions":4844,"interventions":4845},"NCT02023125","A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.",[89],[21],[43,4846],"Esomeprazole",{"trials":4848,"activeCount":706,"soonestReadout":4893},[4849,4880,4889,4897,4905,4914,4918,4922],{"nctId":4850,"briefTitle":4851,"status":130,"phases":4852,"primaryCompletion":1392,"completion":1392,"start":4853,"enrollment":350,"conditions":4854,"interventions":4879},"NCT04644315","A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",[90],"2021-05-24",[1241,4098,1285,4855,4856,2552,4857,4858,4859,4860,4861,4862,4863,4864,4865,4866,4867,4868,4869,4870,4871,4872,4873,4874,4875,4876,4877,4878],"Pancreatic Neoplasms","Sarcoma","Brain Neoplasms","Thyroid Neoplasms","Neuroendocrine Tumors","Cholangiocarcinoma","Salivary Gland Neoplasms","Head and Neck Neoplasms","Thyroid Cancer, Papillary","Lymphoma, Large-Cell, Anaplastic","Neoplasms by Site","Respiratory Tract Neoplasms","Thoracic Neoplasms","Respiratory Tract Diseases","Carcinoma, Bronchogenic","Bronchial Neoplasms","Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Digestive System Diseases","Gastrointestinal Diseases","Colonic Diseases","Intestinal Diseases","Central Nervous System",[43],{"nctId":4881,"briefTitle":4882,"status":107,"phases":4883,"primaryCompletion":4884,"completion":4884,"start":4885,"enrollment":4886,"conditions":4887,"interventions":4888},"NCT03155009","A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer",[90],"2019-09-26","2017-07-10",44,[1316],[43],{"nctId":4890,"briefTitle":4891,"status":140,"phases":4892,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":2563,"conditions":4895,"interventions":4896},"NCT06624059","A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)",[89,90],"2026-08-28","2024-11-18",[975],[43,1167,990,1319],{"nctId":4898,"briefTitle":4899,"status":107,"phases":4900,"primaryCompletion":4901,"completion":3904,"start":4902,"enrollment":19,"conditions":4903,"interventions":4904},"NCT01871805","A Study of Alectinib (CH5424802\u002FRO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)",[89,90],"2014-10-24","2013-09-30",[975],[43],{"nctId":4906,"briefTitle":4907,"status":152,"phases":4908,"primaryCompletion":4909,"completion":4909,"start":4910,"enrollment":1733,"conditions":4911,"interventions":4913},"NCT04774718","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors",[89,90],"2032-02-28","2021-09-14",[4912],"ALK Fusion-positive Solid or CNS Tumors",[43],{"nctId":1687,"briefTitle":1688,"status":140,"phases":4915,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":4916,"interventions":4917},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"nctId":1760,"briefTitle":1761,"status":107,"phases":4919,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":4920,"interventions":4921},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"nctId":4923,"briefTitle":4924,"status":107,"phases":4925,"primaryCompletion":4901,"completion":4926,"start":4927,"enrollment":897,"conditions":4928,"interventions":4930},"NCT01801111","A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment",[89,90],"2017-10-27","2013-06-20",[4929],"Non-Small-Cell Lung Carcinoma",[977,43],{"trials":4932,"activeCount":2631,"soonestReadout":42},[4933,4941,4949,4958,4965,4969,4973],{"nctId":4934,"briefTitle":4935,"status":140,"phases":4936,"primaryCompletion":4937,"completion":4937,"start":1508,"enrollment":2708,"conditions":4938,"interventions":4939},"NCT03194893","A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer",[91],"2026-05-30",[1241],[43,4940],"Crizotinib",{"nctId":4942,"briefTitle":4943,"status":140,"phases":4944,"primaryCompletion":4945,"completion":4945,"start":4946,"enrollment":4683,"conditions":4947,"interventions":4948},"NCT05170204","A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)",[91],"2030-06-16","2022-11-01",[975],[43,1695,1948],{"nctId":4950,"briefTitle":4951,"status":107,"phases":4952,"primaryCompletion":4953,"completion":4954,"start":4955,"enrollment":1651,"conditions":4956,"interventions":4957},"NCT02604342","Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib",[91],"2017-01-26","2018-08-13","2015-11-03",[1684],[43,947,1319],{"nctId":40,"briefTitle":41,"status":140,"phases":4959,"primaryCompletion":42,"completion":2025,"start":4960,"enrollment":4961,"conditions":4962,"interventions":4964},[91],"2016-08-03",187,[4963],"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer",[43,4940],{"nctId":1959,"briefTitle":1960,"status":140,"phases":4966,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":4967,"interventions":4968},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":2144,"briefTitle":2145,"status":140,"phases":4970,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":4971,"interventions":4972},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":4974,"briefTitle":4975,"status":107,"phases":4976,"primaryCompletion":4977,"completion":2483,"start":4978,"enrollment":3856,"conditions":4979,"interventions":4980},"NCT02075840","A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants",[91],"2017-02-09","2014-08-19",[975],[43,4940],{"trials":4982,"activeCount":101},[],{"trials":4984,"activeCount":162,"soonestReadout":4989},[4985,4995,5003],{"nctId":4986,"briefTitle":4987,"status":140,"phases":4988,"primaryCompletion":4989,"completion":4989,"start":4990,"enrollment":4991,"conditions":4992,"interventions":4994},"NCT04764188","An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib",[],"2027-05-10","2021-05-10",800,[4993],"NSCLC",[43],{"nctId":4996,"briefTitle":4997,"status":152,"phases":4998,"primaryCompletion":4999,"completion":815,"start":5000,"enrollment":4991,"conditions":5001,"interventions":5002},"NCT06862869","Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy",[],"2028-10-30","2025-04-30",[1316],[43],{"nctId":5004,"briefTitle":5005,"status":107,"phases":5006,"primaryCompletion":5007,"completion":5007,"start":5008,"enrollment":5009,"conditions":5010,"interventions":5011},"NCT03271554","Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea",[],"2021-05-28","2017-11-09",355,[975],[43],{"intervention":988,"totalTrials":5013,"cells":5014},31,{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5027,"PHASE3":5111,"PHASE4":5153,"NA":5155},{"trials":5016,"activeCount":101},[],{"trials":5018,"activeCount":350,"soonestReadout":1131},[5019,5023],{"nctId":979,"briefTitle":980,"status":107,"phases":5020,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":5021,"interventions":5022},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"nctId":1128,"briefTitle":1129,"status":152,"phases":5024,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":5025,"interventions":5026},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"trials":5028,"activeCount":5110,"soonestReadout":1721},[5029,5033,5037,5041,5045,5049,5058,5062,5066,5070,5074,5078,5082,5086,5090,5094,5098,5102,5106],{"nctId":1277,"briefTitle":1278,"status":107,"phases":5030,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":5031,"interventions":5032},[89,90],[1285],[1287,1017,1288,68,988,1289],{"nctId":1308,"briefTitle":1309,"status":130,"phases":5034,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":5035,"interventions":5036},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1326,"briefTitle":1327,"status":130,"phases":5038,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":306,"conditions":5039,"interventions":5040},[89,90],[1332],[1334,988,68],{"nctId":1361,"briefTitle":1362,"status":107,"phases":5042,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":709,"conditions":5043,"interventions":5044},[89,90],[1367],[68,988,990,1106],{"nctId":1436,"briefTitle":1437,"status":107,"phases":5046,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":447,"conditions":5047,"interventions":5048},[89,90],[1443],[68,1015,988,1445],{"nctId":5050,"briefTitle":5051,"status":140,"phases":5052,"primaryCompletion":1962,"completion":1962,"start":5053,"enrollment":5054,"conditions":5055,"interventions":5056},"NCT05805501","A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",[90],"2023-04-21",199,[1049],[1445,988,1957,5057],"Axitinib",{"nctId":1461,"briefTitle":1462,"status":130,"phases":5059,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":5060,"interventions":5061},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":1481,"briefTitle":1482,"status":130,"phases":5063,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":931,"conditions":5064,"interventions":5065},[89,90],[1487],[68,1166,1165,988],{"nctId":1504,"briefTitle":1505,"status":107,"phases":5067,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":5068,"interventions":5069},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1530,"briefTitle":1531,"status":107,"phases":5071,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":5072,"interventions":5073},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"nctId":1544,"briefTitle":1545,"status":107,"phases":5075,"primaryCompletion":1547,"completion":1439,"start":593,"enrollment":1548,"conditions":5076,"interventions":5077},[90],[1550],[68,988],{"nctId":1579,"briefTitle":1580,"status":140,"phases":5079,"primaryCompletion":1582,"completion":1582,"start":1474,"enrollment":1583,"conditions":5080,"interventions":5081},[90],[1585],[68,1445,988],{"nctId":1588,"briefTitle":1589,"status":107,"phases":5083,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":5084,"interventions":5085},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":1639,"briefTitle":1640,"status":343,"phases":5087,"primaryCompletion":1642,"completion":1643,"start":1644,"enrollment":101,"conditions":5088,"interventions":5089},[90],[922],[68,988],{"nctId":1655,"briefTitle":1656,"status":107,"phases":5091,"primaryCompletion":1658,"completion":1659,"start":1660,"enrollment":1661,"conditions":5092,"interventions":5093},[90],[1663],[988,68],{"nctId":1710,"briefTitle":1711,"status":130,"phases":5095,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":425,"conditions":5096,"interventions":5097},[90],[1274],[68,988],{"nctId":1718,"briefTitle":1719,"status":140,"phases":5099,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":5100,"interventions":5101},[90],[1726,1727],[1166,1513,68,988],{"nctId":1739,"briefTitle":1740,"status":152,"phases":5103,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":5104,"interventions":5105},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"nctId":1788,"briefTitle":1789,"status":130,"phases":5107,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1174,"conditions":5108,"interventions":5109},[90],[1794,1735,1736],[68,988,1165,1166],4,{"trials":5112,"activeCount":5110,"soonestReadout":2187},[5113,5117,5121,5125,5129,5133,5137,5141,5145,5149],{"nctId":1867,"briefTitle":1868,"status":107,"phases":5114,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":1872,"conditions":5115,"interventions":5116},[91],[975],[68,988],{"nctId":1920,"briefTitle":1921,"status":107,"phases":5118,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":5119,"interventions":5120},[91],[1071],[988,68,990,1074],{"nctId":1940,"briefTitle":1941,"status":107,"phases":5122,"primaryCompletion":1943,"completion":1924,"start":1944,"enrollment":1945,"conditions":5123,"interventions":5124},[91],[1432],[68,988,1948],{"nctId":1950,"briefTitle":1951,"status":107,"phases":5126,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":5127,"interventions":5128},[90,91],[1432],[988,68,1319,990,1167,1957],{"nctId":1994,"briefTitle":1995,"status":107,"phases":5130,"primaryCompletion":1997,"completion":1997,"start":1998,"enrollment":1272,"conditions":5131,"interventions":5132},[91],[1432],[68,988],{"nctId":2013,"briefTitle":2014,"status":140,"phases":5134,"primaryCompletion":2016,"completion":2016,"start":983,"enrollment":2017,"conditions":5135,"interventions":5136},[91],[2019],[988,68],{"nctId":2073,"briefTitle":2074,"status":107,"phases":5138,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":5139,"interventions":5140},[91],[2081],[68,988,1106,1167],{"nctId":2184,"briefTitle":2185,"status":140,"phases":5142,"primaryCompletion":2187,"completion":2025,"start":2188,"enrollment":1548,"conditions":5143,"interventions":5144},[91],[2038],[988,68,990,1074],{"nctId":2242,"briefTitle":2243,"status":152,"phases":5146,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":5147,"interventions":5148},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"nctId":2260,"briefTitle":2261,"status":140,"phases":5150,"primaryCompletion":2263,"completion":2264,"start":2265,"enrollment":2266,"conditions":5151,"interventions":5152},[91],[2047],[68,1015,988],{"trials":5154,"activeCount":101},[],{"trials":5156,"activeCount":101},[],{"intervention":1319,"totalTrials":145,"cells":5158},{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5163,"PHASE3":5209,"PHASE4":5327,"NA":5329},{"trials":5160,"activeCount":101},[],{"trials":5162,"activeCount":101},[],{"trials":5164,"activeCount":706,"soonestReadout":5192},[5165,5169,5177,5188,5197,5201,5205],{"nctId":1308,"briefTitle":1309,"status":130,"phases":5166,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":5167,"interventions":5168},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":5170,"briefTitle":5171,"status":152,"phases":5172,"primaryCompletion":795,"completion":795,"start":5173,"enrollment":5174,"conditions":5175,"interventions":5176},"NCT05789082","A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",[89,90],"2023-06-20",320,[975],[1140,1957,990,1167,1319],{"nctId":5178,"briefTitle":5179,"status":107,"phases":5180,"primaryCompletion":3146,"completion":3146,"start":5181,"enrollment":2743,"conditions":5182,"interventions":5183},"NCT01185847","A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer",[90],"2010-11",[2257],[5184,5185,5186,5187],"RO5083945","cisplatin","gemcitabine","pemetrexed",{"nctId":5189,"briefTitle":5190,"status":140,"phases":5191,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":3015,"conditions":5195,"interventions":5196},"NCT05775289","A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer",[90],"2024-06-20","2026-06-01","2023-03-15",[1684],[1445,1957,1106,1319,990],{"nctId":1461,"briefTitle":1462,"status":130,"phases":5198,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":5199,"interventions":5200},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":4890,"briefTitle":4891,"status":140,"phases":5202,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":2563,"conditions":5203,"interventions":5204},[89,90],[975],[43,1167,990,1319],{"nctId":1620,"briefTitle":1621,"status":343,"phases":5206,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":5207,"interventions":5208},[90],[1627],[68,990,1167,1319,1163,1106],{"trials":5210,"activeCount":942,"soonestReadout":5280},[5211,5215,5219,5223,5227,5231,5235,5239,5250,5259,5263,5267,5276,5287,5298,5317],{"nctId":1825,"briefTitle":1826,"status":140,"phases":5212,"primaryCompletion":690,"completion":690,"start":1714,"enrollment":1001,"conditions":5213,"interventions":5214},[91],[1241],[68,1015,1319,1106,1830],{"nctId":4384,"briefTitle":4385,"status":107,"phases":5216,"primaryCompletion":4387,"completion":4387,"start":4388,"enrollment":4389,"conditions":5217,"interventions":5218},[91],[2257],[1015,947,977,1319],{"nctId":4950,"briefTitle":4951,"status":107,"phases":5220,"primaryCompletion":4953,"completion":4954,"start":4955,"enrollment":1651,"conditions":5221,"interventions":5222},[91],[1684],[43,947,1319],{"nctId":1930,"briefTitle":1931,"status":107,"phases":5224,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":5225,"interventions":5226},[91],[1316],[68,1015,1106,1319,990],{"nctId":1950,"briefTitle":1951,"status":107,"phases":5228,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":5229,"interventions":5230},[90,91],[1432],[988,68,1319,990,1167,1957],{"nctId":1959,"briefTitle":1960,"status":140,"phases":5232,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":5233,"interventions":5234},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":1974,"briefTitle":1975,"status":140,"phases":5236,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":5237,"interventions":5238},[91],[975],[68,1167,1983,947,1163,1319],{"nctId":5240,"briefTitle":5241,"status":107,"phases":5242,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":5247,"interventions":5249},"NCT03456063","A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)",[91],"2025-10-01","2025-12-31","2018-04-24",453,[5248],"Non-Small-Cell Lung",[4468,989,1319,990,1167,1163],{"nctId":5251,"briefTitle":5252,"status":107,"phases":5253,"primaryCompletion":2007,"completion":1691,"start":5254,"enrollment":5255,"conditions":5256,"interventions":5258},"NCT02367781","A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",[91],"2015-04-16",723,[5257],"Carcinoma, Non-Squamous Non-Small Cell Lung",[4468,990,1107,1319],{"nctId":2134,"briefTitle":2135,"status":107,"phases":5260,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":2140,"conditions":5261,"interventions":5262},[91],[975],[68,990,1167,1319],{"nctId":2144,"briefTitle":2145,"status":140,"phases":5264,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":5265,"interventions":5266},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":5268,"briefTitle":5269,"status":107,"phases":5270,"primaryCompletion":2931,"completion":2931,"start":5271,"enrollment":5272,"conditions":5273,"interventions":5274},"NCT00961415","AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer",[91],"2009-08",376,[2257],[5275,5185,5187],"bevacizumab [Avastin]",{"nctId":5277,"briefTitle":5278,"status":140,"phases":5279,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":5284,"interventions":5285},"NCT03456076","A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer",[91],"2023-06-26","2031-11-19","2018-08-16",257,[1316],[5286,1167,1983,1163,1319,990],"Alectnib",{"nctId":5288,"briefTitle":5289,"status":107,"phases":5290,"primaryCompletion":1925,"completion":5291,"start":5292,"enrollment":5293,"conditions":5294,"interventions":5296},"NCT02409342","A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]",[91],"2022-03-08","2015-07-20",572,[5295],"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer",[5297,990,1167,1163,1319],"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody",{"nctId":5299,"briefTitle":5300,"status":130,"phases":5301,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":5305,"interventions":5316},"NCT04222972","A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)",[91],"2025-01-27","2020-07-24",223,[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],"RET-fusion Non Small Cell Lung Cancer","Lung Neoplasm","Lung Diseases","Respiratory Tract Disease","Bronchial Diseases","Adenocarcinoma","Carcinoma","Neoplasms by Histologic Type","Neoplasms, Germ Cell and Embryonal","Neoplasms, Nerve Tissue",[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":5318,"briefTitle":5319,"status":152,"phases":5320,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":3996,"conditions":5324,"interventions":5326},"NCT06793215","A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",[91],"2028-11-30","2030-10-31","2025-10-24",[975,5325],"KRAS G12C Lung Cancer",[1140,1957,1319,990,1167],{"trials":5328,"activeCount":101},[],{"trials":5330,"activeCount":101},[],{"intervention":990,"totalTrials":3574,"cells":5332},{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5391,"PHASE3":5481,"PHASE4":5620,"NA":5630},{"trials":5334,"activeCount":101},[],{"trials":5336,"activeCount":101},[5337,5341,5345,5349,5360,5368,5372],{"nctId":2405,"briefTitle":2406,"status":107,"phases":5338,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":5339,"interventions":5340},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"nctId":979,"briefTitle":980,"status":107,"phases":5342,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":5343,"interventions":5344},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"nctId":1065,"briefTitle":1066,"status":130,"phases":5346,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":162,"conditions":5347,"interventions":5348},[89],[1071],[1073,68,990,1074],{"nctId":5350,"briefTitle":5351,"status":107,"phases":5352,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":5356,"interventions":5358},"NCT05240898","A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors",[89],"2025-11-26","2021-08-26",116,[5357],"Advanced Solid Tumors",[5359,1423,990],"RO7623066",{"nctId":5361,"briefTitle":5362,"status":343,"phases":5363,"primaryCompletion":2602,"completion":2602,"start":5364,"enrollment":101,"conditions":5365,"interventions":5366},"NCT01702714","A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease",[89],"2014-07",[2257],[5184,5367,5185,5186,4503],"carboplatin",{"nctId":1210,"briefTitle":1211,"status":107,"phases":5369,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":5370,"interventions":5371},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"nctId":5373,"briefTitle":5374,"status":130,"phases":5375,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":5377,"interventions":5378},"NCT00811993","A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors",[89],104,[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],"RG1507","RO1507","capecitabine [Xeloda]","cetuximab","docetaxel","erlotinib [Tarceva]","etoposide","mFOLFOX6","pemetrexel","sorafenib","temozolomide","trastuzumab [Herceptin]",{"trials":5392,"activeCount":5110,"soonestReadout":5192},[5393,5397,5401,5405,5409,5413,5423,5427,5431,5435,5439,5445,5449,5453,5461,5465,5473,5477],{"nctId":1266,"briefTitle":1267,"status":107,"phases":5394,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":5395,"interventions":5396},[90],[1274],[68,1167,990,1074],{"nctId":4074,"briefTitle":4075,"status":107,"phases":5398,"primaryCompletion":3285,"completion":4077,"start":4078,"enrollment":4079,"conditions":5399,"interventions":5400},[90],[1417],[1015,1106,990],{"nctId":1308,"briefTitle":1309,"status":130,"phases":5402,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":5403,"interventions":5404},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1361,"briefTitle":1362,"status":107,"phases":5406,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":709,"conditions":5407,"interventions":5408},[89,90],[1367],[68,988,990,1106],{"nctId":5170,"briefTitle":5171,"status":152,"phases":5410,"primaryCompletion":795,"completion":795,"start":5173,"enrollment":5174,"conditions":5411,"interventions":5412},[89,90],[975],[1140,1957,990,1167,1319],{"nctId":5414,"briefTitle":5415,"status":130,"phases":5416,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":709,"conditions":5419,"interventions":5421},"NCT02204345","A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology",[89,90],"2016-03","2014-10",[5420],"Squamous Non-Small Cell Lung Cancer",[990,1106,5422],"RO5479599",{"nctId":5189,"briefTitle":5190,"status":140,"phases":5424,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":3015,"conditions":5425,"interventions":5426},[90],[1684],[1445,1957,1106,1319,990],{"nctId":1461,"briefTitle":1462,"status":130,"phases":5428,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":5429,"interventions":5430},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":4890,"briefTitle":4891,"status":140,"phases":5432,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":2563,"conditions":5433,"interventions":5434},[89,90],[975],[43,1167,990,1319],{"nctId":2689,"briefTitle":2690,"status":152,"phases":5436,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":5437,"interventions":5438},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"nctId":5440,"briefTitle":5441,"status":107,"phases":5442,"primaryCompletion":2809,"completion":2809,"start":4322,"enrollment":1352,"conditions":5443,"interventions":5444},"NCT00800202","A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis",[90],[975],[5275,5367,5384,4503],{"nctId":4229,"briefTitle":4230,"status":107,"phases":5446,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":931,"conditions":5447,"interventions":5448},[90],[18],[1015,990,1163],{"nctId":4253,"briefTitle":4254,"status":107,"phases":5450,"primaryCompletion":1192,"completion":3592,"start":4256,"enrollment":806,"conditions":5451,"interventions":5452},[90],[1663],[1015,990,1106],{"nctId":5454,"briefTitle":5455,"status":107,"phases":5456,"primaryCompletion":2685,"completion":2685,"start":5457,"enrollment":5458,"conditions":5459,"interventions":5460},"NCT01998919","A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.",[90],"2006-08",154,[975],[5384,5186,5185,5367],{"nctId":1620,"briefTitle":1621,"status":343,"phases":5462,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":5463,"interventions":5464},[90],[1627],[68,990,1167,1319,1163,1106],{"nctId":5466,"briefTitle":5467,"status":107,"phases":5468,"primaryCompletion":4113,"completion":4113,"start":5469,"enrollment":2524,"conditions":5470,"interventions":5471},"NCT02004093","A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer",[90],"2005-12",[1417],[5472,4503,5186,5367],"pertuzumab",{"nctId":4294,"briefTitle":4295,"status":107,"phases":5474,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":559,"conditions":5475,"interventions":5476},[90],[1417],[990,1106,1015],{"nctId":1760,"briefTitle":1761,"status":107,"phases":5478,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":5479,"interventions":5480},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":5482,"activeCount":2631,"soonestReadout":5280},[5483,5487,5491,5495,5499,5509,5513,5517,5521,5530,5534,5538,5542,5551,5555,5559,5563,5567,5577,5581,5585,5589,5593,5597,5601,5605,5609],{"nctId":4352,"briefTitle":4353,"status":107,"phases":5484,"primaryCompletion":4355,"completion":4356,"start":4357,"enrollment":4358,"conditions":5485,"interventions":5486},[91],[975],[1015,990,1106],{"nctId":1859,"briefTitle":1860,"status":130,"phases":5488,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":306,"conditions":5489,"interventions":5490},[91],[975],[68,990,1167,1163],{"nctId":1920,"briefTitle":1921,"status":107,"phases":5492,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":5493,"interventions":5494},[91],[1071],[988,68,990,1074],{"nctId":1930,"briefTitle":1931,"status":107,"phases":5496,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":5497,"interventions":5498},[91],[1316],[68,1015,1106,1319,990],{"nctId":5500,"briefTitle":5501,"status":107,"phases":5502,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":5506,"interventions":5507},"NCT01964391","A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer",[91],"2016-12-22","2018-11-25","2014-02-21",[18],[1222,991,992,1106,947,990,5508],"Neo-adjuvant chemotherapy",{"nctId":1950,"briefTitle":1951,"status":107,"phases":5510,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":5511,"interventions":5512},[90,91],[1432],[988,68,1319,990,1167,1957],{"nctId":1959,"briefTitle":1960,"status":140,"phases":5514,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":5515,"interventions":5516},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":4420,"briefTitle":4421,"status":107,"phases":5518,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":1847,"conditions":5519,"interventions":5520},[91],[1417,2211,4427],[1106,1015,990],{"nctId":5522,"briefTitle":5523,"status":107,"phases":5524,"primaryCompletion":5245,"completion":5525,"start":5526,"enrollment":5527,"conditions":5528,"interventions":5529},"NCT02763579","A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)",[91],"2022-07-07","2016-06-07",503,[2038],[4468,990,1074],{"nctId":5240,"briefTitle":5241,"status":107,"phases":5531,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":5532,"interventions":5533},[91],[5248],[4468,989,1319,990,1167,1163],{"nctId":2033,"briefTitle":2034,"status":107,"phases":5535,"primaryCompletion":2036,"completion":2036,"start":110,"enrollment":1259,"conditions":5536,"interventions":5537},[91],[2038],[68,990,1074],{"nctId":2051,"briefTitle":2052,"status":140,"phases":5539,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":2057,"conditions":5540,"interventions":5541},[91],[2059],[68,2061,990,1074],{"nctId":5543,"briefTitle":5544,"status":107,"phases":5545,"primaryCompletion":1214,"completion":5546,"start":5547,"enrollment":5548,"conditions":5549,"interventions":5550},"NCT02131064","A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",[91],"2018-05-29","2014-06-25",444,[4139],[990,947,1221,1222,1419],{"nctId":4470,"briefTitle":4471,"status":107,"phases":5552,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":4475,"conditions":5553,"interventions":5554},[91],[1417],[1106,1015,990],{"nctId":2103,"briefTitle":2104,"status":107,"phases":5556,"primaryCompletion":2106,"completion":2106,"start":534,"enrollment":2107,"conditions":5557,"interventions":5558},[91],[2109],[68,1163,1166,990],{"nctId":5251,"briefTitle":5252,"status":107,"phases":5560,"primaryCompletion":2007,"completion":1691,"start":5254,"enrollment":5255,"conditions":5561,"interventions":5562},[91],[5257],[4468,990,1107,1319],{"nctId":2134,"briefTitle":2135,"status":107,"phases":5564,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":2140,"conditions":5565,"interventions":5566},[91],[975],[68,990,1167,1319],{"nctId":5568,"briefTitle":5569,"status":107,"phases":5570,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":4475,"conditions":5574,"interventions":5575},"NCT02367794","A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]",[91],"2018-10-03","2021-02-17","2015-06-11",[5420],[5576,990,1107,1106],"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody",{"nctId":2175,"briefTitle":2176,"status":107,"phases":5578,"primaryCompletion":1383,"completion":2178,"start":2179,"enrollment":2180,"conditions":5579,"interventions":5580},[91],[1538],[68,990,1163,1167],{"nctId":5277,"briefTitle":5278,"status":140,"phases":5582,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":5583,"interventions":5584},[91],[1316],[5286,1167,1983,1163,1319,990],{"nctId":2184,"briefTitle":2185,"status":140,"phases":5586,"primaryCompletion":2187,"completion":2025,"start":2188,"enrollment":1548,"conditions":5587,"interventions":5588},[91],[2038],[988,68,990,1074],{"nctId":5288,"briefTitle":5289,"status":107,"phases":5590,"primaryCompletion":1925,"completion":5291,"start":5292,"enrollment":5293,"conditions":5591,"interventions":5592},[91],[5295],[5297,990,1167,1163,1319],{"nctId":5299,"briefTitle":5300,"status":130,"phases":5594,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":5595,"interventions":5596},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":2203,"briefTitle":2204,"status":107,"phases":5598,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":5599,"interventions":5600},[91],[1417,2211,2212],[1106,990,68,1015,2093],{"nctId":4523,"briefTitle":4524,"status":107,"phases":5602,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":4529,"conditions":5603,"interventions":5604},[91],[1316],[4468,1015,990,1106],{"nctId":5318,"briefTitle":5319,"status":152,"phases":5606,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":3996,"conditions":5607,"interventions":5608},[91],[975,5325],[1140,1957,1319,990,1167],{"nctId":5610,"briefTitle":5611,"status":107,"phases":5612,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":5617,"interventions":5618},"NCT01358877","A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer",[91],"2016-12-19","2024-11-28","2011-11-08",4804,[18],[1597,990,992,947,991,5619,1106,1221,1222],"Epirubicin",{"trials":5621,"activeCount":101},[5622],{"nctId":5623,"briefTitle":5624,"status":107,"phases":5625,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":5628,"interventions":5629},"NCT02419742","Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen",[92],"2021-06-24","2015-08-18",[18],[990,992,947,991,1106,1222],{"trials":5631,"activeCount":101},[5632],{"nctId":4615,"briefTitle":4616,"status":107,"phases":5633,"primaryCompletion":4618,"completion":4618,"start":4619,"enrollment":537,"conditions":5634,"interventions":5635},[],[1417],[1015,990,1106],{"intervention":63,"totalTrials":1796,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5679,"PHASE4":5725,"NA":5727},{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":5110,"soonestReadout":62},[5644,5648,5658,5662,5671],{"nctId":1410,"briefTitle":1411,"status":140,"phases":5645,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":5646,"interventions":5647},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":5649,"briefTitle":5650,"status":107,"phases":5651,"primaryCompletion":5652,"completion":2363,"start":5653,"enrollment":11,"conditions":5654,"interventions":5656},"NCT04436744","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)",[90],"2021-07-06","2020-09-04",[5655],"Early Breast Cancer",[63,5657,1421],"Anastrozole",{"nctId":1447,"briefTitle":1448,"status":152,"phases":5659,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":5660,"interventions":5661},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":60,"briefTitle":61,"status":140,"phases":5663,"primaryCompletion":62,"completion":5664,"start":5665,"enrollment":3856,"conditions":5666,"interventions":5668},[90],"2027-08-25","2020-11-27",[5667],"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer",[63,5669,5670],"Fulvestrant or an Aromatase Inhibitor","LHRH Agonist",{"nctId":5672,"briefTitle":5673,"status":140,"phases":5674,"primaryCompletion":4893,"completion":4893,"start":5675,"enrollment":1184,"conditions":5676,"interventions":5678},"NCT05634499","A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer",[90],"2023-06-27",[5677],"Endometrial Cancer",[63],{"trials":5680,"activeCount":5110,"soonestReadout":5685},[5681,5692,5702,5715],{"nctId":5682,"briefTitle":5683,"status":140,"phases":5684,"primaryCompletion":5685,"completion":5686,"start":5687,"enrollment":5688,"conditions":5689,"interventions":5690},"NCT04961996","A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",[91],"2025-08-08","2033-09-30","2021-08-27",4170,[5655],[63,5691,5670],"Physician's Choice of Endocrine Therapy",{"nctId":5693,"briefTitle":5694,"status":152,"phases":5695,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":5699,"interventions":5701},"NCT06065748","A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4\u002F6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",[91],"2027-02-19","2029-02-12",1050,[5700],"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",[63,1573,1420,1421,1456,5670],{"nctId":5703,"briefTitle":5704,"status":140,"phases":5705,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":5710,"interventions":5712},"NCT04546009","A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",[91],"2026-01-30","2028-03-25","2020-10-09",992,[5711],"Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",[63,5713,1422,5714,1421,5670],"Giredestrant-matched Placebo","Letrozole-matched Placebo",{"nctId":5716,"briefTitle":5717,"status":140,"phases":5718,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":5722,"interventions":5724},"NCT05296798","A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)",[91],"2027-10-31","2022-07-18",922,[5723],"Locally Advanced or Metastatic Breast Cancer",[3426,63,947,1106,5670,3428],{"trials":5726,"activeCount":101},[],{"trials":5728,"activeCount":101},[],{"intervention":1140,"totalTrials":306,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5739,"PHASE3":5749,"PHASE4":5781,"NA":5783},{"trials":5732,"activeCount":101},[],{"trials":5734,"activeCount":350,"soonestReadout":1131},[5735],{"nctId":1128,"briefTitle":1129,"status":152,"phases":5736,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":5737,"interventions":5738},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"trials":5740,"activeCount":162,"soonestReadout":795},[5741,5745],{"nctId":5170,"briefTitle":5171,"status":152,"phases":5742,"primaryCompletion":795,"completion":795,"start":5173,"enrollment":5174,"conditions":5743,"interventions":5744},[89,90],[975],[1140,1957,990,1167,1319],{"nctId":1687,"briefTitle":1688,"status":140,"phases":5746,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":5747,"interventions":5748},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"trials":5750,"activeCount":2631,"soonestReadout":1962},[5751,5755,5763,5773,5777],{"nctId":1959,"briefTitle":1960,"status":140,"phases":5752,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":5753,"interventions":5754},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":5756,"briefTitle":5757,"status":3955,"phases":5758,"primaryCompletion":5759,"completion":5760,"start":2264,"enrollment":4013,"conditions":5761,"interventions":5762},"NCT07541170","A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)",[91],"2032-01-31","2035-03-31",[1684],[1140,1957,1287],{"nctId":5764,"briefTitle":5765,"status":140,"phases":5766,"primaryCompletion":1743,"completion":2692,"start":5767,"enrollment":5768,"conditions":5769,"interventions":5770},"NCT06497556","A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer",[91],"2024-09-23",338,[975,5325],[1140,5771,5772],"Sotorasib","Adagrasib",{"nctId":5318,"briefTitle":5319,"status":152,"phases":5774,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":3996,"conditions":5775,"interventions":5776},[91],[975,5325],[1140,1957,1319,990,1167],{"nctId":2242,"briefTitle":2243,"status":152,"phases":5778,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":5779,"interventions":5780},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"trials":5782,"activeCount":101},[],{"trials":5784,"activeCount":101},[],{"intervention":274,"totalTrials":510,"cells":5786},{"EARLY_PHASE1":5787,"PHASE1":5789,"PHASE2":5791,"PHASE3":5810,"PHASE4":5867,"NA":5915},{"trials":5788,"activeCount":101},[],{"trials":5790,"activeCount":101},[],{"trials":5792,"activeCount":350,"soonestReadout":3703},[5793,5797,5801],{"nctId":3589,"briefTitle":3590,"status":107,"phases":5794,"primaryCompletion":3592,"completion":3593,"start":3594,"enrollment":3595,"conditions":5795,"interventions":5796},[90],[3597],[3599,1018,274,1357],{"nctId":3700,"briefTitle":3701,"status":152,"phases":5798,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":5799,"interventions":5800},[90],[3597],[1018,3707,3708,3709,274,1357],{"nctId":5802,"briefTitle":5803,"status":107,"phases":5804,"primaryCompletion":2948,"completion":2948,"start":5805,"enrollment":5806,"conditions":5807,"interventions":5808},"NCT02093026","Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)",[90],"2002-08",465,[15],[1359,2824,274,5809],"Folic Acid",{"trials":5811,"activeCount":942,"soonestReadout":1364},[5812,5816,5825,5829,5840,5851,5855,5859,5863],{"nctId":3745,"briefTitle":3746,"status":140,"phases":5813,"primaryCompletion":1534,"completion":3748,"start":3749,"enrollment":3750,"conditions":5814,"interventions":5815},[91],[3752],[1018,3754,274,3755,2579],{"nctId":5817,"briefTitle":5818,"status":107,"phases":5819,"primaryCompletion":3084,"completion":4445,"start":5820,"enrollment":5821,"conditions":5822,"interventions":5823},"NCT00578305","A Study of Rituximab (MabThera®\u002FRituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate",[91],"2007-11",185,[15],[1359,274,2824,5824],"Folic acid or folate",{"nctId":3766,"briefTitle":3767,"status":140,"phases":5826,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":5827,"interventions":5828},[91],[3771],[1018,3773,1357,274,3774,3775],{"nctId":5830,"briefTitle":5831,"status":107,"phases":5832,"primaryCompletion":5833,"completion":5833,"start":5834,"enrollment":2619,"conditions":5835,"interventions":5836},"NCT02006706","A Study of MabThera\u002FRituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy",[91],"2007-11-23","2006-08-10",[15],[5837,5838,5839],"rituximab [MabThera\u002FRituxan]","methotrexate","methylprednisolone",{"nctId":5841,"briefTitle":5842,"status":107,"phases":5843,"primaryCompletion":3325,"completion":3325,"start":4282,"enrollment":5844,"conditions":5845,"interventions":5847},"NCT02005562","OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.",[91],252,[5846],"Kidney Transplantation",[5848,5848,5849,5839,5850],"mycophenolate mofetil","anti-IL-2R","cyclosporine",{"nctId":3809,"briefTitle":3810,"status":140,"phases":5852,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":5853,"interventions":5854},[91],[3597],[1018,3773,1357,274,3755,2579],{"nctId":264,"briefTitle":265,"status":140,"phases":5856,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":5857,"interventions":5858},[91],[147],[96,96,273,274],{"nctId":3851,"briefTitle":3852,"status":140,"phases":5860,"primaryCompletion":3854,"completion":3855,"start":2540,"enrollment":3856,"conditions":5861,"interventions":5862},[91],[2621],[1018,3859,3709,274],{"nctId":297,"briefTitle":298,"status":140,"phases":5864,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":5865,"interventions":5866},[91],[147],[96,96,273,274],{"trials":5868,"activeCount":101},[5869,5878,5887,5895,5904],{"nctId":5870,"briefTitle":5871,"status":107,"phases":5872,"primaryCompletion":5873,"completion":5873,"start":3823,"enrollment":4637,"conditions":5874,"interventions":5875},"NCT01382940","A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis",[92],"2013-01-06",[15],[3677,5838,5839,5876,5877],"acetaminophen","antihistamine",{"nctId":5879,"briefTitle":5880,"status":107,"phases":5881,"primaryCompletion":5882,"completion":5882,"start":5883,"enrollment":1184,"conditions":5884,"interventions":5886},"NCT02115997","A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis",[92],"2022-06-07","2015-07-06",[5885],"Wegener's Granulomatosis or Microscopic Polyangiitis",[274,1357,1359],{"nctId":5888,"briefTitle":5889,"status":107,"phases":5890,"primaryCompletion":3674,"completion":3674,"start":5891,"enrollment":4683,"conditions":5892,"interventions":5893},"NCT01219933","A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra\u002FActemra (Tocilizumab) (ACT-ALONE)",[92],"2011-01",[15],[5839,5894],"tocilizumab [RoActemra\u002FActemra]",{"nctId":5896,"briefTitle":5897,"status":107,"phases":5898,"primaryCompletion":5899,"completion":5899,"start":5900,"enrollment":5901,"conditions":5902,"interventions":5903},"NCT01000610","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate",[92],"2012-05-16","2008-03-17",18,[15],[5837,5838,5839],{"nctId":5905,"briefTitle":5906,"status":107,"phases":5907,"primaryCompletion":5805,"completion":5805,"start":5908,"enrollment":5909,"conditions":5910,"interventions":5912},"NCT00048165","A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation",[92],"1999-08",434,[5911],"Heart Transplantation",[5913,274,5914,5850],"Daclizumab","Mycophenolate mofetil",{"trials":5916,"activeCount":101},[],{"intervention":1957,"totalTrials":2563,"cells":5918},{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5930,"PHASE3":5951,"PHASE4":5977,"NA":5979},{"trials":5920,"activeCount":101},[],{"trials":5922,"activeCount":101},[5923],{"nctId":5924,"briefTitle":5925,"status":107,"phases":5926,"primaryCompletion":5927,"completion":5927,"start":1835,"enrollment":984,"conditions":5928,"interventions":5929},"NCT03875079","A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma",[89],"2022-07-14",[1477],[1051,1957],{"trials":5931,"activeCount":5110,"soonestReadout":5192},[5932,5936,5943,5947],{"nctId":5170,"briefTitle":5171,"status":152,"phases":5933,"primaryCompletion":795,"completion":795,"start":5173,"enrollment":5174,"conditions":5934,"interventions":5935},[89,90],[975],[1140,1957,990,1167,1319],{"nctId":5937,"briefTitle":5938,"status":140,"phases":5939,"primaryCompletion":1962,"completion":1962,"start":5940,"enrollment":984,"conditions":5941,"interventions":5942},"NCT05852691","A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer",[90],"2023-07-18",[18],[1445,1957,1107],{"nctId":5050,"briefTitle":5051,"status":140,"phases":5944,"primaryCompletion":1962,"completion":1962,"start":5053,"enrollment":5054,"conditions":5945,"interventions":5946},[90],[1049],[1445,988,1957,5057],{"nctId":5189,"briefTitle":5190,"status":140,"phases":5948,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":3015,"conditions":5949,"interventions":5950},[90],[1684],[1445,1957,1106,1319,990],{"trials":5952,"activeCount":706,"soonestReadout":2147},[5953,5957,5961,5965,5969,5973],{"nctId":1950,"briefTitle":1951,"status":107,"phases":5954,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":5955,"interventions":5956},[90,91],[1432],[988,68,1319,990,1167,1957],{"nctId":5756,"briefTitle":5757,"status":3955,"phases":5958,"primaryCompletion":5759,"completion":5760,"start":2264,"enrollment":4013,"conditions":5959,"interventions":5960},[91],[1684],[1140,1957,1287],{"nctId":2063,"briefTitle":2064,"status":130,"phases":5962,"primaryCompletion":2066,"completion":2067,"start":1669,"enrollment":2068,"conditions":5963,"interventions":5964},[91],[2070],[1084,68,1957],{"nctId":2144,"briefTitle":2145,"status":140,"phases":5966,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":5967,"interventions":5968},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":5299,"briefTitle":5300,"status":130,"phases":5970,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":5971,"interventions":5972},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":5318,"briefTitle":5319,"status":152,"phases":5974,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":3996,"conditions":5975,"interventions":5976},[91],[975,5325],[1140,1957,1319,990,1167],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"intervention":1359,"totalTrials":5982,"cells":5983},78,{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":6025,"PHASE3":6151,"PHASE4":6371,"NA":6405},{"trials":5985,"activeCount":101},[],{"trials":5987,"activeCount":101},[5988,5992,5996,6000,6008,6017],{"nctId":2384,"briefTitle":2385,"status":107,"phases":5989,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":5990,"interventions":5991},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":3492,"briefTitle":3493,"status":107,"phases":5993,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":3497,"conditions":5994,"interventions":5995},[89],[125],[3500,1359,1018],{"nctId":2405,"briefTitle":2406,"status":107,"phases":5997,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":5998,"interventions":5999},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"nctId":6001,"briefTitle":6002,"status":107,"phases":6003,"primaryCompletion":2515,"completion":2515,"start":6004,"enrollment":6005,"conditions":6006,"interventions":6007},"NCT00930514","A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma",[89],"2009-09",281,[3607],[1359,1359,1359,1359,1359],{"nctId":6009,"briefTitle":6010,"status":107,"phases":6011,"primaryCompletion":1890,"completion":1890,"start":6012,"enrollment":6013,"conditions":6014,"interventions":6016},"NCT03255096","A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed\u002FRefractory DLBCL and\u002For High-Grade B-Cell Lymphoma and\u002For High Grade B-Cell Lymphoma With MYC and\u002For BCL2 and\u002For BCL6",[89],"2017-08-28",39,[2652,6015],"High-Grade B-cell Lymphoma",[1063,1073,1359],{"nctId":6018,"briefTitle":6019,"status":130,"phases":6020,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":6023,"interventions":6024},"NCT04790903","A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",[89],"2024-05-21","2021-07-02",[3644],[1073,1785,1359,992,991,1357],{"trials":6026,"activeCount":706,"soonestReadout":2673},[6027,6031,6040,6044,6053,6057,6064,6068,6072,6076,6082,6086,6090,6096,6100,6104,6114,6122,6130,6139,6143,6147],{"nctId":3581,"briefTitle":3582,"status":107,"phases":6028,"primaryCompletion":3584,"completion":3584,"start":3585,"enrollment":2857,"conditions":6029,"interventions":6030},[89,90],[125],[1018,1359,1785,1073],{"nctId":6032,"briefTitle":6033,"status":107,"phases":6034,"primaryCompletion":805,"completion":6035,"start":6036,"enrollment":6037,"conditions":6038,"interventions":6039},"NCT02187861","A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)",[90],"2018-03-16","2014-12-01",163,[2642],[1073,1356,1359],{"nctId":1346,"briefTitle":1347,"status":107,"phases":6041,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":6042,"interventions":6043},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":6045,"briefTitle":6046,"status":107,"phases":6047,"primaryCompletion":6048,"completion":6048,"start":6049,"enrollment":97,"conditions":6050,"interventions":6052},"NCT01750697","A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis",[90],"2018-05-10","2013-05-23",[6051],"Granulomatosis With Polyangiitis",[1359],{"nctId":3619,"briefTitle":3620,"status":107,"phases":6054,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":3624,"conditions":6055,"interventions":6056},[89,90],[1038],[1356,1018,2394,1359,2394],{"nctId":6058,"briefTitle":6059,"status":130,"phases":6060,"primaryCompletion":3246,"completion":3246,"start":4409,"enrollment":306,"conditions":6061,"interventions":6062},"NCT01144403","A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.",[90],[3826],[992,3482,6063,1359],"Mitoxantrone",{"nctId":3628,"briefTitle":3629,"status":107,"phases":6065,"primaryCompletion":3631,"completion":3632,"start":3633,"enrollment":1058,"conditions":6066,"interventions":6067},[89,90],[1038],[3636,1018,1785,1359],{"nctId":2670,"briefTitle":2671,"status":140,"phases":6069,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":2676,"conditions":6070,"interventions":6071},[89,90],[2678],[2433,2433,2394,1096,1359],{"nctId":3638,"briefTitle":3639,"status":130,"phases":6073,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":1174,"conditions":6074,"interventions":6075},[89,90],[2642,3644],[1500,1018,1073,1359],{"nctId":6077,"briefTitle":6078,"status":107,"phases":6079,"primaryCompletion":2793,"completion":2793,"start":5820,"enrollment":1847,"conditions":6080,"interventions":6081},"NCT00532129","A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.",[90],[3741],[1359,2496],{"nctId":3647,"briefTitle":3648,"status":107,"phases":6083,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":22,"conditions":6084,"interventions":6085},[89,90],[3653],[2644,1018,1785,1359],{"nctId":2689,"briefTitle":2690,"status":152,"phases":6087,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":6088,"interventions":6089},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"nctId":6091,"briefTitle":6092,"status":107,"phases":6093,"primaryCompletion":3324,"completion":3324,"start":4446,"enrollment":1705,"conditions":6094,"interventions":6095},"NCT02533401","A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)",[90],[3741],[992,3482,1359],{"nctId":3671,"briefTitle":3672,"status":107,"phases":6097,"primaryCompletion":3189,"completion":3674,"start":121,"enrollment":134,"conditions":6098,"interventions":6099},[90],[125],[3669,3677],{"nctId":3679,"briefTitle":3680,"status":107,"phases":6101,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":6102,"interventions":6103},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":6105,"briefTitle":6106,"status":107,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":6110,"conditions":6111,"interventions":6113},"NCT00545714","A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)",[90],"2016-05-20","2007-11-21",86,[6112],"Leukemia, Lymphocytic, Chronic, B-Cell",[992,3482,1359],{"nctId":6115,"briefTitle":6116,"status":107,"phases":6117,"primaryCompletion":6118,"completion":6118,"start":6119,"enrollment":1733,"conditions":6120,"interventions":6121},"NCT01263704","A Study of MabThera\u002FRituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia",[90],"2017-04-03","2011-07-17",[3741],[992,3482,1359],{"nctId":6123,"briefTitle":6124,"status":107,"phases":6125,"primaryCompletion":6126,"completion":6126,"start":6127,"enrollment":1092,"conditions":6128,"interventions":6129},"NCT01153971","A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas",[90],"2010-09-24","2005-07-20",[125],[3677],{"nctId":6131,"briefTitle":6132,"status":107,"phases":6133,"primaryCompletion":5805,"completion":6134,"start":6135,"enrollment":6136,"conditions":6137,"interventions":6138},"NCT02693210","A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis",[90],"2004-08","2001-02",161,[15],[992,2824,1359],{"nctId":3711,"briefTitle":3712,"status":130,"phases":6140,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":97,"conditions":6141,"interventions":6142},[89,90],[125],[1500,1018,1359],{"nctId":5802,"briefTitle":5803,"status":107,"phases":6144,"primaryCompletion":2948,"completion":2948,"start":5805,"enrollment":5806,"conditions":6145,"interventions":6146},[90],[15],[1359,2824,274,5809],{"nctId":2751,"briefTitle":2752,"status":140,"phases":6148,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":6149,"interventions":6150},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"trials":6152,"activeCount":5110,"soonestReadout":2983},[6153,6160,6170,6174,6182,6191,6202,6211,6215,6219,6228,6232,6241,6245,6255,6265,6273,6281,6285,6294,6298,6302,6311,6321,6325,6335,6339,6348,6352,6364],{"nctId":6154,"briefTitle":6155,"status":107,"phases":6156,"primaryCompletion":6157,"completion":6157,"start":4323,"enrollment":4159,"conditions":6158,"interventions":6159},"NCT02569996","A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma",[91],"2013-08",[3607],[1359],{"nctId":6161,"briefTitle":6162,"status":140,"phases":6163,"primaryCompletion":2025,"completion":209,"start":6164,"enrollment":6165,"conditions":6166,"interventions":6168},"NCT04712097","A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma",[91],"2021-10-27",478,[6167],"Relapsed or Refractory Follicular Lymphoma",[2433,2644,1359,6169],"Tociluzumab",{"nctId":3733,"briefTitle":3734,"status":107,"phases":6171,"primaryCompletion":3736,"completion":3737,"start":3738,"enrollment":3739,"conditions":6172,"interventions":6173},[91],[3741],[3669,3677,3743],{"nctId":6175,"briefTitle":6176,"status":107,"phases":6177,"primaryCompletion":6178,"completion":6178,"start":6179,"enrollment":2940,"conditions":6180,"interventions":6181},"NCT04182204","A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[91],"2024-11-29","2020-02-07",[3826],[1785,1359,1163,1165],{"nctId":6183,"briefTitle":6184,"status":107,"phases":6185,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":6189,"interventions":6190},"NCT01889069","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera\u002FRituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)",[91],"2019-05-28","2013-07-31",159,[1038],[1359,992,1358,991,1357,1356],{"nctId":6192,"briefTitle":6193,"status":107,"phases":6194,"primaryCompletion":6195,"completion":6195,"start":2948,"enrollment":6196,"conditions":6197,"interventions":6199},"NCT01724021","A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera\u002FRituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a",[91],"2015-01",743,[6198],"Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma",[6200,6201,1356,1359,1359,1359,1359],"Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone\u002FPrednisolone","Cyclophosphamide, Vincristine, Prednisone\u002FPrednisolone",{"nctId":6203,"briefTitle":6204,"status":107,"phases":6205,"primaryCompletion":6206,"completion":752,"start":6207,"enrollment":6208,"conditions":6209,"interventions":6210},"NCT02005471","A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[91],"2017-05-08","2014-03-17",389,[2431],[1356,1073,1359],{"nctId":5817,"briefTitle":5818,"status":107,"phases":6212,"primaryCompletion":3084,"completion":4445,"start":5820,"enrollment":5821,"conditions":6213,"interventions":6214},[91],[15],[1359,274,2824,5824],{"nctId":3777,"briefTitle":3778,"status":107,"phases":6216,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":6217,"interventions":6218},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":6220,"briefTitle":6221,"status":107,"phases":6222,"primaryCompletion":6223,"completion":6223,"start":6224,"enrollment":4573,"conditions":6225,"interventions":6226},"NCT00718549","A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)",[91],"2015-09-14","2009-07-21",[3741],[6227,992,1359],"Cladribine",{"nctId":3787,"briefTitle":3788,"status":107,"phases":6229,"primaryCompletion":3790,"completion":3737,"start":3791,"enrollment":3739,"conditions":6230,"interventions":6231},[91],[3741],[3669,3677,3743],{"nctId":6233,"briefTitle":6234,"status":107,"phases":6235,"primaryCompletion":6236,"completion":6236,"start":6237,"enrollment":6238,"conditions":6239,"interventions":6240},"NCT01461928","A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab",[91],"2018-06-02","2011-12-20",692,[125],[1572,1359],{"nctId":4783,"briefTitle":4784,"status":140,"phases":6242,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":6243,"interventions":6244},[91],[4791],[1784,2394,1359,992,991,1357],{"nctId":6246,"briefTitle":6247,"status":130,"phases":6248,"primaryCompletion":6249,"completion":6250,"start":6251,"enrollment":1733,"conditions":6252,"interventions":6254},"NCT04236141","A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R\u002FR DLBCL).",[91],"2021-07-12","2022-02-07","2020-07-10",[6253],"Diffuse, Large B-Cell, Lymphoma",[1785,1356,1359],{"nctId":6256,"briefTitle":6257,"status":107,"phases":6258,"primaryCompletion":6259,"completion":2973,"start":6260,"enrollment":6261,"conditions":6262,"interventions":6263},"NCT00090051","FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients",[91],"2008-07-23","2003-07-31",552,[2431],[1359,6264,992],"Fludarabine Phosphate",{"nctId":6266,"briefTitle":6267,"status":107,"phases":6268,"primaryCompletion":6269,"completion":6269,"start":6270,"enrollment":1239,"conditions":6271,"interventions":6272},"NCT01272908","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)",[91],"2009-03-12","2006-07-18",[15],[3677],{"nctId":6274,"briefTitle":6275,"status":107,"phases":6276,"primaryCompletion":2685,"completion":2685,"start":6277,"enrollment":6278,"conditions":6279,"interventions":6280},"NCT01126541","SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy",[91],"2006-09",224,[15],[3677],{"nctId":3799,"briefTitle":3800,"status":107,"phases":6282,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":6283,"interventions":6284},[91],[3806],[1018,1073,3482,992,1359,1356],{"nctId":6286,"briefTitle":6287,"status":107,"phases":6288,"primaryCompletion":6289,"completion":6289,"start":6290,"enrollment":1026,"conditions":6291,"interventions":6293},"NCT01987505","MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma",[91],"2017-04-11","2013-11-11",[6292],"Lymphoma, Non Hodgkin",[1359],{"nctId":3818,"briefTitle":3819,"status":130,"phases":6295,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":6296,"interventions":6297},[91],[3826],[1359,1018,992,991,1358,1357],{"nctId":2980,"briefTitle":2981,"status":140,"phases":6299,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":6300,"interventions":6301},[91],[2392],[2433,2394,1096,1359,1163,1165],{"nctId":6303,"briefTitle":6304,"status":107,"phases":6305,"primaryCompletion":4314,"completion":4314,"start":6306,"enrollment":6307,"conditions":6308,"interventions":6309},"NCT01609010","A Study of MabThera\u002FRituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma",[91],"2002-10",313,[1038],[3677,6310],"interferon-a-2a",{"nctId":6312,"briefTitle":6313,"status":107,"phases":6314,"primaryCompletion":4315,"completion":6315,"start":6316,"enrollment":6317,"conditions":6318,"interventions":6320},"NCT00281918","Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia",[91],"2011-10","2003-07",817,[6319],"Leukemia",[1359,992,6264],{"nctId":3011,"briefTitle":3012,"status":152,"phases":6322,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":6323,"interventions":6324},[91],[1038],[1018,1784,1359,1356,2644,1096],{"nctId":6326,"briefTitle":6327,"status":107,"phases":6328,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":6331,"interventions":6332},"NCT03274492","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",[91],"2026-04-30","2017-11-16",[3826],[1785,1359,992,991,1358,6333,1357,6334],"Vincristine Placebo","Polatuzumab vedotin Placebo",{"nctId":3833,"briefTitle":3834,"status":107,"phases":6336,"primaryCompletion":3836,"completion":3737,"start":3837,"enrollment":3739,"conditions":6337,"interventions":6338},[91],[3741],[3669,3677,3743],{"nctId":6340,"briefTitle":6341,"status":107,"phases":6342,"primaryCompletion":6343,"completion":6343,"start":4323,"enrollment":6344,"conditions":6345,"interventions":6347},"NCT00770562","A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)",[91],"2008-07",103,[6346],"Idiopathic Thrombocytopenic Purpura",[3677,2577],{"nctId":4533,"briefTitle":4534,"status":130,"phases":6349,"primaryCompletion":2914,"completion":2914,"start":4536,"enrollment":3739,"conditions":6350,"interventions":6351},[91],[2543],[1015,1359,4539],{"nctId":6353,"briefTitle":6354,"status":107,"phases":6355,"primaryCompletion":6356,"completion":6357,"start":6358,"enrollment":3295,"conditions":6359,"interventions":6361},"NCT02383589","A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)",[91],"2018-11-28","2019-10-29","2015-05-26",[6360],"Pemphigus Vulgaris",[6362,3707,1359,6363],"Mycophenolate Mofetil Placebo","Rituximab Placebo",{"nctId":6365,"briefTitle":6366,"status":107,"phases":6367,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":6369,"interventions":6370},"NCT02406092","Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A",[91],"2021-06-30",[2392],[1359,992,991,1358,1357,3482],{"trials":6372,"activeCount":101},[6373,6381,6385,6389,6397],{"nctId":6374,"briefTitle":6375,"status":107,"phases":6376,"primaryCompletion":4488,"completion":4488,"start":6377,"enrollment":931,"conditions":6378,"interventions":6379},"NCT00462345","A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.",[92],"2007-06",[15],[3677,2824,6380],"Corticosteroid or NSAID",{"nctId":5870,"briefTitle":5871,"status":107,"phases":6382,"primaryCompletion":5873,"completion":5873,"start":3823,"enrollment":4637,"conditions":6383,"interventions":6384},[92],[15],[3677,5838,5839,5876,5877],{"nctId":5879,"briefTitle":5880,"status":107,"phases":6386,"primaryCompletion":5882,"completion":5882,"start":5883,"enrollment":1184,"conditions":6387,"interventions":6388},[92],[5885],[274,1357,1359],{"nctId":6390,"briefTitle":6391,"status":130,"phases":6392,"primaryCompletion":6393,"completion":6393,"start":6394,"enrollment":316,"conditions":6395,"interventions":6396},"NCT01283386","A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status",[92],"2016-03-16","2011-04-27",[3741],[2496,992,3482,1359],{"nctId":6398,"briefTitle":6399,"status":130,"phases":6400,"primaryCompletion":6401,"completion":6401,"start":6402,"enrollment":25,"conditions":6403,"interventions":6404},"NCT01271010","A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status",[92],"2016-05-04","2011-06-17",[3741],[992,3482,1359],{"trials":6406,"activeCount":101},[6407,6414,6421,6428,6435,6441,6448,6456,6463,6469,6477,6483,6493,6502,6510],{"nctId":6408,"briefTitle":6409,"status":107,"phases":6410,"primaryCompletion":5418,"completion":5418,"start":4206,"enrollment":6411,"conditions":6412,"interventions":6413},"NCT01071798","An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis",[],1653,[15],[1359],{"nctId":6415,"briefTitle":6416,"status":107,"phases":6417,"primaryCompletion":4682,"completion":4682,"start":2965,"enrollment":6418,"conditions":6419,"interventions":6420},"NCT02699892","Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis",[],130,[15],[1359],{"nctId":6422,"briefTitle":6423,"status":107,"phases":6424,"primaryCompletion":3174,"completion":3174,"start":6004,"enrollment":6425,"conditions":6426,"interventions":6427},"NCT02536664","Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants",[],505,[2642],[1359],{"nctId":6429,"briefTitle":6430,"status":107,"phases":6431,"primaryCompletion":3085,"completion":3085,"start":4582,"enrollment":6432,"conditions":6433,"interventions":6434},"NCT02622503","A Study on Rheumatoid Arthritis Patients Treated With Rituximab",[],81,[15],[1359],{"nctId":6436,"briefTitle":6437,"status":107,"phases":6438,"primaryCompletion":6195,"completion":6195,"start":6315,"enrollment":6425,"conditions":6439,"interventions":6440},"NCT01641952","An Observational Study of MabThera\u002FRituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent",[],[15],[1359],{"nctId":6442,"briefTitle":6443,"status":107,"phases":6444,"primaryCompletion":3324,"completion":3324,"start":2685,"enrollment":2743,"conditions":6445,"interventions":6446},"NCT01592292","An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy",[],[15],[1359,2382,3159,6447],"Infliximab",{"nctId":6449,"briefTitle":6450,"status":107,"phases":6451,"primaryCompletion":6452,"completion":6452,"start":6453,"enrollment":2289,"conditions":6454,"interventions":6455},"NCT01684865","An Observational Study of First-Line Maintenance Rituximab (MabThera\u002FRituxan) in Participants With Follicular Non-Hodgkin's Lymphoma",[],"2017-11-27","2012-10-22",[125],[1359],{"nctId":6457,"briefTitle":6458,"status":107,"phases":6459,"primaryCompletion":4699,"completion":4699,"start":6460,"enrollment":202,"conditions":6461,"interventions":6462},"NCT01178086","A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)",[],"2010-02-22",[3741],[1359],{"nctId":6464,"briefTitle":6465,"status":107,"phases":6466,"primaryCompletion":2808,"completion":2808,"start":2768,"enrollment":3295,"conditions":6467,"interventions":6468},"NCT01613027","An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis",[],[15],[1359],{"nctId":6470,"briefTitle":6471,"status":107,"phases":6472,"primaryCompletion":6473,"completion":6473,"start":6474,"enrollment":2440,"conditions":6475,"interventions":6476},"NCT02472756","A Study of Rituximab in Combination With Chemotherapy in Relapsed\u002FRefractory Follicular Lymphoma",[],"2014-05-30","2008-09-19",[3607],[1572,1359],{"nctId":6478,"briefTitle":6479,"status":107,"phases":6480,"primaryCompletion":2956,"completion":2956,"start":4582,"enrollment":559,"conditions":6481,"interventions":6482},"NCT02461290","Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1",[],[2642],[1359],{"nctId":6484,"briefTitle":6485,"status":107,"phases":6486,"primaryCompletion":6487,"completion":6487,"start":6488,"enrollment":6489,"conditions":6490,"interventions":6492},"NCT02654379","Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe",[],"2017-09-29","2015-12-18",1408,[6491],"Off-Label Use",[1359],{"nctId":6494,"briefTitle":6495,"status":107,"phases":6496,"primaryCompletion":5891,"completion":5891,"start":2923,"enrollment":5458,"conditions":6497,"interventions":6499},"NCT02486952","MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma",[],[6498],"Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[992,6500,6501,1357,1359],"Hydroxydaunorubicin","Oncovin",{"nctId":6503,"briefTitle":6504,"status":107,"phases":6505,"primaryCompletion":3029,"completion":3029,"start":6506,"enrollment":6507,"conditions":6508,"interventions":6509},"NCT02316613","Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)",[],"2007-02",260,[2642],[1359],{"nctId":6511,"briefTitle":6512,"status":107,"phases":6513,"primaryCompletion":3478,"completion":3478,"start":2793,"enrollment":6514,"conditions":6515,"interventions":6516},"NCT01609023","A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia",[],67,[3741],[1359],{"intervention":1163,"totalTrials":123,"cells":6518},{"EARLY_PHASE1":6519,"PHASE1":6521,"PHASE2":6555,"PHASE3":6680,"PHASE4":6771,"NA":6779},{"trials":6520,"activeCount":101},[],{"trials":6522,"activeCount":350,"soonestReadout":2482},[6523,6531,6535,6539,6543,6547,6551],{"nctId":6524,"briefTitle":6525,"status":130,"phases":6526,"primaryCompletion":2955,"completion":2955,"start":3324,"enrollment":2619,"conditions":6527,"interventions":6528},"NCT02317419","A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and\u002For Locally Advanced Malignant Solid Tumors",[89],[1883],[6529,6529,5186,6530],"RO6927005","nab-paclitaxel",{"nctId":2479,"briefTitle":2480,"status":152,"phases":6532,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":37,"conditions":6533,"interventions":6534},[89],[1038],[1784,1096,1018,1163,1165],{"nctId":2537,"briefTitle":2538,"status":107,"phases":6536,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":6537,"interventions":6538},[89],[2543],[1784,1163,1165,2433,1018,1096],{"nctId":1153,"briefTitle":1154,"status":107,"phases":6540,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":6541,"interventions":6542},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"nctId":5361,"briefTitle":5362,"status":343,"phases":6544,"primaryCompletion":2602,"completion":2602,"start":5364,"enrollment":101,"conditions":6545,"interventions":6546},[89],[2257],[5184,5367,5185,5186,4503],{"nctId":5373,"briefTitle":5374,"status":130,"phases":6548,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":6549,"interventions":6550},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"nctId":1234,"briefTitle":1235,"status":107,"phases":6552,"primaryCompletion":1237,"completion":1238,"start":393,"enrollment":1239,"conditions":6553,"interventions":6554},[89],[1241],[68,1163,1167],{"trials":6556,"activeCount":350,"soonestReadout":3722},[6557,6568,6574,6581,6585,6592,6596,6600,6604,6608,6612,6616,6624,6632,6636,6640,6648,6652,6656,6665,6669,6676],{"nctId":6558,"briefTitle":6559,"status":130,"phases":6560,"primaryCompletion":6561,"completion":6561,"start":6562,"enrollment":6563,"conditions":6564,"interventions":6566},"NCT03386721","Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and\u002For Metastatic Solid Tumors",[90],"2021-12-30","2018-02-19",256,[6565],"Advanced\u002FMetastatic Head and Neck, Oesophageal and Cervical Cancers",[6567,4219,1163,1983],"simlukafusp alfa",{"nctId":6569,"briefTitle":6570,"status":130,"phases":6571,"primaryCompletion":3189,"completion":3189,"start":2963,"enrollment":3574,"conditions":6572,"interventions":6573},"NCT00940875","A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer",[90],[975],[5384,5186,5186],{"nctId":6575,"briefTitle":6576,"status":107,"phases":6577,"primaryCompletion":5364,"completion":5364,"start":6578,"enrollment":6110,"conditions":6579,"interventions":6580},"NCT01077713","A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer",[90],"2010-02",[2257],[5275,5185,5186,5186],{"nctId":1308,"briefTitle":1309,"status":130,"phases":6582,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":6583,"interventions":6584},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":6586,"briefTitle":6587,"status":107,"phases":6588,"primaryCompletion":2906,"completion":4474,"start":3085,"enrollment":2375,"conditions":6589,"interventions":6591},"NCT00701558","A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and\u002For Metastatic Non-Small Cell Lung Cancer",[90],[6590],"Non-small Cell Lung Cancer Metastatic",[977,1163],{"nctId":5178,"briefTitle":5179,"status":107,"phases":6593,"primaryCompletion":3146,"completion":3146,"start":5181,"enrollment":2743,"conditions":6594,"interventions":6595},[90],[2257],[5184,5185,5186,5187],{"nctId":1389,"briefTitle":1390,"status":107,"phases":6597,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":6598,"interventions":6599},[90],[1397],[68,1015,1167,1163],{"nctId":1461,"briefTitle":1462,"status":130,"phases":6601,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":6602,"interventions":6603},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":1504,"briefTitle":1505,"status":107,"phases":6605,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":6606,"interventions":6607},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1530,"briefTitle":1531,"status":107,"phases":6609,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":6610,"interventions":6611},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"nctId":4229,"briefTitle":4230,"status":107,"phases":6613,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":931,"conditions":6614,"interventions":6615},[90],[18],[1015,990,1163],{"nctId":6617,"briefTitle":6618,"status":107,"phases":6619,"primaryCompletion":5181,"completion":5181,"start":6620,"enrollment":1249,"conditions":6621,"interventions":6623},"NCT00461708","A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and\u002For Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival",[90],"2007-05",[6622],"Pancreatic Cancer",[977,1163],{"nctId":6625,"briefTitle":6626,"status":107,"phases":6627,"primaryCompletion":6277,"completion":6277,"start":6628,"enrollment":6629,"conditions":6630,"interventions":6631},"NCT02565641","A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer",[90],"2003-03",63,[6622],[1166,1163],{"nctId":4246,"briefTitle":4247,"status":107,"phases":6633,"primaryCompletion":2905,"completion":4249,"start":3308,"enrollment":2743,"conditions":6634,"interventions":6635},[90],[18],[1015,1106,1163],{"nctId":5454,"briefTitle":5455,"status":107,"phases":6637,"primaryCompletion":2685,"completion":2685,"start":5457,"enrollment":5458,"conditions":6638,"interventions":6639},[90],[975],[5384,5186,5185,5367],{"nctId":6641,"briefTitle":6642,"status":107,"phases":6643,"primaryCompletion":4206,"completion":4206,"start":6644,"enrollment":372,"conditions":6645,"interventions":6646},"NCT02006667","A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer",[90],"2001-01",[2232],[6647,5186,5185],"trastuzumab",{"nctId":1620,"briefTitle":1621,"status":343,"phases":6649,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":6650,"interventions":6651},[90],[1627],[68,990,1167,1319,1163,1106],{"nctId":5466,"briefTitle":5467,"status":107,"phases":6653,"primaryCompletion":4113,"completion":4113,"start":5469,"enrollment":2524,"conditions":6654,"interventions":6655},[90],[1417],[5472,4503,5186,5367],{"nctId":6657,"briefTitle":6658,"status":107,"phases":6659,"primaryCompletion":2768,"completion":2768,"start":4281,"enrollment":6660,"conditions":6661,"interventions":6662},"NCT00652366","A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",[90],467,[6622],[6663,6664,1163],"Erlotinib, escalating dose","Erlotinib, standard dose",{"nctId":3719,"briefTitle":3720,"status":152,"phases":6666,"primaryCompletion":3722,"completion":2719,"start":1464,"enrollment":1847,"conditions":6667,"interventions":6668},[90],[3724],[1018,1784,1163,1165],{"nctId":6670,"briefTitle":6671,"status":107,"phases":6672,"primaryCompletion":3479,"completion":3479,"start":6673,"enrollment":510,"conditions":6674,"interventions":6675},"NCT00518011","A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.",[90],"2007-08",[2257],[977,1163],{"nctId":1760,"briefTitle":1761,"status":107,"phases":6677,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":6678,"interventions":6679},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":6681,"activeCount":2631,"soonestReadout":5280},[6682,6686,6694,6698,6705,6714,6718,6722,6726,6730,6739,6747,6751,6755,6759,6763,6767],{"nctId":6175,"briefTitle":6176,"status":107,"phases":6683,"primaryCompletion":6178,"completion":6178,"start":6179,"enrollment":2940,"conditions":6684,"interventions":6685},[91],[3826],[1785,1359,1163,1165],{"nctId":6687,"briefTitle":6688,"status":107,"phases":6689,"primaryCompletion":6690,"completion":6690,"start":6691,"enrollment":920,"conditions":6692,"interventions":6693},"NCT02694536","A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",[91],"2009-11-19","2006-08-01",[6622],[977,1163],{"nctId":1859,"briefTitle":1860,"status":130,"phases":6695,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":306,"conditions":6696,"interventions":6697},[91],[975],[68,990,1167,1163],{"nctId":6699,"briefTitle":6700,"status":107,"phases":6701,"primaryCompletion":4233,"completion":4233,"start":6702,"enrollment":1523,"conditions":6703,"interventions":6704},"NCT00806923","A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",[91],"2005-02",[2257],[1167,1163,5275,5275],{"nctId":6706,"briefTitle":6707,"status":107,"phases":6708,"primaryCompletion":6709,"completion":6710,"start":6453,"enrollment":8,"conditions":6711,"interventions":6712},"NCT01684878","Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)",[91],"2015-01-30","2016-04-28",[1417],[1163,1106,1221,6713],"Topotecan",{"nctId":1959,"briefTitle":1960,"status":140,"phases":6715,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":6716,"interventions":6717},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":1974,"briefTitle":1975,"status":140,"phases":6719,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":6720,"interventions":6721},[91],[975],[68,1167,1983,947,1163,1319],{"nctId":5240,"briefTitle":5241,"status":107,"phases":6723,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":6724,"interventions":6725},[91],[5248],[4468,989,1319,990,1167,1163],{"nctId":2937,"briefTitle":2938,"status":140,"phases":6727,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":6728,"interventions":6729},[91],[2652],[1018,1784,2736,1096,1163,1165],{"nctId":6731,"briefTitle":6732,"status":107,"phases":6733,"primaryCompletion":6734,"completion":6735,"start":6736,"enrollment":5246,"conditions":6737,"interventions":6738},"NCT03191786","A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy",[91],"2022-04-30","2023-10-25","2017-09-11",[975],[4468,1983,1163],{"nctId":6740,"briefTitle":6741,"status":107,"phases":6742,"primaryCompletion":3324,"completion":3324,"start":4322,"enrollment":6743,"conditions":6744,"interventions":6745},"NCT00883779","A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer",[91],451,[2257],[6746,5384,5186],"Platinum chemotherapy",{"nctId":2103,"briefTitle":2104,"status":107,"phases":6748,"primaryCompletion":2106,"completion":2106,"start":534,"enrollment":2107,"conditions":6749,"interventions":6750},[91],[2109],[68,1163,1166,990],{"nctId":2980,"briefTitle":2981,"status":140,"phases":6752,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":6753,"interventions":6754},[91],[2392],[2433,2394,1096,1359,1163,1165],{"nctId":2175,"briefTitle":2176,"status":107,"phases":6756,"primaryCompletion":1383,"completion":2178,"start":2179,"enrollment":2180,"conditions":6757,"interventions":6758},[91],[1538],[68,990,1163,1167],{"nctId":5277,"briefTitle":5278,"status":140,"phases":6760,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":6761,"interventions":6762},[91],[1316],[5286,1167,1983,1163,1319,990],{"nctId":5288,"briefTitle":5289,"status":107,"phases":6764,"primaryCompletion":1925,"completion":5291,"start":5292,"enrollment":5293,"conditions":6765,"interventions":6766},[91],[5295],[5297,990,1167,1163,1319],{"nctId":5299,"briefTitle":5300,"status":130,"phases":6768,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":6769,"interventions":6770},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"trials":6772,"activeCount":101},[6773],{"nctId":6774,"briefTitle":6775,"status":130,"phases":6776,"primaryCompletion":4322,"completion":4322,"start":6673,"enrollment":942,"conditions":6777,"interventions":6778},"NCT00642733","A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer",[92],[6622],[5384,5186],{"trials":6780,"activeCount":101},[6781],{"nctId":6782,"briefTitle":6783,"status":107,"phases":6784,"primaryCompletion":6785,"completion":6785,"start":6786,"enrollment":5768,"conditions":6787,"interventions":6788},"NCT01782690","An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",[],"2015-02-28","2012-03-31",[6622],[4201,5186],{"intervention":1695,"totalTrials":709,"cells":6790},{"EARLY_PHASE1":6791,"PHASE1":6793,"PHASE2":6826,"PHASE3":6856,"PHASE4":6879,"NA":6881},{"trials":6792,"activeCount":101},[],{"trials":6794,"activeCount":101},[6795,6805,6815],{"nctId":6796,"briefTitle":6797,"status":107,"phases":6798,"primaryCompletion":6799,"completion":6799,"start":6800,"enrollment":2619,"conditions":6801,"interventions":6803},"NCT03330990","Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients",[89],"2018-07-11","2017-11-14",[6802],"Advanced Solid Tumor",[1695,6804],"Midazolam Hydrochloride",{"nctId":6806,"briefTitle":6807,"status":107,"phases":6808,"primaryCompletion":6809,"completion":6809,"start":6810,"enrollment":2492,"conditions":6811,"interventions":6813},"NCT04226833","A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function",[89],"2021-09-27","2020-02-11",[6812],"Hepatic Insufficiency",[6814],"entrectinib",{"nctId":6816,"briefTitle":6817,"status":107,"phases":6818,"primaryCompletion":6819,"completion":6819,"start":6820,"enrollment":6821,"conditions":6822,"interventions":6825},"NCT02097810","Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.",[89],"2020-06-02","2014-07-28",84,[6823,6824],"Locally Advanced Solid Tumors","Metastatic Solid Tumors",[1695],{"trials":6827,"activeCount":706,"soonestReadout":2025},[6828,6836,6848,6852],{"nctId":6829,"briefTitle":6830,"status":140,"phases":6831,"primaryCompletion":2025,"completion":2025,"start":6832,"enrollment":1047,"conditions":6833,"interventions":6835},"NCT02650401","Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And\u002FOr Who Have No Satisfactory Treatment Options",[89,90],"2016-05-03",[922,6834],"CNS Tumors",[1695],{"nctId":6837,"briefTitle":6838,"status":140,"phases":6839,"primaryCompletion":690,"completion":690,"start":1373,"enrollment":6840,"conditions":6841,"interventions":6847},"NCT02568267","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1\u002F2\u002F3 (Trk A\u002FB\u002FC), ROS1, or ALK Gene Rearrangements (Fusions)",[90],534,[18,4860,30,4862,4864,1285,4859,975,1417,6622,6842,6843,1049,6844,6845,6846],"Papillary Thyroid Cancer","Primary Brain Tumors","Sarcomas","Salivary Gland Cancers","Adult Solid Tumor",[1695],{"nctId":1687,"briefTitle":1688,"status":140,"phases":6849,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":6850,"interventions":6851},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"nctId":1760,"briefTitle":1761,"status":107,"phases":6853,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":6854,"interventions":6855},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":6857,"activeCount":5110,"soonestReadout":1962},[6858,6862,6866,6875],{"nctId":4942,"briefTitle":4943,"status":140,"phases":6859,"primaryCompletion":4945,"completion":4945,"start":4946,"enrollment":4683,"conditions":6860,"interventions":6861},[91],[975],[43,1695,1948],{"nctId":1959,"briefTitle":1960,"status":140,"phases":6863,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":6864,"interventions":6865},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":6867,"briefTitle":6868,"status":140,"phases":6869,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":6872,"conditions":6873,"interventions":6874},"NCT04603807","A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases",[91],"2028-06-26","2021-09-30",220,[1316],[1695,4940],{"nctId":2242,"briefTitle":2243,"status":152,"phases":6876,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":6877,"interventions":6878},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"trials":6880,"activeCount":101},[],{"trials":6882,"activeCount":101},[6883],{"nctId":6884,"briefTitle":6885,"status":6886,"phases":6887,"conditions":6888,"interventions":6890},"NCT03066661","Expanded Access to Entrectinib for Cancers With NTRK1\u002F2\u002F3, ROS1, or ALK Gene Fusions","NO_LONGER_AVAILABLE",[],[6889],"Cancers With NTRK, ROS1, or ALK Gene Fusions",[1695],{"intervention":1573,"totalTrials":2563,"cells":6892},{"EARLY_PHASE1":6893,"PHASE1":6895,"PHASE2":6905,"PHASE3":6931,"PHASE4":6955,"NA":6957},{"trials":6894,"activeCount":101},[],{"trials":6896,"activeCount":101},[6897],{"nctId":6898,"briefTitle":6899,"status":130,"phases":6900,"primaryCompletion":6901,"completion":6901,"start":6902,"enrollment":2375,"conditions":6903,"interventions":6904},"NCT04060862","A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer",[89],"2023-08-29","2019-11-21",[18],[946,1421,1573],{"trials":6906,"activeCount":706,"soonestReadout":3376},[6907,6915,6919,6923,6927],{"nctId":6908,"briefTitle":6909,"status":130,"phases":6910,"primaryCompletion":655,"completion":6911,"start":1374,"enrollment":6344,"conditions":6912,"interventions":6914},"NCT03584009","A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4\u002F6 Inhibitor Therapy",[90],"2021-05-06",[6913],"Estrogen Receptor-positive (ER+)\u002FHuman Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer",[1073,1573],{"nctId":4133,"briefTitle":4134,"status":107,"phases":6916,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":6917,"interventions":6918},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"nctId":3373,"briefTitle":3374,"status":152,"phases":6920,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":920,"conditions":6921,"interventions":6922},[90],[18],[1137,1456,1573],{"nctId":1562,"briefTitle":1563,"status":152,"phases":6924,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":6925,"interventions":6926},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":3386,"briefTitle":3387,"status":152,"phases":6928,"primaryCompletion":3389,"completion":3389,"start":3390,"enrollment":920,"conditions":6929,"interventions":6930},[90],[18],[1137,1573],{"trials":6932,"activeCount":706,"soonestReadout":3412},[6933,6943,6947,6951],{"nctId":6934,"briefTitle":6935,"status":130,"phases":6936,"primaryCompletion":6937,"completion":6937,"start":6938,"enrollment":6939,"conditions":6940,"interventions":6941},"NCT02340221","A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy",[91],"2021-06-29","2015-04-09",631,[18],[6942,1573],"Taselisib",{"nctId":5693,"briefTitle":5694,"status":152,"phases":6944,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":6945,"interventions":6946},[91],[5700],[63,1573,1420,1421,1456,5670],{"nctId":3409,"briefTitle":3410,"status":140,"phases":6948,"primaryCompletion":3412,"completion":701,"start":3413,"enrollment":3414,"conditions":6949,"interventions":6950},[90,91],[18],[1137,1421,1573],{"nctId":3440,"briefTitle":3441,"status":140,"phases":6952,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":6953,"interventions":6954},[91],[18],[1137,1573,3448,3449,3450,388],{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":350,"soonestReadout":2347},[6959],{"nctId":3460,"briefTitle":3461,"status":152,"phases":6960,"primaryCompletion":2347,"completion":3463,"start":3464,"enrollment":211,"conditions":6961,"interventions":6962},[],[3466,1569],[1137,1421,1573],{"intervention":1421,"totalTrials":1796,"cells":6964},{"EARLY_PHASE1":6965,"PHASE1":6967,"PHASE2":6973,"PHASE3":6991,"PHASE4":7005,"NA":7007},{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[6969],{"nctId":6898,"briefTitle":6899,"status":130,"phases":6970,"primaryCompletion":6901,"completion":6901,"start":6902,"enrollment":2375,"conditions":6971,"interventions":6972},[89],[18],[946,1421,1573],{"trials":6974,"activeCount":706,"soonestReadout":1413},[6975,6979,6983,6987],{"nctId":1410,"briefTitle":1411,"status":140,"phases":6976,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":6977,"interventions":6978},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":5649,"briefTitle":5650,"status":107,"phases":6980,"primaryCompletion":5652,"completion":2363,"start":5653,"enrollment":11,"conditions":6981,"interventions":6982},[90],[5655],[63,5657,1421],{"nctId":1447,"briefTitle":1448,"status":152,"phases":6984,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":6985,"interventions":6986},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":1562,"briefTitle":1563,"status":152,"phases":6988,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":6989,"interventions":6990},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":6992,"activeCount":706,"soonestReadout":3412},[6993,6997,7001],{"nctId":5693,"briefTitle":5694,"status":152,"phases":6994,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":6995,"interventions":6996},[91],[5700],[63,1573,1420,1421,1456,5670],{"nctId":3409,"briefTitle":3410,"status":140,"phases":6998,"primaryCompletion":3412,"completion":701,"start":3413,"enrollment":3414,"conditions":6999,"interventions":7000},[90,91],[18],[1137,1421,1573],{"nctId":5703,"briefTitle":5704,"status":140,"phases":7002,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":7003,"interventions":7004},[91],[5711],[63,5713,1422,5714,1421,5670],{"trials":7006,"activeCount":101},[],{"trials":7008,"activeCount":350,"soonestReadout":2347},[7009],{"nctId":3460,"briefTitle":3461,"status":152,"phases":7010,"primaryCompletion":2347,"completion":3463,"start":3464,"enrollment":211,"conditions":7011,"interventions":7012},[],[3466,1569],[1137,1421,1573],{"intervention":1167,"totalTrials":2440,"cells":7014},{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7044,"PHASE3":7127,"PHASE4":7219,"NA":7221},{"trials":7016,"activeCount":101},[],{"trials":7018,"activeCount":101},[7019,7026,7032,7036,7040],{"nctId":7020,"briefTitle":7021,"status":107,"phases":7022,"primaryCompletion":2906,"completion":2906,"start":4562,"enrollment":942,"conditions":7023,"interventions":7024},"NCT00773188","A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.",[89],[2257],[5275,5185,7025],"vinorelbine",{"nctId":7027,"briefTitle":7028,"status":107,"phases":7029,"primaryCompletion":6578,"completion":6578,"start":4322,"enrollment":350,"conditions":7030,"interventions":7031},"NCT00776698","A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.",[89],[2257],[5275,5185,5385],{"nctId":1153,"briefTitle":1154,"status":107,"phases":7033,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":7034,"interventions":7035},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"nctId":5361,"briefTitle":5362,"status":343,"phases":7037,"primaryCompletion":2602,"completion":2602,"start":5364,"enrollment":101,"conditions":7038,"interventions":7039},[89],[2257],[5184,5367,5185,5186,4503],{"nctId":1234,"briefTitle":1235,"status":107,"phases":7041,"primaryCompletion":1237,"completion":1238,"start":393,"enrollment":1239,"conditions":7042,"interventions":7043},[89],[1241],[68,1163,1167],{"trials":7045,"activeCount":162,"soonestReadout":4893},[7046,7050,7058,7062,7071,7075,7079,7083,7087,7091,7099,7103,7107,7111,7115,7119,7123],{"nctId":1266,"briefTitle":1267,"status":107,"phases":7047,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":7048,"interventions":7049},[90],[1274],[68,1167,990,1074],{"nctId":7051,"briefTitle":7052,"status":107,"phases":7053,"primaryCompletion":3084,"completion":3084,"start":7054,"enrollment":909,"conditions":7055,"interventions":7057},"NCT02608073","A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer",[90],"2004-11",[7056],"Nasopharyngeal Cancer",[1166,1167],{"nctId":6575,"briefTitle":6576,"status":107,"phases":7059,"primaryCompletion":5364,"completion":5364,"start":6578,"enrollment":6110,"conditions":7060,"interventions":7061},[90],[2257],[5275,5185,5186,5186],{"nctId":7063,"briefTitle":7064,"status":107,"phases":7065,"primaryCompletion":7066,"completion":7067,"start":7068,"enrollment":1184,"conditions":7069,"interventions":7070},"NCT01461057","A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer",[90],"2015-03-01","2017-10-31","2011-12-06",[1735],[1166,1167,1221,1221,1222],{"nctId":5170,"briefTitle":5171,"status":152,"phases":7072,"primaryCompletion":795,"completion":795,"start":5173,"enrollment":5174,"conditions":7073,"interventions":7074},[89,90],[975],[1140,1957,990,1167,1319],{"nctId":5178,"briefTitle":5179,"status":107,"phases":7076,"primaryCompletion":3146,"completion":3146,"start":5181,"enrollment":2743,"conditions":7077,"interventions":7078},[90],[2257],[5184,5185,5186,5187],{"nctId":1389,"briefTitle":1390,"status":107,"phases":7080,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":7081,"interventions":7082},[90],[1397],[68,1015,1167,1163],{"nctId":1461,"briefTitle":1462,"status":130,"phases":7084,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":7085,"interventions":7086},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":4890,"briefTitle":4891,"status":140,"phases":7088,"primaryCompletion":4893,"completion":4893,"start":4894,"enrollment":2563,"conditions":7089,"interventions":7090},[89,90],[975],[43,1167,990,1319],{"nctId":7092,"briefTitle":7093,"status":107,"phases":7094,"primaryCompletion":7095,"completion":7095,"start":7096,"enrollment":1011,"conditions":7097,"interventions":7098},"NCT00454636","A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and\u002For Metastatic Gastric Cancer.",[90],"2010-07","2007-03",[1735],[1167,1166,5619,1167,1166,1165,947,1166],{"nctId":1530,"briefTitle":1531,"status":107,"phases":7100,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":7101,"interventions":7102},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"nctId":5454,"briefTitle":5455,"status":107,"phases":7104,"primaryCompletion":2685,"completion":2685,"start":5457,"enrollment":5458,"conditions":7105,"interventions":7106},[90],[975],[5384,5186,5185,5367],{"nctId":1588,"briefTitle":1589,"status":107,"phases":7108,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":7109,"interventions":7110},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":6641,"briefTitle":6642,"status":107,"phases":7112,"primaryCompletion":4206,"completion":4206,"start":6644,"enrollment":372,"conditions":7113,"interventions":7114},[90],[2232],[6647,5186,5185],{"nctId":1620,"briefTitle":1621,"status":343,"phases":7116,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":7117,"interventions":7118},[90],[1627],[68,990,1167,1319,1163,1106],{"nctId":4311,"briefTitle":4312,"status":107,"phases":7120,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":37,"conditions":7121,"interventions":7122},[90],[1684],[1015,1167,947],{"nctId":1760,"briefTitle":1761,"status":107,"phases":7124,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":7125,"interventions":7126},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":7128,"activeCount":5110,"soonestReadout":5280},[7129,7133,7140,7148,7156,7160,7164,7168,7175,7179,7183,7187,7191,7195,7199,7203,7207,7211,7215],{"nctId":4338,"briefTitle":4339,"status":107,"phases":7130,"primaryCompletion":2931,"completion":3246,"start":3325,"enrollment":1672,"conditions":7131,"interventions":7132},[91],[1735],[1015,1166,1167],{"nctId":7134,"briefTitle":7135,"status":130,"phases":7136,"primaryCompletion":3006,"completion":2955,"start":2905,"enrollment":4066,"conditions":7137,"interventions":7138},"NCT01450696","A Study of Herceptin (Trastuzumab) in Combination With Cisplatin\u002FCapecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer",[91],[1735],[1166,1167,7139],"Herceptin",{"nctId":7141,"briefTitle":7142,"status":107,"phases":7143,"primaryCompletion":7144,"completion":1802,"start":3096,"enrollment":7145,"conditions":7146,"interventions":7147},"NCT01774786","A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer",[91],"2016-12-09",780,[1735],[1597,1166,1167,1221,1222],{"nctId":7149,"briefTitle":7150,"status":107,"phases":7151,"primaryCompletion":7152,"completion":7152,"start":7153,"enrollment":1452,"conditions":7154,"interventions":7155},"NCT02563054","A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer",[91],"2010-08","2003-04",[1735],[1597,1166,1167],{"nctId":1859,"briefTitle":1860,"status":130,"phases":7157,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":306,"conditions":7158,"interventions":7159},[91],[975],[68,990,1167,1163],{"nctId":6699,"briefTitle":6700,"status":107,"phases":7161,"primaryCompletion":4233,"completion":4233,"start":6702,"enrollment":1523,"conditions":7162,"interventions":7163},[91],[2257],[1167,1163,5275,5275],{"nctId":1950,"briefTitle":1951,"status":107,"phases":7165,"primaryCompletion":1953,"completion":1954,"start":200,"enrollment":1133,"conditions":7166,"interventions":7167},[90,91],[1432],[988,68,1319,990,1167,1957],{"nctId":7169,"briefTitle":7170,"status":107,"phases":7171,"primaryCompletion":4409,"completion":4409,"start":3030,"enrollment":7172,"conditions":7173,"interventions":7174},"NCT01041404","ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer",[91],584,[1735],[1222,1513,1167,1166],{"nctId":1959,"briefTitle":1960,"status":140,"phases":7176,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":7177,"interventions":7178},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":1974,"briefTitle":1975,"status":140,"phases":7180,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":7181,"interventions":7182},[91],[975],[68,1167,1983,947,1163,1319],{"nctId":5240,"briefTitle":5241,"status":107,"phases":7184,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":7185,"interventions":7186},[91],[5248],[4468,989,1319,990,1167,1163],{"nctId":2073,"briefTitle":2074,"status":107,"phases":7188,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":7189,"interventions":7190},[91],[2081],[68,988,1106,1167],{"nctId":2134,"briefTitle":2135,"status":107,"phases":7192,"primaryCompletion":2137,"completion":2138,"start":2139,"enrollment":2140,"conditions":7193,"interventions":7194},[91],[975],[68,990,1167,1319],{"nctId":5268,"briefTitle":5269,"status":107,"phases":7196,"primaryCompletion":2931,"completion":2931,"start":5271,"enrollment":5272,"conditions":7197,"interventions":7198},[91],[2257],[5275,5185,5187],{"nctId":2175,"briefTitle":2176,"status":107,"phases":7200,"primaryCompletion":1383,"completion":2178,"start":2179,"enrollment":2180,"conditions":7201,"interventions":7202},[91],[1538],[68,990,1163,1167],{"nctId":5277,"briefTitle":5278,"status":140,"phases":7204,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":7205,"interventions":7206},[91],[1316],[5286,1167,1983,1163,1319,990],{"nctId":5288,"briefTitle":5289,"status":107,"phases":7208,"primaryCompletion":1925,"completion":5291,"start":5292,"enrollment":5293,"conditions":7209,"interventions":7210},[91],[5295],[5297,990,1167,1163,1319],{"nctId":5299,"briefTitle":5300,"status":130,"phases":7212,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":7213,"interventions":7214},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":5318,"briefTitle":5319,"status":152,"phases":7216,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":3996,"conditions":7217,"interventions":7218},[91],[975,5325],[1140,1957,1319,990,1167],{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[],{"intervention":58,"totalTrials":462,"cells":7224},{"EARLY_PHASE1":7225,"PHASE1":7227,"PHASE2":7239,"PHASE3":7269,"PHASE4":7316,"NA":7318},{"trials":7226,"activeCount":101},[],{"trials":7228,"activeCount":101},[7229],{"nctId":7230,"briefTitle":7231,"status":107,"phases":7232,"primaryCompletion":7233,"completion":7234,"start":7235,"enrollment":1184,"conditions":7236,"interventions":7238},"NCT04912869","A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).",[89],"2024-12-23","2025-08-15","2022-03-26",[7237],"Sickle Cell Disease",[58],{"trials":7240,"activeCount":350,"soonestReadout":2754},[7241,7250,7258],{"nctId":7242,"briefTitle":7243,"status":107,"phases":7244,"primaryCompletion":7245,"completion":7246,"start":7247,"enrollment":4021,"conditions":7248,"interventions":7249},"NCT05075824","A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)",[90],"2025-06-11","2026-04-09","2022-03-09",[7237],[58],{"nctId":7251,"briefTitle":7252,"status":140,"phases":7253,"primaryCompletion":2754,"completion":2754,"start":7254,"enrollment":2572,"conditions":7255,"interventions":7257},"NCT03157635","Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria",[89,90],"2016-11-14",[7256],"Paroxysmal Hemoglobinuria, Nocturnal",[58],{"nctId":7259,"briefTitle":7260,"status":343,"phases":7261,"primaryCompletion":7262,"completion":7263,"start":7264,"enrollment":101,"conditions":7265,"interventions":7267},"NCT07172022","A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)",[90],"2030-03-11","2030-12-02","2026-03-16",[7266],"Antiphospholipid Syndrome",[58,7268],"VKA",{"trials":7270,"activeCount":2631,"soonestReadout":57},[7271,7279,7285,7291,7301,7308],{"nctId":7272,"briefTitle":7273,"status":140,"phases":7274,"primaryCompletion":1591,"completion":7275,"start":1132,"enrollment":984,"conditions":7276,"interventions":7278},"NCT04861259","A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",[91],"2029-08-20",[7277],"Atypical Hemolytic Uremic Syndrome",[58],{"nctId":55,"briefTitle":56,"status":140,"phases":7280,"primaryCompletion":57,"completion":1582,"start":7281,"enrollment":1115,"conditions":7282,"interventions":7284},[91],"2021-03-17",[7283],"Paroxysmal Nocturnal Hemoglobinuria",[58],{"nctId":70,"briefTitle":71,"status":140,"phases":7286,"primaryCompletion":72,"completion":1743,"start":7287,"enrollment":4701,"conditions":7288,"interventions":7289},[91],"2020-10-08",[7283],[58,7290],"Eculizumab",{"nctId":7292,"briefTitle":7293,"status":343,"phases":7294,"primaryCompletion":7295,"completion":2754,"start":7296,"enrollment":101,"conditions":7297,"interventions":7299},"NCT05494619","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)",[91],"2026-03-19","2022-11-30",[7298],"Guillain-Barré Syndrome",[58,7300],"Intravenous immunoglobulin therapy",{"nctId":7302,"briefTitle":7303,"status":140,"phases":7304,"primaryCompletion":1743,"completion":1743,"start":7305,"enrollment":4079,"conditions":7306,"interventions":7307},"NCT04432584","A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors",[91],"2020-09-30",[7283],[58,7290],{"nctId":7309,"briefTitle":7310,"status":140,"phases":7311,"primaryCompletion":335,"completion":7312,"start":7313,"enrollment":2440,"conditions":7314,"interventions":7315},"NCT04958265","A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",[91],"2029-05-19","2021-11-17",[7277],[58],{"trials":7317,"activeCount":101},[],{"trials":7319,"activeCount":101},[],{"intervention":7321,"totalTrials":462,"cells":7322},"Satralizumab",{"EARLY_PHASE1":7323,"PHASE1":7325,"PHASE2":7327,"PHASE3":7339,"PHASE4":7431,"NA":7433},{"trials":7324,"activeCount":101},[],{"trials":7326,"activeCount":101},[],{"trials":7328,"activeCount":350,"soonestReadout":7333},[7329],{"nctId":7330,"briefTitle":7331,"status":140,"phases":7332,"primaryCompletion":7333,"completion":7334,"start":7335,"enrollment":1184,"conditions":7336,"interventions":7338},"NCT06450639","A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)",[90],"2026-08-26","2026-11-18","2025-04-04",[7337],"Duchenne Muscular Dystrophy",[7321],{"trials":7340,"activeCount":2631,"soonestReadout":7385},[7341,7353,7363,7372,7381,7391,7401,7411,7420],{"nctId":7342,"briefTitle":7343,"status":107,"phases":7344,"primaryCompletion":7345,"completion":7346,"start":7347,"enrollment":755,"conditions":7348,"interventions":7351},"NCT02028884","Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)",[91],"2018-06-06","2021-12-23","2014-02-20",[7349,7350],"Neuromyelitis Optica (NMO)","NMO Spectrum Disorder (NMOSD)",[7321,7352],"Baseline Treatment",{"nctId":7354,"briefTitle":7355,"status":152,"phases":7356,"primaryCompletion":2016,"completion":7357,"start":7358,"enrollment":306,"conditions":7359,"interventions":7362},"NCT05199688","A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)",[91],"2029-09-12","2026-05-06",[7360,7361],"Neuromyelitis Optica Spectrum Disorder","NMOSD",[7321],{"nctId":7364,"briefTitle":7365,"status":107,"phases":7366,"primaryCompletion":1281,"completion":1281,"start":593,"enrollment":1651,"conditions":7367,"interventions":7368},"NCT04660539","A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)",[91],[7360],[7369,7370,5848,7371],"satralizumab","azathioprine","oral corticosteroids",{"nctId":7373,"briefTitle":7374,"status":107,"phases":7375,"primaryCompletion":7376,"completion":7377,"start":7378,"enrollment":4021,"conditions":7379,"interventions":7380},"NCT02073279","Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)",[91],"2018-10-12","2022-01-31","2014-08-05",[7349,7350],[7321],{"nctId":7382,"briefTitle":7383,"status":140,"phases":7384,"primaryCompletion":7385,"completion":3958,"start":7386,"enrollment":414,"conditions":7387,"interventions":7390},"NCT05987423","Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease",[91],"2025-07-08","2023-10-26",[7388,7389],"Thyroid Eye Disease","TED",[7321],{"nctId":7392,"briefTitle":7393,"status":130,"phases":7394,"primaryCompletion":7395,"completion":7396,"start":7397,"enrollment":291,"conditions":7398,"interventions":7400},"NCT04963270","A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis",[91],"2024-01-29","2024-09-02","2021-10-19",[7399],"Generalized Myasthenia Gravis",[7321],{"nctId":7402,"briefTitle":7403,"status":140,"phases":7404,"primaryCompletion":7405,"completion":7406,"start":7407,"enrollment":7408,"conditions":7409,"interventions":7410},"NCT06106828","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease",[91],"2025-07-24","2026-06-25","2023-11-15",127,[7388],[7321],{"nctId":7412,"briefTitle":7413,"status":152,"phases":7414,"primaryCompletion":1954,"completion":7415,"start":7416,"enrollment":806,"conditions":7417,"interventions":7419},"NCT05271409","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease",[91],"2028-05-20","2022-08-30",[7418],"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)",[7321],{"nctId":7421,"briefTitle":7422,"status":152,"phases":7423,"primaryCompletion":7424,"completion":7425,"start":7426,"enrollment":806,"conditions":7427,"interventions":7430},"NCT05503264","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis",[91],"2026-12-16","2029-12-14","2022-09-27",[7428,7429],"NMDAR Autoimmune Encephalitis","LGI1 Autoimmune Encephalitis",[7321],{"trials":7432,"activeCount":101},[],{"trials":7434,"activeCount":101},[],{"intervention":2433,"totalTrials":1796,"cells":7436},{"EARLY_PHASE1":7437,"PHASE1":7439,"PHASE2":7453,"PHASE3":7475,"PHASE4":7485,"NA":7487},{"trials":7438,"activeCount":101},[],{"trials":7440,"activeCount":350,"soonestReadout":2426},[7441,7445,7449],{"nctId":2423,"briefTitle":2424,"status":152,"phases":7442,"primaryCompletion":2426,"completion":2427,"start":2428,"enrollment":2429,"conditions":7443,"interventions":7444},[89],[2431],[2433,1096,1073],{"nctId":2537,"briefTitle":2538,"status":107,"phases":7446,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":7447,"interventions":7448},[89],[2543],[1784,1163,1165,2433,1018,1096],{"nctId":2614,"briefTitle":2615,"status":107,"phases":7450,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":2619,"conditions":7451,"interventions":7452},[89],[2621],[2433,1096],{"trials":7454,"activeCount":706,"soonestReadout":2673},[7455,7459,7467,7471],{"nctId":2635,"briefTitle":2636,"status":140,"phases":7456,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":7457,"interventions":7458},[89,90],[2642],[2433,1096,2644,2433],{"nctId":7460,"briefTitle":7461,"status":152,"phases":7462,"primaryCompletion":1413,"completion":268,"start":7463,"enrollment":1184,"conditions":7464,"interventions":7466},"NCT07598396","A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis",[90],"2026-05-25",[7465,2621,3597],"Lupus",[2433],{"nctId":2670,"briefTitle":2671,"status":140,"phases":7468,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":2676,"conditions":7469,"interventions":7470},[89,90],[2678],[2433,2433,2394,1096,1359],{"nctId":2728,"briefTitle":2729,"status":107,"phases":7472,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":7473,"interventions":7474},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"trials":7476,"activeCount":162,"soonestReadout":2983},[7477,7481],{"nctId":6161,"briefTitle":6162,"status":140,"phases":7478,"primaryCompletion":2025,"completion":209,"start":6164,"enrollment":6165,"conditions":7479,"interventions":7480},[91],[6167],[2433,2644,1359,6169],{"nctId":2980,"briefTitle":2981,"status":140,"phases":7482,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":7483,"interventions":7484},[91],[2392],[2433,2394,1096,1359,1163,1165],{"trials":7486,"activeCount":101},[],{"trials":7488,"activeCount":101},[],{"intervention":946,"totalTrials":510,"cells":7490},{"EARLY_PHASE1":7491,"PHASE1":7493,"PHASE2":7532,"PHASE3":7562,"PHASE4":7593,"NA":7595},{"trials":7492,"activeCount":101},[],{"trials":7494,"activeCount":101},[7495,7502,7506,7510,7514,7524],{"nctId":7496,"briefTitle":7497,"status":107,"phases":7498,"primaryCompletion":7499,"completion":7499,"start":1228,"enrollment":709,"conditions":7500,"interventions":7501},"NCT04341259","A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.",[89],"2023-04-06",[922],[946],{"nctId":6898,"briefTitle":6899,"status":130,"phases":7503,"primaryCompletion":6901,"completion":6901,"start":6902,"enrollment":2375,"conditions":7504,"interventions":7505},[89],[18],[946,1421,1573],{"nctId":937,"briefTitle":938,"status":130,"phases":7507,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":7508,"interventions":7509},[89],[944],[946,68,947],{"nctId":1098,"briefTitle":1099,"status":107,"phases":7511,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":7512,"interventions":7513},[89],[18],[946,1106,68,1107,1108],{"nctId":7515,"briefTitle":7516,"status":107,"phases":7517,"primaryCompletion":7518,"completion":7519,"start":7520,"enrollment":1115,"conditions":7521,"interventions":7523},"NCT03840200","A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",[89],"2021-12-07","2022-01-04","2019-06-12",[18,7522,1417],"Prostate Cancer",[946,1178],{"nctId":7525,"briefTitle":7526,"status":107,"phases":7527,"primaryCompletion":7528,"completion":7528,"start":7529,"enrollment":2619,"conditions":7530,"interventions":7531},"NCT03222310","A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib",[89],"2017-09-06","2017-07-18",[427],[946,398],{"trials":7533,"activeCount":5110,"soonestReadout":1413},[7534,7538,7542,7546,7550,7554,7558],{"nctId":1308,"briefTitle":1309,"status":130,"phases":7535,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":7536,"interventions":7537},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":4133,"briefTitle":4134,"status":107,"phases":7539,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":7540,"interventions":7541},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"nctId":1410,"briefTitle":1411,"status":140,"phases":7543,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":7544,"interventions":7545},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1447,"briefTitle":1448,"status":152,"phases":7547,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":7548,"interventions":7549},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":1562,"briefTitle":1563,"status":152,"phases":7551,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":7552,"interventions":7553},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":1687,"briefTitle":1688,"status":140,"phases":7555,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":7556,"interventions":7557},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"nctId":1760,"briefTitle":1761,"status":107,"phases":7559,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":7560,"interventions":7561},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":7563,"activeCount":350,"soonestReadout":2245},[7564,7576,7585,7589],{"nctId":7565,"briefTitle":7566,"status":107,"phases":7567,"primaryCompletion":7568,"completion":7569,"start":7570,"enrollment":7571,"conditions":7572,"interventions":7574},"NCT03072238","Ipatasertib Plus Abiraterone Plus Prednisone\u002FPrednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone\u002FPrednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",[91],"2020-03-16","2024-04-24","2017-06-30",1101,[7573],"Metastatic Prostate Cancer",[946,3371,7575],"Prednisone\u002FPrednisolone",{"nctId":7577,"briefTitle":7578,"status":107,"phases":7579,"primaryCompletion":7580,"completion":7580,"start":7581,"enrollment":7582,"conditions":7583,"interventions":7584},"NCT03337724","A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA\u002FAKT1\u002FPTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",[91],"2023-01-04","2018-01-06",579,[18],[946,1106],{"nctId":2096,"briefTitle":2097,"status":107,"phases":7586,"primaryCompletion":1614,"completion":1614,"start":1009,"enrollment":2099,"conditions":7587,"interventions":7588},[91],[986],[68,946,1106],{"nctId":2242,"briefTitle":2243,"status":152,"phases":7590,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":7591,"interventions":7592},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"intervention":528,"totalTrials":709,"cells":7598},{"EARLY_PHASE1":7599,"PHASE1":7601,"PHASE2":7612,"PHASE3":7655,"PHASE4":7695,"NA":7697},{"trials":7600,"activeCount":101},[],{"trials":7602,"activeCount":101},[7603],{"nctId":7604,"briefTitle":7605,"status":107,"phases":7606,"primaryCompletion":7607,"completion":7607,"start":2417,"enrollment":755,"conditions":7608,"interventions":7610},"NCT06771271","A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema",[89],"2023-11-13",[551,7609],"Uveitic Macular Edema",[7611,528],"RO7200220",{"trials":7613,"activeCount":350,"soonestReadout":7618},[7614,7624,7628,7632,7642,7646],{"nctId":7615,"briefTitle":7616,"status":140,"phases":7617,"primaryCompletion":7618,"completion":7618,"start":2374,"enrollment":7619,"conditions":7620,"interventions":7622},"NCT04567303","Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration",[89,90],"2026-08-01",177,[7621],"Macular Degeneration",[7623,528],"Zifibancimig",{"nctId":519,"briefTitle":520,"status":107,"phases":7625,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":7626,"interventions":7627},[90],[526],[509,528,529],{"nctId":531,"briefTitle":532,"status":107,"phases":7629,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":7630,"interventions":7631},[90],[539,540],[509,528,529],{"nctId":7633,"briefTitle":7634,"status":107,"phases":7635,"primaryCompletion":7636,"completion":7637,"start":52,"enrollment":7638,"conditions":7639,"interventions":7640},"NCT05151731","A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema",[90],"2024-11-06","2025-04-21",394,[551],[7641,528],"Vamikibart",{"nctId":543,"briefTitle":544,"status":107,"phases":7643,"primaryCompletion":546,"completion":547,"start":548,"enrollment":549,"conditions":7644,"interventions":7645},[90],[551],[509,528],{"nctId":7647,"briefTitle":7648,"status":107,"phases":7649,"primaryCompletion":7650,"completion":7651,"start":7652,"enrollment":4961,"conditions":7653,"interventions":7654},"NCT05151744","A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema",[90],"2024-04-17","2024-10-01","2021-12-17",[551],[7641,528],{"trials":7656,"activeCount":5110,"soonestReadout":568},[7657,7661,7669,7676,7685],{"nctId":565,"briefTitle":566,"status":140,"phases":7658,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":7659,"interventions":7660},[91],[573],[509,528],{"nctId":7662,"briefTitle":7663,"status":343,"phases":7664,"primaryCompletion":345,"completion":5706,"start":7665,"enrollment":101,"conditions":7666,"interventions":7668},"NCT05126966","A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration",[91],"2023-12-29",[7667],"Neovascular Age-Related Macular Degeneration",[528,586],{"nctId":7670,"briefTitle":7671,"status":140,"phases":7672,"primaryCompletion":7673,"completion":7673,"start":3573,"enrollment":6743,"conditions":7674,"interventions":7675},"NCT04657289","A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)",[91],"2027-01-28",[670],[528],{"nctId":7677,"briefTitle":7678,"status":152,"phases":7679,"primaryCompletion":7680,"completion":7680,"start":7681,"enrollment":7682,"conditions":7683,"interventions":7684},"NCT06847542","A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD",[91],"2028-11-15","2025-11-27",250,[647],[528],{"nctId":7686,"briefTitle":7687,"status":152,"phases":7688,"primaryCompletion":7689,"completion":7690,"start":7691,"enrollment":4683,"conditions":7692,"interventions":7694},"NCT05562947","A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)",[91],"2027-07-27","2029-08-30","2024-06-17",[647,7693],"nAMD",[528],{"trials":7696,"activeCount":101},[],{"trials":7698,"activeCount":101},[],{"intervention":1422,"totalTrials":942,"cells":7700},{"EARLY_PHASE1":7701,"PHASE1":7703,"PHASE2":7705,"PHASE3":7727,"PHASE4":7737,"NA":7739},{"trials":7702,"activeCount":101},[],{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":706,"soonestReadout":3349},[7707,7711,7715,7719],{"nctId":3346,"briefTitle":3347,"status":152,"phases":7708,"primaryCompletion":3349,"completion":3350,"start":3351,"enrollment":336,"conditions":7709,"interventions":7710},[90],[18],[1137,1456,1422],{"nctId":1410,"briefTitle":1411,"status":140,"phases":7712,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":7713,"interventions":7714},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1562,"briefTitle":1563,"status":152,"phases":7716,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":7717,"interventions":7718},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":7720,"briefTitle":7721,"status":130,"phases":7722,"primaryCompletion":7723,"completion":7723,"start":7724,"enrollment":942,"conditions":7725,"interventions":7726},"NCT00796107","A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer",[90],"2010-03-03","2009-01-28",[18],[5379,1422],{"trials":7728,"activeCount":162,"soonestReadout":5706},[7729,7733],{"nctId":5703,"briefTitle":5704,"status":140,"phases":7730,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":7731,"interventions":7732},[91],[5711],[63,5713,1422,5714,1421,5670],{"nctId":3430,"briefTitle":3431,"status":152,"phases":7734,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":3435,"conditions":7735,"interventions":7736},[91],[18],[1137,3438,1422],{"trials":7738,"activeCount":101},[],{"trials":7740,"activeCount":101},[],{"intervention":82,"totalTrials":942,"cells":7742},{"EARLY_PHASE1":7743,"PHASE1":7745,"PHASE2":7756,"PHASE3":7772,"PHASE4":7796,"NA":7798},{"trials":7744,"activeCount":101},[],{"trials":7746,"activeCount":101},[7747],{"nctId":7748,"briefTitle":7749,"status":107,"phases":7750,"primaryCompletion":7751,"completion":7751,"start":7752,"enrollment":306,"conditions":7753,"interventions":7755},"NCT03596632","Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers",[89],"2018-08-23","2018-07-27",[7754],"Healthy Participants",[82],{"trials":7757,"activeCount":162,"soonestReadout":81},[7758,7767],{"nctId":7759,"briefTitle":7760,"status":152,"phases":7761,"primaryCompletion":7762,"completion":7763,"start":7764,"enrollment":709,"conditions":7765,"interventions":7766},"NCT07161258","A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)",[90],"2027-06-08","2029-02-13","2025-10-06",[232],[82],{"nctId":79,"briefTitle":80,"status":140,"phases":7768,"primaryCompletion":81,"completion":7769,"start":1485,"enrollment":4564,"conditions":7770,"interventions":7771},[90],"2026-12-30",[232],[82],{"trials":7773,"activeCount":706,"soonestReadout":7787},[7774,7783,7792],{"nctId":7775,"briefTitle":7776,"status":140,"phases":7777,"primaryCompletion":7778,"completion":678,"start":7281,"enrollment":7779,"conditions":7780,"interventions":7781},"NCT04586010","A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)",[91],"2026-01-27",746,[232],[82,7782],"Teriflunomide",{"nctId":7784,"briefTitle":7785,"status":140,"phases":7786,"primaryCompletion":7787,"completion":7788,"start":1521,"enrollment":7789,"conditions":7790,"interventions":7791},"NCT04586023","Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)",[91],"2025-09-05","2027-07-09",751,[232],[82,7782],{"nctId":215,"briefTitle":216,"status":140,"phases":7793,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":7794,"interventions":7795},[91],[174],[82,96],{"trials":7797,"activeCount":101},[],{"trials":7799,"activeCount":101},[],{"intervention":1456,"totalTrials":2631,"cells":7801},{"EARLY_PHASE1":7802,"PHASE1":7804,"PHASE2":7806,"PHASE3":7824,"PHASE4":7830,"NA":7832},{"trials":7803,"activeCount":101},[],{"trials":7805,"activeCount":101},[],{"trials":7807,"activeCount":5110,"soonestReadout":3349},[7808,7812,7816,7820],{"nctId":3346,"briefTitle":3347,"status":152,"phases":7809,"primaryCompletion":3349,"completion":3350,"start":3351,"enrollment":336,"conditions":7810,"interventions":7811},[90],[18],[1137,1456,1422],{"nctId":1447,"briefTitle":1448,"status":152,"phases":7813,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":7814,"interventions":7815},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":3373,"briefTitle":3374,"status":152,"phases":7817,"primaryCompletion":3376,"completion":3377,"start":3378,"enrollment":920,"conditions":7818,"interventions":7819},[90],[18],[1137,1456,1573],{"nctId":1562,"briefTitle":1563,"status":152,"phases":7821,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":7822,"interventions":7823},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":7825,"activeCount":350,"soonestReadout":5696},[7826],{"nctId":5693,"briefTitle":5694,"status":152,"phases":7827,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":7828,"interventions":7829},[91],[5700],[63,1573,1420,1421,1456,5670],{"trials":7831,"activeCount":101},[],{"trials":7833,"activeCount":101},[],{"intervention":5670,"totalTrials":2631,"cells":7835},{"EARLY_PHASE1":7836,"PHASE1":7838,"PHASE2":7840,"PHASE3":7846,"PHASE4":7864,"NA":7866},{"trials":7837,"activeCount":101},[],{"trials":7839,"activeCount":101},[],{"trials":7841,"activeCount":350,"soonestReadout":62},[7842],{"nctId":60,"briefTitle":61,"status":140,"phases":7843,"primaryCompletion":62,"completion":5664,"start":5665,"enrollment":3856,"conditions":7844,"interventions":7845},[90],[5667],[63,5669,5670],{"trials":7847,"activeCount":5110,"soonestReadout":5685},[7848,7852,7856,7860],{"nctId":5682,"briefTitle":5683,"status":140,"phases":7849,"primaryCompletion":5685,"completion":5686,"start":5687,"enrollment":5688,"conditions":7850,"interventions":7851},[91],[5655],[63,5691,5670],{"nctId":5693,"briefTitle":5694,"status":152,"phases":7853,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":7854,"interventions":7855},[91],[5700],[63,1573,1420,1421,1456,5670],{"nctId":5703,"briefTitle":5704,"status":140,"phases":7857,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":7858,"interventions":7859},[91],[5711],[63,5713,1422,5714,1421,5670],{"nctId":5716,"briefTitle":5717,"status":140,"phases":7861,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":7862,"interventions":7863},[91],[5723],[3426,63,947,1106,5670,3428],{"trials":7865,"activeCount":101},[],{"trials":7867,"activeCount":101},[],{"intervention":1106,"totalTrials":447,"cells":7869},{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7903,"PHASE3":7998,"PHASE4":8190,"NA":8213},{"trials":7871,"activeCount":101},[],{"trials":7873,"activeCount":101},[7874,7883,7887,7895,7899],{"nctId":7875,"briefTitle":7876,"status":107,"phases":7877,"primaryCompletion":7878,"completion":7878,"start":6237,"enrollment":7879,"conditions":7880,"interventions":7881},"NCT01494688","A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors",[89],"2018-02-07",217,[5357],[1106,7882],"RO5509554",{"nctId":1098,"briefTitle":1099,"status":107,"phases":7884,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":7885,"interventions":7886},[89],[18],[946,1106,68,1107,1108],{"nctId":7888,"briefTitle":7889,"status":107,"phases":7890,"primaryCompletion":7891,"completion":7891,"start":1375,"enrollment":3497,"conditions":7892,"interventions":7893},"NCT01918254","A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein",[89],"2016-10-07",[18],[1106,1221,7894],"Lumretuzumab",{"nctId":5361,"briefTitle":5362,"status":343,"phases":7896,"primaryCompletion":2602,"completion":2602,"start":5364,"enrollment":101,"conditions":7897,"interventions":7898},[89],[2257],[5184,5367,5185,5186,4503],{"nctId":5373,"briefTitle":5374,"status":130,"phases":7900,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":7901,"interventions":7902},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":7904,"activeCount":162,"soonestReadout":5192},[7905,7909,7913,7917,7926,7934,7938,7942,7946,7950,7954,7958,7966,7970,7974,7978,7982,7986,7990,7994],{"nctId":4074,"briefTitle":4075,"status":107,"phases":7906,"primaryCompletion":3285,"completion":4077,"start":4078,"enrollment":4079,"conditions":7907,"interventions":7908},[90],[1417],[1015,1106,990],{"nctId":4083,"briefTitle":4084,"status":107,"phases":7910,"primaryCompletion":2792,"completion":2792,"start":4086,"enrollment":1272,"conditions":7911,"interventions":7912},[90],[18],[4089,4090,992,1106,1015],{"nctId":1361,"briefTitle":1362,"status":107,"phases":7914,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":709,"conditions":7915,"interventions":7916},[89,90],[1367],[68,988,990,1106],{"nctId":7918,"briefTitle":7919,"status":107,"phases":7920,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":7924,"interventions":7925},"NCT02132949","A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer",[90],"2016-03-03","2014-07-14",401,[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":7927,"briefTitle":7928,"status":107,"phases":7929,"primaryCompletion":6004,"completion":6004,"start":7930,"enrollment":1047,"conditions":7931,"interventions":7932},"NCT02015676","A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer",[89,90],"2001-07",[18],[6647,4503,7933],"Myocet",{"nctId":1400,"briefTitle":1401,"status":130,"phases":7935,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":7936,"interventions":7937},[90],[18],[1084,1106,68,1107],{"nctId":1410,"briefTitle":1411,"status":140,"phases":7939,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":7940,"interventions":7941},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":5414,"briefTitle":5415,"status":130,"phases":7943,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":709,"conditions":7944,"interventions":7945},[89,90],[5420],[990,1106,5422],{"nctId":4177,"briefTitle":4178,"status":107,"phases":7947,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":7948,"interventions":7949},[90],[18],[4184,1015,4185,1597,992,1106,947],{"nctId":5189,"briefTitle":5190,"status":140,"phases":7951,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":3015,"conditions":7952,"interventions":7953},[90],[1684],[1445,1957,1106,1319,990],{"nctId":1461,"briefTitle":1462,"status":130,"phases":7955,"primaryCompletion":1464,"completion":1464,"start":1465,"enrollment":37,"conditions":7956,"interventions":7957},[90],[1467],[68,988,990,1167,1319,1163,1106],{"nctId":7959,"briefTitle":7960,"status":107,"phases":7961,"primaryCompletion":7962,"completion":7962,"start":7963,"conditions":7964,"interventions":7965},"NCT00005649","Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer",[90],"2002-07-04","1998-07",[18],[4101,4503],{"nctId":5440,"briefTitle":5441,"status":107,"phases":7967,"primaryCompletion":2809,"completion":2809,"start":4322,"enrollment":1352,"conditions":7968,"interventions":7969},[90],[975],[5275,5367,5384,4503],{"nctId":4246,"briefTitle":4247,"status":107,"phases":7971,"primaryCompletion":2905,"completion":4249,"start":3308,"enrollment":2743,"conditions":7972,"interventions":7973},[90],[18],[1015,1106,1163],{"nctId":4253,"briefTitle":4254,"status":107,"phases":7975,"primaryCompletion":1192,"completion":3592,"start":4256,"enrollment":806,"conditions":7976,"interventions":7977},[90],[1663],[1015,990,1106],{"nctId":1588,"briefTitle":1589,"status":107,"phases":7979,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":7980,"interventions":7981},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":1620,"briefTitle":1621,"status":343,"phases":7983,"primaryCompletion":1623,"completion":1624,"start":1625,"enrollment":101,"conditions":7984,"interventions":7985},[90],[1627],[68,990,1167,1319,1163,1106],{"nctId":5466,"briefTitle":5467,"status":107,"phases":7987,"primaryCompletion":4113,"completion":4113,"start":5469,"enrollment":2524,"conditions":7988,"interventions":7989},[90],[1417],[5472,4503,5186,5367],{"nctId":4294,"briefTitle":4295,"status":107,"phases":7991,"primaryCompletion":4297,"completion":4297,"start":4298,"enrollment":559,"conditions":7992,"interventions":7993},[90],[1417],[990,1106,1015],{"nctId":1760,"briefTitle":1761,"status":107,"phases":7995,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":7996,"interventions":7997},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":7999,"activeCount":706,"soonestReadout":690},[8000,8009,8013,8017,8021,8031,8042,8046,8050,8054,8058,8066,8070,8074,8083,8092,8096,8106,8110,8114,8118,8122,8134,8145,8149,8153,8167,8171,8175,8182,8186],{"nctId":8001,"briefTitle":8002,"status":107,"phases":8003,"primaryCompletion":3007,"completion":3007,"start":8004,"enrollment":8005,"conditions":8006,"interventions":8007},"NCT01998906","A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer",[91],"2002-05",330,[18],[1222,991,1106,8008],"CMF",{"nctId":1815,"briefTitle":1816,"status":130,"phases":8010,"primaryCompletion":1818,"completion":1818,"start":1819,"enrollment":1820,"conditions":8011,"interventions":8012},[91],[1061],[68,1106,1823,992],{"nctId":4352,"briefTitle":4353,"status":107,"phases":8014,"primaryCompletion":4355,"completion":4356,"start":4357,"enrollment":4358,"conditions":8015,"interventions":8016},[91],[975],[1015,990,1106],{"nctId":1825,"briefTitle":1826,"status":140,"phases":8018,"primaryCompletion":690,"completion":690,"start":1714,"enrollment":1001,"conditions":8019,"interventions":8020},[91],[1241],[68,1015,1319,1106,1830],{"nctId":8022,"briefTitle":8023,"status":107,"phases":8024,"primaryCompletion":8025,"completion":8026,"start":8027,"enrollment":8028,"conditions":8029,"interventions":8030},"NCT01940497","A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",[91],"2016-04-05","2018-03-27","2013-11-15",240,[18],[991,947,1106,1222],{"nctId":8032,"briefTitle":8033,"status":107,"phases":8034,"primaryCompletion":8035,"completion":8036,"start":8037,"enrollment":8038,"conditions":8039,"interventions":8040},"NCT03125902","A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)",[91],"2019-11-15","2023-01-17","2017-08-25",653,[986],[8041,2093,1106],"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",{"nctId":6706,"briefTitle":6707,"status":107,"phases":8043,"primaryCompletion":6709,"completion":6710,"start":6453,"enrollment":8,"conditions":8044,"interventions":8045},[91],[1417],[1163,1106,1221,6713],{"nctId":1930,"briefTitle":1931,"status":107,"phases":8047,"primaryCompletion":1933,"completion":1934,"start":1935,"enrollment":1936,"conditions":8048,"interventions":8049},[91],[1316],[68,1015,1106,1319,990],{"nctId":5500,"briefTitle":5501,"status":107,"phases":8051,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":8052,"interventions":8053},[91],[18],[1222,991,992,1106,947,990,5508],{"nctId":7577,"briefTitle":7578,"status":107,"phases":8055,"primaryCompletion":7580,"completion":7580,"start":7581,"enrollment":7582,"conditions":8056,"interventions":8057},[91],[18],[946,1106],{"nctId":8059,"briefTitle":8060,"status":107,"phases":8061,"primaryCompletion":8062,"completion":8062,"start":8063,"enrollment":37,"conditions":8064,"interventions":8065},"NCT02019277","A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",[91],"2016-11-04","2013-12-05",[18],[947,989,1106,1221,1222],{"nctId":1985,"briefTitle":1986,"status":107,"phases":8067,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":8068,"interventions":8069},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":4420,"briefTitle":4421,"status":107,"phases":8071,"primaryCompletion":4423,"completion":4424,"start":4425,"enrollment":1847,"conditions":8072,"interventions":8073},[91],[1417,2211,4427],[1106,1015,990],{"nctId":8075,"briefTitle":8076,"status":107,"phases":8077,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":8081,"interventions":8082},"NCT01966471","A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer",[91],"2021-06-04","2014-01-31",1846,[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":8084,"briefTitle":8085,"status":107,"phases":8086,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":8089,"conditions":8090,"interventions":8091},"NCT01572038","A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer",[91],"2019-09-20","2012-06-01",1436,[4139],[947,989,1106,1221,1222],{"nctId":2073,"briefTitle":2074,"status":107,"phases":8093,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":8094,"interventions":8095},[91],[2081],[68,988,1106,1167],{"nctId":8097,"briefTitle":8098,"status":107,"phases":8099,"primaryCompletion":4712,"completion":8100,"start":8101,"enrollment":8102,"conditions":8103,"interventions":8104},"NCT01663727","Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer",[91],"2017-11-21","2012-08-27",481,[1569],[8105,1106],"Bevacizumab [Avastin]",{"nctId":2096,"briefTitle":2097,"status":107,"phases":8107,"primaryCompletion":1614,"completion":1614,"start":1009,"enrollment":2099,"conditions":8108,"interventions":8109},[91],[986],[68,946,1106],{"nctId":5716,"briefTitle":5717,"status":140,"phases":8111,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":8112,"interventions":8113},[91],[5723],[3426,63,947,1106,5670,3428],{"nctId":4470,"briefTitle":4471,"status":107,"phases":8115,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":4475,"conditions":8116,"interventions":8117},[91],[1417],[1106,1015,990],{"nctId":4494,"briefTitle":4495,"status":107,"phases":8119,"primaryCompletion":4497,"completion":4497,"start":4498,"enrollment":4499,"conditions":8120,"interventions":8121},[91],[1417],[1015,4502,4503,4504],{"nctId":8123,"briefTitle":8124,"status":107,"phases":8125,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":8130,"interventions":8131},"NCT01120184","A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab\u002FPertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)",[91],"2014-09-30","2016-09-16","2010-07-31",1095,[18],[5383,4503,5472,8132,5390,8133],"pertuzumab-placebo","trastuzumab emtansine",{"nctId":8135,"briefTitle":8136,"status":107,"phases":8137,"primaryCompletion":8138,"completion":8139,"start":8140,"enrollment":8141,"conditions":8142,"interventions":8143},"NCT02302807","A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]",[91],"2017-03-13","2018-11-08","2015-01-13",931,[1539],[5297,947,1106,8144],"Vinflunine",{"nctId":2144,"briefTitle":2145,"status":140,"phases":8146,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":8147,"interventions":8148},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":5568,"briefTitle":5569,"status":107,"phases":8150,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":4475,"conditions":8151,"interventions":8152},[91],[5420],[5576,990,1107,1106],{"nctId":8154,"briefTitle":8155,"status":107,"phases":8156,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":8160,"interventions":8161},"NCT03493854","A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",[91],"2019-07-04","2023-06-02","2018-06-14",[5655],[992,991,947,1106,8162,8163,8164,8165,8166],"Pertuzumab IV","FDC of Pertuzumab and Trastuzumab SC","Trastuzumab IV","Trastuzumab SC","Hormone Therapy",{"nctId":5299,"briefTitle":5300,"status":130,"phases":8168,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":8169,"interventions":8170},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":2203,"briefTitle":2204,"status":107,"phases":8172,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":8173,"interventions":8174},[91],[1417,2211,2212],[1106,990,68,1015,2093],{"nctId":8176,"briefTitle":8177,"status":107,"phases":8178,"primaryCompletion":181,"completion":181,"start":8179,"enrollment":2743,"conditions":8180,"interventions":8181},"NCT02194166","A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration",[91],"2014-07-18",[18],[1222,1106,947],{"nctId":4523,"briefTitle":4524,"status":107,"phases":8183,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":4529,"conditions":8184,"interventions":8185},[91],[1316],[4468,1015,990,1106],{"nctId":5610,"briefTitle":5611,"status":107,"phases":8187,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":8188,"interventions":8189},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"trials":8191,"activeCount":101},[8192,8196,8202,8209],{"nctId":4552,"briefTitle":4553,"status":107,"phases":8193,"primaryCompletion":2847,"completion":2847,"start":4555,"enrollment":1001,"conditions":8194,"interventions":8195},[92],[18],[1015,1106,947],{"nctId":8197,"briefTitle":8198,"status":343,"phases":8199,"primaryCompletion":2948,"completion":2948,"start":2906,"enrollment":101,"conditions":8200,"interventions":8201},"NCT01156961","A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)",[92],[18],[5275,4503],{"nctId":8203,"briefTitle":8204,"status":107,"phases":8205,"primaryCompletion":5364,"completion":5364,"start":2964,"enrollment":8206,"conditions":8207,"interventions":8208},"NCT01301729","A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment",[92],32,[18],[947,1106,1222],{"nctId":5623,"briefTitle":5624,"status":107,"phases":8210,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":8211,"interventions":8212},[92],[18],[990,992,947,991,1106,1222],{"trials":8214,"activeCount":101},[8215,8219],{"nctId":4615,"briefTitle":4616,"status":107,"phases":8216,"primaryCompletion":4618,"completion":4618,"start":4619,"enrollment":537,"conditions":8217,"interventions":8218},[],[1417],[1015,990,1106],{"nctId":4645,"briefTitle":4646,"status":107,"phases":8220,"primaryCompletion":4648,"completion":4648,"start":4649,"enrollment":2389,"conditions":8221,"interventions":8222},[],[18],[1015,1106],{"intervention":1222,"totalTrials":3574,"cells":8224},{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8248,"PHASE3":8349,"PHASE4":8503,"NA":8521},{"trials":8226,"activeCount":101},[],{"trials":8228,"activeCount":101},[8229,8237,8244],{"nctId":8230,"briefTitle":8231,"status":107,"phases":8232,"primaryCompletion":3895,"completion":3895,"start":8233,"enrollment":19,"conditions":8234,"interventions":8236},"NCT02627274","A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)",[89],"2015-12-07",[1160,18,8235],"Cancer of Head and Neck",[1051,1222,1138],{"nctId":8238,"briefTitle":8239,"status":107,"phases":8240,"primaryCompletion":42,"completion":42,"start":8241,"enrollment":736,"conditions":8242,"interventions":8243},"NCT02738970","A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)",[89],"2016-06-23",[5655],[1222,1221],{"nctId":1210,"briefTitle":1211,"status":107,"phases":8245,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":8246,"interventions":8247},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"trials":8249,"activeCount":350,"soonestReadout":86},[8250,8256,8263,8270,8274,8278,8285,8294,8298,8302,8312,8316,8327,8331,8337,8345],{"nctId":8251,"briefTitle":8252,"status":107,"phases":8253,"primaryCompletion":4086,"completion":2808,"start":4282,"enrollment":4021,"conditions":8254,"interventions":8255},"NCT01674062","A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer",[90],[18],[1221,1222],{"nctId":8257,"briefTitle":8258,"status":130,"phases":8259,"primaryCompletion":4086,"completion":4086,"start":8260,"enrollment":942,"conditions":8261,"interventions":8262},"NCT02005484","A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression",[90],"2004-01",[1735],[1222],{"nctId":8264,"briefTitle":8265,"status":107,"phases":8266,"primaryCompletion":5181,"completion":2801,"start":4113,"enrollment":2429,"conditions":8267,"interventions":8268},"NCT00679341","A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease",[90],[18],[8269,1222,947],"Trastuzumab emtansine [Kadcyla]",{"nctId":7063,"briefTitle":7064,"status":107,"phases":8271,"primaryCompletion":7066,"completion":7067,"start":7068,"enrollment":1184,"conditions":8272,"interventions":8273},[90],[1735],[1166,1167,1221,1221,1222],{"nctId":7918,"briefTitle":7919,"status":107,"phases":8275,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":8276,"interventions":8277},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":8279,"briefTitle":8280,"status":107,"phases":8281,"primaryCompletion":3213,"completion":3213,"start":133,"enrollment":4886,"conditions":8282,"interventions":8283},"NCT00475670","A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer",[90],[18],[1222,8284],"Taxane",{"nctId":8286,"briefTitle":8287,"status":107,"phases":8288,"primaryCompletion":8289,"completion":3642,"start":8290,"enrollment":1705,"conditions":8291,"interventions":8293},"NCT01748773","A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer",[90],"2015-08-21","2013-01-29",[1735,8292],"Gastroesophageal Junction Cancer",[1165,1166,1222],{"nctId":7927,"briefTitle":7928,"status":107,"phases":8295,"primaryCompletion":6004,"completion":6004,"start":7930,"enrollment":1047,"conditions":8296,"interventions":8297},[89,90],[18],[6647,4503,7933],{"nctId":4168,"briefTitle":4169,"status":107,"phases":8299,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":806,"conditions":8300,"interventions":8301},[90],[18],[1015,947,1222,4175],{"nctId":8303,"briefTitle":8304,"status":107,"phases":8305,"primaryCompletion":8306,"completion":444,"start":8307,"enrollment":8308,"conditions":8309,"interventions":8310},"NCT01491737","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer",[90],"2016-03-17","2012-02-17",258,[18],[1221,1222,4184,8311],"Induction Chemotherapy",{"nctId":1517,"briefTitle":1518,"status":107,"phases":8313,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":8314,"interventions":8315},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":8317,"briefTitle":8318,"status":107,"phases":8319,"primaryCompletion":8320,"completion":8321,"start":3084,"enrollment":8322,"conditions":8323,"interventions":8324},"NCT00976989","A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer",[90],"2011-06","2016-01",225,[18],[1221,1222,8325,947,8326],"FEC","TCH",{"nctId":6641,"briefTitle":6642,"status":107,"phases":8328,"primaryCompletion":4206,"completion":4206,"start":6644,"enrollment":372,"conditions":8329,"interventions":8330},[90],[2232],[6647,5186,5185],{"nctId":8332,"briefTitle":8333,"status":130,"phases":8334,"primaryCompletion":4206,"completion":4206,"start":6644,"enrollment":2631,"conditions":8335,"interventions":8336},"NCT02013765","A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer",[90],[2232],[6647],{"nctId":8338,"briefTitle":8339,"status":107,"phases":8340,"primaryCompletion":8341,"completion":8341,"start":2793,"enrollment":8342,"conditions":8343,"interventions":8344},"NCT01565083","A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer",[90],"2015-10",213,[18],[1221,1222,1983],{"nctId":84,"briefTitle":85,"status":140,"phases":8346,"primaryCompletion":86,"completion":1731,"start":1732,"enrollment":1733,"conditions":8347,"interventions":8348},[90],[1735,1736],[68,1222,1166,1165],{"trials":8350,"activeCount":706,"soonestReadout":1582},[8351,8361,8365,8369,8376,8380,8388,8392,8401,8405,8409,8418,8422,8426,8430,8434,8442,8451,8455,8461,8468,8476,8480,8487,8491],{"nctId":8352,"briefTitle":8353,"status":107,"phases":8354,"primaryCompletion":8355,"completion":8356,"start":8357,"enrollment":8358,"conditions":8359,"interventions":8360},"NCT01772472","A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)",[91],"2018-07-25","2024-05-23","2013-04-03",1486,[18],[6647,8133],{"nctId":8001,"briefTitle":8002,"status":107,"phases":8362,"primaryCompletion":3007,"completion":3007,"start":8004,"enrollment":8005,"conditions":8363,"interventions":8364},[91],[18],[1222,991,1106,8008],{"nctId":7141,"briefTitle":7142,"status":107,"phases":8366,"primaryCompletion":7144,"completion":1802,"start":3096,"enrollment":7145,"conditions":8367,"interventions":8368},[91],[1735],[1597,1166,1167,1221,1222],{"nctId":8370,"briefTitle":8371,"status":107,"phases":8372,"primaryCompletion":8373,"completion":8373,"start":5505,"enrollment":4573,"conditions":8374,"interventions":8375},"NCT02040935","A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants",[91],"2018-09-14",[18],[1222],{"nctId":8022,"briefTitle":8023,"status":107,"phases":8377,"primaryCompletion":8025,"completion":8026,"start":8027,"enrollment":8028,"conditions":8378,"interventions":8379},[91],[18],[991,947,1106,1222],{"nctId":8381,"briefTitle":8382,"status":107,"phases":8383,"primaryCompletion":8384,"completion":8385,"start":2855,"enrollment":1158,"conditions":8386,"interventions":8387},"NCT02896855","A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",[91],"2018-06-27","2021-01-22",[18],[947,1221,1222],{"nctId":1912,"briefTitle":1913,"status":140,"phases":8389,"primaryCompletion":268,"completion":1915,"start":1846,"enrollment":1916,"conditions":8390,"interventions":8391},[91],[18],[68,1419,1222],{"nctId":8393,"briefTitle":8394,"status":107,"phases":8395,"primaryCompletion":8396,"completion":8397,"start":8398,"enrollment":3247,"conditions":8399,"interventions":8400},"NCT01926886","A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)",[91],"2015-09-04","2017-07-19","2013-11-19",[18],[1222],{"nctId":5500,"briefTitle":5501,"status":107,"phases":8402,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":8403,"interventions":8404},[91],[18],[1222,991,992,1106,947,990,5508],{"nctId":7169,"briefTitle":7170,"status":107,"phases":8406,"primaryCompletion":4409,"completion":4409,"start":3030,"enrollment":7172,"conditions":8407,"interventions":8408},[91],[1735],[1222,1513,1167,1166],{"nctId":8410,"briefTitle":8411,"status":107,"phases":8412,"primaryCompletion":3254,"completion":8413,"start":4095,"enrollment":8414,"conditions":8415,"interventions":8416},"NCT02586025","Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel",[91],"2022-03-14",329,[18],[8417,947,1221,1222],"FEC Chemotherapy",{"nctId":8059,"briefTitle":8060,"status":107,"phases":8419,"primaryCompletion":8062,"completion":8062,"start":8063,"enrollment":37,"conditions":8420,"interventions":8421},[91],[18],[947,989,1106,1221,1222],{"nctId":1985,"briefTitle":1986,"status":107,"phases":8423,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":8424,"interventions":8425},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":8075,"briefTitle":8076,"status":107,"phases":8427,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":8428,"interventions":8429},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":8084,"briefTitle":8085,"status":107,"phases":8431,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":8089,"conditions":8432,"interventions":8433},[91],[4139],[947,989,1106,1221,1222],{"nctId":8435,"briefTitle":8436,"status":140,"phases":8437,"primaryCompletion":1582,"completion":1582,"start":8438,"enrollment":5458,"conditions":8439,"interventions":8440},"NCT02320435","A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial",[91],"2015-02-02",[922],[1221,1222,8441],"Other Combination Anti-Cancer Therapies",{"nctId":8443,"briefTitle":8444,"status":107,"phases":8445,"primaryCompletion":8446,"completion":8447,"start":8448,"enrollment":3077,"conditions":8449,"interventions":8450},"NCT01026142","A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)",[91],"2015-05-29","2017-08-07","2010-01-26",[18],[1166,1166,1221,1222],{"nctId":5543,"briefTitle":5544,"status":107,"phases":8452,"primaryCompletion":1214,"completion":5546,"start":5547,"enrollment":5548,"conditions":8453,"interventions":8454},[91],[4139],[990,947,1221,1222,1419],{"nctId":8456,"briefTitle":8457,"status":130,"phases":8458,"primaryCompletion":8321,"completion":8321,"start":3174,"enrollment":1001,"conditions":8459,"interventions":8460},"NCT02144012","A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer",[91],[1569],[1222,1419,947],{"nctId":8462,"briefTitle":8463,"status":107,"phases":8464,"primaryCompletion":3022,"completion":3022,"start":6644,"enrollment":8,"conditions":8465,"interventions":8466},"NCT00022672","A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer",[91],[18],[6647,8467],"anastrazole",{"nctId":8469,"briefTitle":8470,"status":107,"phases":8471,"primaryCompletion":8472,"completion":8472,"start":8473,"enrollment":22,"conditions":8474,"interventions":8475},"NCT01810393","A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years",[91],"2019-07-17","2013-06-11",[18],[1222],{"nctId":8176,"briefTitle":8177,"status":107,"phases":8477,"primaryCompletion":181,"completion":181,"start":8179,"enrollment":2743,"conditions":8478,"interventions":8479},[91],[18],[1222,1106,947],{"nctId":8481,"briefTitle":8482,"status":107,"phases":8483,"primaryCompletion":2932,"completion":2932,"start":8484,"enrollment":1724,"conditions":8485,"interventions":8486},"NCT00448279","THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.",[91],"2007-04",[18],[6647,1572],{"nctId":5610,"briefTitle":5611,"status":107,"phases":8488,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":8489,"interventions":8490},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"nctId":8492,"briefTitle":8493,"status":152,"phases":8494,"primaryCompletion":8495,"completion":8496,"start":5193,"enrollment":8497,"conditions":8498,"interventions":8500},"NCT07413939","RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive",[90,91],"2029-05-01","2032-09-29",650,[8499],"HER2-positive Breast Cancer",[8501,8502,1222,1166],"RO7771950","Tucatinib",{"trials":8504,"activeCount":101},[8505,8509,8517],{"nctId":8203,"briefTitle":8204,"status":107,"phases":8506,"primaryCompletion":5364,"completion":5364,"start":2964,"enrollment":8206,"conditions":8507,"interventions":8508},[92],[18],[947,1106,1222],{"nctId":8510,"briefTitle":8511,"status":107,"phases":8512,"primaryCompletion":8513,"completion":8513,"start":8514,"enrollment":973,"conditions":8515,"interventions":8516},"NCT02445586","Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer",[92],"2018-09-26","2015-08-17",[18],[947,1221,1222],{"nctId":5623,"briefTitle":5624,"status":107,"phases":8518,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":8519,"interventions":8520},[92],[18],[990,992,947,991,1106,1222],{"trials":8522,"activeCount":350,"soonestReadout":2025},[8523,8531,8537,8545,8552,8560,8569],{"nctId":8524,"briefTitle":8525,"status":107,"phases":8526,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":3923,"conditions":8529,"interventions":8530},"NCT01480674","An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years",[],"2012-11-16","2011-03-28",[18],[1222],{"nctId":8532,"briefTitle":8533,"status":107,"phases":8534,"primaryCompletion":132,"completion":132,"start":2768,"enrollment":1058,"conditions":8535,"interventions":8536},"NCT02658461","An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)",[],[18],[1222],{"nctId":8538,"briefTitle":8539,"status":130,"phases":8540,"primaryCompletion":8541,"completion":8541,"start":8542,"enrollment":7682,"conditions":8543,"interventions":8544},"NCT01187381","An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",[],"2015-10-15","2010-04-14",[18],[1222],{"nctId":8546,"briefTitle":8547,"status":107,"phases":8548,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":3445,"conditions":8549,"interventions":8551},"NCT02731313","Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma",[],[8550],"Gastric Cancer, Gastroesophageal Junction Cancer",[1222],{"nctId":8553,"briefTitle":8554,"status":107,"phases":8555,"primaryCompletion":8556,"completion":8556,"start":2897,"enrollment":8557,"conditions":8558,"interventions":8559},"NCT01959386","A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer",[],"2019-01-31",1006,[4139],[1222],{"nctId":8561,"briefTitle":8562,"status":107,"phases":8563,"primaryCompletion":8564,"completion":8564,"start":8565,"enrollment":8566,"conditions":8567,"interventions":8568},"NCT01839500","A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer",[],"2018-01-09","2013-04-25",1600,[1735],[1222],{"nctId":2335,"briefTitle":2336,"status":140,"phases":8570,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":8571,"interventions":8572},[],[18],[1015,1222,2342,1221,68,1166],{"intervention":1166,"totalTrials":973,"cells":8574},{"EARLY_PHASE1":8575,"PHASE1":8577,"PHASE2":8591,"PHASE3":8716,"PHASE4":8796,"NA":8820},{"trials":8576,"activeCount":101},[],{"trials":8578,"activeCount":101},[8579,8587],{"nctId":8580,"briefTitle":8581,"status":107,"phases":8582,"primaryCompletion":3030,"completion":3030,"start":8260,"enrollment":8583,"conditions":8584,"interventions":8585},"NCT02494596","A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors",[89],19,[1160],[1166,8586],"RhuMab 2C4",{"nctId":1153,"briefTitle":1154,"status":107,"phases":8588,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":8589,"interventions":8590},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"trials":8592,"activeCount":706,"soonestReadout":86},[8593,8597,8601,8608,8612,8616,8624,8628,8635,8639,8643,8650,8654,8662,8666,8670,8677,8684,8693,8700,8704,8708,8712],{"nctId":7051,"briefTitle":7052,"status":107,"phases":8594,"primaryCompletion":3084,"completion":3084,"start":7054,"enrollment":909,"conditions":8595,"interventions":8596},[90],[7056],[1166,1167],{"nctId":4092,"briefTitle":4093,"status":130,"phases":8598,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":8599,"interventions":8600},[90],[4098],[4089,4100,4101,4102,4103,4104],{"nctId":8602,"briefTitle":8603,"status":107,"phases":8604,"primaryCompletion":2905,"completion":2905,"start":8605,"enrollment":3015,"conditions":8606,"interventions":8607},"NCT02846428","To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer",[90],"2004-03",[18],[1597,1166,992,947,5619],{"nctId":7063,"briefTitle":7064,"status":107,"phases":8609,"primaryCompletion":7066,"completion":7067,"start":7068,"enrollment":1184,"conditions":8610,"interventions":8611},[90],[1735],[1166,1167,1221,1221,1222],{"nctId":8286,"briefTitle":8287,"status":107,"phases":8613,"primaryCompletion":8289,"completion":3642,"start":8290,"enrollment":1705,"conditions":8614,"interventions":8615},[90],[1735,8292],[1165,1166,1222],{"nctId":8617,"briefTitle":8618,"status":130,"phases":8619,"primaryCompletion":8620,"completion":8620,"start":8621,"enrollment":3015,"conditions":8622,"interventions":8623},"NCT01702558","A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced\u002FMetastatic Gastric Cancer (LA\u002FmGC)",[90],"2017-05-31","2012-12-03",[18,1735],[1166,1223,1223,1166],{"nctId":1481,"briefTitle":1482,"status":130,"phases":8625,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":931,"conditions":8626,"interventions":8627},[89,90],[1487],[68,1166,1165,988],{"nctId":8629,"briefTitle":8630,"status":107,"phases":8631,"primaryCompletion":4249,"completion":3029,"start":6620,"enrollment":909,"conditions":8632,"interventions":8634},"NCT01118377","A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas",[90],[8633],"Brainstem Glioma",[1166],{"nctId":7092,"briefTitle":7093,"status":107,"phases":8636,"primaryCompletion":7095,"completion":7095,"start":7096,"enrollment":1011,"conditions":8637,"interventions":8638},[90],[1735],[1167,1166,5619,1167,1166,1165,947,1166],{"nctId":7959,"briefTitle":7960,"status":107,"phases":8640,"primaryCompletion":7962,"completion":7962,"start":7963,"conditions":8641,"interventions":8642},[90],[18],[4101,4503],{"nctId":8644,"briefTitle":8645,"status":130,"phases":8646,"primaryCompletion":4233,"completion":4233,"start":5271,"enrollment":425,"conditions":8647,"interventions":8648},"NCT00977379","A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis",[90],[18],[1166,8649],"Standard of Care",{"nctId":1517,"briefTitle":1518,"status":107,"phases":8651,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":8652,"interventions":8653},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":8655,"briefTitle":8656,"status":107,"phases":8657,"primaryCompletion":5457,"completion":8658,"start":8659,"enrollment":336,"conditions":8660,"interventions":8661},"NCT02694718","A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer",[90],"2006-11","2005-03",[1727],[1166,1165],{"nctId":6625,"briefTitle":6626,"status":107,"phases":8663,"primaryCompletion":6277,"completion":6277,"start":6628,"enrollment":6629,"conditions":8664,"interventions":8665},[90],[6622],[1166,1163],{"nctId":1562,"briefTitle":1563,"status":152,"phases":8667,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":8668,"interventions":8669},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":8671,"briefTitle":8672,"status":107,"phases":8673,"primaryCompletion":4410,"completion":4410,"start":8674,"enrollment":6514,"conditions":8675,"interventions":8676},"NCT00022698","Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer",[90],"2001-05",[30],[1166,4577],{"nctId":8678,"briefTitle":8679,"status":107,"phases":8680,"primaryCompletion":8681,"completion":8681,"start":4563,"enrollment":2933,"conditions":8682,"interventions":8683},"NCT01131078","A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum",[90],"2012-11",[30],[8105,1166,4577],{"nctId":8685,"briefTitle":8686,"status":107,"phases":8687,"primaryCompletion":8688,"completion":8688,"start":8689,"enrollment":721,"conditions":8690,"interventions":8691},"NCT02576964","A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer",[90],"2008-11","2005-01",[1443],[1166,8692],"Peginterferon alfa-2a",{"nctId":8694,"briefTitle":8695,"status":107,"phases":8696,"primaryCompletion":4555,"completion":4555,"start":6316,"enrollment":8697,"conditions":8698,"interventions":8699},"NCT00077857","A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer",[90],470,[18],[4101,5383],{"nctId":1718,"briefTitle":1719,"status":140,"phases":8701,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":8702,"interventions":8703},[90],[1726,1727],[1166,1513,68,988],{"nctId":84,"briefTitle":85,"status":140,"phases":8705,"primaryCompletion":86,"completion":1731,"start":1732,"enrollment":1733,"conditions":8706,"interventions":8707},[90],[1735,1736],[68,1222,1166,1165],{"nctId":4319,"briefTitle":4320,"status":107,"phases":8709,"primaryCompletion":4322,"start":4323,"enrollment":4324,"conditions":8710,"interventions":8711},[90],[30],[4101,1165,4100,4101,1165,4100],{"nctId":1788,"briefTitle":1789,"status":130,"phases":8713,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1174,"conditions":8714,"interventions":8715},[90],[1794,1735,1736],[68,988,1165,1166],{"trials":8717,"activeCount":350,"soonestReadout":8495},[8718,8722,8731,8735,8739,8743,8747,8755,8759,8763,8773,8777,8784,8788,8792],{"nctId":4338,"briefTitle":4339,"status":107,"phases":8719,"primaryCompletion":2931,"completion":3246,"start":3325,"enrollment":1672,"conditions":8720,"interventions":8721},[91],[1735],[1015,1166,1167],{"nctId":8723,"briefTitle":8724,"status":107,"phases":8725,"primaryCompletion":8726,"completion":8726,"start":8727,"enrollment":8728,"conditions":8729,"interventions":8730},"NCT00069121","A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer",[91],"2011-04-21","2003-04-18",1886,[30],[1166,1165,1164,1597],{"nctId":7134,"briefTitle":7135,"status":130,"phases":8732,"primaryCompletion":3006,"completion":2955,"start":2905,"enrollment":4066,"conditions":8733,"interventions":8734},[91],[1735],[1166,1167,7139],{"nctId":7141,"briefTitle":7142,"status":107,"phases":8736,"primaryCompletion":7144,"completion":1802,"start":3096,"enrollment":7145,"conditions":8737,"interventions":8738},[91],[1735],[1597,1166,1167,1221,1222],{"nctId":7149,"briefTitle":7150,"status":107,"phases":8740,"primaryCompletion":7152,"completion":7152,"start":7153,"enrollment":1452,"conditions":8741,"interventions":8742},[91],[1735],[1597,1166,1167],{"nctId":4374,"briefTitle":4375,"status":107,"phases":8744,"primaryCompletion":3674,"completion":3674,"start":4315,"enrollment":571,"conditions":8745,"interventions":8746},[91],[30],[1015,1166],{"nctId":8748,"briefTitle":8749,"status":107,"phases":8750,"primaryCompletion":8681,"completion":8681,"start":8751,"enrollment":8752,"conditions":8753,"interventions":8754},"NCT02560974","A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer",[91],"2006-06",1035,[1735],[1166,1165],{"nctId":7169,"briefTitle":7170,"status":107,"phases":8756,"primaryCompletion":4409,"completion":4409,"start":3030,"enrollment":7172,"conditions":8757,"interventions":8758},[91],[1735],[1222,1513,1167,1166],{"nctId":4406,"briefTitle":4407,"status":107,"phases":8760,"primaryCompletion":4409,"completion":3213,"start":4410,"enrollment":4411,"conditions":8761,"interventions":8762},[91],[30],[1015,1166,1597,4414,1165],{"nctId":8764,"briefTitle":8765,"status":107,"phases":8766,"primaryCompletion":8767,"completion":8768,"start":8769,"enrollment":4637,"conditions":8770,"interventions":8771},"NCT03084939","Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer",[91],"2018-11-23","2023-03-14","2017-04-24",[18],[1419,8772,1166],"Lapatinib",{"nctId":8443,"briefTitle":8444,"status":107,"phases":8774,"primaryCompletion":8446,"completion":8447,"start":8448,"enrollment":3077,"conditions":8775,"interventions":8776},[91],[18],[1166,1166,1221,1222],{"nctId":8778,"briefTitle":8779,"status":107,"phases":8780,"primaryCompletion":3007,"completion":2808,"start":3479,"enrollment":8781,"conditions":8782,"interventions":8783},"NCT00829166","A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer",[91],991,[18],[1223,8772,1166],{"nctId":4479,"briefTitle":4480,"status":107,"phases":8785,"primaryCompletion":2801,"completion":2801,"start":4198,"enrollment":1548,"conditions":8786,"interventions":8787},[91],[30],[1015,1166,1165],{"nctId":2103,"briefTitle":2104,"status":107,"phases":8789,"primaryCompletion":2106,"completion":2106,"start":534,"enrollment":2107,"conditions":8790,"interventions":8791},[91],[2109],[68,1163,1166,990],{"nctId":8492,"briefTitle":8493,"status":152,"phases":8793,"primaryCompletion":8495,"completion":8496,"start":5193,"enrollment":8497,"conditions":8794,"interventions":8795},[90,91],[8499],[8501,8502,1222,1166],{"trials":8797,"activeCount":101},[8798,8802,8806,8814],{"nctId":4559,"briefTitle":4560,"status":107,"phases":8799,"primaryCompletion":4562,"completion":4562,"start":4563,"enrollment":4564,"conditions":8800,"interventions":8801},[92],[18],[1166,1015],{"nctId":4568,"briefTitle":4569,"status":107,"phases":8803,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":8804,"interventions":8805},[92],[4098],[1165,1166,1015,1164,4576,4577],{"nctId":8807,"briefTitle":8808,"status":107,"phases":8809,"primaryCompletion":8810,"completion":8810,"start":8811,"enrollment":496,"conditions":8812,"interventions":8813},"NCT02567331","A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer",[92],"2006-04","2004-10",[30],[1166],{"nctId":8815,"briefTitle":8816,"status":107,"phases":8817,"primaryCompletion":7096,"completion":7096,"start":2923,"enrollment":6629,"conditions":8818,"interventions":8819},"NCT02581423","A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer",[92],[30],[1166],{"trials":8821,"activeCount":350,"soonestReadout":2025},[8822,8831,8838,8842,8846,8850,8856,8862],{"nctId":8823,"briefTitle":8824,"status":107,"phases":8825,"primaryCompletion":3007,"completion":3007,"start":8826,"enrollment":8827,"conditions":8828,"interventions":8830},"NCT01664494","An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer",[],"2010-04",563,[8829],"Breast Cancer, Colorectal Cancer, Gastric Cancer",[1166],{"nctId":8832,"briefTitle":8833,"status":107,"phases":8834,"primaryCompletion":4232,"completion":4232,"start":6315,"enrollment":8835,"conditions":8836,"interventions":8837},"NCT01442155","An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer",[],74,[30],[1166,1165],{"nctId":4666,"briefTitle":4667,"status":107,"phases":8839,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":8840,"interventions":8841},[],[30],[1015,4674,4675,1166,4676,4677],{"nctId":4679,"briefTitle":4680,"status":107,"phases":8843,"primaryCompletion":4682,"completion":4682,"start":4314,"enrollment":4683,"conditions":8844,"interventions":8845},[],[30],[1015,1166,1165],{"nctId":2335,"briefTitle":2336,"status":140,"phases":8847,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":8848,"interventions":8849},[],[18],[1015,1222,2342,1221,68,1166],{"nctId":8851,"briefTitle":8852,"status":107,"phases":8853,"primaryCompletion":3324,"completion":3324,"start":2948,"enrollment":1204,"conditions":8854,"interventions":8855},"NCT01777945","XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer",[],[18],[4101,5383],{"nctId":8857,"briefTitle":8858,"status":107,"phases":8859,"primaryCompletion":3006,"completion":3006,"start":2964,"enrollment":668,"conditions":8860,"interventions":8861},"NCT01725386","An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer",[],[18],[1166],{"nctId":8863,"briefTitle":8864,"status":107,"phases":8865,"primaryCompletion":3324,"completion":3324,"start":4314,"enrollment":8866,"conditions":8867,"interventions":8868},"NCT01696695","An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer",[],882,[30],[1166,1572],{"intervention":1165,"totalTrials":1733,"cells":8870},{"EARLY_PHASE1":8871,"PHASE1":8873,"PHASE2":8894,"PHASE3":9019,"PHASE4":9065,"NA":9084},{"trials":8872,"activeCount":101},[],{"trials":8874,"activeCount":350,"soonestReadout":2482},[8875,8879,8883,8887],{"nctId":2479,"briefTitle":2480,"status":152,"phases":8876,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":37,"conditions":8877,"interventions":8878},[89],[1038],[1784,1096,1018,1163,1165],{"nctId":2537,"briefTitle":2538,"status":107,"phases":8880,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":145,"conditions":8881,"interventions":8882},[89],[2543],[1784,1163,1165,2433,1018,1096],{"nctId":1153,"briefTitle":1154,"status":107,"phases":8884,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":8885,"interventions":8886},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"nctId":8888,"briefTitle":8889,"status":107,"phases":8890,"primaryCompletion":6277,"completion":4582,"start":4323,"enrollment":1058,"conditions":8891,"interventions":8892},"NCT00353262","A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.",[89],[30],[8893,1165,5381],"Avastin",{"trials":8895,"activeCount":162,"soonestReadout":86},[8896,8900,8904,8908,8912,8916,8920,8926,8930,8937,8943,8949,8957,8961,8965,8973,8980,8986,8993,8997,9003,9007,9011,9015],{"nctId":4092,"briefTitle":4093,"status":130,"phases":8897,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":8898,"interventions":8899},[90],[4098],[4089,4100,4101,4102,4103,4104],{"nctId":4124,"briefTitle":4125,"status":107,"phases":8901,"primaryCompletion":2856,"completion":4127,"start":4128,"enrollment":1080,"conditions":8902,"interventions":8903},[90],[30],[1597,1015,4131,1165],{"nctId":8286,"briefTitle":8287,"status":107,"phases":8905,"primaryCompletion":8289,"completion":3642,"start":8290,"enrollment":1705,"conditions":8906,"interventions":8907},[90],[1735,8292],[1165,1166,1222],{"nctId":1481,"briefTitle":1482,"status":130,"phases":8909,"primaryCompletion":1484,"completion":1484,"start":1485,"enrollment":931,"conditions":8910,"interventions":8911},[89,90],[1487],[68,1166,1165,988],{"nctId":7092,"briefTitle":7093,"status":107,"phases":8913,"primaryCompletion":7095,"completion":7095,"start":7096,"enrollment":1011,"conditions":8914,"interventions":8915},[90],[1735],[1167,1166,5619,1167,1166,1165,947,1166],{"nctId":1504,"briefTitle":1505,"status":107,"phases":8917,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":8918,"interventions":8919},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":8921,"briefTitle":8922,"status":107,"phases":8923,"primaryCompletion":6004,"completion":6004,"start":8484,"enrollment":97,"conditions":8924,"interventions":8925},"NCT00439426","A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.",[90],[7056],[1165,5381],{"nctId":8655,"briefTitle":8656,"status":107,"phases":8927,"primaryCompletion":5457,"completion":8658,"start":8659,"enrollment":336,"conditions":8928,"interventions":8929},[90],[1727],[1166,1165],{"nctId":8931,"briefTitle":8932,"status":107,"phases":8933,"primaryCompletion":4454,"completion":4454,"start":8934,"enrollment":920,"conditions":8935,"interventions":8936},"NCT00778102","A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.",[90],"2008-10",[30],[1162,1162,1162,4577,1164,1164,1165,5275],{"nctId":8938,"briefTitle":8939,"status":130,"phases":8940,"primaryCompletion":3325,"completion":3325,"start":4281,"enrollment":2440,"conditions":8941,"interventions":8942},"NCT00642603","A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer",[90],[30],[5381,5381,5275,4104,4102],{"nctId":8944,"briefTitle":8945,"status":107,"phases":8946,"primaryCompletion":2685,"completion":2685,"start":3085,"enrollment":909,"conditions":8947,"interventions":8948},"NCT00700570","A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer",[90],[30],[5275,5381,4104],{"nctId":8950,"briefTitle":8951,"status":107,"phases":8952,"primaryCompletion":3103,"completion":3103,"start":4488,"enrollment":817,"conditions":8953,"interventions":8954},"NCT01077739","A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin",[90],[30],[8955,8956,5275,5381,4104],"fluorouracil","leucovorin",{"nctId":1588,"briefTitle":1589,"status":107,"phases":8958,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":8959,"interventions":8960},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":4264,"briefTitle":4265,"status":130,"phases":8962,"primaryCompletion":3122,"completion":4267,"start":4268,"enrollment":4269,"conditions":8963,"interventions":8964},[90],[30],[1162,1015,4272,1165,4037],{"nctId":8966,"briefTitle":8967,"status":107,"phases":8968,"primaryCompletion":3174,"completion":3174,"start":7095,"enrollment":1058,"conditions":8969,"interventions":8970},"NCT01130337","A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer",[90],[1735],[8971,1165,8972],"Capecitabine [Xeloda]","Trastuzumab [Herceptin]",{"nctId":8974,"briefTitle":8975,"status":107,"phases":8976,"primaryCompletion":7095,"completion":7095,"start":8977,"enrollment":37,"conditions":8978,"interventions":8979},"NCT01159171","A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.",[90],"2006-01",[30],[5275,5381,4104],{"nctId":8981,"briefTitle":8982,"status":107,"phases":8983,"primaryCompletion":5181,"completion":5181,"start":7096,"enrollment":909,"conditions":8984,"interventions":8985},"NCT00436241","A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.",[90],[1735],[1165,5381],{"nctId":8987,"briefTitle":8988,"status":107,"phases":8989,"primaryCompletion":4682,"completion":4682,"start":2963,"enrollment":8990,"conditions":8991,"interventions":8992},"NCT00940303","OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer",[90],97,[30],[1162,5275,4102,8956,4104],{"nctId":4302,"briefTitle":4303,"status":107,"phases":8994,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1352,"conditions":8995,"interventions":8996},[90],[1727],[1015,1165,4309,4089],{"nctId":8998,"briefTitle":8999,"status":107,"phases":9000,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":1548,"conditions":9001,"interventions":9002},"NCT01590719","A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer",[90],[1735],[4244,1165,4272,4131,1597],{"nctId":3719,"briefTitle":3720,"status":152,"phases":9004,"primaryCompletion":3722,"completion":2719,"start":1464,"enrollment":1847,"conditions":9005,"interventions":9006},[90],[3724],[1018,1784,1163,1165],{"nctId":84,"briefTitle":85,"status":140,"phases":9008,"primaryCompletion":86,"completion":1731,"start":1732,"enrollment":1733,"conditions":9009,"interventions":9010},[90],[1735,1736],[68,1222,1166,1165],{"nctId":4319,"briefTitle":4320,"status":107,"phases":9012,"primaryCompletion":4322,"start":4323,"enrollment":4324,"conditions":9013,"interventions":9014},[90],[30],[4101,1165,4100,4101,1165,4100],{"nctId":1788,"briefTitle":1789,"status":130,"phases":9016,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":1174,"conditions":9017,"interventions":9018},[90],[1794,1735,1736],[68,988,1165,1166],{"trials":9020,"activeCount":162,"soonestReadout":2983},[9021,9025,9029,9037,9041,9045,9049,9053,9057],{"nctId":8723,"briefTitle":8724,"status":107,"phases":9022,"primaryCompletion":8726,"completion":8726,"start":8727,"enrollment":8728,"conditions":9023,"interventions":9024},[91],[30],[1166,1165,1164,1597],{"nctId":6175,"briefTitle":6176,"status":107,"phases":9026,"primaryCompletion":6178,"completion":6178,"start":6179,"enrollment":2940,"conditions":9027,"interventions":9028},[91],[3826],[1785,1359,1163,1165],{"nctId":9030,"briefTitle":9031,"status":107,"phases":9032,"primaryCompletion":5457,"completion":5457,"start":6316,"enrollment":9033,"conditions":9034,"interventions":9035},"NCT00069108","A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer",[91],627,[30],[9036,1164,1165,1165,5381],"5 FU",{"nctId":8748,"briefTitle":8749,"status":107,"phases":9038,"primaryCompletion":8681,"completion":8681,"start":8751,"enrollment":8752,"conditions":9039,"interventions":9040},[91],[1735],[1166,1165],{"nctId":4406,"briefTitle":4407,"status":107,"phases":9042,"primaryCompletion":4409,"completion":3213,"start":4410,"enrollment":4411,"conditions":9043,"interventions":9044},[91],[30],[1015,1166,1597,4414,1165],{"nctId":2937,"briefTitle":2938,"status":140,"phases":9046,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":9047,"interventions":9048},[91],[2652],[1018,1784,2736,1096,1163,1165],{"nctId":4479,"briefTitle":4480,"status":107,"phases":9050,"primaryCompletion":2801,"completion":2801,"start":4198,"enrollment":1548,"conditions":9051,"interventions":9052},[91],[30],[1015,1166,1165],{"nctId":2980,"briefTitle":2981,"status":140,"phases":9054,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":9055,"interventions":9056},[91],[2392],[2433,2394,1096,1359,1163,1165],{"nctId":9058,"briefTitle":9059,"status":107,"phases":9060,"primaryCompletion":2847,"completion":2847,"start":8681,"enrollment":9061,"conditions":9062,"interventions":9063},"NCT01662869","A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer",[91],564,[1735],[9064,4272,4244,1165],"5-Fluoruracil",{"trials":9066,"activeCount":101},[9067,9071,9075],{"nctId":4568,"briefTitle":4569,"status":107,"phases":9068,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":9069,"interventions":9070},[92],[4098],[1165,1166,1015,1164,4576,4577],{"nctId":4579,"briefTitle":4580,"status":107,"phases":9072,"primaryCompletion":2965,"completion":4582,"start":122,"enrollment":931,"conditions":9073,"interventions":9074},[92],[30],[1597,1015,4577,1165],{"nctId":9076,"briefTitle":9077,"status":107,"phases":9078,"primaryCompletion":9079,"completion":9079,"start":4086,"enrollment":9080,"conditions":9081,"interventions":9082},"NCT00577031","OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.",[92],"2011-08",205,[30],[5275,1165,9083],"Xeloda",{"trials":9085,"activeCount":101},[9086,9090],{"nctId":8832,"briefTitle":8833,"status":107,"phases":9087,"primaryCompletion":4232,"completion":4232,"start":6315,"enrollment":8835,"conditions":9088,"interventions":9089},[],[30],[1166,1165],{"nctId":4679,"briefTitle":4680,"status":107,"phases":9091,"primaryCompletion":4682,"completion":4682,"start":4314,"enrollment":4683,"conditions":9092,"interventions":9093},[],[30],[1015,1166,1165],{"intervention":1357,"totalTrials":97,"cells":9095},{"EARLY_PHASE1":9096,"PHASE1":9098,"PHASE2":9112,"PHASE3":9158,"PHASE4":9204,"NA":9221},{"trials":9097,"activeCount":101},[],{"trials":9099,"activeCount":101},[9100,9104,9108],{"nctId":3475,"briefTitle":3476,"status":107,"phases":9101,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":9102,"interventions":9103},[89],[125],[1356,992,991,3482,1018,1357,1358],{"nctId":2384,"briefTitle":2385,"status":107,"phases":9105,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":9106,"interventions":9107},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":6018,"briefTitle":6019,"status":130,"phases":9109,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":9110,"interventions":9111},[89],[3644],[1073,1785,1359,992,991,1357],{"trials":9113,"activeCount":162,"soonestReadout":2754},[9114,9118,9122,9135,9139,9146,9150,9154],{"nctId":3589,"briefTitle":3590,"status":107,"phases":9115,"primaryCompletion":3592,"completion":3593,"start":3594,"enrollment":3595,"conditions":9116,"interventions":9117},[90],[3597],[3599,1018,274,1357],{"nctId":1346,"briefTitle":1347,"status":107,"phases":9119,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":9120,"interventions":9121},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":9123,"briefTitle":9124,"status":107,"phases":9125,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":9129,"interventions":9130},"NCT04660799","A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)",[90],"2022-05-23","2022-10-11","2021-02-24",[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],"Rituximab IV","Rituximab SC","Paracetamol","Diphenhydramine hydrochloride or alternative antihistamine",{"nctId":3679,"briefTitle":3680,"status":107,"phases":9136,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":9137,"interventions":9138},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":9140,"briefTitle":9141,"status":107,"phases":9142,"primaryCompletion":2963,"completion":2963,"start":6673,"enrollment":462,"conditions":9143,"interventions":9144},"NCT00551291","A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.",[90],[1206],[5914,1357,9145],"Erythropoietin Beta",{"nctId":2728,"briefTitle":2729,"status":107,"phases":9147,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":9148,"interventions":9149},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"nctId":3700,"briefTitle":3701,"status":152,"phases":9151,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":9152,"interventions":9153},[90],[3597],[1018,3707,3708,3709,274,1357],{"nctId":2751,"briefTitle":2752,"status":140,"phases":9155,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":9156,"interventions":9157},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"trials":9159,"activeCount":706,"soonestReadout":1364},[9160,9164,9172,9176,9180,9184,9188,9192,9196,9200],{"nctId":6183,"briefTitle":6184,"status":107,"phases":9161,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":9162,"interventions":9163},[91],[1038],[1359,992,1358,991,1357,1356],{"nctId":9165,"briefTitle":9166,"status":130,"phases":9167,"primaryCompletion":4562,"completion":4562,"start":4455,"enrollment":721,"conditions":9168,"interventions":9169},"NCT02081183","A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis",[91],[3597],[5914,9170,9171,1357],"Cyclophosphamide, Maintenance Phase","Cyclophosphamide, Induction Phase",{"nctId":3766,"briefTitle":3767,"status":140,"phases":9173,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":9174,"interventions":9175},[91],[3771],[1018,3773,1357,274,3774,3775],{"nctId":3777,"briefTitle":3778,"status":107,"phases":9177,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":9178,"interventions":9179},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":4783,"briefTitle":4784,"status":140,"phases":9181,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":9182,"interventions":9183},[91],[4791],[1784,2394,1359,992,991,1357],{"nctId":3809,"briefTitle":3810,"status":140,"phases":9185,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":9186,"interventions":9187},[91],[3597],[1018,3773,1357,274,3755,2579],{"nctId":3818,"briefTitle":3819,"status":130,"phases":9189,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":9190,"interventions":9191},[91],[3826],[1359,1018,992,991,1358,1357],{"nctId":6326,"briefTitle":6327,"status":107,"phases":9193,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":9194,"interventions":9195},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"nctId":3048,"briefTitle":3049,"status":107,"phases":9197,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":9198,"interventions":9199},[91],[2508],[1096,1357,3057,3058,3059,2824],{"nctId":6365,"briefTitle":6366,"status":107,"phases":9201,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":9202,"interventions":9203},[91],[2392],[1359,992,991,1358,1357,3482],{"trials":9205,"activeCount":101},[9206,9213,9217],{"nctId":9207,"briefTitle":9208,"status":107,"phases":9209,"primaryCompletion":4409,"completion":4409,"start":3084,"enrollment":145,"conditions":9210,"interventions":9211},"NCT01033864","A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients",[92],[5846],[3773,9212,1357],"EC-MPS",{"nctId":5879,"briefTitle":5880,"status":107,"phases":9214,"primaryCompletion":5882,"completion":5882,"start":5883,"enrollment":1184,"conditions":9215,"interventions":9216},[92],[5885],[274,1357,1359],{"nctId":3127,"briefTitle":3128,"status":107,"phases":9218,"primaryCompletion":2331,"completion":2331,"start":3130,"enrollment":1314,"conditions":9219,"interventions":9220},[92],[15],[1357,1096],{"trials":9222,"activeCount":101},[9223],{"nctId":6494,"briefTitle":6495,"status":107,"phases":9224,"primaryCompletion":5891,"completion":5891,"start":2923,"enrollment":5458,"conditions":9225,"interventions":9226},[],[6498],[992,6500,6501,1357,1359],{"intervention":1785,"totalTrials":721,"cells":9228},{"EARLY_PHASE1":9229,"PHASE1":9231,"PHASE2":9241,"PHASE3":9275,"PHASE4":9297,"NA":9299},{"trials":9230,"activeCount":101},[],{"trials":9232,"activeCount":101},[9233,9237],{"nctId":2384,"briefTitle":2385,"status":107,"phases":9234,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":9235,"interventions":9236},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":6018,"briefTitle":6019,"status":130,"phases":9238,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":9239,"interventions":9240},[89],[3644],[1073,1785,1359,992,991,1357],{"trials":9242,"activeCount":162,"soonestReadout":2673},[9243,9247,9251,9255,9259,9263,9267,9271],{"nctId":3581,"briefTitle":3582,"status":107,"phases":9244,"primaryCompletion":3584,"completion":3584,"start":3585,"enrollment":2857,"conditions":9245,"interventions":9246},[89,90],[125],[1018,1359,1785,1073],{"nctId":2646,"briefTitle":2647,"status":107,"phases":9248,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":291,"conditions":9249,"interventions":9250},[89,90],[2652],[2654,2655,1785,1096],{"nctId":3619,"briefTitle":3620,"status":107,"phases":9252,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":3624,"conditions":9253,"interventions":9254},[89,90],[1038],[1356,1018,2394,1359,2394],{"nctId":3628,"briefTitle":3629,"status":107,"phases":9256,"primaryCompletion":3631,"completion":3632,"start":3633,"enrollment":1058,"conditions":9257,"interventions":9258},[89,90],[1038],[3636,1018,1785,1359],{"nctId":2670,"briefTitle":2671,"status":140,"phases":9260,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":2676,"conditions":9261,"interventions":9262},[89,90],[2678],[2433,2433,2394,1096,1359],{"nctId":3647,"briefTitle":3648,"status":107,"phases":9264,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":22,"conditions":9265,"interventions":9266},[89,90],[3653],[2644,1018,1785,1359],{"nctId":2728,"briefTitle":2729,"status":107,"phases":9268,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":9269,"interventions":9270},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"nctId":1775,"briefTitle":1776,"status":140,"phases":9272,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":9273,"interventions":9274},[89,90],[1782],[1784,68,1018,1096,1785,1786],{"trials":9276,"activeCount":162,"soonestReadout":2983},[9277,9281,9285,9289,9293],{"nctId":6175,"briefTitle":6176,"status":107,"phases":9278,"primaryCompletion":6178,"completion":6178,"start":6179,"enrollment":2940,"conditions":9279,"interventions":9280},[91],[3826],[1785,1359,1163,1165],{"nctId":4783,"briefTitle":4784,"status":140,"phases":9282,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":9283,"interventions":9284},[91],[4791],[1784,2394,1359,992,991,1357],{"nctId":6246,"briefTitle":6247,"status":130,"phases":9286,"primaryCompletion":6249,"completion":6250,"start":6251,"enrollment":1733,"conditions":9287,"interventions":9288},[91],[6253],[1785,1356,1359],{"nctId":2980,"briefTitle":2981,"status":140,"phases":9290,"primaryCompletion":2983,"completion":452,"start":2984,"enrollment":8,"conditions":9291,"interventions":9292},[91],[2392],[2433,2394,1096,1359,1163,1165],{"nctId":6326,"briefTitle":6327,"status":107,"phases":9294,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":9295,"interventions":9296},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"trials":9298,"activeCount":101},[],{"trials":9300,"activeCount":350,"soonestReadout":9305},[9301],{"nctId":9302,"briefTitle":9303,"status":140,"phases":9304,"primaryCompletion":9305,"completion":9305,"start":1393,"enrollment":703,"conditions":9306,"interventions":9307},"NCT05954910","A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma",[],"2027-05-31",[3826],[1785],{"intervention":2644,"totalTrials":4548,"cells":9309},{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9324,"PHASE3":9342,"PHASE4":9352,"NA":9354},{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[9314],{"nctId":9315,"briefTitle":9316,"status":107,"phases":9317,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":755,"conditions":9320,"interventions":9321},"NCT02431208","A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and\u002For Daratumumab in Participants With Multiple Myeloma (MM)",[89],"2021-03-19","2015-07-22",[1305],[4468,9322,2644,9323,2577],"Daratumumab","Pomalidomide",{"trials":9325,"activeCount":162,"soonestReadout":2706},[9326,9330,9334,9338],{"nctId":2635,"briefTitle":2636,"status":140,"phases":9327,"primaryCompletion":2638,"completion":2638,"start":2639,"enrollment":2640,"conditions":9328,"interventions":9329},[89,90],[2642],[2433,1096,2644,2433],{"nctId":3601,"briefTitle":3602,"status":107,"phases":9331,"primaryCompletion":3604,"completion":3605,"start":1214,"enrollment":2492,"conditions":9332,"interventions":9333},[89,90],[3607],[3609,2644,1018],{"nctId":3647,"briefTitle":3648,"status":107,"phases":9335,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":22,"conditions":9336,"interventions":9337},[89,90],[3653],[2644,1018,1785,1359],{"nctId":2703,"briefTitle":2704,"status":152,"phases":9339,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":9340,"interventions":9341},[89,90],[1305],[2596,2644,1096,2467,2577],{"trials":9343,"activeCount":162,"soonestReadout":2025},[9344,9348],{"nctId":6161,"briefTitle":6162,"status":140,"phases":9345,"primaryCompletion":2025,"completion":209,"start":6164,"enrollment":6165,"conditions":9346,"interventions":9347},[91],[6167],[2433,2644,1359,6169],{"nctId":3011,"briefTitle":3012,"status":152,"phases":9349,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":9350,"interventions":9351},[91],[1038],[1018,1784,1359,1356,2644,1096],{"trials":9353,"activeCount":101},[],{"trials":9355,"activeCount":101},[],{"intervention":1420,"totalTrials":2631,"cells":9357},{"EARLY_PHASE1":9358,"PHASE1":9360,"PHASE2":9362,"PHASE3":9380,"PHASE4":9386,"NA":9388},{"trials":9359,"activeCount":101},[],{"trials":9361,"activeCount":101},[],{"trials":9363,"activeCount":706,"soonestReadout":1413},[9364,9368,9372,9376],{"nctId":4133,"briefTitle":4134,"status":107,"phases":9365,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":9366,"interventions":9367},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"nctId":1410,"briefTitle":1411,"status":140,"phases":9369,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":9370,"interventions":9371},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1447,"briefTitle":1448,"status":152,"phases":9373,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":9374,"interventions":9375},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"nctId":1562,"briefTitle":1563,"status":152,"phases":9377,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":9378,"interventions":9379},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":9381,"activeCount":350,"soonestReadout":5696},[9382],{"nctId":5693,"briefTitle":5694,"status":152,"phases":9383,"primaryCompletion":5696,"completion":5697,"start":1183,"enrollment":5698,"conditions":9384,"interventions":9385},[91],[5700],[63,1573,1420,1421,1456,5670],{"trials":9387,"activeCount":101},[],{"trials":9389,"activeCount":101},[],{"intervention":2596,"totalTrials":5110,"cells":9391},{"EARLY_PHASE1":9392,"PHASE1":9394,"PHASE2":9400,"PHASE3":9410,"PHASE4":9423,"NA":9425},{"trials":9393,"activeCount":101},[],{"trials":9395,"activeCount":350,"soonestReadout":2592},[9396],{"nctId":2589,"briefTitle":2590,"status":152,"phases":9397,"primaryCompletion":2592,"completion":2592,"start":2593,"enrollment":2375,"conditions":9398,"interventions":9399},[89],[1305],[2596,1096],{"trials":9401,"activeCount":162,"soonestReadout":2741},[9402,9406],{"nctId":2703,"briefTitle":2704,"status":152,"phases":9403,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":9404,"interventions":9405},[89,90],[1305],[2596,2644,1096,2467,2577],{"nctId":2738,"briefTitle":2739,"status":140,"phases":9407,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":2743,"conditions":9408,"interventions":9409},[89,90],[1305],[2596,1096],{"trials":9411,"activeCount":350,"soonestReadout":9416},[9412],{"nctId":9413,"briefTitle":9414,"status":152,"phases":9415,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":9419,"interventions":9420},"NCT07555938","Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma",[91],"2028-10-31","2033-01-31",380,[1305],[2596,9323,2577,9322,9421,9422],"Elotuzumab","Carfilzomib",{"trials":9424,"activeCount":101},[],{"trials":9426,"activeCount":101},[],{"intervention":487,"totalTrials":5110,"cells":9428},{"EARLY_PHASE1":9429,"PHASE1":9431,"PHASE2":9443,"PHASE3":9467,"PHASE4":9473,"NA":9475},{"trials":9430,"activeCount":101},[],{"trials":9432,"activeCount":350,"soonestReadout":9437},[9433],{"nctId":9434,"briefTitle":9435,"status":140,"phases":9436,"primaryCompletion":9437,"completion":452,"start":1429,"enrollment":1184,"conditions":9438,"interventions":9442},"NCT07137585","A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity",[89],"2026-09-13",[9439,9440,9441],"Type 2 Diabetes Mellitus","Obesity","Overweight",[487],{"trials":9444,"activeCount":162,"soonestReadout":9449},[9445,9455],{"nctId":9446,"briefTitle":9447,"status":140,"phases":9448,"primaryCompletion":9449,"completion":9450,"start":9451,"enrollment":1115,"conditions":9452,"interventions":9454},"NCT05548556","A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy",[90],"2025-05-02","2026-10-23","2023-02-07",[9453],"Facioscapulohumeral Muscular Dystrophy (FSHD)",[487],{"nctId":9456,"briefTitle":9457,"status":140,"phases":9458,"primaryCompletion":9459,"completion":9460,"start":9461,"enrollment":9462,"conditions":9463,"interventions":9465},"NCT06965413","A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity",[90],"2026-08-24","2027-07-23","2025-05-05",285,[9440,9441,9464],"Overweight With One Weight Related Comorbidity",[487,9466],"Tirzepatide",{"trials":9468,"activeCount":350,"soonestReadout":481},[9469],{"nctId":478,"briefTitle":479,"status":140,"phases":9470,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":9471,"interventions":9472},[90,91],[485],[487,77],{"trials":9474,"activeCount":101},[],{"trials":9476,"activeCount":101},[],{"intervention":947,"totalTrials":1724,"cells":9478},{"EARLY_PHASE1":9479,"PHASE1":9481,"PHASE2":9502,"PHASE3":9605,"PHASE4":9741,"NA":9765},{"trials":9480,"activeCount":101},[],{"trials":9482,"activeCount":101},[9483,9487,9491,9495],{"nctId":937,"briefTitle":938,"status":130,"phases":9484,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":9485,"interventions":9486},[89],[944],[946,68,947],{"nctId":1210,"briefTitle":1211,"status":107,"phases":9488,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":9489,"interventions":9490},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"nctId":5373,"briefTitle":5374,"status":130,"phases":9492,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":9493,"interventions":9494},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"nctId":9496,"briefTitle":9497,"status":107,"phases":9498,"primaryCompletion":8810,"completion":8810,"start":9499,"enrollment":8583,"conditions":9500,"interventions":9501},"NCT02490475","A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors",[89],"2004-02",[1160],[947,8586],{"trials":9503,"activeCount":350,"soonestReadout":366},[9504,9508,9512,9516,9520,9526,9530,9534,9538,9542,9548,9552,9558,9562,9568,9577,9581,9588,9592,9599],{"nctId":8602,"briefTitle":8603,"status":107,"phases":9505,"primaryCompletion":2905,"completion":2905,"start":8605,"enrollment":3015,"conditions":9506,"interventions":9507},[90],[18],[1597,1166,992,947,5619],{"nctId":8264,"briefTitle":8265,"status":107,"phases":9509,"primaryCompletion":5181,"completion":2801,"start":4113,"enrollment":2429,"conditions":9510,"interventions":9511},[90],[18],[8269,1222,947],{"nctId":1308,"briefTitle":1309,"status":130,"phases":9513,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":9514,"interventions":9515},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":7918,"briefTitle":7919,"status":107,"phases":9517,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":9518,"interventions":9519},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":9521,"briefTitle":9522,"status":107,"phases":9523,"primaryCompletion":4454,"completion":4454,"start":4488,"enrollment":1215,"conditions":9524,"interventions":9525},"NCT00934856","A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer",[89,90],[18],[947,1221,1223],{"nctId":1370,"briefTitle":1371,"status":107,"phases":9527,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":9528,"interventions":9529},[90],[975],[947,68],{"nctId":4168,"briefTitle":4169,"status":107,"phases":9531,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":806,"conditions":9532,"interventions":9533},[90],[18],[1015,947,1222,4175],{"nctId":4177,"briefTitle":4178,"status":107,"phases":9535,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":9536,"interventions":9537},[90],[18],[4184,1015,4185,1597,992,1106,947],{"nctId":3363,"briefTitle":3364,"status":152,"phases":9539,"primaryCompletion":366,"completion":3366,"start":3367,"enrollment":1847,"conditions":9540,"interventions":9541},[90],[3369],[1137,1830,3371,947],{"nctId":9543,"briefTitle":9544,"status":130,"phases":9545,"primaryCompletion":2963,"completion":2963,"start":5820,"enrollment":145,"conditions":9546,"interventions":9547},"NCT00576901","A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.",[90],[18],[5275,947,9083],{"nctId":7092,"briefTitle":7093,"status":107,"phases":9549,"primaryCompletion":7095,"completion":7095,"start":7096,"enrollment":1011,"conditions":9550,"interventions":9551},[90],[1735],[1167,1166,5619,1167,1166,1165,947,1166],{"nctId":9553,"briefTitle":9554,"status":107,"phases":9555,"primaryCompletion":5364,"completion":5364,"start":5181,"enrollment":8835,"conditions":9556,"interventions":9557},"NCT01204697","A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)",[90],[2257],[5383,5384,5384],{"nctId":8317,"briefTitle":8318,"status":107,"phases":9559,"primaryCompletion":8320,"completion":8321,"start":3084,"enrollment":8322,"conditions":9560,"interventions":9561},[90],[18],[1221,1222,8325,947,8326],{"nctId":9563,"briefTitle":9564,"status":107,"phases":9565,"primaryCompletion":4582,"completion":4582,"start":4446,"enrollment":5901,"conditions":9566,"interventions":9567},"NCT02005549","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer",[90],[18],[5275,5383,5381],{"nctId":9569,"briefTitle":9570,"status":107,"phases":9571,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":9574,"conditions":9575,"interventions":9576},"NCT00545688","A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.",[90],"2014-09-22","2006-06-26",417,[18],[7139,947,1221],{"nctId":4311,"briefTitle":4312,"status":107,"phases":9578,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":37,"conditions":9579,"interventions":9580},[90],[1684],[1015,1167,947],{"nctId":9582,"briefTitle":9583,"status":107,"phases":9584,"primaryCompletion":2932,"completion":2932,"start":4513,"enrollment":3665,"conditions":9585,"interventions":9586},"NCT00559754","A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.",[90],[18],[5275,947,9587],"Standard chemotherapy",{"nctId":8694,"briefTitle":8695,"status":107,"phases":9589,"primaryCompletion":4555,"completion":4555,"start":6316,"enrollment":8697,"conditions":9590,"interventions":9591},[90],[18],[4101,5383],{"nctId":9593,"briefTitle":9594,"status":130,"phases":9595,"primaryCompletion":2931,"completion":2931,"start":9596,"enrollment":2289,"conditions":9597,"interventions":9598},"NCT00845910","A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer",[90],"2009-05",[18],[5275,5381,5383],{"nctId":9600,"briefTitle":9601,"status":343,"phases":9602,"primaryCompletion":6157,"completion":6157,"start":2964,"enrollment":101,"conditions":9603,"interventions":9604},"NCT00964704","A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer",[90],[18],[5275,5381,5383,5390],{"trials":9606,"activeCount":706,"soonestReadout":1977},[9607,9611,9615,9619,9628,9632,9640,9647,9651,9655,9659,9663,9667,9671,9675,9679,9689,9693,9697,9701,9705,9709,9713,9725,9729,9733,9737],{"nctId":8022,"briefTitle":8023,"status":107,"phases":9608,"primaryCompletion":8025,"completion":8026,"start":8027,"enrollment":8028,"conditions":9609,"interventions":9610},[91],[18],[991,947,1106,1222],{"nctId":8381,"briefTitle":8382,"status":107,"phases":9612,"primaryCompletion":8384,"completion":8385,"start":2855,"enrollment":1158,"conditions":9613,"interventions":9614},[91],[18],[947,1221,1222],{"nctId":4384,"briefTitle":4385,"status":107,"phases":9616,"primaryCompletion":4387,"completion":4387,"start":4388,"enrollment":4389,"conditions":9617,"interventions":9618},[91],[2257],[1015,947,977,1319],{"nctId":9620,"briefTitle":9621,"status":107,"phases":9622,"primaryCompletion":9623,"completion":9624,"start":4635,"enrollment":9625,"conditions":9626,"interventions":9627},"NCT02813785","A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy",[91],"2019-08-01","2022-12-27",565,[1316],[4468,947],{"nctId":4950,"briefTitle":4951,"status":107,"phases":9629,"primaryCompletion":4953,"completion":4954,"start":4955,"enrollment":1651,"conditions":9630,"interventions":9631},[91],[1684],[43,947,1319],{"nctId":9633,"briefTitle":9634,"status":107,"phases":9635,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":9636,"interventions":9638},"NCT04024462","A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer",[91],[9637],"HER2-positive Early Breast Cancer",[8162,8164,9639,991,992,947,8166],"Pertuzumab and Trastuzumab FDC SC",{"nctId":9641,"briefTitle":9642,"status":107,"phases":9643,"primaryCompletion":3246,"completion":3246,"start":6277,"enrollment":9644,"conditions":9645,"interventions":9646},"NCT00391092","A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)\u002FDocetaxel in Patients With HER2 Positive Metastatic Breast Cancer.",[91],424,[18],[5275,947,7139],{"nctId":5500,"briefTitle":5501,"status":107,"phases":9648,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":9649,"interventions":9650},[91],[18],[1222,991,992,1106,947,990,5508],{"nctId":8410,"briefTitle":8411,"status":107,"phases":9652,"primaryCompletion":3254,"completion":8413,"start":4095,"enrollment":8414,"conditions":9653,"interventions":9654},[91],[18],[8417,947,1221,1222],{"nctId":8059,"briefTitle":8060,"status":107,"phases":9656,"primaryCompletion":8062,"completion":8062,"start":8063,"enrollment":37,"conditions":9657,"interventions":9658},[91],[18],[947,989,1106,1221,1222],{"nctId":1959,"briefTitle":1960,"status":140,"phases":9660,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":9661,"interventions":9662},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":1974,"briefTitle":1975,"status":140,"phases":9664,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":9665,"interventions":9666},[91],[975],[68,1167,1983,947,1163,1319],{"nctId":8075,"briefTitle":8076,"status":107,"phases":9668,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":9669,"interventions":9670},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":4451,"briefTitle":4452,"status":107,"phases":9672,"primaryCompletion":2965,"completion":4454,"start":4455,"enrollment":4456,"conditions":9673,"interventions":9674},[91],[18],[947,1015],{"nctId":8084,"briefTitle":8085,"status":107,"phases":9676,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":8089,"conditions":9677,"interventions":9678},[91],[4139],[947,989,1106,1221,1222],{"nctId":9680,"briefTitle":9681,"status":107,"phases":9682,"primaryCompletion":9683,"completion":9683,"start":9684,"enrollment":9685,"conditions":9686,"interventions":9687},"NCT02402712","Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer",[91],"2019-02-22","2015-05-06",418,[18],[947,9688,5390],"pertuzumab [Perjeta]",{"nctId":5543,"briefTitle":5544,"status":107,"phases":9690,"primaryCompletion":1214,"completion":5546,"start":5547,"enrollment":5548,"conditions":9691,"interventions":9692},[91],[4139],[990,947,1221,1222,1419],{"nctId":5716,"briefTitle":5717,"status":140,"phases":9694,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":9695,"interventions":9696},[91],[5723],[3426,63,947,1106,5670,3428],{"nctId":2112,"briefTitle":2113,"status":107,"phases":9698,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":9699,"interventions":9700},[91],[1316],[2121,68,947],{"nctId":8123,"briefTitle":8124,"status":107,"phases":9702,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":9703,"interventions":9704},[91],[18],[5383,4503,5472,8132,5390,8133],{"nctId":8135,"briefTitle":8136,"status":107,"phases":9706,"primaryCompletion":8138,"completion":8139,"start":8140,"enrollment":8141,"conditions":9707,"interventions":9708},[91],[1539],[5297,947,1106,8144],{"nctId":8154,"briefTitle":8155,"status":107,"phases":9710,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":9711,"interventions":9712},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"nctId":9714,"briefTitle":9715,"status":107,"phases":9716,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":9721,"interventions":9722},"NCT00950300","A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer",[91],"2011-07-12","2017-01-24","2009-10-16",596,[18],[1597,992,947,5619,9723,9724],"Herceptin IV [trastuzumab]","Herceptin SC [trastuzumab]",{"nctId":8456,"briefTitle":8457,"status":130,"phases":9726,"primaryCompletion":8321,"completion":8321,"start":3174,"enrollment":1001,"conditions":9727,"interventions":9728},[91],[1569],[1222,1419,947],{"nctId":8176,"briefTitle":8177,"status":107,"phases":9730,"primaryCompletion":181,"completion":181,"start":8179,"enrollment":2743,"conditions":9731,"interventions":9732},[91],[18],[1222,1106,947],{"nctId":5610,"briefTitle":5611,"status":107,"phases":9734,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":9735,"interventions":9736},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"nctId":2251,"briefTitle":2252,"status":107,"phases":9738,"primaryCompletion":2254,"completion":1079,"start":2255,"enrollment":191,"conditions":9739,"interventions":9740},[91],[2257],[68,947],{"trials":9742,"activeCount":101},[9743,9747,9751,9755,9759],{"nctId":4552,"briefTitle":4553,"status":107,"phases":9744,"primaryCompletion":2847,"completion":2847,"start":4555,"enrollment":1001,"conditions":9745,"interventions":9746},[92],[18],[1015,1106,947],{"nctId":8203,"briefTitle":8204,"status":107,"phases":9748,"primaryCompletion":5364,"completion":5364,"start":2964,"enrollment":8206,"conditions":9749,"interventions":9750},[92],[18],[947,1106,1222],{"nctId":8510,"briefTitle":8511,"status":107,"phases":9752,"primaryCompletion":8513,"completion":8513,"start":8514,"enrollment":973,"conditions":9753,"interventions":9754},[92],[18],[947,1221,1222],{"nctId":5623,"briefTitle":5624,"status":107,"phases":9756,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":9757,"interventions":9758},[92],[18],[990,992,947,991,1106,1222],{"nctId":9760,"briefTitle":9761,"status":343,"phases":9762,"primaryCompletion":2956,"completion":2956,"start":4206,"enrollment":101,"conditions":9763,"interventions":9764},"NCT00774241","PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer",[92],[18],[5275,5383],{"trials":9766,"activeCount":101},[9767,9776],{"nctId":9768,"briefTitle":9769,"status":107,"phases":9770,"primaryCompletion":2963,"completion":2963,"start":9771,"enrollment":9772,"conditions":9773,"interventions":9775},"NCT02479217","Safety of Xeloda in Solid Tumours",[],"2006-07",1268,[9774],"Metastatic Breast Cancer, Colon Cancer",[947,9083],{"nctId":8851,"briefTitle":8852,"status":107,"phases":9777,"primaryCompletion":3324,"completion":3324,"start":2948,"enrollment":1204,"conditions":9778,"interventions":9779},[],[18],[4101,5383],{"intervention":1074,"totalTrials":2563,"cells":9781},{"EARLY_PHASE1":9782,"PHASE1":9784,"PHASE2":9802,"PHASE3":9812,"PHASE4":9834,"NA":9836},{"trials":9783,"activeCount":101},[],{"trials":9785,"activeCount":101},[9786,9790,9794,9798],{"nctId":2405,"briefTitle":2406,"status":107,"phases":9787,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":9788,"interventions":9789},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"nctId":1065,"briefTitle":1066,"status":130,"phases":9791,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":162,"conditions":9792,"interventions":9793},[89],[1071],[1073,68,990,1074],{"nctId":7027,"briefTitle":7028,"status":107,"phases":9795,"primaryCompletion":6578,"completion":6578,"start":4322,"enrollment":350,"conditions":9796,"interventions":9797},[89],[2257],[5275,5185,5385],{"nctId":5373,"briefTitle":5374,"status":130,"phases":9799,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":9800,"interventions":9801},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":9803,"activeCount":350,"soonestReadout":2692},[9804,9808],{"nctId":1266,"briefTitle":1267,"status":107,"phases":9805,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":9806,"interventions":9807},[90],[1274],[68,1167,990,1074],{"nctId":2689,"briefTitle":2690,"status":152,"phases":9809,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":9810,"interventions":9811},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"trials":9813,"activeCount":162,"soonestReadout":2187},[9814,9818,9822,9826,9830],{"nctId":1920,"briefTitle":1921,"status":107,"phases":9815,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":9816,"interventions":9817},[91],[1071],[988,68,990,1074],{"nctId":5522,"briefTitle":5523,"status":107,"phases":9819,"primaryCompletion":5245,"completion":5525,"start":5526,"enrollment":5527,"conditions":9820,"interventions":9821},[91],[2038],[4468,990,1074],{"nctId":2033,"briefTitle":2034,"status":107,"phases":9823,"primaryCompletion":2036,"completion":2036,"start":110,"enrollment":1259,"conditions":9824,"interventions":9825},[91],[2038],[68,990,1074],{"nctId":2051,"briefTitle":2052,"status":140,"phases":9827,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":2057,"conditions":9828,"interventions":9829},[91],[2059],[68,2061,990,1074],{"nctId":2184,"briefTitle":2185,"status":140,"phases":9831,"primaryCompletion":2187,"completion":2025,"start":2188,"enrollment":1548,"conditions":9832,"interventions":9833},[91],[2038],[988,68,990,1074],{"trials":9835,"activeCount":101},[],{"trials":9837,"activeCount":101},[],{"intervention":1830,"totalTrials":5110,"cells":9839},{"EARLY_PHASE1":9840,"PHASE1":9842,"PHASE2":9844,"PHASE3":9850,"PHASE4":9864,"NA":9866},{"trials":9841,"activeCount":101},[],{"trials":9843,"activeCount":101},[],{"trials":9845,"activeCount":350,"soonestReadout":366},[9846],{"nctId":3363,"briefTitle":3364,"status":152,"phases":9847,"primaryCompletion":366,"completion":3366,"start":3367,"enrollment":1847,"conditions":9848,"interventions":9849},[90],[3369],[1137,1830,3371,947],{"trials":9851,"activeCount":162,"soonestReadout":690},[9852,9856,9860],{"nctId":1825,"briefTitle":1826,"status":140,"phases":9853,"primaryCompletion":690,"completion":690,"start":1714,"enrollment":1001,"conditions":9854,"interventions":9855},[91],[1241],[68,1015,1319,1106,1830],{"nctId":1832,"briefTitle":1833,"status":107,"phases":9857,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":9858,"interventions":9859},[91],[1840],[68,1830],{"nctId":2144,"briefTitle":2145,"status":140,"phases":9861,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":9862,"interventions":9863},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":9865,"activeCount":101},[],{"trials":9867,"activeCount":101},[],{"intervention":4940,"totalTrials":5110,"cells":9869},{"EARLY_PHASE1":9870,"PHASE1":9872,"PHASE2":9874,"PHASE3":9876,"PHASE4":9894,"NA":9896},{"trials":9871,"activeCount":101},[],{"trials":9873,"activeCount":101},[],{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":706,"soonestReadout":42},[9878,9882,9886,9890],{"nctId":4934,"briefTitle":4935,"status":140,"phases":9879,"primaryCompletion":4937,"completion":4937,"start":1508,"enrollment":2708,"conditions":9880,"interventions":9881},[91],[1241],[43,4940],{"nctId":40,"briefTitle":41,"status":140,"phases":9883,"primaryCompletion":42,"completion":2025,"start":4960,"enrollment":4961,"conditions":9884,"interventions":9885},[91],[4963],[43,4940],{"nctId":6867,"briefTitle":6868,"status":140,"phases":9887,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":6872,"conditions":9888,"interventions":9889},[91],[1316],[1695,4940],{"nctId":4974,"briefTitle":4975,"status":107,"phases":9891,"primaryCompletion":4977,"completion":2483,"start":4978,"enrollment":3856,"conditions":9892,"interventions":9893},[91],[975],[43,4940],{"trials":9895,"activeCount":101},[],{"trials":9897,"activeCount":101},[],{"intervention":799,"totalTrials":5110,"cells":9899},{"EARLY_PHASE1":9900,"PHASE1":9902,"PHASE2":9913,"PHASE3":9922,"PHASE4":9938,"NA":9940},{"trials":9901,"activeCount":101},[],{"trials":9903,"activeCount":101},[9904],{"nctId":9905,"briefTitle":9906,"status":107,"phases":9907,"primaryCompletion":9908,"completion":9908,"start":9909,"enrollment":123,"conditions":9910,"interventions":9912},"NCT06189508","A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants",[89],"2024-12-22","2024-02-14",[9911],"Healthy Male Participants",[799],{"trials":9914,"activeCount":350,"soonestReadout":4945},[9915],{"nctId":9916,"briefTitle":9917,"status":152,"phases":9918,"primaryCompletion":4945,"completion":4945,"start":9919,"enrollment":336,"conditions":9920,"interventions":9921},"NCT05987449","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A",[89,90],"2023-09-21",[723],[799],{"trials":9923,"activeCount":162,"soonestReadout":9928},[9924,9934],{"nctId":9925,"briefTitle":9926,"status":152,"phases":9927,"primaryCompletion":9928,"completion":9929,"start":9930,"enrollment":3595,"conditions":9931,"interventions":9932},"NCT07416526","A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A",[91],"2027-09-23","2031-09-23","2026-05-09",[723],[799,9933],"Human Coagulation Factor VIII",{"nctId":791,"briefTitle":792,"status":152,"phases":9935,"primaryCompletion":794,"completion":795,"start":796,"enrollment":157,"conditions":9936,"interventions":9937},[91],[723],[799,708],{"trials":9939,"activeCount":101},[],{"trials":9941,"activeCount":101},[],{"intervention":9943,"totalTrials":706,"cells":9944},"Enicepatide",{"EARLY_PHASE1":9945,"PHASE1":9947,"PHASE2":9949,"PHASE3":9962,"PHASE4":9981,"NA":9983},{"trials":9946,"activeCount":101},[],{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":350,"soonestReadout":9955},[9951],{"nctId":9952,"briefTitle":9953,"status":3955,"phases":9954,"primaryCompletion":9955,"completion":9956,"start":2025,"enrollment":9957,"conditions":9958,"interventions":9960},"NCT07589686","A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight",[90],"2027-11-12","2028-01-31",486,[9959],"Obesity or Overweight",[9961,9943],"Petrelintide",{"trials":9963,"activeCount":162,"soonestReadout":9968},[9964,9973],{"nctId":9965,"briefTitle":9966,"status":152,"phases":9967,"primaryCompletion":9968,"completion":9969,"start":7264,"enrollment":9970,"conditions":9971,"interventions":9972},"NCT07351045","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes",[91],"2028-07-24","2028-08-28",2000,[9959],[9943],{"nctId":9974,"briefTitle":9975,"status":152,"phases":9976,"primaryCompletion":9977,"completion":9977,"start":9978,"enrollment":8566,"conditions":9979,"interventions":9980},"NCT07351058","A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes",[91],"2028-08-07","2026-03-23",[9959,9439],[9943],{"trials":9982,"activeCount":101},[],{"trials":9984,"activeCount":101},[],{"intervention":3709,"totalTrials":706,"cells":9986},{"EARLY_PHASE1":9987,"PHASE1":9989,"PHASE2":9991,"PHASE3":9997,"PHASE4":10007,"NA":10009},{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[],{"trials":9992,"activeCount":350,"soonestReadout":3703},[9993],{"nctId":3700,"briefTitle":3701,"status":152,"phases":9994,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":9995,"interventions":9996},[90],[3597],[1018,3707,3708,3709,274,1357],{"trials":9998,"activeCount":162,"soonestReadout":1484},[9999,10003],{"nctId":3766,"briefTitle":3767,"status":140,"phases":10000,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":10001,"interventions":10002},[91],[3771],[1018,3773,1357,274,3774,3775],{"nctId":3851,"briefTitle":3852,"status":140,"phases":10004,"primaryCompletion":3854,"completion":3855,"start":2540,"enrollment":3856,"conditions":10005,"interventions":10006},[91],[2621],[1018,3859,3709,274],{"trials":10008,"activeCount":101},[],{"trials":10010,"activeCount":101},[],{"intervention":992,"totalTrials":1115,"cells":10012},{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10047,"PHASE3":10132,"PHASE4":10244,"NA":10262},{"trials":10014,"activeCount":101},[],{"trials":10016,"activeCount":101},[10017,10021,10025,10029,10033,10037],{"nctId":3475,"briefTitle":3476,"status":107,"phases":10018,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":10019,"interventions":10020},[89],[125],[1356,992,991,3482,1018,1357,1358],{"nctId":2384,"briefTitle":2385,"status":107,"phases":10022,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":10023,"interventions":10024},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":979,"briefTitle":980,"status":107,"phases":10026,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":10027,"interventions":10028},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"nctId":1210,"briefTitle":1211,"status":107,"phases":10030,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":10031,"interventions":10032},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"nctId":6018,"briefTitle":6019,"status":130,"phases":10034,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":10035,"interventions":10036},[89],[3644],[1073,1785,1359,992,991,1357],{"nctId":10038,"briefTitle":10039,"status":107,"phases":10040,"primaryCompletion":10041,"completion":10042,"start":10043,"enrollment":8028,"conditions":10044,"interventions":10045},"NCT01292603","A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia",[89],"2014-05-07","2017-11-17","2011-04-18",[3741],[992,3482,10046,10046,10046],"rituximab [MabThera]",{"trials":10048,"activeCount":162,"soonestReadout":2754},[10049,10053,10057,10061,10065,10069,10073,10077,10090,10094,10098,10102,10106,10110,10114,10124,10128],{"nctId":4083,"briefTitle":4084,"status":107,"phases":10050,"primaryCompletion":2792,"completion":2792,"start":4086,"enrollment":1272,"conditions":10051,"interventions":10052},[90],[18],[4089,4090,992,1106,1015],{"nctId":8602,"briefTitle":8603,"status":107,"phases":10054,"primaryCompletion":2905,"completion":2905,"start":8605,"enrollment":3015,"conditions":10055,"interventions":10056},[90],[18],[1597,1166,992,947,5619],{"nctId":1346,"briefTitle":1347,"status":107,"phases":10058,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":10059,"interventions":10060},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":7918,"briefTitle":7919,"status":107,"phases":10062,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":10063,"interventions":10064},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":6058,"briefTitle":6059,"status":130,"phases":10066,"primaryCompletion":3246,"completion":3246,"start":4409,"enrollment":306,"conditions":10067,"interventions":10068},[90],[3826],[992,3482,6063,1359],{"nctId":1410,"briefTitle":1411,"status":140,"phases":10070,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":10071,"interventions":10072},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":4177,"briefTitle":4178,"status":107,"phases":10074,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":10075,"interventions":10076},[90],[18],[4184,1015,4185,1597,992,1106,947],{"nctId":10078,"briefTitle":10079,"status":130,"phases":10080,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":10083,"interventions":10087},"NCT04029688","A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed\u002FRefractory Acute Leukemias or Solid Tumors",[89,90],"2024-05-06","2020-01-27",[10084,10085,10086,922],"Acute Myeloid Leukemia (AML)","Acute Lymphoblastic Leukemia (ALL)","Neuroblastoma",[1500,1073,992,6713,3482,10088,10089],"Cytarabine","Intrathecal Chemotherapy",{"nctId":9123,"briefTitle":9124,"status":107,"phases":10091,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":10092,"interventions":10093},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"nctId":6091,"briefTitle":6092,"status":107,"phases":10095,"primaryCompletion":3324,"completion":3324,"start":4446,"enrollment":1705,"conditions":10096,"interventions":10097},[90],[3741],[992,3482,1359],{"nctId":3679,"briefTitle":3680,"status":107,"phases":10099,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":10100,"interventions":10101},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":2728,"briefTitle":2729,"status":107,"phases":10103,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":10104,"interventions":10105},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"nctId":6105,"briefTitle":6106,"status":107,"phases":10107,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":6110,"conditions":10108,"interventions":10109},[90],[6112],[992,3482,1359],{"nctId":6115,"briefTitle":6116,"status":107,"phases":10111,"primaryCompletion":6118,"completion":6118,"start":6119,"enrollment":1733,"conditions":10112,"interventions":10113},[90],[3741],[992,3482,1359],{"nctId":10115,"briefTitle":10116,"status":107,"phases":10117,"primaryCompletion":10118,"completion":10118,"start":10119,"enrollment":1385,"conditions":10120,"interventions":10121},"NCT02013817","CHAIROS Study A Study of MabThera\u002FRituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy",[90],"2012-09-24","2005-10-11",[3741],[5837,10122,10123],"fludarabine","cyclophosphamide",{"nctId":6131,"briefTitle":6132,"status":107,"phases":10125,"primaryCompletion":5805,"completion":6134,"start":6135,"enrollment":6136,"conditions":10126,"interventions":10127},[90],[15],[992,2824,1359],{"nctId":2751,"briefTitle":2752,"status":140,"phases":10129,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":10130,"interventions":10131},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"trials":10133,"activeCount":350,"soonestReadout":4786},[10134,10138,10144,10148,10156,10160,10164,10168,10172,10183,10187,10191,10195,10199,10203,10207,10211,10215,10224,10228,10232,10236,10240],{"nctId":1815,"briefTitle":1816,"status":130,"phases":10135,"primaryCompletion":1818,"completion":1818,"start":1819,"enrollment":1820,"conditions":10136,"interventions":10137},[91],[1061],[68,1106,1823,992],{"nctId":10139,"briefTitle":10140,"status":130,"phases":10141,"primaryCompletion":4582,"completion":4582,"start":7096,"enrollment":973,"conditions":10142,"interventions":10143},"NCT00425438","A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.",[91],[3597],[3707,3059,2820,992],{"nctId":6183,"briefTitle":6184,"status":107,"phases":10145,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":10146,"interventions":10147},[91],[1038],[1359,992,1358,991,1357,1356],{"nctId":10149,"briefTitle":10150,"status":107,"phases":10151,"primaryCompletion":7096,"completion":4555,"start":4323,"enrollment":10152,"conditions":10153,"interventions":10154},"NCT00377637","A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.",[91],370,[3597],[5914,992,2820,10155],"Corticosteroid",{"nctId":3777,"briefTitle":3778,"status":107,"phases":10157,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":10158,"interventions":10159},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":6220,"briefTitle":6221,"status":107,"phases":10161,"primaryCompletion":6223,"completion":6223,"start":6224,"enrollment":4573,"conditions":10162,"interventions":10163},[91],[3741],[6227,992,1359],{"nctId":9633,"briefTitle":9634,"status":107,"phases":10165,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":10166,"interventions":10167},[91],[9637],[8162,8164,9639,991,992,947,8166],{"nctId":5500,"briefTitle":5501,"status":107,"phases":10169,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":10170,"interventions":10171},[91],[18],[1222,991,992,1106,947,990,5508],{"nctId":10173,"briefTitle":10174,"status":107,"phases":10175,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":10178,"interventions":10180},"NCT03197935","A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer",[91],"2017-07-24",333,[10179],"Triple-negative Breast Cancer",[8041,989,991,992,10181,10182],"Filgrastim","Pegfilgrastim",{"nctId":1985,"briefTitle":1986,"status":107,"phases":10184,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":10185,"interventions":10186},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":8075,"briefTitle":8076,"status":107,"phases":10188,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":10189,"interventions":10190},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":4783,"briefTitle":4784,"status":140,"phases":10192,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":10193,"interventions":10194},[91],[4791],[1784,2394,1359,992,991,1357],{"nctId":6256,"briefTitle":6257,"status":107,"phases":10196,"primaryCompletion":6259,"completion":2973,"start":6260,"enrollment":6261,"conditions":10197,"interventions":10198},[91],[2431],[1359,6264,992],{"nctId":3799,"briefTitle":3800,"status":107,"phases":10200,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":10201,"interventions":10202},[91],[3806],[1018,1073,3482,992,1359,1356],{"nctId":3818,"briefTitle":3819,"status":130,"phases":10204,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":10205,"interventions":10206},[91],[3826],[1359,1018,992,991,1358,1357],{"nctId":6312,"briefTitle":6313,"status":107,"phases":10208,"primaryCompletion":4315,"completion":6315,"start":6316,"enrollment":6317,"conditions":10209,"interventions":10210},[91],[6319],[1359,992,6264],{"nctId":6326,"briefTitle":6327,"status":107,"phases":10212,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":10213,"interventions":10214},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"nctId":10216,"briefTitle":10217,"status":107,"phases":10218,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":10222,"interventions":10223},"NCT01200758","A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma",[91],"2012-06-12","2011-02-15",410,[125],[9132,9131,992,991,1358,7575],{"nctId":3841,"briefTitle":3842,"status":107,"phases":10225,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":3847,"conditions":10226,"interventions":10227},[91],[2431],[1356,2496,992,3482,1018],{"nctId":8154,"briefTitle":8155,"status":107,"phases":10229,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":10230,"interventions":10231},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"nctId":9714,"briefTitle":9715,"status":107,"phases":10233,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":10234,"interventions":10235},[91],[18],[1597,992,947,5619,9723,9724],{"nctId":5610,"briefTitle":5611,"status":107,"phases":10237,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":10238,"interventions":10239},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"nctId":6365,"briefTitle":6366,"status":107,"phases":10241,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":10242,"interventions":10243},[91],[2392],[1359,992,991,1358,1357,3482],{"trials":10245,"activeCount":101},[10246,10250,10254,10258],{"nctId":6390,"briefTitle":6391,"status":130,"phases":10247,"primaryCompletion":6393,"completion":6393,"start":6394,"enrollment":316,"conditions":10248,"interventions":10249},[92],[3741],[2496,992,3482,1359],{"nctId":3863,"briefTitle":3864,"status":107,"phases":10251,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":10252,"interventions":10253},[92],[3869],[1018,1356,992,991,3871,1358],{"nctId":5623,"briefTitle":5624,"status":107,"phases":10255,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":10256,"interventions":10257},[92],[18],[990,992,947,991,1106,1222],{"nctId":6398,"briefTitle":6399,"status":130,"phases":10259,"primaryCompletion":6401,"completion":6401,"start":6402,"enrollment":25,"conditions":10260,"interventions":10261},[92],[3741],[992,3482,1359],{"trials":10263,"activeCount":101},[10264],{"nctId":6494,"briefTitle":6495,"status":107,"phases":10265,"primaryCompletion":5891,"completion":5891,"start":2923,"enrollment":5458,"conditions":10266,"interventions":10267},[],[6498],[992,6500,6501,1357,1359],{"intervention":1419,"totalTrials":496,"cells":10269},{"EARLY_PHASE1":10270,"PHASE1":10272,"PHASE2":10290,"PHASE3":10343,"PHASE4":10423,"NA":10434},{"trials":10271,"activeCount":101},[],{"trials":10273,"activeCount":101},[10274,10280,10286],{"nctId":10275,"briefTitle":10276,"status":107,"phases":10277,"primaryCompletion":1494,"completion":1494,"start":1258,"enrollment":2563,"conditions":10278,"interventions":10279},"NCT03153163","Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer",[89],[4139],[1419],{"nctId":10281,"briefTitle":10282,"status":107,"phases":10283,"primaryCompletion":3182,"completion":3182,"start":2768,"enrollment":496,"conditions":10284,"interventions":10285},"NCT01513083","A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function",[89],[18],[8133],{"nctId":1210,"briefTitle":1211,"status":107,"phases":10287,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":10288,"interventions":10289},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"trials":10291,"activeCount":162,"soonestReadout":1413},[10292,10296,10300,10307,10311,10319,10328,10335,10339],{"nctId":9521,"briefTitle":9522,"status":107,"phases":10293,"primaryCompletion":4454,"completion":4454,"start":4488,"enrollment":1215,"conditions":10294,"interventions":10295},[89,90],[18],[947,1221,1223],{"nctId":1410,"briefTitle":1411,"status":140,"phases":10297,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":10298,"interventions":10299},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":10301,"briefTitle":10302,"status":130,"phases":10303,"primaryCompletion":785,"completion":785,"start":10304,"enrollment":350,"conditions":10305,"interventions":10306},"NCT04298918","A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer",[89,90],"2020-09-23",[18],[1073,1223],{"nctId":8617,"briefTitle":8618,"status":130,"phases":10308,"primaryCompletion":8620,"completion":8620,"start":8621,"enrollment":3015,"conditions":10309,"interventions":10310},[90],[18,1735],[1166,1223,1223,1166],{"nctId":10312,"briefTitle":10313,"status":107,"phases":10314,"primaryCompletion":829,"completion":10315,"start":10316,"enrollment":1001,"conditions":10317,"interventions":10318},"NCT02289833","A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[90],"2018-08-20","2014-12-15",[975],[1419],{"nctId":10320,"briefTitle":10321,"status":107,"phases":10322,"primaryCompletion":10323,"completion":10323,"start":446,"enrollment":2375,"conditions":10324,"interventions":10327},"NCT02999672","A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors",[90],"2018-04-10",[1539,10325,10326],"Pancreas Cancer","Cholangiocellular Carcinoma",[1419],{"nctId":10329,"briefTitle":10330,"status":107,"phases":10331,"primaryCompletion":10332,"completion":10332,"start":2906,"enrollment":1249,"conditions":10333,"interventions":10334},"NCT01196052","A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer",[90],"2013-06",[18],[1223],{"nctId":1666,"briefTitle":1667,"status":107,"phases":10336,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":10337,"interventions":10338},[90],[1569],[68,1223],{"nctId":1687,"briefTitle":1688,"status":140,"phases":10340,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":10341,"interventions":10342},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"trials":10344,"activeCount":350,"soonestReadout":268},[10345,10349,10353,10366,10370,10374,10378,10382,10390,10394,10398,10402,10411,10415],{"nctId":8352,"briefTitle":8353,"status":107,"phases":10346,"primaryCompletion":8355,"completion":8356,"start":8357,"enrollment":8358,"conditions":10347,"interventions":10348},[91],[18],[6647,8133],{"nctId":1912,"briefTitle":1913,"status":140,"phases":10350,"primaryCompletion":268,"completion":1915,"start":1846,"enrollment":1916,"conditions":10351,"interventions":10352},[91],[18],[68,1419,1222],{"nctId":10354,"briefTitle":10355,"status":107,"phases":10356,"primaryCompletion":10357,"completion":10358,"start":10359,"enrollment":10360,"conditions":10361,"interventions":10363},"NCT05415215","A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced\u002FInflammatory HER2-Positive Breast Cancer",[91],"2024-11-20","2025-11-07","2022-07-05",346,[5655,3466,10362],"Inflammatory Breast Cancer",[10364,8162,8164,1419,10365],"Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use","Investigator's Choice of Chemotherapy",{"nctId":8764,"briefTitle":8765,"status":107,"phases":10367,"primaryCompletion":8767,"completion":8768,"start":8769,"enrollment":4637,"conditions":10368,"interventions":10369},[91],[18],[1419,8772,1166],{"nctId":1967,"briefTitle":1968,"status":130,"phases":10371,"primaryCompletion":1970,"completion":1970,"start":1473,"enrollment":1036,"conditions":10372,"interventions":10373},[91],[1569],[1419,68],{"nctId":1985,"briefTitle":1986,"status":107,"phases":10375,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":10376,"interventions":10377},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":8075,"briefTitle":8076,"status":107,"phases":10379,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":10380,"interventions":10381},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":10383,"briefTitle":10384,"status":107,"phases":10385,"primaryCompletion":132,"completion":2955,"start":3189,"enrollment":10386,"conditions":10387,"interventions":10388},"NCT01419197","A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy",[91],602,[18],[1223,10389],"Treatment of physician's choice",{"nctId":8778,"briefTitle":8779,"status":107,"phases":10391,"primaryCompletion":3007,"completion":2808,"start":3479,"enrollment":8781,"conditions":10392,"interventions":10393},[91],[18],[1223,8772,1166],{"nctId":5543,"briefTitle":5544,"status":107,"phases":10395,"primaryCompletion":1214,"completion":5546,"start":5547,"enrollment":5548,"conditions":10396,"interventions":10397},[91],[4139],[990,947,1221,1222,1419],{"nctId":8123,"briefTitle":8124,"status":107,"phases":10399,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":10400,"interventions":10401},[91],[18],[5383,4503,5472,8132,5390,8133],{"nctId":10403,"briefTitle":10404,"status":107,"phases":10405,"primaryCompletion":10406,"completion":10406,"start":10407,"enrollment":10408,"conditions":10409,"interventions":10410},"NCT01702571","A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment",[91],"2020-07-31","2012-11-27",2185,[18],[1419],{"nctId":8456,"briefTitle":8457,"status":130,"phases":10412,"primaryCompletion":8321,"completion":8321,"start":3174,"enrollment":1001,"conditions":10413,"interventions":10414},[91],[1569],[1222,1419,947],{"nctId":10416,"briefTitle":10417,"status":130,"phases":10418,"primaryCompletion":4699,"completion":2139,"start":10419,"enrollment":10420,"conditions":10421,"interventions":10422},"NCT01641939","A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer",[90,91],"2012-09-03",415,[1735],[8284,8133,8133],{"trials":10424,"activeCount":101},[10425],{"nctId":10426,"briefTitle":10427,"status":107,"phases":10428,"primaryCompletion":10429,"completion":10429,"start":10430,"enrollment":31,"conditions":10431,"interventions":10433},"NCT02658734","A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane",[92],"2019-12-14","2016-11-01",[10432],"HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",[1223],{"trials":10435,"activeCount":101},[10436],{"nctId":10437,"briefTitle":10438,"status":107,"phases":10439,"primaryCompletion":10440,"completion":10440,"start":10441,"enrollment":10442,"conditions":10443,"interventions":10444},"NCT05945927","A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer",[],"2025-08-30","2023-09-13",178,[18],[1223],{"intervention":1084,"totalTrials":316,"cells":10446},{"EARLY_PHASE1":10447,"PHASE1":10449,"PHASE2":10491,"PHASE3":10549,"PHASE4":10586,"NA":10588},{"trials":10448,"activeCount":101},[],{"trials":10450,"activeCount":101},[10451,10457,10467,10471,10475,10483,10487],{"nctId":10452,"briefTitle":10453,"status":343,"phases":10454,"primaryCompletion":5364,"completion":5364,"start":4682,"enrollment":101,"conditions":10455,"interventions":10456},"NCT01974258","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and\u002For Cobimetinib in Cancer Patients",[89],[1241],[1084,1084,4244,1479],{"nctId":10458,"briefTitle":10459,"status":107,"phases":10460,"primaryCompletion":10461,"completion":10462,"start":10463,"enrollment":414,"conditions":10464,"interventions":10465},"NCT01271803","A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma",[89],"2013-10-01","2017-12-12","2011-02-17",[1261],[1084,10466],"vemurafenib",{"nctId":1076,"briefTitle":1077,"status":107,"phases":10468,"primaryCompletion":592,"completion":592,"start":1079,"enrollment":1080,"conditions":10469,"interventions":10470},[89],[1082],[1084,1085,68],{"nctId":1110,"briefTitle":1111,"status":107,"phases":10472,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":10473,"interventions":10474},[89],[30],[68,1015,1084],{"nctId":10476,"briefTitle":10477,"status":107,"phases":10478,"primaryCompletion":10479,"completion":10479,"start":3585,"enrollment":736,"conditions":10480,"interventions":10482},"NCT02670044","A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy",[89],"2020-12-10",[10481],"Leukemia, Myeloid, Acute",[1084,1500,1073],{"nctId":1244,"briefTitle":1245,"status":107,"phases":10484,"primaryCompletion":1247,"completion":1247,"start":1248,"enrollment":1249,"conditions":10485,"interventions":10486},[89],[922],[68,1084],{"nctId":1253,"briefTitle":1254,"status":107,"phases":10488,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":10489,"interventions":10490},[89],[1261],[68,1084,68,68],{"trials":10492,"activeCount":350,"soonestReadout":1413},[10493,10500,10504,10513,10517,10521,10525,10529,10533,10537,10541,10545],{"nctId":10494,"briefTitle":10495,"status":107,"phases":10496,"primaryCompletion":10497,"completion":10497,"start":6108,"enrollment":1272,"conditions":10498,"interventions":10499},"NCT02639546","Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors",[89,90],"2021-07-21",[922],[1084],{"nctId":1300,"briefTitle":1301,"status":107,"phases":10501,"primaryCompletion":919,"completion":919,"start":1303,"enrollment":1001,"conditions":10502,"interventions":10503},[89,90],[1305],[1084,1073,68],{"nctId":10505,"briefTitle":10506,"status":107,"phases":10507,"primaryCompletion":10508,"completion":10509,"start":10510,"enrollment":931,"conditions":10511,"interventions":10512},"NCT02768207","A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma",[90],"2017-12-20","2019-06-27","2016-05-23",[1477],[1084,1479],{"nctId":1308,"briefTitle":1309,"status":130,"phases":10514,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":10515,"interventions":10516},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1400,"briefTitle":1401,"status":130,"phases":10518,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":10519,"interventions":10520},[90],[18],[1084,1106,68,1107],{"nctId":1410,"briefTitle":1411,"status":140,"phases":10522,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":10523,"interventions":10524},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1470,"briefTitle":1471,"status":107,"phases":10526,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":920,"conditions":10527,"interventions":10528},[90],[1477],[1084,68,1479],{"nctId":1504,"briefTitle":1505,"status":107,"phases":10530,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":10531,"interventions":10532},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1517,"briefTitle":1518,"status":107,"phases":10534,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":10535,"interventions":10536},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":1553,"briefTitle":1554,"status":107,"phases":10538,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1296,"conditions":10539,"interventions":10540},[90],[922],[1084,68,1560],{"nctId":1588,"briefTitle":1589,"status":107,"phases":10542,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":10543,"interventions":10544},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":1760,"briefTitle":1761,"status":107,"phases":10546,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":10547,"interventions":10548},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":10550,"activeCount":162,"soonestReadout":1962},[10551,10555,10559,10569,10573,10582],{"nctId":1959,"briefTitle":1960,"status":140,"phases":10552,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":10553,"interventions":10554},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":2063,"briefTitle":2064,"status":130,"phases":10556,"primaryCompletion":2066,"completion":2067,"start":1669,"enrollment":2068,"conditions":10557,"interventions":10558},[91],[2070],[1084,68,1957],{"nctId":10560,"briefTitle":10561,"status":107,"phases":10562,"primaryCompletion":10563,"completion":10564,"start":10565,"enrollment":10566,"conditions":10567,"interventions":10568},"NCT01689519","A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma",[91],"2014-05-09","2019-07-21","2013-01-08",495,[1261],[1479,1084],{"nctId":2084,"briefTitle":2085,"status":107,"phases":10570,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":2090,"conditions":10571,"interventions":10572},[91],[1285],[68,2093,1084,1479,2094],{"nctId":10574,"briefTitle":10575,"status":107,"phases":10576,"primaryCompletion":3896,"completion":10577,"start":2865,"enrollment":10578,"conditions":10579,"interventions":10580},"NCT02788279","A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)",[91],"2018-12-26",363,[30],[10581,1084,1497],"Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody",{"nctId":2144,"briefTitle":2145,"status":140,"phases":10583,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":10584,"interventions":10585},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":10587,"activeCount":101},[],{"trials":10589,"activeCount":101},[10590],{"nctId":10591,"briefTitle":10592,"status":107,"phases":10593,"primaryCompletion":10594,"completion":10594,"start":10595,"enrollment":2708,"conditions":10596,"interventions":10597},"NCT03139513","A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])",[],"2018-08-22","2016-10-27",[1285],[1084,1479],{"intervention":991,"totalTrials":1184,"cells":10599},{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10632,"PHASE3":10658,"PHASE4":10724,"NA":10734},{"trials":10601,"activeCount":101},[],{"trials":10603,"activeCount":101},[10604,10608,10612,10620,10624,10628],{"nctId":3475,"briefTitle":3476,"status":107,"phases":10605,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":10606,"interventions":10607},[89],[125],[1356,992,991,3482,1018,1357,1358],{"nctId":2384,"briefTitle":2385,"status":107,"phases":10609,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":10610,"interventions":10611},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"nctId":10613,"briefTitle":10614,"status":107,"phases":10615,"primaryCompletion":10332,"completion":10332,"start":2801,"enrollment":145,"conditions":10616,"interventions":10617},"NCT01605526","A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma",[89],[4856],[10618,10619],"RO5045337","doxorubicin",{"nctId":979,"briefTitle":980,"status":107,"phases":10621,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":10622,"interventions":10623},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"nctId":1210,"briefTitle":1211,"status":107,"phases":10625,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":10626,"interventions":10627},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"nctId":6018,"briefTitle":6019,"status":130,"phases":10629,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":10630,"interventions":10631},[89],[3644],[1073,1785,1359,992,991,1357],{"trials":10633,"activeCount":350,"soonestReadout":2754},[10634,10638,10642,10646,10650,10654],{"nctId":1346,"briefTitle":1347,"status":107,"phases":10635,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":10636,"interventions":10637},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":7918,"briefTitle":7919,"status":107,"phases":10639,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":10640,"interventions":10641},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":9123,"briefTitle":9124,"status":107,"phases":10643,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":10644,"interventions":10645},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"nctId":3679,"briefTitle":3680,"status":107,"phases":10647,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":10648,"interventions":10649},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":2728,"briefTitle":2729,"status":107,"phases":10651,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":10652,"interventions":10653},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"nctId":2751,"briefTitle":2752,"status":140,"phases":10655,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":10656,"interventions":10657},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"trials":10659,"activeCount":350,"soonestReadout":4786},[10660,10664,10668,10672,10676,10680,10684,10688,10692,10696,10700,10704,10708,10712,10716,10720],{"nctId":8001,"briefTitle":8002,"status":107,"phases":10661,"primaryCompletion":3007,"completion":3007,"start":8004,"enrollment":8005,"conditions":10662,"interventions":10663},[91],[18],[1222,991,1106,8008],{"nctId":8022,"briefTitle":8023,"status":107,"phases":10665,"primaryCompletion":8025,"completion":8026,"start":8027,"enrollment":8028,"conditions":10666,"interventions":10667},[91],[18],[991,947,1106,1222],{"nctId":6183,"briefTitle":6184,"status":107,"phases":10669,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":10670,"interventions":10671},[91],[1038],[1359,992,1358,991,1357,1356],{"nctId":3777,"briefTitle":3778,"status":107,"phases":10673,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":10674,"interventions":10675},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":9633,"briefTitle":9634,"status":107,"phases":10677,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":10678,"interventions":10679},[91],[9637],[8162,8164,9639,991,992,947,8166],{"nctId":5500,"briefTitle":5501,"status":107,"phases":10681,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":10682,"interventions":10683},[91],[18],[1222,991,992,1106,947,990,5508],{"nctId":10173,"briefTitle":10174,"status":107,"phases":10685,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":10686,"interventions":10687},[91],[10179],[8041,989,991,992,10181,10182],{"nctId":1985,"briefTitle":1986,"status":107,"phases":10689,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":10690,"interventions":10691},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":8075,"briefTitle":8076,"status":107,"phases":10693,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":10694,"interventions":10695},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":4783,"briefTitle":4784,"status":140,"phases":10697,"primaryCompletion":4786,"completion":4787,"start":4788,"enrollment":4789,"conditions":10698,"interventions":10699},[91],[4791],[1784,2394,1359,992,991,1357],{"nctId":3818,"briefTitle":3819,"status":130,"phases":10701,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":10702,"interventions":10703},[91],[3826],[1359,1018,992,991,1358,1357],{"nctId":6326,"briefTitle":6327,"status":107,"phases":10705,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":10706,"interventions":10707},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"nctId":10216,"briefTitle":10217,"status":107,"phases":10709,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":10710,"interventions":10711},[91],[125],[9132,9131,992,991,1358,7575],{"nctId":8154,"briefTitle":8155,"status":107,"phases":10713,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":10714,"interventions":10715},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"nctId":5610,"briefTitle":5611,"status":107,"phases":10717,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":10718,"interventions":10719},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"nctId":6365,"briefTitle":6366,"status":107,"phases":10721,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":10722,"interventions":10723},[91],[2392],[1359,992,991,1358,1357,3482],{"trials":10725,"activeCount":101},[10726,10730],{"nctId":3863,"briefTitle":3864,"status":107,"phases":10727,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":10728,"interventions":10729},[92],[3869],[1018,1356,992,991,3871,1358],{"nctId":5623,"briefTitle":5624,"status":107,"phases":10731,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":1283,"conditions":10732,"interventions":10733},[92],[18],[990,992,947,991,1106,1222],{"trials":10735,"activeCount":101},[],{"intervention":1983,"totalTrials":4548,"cells":10737},{"EARLY_PHASE1":10738,"PHASE1":10740,"PHASE2":10746,"PHASE3":10756,"PHASE4":10770,"NA":10778},{"trials":10739,"activeCount":101},[],{"trials":10741,"activeCount":101},[10742],{"nctId":7020,"briefTitle":7021,"status":107,"phases":10743,"primaryCompletion":2906,"completion":2906,"start":4562,"enrollment":942,"conditions":10744,"interventions":10745},[89],[2257],[5275,5185,7025],{"trials":10747,"activeCount":101},[10748,10752],{"nctId":6558,"briefTitle":6559,"status":130,"phases":10749,"primaryCompletion":6561,"completion":6561,"start":6562,"enrollment":6563,"conditions":10750,"interventions":10751},[90],[6565],[6567,4219,1163,1983],{"nctId":8338,"briefTitle":8339,"status":107,"phases":10753,"primaryCompletion":8341,"completion":8341,"start":2793,"enrollment":8342,"conditions":10754,"interventions":10755},[90],[18],[1221,1222,1983],{"trials":10757,"activeCount":162,"soonestReadout":5280},[10758,10762,10766],{"nctId":1974,"briefTitle":1975,"status":140,"phases":10759,"primaryCompletion":1977,"completion":1978,"start":1979,"enrollment":1980,"conditions":10760,"interventions":10761},[91],[975],[68,1167,1983,947,1163,1319],{"nctId":6731,"briefTitle":6732,"status":107,"phases":10763,"primaryCompletion":6734,"completion":6735,"start":6736,"enrollment":5246,"conditions":10764,"interventions":10765},[91],[975],[4468,1983,1163],{"nctId":5277,"briefTitle":5278,"status":140,"phases":10767,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":10768,"interventions":10769},[91],[1316],[5286,1167,1983,1163,1319,990],{"trials":10771,"activeCount":101},[10772],{"nctId":10773,"briefTitle":10774,"status":107,"phases":10775,"primaryCompletion":4474,"completion":4474,"start":6506,"enrollment":22,"conditions":10776,"interventions":10777},"NCT01196078","A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer",[92],[975],[5384,7025],{"trials":10779,"activeCount":101},[],{"intervention":3773,"totalTrials":706,"cells":10781},{"EARLY_PHASE1":10782,"PHASE1":10784,"PHASE2":10786,"PHASE3":10788,"PHASE4":10798,"NA":10804},{"trials":10783,"activeCount":101},[],{"trials":10785,"activeCount":101},[],{"trials":10787,"activeCount":101},[],{"trials":10789,"activeCount":162,"soonestReadout":1364},[10790,10794],{"nctId":3766,"briefTitle":3767,"status":140,"phases":10791,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":10792,"interventions":10793},[91],[3771],[1018,3773,1357,274,3774,3775],{"nctId":3809,"briefTitle":3810,"status":140,"phases":10795,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":10796,"interventions":10797},[91],[3597],[1018,3773,1357,274,3755,2579],{"trials":10799,"activeCount":101},[10800],{"nctId":9207,"briefTitle":9208,"status":107,"phases":10801,"primaryCompletion":4409,"completion":4409,"start":3084,"enrollment":145,"conditions":10802,"interventions":10803},[92],[5846],[3773,9212,1357],{"trials":10805,"activeCount":101},[],{"intervention":3755,"totalTrials":706,"cells":10807},{"EARLY_PHASE1":10808,"PHASE1":10810,"PHASE2":10812,"PHASE3":10814,"PHASE4":10824,"NA":10830},{"trials":10809,"activeCount":101},[],{"trials":10811,"activeCount":101},[],{"trials":10813,"activeCount":101},[],{"trials":10815,"activeCount":162,"soonestReadout":1364},[10816,10820],{"nctId":3745,"briefTitle":3746,"status":140,"phases":10817,"primaryCompletion":1534,"completion":3748,"start":3749,"enrollment":3750,"conditions":10818,"interventions":10819},[91],[3752],[1018,3754,274,3755,2579],{"nctId":3809,"briefTitle":3810,"status":140,"phases":10821,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":10822,"interventions":10823},[91],[3597],[1018,3773,1357,274,3755,2579],{"trials":10825,"activeCount":101},[10826],{"nctId":5870,"briefTitle":5871,"status":107,"phases":10827,"primaryCompletion":5873,"completion":5873,"start":3823,"enrollment":4637,"conditions":10828,"interventions":10829},[92],[15],[3677,5838,5839,5876,5877],{"trials":10831,"activeCount":101},[],{"intervention":273,"totalTrials":706,"cells":10833},{"EARLY_PHASE1":10834,"PHASE1":10836,"PHASE2":10838,"PHASE3":10840,"PHASE4":10850,"NA":10856},{"trials":10835,"activeCount":101},[],{"trials":10837,"activeCount":101},[],{"trials":10839,"activeCount":101},[],{"trials":10841,"activeCount":162,"soonestReadout":267},[10842,10846],{"nctId":264,"briefTitle":265,"status":140,"phases":10843,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":10844,"interventions":10845},[91],[147],[96,96,273,274],{"nctId":297,"briefTitle":298,"status":140,"phases":10847,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":10848,"interventions":10849},[91],[147],[96,96,273,274],{"trials":10851,"activeCount":101},[10852],{"nctId":5870,"briefTitle":5871,"status":107,"phases":10853,"primaryCompletion":5873,"completion":5873,"start":3823,"enrollment":4637,"conditions":10854,"interventions":10855},[92],[15],[3677,5838,5839,5876,5877],{"trials":10857,"activeCount":101},[],{"intervention":1073,"totalTrials":510,"cells":10859},{"EARLY_PHASE1":10860,"PHASE1":10862,"PHASE2":10884,"PHASE3":10918,"PHASE4":10936,"NA":10938},{"trials":10861,"activeCount":101},[],{"trials":10863,"activeCount":350,"soonestReadout":2426},[10864,10868,10872,10876,10880],{"nctId":2423,"briefTitle":2424,"status":152,"phases":10865,"primaryCompletion":2426,"completion":2427,"start":2428,"enrollment":2429,"conditions":10866,"interventions":10867},[89],[2431],[2433,1096,1073],{"nctId":1065,"briefTitle":1066,"status":130,"phases":10869,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":162,"conditions":10870,"interventions":10871},[89],[1071],[1073,68,990,1074],{"nctId":10476,"briefTitle":10477,"status":107,"phases":10873,"primaryCompletion":10479,"completion":10479,"start":3585,"enrollment":736,"conditions":10874,"interventions":10875},[89],[10481],[1084,1500,1073],{"nctId":6009,"briefTitle":6010,"status":107,"phases":10877,"primaryCompletion":1890,"completion":1890,"start":6012,"enrollment":6013,"conditions":10878,"interventions":10879},[89],[2652,6015],[1063,1073,1359],{"nctId":6018,"briefTitle":6019,"status":130,"phases":10881,"primaryCompletion":6021,"completion":6021,"start":6022,"enrollment":37,"conditions":10882,"interventions":10883},[89],[3644],[1073,1785,1359,992,991,1357],{"trials":10885,"activeCount":101},[10886,10890,10894,10898,10902,10906,10910,10914],{"nctId":6908,"briefTitle":6909,"status":130,"phases":10887,"primaryCompletion":655,"completion":6911,"start":1374,"enrollment":6344,"conditions":10888,"interventions":10889},[90],[6913],[1073,1573],{"nctId":3581,"briefTitle":3582,"status":107,"phases":10891,"primaryCompletion":3584,"completion":3584,"start":3585,"enrollment":2857,"conditions":10892,"interventions":10893},[89,90],[125],[1018,1359,1785,1073],{"nctId":1300,"briefTitle":1301,"status":107,"phases":10895,"primaryCompletion":919,"completion":919,"start":1303,"enrollment":1001,"conditions":10896,"interventions":10897},[89,90],[1305],[1084,1073,68],{"nctId":6032,"briefTitle":6033,"status":107,"phases":10899,"primaryCompletion":805,"completion":6035,"start":6036,"enrollment":6037,"conditions":10900,"interventions":10901},[90],[2642],[1073,1356,1359],{"nctId":3638,"briefTitle":3639,"status":130,"phases":10903,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":1174,"conditions":10904,"interventions":10905},[89,90],[2642,3644],[1500,1018,1073,1359],{"nctId":10078,"briefTitle":10079,"status":130,"phases":10907,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":10908,"interventions":10909},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"nctId":10301,"briefTitle":10302,"status":130,"phases":10911,"primaryCompletion":785,"completion":785,"start":10304,"enrollment":350,"conditions":10912,"interventions":10913},[89,90],[18],[1073,1223],{"nctId":3679,"briefTitle":3680,"status":107,"phases":10915,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":10916,"interventions":10917},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"trials":10919,"activeCount":350,"soonestReadout":2147},[10920,10924,10928,10932],{"nctId":3757,"briefTitle":3758,"status":107,"phases":10921,"primaryCompletion":3760,"completion":1439,"start":3761,"enrollment":3762,"conditions":10922,"interventions":10923},[91],[3741],[2496,1073,1018],{"nctId":6203,"briefTitle":6204,"status":107,"phases":10925,"primaryCompletion":6206,"completion":752,"start":6207,"enrollment":6208,"conditions":10926,"interventions":10927},[91],[2431],[1356,1073,1359],{"nctId":3799,"briefTitle":3800,"status":107,"phases":10929,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":10930,"interventions":10931},[91],[3806],[1018,1073,3482,992,1359,1356],{"nctId":2144,"briefTitle":2145,"status":140,"phases":10933,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":10934,"interventions":10935},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":10937,"activeCount":101},[],{"trials":10939,"activeCount":101},[],{"intervention":2577,"totalTrials":2631,"cells":10941},{"EARLY_PHASE1":10942,"PHASE1":10944,"PHASE2":10954,"PHASE3":10960,"PHASE4":10970,"NA":10972},{"trials":10943,"activeCount":101},[],{"trials":10945,"activeCount":101},[10946,10950],{"nctId":9315,"briefTitle":9316,"status":107,"phases":10947,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":755,"conditions":10948,"interventions":10949},[89],[1305],[4468,9322,2644,9323,2577],{"nctId":2567,"briefTitle":2568,"status":107,"phases":10951,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":10952,"interventions":10953},[89],[933],[2575,2575,1096,2576,2577,2578,2579],{"trials":10955,"activeCount":350,"soonestReadout":2706},[10956],{"nctId":2703,"briefTitle":2704,"status":152,"phases":10957,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":10958,"interventions":10959},[89,90],[1305],[2596,2644,1096,2467,2577],{"trials":10961,"activeCount":350,"soonestReadout":9416},[10962,10966],{"nctId":9413,"briefTitle":9414,"status":152,"phases":10963,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":10964,"interventions":10965},[91],[1305],[2596,9323,2577,9322,9421,9422],{"nctId":6340,"briefTitle":6341,"status":107,"phases":10967,"primaryCompletion":6343,"completion":6343,"start":4323,"enrollment":6344,"conditions":10968,"interventions":10969},[91],[6346],[3677,2577],{"trials":10971,"activeCount":101},[],{"trials":10973,"activeCount":101},[],{"intervention":1287,"totalTrials":5110,"cells":10975},{"EARLY_PHASE1":10976,"PHASE1":10978,"PHASE2":10980,"PHASE3":11007,"PHASE4":11013,"NA":11015},{"trials":10977,"activeCount":101},[],{"trials":10979,"activeCount":101},[],{"trials":10981,"activeCount":350,"soonestReadout":10999},[10982,10986,10995],{"nctId":1277,"briefTitle":1278,"status":107,"phases":10983,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":10984,"interventions":10985},[89,90],[1285],[1287,1017,1288,68,988,1289],{"nctId":10987,"briefTitle":10988,"status":107,"phases":10989,"primaryCompletion":10990,"completion":10990,"start":3749,"enrollment":4079,"conditions":10991,"interventions":10993},"NCT04785820","A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus",[90],"2025-01-30",[10992],"Advanced or Metastatic Esophageal Squamous Cell Carcinoma",[10994,1445,1287],"Lomvastomig",{"nctId":10996,"briefTitle":10997,"status":152,"phases":10998,"primaryCompletion":10999,"completion":10999,"start":11000,"enrollment":11001,"conditions":11002,"interventions":11004},"NCT06534983","A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)",[90],"2027-11-10","2024-12-09",362,[11003],"Muscle-invasive Urothelial Carcinoma",[11005,1287,11006],"Autogene Cevumeran","Saline",{"trials":11008,"activeCount":350,"soonestReadout":5759},[11009],{"nctId":5756,"briefTitle":5757,"status":3955,"phases":11010,"primaryCompletion":5759,"completion":5760,"start":2264,"enrollment":4013,"conditions":11011,"interventions":11012},[91],[1684],[1140,1957,1287],{"trials":11014,"activeCount":101},[],{"trials":11016,"activeCount":101},[],{"intervention":2579,"totalTrials":706,"cells":11018},{"EARLY_PHASE1":11019,"PHASE1":11021,"PHASE2":11027,"PHASE3":11029,"PHASE4":11039,"NA":11041},{"trials":11020,"activeCount":101},[],{"trials":11022,"activeCount":101},[11023],{"nctId":2567,"briefTitle":2568,"status":107,"phases":11024,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":11025,"interventions":11026},[89],[933],[2575,2575,1096,2576,2577,2578,2579],{"trials":11028,"activeCount":101},[],{"trials":11030,"activeCount":162,"soonestReadout":1364},[11031,11035],{"nctId":3745,"briefTitle":3746,"status":140,"phases":11032,"primaryCompletion":1534,"completion":3748,"start":3749,"enrollment":3750,"conditions":11033,"interventions":11034},[91],[3752],[1018,3754,274,3755,2579],{"nctId":3809,"briefTitle":3810,"status":140,"phases":11036,"primaryCompletion":1364,"completion":3812,"start":3813,"enrollment":3814,"conditions":11037,"interventions":11038},[91],[3597],[1018,3773,1357,274,3755,2579],{"trials":11040,"activeCount":101},[],{"trials":11042,"activeCount":101},[],{"intervention":11044,"totalTrials":162,"cells":11045},"Astegolimab",{"EARLY_PHASE1":11046,"PHASE1":11048,"PHASE2":11050,"PHASE3":11052,"PHASE4":11074,"NA":11076},{"trials":11047,"activeCount":101},[],{"trials":11049,"activeCount":101},[],{"trials":11051,"activeCount":101},[],{"trials":11053,"activeCount":162,"soonestReadout":11058},[11054,11065],{"nctId":11055,"briefTitle":11056,"status":140,"phases":11057,"primaryCompletion":11058,"completion":11059,"start":11060,"enrollment":11061,"conditions":11062,"interventions":11064},"NCT05595642","A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease",[91],"2025-06-24","2027-09-24","2022-12-29",1290,[11063],"Chronic Obstructive Pulmonary Disease (COPD)",[11044],{"nctId":11066,"briefTitle":11067,"status":152,"phases":11068,"primaryCompletion":11069,"completion":11069,"start":11070,"enrollment":9970,"conditions":11071,"interventions":11073},"NCT05878769","A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[91],"2034-07-01","2023-06-28",[11072],"Chronic Obstructive Pulmonary Disease",[11044],{"trials":11075,"activeCount":101},[],{"trials":11077,"activeCount":101},[],{"intervention":7782,"totalTrials":162,"cells":11079},{"EARLY_PHASE1":11080,"PHASE1":11082,"PHASE2":11084,"PHASE3":11086,"PHASE4":11096,"NA":11098},{"trials":11081,"activeCount":101},[],{"trials":11083,"activeCount":101},[],{"trials":11085,"activeCount":101},[],{"trials":11087,"activeCount":162,"soonestReadout":7787},[11088,11092],{"nctId":7775,"briefTitle":7776,"status":140,"phases":11089,"primaryCompletion":7778,"completion":678,"start":7281,"enrollment":7779,"conditions":11090,"interventions":11091},[91],[232],[82,7782],{"nctId":7784,"briefTitle":7785,"status":140,"phases":11093,"primaryCompletion":7787,"completion":7788,"start":1521,"enrollment":7789,"conditions":11094,"interventions":11095},[91],[232],[82,7782],{"trials":11097,"activeCount":101},[],{"trials":11099,"activeCount":101},[],{"intervention":11101,"totalTrials":162,"cells":11102},"Trontinemab",{"EARLY_PHASE1":11103,"PHASE1":11105,"PHASE2":11107,"PHASE3":11109,"PHASE4":11126,"NA":11128},{"trials":11104,"activeCount":101},[],{"trials":11106,"activeCount":101},[],{"trials":11108,"activeCount":101},[],{"trials":11110,"activeCount":162,"soonestReadout":11115},[11111,11119],{"nctId":11112,"briefTitle":11113,"status":152,"phases":11114,"primaryCompletion":11115,"completion":11115,"start":218,"enrollment":4991,"conditions":11116,"interventions":11118},"NCT07169578","A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",[91],"2028-06-07",[11117],"Alzheimers Disease",[11101],{"nctId":11120,"briefTitle":11121,"status":152,"phases":11122,"primaryCompletion":11115,"completion":11115,"start":11123,"enrollment":4991,"conditions":11124,"interventions":11125},"NCT07170150","A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease",[91],"2025-11-12",[11117],[11101],{"trials":11127,"activeCount":101},[],{"trials":11129,"activeCount":101},[],{"intervention":3426,"totalTrials":162,"cells":11131},{"EARLY_PHASE1":11132,"PHASE1":11134,"PHASE2":11136,"PHASE3":11138,"PHASE4":11148,"NA":11150},{"trials":11133,"activeCount":101},[],{"trials":11135,"activeCount":101},[],{"trials":11137,"activeCount":101},[],{"trials":11139,"activeCount":162,"soonestReadout":1582},[11140,11144],{"nctId":3418,"briefTitle":3419,"status":152,"phases":11141,"primaryCompletion":1582,"completion":3421,"start":3422,"enrollment":3423,"conditions":11142,"interventions":11143},[91],[1569],[1137,3426,3427,3428],{"nctId":5716,"briefTitle":5717,"status":140,"phases":11145,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":11146,"interventions":11147},[91],[5723],[3426,63,947,1106,5670,3428],{"trials":11149,"activeCount":101},[],{"trials":11151,"activeCount":101},[],{"intervention":3428,"totalTrials":162,"cells":11153},{"EARLY_PHASE1":11154,"PHASE1":11156,"PHASE2":11158,"PHASE3":11160,"PHASE4":11170,"NA":11172},{"trials":11155,"activeCount":101},[],{"trials":11157,"activeCount":101},[],{"trials":11159,"activeCount":101},[],{"trials":11161,"activeCount":162,"soonestReadout":1582},[11162,11166],{"nctId":3418,"briefTitle":3419,"status":152,"phases":11163,"primaryCompletion":1582,"completion":3421,"start":3422,"enrollment":3423,"conditions":11164,"interventions":11165},[91],[1569],[1137,3426,3427,3428],{"nctId":5716,"briefTitle":5717,"status":140,"phases":11167,"primaryCompletion":5719,"completion":3937,"start":5720,"enrollment":5721,"conditions":11168,"interventions":11169},[91],[5723],[3426,63,947,1106,5670,3428],{"trials":11171,"activeCount":101},[],{"trials":11173,"activeCount":101},[],{"intervention":11175,"totalTrials":162,"cells":11176},"Prasinezumab",{"EARLY_PHASE1":11177,"PHASE1":11179,"PHASE2":11181,"PHASE3":11193,"PHASE4":11206,"NA":11208},{"trials":11178,"activeCount":101},[],{"trials":11180,"activeCount":101},[],{"trials":11182,"activeCount":350,"soonestReadout":11187},[11183],{"nctId":11184,"briefTitle":11185,"status":140,"phases":11186,"primaryCompletion":11187,"completion":7769,"start":11188,"enrollment":11189,"conditions":11190,"interventions":11192},"NCT04777331","A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease",[90],"2024-09-11","2021-05-05",586,[11191],"Parkinsons Disease",[11175],{"trials":11194,"activeCount":350,"soonestReadout":11199},[11195],{"nctId":11196,"briefTitle":11197,"status":152,"phases":11198,"primaryCompletion":11199,"completion":11200,"start":11201,"enrollment":11202,"conditions":11203,"interventions":11205},"NCT07174310","A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease",[91],"2029-06-30","2031-06-30","2025-11-24",900,[11204],"Parkinson's Disease",[11175],{"trials":11207,"activeCount":101},[],{"trials":11209,"activeCount":101},[],{"intervention":3708,"totalTrials":162,"cells":11211},{"EARLY_PHASE1":11212,"PHASE1":11214,"PHASE2":11216,"PHASE3":11222,"PHASE4":11228,"NA":11230},{"trials":11213,"activeCount":101},[],{"trials":11215,"activeCount":101},[],{"trials":11217,"activeCount":350,"soonestReadout":3703},[11218],{"nctId":3700,"briefTitle":3701,"status":152,"phases":11219,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":11220,"interventions":11221},[90],[3597],[1018,3707,3708,3709,274,1357],{"trials":11223,"activeCount":350,"soonestReadout":3854},[11224],{"nctId":3851,"briefTitle":3852,"status":140,"phases":11225,"primaryCompletion":3854,"completion":3855,"start":2540,"enrollment":3856,"conditions":11226,"interventions":11227},[91],[2621],[1018,3859,3709,274],{"trials":11229,"activeCount":101},[],{"trials":11231,"activeCount":101},[],{"intervention":7290,"totalTrials":162,"cells":11233},{"EARLY_PHASE1":11234,"PHASE1":11236,"PHASE2":11238,"PHASE3":11240,"PHASE4":11250,"NA":11252},{"trials":11235,"activeCount":101},[],{"trials":11237,"activeCount":101},[],{"trials":11239,"activeCount":101},[],{"trials":11241,"activeCount":162,"soonestReadout":72},[11242,11246],{"nctId":70,"briefTitle":71,"status":140,"phases":11243,"primaryCompletion":72,"completion":1743,"start":7287,"enrollment":4701,"conditions":11244,"interventions":11245},[91],[7283],[58,7290],{"nctId":7302,"briefTitle":7303,"status":140,"phases":11247,"primaryCompletion":1743,"completion":1743,"start":7305,"enrollment":4079,"conditions":11248,"interventions":11249},[91],[7283],[58,7290],{"trials":11251,"activeCount":101},[],{"trials":11253,"activeCount":101},[],{"intervention":1221,"totalTrials":395,"cells":11255},{"EARLY_PHASE1":11256,"PHASE1":11258,"PHASE2":11278,"PHASE3":11339,"PHASE4":11393,"NA":11399},{"trials":11257,"activeCount":101},[],{"trials":11259,"activeCount":101},[11260,11264,11268,11274],{"nctId":8238,"briefTitle":8239,"status":107,"phases":11261,"primaryCompletion":42,"completion":42,"start":8241,"enrollment":736,"conditions":11262,"interventions":11263},[89],[5655],[1222,1221],{"nctId":7888,"briefTitle":7889,"status":107,"phases":11265,"primaryCompletion":7891,"completion":7891,"start":1375,"enrollment":3497,"conditions":11266,"interventions":11267},[89],[18],[1106,1221,7894],{"nctId":11269,"briefTitle":11270,"status":107,"phases":11271,"primaryCompletion":4562,"completion":4562,"start":6277,"enrollment":510,"conditions":11272,"interventions":11273},"NCT02507375","A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[89],[975],[977,1221],{"nctId":1210,"briefTitle":1211,"status":107,"phases":11275,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":1215,"conditions":11276,"interventions":11277},[89],[1217,1218,1219],[68,990,947,1221,1222,1223,991,992],{"trials":11279,"activeCount":101},[11280,11284,11288,11292,11296,11304,11308,11312,11316,11323,11327,11331,11335],{"nctId":8251,"briefTitle":8252,"status":107,"phases":11281,"primaryCompletion":4086,"completion":2808,"start":4282,"enrollment":4021,"conditions":11282,"interventions":11283},[90],[18],[1221,1222],{"nctId":7063,"briefTitle":7064,"status":107,"phases":11285,"primaryCompletion":7066,"completion":7067,"start":7068,"enrollment":1184,"conditions":11286,"interventions":11287},[90],[1735],[1166,1167,1221,1221,1222],{"nctId":7918,"briefTitle":7919,"status":107,"phases":11289,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":11290,"interventions":11291},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":9521,"briefTitle":9522,"status":107,"phases":11293,"primaryCompletion":4454,"completion":4454,"start":4488,"enrollment":1215,"conditions":11294,"interventions":11295},[89,90],[18],[947,1221,1223],{"nctId":11297,"briefTitle":11298,"status":107,"phases":11299,"primaryCompletion":11300,"completion":11300,"start":11301,"enrollment":28,"conditions":11302,"interventions":11303},"NCT02491892","A Study of Pertuzumab in Participants With Metastatic Breast Cancer",[90],"2005-04","2003-02",[18],[1221],{"nctId":8303,"briefTitle":8304,"status":107,"phases":11305,"primaryCompletion":8306,"completion":444,"start":8307,"enrollment":8308,"conditions":11306,"interventions":11307},[90],[18],[1221,1222,4184,8311],{"nctId":1517,"briefTitle":1518,"status":107,"phases":11309,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":11310,"interventions":11311},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":8317,"briefTitle":8318,"status":107,"phases":11313,"primaryCompletion":8320,"completion":8321,"start":3084,"enrollment":8322,"conditions":11314,"interventions":11315},[90],[18],[1221,1222,8325,947,8326],{"nctId":11317,"briefTitle":11318,"status":130,"phases":11319,"primaryCompletion":3030,"completion":3030,"start":11320,"enrollment":4683,"conditions":11321,"interventions":11322},"NCT02480010","A Study of Pertuzumab in Participants With Prostate Cancer",[90],"2003-09",[7522],[1221],{"nctId":5466,"briefTitle":5467,"status":107,"phases":11324,"primaryCompletion":4113,"completion":4113,"start":5469,"enrollment":2524,"conditions":11325,"interventions":11326},[90],[1417],[5472,4503,5186,5367],{"nctId":8338,"briefTitle":8339,"status":107,"phases":11328,"primaryCompletion":8341,"completion":8341,"start":2793,"enrollment":8342,"conditions":11329,"interventions":11330},[90],[18],[1221,1222,1983],{"nctId":9569,"briefTitle":9570,"status":107,"phases":11332,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":9574,"conditions":11333,"interventions":11334},[90],[18],[7139,947,1221],{"nctId":1760,"briefTitle":1761,"status":107,"phases":11336,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":11337,"interventions":11338},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":11340,"activeCount":350,"soonestReadout":1582},[11341,11345,11349,11353,11357,11361,11365,11369,11373,11377,11381,11385,11389],{"nctId":7141,"briefTitle":7142,"status":107,"phases":11342,"primaryCompletion":7144,"completion":1802,"start":3096,"enrollment":7145,"conditions":11343,"interventions":11344},[91],[1735],[1597,1166,1167,1221,1222],{"nctId":8381,"briefTitle":8382,"status":107,"phases":11346,"primaryCompletion":8384,"completion":8385,"start":2855,"enrollment":1158,"conditions":11347,"interventions":11348},[91],[18],[947,1221,1222],{"nctId":6706,"briefTitle":6707,"status":107,"phases":11350,"primaryCompletion":6709,"completion":6710,"start":6453,"enrollment":8,"conditions":11351,"interventions":11352},[91],[1417],[1163,1106,1221,6713],{"nctId":8410,"briefTitle":8411,"status":107,"phases":11354,"primaryCompletion":3254,"completion":8413,"start":4095,"enrollment":8414,"conditions":11355,"interventions":11356},[91],[18],[8417,947,1221,1222],{"nctId":8059,"briefTitle":8060,"status":107,"phases":11358,"primaryCompletion":8062,"completion":8062,"start":8063,"enrollment":37,"conditions":11359,"interventions":11360},[91],[18],[947,989,1106,1221,1222],{"nctId":1985,"briefTitle":1986,"status":107,"phases":11362,"primaryCompletion":1988,"completion":1989,"start":1340,"enrollment":1990,"conditions":11363,"interventions":11364},[91],[18],[68,991,992,1106,1222,1221,1419],{"nctId":8075,"briefTitle":8076,"status":107,"phases":11366,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":11367,"interventions":11368},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":8084,"briefTitle":8085,"status":107,"phases":11370,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":8089,"conditions":11371,"interventions":11372},[91],[4139],[947,989,1106,1221,1222],{"nctId":8435,"briefTitle":8436,"status":140,"phases":11374,"primaryCompletion":1582,"completion":1582,"start":8438,"enrollment":5458,"conditions":11375,"interventions":11376},[91],[922],[1221,1222,8441],{"nctId":8443,"briefTitle":8444,"status":107,"phases":11378,"primaryCompletion":8446,"completion":8447,"start":8448,"enrollment":3077,"conditions":11379,"interventions":11380},[91],[18],[1166,1166,1221,1222],{"nctId":5543,"briefTitle":5544,"status":107,"phases":11382,"primaryCompletion":1214,"completion":5546,"start":5547,"enrollment":5548,"conditions":11383,"interventions":11384},[91],[4139],[990,947,1221,1222,1419],{"nctId":8123,"briefTitle":8124,"status":107,"phases":11386,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":11387,"interventions":11388},[91],[18],[5383,4503,5472,8132,5390,8133],{"nctId":5610,"briefTitle":5611,"status":107,"phases":11390,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":11391,"interventions":11392},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"trials":11394,"activeCount":101},[11395],{"nctId":8510,"briefTitle":8511,"status":107,"phases":11396,"primaryCompletion":8513,"completion":8513,"start":8514,"enrollment":973,"conditions":11397,"interventions":11398},[92],[18],[947,1221,1222],{"trials":11400,"activeCount":350,"soonestReadout":2025},[11401,11405],{"nctId":2335,"briefTitle":2336,"status":140,"phases":11402,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":11403,"interventions":11404},[],[18],[1015,1222,2342,1221,68,1166],{"nctId":11406,"briefTitle":11407,"status":107,"phases":11408,"primaryCompletion":3064,"completion":3064,"start":11409,"enrollment":4789,"conditions":11410,"interventions":11411},"NCT02266173","Observational Study of Pertuzumab Safety in Participants With Breast Cancer",[],"2015-02-05",[18],[1221],{"intervention":1479,"totalTrials":1174,"cells":11413},{"EARLY_PHASE1":11414,"PHASE1":11416,"PHASE2":11507,"PHASE3":11557,"PHASE4":11599,"NA":11610},{"trials":11415,"activeCount":101},[],{"trials":11417,"activeCount":101},[11418,11429,11433,11442,11450,11459,11465,11469,11477,11484,11491,11500],{"nctId":11419,"briefTitle":11420,"status":107,"phases":11421,"primaryCompletion":11422,"completion":11423,"start":11424,"enrollment":942,"conditions":11425,"interventions":11427},"NCT02441465","Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies",[89],"2016-08-18","2017-01-09","2015-08-13",[11426],"Malignant Melanoma, Cancer",[1479,11428],"14C-Labeled Vemurafenib",{"nctId":10452,"briefTitle":10453,"status":343,"phases":11430,"primaryCompletion":5364,"completion":5364,"start":4682,"enrollment":101,"conditions":11431,"interventions":11432},[89],[1241],[1084,1084,4244,1479],{"nctId":11434,"briefTitle":11435,"status":107,"phases":11436,"primaryCompletion":11437,"completion":11437,"start":2684,"enrollment":162,"conditions":11438,"interventions":11440},"NCT01849666","A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",[89],"2014-04",[11439],"Malignant Melanoma, Neoplasms",[11441,10466],"phenprocoumon",{"nctId":11443,"briefTitle":11444,"status":107,"phases":11445,"primaryCompletion":11446,"completion":11446,"start":11447,"enrollment":306,"conditions":11448,"interventions":11449},"NCT01767623","A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants",[89],"2017-04-20","2013-08-20",[1241],[1479],{"nctId":11451,"briefTitle":11452,"status":107,"phases":11453,"primaryCompletion":11454,"completion":11455,"start":11456,"enrollment":1204,"conditions":11457,"interventions":11458},"NCT01910181","A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma",[89],"2013-10-22","2018-04-20","2013-08-17",[1261],[1479],{"nctId":11460,"briefTitle":11461,"status":130,"phases":11462,"primaryCompletion":2847,"completion":2847,"start":4249,"enrollment":942,"conditions":11463,"interventions":11464},"NCT01519323","BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations",[89],[1261],[10466],{"nctId":10458,"briefTitle":10459,"status":107,"phases":11466,"primaryCompletion":10461,"completion":10462,"start":10463,"enrollment":414,"conditions":11467,"interventions":11468},[89],[1261],[1084,10466],{"nctId":11470,"briefTitle":11471,"status":107,"phases":11472,"primaryCompletion":3478,"completion":3478,"start":2515,"enrollment":11473,"conditions":11474,"interventions":11475},"NCT01765543","A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)",[89],27,[11439],[11476,1479],"Rifampin",{"nctId":11478,"briefTitle":11479,"status":343,"phases":11480,"primaryCompletion":4454,"completion":4454,"start":4454,"enrollment":101,"conditions":11481,"interventions":11482},"NCT01765556","A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma",[89],[11439],[11483,10466],"ketoconazole",{"nctId":11485,"briefTitle":11486,"status":107,"phases":11487,"primaryCompletion":3174,"completion":3174,"start":6157,"enrollment":1796,"conditions":11488,"interventions":11489},"NCT01851824","A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",[89],[11439],[11490,10466],"acenocoumarol",{"nctId":11492,"briefTitle":11493,"status":107,"phases":11494,"primaryCompletion":11495,"completion":11495,"start":11496,"enrollment":5901,"conditions":11497,"interventions":11498},"NCT01844674","A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies",[89],"2014-08-26","2013-09-02",[11439],[11499,1479],"Tizanidine",{"nctId":11501,"briefTitle":11502,"status":107,"phases":11503,"primaryCompletion":3174,"completion":3174,"start":2515,"enrollment":1174,"conditions":11504,"interventions":11505},"NCT01765569","A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma",[89],[11439],[11506,1479],"Digoxin",{"trials":11508,"activeCount":101},[11509,11513,11522,11526,11530,11539,11546,11553],{"nctId":10505,"briefTitle":10506,"status":107,"phases":11510,"primaryCompletion":10508,"completion":10509,"start":10510,"enrollment":931,"conditions":11511,"interventions":11512},[90],[1477],[1084,1479],{"nctId":11514,"briefTitle":11515,"status":107,"phases":11516,"primaryCompletion":11517,"completion":11517,"start":11518,"enrollment":8,"conditions":11519,"interventions":11521},"NCT01524978","A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers",[90],"2016-10-28","2012-04-12",[11520],"Multiple Myeloma, Neoplasms",[5382,10466,10466],{"nctId":1470,"briefTitle":1471,"status":107,"phases":11523,"primaryCompletion":1473,"completion":1474,"start":1475,"enrollment":920,"conditions":11524,"interventions":11525},[90],[1477],[1084,68,1479],{"nctId":1517,"briefTitle":1518,"status":107,"phases":11527,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":11528,"interventions":11529},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"nctId":11531,"briefTitle":11532,"status":107,"phases":11533,"primaryCompletion":11534,"completion":11535,"start":11536,"enrollment":3044,"conditions":11537,"interventions":11538},"NCT00949702","A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma",[90],"2010-09-27","2014-06-03","2009-09-30",[1261],[10466],{"nctId":11540,"briefTitle":11541,"status":107,"phases":11542,"primaryCompletion":2792,"completion":2792,"start":4314,"enrollment":11543,"conditions":11544,"interventions":11545},"NCT01378975","A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases",[90],146,[1261],[1479],{"nctId":11547,"briefTitle":11548,"status":107,"phases":11549,"primaryCompletion":11550,"completion":2947,"start":8320,"enrollment":1115,"conditions":11551,"interventions":11552},"NCT01286753","A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",[90],"2014-11",[1241],[1479],{"nctId":1760,"briefTitle":1761,"status":107,"phases":11554,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":11555,"interventions":11556},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":11558,"activeCount":162,"soonestReadout":1962},[11559,11568,11575,11579,11583,11587,11591],{"nctId":11560,"briefTitle":11561,"status":107,"phases":11562,"primaryCompletion":11563,"completion":11563,"start":11564,"enrollment":11565,"conditions":11566,"interventions":11567},"NCT01307397","A Study of Vemurafenib in Participants With Metastatic Melanoma",[91],"2016-02-24","2011-03-01",3219,[1261],[1479],{"nctId":11569,"briefTitle":11570,"status":107,"phases":11571,"primaryCompletion":4474,"completion":2792,"start":4206,"enrollment":11572,"conditions":11573,"interventions":11574},"NCT01006980","A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)",[91],675,[1261],[1479,4292],{"nctId":1959,"briefTitle":1960,"status":140,"phases":11576,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":703,"conditions":11577,"interventions":11578},[90,91],[975],[43,68,1319,1167,990,1163,1695,1084,1479,1015,1140,947],{"nctId":10560,"briefTitle":10561,"status":107,"phases":11580,"primaryCompletion":10563,"completion":10564,"start":10565,"enrollment":10566,"conditions":11581,"interventions":11582},[91],[1261],[1479,1084],{"nctId":2084,"briefTitle":2085,"status":107,"phases":11584,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":2090,"conditions":11585,"interventions":11586},[91],[1285],[68,2093,1084,1479,2094],{"nctId":2144,"briefTitle":2145,"status":140,"phases":11588,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":11589,"interventions":11590},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":11592,"briefTitle":11593,"status":107,"phases":11594,"primaryCompletion":11595,"completion":11596,"start":10118,"enrollment":2665,"conditions":11597,"interventions":11598},"NCT01667419","A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma",[91],"2017-06-23","2018-07-13",[1285],[1479],{"trials":11600,"activeCount":101},[11601],{"nctId":11602,"briefTitle":11603,"status":107,"phases":11604,"primaryCompletion":11605,"completion":11605,"start":11606,"enrollment":11607,"conditions":11608,"interventions":11609},"NCT01739764","An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol",[92],"2020-02-17","2013-02-19",215,[1241],[1479],{"trials":11611,"activeCount":101},[11612],{"nctId":10591,"briefTitle":10592,"status":107,"phases":11613,"primaryCompletion":10594,"completion":10594,"start":10595,"enrollment":2708,"conditions":11614,"interventions":11615},[],[1285],[1084,1479],{"intervention":1356,"totalTrials":2619,"cells":11617},{"EARLY_PHASE1":11618,"PHASE1":11620,"PHASE2":11626,"PHASE3":11644,"PHASE4":11678,"NA":11691},{"trials":11619,"activeCount":101},[],{"trials":11621,"activeCount":101},[11622],{"nctId":3475,"briefTitle":3476,"status":107,"phases":11623,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":11624,"interventions":11625},[89],[125],[1356,992,991,3482,1018,1357,1358],{"trials":11627,"activeCount":101},[11628,11632,11636,11640],{"nctId":6032,"briefTitle":6033,"status":107,"phases":11629,"primaryCompletion":805,"completion":6035,"start":6036,"enrollment":6037,"conditions":11630,"interventions":11631},[90],[2642],[1073,1356,1359],{"nctId":1346,"briefTitle":1347,"status":107,"phases":11633,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":11634,"interventions":11635},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":3619,"briefTitle":3620,"status":107,"phases":11637,"primaryCompletion":3622,"completion":3622,"start":3623,"enrollment":3624,"conditions":11638,"interventions":11639},[89,90],[1038],[1356,1018,2394,1359,2394],{"nctId":3660,"briefTitle":3661,"status":107,"phases":11641,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":3665,"conditions":11642,"interventions":11643},[90],[2431],[3668,3669],{"trials":11645,"activeCount":350,"soonestReadout":1978},[11646,11650,11654,11658,11662,11666,11670,11674],{"nctId":6183,"briefTitle":6184,"status":107,"phases":11647,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":11648,"interventions":11649},[91],[1038],[1359,992,1358,991,1357,1356],{"nctId":6192,"briefTitle":6193,"status":107,"phases":11651,"primaryCompletion":6195,"completion":6195,"start":2948,"enrollment":6196,"conditions":11652,"interventions":11653},[91],[6198],[6200,6201,1356,1359,1359,1359,1359],{"nctId":6203,"briefTitle":6204,"status":107,"phases":11655,"primaryCompletion":6206,"completion":752,"start":6207,"enrollment":6208,"conditions":11656,"interventions":11657},[91],[2431],[1356,1073,1359],{"nctId":3777,"briefTitle":3778,"status":107,"phases":11659,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":11660,"interventions":11661},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":6246,"briefTitle":6247,"status":130,"phases":11663,"primaryCompletion":6249,"completion":6250,"start":6251,"enrollment":1733,"conditions":11664,"interventions":11665},[91],[6253],[1785,1356,1359],{"nctId":3799,"briefTitle":3800,"status":107,"phases":11667,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":11668,"interventions":11669},[91],[3806],[1018,1073,3482,992,1359,1356],{"nctId":3011,"briefTitle":3012,"status":152,"phases":11671,"primaryCompletion":1978,"completion":366,"start":3014,"enrollment":3015,"conditions":11672,"interventions":11673},[91],[1038],[1018,1784,1359,1356,2644,1096],{"nctId":3841,"briefTitle":3842,"status":107,"phases":11675,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":3847,"conditions":11676,"interventions":11677},[91],[2431],[1356,2496,992,3482,1018],{"trials":11679,"activeCount":101},[11680,11687],{"nctId":11681,"briefTitle":11682,"status":107,"phases":11683,"primaryCompletion":3197,"completion":3197,"start":4555,"enrollment":11684,"conditions":11685,"interventions":11686},"NCT01056510","A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)",[92],357,[3741],[3668,3743,5837],{"nctId":3863,"briefTitle":3864,"status":107,"phases":11688,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":11689,"interventions":11690},[92],[3869],[1018,1356,992,991,3871,1358],{"trials":11692,"activeCount":101},[],{"intervention":3754,"totalTrials":5110,"cells":11694},{"EARLY_PHASE1":11695,"PHASE1":11697,"PHASE2":11699,"PHASE3":11701,"PHASE4":11707,"NA":11739},{"trials":11696,"activeCount":101},[],{"trials":11698,"activeCount":101},[],{"trials":11700,"activeCount":101},[],{"trials":11702,"activeCount":350,"soonestReadout":1534},[11703],{"nctId":3745,"briefTitle":3746,"status":140,"phases":11704,"primaryCompletion":1534,"completion":3748,"start":3749,"enrollment":3750,"conditions":11705,"interventions":11706},[91],[3752],[1018,3754,274,3755,2579],{"trials":11708,"activeCount":101},[11709,11718,11730],{"nctId":11710,"briefTitle":11711,"status":107,"phases":11712,"primaryCompletion":3692,"completion":3692,"start":11713,"enrollment":11714,"conditions":11715,"interventions":11716},"NCT00087581","Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF\u002FCellCept) After Kidney Transplantation",[92],"2004-06",720,[5846],[5914,11717,3754],"Cyclosporine",{"nctId":11719,"briefTitle":11720,"status":107,"phases":11721,"primaryCompletion":4314,"completion":4314,"start":5820,"enrollment":11722,"conditions":11723,"interventions":11725},"NCT00545402","A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.",[92],180,[11724],"Liver Transplantation",[11726,3754,11727,11728,11729],"Mycophenolate mofetil, adjusted dose","Corticosteroids, IV","Mycophenolate mofetil, Standard dose","Corticosteroids, PO",{"nctId":11731,"briefTitle":11732,"status":107,"phases":11733,"primaryCompletion":6343,"completion":4562,"start":2923,"enrollment":11734,"conditions":11735,"interventions":11736},"NCT00118742","Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant",[92],293,[11724],[11737,3754,11717,11738],"mycophenolate mofetil [CellCept]","Sirolimus",{"trials":11740,"activeCount":101},[],{"intervention":388,"totalTrials":942,"cells":11742},{"EARLY_PHASE1":11743,"PHASE1":11745,"PHASE2":11793,"PHASE3":11795,"PHASE4":11801,"NA":11803},{"trials":11744,"activeCount":101},[],{"trials":11746,"activeCount":101},[11747,11751,11760,11774,11783],{"nctId":379,"briefTitle":380,"status":107,"phases":11748,"primaryCompletion":382,"completion":382,"start":383,"enrollment":384,"conditions":11749,"interventions":11750},[89],[386],[77,388],{"nctId":11752,"briefTitle":11753,"status":343,"phases":11754,"primaryCompletion":11755,"completion":11755,"start":11756,"enrollment":101,"conditions":11757,"interventions":11758},"NCT02019290","A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.",[89],"2014-03-31","2014-02-10",[21],[388,11759],"bitopertin",{"nctId":11761,"briefTitle":11762,"status":107,"phases":11763,"primaryCompletion":11764,"completion":11764,"start":11765,"enrollment":736,"conditions":11766,"interventions":11772},"NCT04475848","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants",[89],"2022-02-06","2020-07-15",[11767,11768,11769,11770,11771],"Autistic Disorder","Autism Spectrum Disorder","Child Development Disorders, Pervasive","Mental Disorders","Neurodevelopmental Disorders",[11773,388],"RO6953958",{"nctId":11775,"briefTitle":11776,"status":130,"phases":11777,"primaryCompletion":11778,"completion":11778,"start":10316,"enrollment":1847,"conditions":11779,"interventions":11780},"NCT02321384","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants",[89],"2015-11-26",[21],[11781,388,11782],"RO6889678","Ritonavir",{"nctId":11784,"briefTitle":11785,"status":107,"phases":11786,"primaryCompletion":1101,"completion":1101,"start":11787,"enrollment":11788,"conditions":11789,"interventions":11791},"NCT02952924","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants",[89],"2016-12-14",192,[11790],"Hepatitis B, Chronic",[388,11792],"RO7049389",{"trials":11794,"activeCount":101},[],{"trials":11796,"activeCount":350,"soonestReadout":3443},[11797],{"nctId":3440,"briefTitle":3441,"status":140,"phases":11798,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":11799,"interventions":11800},[91],[18],[1137,1573,3448,3449,3450,388],{"trials":11802,"activeCount":101},[],{"trials":11804,"activeCount":101},[],{"intervention":2011,"totalTrials":2631,"cells":11806},{"EARLY_PHASE1":11807,"PHASE1":11809,"PHASE2":11828,"PHASE3":11830,"PHASE4":11840,"NA":11842},{"trials":11808,"activeCount":101},[],{"trials":11810,"activeCount":101},[11811,11817,11824],{"nctId":11812,"briefTitle":11813,"status":107,"phases":11814,"primaryCompletion":4473,"completion":4473,"start":2684,"enrollment":1796,"conditions":11815,"interventions":11816},"NCT01897038","A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma",[89],[1443],[4244,2011],{"nctId":11818,"briefTitle":11819,"status":107,"phases":11820,"primaryCompletion":3103,"completion":3103,"start":2964,"enrollment":942,"conditions":11821,"interventions":11822},"NCT01308723","A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma",[89],[1443],[11823,11823,5388],"RO5323441",{"nctId":5373,"briefTitle":5374,"status":130,"phases":11825,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":11826,"interventions":11827},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":11829,"activeCount":101},[],{"trials":11831,"activeCount":350,"soonestReadout":2025},[11832,11836],{"nctId":2002,"briefTitle":2003,"status":107,"phases":11833,"primaryCompletion":2005,"completion":2006,"start":2007,"enrollment":2008,"conditions":11834,"interventions":11835},[91],[1443],[68,1015,2011],{"nctId":2022,"briefTitle":2023,"status":140,"phases":11837,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":11838,"interventions":11839},[91],[2029],[68,2031,2011],{"trials":11841,"activeCount":101},[],{"trials":11843,"activeCount":101},[],{"intervention":9322,"totalTrials":5110,"cells":11845},{"EARLY_PHASE1":11846,"PHASE1":11848,"PHASE2":11862,"PHASE3":11873,"PHASE4":11879,"NA":11881},{"trials":11847,"activeCount":101},[],{"trials":11849,"activeCount":101},[11850,11858],{"nctId":11851,"briefTitle":11852,"status":107,"phases":11853,"primaryCompletion":9623,"completion":9623,"start":11854,"enrollment":425,"conditions":11855,"interventions":11856},"NCT03068351","Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma",[89],"2017-06-26",[1305],[1063,11857],"daratumumab",{"nctId":9315,"briefTitle":9316,"status":107,"phases":11859,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":755,"conditions":11860,"interventions":11861},[89],[1305],[4468,9322,2644,9323,2577],{"trials":11863,"activeCount":101},[11864],{"nctId":11865,"briefTitle":11866,"status":107,"phases":11867,"primaryCompletion":7385,"completion":7385,"start":11868,"enrollment":8583,"conditions":11869,"interventions":11871},"NCT06055075","A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma",[89,90],"2023-12-12",[11870],"Relapsed or Refractory Multiple Myeloma",[11872,9422,9322],"Forimtamig",{"trials":11874,"activeCount":350,"soonestReadout":9416},[11875],{"nctId":9413,"briefTitle":9414,"status":152,"phases":11876,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":11877,"interventions":11878},[91],[1305],[2596,9323,2577,9322,9421,9422],{"trials":11880,"activeCount":101},[],{"trials":11882,"activeCount":101},[],{"intervention":2121,"totalTrials":5110,"cells":11884},{"EARLY_PHASE1":11885,"PHASE1":11887,"PHASE2":11889,"PHASE3":11891,"PHASE4":11916,"NA":11918},{"trials":11886,"activeCount":101},[],{"trials":11888,"activeCount":101},[],{"trials":11890,"activeCount":101},[],{"trials":11892,"activeCount":350,"soonestReadout":2147},[11893,11904,11908,11912],{"nctId":11894,"briefTitle":11895,"status":343,"phases":11896,"primaryCompletion":11897,"completion":11898,"start":11899,"enrollment":101,"conditions":11900,"interventions":11902},"NCT04760288","A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).",[91],"2027-10-06","2035-04-12","2023-11-30",[11901],"Medullary Thyroid Cancer",[1697,2121,11903],"Vandetanib",{"nctId":2112,"briefTitle":2113,"status":107,"phases":11905,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":11906,"interventions":11907},[91],[1316],[2121,68,947],{"nctId":2144,"briefTitle":2145,"status":140,"phases":11909,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":11910,"interventions":11911},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"nctId":2192,"briefTitle":2193,"status":130,"phases":11913,"primaryCompletion":2195,"completion":2196,"start":2197,"enrollment":2198,"conditions":11914,"interventions":11915},[91],[2200],[68,2121],{"trials":11917,"activeCount":101},[],{"trials":11919,"activeCount":101},[],{"intervention":1126,"totalTrials":5110,"cells":11921},{"EARLY_PHASE1":11922,"PHASE1":11924,"PHASE2":11943,"PHASE3":11945,"PHASE4":11951,"NA":11953},{"trials":11923,"activeCount":101},[],{"trials":11925,"activeCount":101},[11926,11930,11939],{"nctId":1119,"briefTitle":1120,"status":107,"phases":11927,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":11,"conditions":11928,"interventions":11929},[89],[1013],[68,1126],{"nctId":11931,"briefTitle":11932,"status":107,"phases":11933,"primaryCompletion":11934,"completion":11934,"start":11935,"enrollment":2492,"conditions":11936,"interventions":11937},"NCT02760797","A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors",[89],"2018-04-06","2016-05-09",[1241],[1126,11938],"RO7009789",{"nctId":1189,"briefTitle":1190,"status":343,"phases":11940,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":101,"conditions":11941,"interventions":11942},[89],[1196],[68,1126,1018],{"trials":11944,"activeCount":101},[],{"trials":11946,"activeCount":350,"soonestReadout":2147},[11947],{"nctId":2144,"briefTitle":2145,"status":140,"phases":11948,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":11949,"interventions":11950},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":11952,"activeCount":101},[],{"trials":11954,"activeCount":101},[],{"intervention":418,"totalTrials":706,"cells":11956},{"EARLY_PHASE1":11957,"PHASE1":11959,"PHASE2":11974,"PHASE3":11976,"PHASE4":11982,"NA":11984},{"trials":11958,"activeCount":101},[],{"trials":11960,"activeCount":101},[11961,11970],{"nctId":11962,"briefTitle":11963,"status":107,"phases":11964,"primaryCompletion":3189,"completion":3189,"start":4314,"enrollment":8206,"conditions":11965,"interventions":11966},"NCT01392755","A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers",[89],[21],[11967,418,11968,11969],"danoprevir","ranitidine","ritonavir",{"nctId":409,"briefTitle":410,"status":107,"phases":11971,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":11972,"interventions":11973},[89],[406],[417,418],{"trials":11975,"activeCount":101},[],{"trials":11977,"activeCount":350,"soonestReadout":3443},[11978],{"nctId":3440,"briefTitle":3441,"status":140,"phases":11979,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":11980,"interventions":11981},[91],[18],[1137,1573,3448,3449,3450,388],{"trials":11983,"activeCount":101},[],{"trials":11985,"activeCount":101},[],{"intervention":1085,"totalTrials":706,"cells":11987},{"EARLY_PHASE1":11988,"PHASE1":11990,"PHASE2":11996,"PHASE3":12002,"PHASE4":12008,"NA":12010},{"trials":11989,"activeCount":101},[],{"trials":11991,"activeCount":101},[11992],{"nctId":1076,"briefTitle":1077,"status":107,"phases":11993,"primaryCompletion":592,"completion":592,"start":1079,"enrollment":1080,"conditions":11994,"interventions":11995},[89],[1082],[1084,1085,68],{"trials":11997,"activeCount":101},[11998],{"nctId":1530,"briefTitle":1531,"status":107,"phases":11999,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":12000,"interventions":12001},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"trials":12003,"activeCount":350,"soonestReadout":2147},[12004],{"nctId":2144,"briefTitle":2145,"status":140,"phases":12005,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":12006,"interventions":12007},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":12009,"activeCount":101},[],{"trials":12011,"activeCount":101},[],{"intervention":2152,"totalTrials":706,"cells":12013},{"EARLY_PHASE1":12014,"PHASE1":12016,"PHASE2":12018,"PHASE3":12024,"PHASE4":12034,"NA":12036},{"trials":12015,"activeCount":101},[],{"trials":12017,"activeCount":101},[],{"trials":12019,"activeCount":101},[12020],{"nctId":4211,"briefTitle":4212,"status":107,"phases":12021,"primaryCompletion":4214,"completion":4215,"start":4216,"enrollment":1936,"conditions":12022,"interventions":12023},[90],[1049],[4219,1015,2152],{"trials":12025,"activeCount":350,"soonestReadout":2147},[12026,12030],{"nctId":4460,"briefTitle":4461,"status":107,"phases":12027,"primaryCompletion":4463,"completion":4464,"start":3277,"enrollment":4465,"conditions":12028,"interventions":12029},[91],[1049],[4468,1015,2152],{"nctId":2144,"briefTitle":2145,"status":140,"phases":12031,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":12032,"interventions":12033},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":12035,"activeCount":101},[],{"trials":12037,"activeCount":101},[],{"intervention":1178,"totalTrials":706,"cells":12039},{"EARLY_PHASE1":12040,"PHASE1":12042,"PHASE2":12052,"PHASE3":12054,"PHASE4":12060,"NA":12062},{"trials":12041,"activeCount":101},[],{"trials":12043,"activeCount":101},[12044,12048],{"nctId":7515,"briefTitle":7516,"status":107,"phases":12045,"primaryCompletion":7518,"completion":7519,"start":7520,"enrollment":1115,"conditions":12046,"interventions":12047},[89],[18,7522,1417],[946,1178],{"nctId":1169,"briefTitle":1170,"status":107,"phases":12049,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":1174,"conditions":12050,"interventions":12051},[89],[1176],[68,1178],{"trials":12053,"activeCount":101},[],{"trials":12055,"activeCount":350,"soonestReadout":2147},[12056],{"nctId":2144,"briefTitle":2145,"status":140,"phases":12057,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":12058,"interventions":12059},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":12061,"activeCount":101},[],{"trials":12063,"activeCount":101},[],{"intervention":9323,"totalTrials":162,"cells":12065},{"EARLY_PHASE1":12066,"PHASE1":12068,"PHASE2":12074,"PHASE3":12076,"PHASE4":12082,"NA":12084},{"trials":12067,"activeCount":101},[],{"trials":12069,"activeCount":101},[12070],{"nctId":9315,"briefTitle":9316,"status":107,"phases":12071,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":755,"conditions":12072,"interventions":12073},[89],[1305],[4468,9322,2644,9323,2577],{"trials":12075,"activeCount":101},[],{"trials":12077,"activeCount":350,"soonestReadout":9416},[12078],{"nctId":9413,"briefTitle":9414,"status":152,"phases":12079,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":12080,"interventions":12081},[91],[1305],[2596,9323,2577,9322,9421,9422],{"trials":12083,"activeCount":101},[],{"trials":12085,"activeCount":101},[],{"intervention":9422,"totalTrials":162,"cells":12087},{"EARLY_PHASE1":12088,"PHASE1":12090,"PHASE2":12092,"PHASE3":12098,"PHASE4":12104,"NA":12106},{"trials":12089,"activeCount":101},[],{"trials":12091,"activeCount":101},[],{"trials":12093,"activeCount":101},[12094],{"nctId":11865,"briefTitle":11866,"status":107,"phases":12095,"primaryCompletion":7385,"completion":7385,"start":11868,"enrollment":8583,"conditions":12096,"interventions":12097},[89,90],[11870],[11872,9422,9322],{"trials":12099,"activeCount":350,"soonestReadout":9416},[12100],{"nctId":9413,"briefTitle":9414,"status":152,"phases":12101,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":12102,"interventions":12103},[91],[1305],[2596,9323,2577,9322,9421,9422],{"trials":12105,"activeCount":101},[],{"trials":12107,"activeCount":101},[],{"intervention":1948,"totalTrials":162,"cells":12109},{"EARLY_PHASE1":12110,"PHASE1":12112,"PHASE2":12114,"PHASE3":12116,"PHASE4":12126,"NA":12128},{"trials":12111,"activeCount":101},[],{"trials":12113,"activeCount":101},[],{"trials":12115,"activeCount":101},[],{"trials":12117,"activeCount":350,"soonestReadout":4945},[12118,12122],{"nctId":4942,"briefTitle":4943,"status":140,"phases":12119,"primaryCompletion":4945,"completion":4945,"start":4946,"enrollment":4683,"conditions":12120,"interventions":12121},[91],[975],[43,1695,1948],{"nctId":1940,"briefTitle":1941,"status":107,"phases":12123,"primaryCompletion":1943,"completion":1924,"start":1944,"enrollment":1945,"conditions":12124,"interventions":12125},[91],[1432],[68,988,1948],{"trials":12127,"activeCount":101},[],{"trials":12129,"activeCount":101},[],{"intervention":2736,"totalTrials":162,"cells":12131},{"EARLY_PHASE1":12132,"PHASE1":12134,"PHASE2":12136,"PHASE3":12142,"PHASE4":12148,"NA":12150},{"trials":12133,"activeCount":101},[],{"trials":12135,"activeCount":101},[],{"trials":12137,"activeCount":101},[12138],{"nctId":2728,"briefTitle":2729,"status":107,"phases":12139,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":12140,"interventions":12141},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"trials":12143,"activeCount":350,"soonestReadout":366},[12144],{"nctId":2937,"briefTitle":2938,"status":140,"phases":12145,"primaryCompletion":366,"completion":366,"start":1394,"enrollment":2940,"conditions":12146,"interventions":12147},[91],[2652],[1018,1784,2736,1096,1163,1165],{"trials":12149,"activeCount":101},[],{"trials":12151,"activeCount":101},[],{"intervention":12153,"totalTrials":162,"cells":12154},"Taxane-based chemotherapy",{"EARLY_PHASE1":12155,"PHASE1":12157,"PHASE2":12159,"PHASE3":12161,"PHASE4":12174,"NA":12176},{"trials":12156,"activeCount":101},[],{"trials":12158,"activeCount":101},[],{"trials":12160,"activeCount":101},[],{"trials":12162,"activeCount":350,"soonestReadout":1582},[12163,12170],{"nctId":12164,"briefTitle":12165,"status":107,"phases":12166,"primaryCompletion":132,"completion":132,"start":6277,"enrollment":12167,"conditions":12168,"interventions":12169},"NCT00448591","A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.",[91],2296,[18],[5275,12153],{"nctId":3418,"briefTitle":3419,"status":152,"phases":12171,"primaryCompletion":1582,"completion":3421,"start":3422,"enrollment":3423,"conditions":12172,"interventions":12173},[91],[1569],[1137,3426,3427,3428],{"trials":12175,"activeCount":101},[],{"trials":12177,"activeCount":101},[],{"intervention":12179,"totalTrials":162,"cells":12180},"PDS Implant Pre-Filled with 100 mg\u002FmL Ranibizumab",{"EARLY_PHASE1":12181,"PHASE1":12183,"PHASE2":12185,"PHASE3":12187,"PHASE4":12209,"NA":12211},{"trials":12182,"activeCount":101},[],{"trials":12184,"activeCount":101},[],{"trials":12186,"activeCount":101},[],{"trials":12188,"activeCount":350,"soonestReadout":12193},[12189,12200],{"nctId":12190,"briefTitle":12191,"status":152,"phases":12192,"primaryCompletion":12193,"completion":12193,"start":12194,"enrollment":12195,"conditions":12196,"interventions":12197},"NCT04108156","A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME",[91],"2027-11-16","2019-09-30",634,[551],[12179,12198,12199],"Intravitreal Ranibizumab 0.5 mg","Ranibizumab refill exchange",{"nctId":12201,"briefTitle":12202,"status":107,"phases":12203,"primaryCompletion":12204,"completion":12205,"start":3813,"enrollment":437,"conditions":12206,"interventions":12208},"NCT04503551","A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm",[91],"2022-10-03","2026-02-23",[12207],"Diabetic Retinopathy",[12179,12198],{"trials":12210,"activeCount":101},[],{"trials":12212,"activeCount":101},[],{"intervention":12198,"totalTrials":162,"cells":12214},{"EARLY_PHASE1":12215,"PHASE1":12217,"PHASE2":12219,"PHASE3":12221,"PHASE4":12231,"NA":12233},{"trials":12216,"activeCount":101},[],{"trials":12218,"activeCount":101},[],{"trials":12220,"activeCount":101},[],{"trials":12222,"activeCount":350,"soonestReadout":12193},[12223,12227],{"nctId":12190,"briefTitle":12191,"status":152,"phases":12224,"primaryCompletion":12193,"completion":12193,"start":12194,"enrollment":12195,"conditions":12225,"interventions":12226},[91],[551],[12179,12198,12199],{"nctId":12201,"briefTitle":12202,"status":107,"phases":12228,"primaryCompletion":12204,"completion":12205,"start":3813,"enrollment":437,"conditions":12229,"interventions":12230},[91],[12207],[12179,12198],{"trials":12232,"activeCount":101},[],{"trials":12234,"activeCount":101},[],{"intervention":9421,"totalTrials":350,"cells":12236},{"EARLY_PHASE1":12237,"PHASE1":12239,"PHASE2":12241,"PHASE3":12243,"PHASE4":12249,"NA":12251},{"trials":12238,"activeCount":101},[],{"trials":12240,"activeCount":101},[],{"trials":12242,"activeCount":101},[],{"trials":12244,"activeCount":350,"soonestReadout":9416},[12245],{"nctId":9413,"briefTitle":9414,"status":152,"phases":12246,"primaryCompletion":9416,"completion":9417,"start":2025,"enrollment":9418,"conditions":12247,"interventions":12248},[91],[1305],[2596,9323,2577,9322,9421,9422],{"trials":12250,"activeCount":101},[],{"trials":12252,"activeCount":101},[],{"intervention":6169,"totalTrials":350,"cells":12254},{"EARLY_PHASE1":12255,"PHASE1":12257,"PHASE2":12259,"PHASE3":12261,"PHASE4":12267,"NA":12269},{"trials":12256,"activeCount":101},[],{"trials":12258,"activeCount":101},[],{"trials":12260,"activeCount":101},[],{"trials":12262,"activeCount":350,"soonestReadout":2025},[12263],{"nctId":6161,"briefTitle":6162,"status":140,"phases":12264,"primaryCompletion":2025,"completion":209,"start":6164,"enrollment":6165,"conditions":12265,"interventions":12266},[91],[6167],[2433,2644,1359,6169],{"trials":12268,"activeCount":101},[],{"trials":12270,"activeCount":101},[],{"intervention":5691,"totalTrials":350,"cells":12272},{"EARLY_PHASE1":12273,"PHASE1":12275,"PHASE2":12277,"PHASE3":12279,"PHASE4":12285,"NA":12287},{"trials":12274,"activeCount":101},[],{"trials":12276,"activeCount":101},[],{"trials":12278,"activeCount":101},[],{"trials":12280,"activeCount":350,"soonestReadout":5685},[12281],{"nctId":5682,"briefTitle":5683,"status":140,"phases":12282,"primaryCompletion":5685,"completion":5686,"start":5687,"enrollment":5688,"conditions":12283,"interventions":12284},[91],[5655],[63,5691,5670],{"trials":12286,"activeCount":101},[],{"trials":12288,"activeCount":101},[],{"intervention":12290,"totalTrials":350,"cells":12291},"Sefaxersen",{"EARLY_PHASE1":12292,"PHASE1":12294,"PHASE2":12296,"PHASE3":12298,"PHASE4":12310,"NA":12312},{"trials":12293,"activeCount":101},[],{"trials":12295,"activeCount":101},[],{"trials":12297,"activeCount":101},[],{"trials":12299,"activeCount":350,"soonestReadout":12304},[12300],{"nctId":12301,"briefTitle":12302,"status":152,"phases":12303,"primaryCompletion":12304,"completion":494,"start":12305,"enrollment":12306,"conditions":12307,"interventions":12309},"NCT05797610","A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",[91],"2026-08-31","2023-08-08",428,[12308],"Primary IgA Nephropathy",[12290],{"trials":12311,"activeCount":101},[],{"trials":12313,"activeCount":101},[],{"intervention":9933,"totalTrials":350,"cells":12315},{"EARLY_PHASE1":12316,"PHASE1":12318,"PHASE2":12320,"PHASE3":12322,"PHASE4":12328,"NA":12330},{"trials":12317,"activeCount":101},[],{"trials":12319,"activeCount":101},[],{"trials":12321,"activeCount":101},[],{"trials":12323,"activeCount":350,"soonestReadout":9928},[12324],{"nctId":9925,"briefTitle":9926,"status":152,"phases":12325,"primaryCompletion":9928,"completion":9929,"start":9930,"enrollment":3595,"conditions":12326,"interventions":12327},[91],[723],[799,9933],{"trials":12329,"activeCount":101},[],{"trials":12331,"activeCount":101},[],{"intervention":3774,"totalTrials":350,"cells":12333},{"EARLY_PHASE1":12334,"PHASE1":12336,"PHASE2":12338,"PHASE3":12340,"PHASE4":12346,"NA":12348},{"trials":12335,"activeCount":101},[],{"trials":12337,"activeCount":101},[],{"trials":12339,"activeCount":101},[],{"trials":12341,"activeCount":350,"soonestReadout":1484},[12342],{"nctId":3766,"briefTitle":3767,"status":140,"phases":12343,"primaryCompletion":1484,"completion":3769,"start":81,"enrollment":755,"conditions":12344,"interventions":12345},[91],[3771],[1018,3773,1357,274,3774,3775],{"trials":12347,"activeCount":101},[],{"trials":12349,"activeCount":101},[],{"intervention":5771,"totalTrials":350,"cells":12351},{"EARLY_PHASE1":12352,"PHASE1":12354,"PHASE2":12356,"PHASE3":12358,"PHASE4":12364,"NA":12366},{"trials":12353,"activeCount":101},[],{"trials":12355,"activeCount":101},[],{"trials":12357,"activeCount":101},[],{"trials":12359,"activeCount":350,"soonestReadout":1743},[12360],{"nctId":5764,"briefTitle":5765,"status":140,"phases":12361,"primaryCompletion":1743,"completion":2692,"start":5767,"enrollment":5768,"conditions":12362,"interventions":12363},[91],[975,5325],[1140,5771,5772],{"trials":12365,"activeCount":101},[],{"trials":12367,"activeCount":101},[],{"intervention":5772,"totalTrials":350,"cells":12369},{"EARLY_PHASE1":12370,"PHASE1":12372,"PHASE2":12374,"PHASE3":12376,"PHASE4":12382,"NA":12384},{"trials":12371,"activeCount":101},[],{"trials":12373,"activeCount":101},[],{"trials":12375,"activeCount":101},[],{"trials":12377,"activeCount":350,"soonestReadout":1743},[12378],{"nctId":5764,"briefTitle":5765,"status":140,"phases":12379,"primaryCompletion":1743,"completion":2692,"start":5767,"enrollment":5768,"conditions":12380,"interventions":12381},[91],[975,5325],[1140,5771,5772],{"trials":12383,"activeCount":101},[],{"trials":12385,"activeCount":101},[],{"intervention":12387,"totalTrials":350,"cells":12388},"PDS Implant with Ranibizumab 100 mg\u002FmL",{"EARLY_PHASE1":12389,"PHASE1":12391,"PHASE2":12393,"PHASE3":12395,"PHASE4":12405,"NA":12407},{"trials":12390,"activeCount":101},[],{"trials":12392,"activeCount":101},[],{"trials":12394,"activeCount":101},[],{"trials":12396,"activeCount":350,"soonestReadout":12401},[12397],{"nctId":12398,"briefTitle":12399,"status":152,"phases":12400,"primaryCompletion":12401,"completion":12401,"start":12402,"enrollment":703,"conditions":12403,"interventions":12404},"NCT03683251","Extension Study for the Port Delivery System With Ranibizumab (Portal)",[91],"2029-10-31","2018-09-20",[7667],[12387],{"trials":12406,"activeCount":101},[],{"trials":12408,"activeCount":101},[],{"intervention":2031,"totalTrials":350,"cells":12410},{"EARLY_PHASE1":12411,"PHASE1":12413,"PHASE2":12415,"PHASE3":12417,"PHASE4":12423,"NA":12425},{"trials":12412,"activeCount":101},[],{"trials":12414,"activeCount":101},[],{"trials":12416,"activeCount":101},[],{"trials":12418,"activeCount":350,"soonestReadout":2025},[12419],{"nctId":2022,"briefTitle":2023,"status":140,"phases":12420,"primaryCompletion":2025,"completion":2025,"start":2026,"enrollment":2027,"conditions":12421,"interventions":12422},[91],[2029],[68,2031,2011],{"trials":12424,"activeCount":101},[],{"trials":12426,"activeCount":101},[],{"intervention":2049,"totalTrials":350,"cells":12428},{"EARLY_PHASE1":12429,"PHASE1":12431,"PHASE2":12433,"PHASE3":12435,"PHASE4":12441,"NA":12443},{"trials":12430,"activeCount":101},[],{"trials":12432,"activeCount":101},[],{"trials":12434,"activeCount":101},[],{"trials":12436,"activeCount":350,"soonestReadout":2044},[12437],{"nctId":2041,"briefTitle":2042,"status":140,"phases":12438,"primaryCompletion":2044,"completion":2044,"start":1732,"enrollment":2045,"conditions":12439,"interventions":12440},[91],[2047],[68,2049],{"trials":12442,"activeCount":101},[],{"trials":12444,"activeCount":101},[],{"intervention":2061,"totalTrials":350,"cells":12446},{"EARLY_PHASE1":12447,"PHASE1":12449,"PHASE2":12451,"PHASE3":12453,"PHASE4":12459,"NA":12461},{"trials":12448,"activeCount":101},[],{"trials":12450,"activeCount":101},[],{"trials":12452,"activeCount":101},[],{"trials":12454,"activeCount":350,"soonestReadout":2054},[12455],{"nctId":2051,"briefTitle":2052,"status":140,"phases":12456,"primaryCompletion":2054,"completion":2055,"start":2056,"enrollment":2057,"conditions":12457,"interventions":12458},[91],[2059],[68,2061,990,1074],{"trials":12460,"activeCount":101},[],{"trials":12462,"activeCount":101},[],{"intervention":8441,"totalTrials":350,"cells":12464},{"EARLY_PHASE1":12465,"PHASE1":12467,"PHASE2":12469,"PHASE3":12471,"PHASE4":12477,"NA":12479},{"trials":12466,"activeCount":101},[],{"trials":12468,"activeCount":101},[],{"trials":12470,"activeCount":101},[],{"trials":12472,"activeCount":350,"soonestReadout":1582},[12473],{"nctId":8435,"briefTitle":8436,"status":140,"phases":12474,"primaryCompletion":1582,"completion":1582,"start":8438,"enrollment":5458,"conditions":12475,"interventions":12476},[91],[922],[1221,1222,8441],{"trials":12478,"activeCount":101},[],{"trials":12480,"activeCount":101},[],{"intervention":5713,"totalTrials":350,"cells":12482},{"EARLY_PHASE1":12483,"PHASE1":12485,"PHASE2":12487,"PHASE3":12489,"PHASE4":12495,"NA":12497},{"trials":12484,"activeCount":101},[],{"trials":12486,"activeCount":101},[],{"trials":12488,"activeCount":101},[],{"trials":12490,"activeCount":350,"soonestReadout":5706},[12491],{"nctId":5703,"briefTitle":5704,"status":140,"phases":12492,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":12493,"interventions":12494},[91],[5711],[63,5713,1422,5714,1421,5670],{"trials":12496,"activeCount":101},[],{"trials":12498,"activeCount":101},[],{"intervention":5714,"totalTrials":350,"cells":12500},{"EARLY_PHASE1":12501,"PHASE1":12503,"PHASE2":12505,"PHASE3":12507,"PHASE4":12513,"NA":12515},{"trials":12502,"activeCount":101},[],{"trials":12504,"activeCount":101},[],{"trials":12506,"activeCount":101},[],{"trials":12508,"activeCount":350,"soonestReadout":5706},[12509],{"nctId":5703,"briefTitle":5704,"status":140,"phases":12510,"primaryCompletion":5706,"completion":5707,"start":5708,"enrollment":5709,"conditions":12511,"interventions":12512},[91],[5711],[63,5713,1422,5714,1421,5670],{"trials":12514,"activeCount":101},[],{"trials":12516,"activeCount":101},[],{"intervention":3438,"totalTrials":350,"cells":12518},{"EARLY_PHASE1":12519,"PHASE1":12521,"PHASE2":12523,"PHASE3":12525,"PHASE4":12531,"NA":12533},{"trials":12520,"activeCount":101},[],{"trials":12522,"activeCount":101},[],{"trials":12524,"activeCount":101},[],{"trials":12526,"activeCount":350,"soonestReadout":3433},[12527],{"nctId":3430,"briefTitle":3431,"status":152,"phases":12528,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":3435,"conditions":12529,"interventions":12530},[91],[18],[1137,3438,1422],{"trials":12532,"activeCount":101},[],{"trials":12534,"activeCount":101},[],{"intervention":3448,"totalTrials":350,"cells":12536},{"EARLY_PHASE1":12537,"PHASE1":12539,"PHASE2":12541,"PHASE3":12543,"PHASE4":12549,"NA":12551},{"trials":12538,"activeCount":101},[],{"trials":12540,"activeCount":101},[],{"trials":12542,"activeCount":101},[],{"trials":12544,"activeCount":350,"soonestReadout":3443},[12545],{"nctId":3440,"briefTitle":3441,"status":140,"phases":12546,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":12547,"interventions":12548},[91],[18],[1137,1573,3448,3449,3450,388],{"trials":12550,"activeCount":101},[],{"trials":12552,"activeCount":101},[],{"intervention":3449,"totalTrials":350,"cells":12554},{"EARLY_PHASE1":12555,"PHASE1":12557,"PHASE2":12559,"PHASE3":12561,"PHASE4":12567,"NA":12569},{"trials":12556,"activeCount":101},[],{"trials":12558,"activeCount":101},[],{"trials":12560,"activeCount":101},[],{"trials":12562,"activeCount":350,"soonestReadout":3443},[12563],{"nctId":3440,"briefTitle":3441,"status":140,"phases":12564,"primaryCompletion":3443,"completion":2719,"start":3444,"enrollment":3445,"conditions":12565,"interventions":12566},[91],[18],[1137,1573,3448,3449,3450,388],{"trials":12568,"activeCount":101},[],{"trials":12570,"activeCount":101},[],{"intervention":2151,"totalTrials":350,"cells":12572},{"EARLY_PHASE1":12573,"PHASE1":12575,"PHASE2":12577,"PHASE3":12579,"PHASE4":12585,"NA":12587},{"trials":12574,"activeCount":101},[],{"trials":12576,"activeCount":101},[],{"trials":12578,"activeCount":101},[],{"trials":12580,"activeCount":350,"soonestReadout":2147},[12581],{"nctId":2144,"briefTitle":2145,"status":140,"phases":12582,"primaryCompletion":2147,"completion":2147,"start":2148,"enrollment":703,"conditions":12583,"interventions":12584},[91],[1883],[68,1015,43,1084,1479,2151,1073,1830,1957,2152,1085,2121,1319,1106,1126,1178],{"trials":12586,"activeCount":101},[],{"trials":12588,"activeCount":101},[],{"intervention":5286,"totalTrials":350,"cells":12590},{"EARLY_PHASE1":12591,"PHASE1":12593,"PHASE2":12595,"PHASE3":12597,"PHASE4":12603,"NA":12605},{"trials":12592,"activeCount":101},[],{"trials":12594,"activeCount":101},[],{"trials":12596,"activeCount":101},[],{"trials":12598,"activeCount":350,"soonestReadout":5280},[12599],{"nctId":5277,"briefTitle":5278,"status":140,"phases":12600,"primaryCompletion":5280,"completion":5281,"start":5282,"enrollment":5283,"conditions":12601,"interventions":12602},[91],[1316],[5286,1167,1983,1163,1319,990],{"trials":12604,"activeCount":101},[],{"trials":12606,"activeCount":101},[],{"intervention":12199,"totalTrials":350,"cells":12608},{"EARLY_PHASE1":12609,"PHASE1":12611,"PHASE2":12613,"PHASE3":12615,"PHASE4":12621,"NA":12623},{"trials":12610,"activeCount":101},[],{"trials":12612,"activeCount":101},[],{"trials":12614,"activeCount":101},[],{"trials":12616,"activeCount":350,"soonestReadout":12193},[12617],{"nctId":12190,"briefTitle":12191,"status":152,"phases":12618,"primaryCompletion":12193,"completion":12193,"start":12194,"enrollment":12195,"conditions":12619,"interventions":12620},[91],[551],[12179,12198,12199],{"trials":12622,"activeCount":101},[],{"trials":12624,"activeCount":101},[],{"intervention":821,"totalTrials":350,"cells":12626},{"EARLY_PHASE1":12627,"PHASE1":12629,"PHASE2":12631,"PHASE3":12633,"PHASE4":12639,"NA":12641},{"trials":12628,"activeCount":101},[],{"trials":12630,"activeCount":101},[],{"trials":12632,"activeCount":101},[],{"trials":12634,"activeCount":350,"soonestReadout":814},[12635],{"nctId":811,"briefTitle":812,"status":152,"phases":12636,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":12637,"interventions":12638},[91],[819],[708,821,822,823,824],{"trials":12640,"activeCount":101},[],{"trials":12642,"activeCount":101},[],{"intervention":822,"totalTrials":350,"cells":12644},{"EARLY_PHASE1":12645,"PHASE1":12647,"PHASE2":12649,"PHASE3":12651,"PHASE4":12657,"NA":12659},{"trials":12646,"activeCount":101},[],{"trials":12648,"activeCount":101},[],{"trials":12650,"activeCount":101},[],{"trials":12652,"activeCount":350,"soonestReadout":814},[12653],{"nctId":811,"briefTitle":812,"status":152,"phases":12654,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":12655,"interventions":12656},[91],[819],[708,821,822,823,824],{"trials":12658,"activeCount":101},[],{"trials":12660,"activeCount":101},[],{"intervention":823,"totalTrials":350,"cells":12662},{"EARLY_PHASE1":12663,"PHASE1":12665,"PHASE2":12667,"PHASE3":12669,"PHASE4":12675,"NA":12677},{"trials":12664,"activeCount":101},[],{"trials":12666,"activeCount":101},[],{"trials":12668,"activeCount":101},[],{"trials":12670,"activeCount":350,"soonestReadout":814},[12671],{"nctId":811,"briefTitle":812,"status":152,"phases":12672,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":12673,"interventions":12674},[91],[819],[708,821,822,823,824],{"trials":12676,"activeCount":101},[],{"trials":12678,"activeCount":101},[],{"intervention":295,"totalTrials":350,"cells":12680},{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12685,"PHASE3":12687,"PHASE4":12693,"NA":12695},{"trials":12682,"activeCount":101},[],{"trials":12684,"activeCount":101},[],{"trials":12686,"activeCount":101},[],{"trials":12688,"activeCount":350,"soonestReadout":288},[12689],{"nctId":285,"briefTitle":286,"status":140,"phases":12690,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":12691,"interventions":12692},[91],[293],[96,295],{"trials":12694,"activeCount":101},[],{"trials":12696,"activeCount":101},[],{"intervention":8501,"totalTrials":350,"cells":12698},{"EARLY_PHASE1":12699,"PHASE1":12701,"PHASE2":12703,"PHASE3":12705,"PHASE4":12711,"NA":12713},{"trials":12700,"activeCount":101},[],{"trials":12702,"activeCount":101},[],{"trials":12704,"activeCount":101},[],{"trials":12706,"activeCount":350,"soonestReadout":8495},[12707],{"nctId":8492,"briefTitle":8493,"status":152,"phases":12708,"primaryCompletion":8495,"completion":8496,"start":5193,"enrollment":8497,"conditions":12709,"interventions":12710},[90,91],[8499],[8501,8502,1222,1166],{"trials":12712,"activeCount":101},[],{"trials":12714,"activeCount":101},[],{"intervention":8502,"totalTrials":350,"cells":12716},{"EARLY_PHASE1":12717,"PHASE1":12719,"PHASE2":12721,"PHASE3":12723,"PHASE4":12729,"NA":12731},{"trials":12718,"activeCount":101},[],{"trials":12720,"activeCount":101},[],{"trials":12722,"activeCount":101},[],{"trials":12724,"activeCount":350,"soonestReadout":8495},[12725],{"nctId":8492,"briefTitle":8493,"status":152,"phases":12726,"primaryCompletion":8495,"completion":8496,"start":5193,"enrollment":8497,"conditions":12727,"interventions":12728},[90,91],[8499],[8501,8502,1222,1166],{"trials":12730,"activeCount":101},[],{"trials":12732,"activeCount":101},[],{"intervention":2249,"totalTrials":350,"cells":12734},{"EARLY_PHASE1":12735,"PHASE1":12737,"PHASE2":12739,"PHASE3":12741,"PHASE4":12747,"NA":12749},{"trials":12736,"activeCount":101},[],{"trials":12738,"activeCount":101},[],{"trials":12740,"activeCount":101},[],{"trials":12742,"activeCount":350,"soonestReadout":2245},[12743],{"nctId":2242,"briefTitle":2243,"status":152,"phases":12744,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":1847,"conditions":12745,"interventions":12746},[91],[1883],[946,988,68,2249,1015,1695,1137,1140],{"trials":12748,"activeCount":101},[],{"trials":12750,"activeCount":101},[],{"intervention":12752,"totalTrials":4548,"cells":12753},"Baloxavir Marboxil",{"EARLY_PHASE1":12754,"PHASE1":12756,"PHASE2":12758,"PHASE3":12760,"PHASE4":12812,"NA":12814},{"trials":12755,"activeCount":101},[],{"trials":12757,"activeCount":101},[],{"trials":12759,"activeCount":101},[],{"trials":12761,"activeCount":350,"soonestReadout":12766},[12762,12772,12780,12789,12797,12806],{"nctId":12763,"briefTitle":12764,"status":152,"phases":12765,"primaryCompletion":12766,"completion":690,"start":12767,"enrollment":12768,"conditions":12769,"interventions":12771},"NCT06094010","A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts",[91],"2027-05-11","2023-11-22",1100,[12770],"Influenza",[12752],{"nctId":12773,"briefTitle":12774,"status":107,"phases":12775,"primaryCompletion":12776,"completion":12776,"start":12777,"enrollment":1001,"conditions":12778,"interventions":12779},"NCT03653364","Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to \u003C 1 Year With Influenza-Like Symptoms",[91],"2023-04-03","2019-01-23",[12770],[12752],{"nctId":12781,"briefTitle":12782,"status":107,"phases":12783,"primaryCompletion":12784,"completion":12784,"start":12785,"enrollment":12786,"conditions":12787,"interventions":12788},"NCT03969212","Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households",[91],"2024-05-10","2019-10-10",4138,[12770],[12752],{"nctId":12790,"briefTitle":12791,"status":107,"phases":12792,"primaryCompletion":2263,"completion":2263,"start":12793,"enrollment":1847,"conditions":12794,"interventions":12795},"NCT06774859","Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to \u003C12 Years of Age With Influenza Symptoms",[91],"2024-10-27",[12770],[12752,12796],"Oseltamivir",{"nctId":12798,"briefTitle":12799,"status":107,"phases":12800,"primaryCompletion":12801,"completion":12801,"start":12802,"enrollment":12803,"conditions":12804,"interventions":12805},"NCT03629184","Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms",[91],"2019-04-03","2018-11-20",173,[12770],[12752,12796],{"nctId":12807,"briefTitle":12808,"status":107,"phases":12809,"primaryCompletion":7568,"completion":7568,"start":4215,"enrollment":10578,"conditions":12810,"interventions":12811},"NCT03684044","Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza",[91],[12770],[12752],{"trials":12813,"activeCount":101},[],{"trials":12815,"activeCount":101},[12816],{"nctId":12817,"briefTitle":12818,"status":107,"phases":12819,"primaryCompletion":12820,"completion":12820,"start":12821,"enrollment":8206,"conditions":12822,"interventions":12823},"NCT03959332","Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants",[93],"2019-07-11","2019-06-19",[21],[12752],{"intervention":824,"totalTrials":162,"cells":12825},{"EARLY_PHASE1":12826,"PHASE1":12828,"PHASE2":12830,"PHASE3":12832,"PHASE4":12838,"NA":12840},{"trials":12827,"activeCount":101},[],{"trials":12829,"activeCount":101},[],{"trials":12831,"activeCount":101},[],{"trials":12833,"activeCount":350,"soonestReadout":814},[12834],{"nctId":811,"briefTitle":812,"status":152,"phases":12835,"primaryCompletion":814,"completion":815,"start":816,"enrollment":817,"conditions":12836,"interventions":12837},[91],[819],[708,821,822,823,824],{"trials":12839,"activeCount":101},[],{"trials":12841,"activeCount":101},[12842],{"nctId":12843,"briefTitle":12844,"status":107,"phases":12845,"primaryCompletion":12846,"completion":12846,"start":6358,"enrollment":11,"conditions":12847,"interventions":12848},"NCT02476942","A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment",[],"2017-03-31",[723],[824,12849],"FVIII Replacement",{"intervention":1445,"totalTrials":942,"cells":12851},{"EARLY_PHASE1":12852,"PHASE1":12854,"PHASE2":12856,"PHASE3":12882,"PHASE4":12884,"NA":12886},{"trials":12853,"activeCount":101},[],{"trials":12855,"activeCount":101},[],{"trials":12857,"activeCount":5110,"soonestReadout":5192},[12858,12862,12866,12870,12874,12878],{"nctId":10987,"briefTitle":10988,"status":107,"phases":12859,"primaryCompletion":10990,"completion":10990,"start":3749,"enrollment":4079,"conditions":12860,"interventions":12861},[90],[10992],[10994,1445,1287],{"nctId":5937,"briefTitle":5938,"status":140,"phases":12863,"primaryCompletion":1962,"completion":1962,"start":5940,"enrollment":984,"conditions":12864,"interventions":12865},[90],[18],[1445,1957,1107],{"nctId":1436,"briefTitle":1437,"status":107,"phases":12867,"primaryCompletion":1439,"completion":1440,"start":1441,"enrollment":447,"conditions":12868,"interventions":12869},[89,90],[1443],[68,1015,988,1445],{"nctId":5050,"briefTitle":5051,"status":140,"phases":12871,"primaryCompletion":1962,"completion":1962,"start":5053,"enrollment":5054,"conditions":12872,"interventions":12873},[90],[1049],[1445,988,1957,5057],{"nctId":5189,"briefTitle":5190,"status":140,"phases":12875,"primaryCompletion":5192,"completion":5193,"start":5194,"enrollment":3015,"conditions":12876,"interventions":12877},[90],[1684],[1445,1957,1106,1319,990],{"nctId":1579,"briefTitle":1580,"status":140,"phases":12879,"primaryCompletion":1582,"completion":1582,"start":1474,"enrollment":1583,"conditions":12880,"interventions":12881},[90],[1585],[68,1445,988],{"trials":12883,"activeCount":101},[],{"trials":12885,"activeCount":101},[],{"trials":12887,"activeCount":101},[],{"intervention":12889,"totalTrials":2631,"cells":12890},"RO7795081",{"EARLY_PHASE1":12891,"PHASE1":12893,"PHASE2":12922,"PHASE3":12943,"PHASE4":12945,"NA":12947},{"trials":12892,"activeCount":101},[],{"trials":12894,"activeCount":162,"soonestReadout":843},[12895,12904,12913],{"nctId":12896,"briefTitle":12897,"status":152,"phases":12898,"primaryCompletion":843,"completion":843,"start":12899,"enrollment":931,"conditions":12900,"interventions":12901},"NCT06982131","A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants",[89],"2025-06-04",[9441,9440],[12889,12902,12903],"Rosuvastatin","Pitavastatin",{"nctId":12905,"briefTitle":12906,"status":152,"phases":12907,"primaryCompletion":12908,"completion":12908,"start":12909,"enrollment":1184,"conditions":12910,"interventions":12912},"NCT07499050","A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight",[89],"2026-12-29","2026-03-30",[427,12911],"Overweight or Obesity",[12889],{"nctId":12914,"briefTitle":12915,"status":107,"phases":12916,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1058,"conditions":12919,"interventions":12920},"NCT06809608","A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081",[89],"2025-06-16","2025-02-13",[7754],[12889,398,12921,11717],"Gemfibrozil",{"trials":12923,"activeCount":162,"soonestReadout":12928},[12924,12934],{"nctId":12925,"briefTitle":12926,"status":140,"phases":12927,"primaryCompletion":12928,"completion":12929,"start":12930,"enrollment":12931,"conditions":12932,"interventions":12933},"NCT07081958","A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity",[90],"2026-04-28","2026-07-17","2025-07-29",352,[9959],[12889],{"nctId":12935,"briefTitle":12936,"status":140,"phases":12937,"primaryCompletion":12938,"completion":12938,"start":12939,"enrollment":8028,"conditions":12940,"interventions":12941},"NCT07112872","A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes",[90],"2026-11-27","2025-08-19",[9439],[12889,12942],"Semaglutide",{"trials":12944,"activeCount":101},[],{"trials":12946,"activeCount":101},[],{"trials":12948,"activeCount":101},[],{"intervention":1107,"totalTrials":510,"cells":12950},{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12971,"PHASE3":12989,"PHASE4":13033,"NA":13035},{"trials":12952,"activeCount":101},[],{"trials":12954,"activeCount":101},[12955,12959,12963,12967],{"nctId":979,"briefTitle":980,"status":107,"phases":12956,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":12957,"interventions":12958},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"nctId":6524,"briefTitle":6525,"status":130,"phases":12960,"primaryCompletion":2955,"completion":2955,"start":3324,"enrollment":2619,"conditions":12961,"interventions":12962},[89],[1883],[6529,6529,5186,6530],{"nctId":1098,"briefTitle":1099,"status":107,"phases":12964,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":12965,"interventions":12966},[89],[18],[946,1106,68,1107,1108],{"nctId":1153,"briefTitle":1154,"status":107,"phases":12968,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":12969,"interventions":12970},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"trials":12972,"activeCount":162,"soonestReadout":1962},[12973,12977,12981,12985],{"nctId":5937,"briefTitle":5938,"status":140,"phases":12974,"primaryCompletion":1962,"completion":1962,"start":5940,"enrollment":984,"conditions":12975,"interventions":12976},[90],[18],[1445,1957,1107],{"nctId":1400,"briefTitle":1401,"status":130,"phases":12978,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":12979,"interventions":12980},[90],[18],[1084,1106,68,1107],{"nctId":1504,"briefTitle":1505,"status":107,"phases":12982,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":12983,"interventions":12984},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1562,"briefTitle":1563,"status":152,"phases":12986,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":12987,"interventions":12988},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":12990,"activeCount":101},[12991,12995,12999,13003,13007,13011,13015,13019,13023],{"nctId":1904,"briefTitle":1905,"status":107,"phases":12992,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":16,"conditions":12993,"interventions":12994},[91],[986],[68,1107],{"nctId":10173,"briefTitle":10174,"status":107,"phases":12996,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":12997,"interventions":12998},[91],[10179],[8041,989,991,992,10181,10182],{"nctId":8059,"briefTitle":8060,"status":107,"phases":13000,"primaryCompletion":8062,"completion":8062,"start":8063,"enrollment":37,"conditions":13001,"interventions":13002},[91],[18],[947,989,1106,1221,1222],{"nctId":5240,"briefTitle":5241,"status":107,"phases":13004,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":13005,"interventions":13006},[91],[5248],[4468,989,1319,990,1167,1163],{"nctId":8084,"briefTitle":8085,"status":107,"phases":13008,"primaryCompletion":8087,"completion":8087,"start":8088,"enrollment":8089,"conditions":13009,"interventions":13010},[91],[4139],[947,989,1106,1221,1222],{"nctId":5251,"briefTitle":5252,"status":107,"phases":13012,"primaryCompletion":2007,"completion":1691,"start":5254,"enrollment":5255,"conditions":13013,"interventions":13014},[91],[5257],[4468,990,1107,1319],{"nctId":5568,"briefTitle":5569,"status":107,"phases":13016,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":4475,"conditions":13017,"interventions":13018},[91],[5420],[5576,990,1107,1106],{"nctId":5299,"briefTitle":5300,"status":130,"phases":13020,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":13021,"interventions":13022},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"nctId":13024,"briefTitle":13025,"status":107,"phases":13026,"primaryCompletion":13027,"completion":13028,"start":13029,"enrollment":13030,"conditions":13031,"interventions":13032},"NCT02425891","A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)",[91],"2020-04-14","2021-08-31","2015-06-23",902,[1061],[8041,1107],{"trials":13034,"activeCount":101},[],{"trials":13036,"activeCount":101},[],{"intervention":2467,"totalTrials":162,"cells":13038},{"EARLY_PHASE1":13039,"PHASE1":13041,"PHASE2":13047,"PHASE3":13053,"PHASE4":13055,"NA":13057},{"trials":13040,"activeCount":101},[],{"trials":13042,"activeCount":350,"soonestReadout":2460},[13043],{"nctId":2457,"briefTitle":2458,"status":152,"phases":13044,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":13045,"interventions":13046},[89],[2392],[2465,2466,2467,2468,1018,1096],{"trials":13048,"activeCount":350,"soonestReadout":2706},[13049],{"nctId":2703,"briefTitle":2704,"status":152,"phases":13050,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":13051,"interventions":13052},[89,90],[1305],[2596,2644,1096,2467,2577],{"trials":13054,"activeCount":101},[],{"trials":13056,"activeCount":101},[],{"trials":13058,"activeCount":101},[],{"intervention":1358,"totalTrials":13060,"cells":13061},14,{"EARLY_PHASE1":13062,"PHASE1":13064,"PHASE2":13074,"PHASE3":13096,"PHASE4":13122,"NA":13128},{"trials":13063,"activeCount":101},[],{"trials":13065,"activeCount":101},[13066,13070],{"nctId":3475,"briefTitle":3476,"status":107,"phases":13067,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":13068,"interventions":13069},[89],[125],[1356,992,991,3482,1018,1357,1358],{"nctId":2384,"briefTitle":2385,"status":107,"phases":13071,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":2389,"conditions":13072,"interventions":13073},[89],[2391,2392],[1784,1018,1359,1096,992,991,1358,1357,2394],{"trials":13075,"activeCount":350,"soonestReadout":2754},[13076,13080,13084,13088,13092],{"nctId":1346,"briefTitle":1347,"status":107,"phases":13077,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":13078,"interventions":13079},[89,90],[1354],[68,1356,992,991,1018,1357,1358,1359],{"nctId":9123,"briefTitle":9124,"status":107,"phases":13081,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":13082,"interventions":13083},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"nctId":3679,"briefTitle":3680,"status":107,"phases":13085,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":3685,"conditions":13086,"interventions":13087},[89,90],[1196],[1073,992,1018,1359,991,1358,1357],{"nctId":2728,"briefTitle":2729,"status":107,"phases":13089,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":13090,"interventions":13091},[89,90],[2678],[2433,1785,2736,992,991,1358,1357,1096],{"nctId":2751,"briefTitle":2752,"status":140,"phases":13093,"primaryCompletion":2754,"completion":2754,"start":2755,"enrollment":1204,"conditions":13094,"interventions":13095},[90],[1038],[1784,1096,991,1358,1357,1359,992],{"trials":13097,"activeCount":101},[13098,13102,13106,13110,13114,13118],{"nctId":6183,"briefTitle":6184,"status":107,"phases":13099,"primaryCompletion":6186,"completion":6186,"start":6187,"enrollment":6188,"conditions":13100,"interventions":13101},[91],[1038],[1359,992,1358,991,1357,1356],{"nctId":3777,"briefTitle":3778,"status":107,"phases":13103,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":3783,"conditions":13104,"interventions":13105},[91],[125],[1018,992,991,1358,1357,1356,1359],{"nctId":3818,"briefTitle":3819,"status":130,"phases":13107,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":13108,"interventions":13109},[91],[3826],[1359,1018,992,991,1358,1357],{"nctId":6326,"briefTitle":6327,"status":107,"phases":13111,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":13112,"interventions":13113},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"nctId":10216,"briefTitle":10217,"status":107,"phases":13115,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":13116,"interventions":13117},[91],[125],[9132,9131,992,991,1358,7575],{"nctId":6365,"briefTitle":6366,"status":107,"phases":13119,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":13120,"interventions":13121},[91],[2392],[1359,992,991,1358,1357,3482],{"trials":13123,"activeCount":101},[13124],{"nctId":3863,"briefTitle":3864,"status":107,"phases":13125,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":13126,"interventions":13127},[92],[3869],[1018,1356,992,991,3871,1358],{"trials":13129,"activeCount":101},[],{"intervention":13131,"totalTrials":709,"cells":13132},"metformin",{"EARLY_PHASE1":13133,"PHASE1":13135,"PHASE2":13151,"PHASE3":13187,"PHASE4":13226,"NA":13228},{"trials":13134,"activeCount":101},[],{"trials":13136,"activeCount":101},[13137,13144],{"nctId":13138,"briefTitle":13139,"status":107,"phases":13140,"primaryCompletion":2906,"completion":2906,"start":2963,"enrollment":3190,"conditions":13141,"interventions":13142},"NCT00961909","A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus",[89],[36],[13143,13143,13131],"RO5095932",{"nctId":13145,"briefTitle":13146,"status":107,"phases":13147,"primaryCompletion":2947,"completion":2947,"start":3006,"enrollment":510,"conditions":13148,"interventions":13149},"NCT02342925","A Study of the Effect of RG1662 on Metformin in Healthy Volunteers",[89],[21],[13150,13131],"RG1662",{"trials":13152,"activeCount":350,"soonestReadout":1565},[13153,13160,13167,13176,13183],{"nctId":13154,"briefTitle":13155,"status":107,"phases":13156,"primaryCompletion":2965,"completion":2965,"start":4446,"enrollment":483,"conditions":13157,"interventions":13158},"NCT00316758","A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.",[90],[36],[13159,1576],"GK Activator",{"nctId":13161,"briefTitle":13162,"status":107,"phases":13163,"primaryCompletion":7096,"completion":7096,"start":13164,"enrollment":6872,"conditions":13165,"interventions":13166},"NCT00266253","A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin",[90],"2005-11",[36],[13159,1576],{"nctId":13168,"briefTitle":13169,"status":107,"phases":13170,"primaryCompletion":13171,"completion":13171,"start":122,"enrollment":13172,"conditions":13173,"interventions":13174},"NCT00111631","A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes",[90],"2006-10",218,[36],[13175,1576],"DPP-IV Inhibitor",{"nctId":13177,"briefTitle":13178,"status":107,"phases":13179,"primaryCompletion":2684,"completion":2684,"start":2948,"enrollment":2999,"conditions":13180,"interventions":13181},"NCT01729403","A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin",[90],[36],[13182,13131],"aleglitazar",{"nctId":1562,"briefTitle":1563,"status":152,"phases":13184,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13185,"interventions":13186},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13188,"activeCount":101},[13189,13198,13207,13213,13220],{"nctId":13190,"briefTitle":13191,"status":107,"phases":13192,"primaryCompletion":2964,"completion":2964,"start":8934,"enrollment":13193,"conditions":13194,"interventions":13195},"NCT00754988","A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.",[91],666,[36],[1576,13196,13197],"Sitagliptin","Taspoglutide",{"nctId":13199,"briefTitle":13200,"status":107,"phases":13201,"primaryCompletion":4474,"completion":4474,"start":8688,"enrollment":13202,"conditions":13203,"interventions":13204},"NCT00755287","A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.",[91],1072,[36],[13205,13131,13206,13206],"insulin glargine","taspoglutide",{"nctId":13208,"briefTitle":13209,"status":107,"phases":13210,"primaryCompletion":6157,"completion":6157,"start":4445,"enrollment":4548,"conditions":13211,"interventions":13212},"NCT01871415","A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy",[91],[36],[13182,13131],{"nctId":13214,"briefTitle":13215,"status":107,"phases":13216,"primaryCompletion":5181,"completion":5181,"start":8934,"enrollment":3105,"conditions":13217,"interventions":13218},"NCT00744367","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.",[91],[36],[13131,13219,13206,13206],"pioglitazone",{"nctId":13221,"briefTitle":13222,"status":130,"phases":13223,"primaryCompletion":4474,"completion":4474,"start":4206,"enrollment":10152,"conditions":13224,"interventions":13225},"NCT01051011","A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy",[91],[36],[13205,13131,13206,13206],{"trials":13227,"activeCount":101},[],{"trials":13229,"activeCount":101},[],{"intervention":1513,"totalTrials":2631,"cells":13231},{"EARLY_PHASE1":13232,"PHASE1":13234,"PHASE2":13236,"PHASE3":13250,"PHASE4":13262,"NA":13264},{"trials":13233,"activeCount":101},[],{"trials":13235,"activeCount":101},[],{"trials":13237,"activeCount":350,"soonestReadout":1721},[13238,13242,13246],{"nctId":1504,"briefTitle":1505,"status":107,"phases":13239,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":13240,"interventions":13241},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":8950,"briefTitle":8951,"status":107,"phases":13243,"primaryCompletion":3103,"completion":3103,"start":4488,"enrollment":817,"conditions":13244,"interventions":13245},[90],[30],[8955,8956,5275,5381,4104],{"nctId":1718,"briefTitle":1719,"status":140,"phases":13247,"primaryCompletion":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":13248,"interventions":13249},[90],[1726,1727],[1166,1513,68,988],{"trials":13251,"activeCount":101},[13252,13256],{"nctId":7169,"briefTitle":7170,"status":107,"phases":13253,"primaryCompletion":4409,"completion":4409,"start":3030,"enrollment":7172,"conditions":13254,"interventions":13255},[91],[1735],[1222,1513,1167,1166],{"nctId":13257,"briefTitle":13258,"status":107,"phases":13259,"primaryCompletion":4474,"completion":4474,"start":4315,"enrollment":1593,"conditions":13260,"interventions":13261},"NCT00642577","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.",[91],[30],[5275,4102,8956,8955],{"trials":13263,"activeCount":101},[],{"trials":13265,"activeCount":101},[],{"intervention":1697,"totalTrials":5110,"cells":13267},{"EARLY_PHASE1":13268,"PHASE1":13270,"PHASE2":13272,"PHASE3":13304,"PHASE4":13314,"NA":13316},{"trials":13269,"activeCount":101},[],{"trials":13271,"activeCount":101},[],{"trials":13273,"activeCount":350,"soonestReadout":1690},[13274,13278],{"nctId":1687,"briefTitle":1688,"status":140,"phases":13275,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":13276,"interventions":13277},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"nctId":13279,"briefTitle":13280,"status":107,"phases":13281,"primaryCompletion":1998,"completion":1998,"start":13282,"enrollment":13283,"conditions":13284,"interventions":13302},"NCT03037385","Phase 1\u002F2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",[89,90],"2017-03-17",590,[13285,11901,13286,13287,13288,5307,1316,13289,13290,4863,13291,4866,4867,4865,1241,5308,5309,4869,4870,13292,13293,4862,13294,5311,5312,13295,5313,4859,13296,5314,5315,13297,4098,4871,4872,13298,13299,13300,4876,13301],"RET-altered Non Small Cell Lung Cancer","RET-altered Papillary Thyroid Cancer","RET-altered Colon Cancer","RET-altered Solid Tumors","Thyroid Diseases","Thyroid Neoplasm","Carcinoma, Neuroendocrine","Endocrine System Diseases","Endocrine Gland Neoplasm","Adenocarcinoma, Papillary","Neoplasms, Glandular and Epithelial","Neuroectodermal Tumors","Colonic Neoplasms","Digestive System Neoplasm","Digestive System Disease","Gastrointestinal Disease","Intestinal Disease",[13303],"pralsetinib",{"trials":13305,"activeCount":101},[13306,13310],{"nctId":11894,"briefTitle":11895,"status":343,"phases":13307,"primaryCompletion":11897,"completion":11898,"start":11899,"enrollment":101,"conditions":13308,"interventions":13309},[91],[11901],[1697,2121,11903],{"nctId":5299,"briefTitle":5300,"status":130,"phases":13311,"primaryCompletion":5302,"completion":5302,"start":5303,"enrollment":5304,"conditions":13312,"interventions":13313},[91],[5306,5307,1316,4866,4867,4865,1241,5308,5309,4869,5310,4862,5311,5312,5313,5314,5315],[1697,990,1167,1319,1957,1163,1106,1107],{"trials":13315,"activeCount":101},[],{"trials":13317,"activeCount":101},[],{"intervention":3371,"totalTrials":162,"cells":13319},{"EARLY_PHASE1":13320,"PHASE1":13322,"PHASE2":13324,"PHASE3":13330,"PHASE4":13336,"NA":13338},{"trials":13321,"activeCount":101},[],{"trials":13323,"activeCount":101},[],{"trials":13325,"activeCount":350,"soonestReadout":366},[13326],{"nctId":3363,"briefTitle":3364,"status":152,"phases":13327,"primaryCompletion":366,"completion":3366,"start":3367,"enrollment":1847,"conditions":13328,"interventions":13329},[90],[3369],[1137,1830,3371,947],{"trials":13331,"activeCount":101},[13332],{"nctId":7565,"briefTitle":7566,"status":107,"phases":13333,"primaryCompletion":7568,"completion":7569,"start":7570,"enrollment":7571,"conditions":13334,"interventions":13335},[91],[7573],[946,3371,7575],{"trials":13337,"activeCount":101},[],{"trials":13339,"activeCount":101},[],{"intervention":1029,"totalTrials":2631,"cells":13341},{"EARLY_PHASE1":13342,"PHASE1":13344,"PHASE2":13354,"PHASE3":13368,"PHASE4":13370,"NA":13372},{"trials":13343,"activeCount":101},[],{"trials":13345,"activeCount":101},[13346,13350],{"nctId":4028,"briefTitle":4029,"status":107,"phases":13347,"primaryCompletion":4031,"completion":4031,"start":4032,"enrollment":4033,"conditions":13348,"interventions":13349},[89],[4035],[1029,4037,1015],{"nctId":1021,"briefTitle":1022,"status":107,"phases":13351,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":13352,"interventions":13353},[89],[922],[68,1029],{"trials":13355,"activeCount":350,"soonestReadout":1565},[13356,13360,13364],{"nctId":1490,"briefTitle":1491,"status":130,"phases":13357,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":13358,"interventions":13359},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"nctId":1504,"briefTitle":1505,"status":107,"phases":13361,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":13362,"interventions":13363},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13365,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13366,"interventions":13367},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13369,"activeCount":101},[],{"trials":13371,"activeCount":101},[],{"trials":13373,"activeCount":101},[],{"intervention":1321,"totalTrials":706,"cells":13375},{"EARLY_PHASE1":13376,"PHASE1":13378,"PHASE2":13380,"PHASE3":13394,"PHASE4":13396,"NA":13398},{"trials":13377,"activeCount":101},[],{"trials":13379,"activeCount":101},[],{"trials":13381,"activeCount":350,"soonestReadout":1565},[13382,13386,13390],{"nctId":1308,"briefTitle":1309,"status":130,"phases":13383,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":13384,"interventions":13385},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1530,"briefTitle":1531,"status":107,"phases":13387,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":13388,"interventions":13389},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13391,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13392,"interventions":13393},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13395,"activeCount":101},[],{"trials":13397,"activeCount":101},[],{"trials":13399,"activeCount":101},[],{"intervention":1423,"totalTrials":706,"cells":13401},{"EARLY_PHASE1":13402,"PHASE1":13404,"PHASE2":13410,"PHASE3":13420,"PHASE4":13422,"NA":13424},{"trials":13403,"activeCount":101},[],{"trials":13405,"activeCount":101},[13406],{"nctId":5350,"briefTitle":5351,"status":107,"phases":13407,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":13408,"interventions":13409},[89],[5357],[5359,1423,990],{"trials":13411,"activeCount":350,"soonestReadout":1413},[13412,13416],{"nctId":1410,"briefTitle":1411,"status":140,"phases":13413,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":13414,"interventions":13415},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"nctId":1760,"briefTitle":1761,"status":107,"phases":13417,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":13418,"interventions":13419},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":13421,"activeCount":101},[],{"trials":13423,"activeCount":101},[],{"trials":13425,"activeCount":101},[],{"intervention":2412,"totalTrials":162,"cells":13427},{"EARLY_PHASE1":13428,"PHASE1":13430,"PHASE2":13436,"PHASE3":13442,"PHASE4":13444,"NA":13446},{"trials":13429,"activeCount":101},[],{"trials":13431,"activeCount":101},[13432],{"nctId":2405,"briefTitle":2406,"status":107,"phases":13433,"primaryCompletion":2408,"completion":2408,"start":1238,"enrollment":1385,"conditions":13434,"interventions":13435},[89],[2410],[1784,1018,1096,1359,2412,990,1074],{"trials":13437,"activeCount":350,"soonestReadout":2692},[13438],{"nctId":2689,"briefTitle":2690,"status":152,"phases":13439,"primaryCompletion":2692,"completion":2693,"start":72,"enrollment":2694,"conditions":13440,"interventions":13441},[89,90],[2696],[1018,1784,1359,2412,990,1074,1096],{"trials":13443,"activeCount":101},[],{"trials":13445,"activeCount":101},[],{"trials":13447,"activeCount":101},[],{"intervention":1324,"totalTrials":162,"cells":13449},{"EARLY_PHASE1":13450,"PHASE1":13452,"PHASE2":13454,"PHASE3":13464,"PHASE4":13466,"NA":13468},{"trials":13451,"activeCount":101},[],{"trials":13453,"activeCount":101},[],{"trials":13455,"activeCount":350,"soonestReadout":1690},[13456,13460],{"nctId":1308,"briefTitle":1309,"status":130,"phases":13457,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":13458,"interventions":13459},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1687,"briefTitle":1688,"status":140,"phases":13461,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":13462,"interventions":13463},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"trials":13465,"activeCount":101},[],{"trials":13467,"activeCount":101},[],{"trials":13469,"activeCount":101},[],{"intervention":13471,"totalTrials":162,"cells":13472},"RO7126209",{"EARLY_PHASE1":13473,"PHASE1":13475,"PHASE2":13485,"PHASE3":13496,"PHASE4":13498,"NA":13500},{"trials":13474,"activeCount":101},[],{"trials":13476,"activeCount":101},[13477],{"nctId":13478,"briefTitle":13479,"status":107,"phases":13480,"primaryCompletion":13481,"completion":13481,"start":13482,"enrollment":1058,"conditions":13483,"interventions":13484},"NCT04023994","A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",[89],"2020-07-17","2019-08-03",[11117],[13471],{"trials":13486,"activeCount":350,"soonestReadout":13491},[13487],{"nctId":13488,"briefTitle":13489,"status":140,"phases":13490,"primaryCompletion":13491,"completion":13491,"start":13492,"enrollment":13493,"conditions":13494,"interventions":13495},"NCT04639050","Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease",[89,90],"2030-06-30","2021-03-15",241,[11117],[13471],{"trials":13497,"activeCount":101},[],{"trials":13499,"activeCount":101},[],{"trials":13501,"activeCount":101},[],{"intervention":13503,"totalTrials":162,"cells":13504},"RO7247669",{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13509,"PHASE3":13528,"PHASE4":13530,"NA":13532},{"trials":13506,"activeCount":101},[],{"trials":13508,"activeCount":101},[],{"trials":13510,"activeCount":350,"soonestReadout":690},[13511,13519],{"nctId":13512,"briefTitle":13513,"status":140,"phases":13514,"primaryCompletion":690,"completion":690,"start":13515,"enrollment":13516,"conditions":13517,"interventions":13518},"NCT04140500","Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and\u002For Metastatic Solid Tumors",[89,90],"2019-11-11",170,[922,1477,1684,2019],[13503],{"nctId":13520,"briefTitle":13521,"status":107,"phases":13522,"primaryCompletion":13523,"completion":7681,"start":13524,"enrollment":13525,"conditions":13526,"interventions":13527},"NCT05419388","A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma",[90],"2024-05-01","2022-08-15",93,[1285],[13503],{"trials":13529,"activeCount":101},[],{"trials":13531,"activeCount":101},[],{"trials":13533,"activeCount":101},[],{"intervention":7623,"totalTrials":350,"cells":13535},{"EARLY_PHASE1":13536,"PHASE1":13538,"PHASE2":13540,"PHASE3":13546,"PHASE4":13548,"NA":13550},{"trials":13537,"activeCount":101},[],{"trials":13539,"activeCount":101},[],{"trials":13541,"activeCount":350,"soonestReadout":7618},[13542],{"nctId":7615,"briefTitle":7616,"status":140,"phases":13543,"primaryCompletion":7618,"completion":7618,"start":2374,"enrollment":7619,"conditions":13544,"interventions":13545},[89,90],[7621],[7623,528],{"trials":13547,"activeCount":101},[],{"trials":13549,"activeCount":101},[],{"trials":13551,"activeCount":101},[],{"intervention":2668,"totalTrials":350,"cells":13553},{"EARLY_PHASE1":13554,"PHASE1":13556,"PHASE2":13558,"PHASE3":13564,"PHASE4":13566,"NA":13568},{"trials":13555,"activeCount":101},[],{"trials":13557,"activeCount":101},[],{"trials":13559,"activeCount":350,"soonestReadout":2016},[13560],{"nctId":2661,"briefTitle":2662,"status":140,"phases":13561,"primaryCompletion":2016,"completion":2016,"start":2664,"enrollment":2665,"conditions":13562,"interventions":13563},[89,90],[1196],[2668,1018,1784,1096],{"trials":13565,"activeCount":101},[],{"trials":13567,"activeCount":101},[],{"trials":13569,"activeCount":101},[],{"intervention":13571,"totalTrials":350,"cells":13572},"SPK-10001",{"EARLY_PHASE1":13573,"PHASE1":13575,"PHASE2":13577,"PHASE3":13588,"PHASE4":13590,"NA":13592},{"trials":13574,"activeCount":101},[],{"trials":13576,"activeCount":101},[],{"trials":13578,"activeCount":350,"soonestReadout":13583},[13579],{"nctId":13580,"briefTitle":13581,"status":152,"phases":13582,"primaryCompletion":13583,"completion":13583,"start":13584,"enrollment":2532,"conditions":13585,"interventions":13587},"NCT06826612","A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease",[89,90],"2035-01-12","2025-02-21",[13586],"Huntington Disease",[13571],{"trials":13589,"activeCount":101},[],{"trials":13591,"activeCount":101},[],{"trials":13593,"activeCount":101},[],{"intervention":48,"totalTrials":350,"cells":13595},{"EARLY_PHASE1":13596,"PHASE1":13598,"PHASE2":13600,"PHASE3":13608,"PHASE4":13610,"NA":13612},{"trials":13597,"activeCount":101},[],{"trials":13599,"activeCount":101},[],{"trials":13601,"activeCount":350,"soonestReadout":47},[13602],{"nctId":45,"briefTitle":46,"status":140,"phases":13603,"primaryCompletion":47,"completion":13604,"start":13605,"enrollment":1452,"conditions":13606,"interventions":13607},[90],"2031-12-01","2017-06-27",[11204],[48,48],{"trials":13609,"activeCount":101},[],{"trials":13611,"activeCount":101},[],{"trials":13613,"activeCount":101},[],{"intervention":9961,"totalTrials":350,"cells":13615},{"EARLY_PHASE1":13616,"PHASE1":13618,"PHASE2":13620,"PHASE3":13626,"PHASE4":13628,"NA":13630},{"trials":13617,"activeCount":101},[],{"trials":13619,"activeCount":101},[],{"trials":13621,"activeCount":350,"soonestReadout":9955},[13622],{"nctId":9952,"briefTitle":9953,"status":3955,"phases":13623,"primaryCompletion":9955,"completion":9956,"start":2025,"enrollment":9957,"conditions":13624,"interventions":13625},[90],[9959],[9961,9943],{"trials":13627,"activeCount":101},[],{"trials":13629,"activeCount":101},[],{"trials":13631,"activeCount":101},[],{"intervention":1424,"totalTrials":350,"cells":13633},{"EARLY_PHASE1":13634,"PHASE1":13636,"PHASE2":13638,"PHASE3":13644,"PHASE4":13646,"NA":13648},{"trials":13635,"activeCount":101},[],{"trials":13637,"activeCount":101},[],{"trials":13639,"activeCount":350,"soonestReadout":1413},[13640],{"nctId":1410,"briefTitle":1411,"status":140,"phases":13641,"primaryCompletion":1413,"completion":154,"start":1414,"enrollment":1415,"conditions":13642,"interventions":13643},[90],[1417],[946,1084,1419,68,1015,1106,63,1420,1137,1421,1422,1423,1424,992,1137],{"trials":13645,"activeCount":101},[],{"trials":13647,"activeCount":101},[],{"trials":13649,"activeCount":101},[],{"intervention":53,"totalTrials":350,"cells":13651},{"EARLY_PHASE1":13652,"PHASE1":13654,"PHASE2":13656,"PHASE3":13665,"PHASE4":13667,"NA":13669},{"trials":13653,"activeCount":101},[],{"trials":13655,"activeCount":101},[],{"trials":13657,"activeCount":350,"soonestReadout":52},[13658],{"nctId":50,"briefTitle":51,"status":140,"phases":13659,"primaryCompletion":52,"completion":13660,"start":13661,"enrollment":425,"conditions":13662,"interventions":13664},[89,90],"2031-01-31","2015-04-01",[13663],"Age-Related Macular Degeneration",[53],{"trials":13666,"activeCount":101},[],{"trials":13668,"activeCount":101},[],{"trials":13670,"activeCount":101},[],{"intervention":5057,"totalTrials":350,"cells":13672},{"EARLY_PHASE1":13673,"PHASE1":13675,"PHASE2":13677,"PHASE3":13683,"PHASE4":13685,"NA":13687},{"trials":13674,"activeCount":101},[],{"trials":13676,"activeCount":101},[],{"trials":13678,"activeCount":350,"soonestReadout":1962},[13679],{"nctId":5050,"briefTitle":5051,"status":140,"phases":13680,"primaryCompletion":1962,"completion":1962,"start":5053,"enrollment":5054,"conditions":13681,"interventions":13682},[90],[1049],[1445,988,1957,5057],{"trials":13684,"activeCount":101},[],{"trials":13686,"activeCount":101},[],{"trials":13688,"activeCount":101},[],{"intervention":1457,"totalTrials":350,"cells":13690},{"EARLY_PHASE1":13691,"PHASE1":13693,"PHASE2":13695,"PHASE3":13701,"PHASE4":13703,"NA":13705},{"trials":13692,"activeCount":101},[],{"trials":13694,"activeCount":101},[],{"trials":13696,"activeCount":350,"soonestReadout":1450},[13697],{"nctId":1447,"briefTitle":1448,"status":152,"phases":13698,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":13699,"interventions":13700},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"trials":13702,"activeCount":101},[],{"trials":13704,"activeCount":101},[],{"trials":13706,"activeCount":101},[],{"intervention":1458,"totalTrials":350,"cells":13708},{"EARLY_PHASE1":13709,"PHASE1":13711,"PHASE2":13713,"PHASE3":13719,"PHASE4":13721,"NA":13723},{"trials":13710,"activeCount":101},[],{"trials":13712,"activeCount":101},[],{"trials":13714,"activeCount":350,"soonestReadout":1450},[13715],{"nctId":1447,"briefTitle":1448,"status":152,"phases":13716,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":13717,"interventions":13718},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"trials":13720,"activeCount":101},[],{"trials":13722,"activeCount":101},[],{"trials":13724,"activeCount":101},[],{"intervention":1459,"totalTrials":350,"cells":13726},{"EARLY_PHASE1":13727,"PHASE1":13729,"PHASE2":13731,"PHASE3":13737,"PHASE4":13739,"NA":13741},{"trials":13728,"activeCount":101},[],{"trials":13730,"activeCount":101},[],{"trials":13732,"activeCount":350,"soonestReadout":1450},[13733],{"nctId":1447,"briefTitle":1448,"status":152,"phases":13734,"primaryCompletion":1450,"completion":1450,"start":1451,"enrollment":1452,"conditions":13735,"interventions":13736},[89,90],[1454],[63,1420,946,1137,1456,1457,1458,1459,1421,68],{"trials":13738,"activeCount":101},[],{"trials":13740,"activeCount":101},[],{"trials":13742,"activeCount":101},[],{"intervention":13744,"totalTrials":350,"cells":13745},"Ocrelizumab Test Formulation",{"EARLY_PHASE1":13746,"PHASE1":13748,"PHASE2":13750,"PHASE3":13759,"PHASE4":13761,"NA":13763},{"trials":13747,"activeCount":101},[],{"trials":13749,"activeCount":101},[],{"trials":13751,"activeCount":350,"soonestReadout":3722},[13752],{"nctId":13753,"briefTitle":13754,"status":152,"phases":13755,"primaryCompletion":3722,"completion":4787,"start":1440,"enrollment":3015,"conditions":13756,"interventions":13757},"NCT07074886","A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)",[90],[147],[13744,13758],"Ocrelizumab Reference Formulation",{"trials":13760,"activeCount":101},[],{"trials":13762,"activeCount":101},[],{"trials":13764,"activeCount":101},[],{"intervention":13758,"totalTrials":350,"cells":13766},{"EARLY_PHASE1":13767,"PHASE1":13769,"PHASE2":13771,"PHASE3":13777,"PHASE4":13779,"NA":13781},{"trials":13768,"activeCount":101},[],{"trials":13770,"activeCount":101},[],{"trials":13772,"activeCount":350,"soonestReadout":3722},[13773],{"nctId":13753,"briefTitle":13754,"status":152,"phases":13774,"primaryCompletion":3722,"completion":4787,"start":1440,"enrollment":3015,"conditions":13775,"interventions":13776},[90],[147],[13744,13758],{"trials":13778,"activeCount":101},[],{"trials":13780,"activeCount":101},[],{"trials":13782,"activeCount":101},[],{"intervention":12942,"totalTrials":350,"cells":13784},{"EARLY_PHASE1":13785,"PHASE1":13787,"PHASE2":13789,"PHASE3":13795,"PHASE4":13797,"NA":13799},{"trials":13786,"activeCount":101},[],{"trials":13788,"activeCount":101},[],{"trials":13790,"activeCount":350,"soonestReadout":12938},[13791],{"nctId":12935,"briefTitle":12936,"status":140,"phases":13792,"primaryCompletion":12938,"completion":12938,"start":12939,"enrollment":8028,"conditions":13793,"interventions":13794},[90],[9439],[12889,12942],{"trials":13796,"activeCount":101},[],{"trials":13798,"activeCount":101},[],{"trials":13800,"activeCount":101},[],{"intervention":13802,"totalTrials":350,"cells":13803},"SPK-8011QQ",{"EARLY_PHASE1":13804,"PHASE1":13806,"PHASE2":13808,"PHASE3":13817,"PHASE4":13819,"NA":13821},{"trials":13805,"activeCount":101},[],{"trials":13807,"activeCount":101},[],{"trials":13809,"activeCount":350,"soonestReadout":13814},[13810],{"nctId":13811,"briefTitle":13812,"status":152,"phases":13813,"primaryCompletion":13814,"completion":13814,"start":2025,"enrollment":2631,"conditions":13815,"interventions":13816},"NCT07226206","A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A",[89,90],"2031-07-31",[723],[13802],{"trials":13818,"activeCount":101},[],{"trials":13820,"activeCount":101},[],{"trials":13822,"activeCount":101},[],{"intervention":13824,"totalTrials":350,"cells":13825},"Tominersen",{"EARLY_PHASE1":13826,"PHASE1":13828,"PHASE2":13830,"PHASE3":13842,"PHASE4":13844,"NA":13846},{"trials":13827,"activeCount":101},[],{"trials":13829,"activeCount":101},[],{"trials":13831,"activeCount":350,"soonestReadout":13836},[13832],{"nctId":13833,"briefTitle":13834,"status":140,"phases":13835,"primaryCompletion":13836,"completion":13837,"start":13838,"enrollment":13839,"conditions":13840,"interventions":13841},"NCT05686551","GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease",[90],"2026-05-14","2027-04-01","2023-02-03",301,[13586],[13824],{"trials":13843,"activeCount":101},[],{"trials":13845,"activeCount":101},[],{"trials":13847,"activeCount":101},[],{"intervention":1571,"totalTrials":350,"cells":13849},{"EARLY_PHASE1":13850,"PHASE1":13852,"PHASE2":13854,"PHASE3":13860,"PHASE4":13862,"NA":13864},{"trials":13851,"activeCount":101},[],{"trials":13853,"activeCount":101},[],{"trials":13855,"activeCount":350,"soonestReadout":1565},[13856],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13857,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13858,"interventions":13859},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13861,"activeCount":101},[],{"trials":13863,"activeCount":101},[],{"trials":13865,"activeCount":101},[],{"intervention":1574,"totalTrials":350,"cells":13867},{"EARLY_PHASE1":13868,"PHASE1":13870,"PHASE2":13872,"PHASE3":13878,"PHASE4":13880,"NA":13882},{"trials":13869,"activeCount":101},[],{"trials":13871,"activeCount":101},[],{"trials":13873,"activeCount":350,"soonestReadout":1565},[13874],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13875,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13876,"interventions":13877},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13879,"activeCount":101},[],{"trials":13881,"activeCount":101},[],{"trials":13883,"activeCount":101},[],{"intervention":1575,"totalTrials":350,"cells":13885},{"EARLY_PHASE1":13886,"PHASE1":13888,"PHASE2":13890,"PHASE3":13896,"PHASE4":13898,"NA":13900},{"trials":13887,"activeCount":101},[],{"trials":13889,"activeCount":101},[],{"trials":13891,"activeCount":350,"soonestReadout":1565},[13892],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13893,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13894,"interventions":13895},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13897,"activeCount":101},[],{"trials":13899,"activeCount":101},[],{"trials":13901,"activeCount":101},[],{"intervention":1577,"totalTrials":350,"cells":13903},{"EARLY_PHASE1":13904,"PHASE1":13906,"PHASE2":13908,"PHASE3":13914,"PHASE4":13916,"NA":13918},{"trials":13905,"activeCount":101},[],{"trials":13907,"activeCount":101},[],{"trials":13909,"activeCount":350,"soonestReadout":1565},[13910],{"nctId":1562,"briefTitle":1563,"status":152,"phases":13911,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":13912,"interventions":13913},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"trials":13915,"activeCount":101},[],{"trials":13917,"activeCount":101},[],{"trials":13919,"activeCount":101},[],{"intervention":9466,"totalTrials":350,"cells":13921},{"EARLY_PHASE1":13922,"PHASE1":13924,"PHASE2":13926,"PHASE3":13932,"PHASE4":13934,"NA":13936},{"trials":13923,"activeCount":101},[],{"trials":13925,"activeCount":101},[],{"trials":13927,"activeCount":350,"soonestReadout":9459},[13928],{"nctId":9456,"briefTitle":9457,"status":140,"phases":13929,"primaryCompletion":9459,"completion":9460,"start":9461,"enrollment":9462,"conditions":13930,"interventions":13931},[90],[9440,9441,9464],[487,9466],{"trials":13933,"activeCount":101},[],{"trials":13935,"activeCount":101},[],{"trials":13937,"activeCount":101},[],{"intervention":13939,"totalTrials":350,"cells":13940},"delandistrogene moxeparvovec",{"EARLY_PHASE1":13941,"PHASE1":13943,"PHASE2":13945,"PHASE3":13956,"PHASE4":13958,"NA":13960},{"trials":13942,"activeCount":101},[],{"trials":13944,"activeCount":101},[],{"trials":13946,"activeCount":350,"soonestReadout":13951},[13947],{"nctId":13948,"briefTitle":13949,"status":140,"phases":13950,"primaryCompletion":13951,"completion":13952,"start":13953,"enrollment":372,"conditions":13954,"interventions":13955},"NCT06128564","A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)",[90],"2026-03-04","2030-02-18","2023-11-29",[7337],[13939],{"trials":13957,"activeCount":101},[],{"trials":13959,"activeCount":101},[],{"trials":13961,"activeCount":101},[],{"intervention":13963,"totalTrials":350,"cells":13964},"ZN-A-1041",{"EARLY_PHASE1":13965,"PHASE1":13967,"PHASE2":13969,"PHASE3":13984,"PHASE4":13986,"NA":13988},{"trials":13966,"activeCount":101},[],{"trials":13968,"activeCount":101},[],{"trials":13970,"activeCount":350,"soonestReadout":1978},[13971],{"nctId":13972,"briefTitle":13973,"status":140,"phases":13974,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":13976,"interventions":13977},"NCT05593094","A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors",[89,90],"2020-09-03",[5357,8499],[13963,13978,13979,13980,13981,13982,13983],"ZN-A-1041 + T-DM1 3.6 mg\u002Fkg iv. for Phase 1b","ZN-A-1041 + T-Dxd 5.4 mg\u002Fkg iv. for Phase 1b","ZN-A-1041 + PHESGO \u002F Herceptin plus Perjeta injection for Phase 1b","ZN-A-1041 + T-DM1 3.6 mg\u002Fkg iv. for Phase 1c","ZN-A-1041 + T-Dxd 5.4 mg\u002Fkg iv. for Phase 1c","ZN-A-1041 + PHESGO \u002F Herceptin plus Perjeta injection for Phase 1c",{"trials":13985,"activeCount":101},[],{"trials":13987,"activeCount":101},[],{"trials":13989,"activeCount":101},[],{"intervention":13978,"totalTrials":350,"cells":13991},{"EARLY_PHASE1":13992,"PHASE1":13994,"PHASE2":13996,"PHASE3":14002,"PHASE4":14004,"NA":14006},{"trials":13993,"activeCount":101},[],{"trials":13995,"activeCount":101},[],{"trials":13997,"activeCount":350,"soonestReadout":1978},[13998],{"nctId":13972,"briefTitle":13973,"status":140,"phases":13999,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14000,"interventions":14001},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14003,"activeCount":101},[],{"trials":14005,"activeCount":101},[],{"trials":14007,"activeCount":101},[],{"intervention":13979,"totalTrials":350,"cells":14009},{"EARLY_PHASE1":14010,"PHASE1":14012,"PHASE2":14014,"PHASE3":14020,"PHASE4":14022,"NA":14024},{"trials":14011,"activeCount":101},[],{"trials":14013,"activeCount":101},[],{"trials":14015,"activeCount":350,"soonestReadout":1978},[14016],{"nctId":13972,"briefTitle":13973,"status":140,"phases":14017,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14018,"interventions":14019},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14021,"activeCount":101},[],{"trials":14023,"activeCount":101},[],{"trials":14025,"activeCount":101},[],{"intervention":13980,"totalTrials":350,"cells":14027},{"EARLY_PHASE1":14028,"PHASE1":14030,"PHASE2":14032,"PHASE3":14038,"PHASE4":14040,"NA":14042},{"trials":14029,"activeCount":101},[],{"trials":14031,"activeCount":101},[],{"trials":14033,"activeCount":350,"soonestReadout":1978},[14034],{"nctId":13972,"briefTitle":13973,"status":140,"phases":14035,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14036,"interventions":14037},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14039,"activeCount":101},[],{"trials":14041,"activeCount":101},[],{"trials":14043,"activeCount":101},[],{"intervention":13981,"totalTrials":350,"cells":14045},{"EARLY_PHASE1":14046,"PHASE1":14048,"PHASE2":14050,"PHASE3":14056,"PHASE4":14058,"NA":14060},{"trials":14047,"activeCount":101},[],{"trials":14049,"activeCount":101},[],{"trials":14051,"activeCount":350,"soonestReadout":1978},[14052],{"nctId":13972,"briefTitle":13973,"status":140,"phases":14053,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14054,"interventions":14055},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14057,"activeCount":101},[],{"trials":14059,"activeCount":101},[],{"trials":14061,"activeCount":101},[],{"intervention":13982,"totalTrials":350,"cells":14063},{"EARLY_PHASE1":14064,"PHASE1":14066,"PHASE2":14068,"PHASE3":14074,"PHASE4":14076,"NA":14078},{"trials":14065,"activeCount":101},[],{"trials":14067,"activeCount":101},[],{"trials":14069,"activeCount":350,"soonestReadout":1978},[14070],{"nctId":13972,"briefTitle":13973,"status":140,"phases":14071,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14072,"interventions":14073},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14075,"activeCount":101},[],{"trials":14077,"activeCount":101},[],{"trials":14079,"activeCount":101},[],{"intervention":13983,"totalTrials":350,"cells":14081},{"EARLY_PHASE1":14082,"PHASE1":14084,"PHASE2":14086,"PHASE3":14092,"PHASE4":14094,"NA":14096},{"trials":14083,"activeCount":101},[],{"trials":14085,"activeCount":101},[],{"trials":14087,"activeCount":350,"soonestReadout":1978},[14088],{"nctId":13972,"briefTitle":13973,"status":140,"phases":14089,"primaryCompletion":1978,"completion":1978,"start":13975,"enrollment":4701,"conditions":14090,"interventions":14091},[89,90],[5357,8499],[13963,13978,13979,13980,13981,13982,13983],{"trials":14093,"activeCount":101},[],{"trials":14095,"activeCount":101},[],{"trials":14097,"activeCount":101},[],{"intervention":161,"totalTrials":350,"cells":14099},{"EARLY_PHASE1":14100,"PHASE1":14102,"PHASE2":14104,"PHASE3":14110,"PHASE4":14112,"NA":14114},{"trials":14101,"activeCount":101},[],{"trials":14103,"activeCount":101},[],{"trials":14105,"activeCount":350,"soonestReadout":154},[14106],{"nctId":150,"briefTitle":151,"status":152,"phases":14107,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":14108,"interventions":14109},[90],[159],[161,96],{"trials":14111,"activeCount":101},[],{"trials":14113,"activeCount":101},[],{"trials":14115,"activeCount":101},[],{"intervention":11005,"totalTrials":350,"cells":14117},{"EARLY_PHASE1":14118,"PHASE1":14120,"PHASE2":14122,"PHASE3":14128,"PHASE4":14130,"NA":14132},{"trials":14119,"activeCount":101},[],{"trials":14121,"activeCount":101},[],{"trials":14123,"activeCount":350,"soonestReadout":10999},[14124],{"nctId":10996,"briefTitle":10997,"status":152,"phases":14125,"primaryCompletion":10999,"completion":10999,"start":11000,"enrollment":11001,"conditions":14126,"interventions":14127},[90],[11003],[11005,1287,11006],{"trials":14129,"activeCount":101},[],{"trials":14131,"activeCount":101},[],{"trials":14133,"activeCount":101},[],{"intervention":11006,"totalTrials":350,"cells":14135},{"EARLY_PHASE1":14136,"PHASE1":14138,"PHASE2":14140,"PHASE3":14146,"PHASE4":14148,"NA":14150},{"trials":14137,"activeCount":101},[],{"trials":14139,"activeCount":101},[],{"trials":14141,"activeCount":350,"soonestReadout":10999},[14142],{"nctId":10996,"briefTitle":10997,"status":152,"phases":14143,"primaryCompletion":10999,"completion":10999,"start":11000,"enrollment":11001,"conditions":14144,"interventions":14145},[90],[11003],[11005,1287,11006],{"trials":14147,"activeCount":101},[],{"trials":14149,"activeCount":101},[],{"trials":14151,"activeCount":101},[],{"intervention":5669,"totalTrials":350,"cells":14153},{"EARLY_PHASE1":14154,"PHASE1":14156,"PHASE2":14158,"PHASE3":14164,"PHASE4":14166,"NA":14168},{"trials":14155,"activeCount":101},[],{"trials":14157,"activeCount":101},[],{"trials":14159,"activeCount":350,"soonestReadout":62},[14160],{"nctId":60,"briefTitle":61,"status":140,"phases":14161,"primaryCompletion":62,"completion":5664,"start":5665,"enrollment":3856,"conditions":14162,"interventions":14163},[90],[5667],[63,5669,5670],{"trials":14165,"activeCount":101},[],{"trials":14167,"activeCount":101},[],{"trials":14169,"activeCount":101},[],{"intervention":1696,"totalTrials":350,"cells":14171},{"EARLY_PHASE1":14172,"PHASE1":14174,"PHASE2":14176,"PHASE3":14182,"PHASE4":14184,"NA":14186},{"trials":14173,"activeCount":101},[],{"trials":14175,"activeCount":101},[],{"trials":14177,"activeCount":350,"soonestReadout":1690},[14178],{"nctId":1687,"briefTitle":1688,"status":140,"phases":14179,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1692,"conditions":14180,"interventions":14181},[90],[922],[1695,1695,43,68,946,1223,1137,1696,1697,1140,1324],{"trials":14183,"activeCount":101},[],{"trials":14185,"activeCount":101},[],{"trials":14187,"activeCount":101},[],{"intervention":1749,"totalTrials":350,"cells":14189},{"EARLY_PHASE1":14190,"PHASE1":14192,"PHASE2":14194,"PHASE3":14200,"PHASE4":14202,"NA":14204},{"trials":14191,"activeCount":101},[],{"trials":14193,"activeCount":101},[],{"trials":14195,"activeCount":350,"soonestReadout":1742},[14196],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14197,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14198,"interventions":14199},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14201,"activeCount":101},[],{"trials":14203,"activeCount":101},[],{"trials":14205,"activeCount":101},[],{"intervention":1750,"totalTrials":350,"cells":14207},{"EARLY_PHASE1":14208,"PHASE1":14210,"PHASE2":14212,"PHASE3":14218,"PHASE4":14220,"NA":14222},{"trials":14209,"activeCount":101},[],{"trials":14211,"activeCount":101},[],{"trials":14213,"activeCount":350,"soonestReadout":1742},[14214],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14215,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14216,"interventions":14217},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14219,"activeCount":101},[],{"trials":14221,"activeCount":101},[],{"trials":14223,"activeCount":101},[],{"intervention":1751,"totalTrials":350,"cells":14225},{"EARLY_PHASE1":14226,"PHASE1":14228,"PHASE2":14230,"PHASE3":14236,"PHASE4":14238,"NA":14240},{"trials":14227,"activeCount":101},[],{"trials":14229,"activeCount":101},[],{"trials":14231,"activeCount":350,"soonestReadout":1742},[14232],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14233,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14234,"interventions":14235},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14237,"activeCount":101},[],{"trials":14239,"activeCount":101},[],{"trials":14241,"activeCount":101},[],{"intervention":1752,"totalTrials":350,"cells":14243},{"EARLY_PHASE1":14244,"PHASE1":14246,"PHASE2":14248,"PHASE3":14254,"PHASE4":14256,"NA":14258},{"trials":14245,"activeCount":101},[],{"trials":14247,"activeCount":101},[],{"trials":14249,"activeCount":350,"soonestReadout":1742},[14250],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14251,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14252,"interventions":14253},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14255,"activeCount":101},[],{"trials":14257,"activeCount":101},[],{"trials":14259,"activeCount":101},[],{"intervention":1753,"totalTrials":350,"cells":14261},{"EARLY_PHASE1":14262,"PHASE1":14264,"PHASE2":14266,"PHASE3":14272,"PHASE4":14274,"NA":14276},{"trials":14263,"activeCount":101},[],{"trials":14265,"activeCount":101},[],{"trials":14267,"activeCount":350,"soonestReadout":1742},[14268],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14269,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14270,"interventions":14271},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14273,"activeCount":101},[],{"trials":14275,"activeCount":101},[],{"trials":14277,"activeCount":101},[],{"intervention":1754,"totalTrials":350,"cells":14279},{"EARLY_PHASE1":14280,"PHASE1":14282,"PHASE2":14284,"PHASE3":14290,"PHASE4":14292,"NA":14294},{"trials":14281,"activeCount":101},[],{"trials":14283,"activeCount":101},[],{"trials":14285,"activeCount":350,"soonestReadout":1742},[14286],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14287,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14288,"interventions":14289},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14291,"activeCount":101},[],{"trials":14293,"activeCount":101},[],{"trials":14295,"activeCount":101},[],{"intervention":1755,"totalTrials":350,"cells":14297},{"EARLY_PHASE1":14298,"PHASE1":14300,"PHASE2":14302,"PHASE3":14308,"PHASE4":14310,"NA":14312},{"trials":14299,"activeCount":101},[],{"trials":14301,"activeCount":101},[],{"trials":14303,"activeCount":350,"soonestReadout":1742},[14304],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14305,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14306,"interventions":14307},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14309,"activeCount":101},[],{"trials":14311,"activeCount":101},[],{"trials":14313,"activeCount":101},[],{"intervention":1756,"totalTrials":350,"cells":14315},{"EARLY_PHASE1":14316,"PHASE1":14318,"PHASE2":14320,"PHASE3":14326,"PHASE4":14328,"NA":14330},{"trials":14317,"activeCount":101},[],{"trials":14319,"activeCount":101},[],{"trials":14321,"activeCount":350,"soonestReadout":1742},[14322],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14323,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14324,"interventions":14325},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14327,"activeCount":101},[],{"trials":14329,"activeCount":101},[],{"trials":14331,"activeCount":101},[],{"intervention":1757,"totalTrials":350,"cells":14333},{"EARLY_PHASE1":14334,"PHASE1":14336,"PHASE2":14338,"PHASE3":14344,"PHASE4":14346,"NA":14348},{"trials":14335,"activeCount":101},[],{"trials":14337,"activeCount":101},[],{"trials":14339,"activeCount":350,"soonestReadout":1742},[14340],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14341,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14342,"interventions":14343},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14345,"activeCount":101},[],{"trials":14347,"activeCount":101},[],{"trials":14349,"activeCount":101},[],{"intervention":1758,"totalTrials":350,"cells":14351},{"EARLY_PHASE1":14352,"PHASE1":14354,"PHASE2":14356,"PHASE3":14362,"PHASE4":14364,"NA":14366},{"trials":14353,"activeCount":101},[],{"trials":14355,"activeCount":101},[],{"trials":14357,"activeCount":350,"soonestReadout":1742},[14358],{"nctId":1739,"briefTitle":1740,"status":152,"phases":14359,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1745,"conditions":14360,"interventions":14361},[89,90],[1747],[68,1749,988,1096,1750,1751,1752,1753,1754,1755,1756,1757,1758],{"trials":14363,"activeCount":101},[],{"trials":14365,"activeCount":101},[],{"trials":14367,"activeCount":101},[],{"intervention":14369,"totalTrials":350,"cells":14370},"RO7269162",{"EARLY_PHASE1":14371,"PHASE1":14373,"PHASE2":14375,"PHASE3":14386,"PHASE4":14388,"NA":14390},{"trials":14372,"activeCount":101},[],{"trials":14374,"activeCount":101},[],{"trials":14376,"activeCount":350,"soonestReadout":14381},[14377],{"nctId":14378,"briefTitle":14379,"status":140,"phases":14380,"primaryCompletion":14381,"completion":14381,"start":14382,"enrollment":6563,"conditions":14383,"interventions":14385},"NCT06402838","A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)",[90],"2026-11-19","2024-05-02",[14384],"Alzheimer's Disease",[14369],{"trials":14387,"activeCount":101},[],{"trials":14389,"activeCount":101},[],{"trials":14391,"activeCount":101},[],{"intervention":1786,"totalTrials":350,"cells":14393},{"EARLY_PHASE1":14394,"PHASE1":14396,"PHASE2":14398,"PHASE3":14404,"PHASE4":14406,"NA":14408},{"trials":14395,"activeCount":101},[],{"trials":14397,"activeCount":101},[],{"trials":14399,"activeCount":350,"soonestReadout":1778},[14400],{"nctId":1775,"briefTitle":1776,"status":140,"phases":14401,"primaryCompletion":1778,"completion":1778,"start":1779,"enrollment":1780,"conditions":14402,"interventions":14403},[89,90],[1782],[1784,68,1018,1096,1785,1786],{"trials":14405,"activeCount":101},[],{"trials":14407,"activeCount":101},[],{"trials":14409,"activeCount":101},[],{"intervention":14411,"totalTrials":350,"cells":14412},"Ocrelizumab co-formulated with rHuPH20",{"EARLY_PHASE1":14413,"PHASE1":14415,"PHASE2":14417,"PHASE3":14428,"PHASE4":14430,"NA":14432},{"trials":14414,"activeCount":101},[],{"trials":14416,"activeCount":101},[],{"trials":14418,"activeCount":350,"soonestReadout":14423},[14419],{"nctId":14420,"briefTitle":14421,"status":3955,"phases":14422,"primaryCompletion":14423,"completion":14424,"start":7618,"enrollment":97,"conditions":14425,"interventions":14427},"NCT07503340","A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)",[90],"2029-08-01","2031-08-01",[14426],"Relapsing-remitting Multiple Sclerosis",[14411],{"trials":14429,"activeCount":101},[],{"trials":14431,"activeCount":101},[],{"trials":14433,"activeCount":101},[],{"intervention":5848,"totalTrials":2375,"cells":14435},{"EARLY_PHASE1":14436,"PHASE1":14438,"PHASE2":14440,"PHASE3":14467,"PHASE4":14521,"NA":14553},{"trials":14437,"activeCount":101},[],{"trials":14439,"activeCount":101},[],{"trials":14441,"activeCount":350,"soonestReadout":3703},[14442,14450,14459,14463],{"nctId":14443,"briefTitle":14444,"status":130,"phases":14445,"primaryCompletion":8689,"completion":8689,"start":14446,"enrollment":1796,"conditions":14447,"interventions":14449},"NCT02630563","Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids",[90],"2003-05",[14448],"Pediatric Liver Transplantation",[3059,11717,5848],{"nctId":14451,"briefTitle":14452,"status":107,"phases":14453,"primaryCompletion":4113,"completion":4113,"start":14454,"enrollment":909,"conditions":14455,"interventions":14456},"NCT01292226","A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).",[90],"2006-12",[5846],[5848,14457,11717,14458],"antibody induction","corticosteroid",{"nctId":9140,"briefTitle":9141,"status":107,"phases":14460,"primaryCompletion":2963,"completion":2963,"start":6673,"enrollment":462,"conditions":14461,"interventions":14462},[90],[1206],[5914,1357,9145],{"nctId":3700,"briefTitle":3701,"status":152,"phases":14464,"primaryCompletion":3703,"completion":3704,"start":804,"enrollment":931,"conditions":14465,"interventions":14466},[90],[3597],[1018,3707,3708,3709,274,1357],{"trials":14468,"activeCount":101},[14469,14473,14477,14485,14489,14493,14497,14504,14511,14515],{"nctId":10139,"briefTitle":10140,"status":130,"phases":14470,"primaryCompletion":4582,"completion":4582,"start":7096,"enrollment":973,"conditions":14471,"interventions":14472},[91],[3597],[3707,3059,2820,992],{"nctId":9165,"briefTitle":9166,"status":130,"phases":14474,"primaryCompletion":4562,"completion":4562,"start":4455,"enrollment":721,"conditions":14475,"interventions":14476},[91],[3597],[5914,9170,9171,1357],{"nctId":14478,"briefTitle":14479,"status":107,"phases":14480,"primaryCompletion":3479,"completion":3479,"start":5457,"enrollment":1058,"conditions":14481,"interventions":14482},"NCT02091414","A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.",[91],[5911],[5848,14483,14484],"cyclosporine A","corticosteroids",{"nctId":10149,"briefTitle":10150,"status":107,"phases":14486,"primaryCompletion":7096,"completion":4555,"start":4323,"enrollment":10152,"conditions":14487,"interventions":14488},[91],[3597],[5914,992,2820,10155],{"nctId":5841,"briefTitle":5842,"status":107,"phases":14490,"primaryCompletion":3325,"completion":3325,"start":4282,"enrollment":5844,"conditions":14491,"interventions":14492},[91],[5846],[5848,5848,5849,5839,5850],{"nctId":7364,"briefTitle":7365,"status":107,"phases":14494,"primaryCompletion":1281,"completion":1281,"start":593,"enrollment":1651,"conditions":14495,"interventions":14496},[91],[7360],[7369,7370,5848,7371],{"nctId":14498,"briefTitle":14499,"status":107,"phases":14500,"primaryCompletion":3213,"completion":3213,"start":4206,"enrollment":4683,"conditions":14501,"interventions":14503},"NCT01014442","A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients",[91],[14502],"Lung Transplantation",[5848],{"nctId":14505,"briefTitle":14506,"status":107,"phases":14507,"completion":6620,"start":6134,"enrollment":846,"conditions":14508,"interventions":14510},"NCT00683969","A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis",[91],[14509],"Myasthenia Gravis, Generalized",[5848],{"nctId":6353,"briefTitle":6354,"status":107,"phases":14512,"primaryCompletion":6356,"completion":6357,"start":6358,"enrollment":3295,"conditions":14513,"interventions":14514},[91],[6360],[6362,3707,1359,6363],{"nctId":14516,"briefTitle":14517,"status":107,"phases":14518,"primaryCompletion":4281,"completion":4281,"start":4563,"enrollment":846,"conditions":14519,"interventions":14520},"NCT00788567","CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants",[91],[5846],[5848],{"trials":14522,"activeCount":101},[14523,14527,14535,14542,14549],{"nctId":11710,"briefTitle":11711,"status":107,"phases":14524,"primaryCompletion":3692,"completion":3692,"start":11713,"enrollment":11714,"conditions":14525,"interventions":14526},[92],[5846],[5914,11717,3754],{"nctId":14528,"briefTitle":14529,"status":107,"phases":14530,"primaryCompletion":4233,"completion":4233,"start":4113,"enrollment":4701,"conditions":14531,"interventions":14532},"NCT00758602","A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.",[92],[5846],[5848,14533,14534,14484],"tacrolimus, standard dose","tacrolimus, low dose",{"nctId":14536,"briefTitle":14537,"status":107,"phases":14538,"primaryCompletion":4513,"completion":4513,"start":9499,"enrollment":1058,"conditions":14539,"interventions":14540},"NCT02554955","A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants",[92],[5911],[5913,5914,14541],"Silrolimus",{"nctId":14543,"briefTitle":14544,"status":107,"phases":14545,"primaryCompletion":4314,"completion":4314,"start":4281,"enrollment":1296,"conditions":14546,"interventions":14547},"NCT00717314","A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.",[92],[11724],[5914,14548,14548],"CNI",{"nctId":5905,"briefTitle":5906,"status":107,"phases":14550,"primaryCompletion":5805,"completion":5805,"start":5908,"enrollment":5909,"conditions":14551,"interventions":14552},[92],[5911],[5913,274,5914,5850],{"trials":14554,"activeCount":101},[14555],{"nctId":14556,"briefTitle":14557,"status":107,"phases":14558,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":4573,"conditions":14559,"interventions":14560},"NCT01672957","An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil",[],[5846],[3707,14561],"Immunosuppressive Therapy",{"intervention":1572,"totalTrials":721,"cells":14563},{"EARLY_PHASE1":14564,"PHASE1":14566,"PHASE2":14578,"PHASE3":14592,"PHASE4":14619,"NA":14634},{"trials":14565,"activeCount":101},[],{"trials":14567,"activeCount":101},[14568],{"nctId":14569,"briefTitle":14570,"status":107,"phases":14571,"primaryCompletion":5891,"completion":5891,"start":14572,"enrollment":2289,"conditions":14573,"interventions":14575},"NCT00711191","A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas",[89],"2008-06",[14574],"Pancreatic Neoplasm",[14576,14577],"monoclonal antibody","chemotherapy",{"trials":14579,"activeCount":350,"soonestReadout":1565},[14580,14584],{"nctId":1562,"briefTitle":1563,"status":152,"phases":14581,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":14582,"interventions":14583},[89,90],[1569],[1166,68,946,1571,1015,1572,1029,1096,1107,1321,1420,1573,1456,1137,1574,1456,1422,1137,1137,1575,1421,1576,1577],{"nctId":14585,"briefTitle":14586,"status":130,"phases":14587,"primaryCompletion":4454,"completion":4454,"start":2684,"enrollment":162,"conditions":14588,"interventions":14589},"NCT01928615","A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer",[90],[18],[14590,14591,1572],"Trastuzumab - intravenous solution","Trastuzumab - subcutaneous solution",{"trials":14593,"activeCount":101},[14594,14600,14604,14608,14615],{"nctId":14595,"briefTitle":14596,"status":107,"phases":14597,"primaryCompletion":3007,"completion":11437,"start":2964,"enrollment":7879,"conditions":14598,"interventions":14599},"NCT01342965","A Study of Erlotinib (Tarceva) Versus Gemcitabine\u002FCisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations",[91],[975],[977,1572],{"nctId":6233,"briefTitle":6234,"status":107,"phases":14601,"primaryCompletion":6236,"completion":6236,"start":6237,"enrollment":6238,"conditions":14602,"interventions":14603},[91],[125],[1572,1359],{"nctId":4442,"briefTitle":4443,"status":107,"phases":14605,"primaryCompletion":4445,"completion":4445,"start":4446,"enrollment":4447,"conditions":14606,"interventions":14607},[91],[30],[1572,1015],{"nctId":14609,"briefTitle":14610,"status":107,"phases":14611,"primaryCompletion":3212,"completion":4473,"start":4233,"enrollment":14612,"conditions":14613,"interventions":14614},"NCT01250379","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)",[91],494,[18],[5275,1572],{"nctId":8481,"briefTitle":8482,"status":107,"phases":14616,"primaryCompletion":2932,"completion":2932,"start":8484,"enrollment":1724,"conditions":14617,"interventions":14618},[91],[18],[6647,1572],{"trials":14620,"activeCount":101},[14621,14628],{"nctId":14622,"briefTitle":14623,"status":107,"phases":14624,"primaryCompletion":2965,"completion":2965,"start":8751,"enrollment":2532,"conditions":14625,"interventions":14626},"NCT02782845","An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)",[92],[125],[1572,14627,10182],"Immunochemotherapy",{"nctId":14629,"briefTitle":14630,"status":107,"phases":14631,"primaryCompletion":3324,"completion":3324,"start":2830,"enrollment":909,"conditions":14632,"interventions":14633},"NCT02000531","Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population",[92],[1316],[977,1572],{"trials":14635,"activeCount":101},[14636,14640,14647,14651,14662,14669],{"nctId":4632,"briefTitle":4633,"status":107,"phases":14637,"primaryCompletion":4635,"completion":4635,"start":4636,"enrollment":4637,"conditions":14638,"interventions":14639},[],[30],[1015,1572],{"nctId":14641,"briefTitle":14642,"status":107,"phases":14643,"primaryCompletion":14644,"completion":14644,"start":8140,"enrollment":4811,"conditions":14645,"interventions":14646},"NCT02305615","An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)",[],"2017-12-29",[30],[1572],{"nctId":6470,"briefTitle":6471,"status":107,"phases":14648,"primaryCompletion":6473,"completion":6473,"start":6474,"enrollment":2440,"conditions":14649,"interventions":14650},[],[3607],[1572,1359],{"nctId":14652,"briefTitle":14653,"status":107,"phases":14654,"primaryCompletion":14655,"completion":14656,"start":14655,"enrollment":14657,"conditions":14658,"interventions":14659},"NCT02831842","A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status",[],"2016-06-09","2017-11-30",4278,[30],[14660,14661,1572],"Anti-EGFR-Containing Regimen","Bevacizumab-containing regimen",{"nctId":14663,"briefTitle":14664,"status":107,"phases":14665,"primaryCompletion":4682,"completion":4682,"start":2906,"enrollment":14666,"conditions":14667,"interventions":14668},"NCT01224093","An Observational Study on the Safety Profile of MabThera\u002FRituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)",[],219,[3741],[1572,5837],{"nctId":8863,"briefTitle":8864,"status":107,"phases":14670,"primaryCompletion":3324,"completion":3324,"start":4314,"enrollment":8866,"conditions":14671,"interventions":14672},[],[30],[1166,1572],{"intervention":5382,"totalTrials":462,"cells":14674},{"EARLY_PHASE1":14675,"PHASE1":14677,"PHASE2":14706,"PHASE3":14729,"PHASE4":14737,"NA":14739},{"trials":14676,"activeCount":101},[],{"trials":14678,"activeCount":350,"soonestReadout":1131},[14679,14687,14691,14695,14699],{"nctId":14680,"briefTitle":14681,"status":107,"phases":14682,"primaryCompletion":2602,"completion":2602,"start":2905,"enrollment":14683,"conditions":14684,"interventions":14685},"NCT01482377","A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and\u002For Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin",[89],145,[1241],[5422,1138,977,14686],"zirconium-89-labeled RO5479599",{"nctId":8230,"briefTitle":8231,"status":107,"phases":14688,"primaryCompletion":3895,"completion":3895,"start":8233,"enrollment":19,"conditions":14689,"interventions":14690},[89],[1160,18,8235],[1051,1222,1138],{"nctId":1128,"briefTitle":1129,"status":152,"phases":14692,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":14693,"interventions":14694},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"nctId":5373,"briefTitle":5374,"status":130,"phases":14696,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":14697,"interventions":14698},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"nctId":14700,"briefTitle":14701,"status":107,"phases":14702,"primaryCompletion":3213,"completion":3213,"start":3084,"enrollment":447,"conditions":14703,"interventions":14705},"NCT01046266","A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma",[89],[14704],"Head and Neck Cancer",[5184,5382],{"trials":14707,"activeCount":101},[14708,14715,14719,14725],{"nctId":14709,"briefTitle":14710,"status":107,"phases":14711,"primaryCompletion":3212,"completion":3212,"start":14712,"enrollment":1406,"conditions":14713,"interventions":14714},"NCT01326000","A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer",[90],"2011-04",[30],[1142,5184,5382],{"nctId":11514,"briefTitle":11515,"status":107,"phases":14716,"primaryCompletion":11517,"completion":11517,"start":11518,"enrollment":8,"conditions":14717,"interventions":14718},[90],[11520],[5382,10466,10466],{"nctId":14720,"briefTitle":14721,"status":343,"phases":14722,"primaryCompletion":3213,"completion":3213,"start":4513,"enrollment":101,"conditions":14723,"interventions":14724},"NCT00577109","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.",[90],[30],[5275,4577,1164,9036,1138],{"nctId":1517,"briefTitle":1518,"status":107,"phases":14726,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":14727,"interventions":14728},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"trials":14730,"activeCount":101},[14731],{"nctId":14732,"briefTitle":14733,"status":343,"phases":14734,"primaryCompletion":2947,"completion":2947,"start":8320,"enrollment":101,"conditions":14735,"interventions":14736},"NCT01338558","A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab",[91],[30],[5275,5382,5386],{"trials":14738,"activeCount":101},[],{"trials":14740,"activeCount":101},[],{"intervention":1142,"totalTrials":706,"cells":14742},{"EARLY_PHASE1":14743,"PHASE1":14745,"PHASE2":14751,"PHASE3":14761,"PHASE4":14763,"NA":14765},{"trials":14744,"activeCount":101},[],{"trials":14746,"activeCount":350,"soonestReadout":1131},[14747],{"nctId":1128,"briefTitle":1129,"status":152,"phases":14748,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":14749,"interventions":14750},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"trials":14752,"activeCount":101},[14753,14757],{"nctId":14709,"briefTitle":14710,"status":107,"phases":14754,"primaryCompletion":3212,"completion":3212,"start":14712,"enrollment":1406,"conditions":14755,"interventions":14756},[90],[30],[1142,5184,5382],{"nctId":3398,"briefTitle":3399,"status":343,"phases":14758,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":101,"conditions":14759,"interventions":14760},[90],[30],[1137,1015,1141,1142],{"trials":14762,"activeCount":101},[],{"trials":14764,"activeCount":101},[],{"trials":14766,"activeCount":101},[],{"intervention":1141,"totalTrials":162,"cells":14768},{"EARLY_PHASE1":14769,"PHASE1":14771,"PHASE2":14777,"PHASE3":14783,"PHASE4":14785,"NA":14787},{"trials":14770,"activeCount":101},[],{"trials":14772,"activeCount":350,"soonestReadout":1131},[14773],{"nctId":1128,"briefTitle":1129,"status":152,"phases":14774,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":14775,"interventions":14776},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"trials":14778,"activeCount":101},[14779],{"nctId":3398,"briefTitle":3399,"status":343,"phases":14780,"primaryCompletion":3401,"completion":3402,"start":3403,"enrollment":101,"conditions":14781,"interventions":14782},[90],[30],[1137,1015,1141,1142],{"trials":14784,"activeCount":101},[],{"trials":14786,"activeCount":101},[],{"trials":14788,"activeCount":101},[],{"intervention":12903,"totalTrials":162,"cells":14790},{"EARLY_PHASE1":14791,"PHASE1":14793,"PHASE2":14806,"PHASE3":14808,"PHASE4":14810,"NA":14812},{"trials":14792,"activeCount":101},[],{"trials":14794,"activeCount":350,"soonestReadout":843},[14795,14802],{"nctId":14796,"briefTitle":14797,"status":107,"phases":14798,"primaryCompletion":3276,"completion":3276,"start":14799,"enrollment":5901,"conditions":14800,"interventions":14801},"NCT03717064","A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers",[89],"2018-11-07",[427],[11792,12903],{"nctId":12896,"briefTitle":12897,"status":152,"phases":14803,"primaryCompletion":843,"completion":843,"start":12899,"enrollment":931,"conditions":14804,"interventions":14805},[89],[9441,9440],[12889,12902,12903],{"trials":14807,"activeCount":101},[],{"trials":14809,"activeCount":101},[],{"trials":14811,"activeCount":101},[],{"trials":14813,"activeCount":101},[],{"intervention":14815,"totalTrials":350,"cells":14816},"RO7812653",{"EARLY_PHASE1":14817,"PHASE1":14819,"PHASE2":14829,"PHASE3":14831,"PHASE4":14833,"NA":14835},{"trials":14818,"activeCount":101},[],{"trials":14820,"activeCount":350,"soonestReadout":14825},[14821],{"nctId":14822,"briefTitle":14823,"status":152,"phases":14824,"primaryCompletion":14825,"completion":14826,"start":7778,"enrollment":37,"conditions":14827,"interventions":14828},"NCT07234942","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)",[89],"2028-04-19","2030-03-05",[14384],[14815],{"trials":14830,"activeCount":101},[],{"trials":14832,"activeCount":101},[],{"trials":14834,"activeCount":101},[],{"trials":14836,"activeCount":101},[],{"intervention":14838,"totalTrials":350,"cells":14839},"RO7663498",{"EARLY_PHASE1":14840,"PHASE1":14842,"PHASE2":14852,"PHASE3":14854,"PHASE4":14856,"NA":14858},{"trials":14841,"activeCount":101},[],{"trials":14843,"activeCount":350,"soonestReadout":14848},[14844],{"nctId":14845,"briefTitle":14846,"status":3955,"phases":14847,"primaryCompletion":14848,"completion":14848,"start":14849,"enrollment":1184,"conditions":14850,"interventions":14851},"NCT07588100","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy",[89],"2027-12-30","2026-05-20",[12207],[14838],{"trials":14853,"activeCount":101},[],{"trials":14855,"activeCount":101},[],{"trials":14857,"activeCount":101},[],{"trials":14859,"activeCount":101},[],{"intervention":14861,"totalTrials":350,"cells":14862},"RO7121932 IV",{"EARLY_PHASE1":14863,"PHASE1":14865,"PHASE2":14877,"PHASE3":14879,"PHASE4":14881,"NA":14883},{"trials":14864,"activeCount":101},[],{"trials":14866,"activeCount":350,"soonestReadout":14871},[14867],{"nctId":14868,"briefTitle":14869,"status":152,"phases":14870,"primaryCompletion":14871,"completion":14871,"start":14872,"enrollment":14873,"conditions":14874,"interventions":14875},"NCT05704361","A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis",[89],"2027-07-08","2021-08-11",129,[147],[14861,14876],"RO7121932 SC",{"trials":14878,"activeCount":101},[],{"trials":14880,"activeCount":101},[],{"trials":14882,"activeCount":101},[],{"trials":14884,"activeCount":101},[],{"intervention":14876,"totalTrials":350,"cells":14886},{"EARLY_PHASE1":14887,"PHASE1":14889,"PHASE2":14895,"PHASE3":14897,"PHASE4":14899,"NA":14901},{"trials":14888,"activeCount":101},[],{"trials":14890,"activeCount":350,"soonestReadout":14871},[14891],{"nctId":14868,"briefTitle":14869,"status":152,"phases":14892,"primaryCompletion":14871,"completion":14871,"start":14872,"enrollment":14873,"conditions":14893,"interventions":14894},[89],[147],[14861,14876],{"trials":14896,"activeCount":101},[],{"trials":14898,"activeCount":101},[],{"trials":14900,"activeCount":101},[],{"trials":14902,"activeCount":101},[],{"intervention":14904,"totalTrials":350,"cells":14905},"RO7763505",{"EARLY_PHASE1":14906,"PHASE1":14908,"PHASE2":14920,"PHASE3":14922,"PHASE4":14924,"NA":14926},{"trials":14907,"activeCount":101},[],{"trials":14909,"activeCount":350,"soonestReadout":14914},[14910],{"nctId":14911,"briefTitle":14912,"status":152,"phases":14913,"primaryCompletion":14914,"completion":14914,"start":14915,"enrollment":14916,"conditions":14917,"interventions":14919},"NCT07495813","A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease",[89],"2028-02-15","2026-03-31",196,[14918,427],"Stable Coronary Artery Disease",[14904],{"trials":14921,"activeCount":101},[],{"trials":14923,"activeCount":101},[],{"trials":14925,"activeCount":101},[],{"trials":14927,"activeCount":101},[],{"intervention":12902,"totalTrials":350,"cells":14929},{"EARLY_PHASE1":14930,"PHASE1":14932,"PHASE2":14938,"PHASE3":14940,"PHASE4":14942,"NA":14944},{"trials":14931,"activeCount":101},[],{"trials":14933,"activeCount":350,"soonestReadout":843},[14934],{"nctId":12896,"briefTitle":12897,"status":152,"phases":14935,"primaryCompletion":843,"completion":843,"start":12899,"enrollment":931,"conditions":14936,"interventions":14937},[89],[9441,9440],[12889,12902,12903],{"trials":14939,"activeCount":101},[],{"trials":14941,"activeCount":101},[],{"trials":14943,"activeCount":101},[],{"trials":14945,"activeCount":101},[],{"intervention":2465,"totalTrials":350,"cells":14947},{"EARLY_PHASE1":14948,"PHASE1":14950,"PHASE2":14956,"PHASE3":14958,"PHASE4":14960,"NA":14962},{"trials":14949,"activeCount":101},[],{"trials":14951,"activeCount":350,"soonestReadout":2460},[14952],{"nctId":2457,"briefTitle":2458,"status":152,"phases":14953,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":14954,"interventions":14955},[89],[2392],[2465,2466,2467,2468,1018,1096],{"trials":14957,"activeCount":101},[],{"trials":14959,"activeCount":101},[],{"trials":14961,"activeCount":101},[],{"trials":14963,"activeCount":101},[],{"intervention":2466,"totalTrials":350,"cells":14965},{"EARLY_PHASE1":14966,"PHASE1":14968,"PHASE2":14974,"PHASE3":14976,"PHASE4":14978,"NA":14980},{"trials":14967,"activeCount":101},[],{"trials":14969,"activeCount":350,"soonestReadout":2460},[14970],{"nctId":2457,"briefTitle":2458,"status":152,"phases":14971,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":14972,"interventions":14973},[89],[2392],[2465,2466,2467,2468,1018,1096],{"trials":14975,"activeCount":101},[],{"trials":14977,"activeCount":101},[],{"trials":14979,"activeCount":101},[],{"trials":14981,"activeCount":101},[],{"intervention":2468,"totalTrials":350,"cells":14983},{"EARLY_PHASE1":14984,"PHASE1":14986,"PHASE2":14992,"PHASE3":14994,"PHASE4":14996,"NA":14998},{"trials":14985,"activeCount":101},[],{"trials":14987,"activeCount":350,"soonestReadout":2460},[14988],{"nctId":2457,"briefTitle":2458,"status":152,"phases":14989,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":14990,"interventions":14991},[89],[2392],[2465,2466,2467,2468,1018,1096],{"trials":14993,"activeCount":101},[],{"trials":14995,"activeCount":101},[],{"trials":14997,"activeCount":101},[],{"trials":14999,"activeCount":101},[],{"intervention":15001,"totalTrials":350,"cells":15002},"SPLIT Abs",{"EARLY_PHASE1":15003,"PHASE1":15005,"PHASE2":15017,"PHASE3":15019,"PHASE4":15021,"NA":15023},{"trials":15004,"activeCount":101},[],{"trials":15006,"activeCount":350,"soonestReadout":15011},[15007],{"nctId":15008,"briefTitle":15009,"status":152,"phases":15010,"primaryCompletion":15011,"completion":15011,"start":15012,"enrollment":11722,"conditions":15013,"interventions":15014},"NCT07416552","A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)",[89],"2034-02-12","2026-05-12",[1135],[15001,15015,15016],"203Pb-DOTAM","212Pb-DOTAM",{"trials":15018,"activeCount":101},[],{"trials":15020,"activeCount":101},[],{"trials":15022,"activeCount":101},[],{"trials":15024,"activeCount":101},[],{"intervention":15015,"totalTrials":350,"cells":15026},{"EARLY_PHASE1":15027,"PHASE1":15029,"PHASE2":15035,"PHASE3":15037,"PHASE4":15039,"NA":15041},{"trials":15028,"activeCount":101},[],{"trials":15030,"activeCount":350,"soonestReadout":15011},[15031],{"nctId":15008,"briefTitle":15009,"status":152,"phases":15032,"primaryCompletion":15011,"completion":15011,"start":15012,"enrollment":11722,"conditions":15033,"interventions":15034},[89],[1135],[15001,15015,15016],{"trials":15036,"activeCount":101},[],{"trials":15038,"activeCount":101},[],{"trials":15040,"activeCount":101},[],{"trials":15042,"activeCount":101},[],{"intervention":15016,"totalTrials":350,"cells":15044},{"EARLY_PHASE1":15045,"PHASE1":15047,"PHASE2":15053,"PHASE3":15055,"PHASE4":15057,"NA":15059},{"trials":15046,"activeCount":101},[],{"trials":15048,"activeCount":350,"soonestReadout":15011},[15049],{"nctId":15008,"briefTitle":15009,"status":152,"phases":15050,"primaryCompletion":15011,"completion":15011,"start":15012,"enrollment":11722,"conditions":15051,"interventions":15052},[89],[1135],[15001,15015,15016],{"trials":15054,"activeCount":101},[],{"trials":15056,"activeCount":101},[],{"trials":15058,"activeCount":101},[],{"trials":15060,"activeCount":101},[],{"intervention":1139,"totalTrials":350,"cells":15062},{"EARLY_PHASE1":15063,"PHASE1":15065,"PHASE2":15071,"PHASE3":15073,"PHASE4":15075,"NA":15077},{"trials":15064,"activeCount":101},[],{"trials":15066,"activeCount":350,"soonestReadout":1131},[15067],{"nctId":1128,"briefTitle":1129,"status":152,"phases":15068,"primaryCompletion":1131,"completion":1131,"start":1132,"enrollment":1133,"conditions":15069,"interventions":15070},[89],[1135],[1137,1015,1138,68,988,1139,1140,1141,1142],{"trials":15072,"activeCount":101},[],{"trials":15074,"activeCount":101},[],{"trials":15076,"activeCount":101},[],{"trials":15078,"activeCount":101},[],{"intervention":15080,"totalTrials":350,"cells":15081},"RG6496",{"EARLY_PHASE1":15082,"PHASE1":15084,"PHASE2":15095,"PHASE3":15097,"PHASE4":15099,"NA":15101},{"trials":15083,"activeCount":101},[],{"trials":15085,"activeCount":350,"soonestReadout":1413},[15086],{"nctId":15087,"briefTitle":15088,"status":152,"phases":15089,"primaryCompletion":1413,"completion":15090,"start":15091,"enrollment":931,"conditions":15092,"interventions":15094},"NCT07246941","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease",[89],"2029-05-23","2025-11-19",[15093],"Huntington's Disease",[15080],{"trials":15096,"activeCount":101},[],{"trials":15098,"activeCount":101},[],{"trials":15100,"activeCount":101},[],{"trials":15102,"activeCount":101},[],{"intervention":15104,"totalTrials":350,"cells":15105},"RO7567132 and Atezolizumab",{"EARLY_PHASE1":15106,"PHASE1":15108,"PHASE2":15120,"PHASE3":15122,"PHASE4":15124,"NA":15126},{"trials":15107,"activeCount":101},[],{"trials":15109,"activeCount":350,"soonestReadout":15114},[15110],{"nctId":15111,"briefTitle":15112,"status":140,"phases":15113,"primaryCompletion":15114,"completion":15115,"start":15116,"enrollment":1705,"conditions":15117,"interventions":15119},"NCT06537310","A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors",[89],"2027-05-12","2027-08-10","2024-09-16",[15118],"Cancer-Neoplasms",[15104,15104],{"trials":15121,"activeCount":101},[],{"trials":15123,"activeCount":101},[],{"trials":15125,"activeCount":101},[],{"trials":15127,"activeCount":101},[],{"intervention":15129,"totalTrials":350,"cells":15130},"RO7806881",{"EARLY_PHASE1":15131,"PHASE1":15133,"PHASE2":15142,"PHASE3":15144,"PHASE4":15146,"NA":15148},{"trials":15132,"activeCount":101},[],{"trials":15134,"activeCount":350,"soonestReadout":15139},[15135],{"nctId":15136,"briefTitle":15137,"status":152,"phases":15138,"primaryCompletion":15139,"completion":15139,"start":1534,"enrollment":4573,"conditions":15140,"interventions":15141},"NCT07271693","A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants",[89],"2027-03-01",[427],[15129],{"trials":15143,"activeCount":101},[],{"trials":15145,"activeCount":101},[],{"trials":15147,"activeCount":101},[],{"trials":15149,"activeCount":101},[],{"intervention":15151,"totalTrials":350,"cells":15152},"RO7673396",{"EARLY_PHASE1":15153,"PHASE1":15155,"PHASE2":15165,"PHASE3":15167,"PHASE4":15169,"NA":15171},{"trials":15154,"activeCount":101},[],{"trials":15156,"activeCount":350,"soonestReadout":268},[15157],{"nctId":15158,"briefTitle":15159,"status":152,"phases":15160,"primaryCompletion":268,"completion":15161,"start":5000,"enrollment":15162,"conditions":15163,"interventions":15164},"NCT06884618","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)",[89],"2029-05-25",405,[1241],[15151],{"trials":15166,"activeCount":101},[],{"trials":15168,"activeCount":101},[],{"trials":15170,"activeCount":101},[],{"trials":15172,"activeCount":101},[],{"intervention":15174,"totalTrials":350,"cells":15175},"RO7669330",{"EARLY_PHASE1":15176,"PHASE1":15178,"PHASE2":15192,"PHASE3":15194,"PHASE4":15196,"NA":15198},{"trials":15177,"activeCount":101},[],{"trials":15179,"activeCount":350,"soonestReadout":15184},[15180],{"nctId":15181,"briefTitle":15182,"status":140,"phases":15183,"primaryCompletion":15184,"completion":15184,"start":15185,"enrollment":11473,"conditions":15186,"interventions":15189},"NCT06961370","A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)",[89],"2027-01-03","2025-07-16",[15187,15188],"Geographic Atrophy","Age-related Macular Degeneration",[15174,15190,15191],"Syfovre™","Izervay™",{"trials":15193,"activeCount":101},[],{"trials":15195,"activeCount":101},[],{"trials":15197,"activeCount":101},[],{"trials":15199,"activeCount":101},[],{"intervention":15190,"totalTrials":350,"cells":15201},{"EARLY_PHASE1":15202,"PHASE1":15204,"PHASE2":15210,"PHASE3":15212,"PHASE4":15214,"NA":15216},{"trials":15203,"activeCount":101},[],{"trials":15205,"activeCount":350,"soonestReadout":15184},[15206],{"nctId":15181,"briefTitle":15182,"status":140,"phases":15207,"primaryCompletion":15184,"completion":15184,"start":15185,"enrollment":11473,"conditions":15208,"interventions":15209},[89],[15187,15188],[15174,15190,15191],{"trials":15211,"activeCount":101},[],{"trials":15213,"activeCount":101},[],{"trials":15215,"activeCount":101},[],{"trials":15217,"activeCount":101},[],{"intervention":15191,"totalTrials":350,"cells":15219},{"EARLY_PHASE1":15220,"PHASE1":15222,"PHASE2":15228,"PHASE3":15230,"PHASE4":15232,"NA":15234},{"trials":15221,"activeCount":101},[],{"trials":15223,"activeCount":350,"soonestReadout":15184},[15224],{"nctId":15181,"briefTitle":15182,"status":140,"phases":15225,"primaryCompletion":15184,"completion":15184,"start":15185,"enrollment":11473,"conditions":15226,"interventions":15227},[89],[15187,15188],[15174,15190,15191],{"trials":15229,"activeCount":101},[],{"trials":15231,"activeCount":101},[],{"trials":15233,"activeCount":101},[],{"trials":15235,"activeCount":101},[],{"intervention":2630,"totalTrials":350,"cells":15237},{"EARLY_PHASE1":15238,"PHASE1":15240,"PHASE2":15246,"PHASE3":15248,"PHASE4":15250,"NA":15252},{"trials":15239,"activeCount":101},[],{"trials":15241,"activeCount":350,"soonestReadout":678},[15242],{"nctId":2624,"briefTitle":2625,"status":152,"phases":15243,"primaryCompletion":678,"completion":678,"start":2627,"enrollment":31,"conditions":15244,"interventions":15245},[89],[2621],[2630,1096],{"trials":15247,"activeCount":101},[],{"trials":15249,"activeCount":101},[],{"trials":15251,"activeCount":101},[],{"trials":15253,"activeCount":101},[],{"intervention":15255,"totalTrials":350,"cells":15256},"RO7790121",{"EARLY_PHASE1":15257,"PHASE1":15259,"PHASE2":15269,"PHASE3":15271,"PHASE4":15273,"NA":15275},{"trials":15258,"activeCount":101},[],{"trials":15260,"activeCount":350,"soonestReadout":2754},[15261],{"nctId":15262,"briefTitle":15263,"status":140,"phases":15264,"primaryCompletion":2754,"completion":7769,"start":15265,"enrollment":37,"conditions":15266,"interventions":15268},"NCT06903065","A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis",[89],"2025-04-14",[15267],"MASH",[15255],{"trials":15270,"activeCount":101},[],{"trials":15272,"activeCount":101},[],{"trials":15274,"activeCount":101},[],{"trials":15276,"activeCount":101},[],{"intervention":685,"totalTrials":350,"cells":15278},{"EARLY_PHASE1":15279,"PHASE1":15281,"PHASE2":15283,"PHASE3":15285,"PHASE4":15287,"NA":15289},{"trials":15280,"activeCount":101},[],{"trials":15282,"activeCount":101},[],{"trials":15284,"activeCount":101},[],{"trials":15286,"activeCount":101},[],{"trials":15288,"activeCount":101},[],{"trials":15290,"activeCount":350,"soonestReadout":460},[15291],{"nctId":675,"briefTitle":676,"status":140,"phases":15292,"primaryCompletion":460,"completion":678,"start":679,"enrollment":680,"conditions":15293,"interventions":15294},[],[647,551,682,618,597,683],[509,685],{"intervention":15296,"totalTrials":350,"cells":15297},"Von Willebrand Factor Concentrates",{"EARLY_PHASE1":15298,"PHASE1":15300,"PHASE2":15302,"PHASE3":15304,"PHASE4":15306,"NA":15308},{"trials":15299,"activeCount":101},[],{"trials":15301,"activeCount":101},[],{"trials":15303,"activeCount":101},[],{"trials":15305,"activeCount":101},[],{"trials":15307,"activeCount":101},[],{"trials":15309,"activeCount":350,"soonestReadout":15314},[15310],{"nctId":15311,"briefTitle":15312,"status":152,"phases":15313,"primaryCompletion":15314,"completion":15314,"start":15315,"enrollment":931,"conditions":15316,"interventions":15317},"NCT06883240","An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment",[],"2026-11-01","2025-04-29",[819],[15296,15318,15319,15320,15321],"Von Willebrand Factor Concentrates and Factor VIII Concentrates","Factor VIII Concentrates","Recombinant Activated Factor VII","Activated Prothrombin Complex Concentrate",{"intervention":15318,"totalTrials":350,"cells":15323},{"EARLY_PHASE1":15324,"PHASE1":15326,"PHASE2":15328,"PHASE3":15330,"PHASE4":15332,"NA":15334},{"trials":15325,"activeCount":101},[],{"trials":15327,"activeCount":101},[],{"trials":15329,"activeCount":101},[],{"trials":15331,"activeCount":101},[],{"trials":15333,"activeCount":101},[],{"trials":15335,"activeCount":350,"soonestReadout":15314},[15336],{"nctId":15311,"briefTitle":15312,"status":152,"phases":15337,"primaryCompletion":15314,"completion":15314,"start":15315,"enrollment":931,"conditions":15338,"interventions":15339},[],[819],[15296,15318,15319,15320,15321],{"intervention":15319,"totalTrials":350,"cells":15341},{"EARLY_PHASE1":15342,"PHASE1":15344,"PHASE2":15346,"PHASE3":15348,"PHASE4":15350,"NA":15352},{"trials":15343,"activeCount":101},[],{"trials":15345,"activeCount":101},[],{"trials":15347,"activeCount":101},[],{"trials":15349,"activeCount":101},[],{"trials":15351,"activeCount":101},[],{"trials":15353,"activeCount":350,"soonestReadout":15314},[15354],{"nctId":15311,"briefTitle":15312,"status":152,"phases":15355,"primaryCompletion":15314,"completion":15314,"start":15315,"enrollment":931,"conditions":15356,"interventions":15357},[],[819],[15296,15318,15319,15320,15321],{"intervention":15320,"totalTrials":350,"cells":15359},{"EARLY_PHASE1":15360,"PHASE1":15362,"PHASE2":15364,"PHASE3":15366,"PHASE4":15368,"NA":15370},{"trials":15361,"activeCount":101},[],{"trials":15363,"activeCount":101},[],{"trials":15365,"activeCount":101},[],{"trials":15367,"activeCount":101},[],{"trials":15369,"activeCount":101},[],{"trials":15371,"activeCount":350,"soonestReadout":15314},[15372],{"nctId":15311,"briefTitle":15312,"status":152,"phases":15373,"primaryCompletion":15314,"completion":15314,"start":15315,"enrollment":931,"conditions":15374,"interventions":15375},[],[819],[15296,15318,15319,15320,15321],{"intervention":15321,"totalTrials":350,"cells":15377},{"EARLY_PHASE1":15378,"PHASE1":15380,"PHASE2":15382,"PHASE3":15384,"PHASE4":15386,"NA":15388},{"trials":15379,"activeCount":101},[],{"trials":15381,"activeCount":101},[],{"trials":15383,"activeCount":101},[],{"trials":15385,"activeCount":101},[],{"trials":15387,"activeCount":101},[],{"trials":15389,"activeCount":350,"soonestReadout":15314},[15390],{"nctId":15311,"briefTitle":15312,"status":152,"phases":15391,"primaryCompletion":15314,"completion":15314,"start":15315,"enrollment":931,"conditions":15392,"interventions":15393},[],[819],[15296,15318,15319,15320,15321],{"intervention":2342,"totalTrials":350,"cells":15395},{"EARLY_PHASE1":15396,"PHASE1":15398,"PHASE2":15400,"PHASE3":15402,"PHASE4":15404,"NA":15406},{"trials":15397,"activeCount":101},[],{"trials":15399,"activeCount":101},[],{"trials":15401,"activeCount":101},[],{"trials":15403,"activeCount":101},[],{"trials":15405,"activeCount":101},[],{"trials":15407,"activeCount":350,"soonestReadout":2025},[15408],{"nctId":2335,"briefTitle":2336,"status":140,"phases":15409,"primaryCompletion":2025,"completion":2025,"start":2338,"enrollment":2339,"conditions":15410,"interventions":15411},[],[18],[1015,1222,2342,1221,68,1166],{"intervention":5894,"totalTrials":973,"cells":15413},{"EARLY_PHASE1":15414,"PHASE1":15416,"PHASE2":15439,"PHASE3":15453,"PHASE4":15689,"NA":15774},{"trials":15415,"activeCount":101},[],{"trials":15417,"activeCount":101},[15418,15425,15432],{"nctId":15419,"briefTitle":15420,"status":107,"phases":15421,"completion":4582,"enrollment":145,"conditions":15422,"interventions":15423},"NCT00365001","A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.",[89],[15],[5894,2824,15424],"Simvastatin",{"nctId":15426,"briefTitle":15427,"status":107,"phases":15428,"completion":4314,"start":5271,"enrollment":1174,"conditions":15429,"interventions":15430},"NCT00965653","A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis",[89],[15],[15431,5838,5894,5894],"folic acid",{"nctId":15433,"briefTitle":15434,"status":107,"phases":15435,"primaryCompletion":2685,"completion":2685,"start":5457,"enrollment":706,"conditions":15436,"interventions":15438},"NCT01183598","A Study to Provide RoActemra\u002FActemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra\u002FActemra Treatment",[89],[15437],"Castleman's Disease",[5894],{"trials":15440,"activeCount":101},[15441,15447],{"nctId":15442,"briefTitle":15443,"status":130,"phases":15444,"primaryCompletion":3674,"completion":3674,"start":3325,"enrollment":425,"conditions":15445,"interventions":15446},"NCT00845832","A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate",[90],[15],[5837,5894],{"nctId":15448,"briefTitle":15449,"status":107,"phases":15450,"primaryCompletion":4474,"completion":4474,"start":9596,"enrollment":537,"conditions":15451,"interventions":15452},"NCT00887341","A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis",[90],[15],[5894,5894],{"trials":15454,"activeCount":101},[15455,15462,15469,15478,15485,15491,15497,15503,15509,15516,15523,15529,15537,15543,15551,15557,15565,15572,15579,15586,15593,15600,15606,15613,15620,15626,15635,15642,15648,15655,15664,15670,15676,15683],{"nctId":15456,"briefTitle":15457,"status":107,"phases":15458,"primaryCompletion":4314,"completion":4314,"start":4113,"enrollment":15459,"conditions":15460,"interventions":15461},"NCT00750880","An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and\u002For Anti-TNF Therapy.",[91],1681,[15],[5894],{"nctId":15463,"briefTitle":15464,"status":107,"phases":15465,"primaryCompletion":5820,"completion":5820,"start":122,"enrollment":15466,"conditions":15467,"interventions":15468},"NCT00106522","A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy",[91],499,[15],[2824,5894,5894],{"nctId":15470,"briefTitle":15471,"status":107,"phases":15472,"primaryCompletion":15473,"completion":15473,"start":15474,"enrollment":15475,"conditions":15476,"interventions":15477},"NCT01063062","A Study With Tocilizumab [RoActemra\u002FActemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)",[91],"2011-01-17","2010-02-28",107,[15],[5894,2824],{"nctId":15479,"briefTitle":15480,"status":107,"phases":15481,"primaryCompletion":2793,"completion":2793,"start":3325,"enrollment":15482,"conditions":15483,"interventions":15484},"NCT00883753","An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and\u002For Anti-tumor Necrosis Factor (TNF) Therapy",[91],934,[15],[5894],{"nctId":15486,"briefTitle":15487,"status":107,"phases":15488,"primaryCompletion":2947,"completion":2947,"start":2809,"enrollment":372,"conditions":15489,"interventions":15490},"NCT01730456","A Long-Term Extension Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926",[91],[15],[5894],{"nctId":15492,"briefTitle":15493,"status":107,"phases":15494,"primaryCompletion":3246,"completion":3246,"start":3189,"enrollment":2694,"conditions":15495,"interventions":15496},"NCT01245439","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis",[91],[15],[5894],{"nctId":15498,"briefTitle":15499,"status":107,"phases":15500,"primaryCompletion":4682,"completion":4682,"start":2768,"enrollment":1080,"conditions":15501,"interventions":15502},"NCT01587989","A Study of RoActemra\u002FActemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate",[91],[15],[5838,5838,5894],{"nctId":15504,"briefTitle":15505,"status":107,"phases":15506,"primaryCompletion":3007,"completion":3007,"start":2964,"enrollment":6013,"conditions":15507,"interventions":15508},"NCT01353859","A Study of RoActemra\u002FActemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs",[91],[15],[5894,5838],{"nctId":15510,"briefTitle":15511,"status":107,"phases":15512,"primaryCompletion":6620,"completion":3007,"start":8689,"enrollment":15513,"conditions":15514,"interventions":15515},"NCT00106535","A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)",[91],1196,[15],[5894,2824],{"nctId":15517,"briefTitle":15518,"status":107,"phases":15519,"primaryCompletion":7152,"completion":4249,"start":3325,"enrollment":15520,"conditions":15521,"interventions":15522},"NCT00810199","A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment",[91],556,[15],[5894,5838],{"nctId":15524,"briefTitle":15525,"status":107,"phases":15526,"primaryCompletion":2948,"completion":2948,"start":4233,"enrollment":3286,"conditions":15527,"interventions":15528},"NCT01235507","A Study of RoActemra\u002FActemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)",[91],[15],[5838,5894],{"nctId":15530,"briefTitle":15531,"status":107,"phases":15532,"primaryCompletion":15533,"completion":15533,"start":15534,"enrollment":13060,"conditions":15535,"interventions":15536},"NCT00810277","A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs",[91],"2010-05-26","2008-11-30",[15],[5894],{"nctId":15538,"briefTitle":15539,"status":107,"phases":15540,"primaryCompletion":3478,"completion":3478,"start":3674,"enrollment":2563,"conditions":15541,"interventions":15542},"NCT01727986","An Extension Long-Term Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study",[91],[2367],[5894],{"nctId":15544,"briefTitle":15545,"status":107,"phases":15546,"primaryCompletion":7095,"completion":2964,"start":9596,"enrollment":15547,"conditions":15548,"interventions":15549},"NCT00891020","A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)",[91],886,[15],[5894,5894,15550],"Nonbiologic DMARDs of investigator's choice",{"nctId":15552,"briefTitle":15553,"status":107,"phases":15554,"primaryCompletion":9079,"completion":9079,"start":4555,"enrollment":2462,"conditions":15555,"interventions":15556},"NCT01610791","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)",[91],[15],[5894],{"nctId":15558,"briefTitle":15559,"status":107,"phases":15560,"primaryCompletion":15561,"completion":15561,"start":15562,"enrollment":1174,"conditions":15563,"interventions":15564},"NCT00848120","A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis",[91],"2010-02-13","2008-12-31",[15],[5894],{"nctId":15566,"briefTitle":15567,"status":107,"phases":15568,"primaryCompletion":2830,"completion":2955,"start":3175,"enrollment":1296,"conditions":15569,"interventions":15571},"NCT01532869","A Study of RoActemra\u002FActemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis",[91],[15570],"Sclerosis, Systemic",[5894,5894],{"nctId":15573,"briefTitle":15574,"status":107,"phases":15575,"primaryCompletion":4682,"completion":4682,"start":2964,"enrollment":15576,"conditions":15577,"interventions":15578},"NCT01332994","A Study of RoActemra\u002FActemra and, if Initially Inadequately Responded to RoActemra\u002FActemra, Followed by MabThera\u002FRituxan in Patients With Rheumatoid Arthritis",[91],519,[15],[5837,5894,5894],{"nctId":15580,"briefTitle":15581,"status":107,"phases":15582,"primaryCompletion":15583,"completion":15583,"start":5364,"enrollment":9462,"conditions":15584,"interventions":15585},"NCT02011334","A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra\u002FActemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.",[91],"2016-10",[15],[5894],{"nctId":15587,"briefTitle":15588,"status":107,"phases":15589,"primaryCompletion":6004,"completion":3246,"start":4281,"enrollment":15590,"conditions":15591,"interventions":15592},"NCT00642460","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)",[91],112,[2367],[5894,3035,5838,14484],{"nctId":15594,"briefTitle":15595,"status":107,"phases":15596,"primaryCompletion":4513,"completion":4513,"start":11300,"enrollment":15597,"conditions":15598,"interventions":15599},"NCT00106574","A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],1220,[15],[5894],{"nctId":15601,"briefTitle":15602,"status":107,"phases":15603,"primaryCompletion":6157,"completion":6157,"start":3103,"enrollment":942,"conditions":15604,"interventions":15605},"NCT01667471","A Long-Term Extension Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study",[91],[2367],[5894],{"nctId":15607,"briefTitle":15608,"status":107,"phases":15609,"primaryCompletion":2792,"completion":5417,"start":2684,"enrollment":7923,"conditions":15610,"interventions":15611},"NCT01995201","A Study of Subcutaneous RoActemra\u002FActemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis",[91],[15],[15612,5838,5894,5894,5894],"DMARD",{"nctId":15614,"briefTitle":15615,"status":107,"phases":15616,"primaryCompletion":4513,"completion":4513,"start":4323,"enrollment":15617,"conditions":15618,"interventions":15619},"NCT00109408","A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis",[91],673,[15],[2824,5894],{"nctId":15621,"briefTitle":15622,"status":107,"phases":15623,"primaryCompletion":2830,"completion":2830,"start":2768,"enrollment":4548,"conditions":15624,"interventions":15625},"NCT01673919","A Long-Term Extension Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study",[91],[2367],[5894],{"nctId":15627,"briefTitle":15628,"status":107,"phases":15629,"primaryCompletion":15630,"completion":15630,"start":2975,"enrollment":15631,"conditions":15632,"interventions":15633},"NCT00951275","A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],"2011-07-22",105,[15],[5894,15634],"Standard DMARDs",{"nctId":15636,"briefTitle":15637,"status":107,"phases":15638,"primaryCompletion":3182,"completion":3182,"start":4206,"enrollment":15639,"conditions":15640,"interventions":15641},"NCT01034137","A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis",[91],317,[15],[5838,5894],{"nctId":15643,"briefTitle":15644,"status":107,"phases":15645,"primaryCompletion":3324,"completion":3324,"start":3007,"enrollment":709,"conditions":15646,"interventions":15647},"NCT01649804","A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis",[91],[15],[5894],{"nctId":15649,"briefTitle":15650,"status":107,"phases":15651,"primaryCompletion":15652,"completion":15652,"start":2914,"enrollment":496,"conditions":15653,"interventions":15654},"NCT01326962","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF",[91],"2013-05-12",[15],[5894],{"nctId":15656,"briefTitle":15657,"status":107,"phases":15658,"primaryCompletion":15659,"completion":15659,"start":15660,"enrollment":15661,"conditions":15662,"interventions":15663},"NCT00773461","A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.",[91],"2010-07-22","2008-10-31",209,[15],[5894],{"nctId":15665,"briefTitle":15666,"status":107,"phases":15667,"primaryCompletion":2931,"completion":2931,"start":2906,"enrollment":1184,"conditions":15668,"interventions":15669},"NCT01214733","A Study of RoActemra\u002FActemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis",[91],[15],[5894],{"nctId":15671,"briefTitle":15672,"status":107,"phases":15673,"primaryCompletion":6315,"completion":6315,"start":2963,"enrollment":6344,"conditions":15674,"interventions":15675},"NCT00977106","TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF",[91],[15],[5894,5894],{"nctId":15677,"briefTitle":15678,"status":107,"phases":15679,"completion":2965,"enrollment":15680,"conditions":15681,"interventions":15682},"NCT00106548","A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],623,[15],[5894,5894,2824],{"nctId":15684,"briefTitle":15685,"status":107,"phases":15686,"primaryCompletion":2809,"completion":2809,"start":3479,"enrollment":9685,"conditions":15687,"interventions":15688},"NCT00754572","A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],[15],[5894,5838],{"trials":15690,"activeCount":101},[15691,15700,15706,15712,15716,15723,15729,15736,15743,15749,15755,15761,15768],{"nctId":15692,"briefTitle":15693,"status":130,"phases":15694,"primaryCompletion":15695,"completion":15695,"start":2931,"enrollment":1036,"conditions":15696,"interventions":15697},"NCT01283971","A Study of RoActemra\u002FActemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor",[92],"2012-08",[15],[5894,15698,5838,15699],"adalimumab","folate",{"nctId":15701,"briefTitle":15702,"status":107,"phases":15703,"primaryCompletion":5364,"completion":5364,"start":2906,"enrollment":14683,"conditions":15704,"interventions":15705},"NCT01149057","A Study of RoActemra\u002FActemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and\u002For Biologic DMARDS",[92],[15],[5894],{"nctId":15707,"briefTitle":15708,"status":107,"phases":15709,"primaryCompletion":3175,"completion":3175,"start":7152,"enrollment":3939,"conditions":15710,"interventions":15711},"NCT01195272","A Study of the Effects of RoActemra\u002FActemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and\u002For Non-biologic DMARDs.",[92],[15],[5894],{"nctId":5888,"briefTitle":5889,"status":107,"phases":15713,"primaryCompletion":3674,"completion":3674,"start":5891,"enrollment":4683,"conditions":15714,"interventions":15715},[92],[15],[5839,5894],{"nctId":15717,"briefTitle":15718,"status":107,"phases":15719,"primaryCompletion":3189,"completion":3189,"start":4555,"enrollment":3574,"conditions":15720,"interventions":15721},"NCT01034397","A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs",[92],[15],[5894,15722],"non-biological DMARDs",{"nctId":15724,"briefTitle":15725,"status":343,"phases":15726,"primaryCompletion":2800,"completion":2800,"start":10332,"enrollment":101,"conditions":15727,"interventions":15728},"NCT01878318","A Study of The Effect of RoActemra\u002FActemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs",[92],[15],[5838,5894],{"nctId":15730,"briefTitle":15731,"status":107,"phases":15732,"primaryCompletion":15733,"completion":15733,"start":2975,"enrollment":4713,"conditions":15734,"interventions":15735},"NCT00996203","A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.",[92],"2011-02-14",[15],[5894,2870],{"nctId":15737,"briefTitle":15738,"status":107,"phases":15739,"primaryCompletion":3324,"completion":3324,"start":15740,"enrollment":5901,"conditions":15741,"interventions":15742},"NCT01991990","A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra\u002FActemra (Tocilizumab) in Healthy Volunteers",[92],"2014-05",[21],[5894],{"nctId":15744,"briefTitle":15745,"status":107,"phases":15746,"primaryCompletion":7095,"completion":7095,"start":4555,"enrollment":145,"conditions":15747,"interventions":15748},"NCT02010216","A Study of RoActemra\u002FActemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)",[92],[15],[5894],{"nctId":15750,"briefTitle":15751,"status":107,"phases":15752,"primaryCompletion":2905,"completion":2905,"start":4206,"enrollment":4021,"conditions":15753,"interventions":15754},"NCT01089023","A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis",[92],[15],[5894],{"nctId":15756,"briefTitle":15757,"status":130,"phases":15758,"primaryCompletion":4249,"completion":4249,"start":2685,"enrollment":162,"conditions":15759,"interventions":15760},"NCT01251120","A Study of RoActemra\u002FActemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis",[92],[15],[5894,15612],{"nctId":15762,"briefTitle":15763,"status":107,"phases":15764,"primaryCompletion":15740,"completion":15740,"start":3189,"enrollment":15765,"conditions":15766,"interventions":15767},"NCT01399697","A Study of RoActemra\u002FActemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra\u002FActemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate",[92],261,[15],[5838,5838,5894],{"nctId":15769,"briefTitle":15770,"status":107,"phases":15771,"primaryCompletion":3104,"completion":3104,"start":2963,"enrollment":8206,"conditions":15772,"interventions":15773},"NCT01010503","A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.",[92],[15],[5894],{"trials":15775,"activeCount":101},[],{"intervention":5381,"totalTrials":8206,"cells":15777},{"EARLY_PHASE1":15778,"PHASE1":15780,"PHASE2":15812,"PHASE3":15918,"PHASE4":15955,"NA":15970},{"trials":15779,"activeCount":101},[],{"trials":15781,"activeCount":101},[15782,15788,15795,15804,15808],{"nctId":15783,"briefTitle":15784,"status":107,"phases":15785,"primaryCompletion":3212,"completion":3212,"start":3308,"enrollment":8206,"conditions":15786,"interventions":15787},"NCT00925769","ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and\u002For Metastatic Pancreatic Cancer",[89],[6622],[5275,5381,5384],{"nctId":15789,"briefTitle":15790,"status":107,"phases":15791,"primaryCompletion":2906,"completion":2906,"start":6620,"enrollment":425,"conditions":15792,"interventions":15794},"NCT00532948","A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas",[89],[15793],"Glioma",[5381],{"nctId":15796,"briefTitle":15797,"status":107,"phases":15798,"primaryCompletion":2809,"completion":2809,"start":2801,"enrollment":15799,"conditions":15800,"interventions":15802},"NCT01493336","A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours",[89],37,[15801],"Breast Cancer, Colorectal Cancer",[15803,5381,5381],"capecitabine RTD",{"nctId":8888,"briefTitle":8889,"status":107,"phases":15805,"primaryCompletion":6277,"completion":4582,"start":4323,"enrollment":1058,"conditions":15806,"interventions":15807},[89],[30],[8893,1165,5381],{"nctId":5373,"briefTitle":5374,"status":130,"phases":15809,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":15810,"interventions":15811},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":15813,"activeCount":101},[15814,15821,15827,15833,15839,15845,15851,15855,15864,15868,15872,15876,15882,15889,15893,15897,15901,15905,15910,15914],{"nctId":15815,"briefTitle":15816,"status":107,"phases":15817,"primaryCompletion":8826,"completion":8826,"start":8658,"enrollment":2743,"conditions":15818,"interventions":15819},"NCT01135498","A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.",[90],[30],[5275,15820,5381,5384],"eloxatin",{"nctId":15822,"briefTitle":15823,"status":107,"phases":15824,"primaryCompletion":4474,"completion":4474,"start":4206,"enrollment":706,"conditions":15825,"interventions":15826},"NCT01077726","A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression",[90],[18],[5381],{"nctId":15828,"briefTitle":15829,"status":130,"phases":15830,"primaryCompletion":2948,"completion":2948,"start":2905,"enrollment":5110,"conditions":15831,"interventions":15832},"NCT01290718","A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.",[90],[18],[5381,5390],{"nctId":15834,"briefTitle":15835,"status":107,"phases":15836,"primaryCompletion":2847,"completion":2847,"start":4562,"enrollment":736,"conditions":15837,"interventions":15838},"NCT00811135","A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer",[90],[18],[5275,5381,5390],{"nctId":15840,"briefTitle":15841,"status":107,"phases":15842,"primaryCompletion":7152,"completion":7152,"start":8934,"enrollment":447,"conditions":15843,"interventions":15844},"NCT00796718","A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer",[90],[30],[8971],{"nctId":15846,"briefTitle":15847,"status":107,"phases":15848,"primaryCompletion":4198,"completion":4198,"start":122,"enrollment":909,"conditions":15849,"interventions":15850},"NCT02013830","A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer",[90],[4121],[5275,5381],{"nctId":8921,"briefTitle":8922,"status":107,"phases":15852,"primaryCompletion":6004,"completion":6004,"start":8484,"enrollment":97,"conditions":15853,"interventions":15854},[90],[7056],[1165,5381],{"nctId":15856,"briefTitle":15857,"status":107,"phases":15858,"primaryCompletion":15859,"completion":15859,"start":15860,"enrollment":395,"conditions":15861,"interventions":15862},"NCT00885755","A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer",[90],"2013-02-18","2009-08-13",[18],[15863,5381,5390],"Standard taxane therapy",{"nctId":8938,"briefTitle":8939,"status":130,"phases":15865,"primaryCompletion":3325,"completion":3325,"start":4281,"enrollment":2440,"conditions":15866,"interventions":15867},[90],[30],[5381,5381,5275,4104,4102],{"nctId":8944,"briefTitle":8945,"status":107,"phases":15869,"primaryCompletion":2685,"completion":2685,"start":3085,"enrollment":909,"conditions":15870,"interventions":15871},[90],[30],[5275,5381,4104],{"nctId":8950,"briefTitle":8951,"status":107,"phases":15873,"primaryCompletion":3103,"completion":3103,"start":4488,"enrollment":817,"conditions":15874,"interventions":15875},[90],[30],[8955,8956,5275,5381,4104],{"nctId":15877,"briefTitle":15878,"status":107,"phases":15879,"primaryCompletion":7152,"completion":7152,"start":13164,"enrollment":1385,"conditions":15880,"interventions":15881},"NCT01227707","A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.",[90],[30],[5275,5381,5275,4089,8956],{"nctId":15883,"briefTitle":15884,"status":107,"phases":15885,"primaryCompletion":4563,"completion":4563,"start":15886,"enrollment":973,"conditions":15887,"interventions":15888},"NCT00048139","A Study of Xeloda (Capecitabine) in Patients With Advanced and\u002For Metastatic Colorectal Cancer",[90],"2001-10",[30],[4577,5381],{"nctId":8966,"briefTitle":8967,"status":107,"phases":15890,"primaryCompletion":3174,"completion":3174,"start":7095,"enrollment":1058,"conditions":15891,"interventions":15892},[90],[1735],[8971,1165,8972],{"nctId":8974,"briefTitle":8975,"status":107,"phases":15894,"primaryCompletion":7095,"completion":7095,"start":8977,"enrollment":37,"conditions":15895,"interventions":15896},[90],[30],[5275,5381,4104],{"nctId":8981,"briefTitle":8982,"status":107,"phases":15898,"primaryCompletion":5181,"completion":5181,"start":7096,"enrollment":909,"conditions":15899,"interventions":15900},[90],[1735],[1165,5381],{"nctId":9563,"briefTitle":9564,"status":107,"phases":15902,"primaryCompletion":4582,"completion":4582,"start":4446,"enrollment":5901,"conditions":15903,"interventions":15904},[90],[18],[5275,5383,5381],{"nctId":15906,"briefTitle":15884,"status":107,"phases":15907,"primaryCompletion":8689,"completion":8689,"start":7930,"enrollment":2999,"conditions":15908,"interventions":15909},"NCT00048126",[90],[30],[4577,5381],{"nctId":9593,"briefTitle":9594,"status":130,"phases":15911,"primaryCompletion":2931,"completion":2931,"start":9596,"enrollment":2289,"conditions":15912,"interventions":15913},[90],[18],[5275,5381,5383],{"nctId":9600,"briefTitle":9601,"status":343,"phases":15915,"primaryCompletion":6157,"completion":6157,"start":2964,"enrollment":101,"conditions":15916,"interventions":15917},[90],[18],[5275,5381,5383,5390],{"trials":15919,"activeCount":101},[15920,15924,15932,15938,15946],{"nctId":9030,"briefTitle":9031,"status":107,"phases":15921,"primaryCompletion":5457,"completion":5457,"start":6316,"enrollment":9033,"conditions":15922,"interventions":15923},[91],[30],[9036,1164,1165,1165,5381],{"nctId":15925,"briefTitle":15926,"status":107,"phases":15927,"primaryCompletion":14712,"completion":14712,"start":4562,"enrollment":15928,"conditions":15929,"interventions":15930},"NCT00661102","A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).",[91],598,[18],[3059,5381,15931],"dexpantenol [Bepantol]",{"nctId":15933,"briefTitle":15934,"status":107,"phases":15935,"primaryCompletion":3174,"completion":3174,"start":4488,"enrollment":1376,"conditions":15936,"interventions":15937},"NCT00929240","A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer",[91],[18],[5275,5381],{"nctId":15939,"briefTitle":15940,"status":107,"phases":15941,"primaryCompletion":4409,"completion":2801,"start":5805,"enrollment":15942,"conditions":15943,"interventions":15944},"NCT00089479","A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer",[91],2611,[18],[5381,15945,15945],"Taxotere",{"nctId":15947,"briefTitle":15948,"status":107,"phases":15949,"primaryCompletion":15950,"completion":15950,"start":15951,"enrollment":15952,"conditions":15953,"interventions":15954},"NCT00009737","A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer",[91],"2004-04","1998-11",1987,[30],[1597,1164,8971],{"trials":15956,"activeCount":101},[15957,15964],{"nctId":15958,"briefTitle":15959,"status":107,"phases":15960,"primaryCompletion":4322,"completion":4488,"start":2923,"enrollment":15961,"conditions":15962,"interventions":15963},"NCT00127933","XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer",[92],157,[18],[5381,15945,7139,5381,15945],{"nctId":15965,"briefTitle":15966,"status":107,"phases":15967,"primaryCompletion":3175,"completion":3175,"start":4315,"enrollment":1148,"conditions":15968,"interventions":15969},"NCT00502671","A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.",[92],[30],[5381],{"trials":15971,"activeCount":101},[],{"intervention":15973,"totalTrials":1184,"cells":15974},"methoxy polyethylene glycol-epoetin beta [Mircera]",{"EARLY_PHASE1":15975,"PHASE1":15977,"PHASE2":15979,"PHASE3":16008,"PHASE4":16121,"NA":16189},{"trials":15976,"activeCount":101},[],{"trials":15978,"activeCount":101},[],{"trials":15980,"activeCount":101},[15981,15988,15994,16001],{"nctId":15982,"briefTitle":15983,"status":107,"phases":15984,"primaryCompletion":4563,"completion":4563,"start":15985,"enrollment":1352,"conditions":15986,"interventions":15987},"NCT00048035","A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia",[90],"2002-03",[24],[15973],{"nctId":15989,"briefTitle":15990,"status":107,"phases":15991,"primaryCompletion":4323,"completion":4323,"start":15886,"enrollment":2429,"conditions":15992,"interventions":15993},"NCT00364832","A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.",[90],[24],[15973],{"nctId":15995,"briefTitle":15996,"status":107,"phases":15997,"primaryCompletion":6620,"completion":6620,"start":4282,"enrollment":1249,"conditions":15998,"interventions":15999},"NCT00327535","A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.",[90],[24],[16000,15973,15973,15973],"Darbepoetin alfa",{"nctId":16002,"briefTitle":16003,"status":107,"phases":16004,"primaryCompletion":16005,"completion":7054,"start":15985,"enrollment":2694,"conditions":16006,"interventions":16007},"NCT00048048","A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.",[90],"2003-10",[24],[15973],{"trials":16009,"activeCount":101},[16010,16016,16024,16030,16037,16043,16051,16058,16066,16072,16078,16084,16090,16098,16103,16109,16115],{"nctId":16011,"briefTitle":16012,"status":107,"phases":16013,"primaryCompletion":4488,"completion":4488,"start":4513,"enrollment":3286,"conditions":16014,"interventions":16015},"NCT00605345","A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.",[91],[24],[16000,15973],{"nctId":16017,"briefTitle":16018,"status":107,"phases":16019,"primaryCompletion":3104,"completion":3104,"start":6620,"enrollment":16020,"conditions":16021,"interventions":16022},"NCT00442793","A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.",[91],265,[24],[16023,15973],"Epoetin beta",{"nctId":16025,"briefTitle":16026,"status":107,"phases":16027,"primaryCompletion":8688,"completion":8688,"start":14454,"enrollment":1926,"conditions":16028,"interventions":16029},"NCT00394953","A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients",[91],[24],[16000,15973],{"nctId":16031,"briefTitle":16032,"status":107,"phases":16033,"primaryCompletion":4474,"completion":4474,"start":4488,"enrollment":6005,"conditions":16034,"interventions":16035},"NCT00773331","A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.",[91],[24],[16036,15973],"epoetin beta",{"nctId":16038,"briefTitle":16039,"status":107,"phases":16040,"primaryCompletion":2906,"completion":2906,"start":3479,"enrollment":1672,"conditions":16041,"interventions":16042},"NCT00882713","A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia",[91],[24],[15973],{"nctId":16044,"briefTitle":16045,"status":107,"phases":16046,"primaryCompletion":4455,"completion":4455,"start":11713,"enrollment":16047,"conditions":16048,"interventions":16049},"NCT00081484","A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients",[91],336,[24],[16050,15973],"epoetin alfa or beta",{"nctId":16052,"briefTitle":16053,"status":107,"phases":16054,"primaryCompletion":8751,"completion":8751,"start":9499,"enrollment":3015,"conditions":16055,"interventions":16056},"NCT00077597","A Study of Mircera for the Treatment of Anemia in Dialysis Patients",[91],[24],[16057,15973],"epoetin",{"nctId":16059,"briefTitle":16060,"status":107,"phases":16061,"primaryCompletion":9771,"completion":9771,"start":11713,"enrollment":16062,"conditions":16063,"interventions":16064},"NCT00081471","A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis",[91],324,[24],[16065,15973],"darbepoetin alfa",{"nctId":16067,"briefTitle":16068,"status":107,"phases":16069,"primaryCompletion":3104,"completion":3104,"start":2965,"enrollment":6037,"conditions":16070,"interventions":16071},"NCT00517413","LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.",[91],[24],[15973],{"nctId":16073,"briefTitle":16074,"status":107,"phases":16075,"primaryCompletion":4488,"completion":4488,"start":5820,"enrollment":291,"conditions":16076,"interventions":16077},"NCT00642850","STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients",[91],[24],[15973],{"nctId":16079,"briefTitle":16080,"status":107,"phases":16081,"primaryCompletion":4409,"completion":4409,"start":4582,"enrollment":2708,"conditions":16082,"interventions":16083},"NCT00576303","A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.",[91],[24],[15973],{"nctId":16085,"briefTitle":16086,"status":107,"phases":16087,"primaryCompletion":8934,"completion":8934,"start":7096,"enrollment":9644,"conditions":16088,"interventions":16089},"NCT00413894","A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.",[91],[24],[15973],{"nctId":16091,"briefTitle":16092,"status":107,"phases":16093,"primaryCompletion":4474,"completion":4474,"start":4582,"enrollment":16094,"conditions":16095,"interventions":16096},"NCT00560404","A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.",[91],233,[24],[15973,16097],"Epoetin alfa",{"nctId":16099,"briefTitle":16086,"status":107,"phases":16100,"primaryCompletion":2923,"completion":2923,"start":8605,"enrollment":6307,"conditions":16101,"interventions":16102},"NCT00077766",[91],[24],[16000,15973],{"nctId":16104,"briefTitle":16105,"status":130,"phases":16106,"primaryCompletion":4206,"completion":4206,"start":4322,"enrollment":5110,"conditions":16107,"interventions":16108},"NCT00680563","A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.",[91],[24],[15973],{"nctId":16110,"briefTitle":16111,"status":130,"phases":16112,"primaryCompletion":121,"completion":121,"start":6506,"enrollment":920,"conditions":16113,"interventions":16114},"NCT00442416","A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.",[91],[24],[16097,15973],{"nctId":16116,"briefTitle":16117,"status":107,"phases":16118,"primaryCompletion":4474,"completion":4474,"start":3085,"enrollment":817,"conditions":16119,"interventions":16120},"NCT00661388","A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.",[91],[24],[15973],{"trials":16122,"activeCount":101},[16123,16129,16137,16146,16152,16161,16168,16174,16182],{"nctId":16124,"briefTitle":16125,"status":107,"phases":16126,"primaryCompletion":3022,"completion":3022,"start":6343,"enrollment":954,"conditions":16127,"interventions":16128},"NCT00737711","A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.",[92],[24],[15973],{"nctId":16130,"briefTitle":16131,"status":107,"phases":16132,"primaryCompletion":16133,"completion":16133,"start":16134,"enrollment":31,"conditions":16135,"interventions":16136},"NCT01342640","A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia",[92],"2012-11-30","2011-07-18",[24],[15973],{"nctId":16138,"briefTitle":16139,"status":107,"phases":16140,"primaryCompletion":16141,"completion":16141,"start":16142,"enrollment":16143,"conditions":16144,"interventions":16145},"NCT00922116","A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis",[92],"2010-11-30","2009-04-30",191,[24],[15973],{"nctId":16147,"briefTitle":16148,"status":107,"phases":16149,"primaryCompletion":4249,"completion":4249,"start":2906,"enrollment":6110,"conditions":16150,"interventions":16151},"NCT01156363","A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia",[92],[24],[15973],{"nctId":16153,"briefTitle":16154,"status":107,"phases":16155,"primaryCompletion":16156,"completion":16156,"start":16157,"enrollment":3247,"conditions":16158,"interventions":16159},"NCT01191983","A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy",[92],"2018-04-23","2010-08-13",[24],[16160],"Methoxy polyethylene glycol-epoetin beta [Mircera]",{"nctId":16162,"briefTitle":16163,"status":130,"phases":16164,"primaryCompletion":16165,"completion":16165,"start":2975,"enrollment":395,"conditions":16166,"interventions":16167},"NCT01066000","A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia",[92],"2011-09-30",[24],[15973],{"nctId":16169,"briefTitle":16170,"status":107,"phases":16171,"primaryCompletion":7095,"completion":7095,"start":3479,"enrollment":496,"conditions":16172,"interventions":16173},"NCT00922610","A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients",[92],[24],[15973],{"nctId":16175,"briefTitle":16176,"status":107,"phases":16177,"primaryCompletion":16178,"completion":16178,"start":16179,"enrollment":3044,"conditions":16180,"interventions":16181},"NCT00737464","A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.",[92],"2009-09-12","2008-08-26",[24],[15973],{"nctId":16183,"briefTitle":16184,"status":130,"phases":16185,"primaryCompletion":6343,"completion":6343,"start":4513,"enrollment":350,"conditions":16186,"interventions":16187},"NCT00576602","A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant",[92],[24],[15973,16188],"Supportive treatment",{"trials":16190,"activeCount":101},[],{"intervention":5384,"totalTrials":316,"cells":16192},{"EARLY_PHASE1":16193,"PHASE1":16195,"PHASE2":16205,"PHASE3":16283,"PHASE4":16329,"NA":16357},{"trials":16194,"activeCount":101},[],{"trials":16196,"activeCount":101},[16197,16201],{"nctId":15783,"briefTitle":15784,"status":107,"phases":16198,"primaryCompletion":3212,"completion":3212,"start":3308,"enrollment":8206,"conditions":16199,"interventions":16200},[89],[6622],[5275,5381,5384],{"nctId":5373,"briefTitle":5374,"status":130,"phases":16202,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":16203,"interventions":16204},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":16206,"activeCount":101},[16207,16213,16217,16224,16232,16236,16240,16244,16250,16254,16263,16270,16276],{"nctId":16208,"briefTitle":16209,"status":130,"phases":16210,"primaryCompletion":6578,"completion":6578,"start":8688,"enrollment":384,"conditions":16211,"interventions":16212},"NCT00773383","A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb\u002FIV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.",[90],[975],[5379,5384],{"nctId":6569,"briefTitle":6570,"status":130,"phases":16214,"primaryCompletion":3189,"completion":3189,"start":2963,"enrollment":3574,"conditions":16215,"interventions":16216},[90],[975],[5384,5186,5186],{"nctId":16218,"briefTitle":16219,"status":107,"phases":16220,"primaryCompletion":2809,"completion":2809,"start":15950,"enrollment":16221,"conditions":16222,"interventions":16223},"NCT01996332","A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[90],1805,[975],[5384],{"nctId":16225,"briefTitle":16226,"status":107,"phases":16227,"primaryCompletion":7152,"completion":7152,"start":2965,"enrollment":16228,"conditions":16229,"interventions":16230},"NCT00531934","A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.",[90],147,[975],[16231,5384],"Doxycline",{"nctId":15815,"briefTitle":15816,"status":107,"phases":16233,"primaryCompletion":8826,"completion":8826,"start":8658,"enrollment":2743,"conditions":16234,"interventions":16235},[90],[30],[5275,15820,5381,5384],{"nctId":5440,"briefTitle":5441,"status":107,"phases":16237,"primaryCompletion":2809,"completion":2809,"start":4322,"enrollment":1352,"conditions":16238,"interventions":16239},[90],[975],[5275,5367,5384,4503],{"nctId":9553,"briefTitle":9554,"status":107,"phases":16241,"primaryCompletion":5364,"completion":5364,"start":5181,"enrollment":8835,"conditions":16242,"interventions":16243},[90],[2257],[5383,5384,5384],{"nctId":16245,"briefTitle":16246,"status":107,"phases":16247,"primaryCompletion":2830,"completion":2830,"start":3103,"enrollment":942,"conditions":16248,"interventions":16249},"NCT01372384","A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations",[90],[2257],[5384],{"nctId":5454,"briefTitle":5455,"status":107,"phases":16251,"primaryCompletion":2685,"completion":2685,"start":5457,"enrollment":5458,"conditions":16252,"interventions":16253},[90],[975],[5384,5186,5185,5367],{"nctId":16255,"briefTitle":16256,"status":130,"phases":16257,"primaryCompletion":16258,"completion":16258,"start":16259,"enrollment":16260,"conditions":16261,"interventions":16262},"NCT00760929","A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb\u002FIV Non-Small Cell Lung Cancer (NSCLC).",[90],"2010-06-25","2008-11-10",171,[2257],[5379,5379,5384],{"nctId":16264,"briefTitle":16265,"status":107,"phases":16266,"primaryCompletion":15740,"completion":15740,"start":2964,"enrollment":16267,"conditions":16268,"interventions":16269},"NCT01250119","A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.",[90],688,[2257],[5384],{"nctId":16271,"briefTitle":16272,"status":107,"phases":16273,"primaryCompletion":2906,"completion":2906,"start":6277,"enrollment":973,"conditions":16274,"interventions":16275},"NCT02013206","A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy",[90],[975],[5384],{"nctId":16277,"briefTitle":16278,"status":107,"phases":16279,"primaryCompletion":16280,"completion":16280,"start":4357,"enrollment":336,"conditions":16281,"interventions":16282},"NCT01174563","A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy",[90],"2016-12-20",[2257],[5384],{"trials":16284,"activeCount":101},[16285,16292,16301,16308,16316,16320],{"nctId":16286,"briefTitle":16287,"status":107,"phases":16288,"primaryCompletion":5181,"completion":5181,"start":8977,"enrollment":16289,"conditions":16290,"interventions":16291},"NCT00556712","A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[91],889,[975],[5384],{"nctId":16293,"briefTitle":16294,"status":107,"phases":16295,"primaryCompletion":3213,"completion":3213,"start":4322,"enrollment":4713,"conditions":16296,"interventions":16297},"NCT00718315","A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.",[91],[975],[5384,16298,16299,16300],"fusidic acid [Verutex]","erythromycin [Eritex]","Fisiogel",{"nctId":16302,"briefTitle":16303,"status":107,"phases":16304,"primaryCompletion":3213,"completion":3213,"start":4455,"enrollment":9644,"conditions":16305,"interventions":16306},"NCT00556322","A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[91],[975],[16307,5384],"Alimta or Taxotere",{"nctId":16309,"briefTitle":16310,"status":107,"phases":16311,"primaryCompletion":4454,"completion":4682,"start":2906,"enrollment":16312,"conditions":16313,"interventions":16314},"NCT01183858","A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)",[91],315,[975],[16315],"Erlotinib [Tarceva]",{"nctId":6740,"briefTitle":6741,"status":107,"phases":16317,"primaryCompletion":3324,"completion":3324,"start":4322,"enrollment":6743,"conditions":16318,"interventions":16319},[91],[2257],[6746,5384,5186],{"nctId":16321,"briefTitle":16322,"status":107,"phases":16323,"primaryCompletion":16324,"completion":16324,"start":1341,"enrollment":16325,"conditions":16326,"interventions":16327},"NCT02031744","A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer",[91],"2016-01-06",530,[975],[5384,16328],"Onartuzumab [MetMAb]",{"trials":16330,"activeCount":101},[16331,16335,16339,16345,16351],{"nctId":6774,"briefTitle":6775,"status":130,"phases":16332,"primaryCompletion":4322,"completion":4322,"start":6673,"enrollment":942,"conditions":16333,"interventions":16334},[92],[6622],[5384,5186],{"nctId":10773,"briefTitle":10774,"status":107,"phases":16336,"primaryCompletion":4474,"completion":4474,"start":6506,"enrollment":22,"conditions":16337,"interventions":16338},[92],[975],[5384,7025],{"nctId":16340,"briefTitle":16341,"status":107,"phases":16342,"primaryCompletion":6195,"completion":6195,"start":2801,"enrollment":447,"conditions":16343,"interventions":16344},"NCT01609543","A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations",[92],[2257],[5384],{"nctId":16346,"briefTitle":16347,"status":107,"phases":16348,"primaryCompletion":2956,"completion":2956,"start":6315,"enrollment":425,"conditions":16349,"interventions":16350},"NCT01287754","A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations",[92],[975],[5384],{"nctId":16352,"briefTitle":16353,"status":107,"phases":16354,"primaryCompletion":3084,"completion":3084,"start":4322,"enrollment":2631,"conditions":16355,"interventions":16356},"NCT01066884","A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer",[92],[2257],[5384],{"trials":16358,"activeCount":101},[],{"intervention":1597,"totalTrials":8583,"cells":16360},{"EARLY_PHASE1":16361,"PHASE1":16363,"PHASE2":16365,"PHASE3":16407,"PHASE4":16441,"NA":16447},{"trials":16362,"activeCount":101},[],{"trials":16364,"activeCount":101},[],{"trials":16366,"activeCount":101},[16367,16371,16375,16379,16383,16387,16391,16395,16399,16403],{"nctId":4083,"briefTitle":4084,"status":107,"phases":16368,"primaryCompletion":2792,"completion":2792,"start":4086,"enrollment":1272,"conditions":16369,"interventions":16370},[90],[18],[4089,4090,992,1106,1015],{"nctId":4092,"briefTitle":4093,"status":130,"phases":16372,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":16373,"interventions":16374},[90],[4098],[4089,4100,4101,4102,4103,4104],{"nctId":8602,"briefTitle":8603,"status":107,"phases":16376,"primaryCompletion":2905,"completion":2905,"start":8605,"enrollment":3015,"conditions":16377,"interventions":16378},[90],[18],[1597,1166,992,947,5619],{"nctId":7918,"briefTitle":7919,"status":107,"phases":16380,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":16381,"interventions":16382},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":4124,"briefTitle":4125,"status":107,"phases":16384,"primaryCompletion":2856,"completion":4127,"start":4128,"enrollment":1080,"conditions":16385,"interventions":16386},[90],[30],[1597,1015,4131,1165],{"nctId":4177,"briefTitle":4178,"status":107,"phases":16388,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":16389,"interventions":16390},[90],[18],[4184,1015,4185,1597,992,1106,947],{"nctId":15877,"briefTitle":15878,"status":107,"phases":16392,"primaryCompletion":7152,"completion":7152,"start":13164,"enrollment":1385,"conditions":16393,"interventions":16394},[90],[30],[5275,5381,5275,4089,8956],{"nctId":1588,"briefTitle":1589,"status":107,"phases":16396,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":16397,"interventions":16398},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":4302,"briefTitle":4303,"status":107,"phases":16400,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1352,"conditions":16401,"interventions":16402},[90],[1727],[1015,1165,4309,4089],{"nctId":8998,"briefTitle":8999,"status":107,"phases":16404,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":1548,"conditions":16405,"interventions":16406},[90],[1735],[4244,1165,4272,4131,1597],{"trials":16408,"activeCount":101},[16409,16413,16417,16421,16425,16429,16433,16437],{"nctId":8723,"briefTitle":8724,"status":107,"phases":16410,"primaryCompletion":8726,"completion":8726,"start":8727,"enrollment":8728,"conditions":16411,"interventions":16412},[91],[30],[1166,1165,1164,1597],{"nctId":7141,"briefTitle":7142,"status":107,"phases":16414,"primaryCompletion":7144,"completion":1802,"start":3096,"enrollment":7145,"conditions":16415,"interventions":16416},[91],[1735],[1597,1166,1167,1221,1222],{"nctId":7149,"briefTitle":7150,"status":107,"phases":16418,"primaryCompletion":7152,"completion":7152,"start":7153,"enrollment":1452,"conditions":16419,"interventions":16420},[91],[1735],[1597,1166,1167],{"nctId":4406,"briefTitle":4407,"status":107,"phases":16422,"primaryCompletion":4409,"completion":3213,"start":4410,"enrollment":4411,"conditions":16423,"interventions":16424},[91],[30],[1015,1166,1597,4414,1165],{"nctId":8075,"briefTitle":8076,"status":107,"phases":16426,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":16427,"interventions":16428},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":15947,"briefTitle":15948,"status":107,"phases":16430,"primaryCompletion":15950,"completion":15950,"start":15951,"enrollment":15952,"conditions":16431,"interventions":16432},[91],[30],[1597,1164,8971],{"nctId":9714,"briefTitle":9715,"status":107,"phases":16434,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":16435,"interventions":16436},[91],[18],[1597,992,947,5619,9723,9724],{"nctId":5610,"briefTitle":5611,"status":107,"phases":16438,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":16439,"interventions":16440},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"trials":16442,"activeCount":101},[16443],{"nctId":4579,"briefTitle":4580,"status":107,"phases":16444,"primaryCompletion":2965,"completion":4582,"start":122,"enrollment":931,"conditions":16445,"interventions":16446},[92],[30],[1597,1015,4577,1165],{"trials":16448,"activeCount":101},[],{"intervention":16450,"totalTrials":510,"cells":16451},"Saquinavir",{"EARLY_PHASE1":16452,"PHASE1":16454,"PHASE2":16469,"PHASE3":16501,"PHASE4":16565,"NA":16579},{"trials":16453,"activeCount":101},[],{"trials":16455,"activeCount":101},[16456,16462],{"nctId":16457,"briefTitle":16458,"status":107,"phases":16459,"enrollment":920,"conditions":16460,"interventions":16461},"NCT00002383","A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients",[89],[33],[16450],{"nctId":16463,"briefTitle":16464,"status":107,"phases":16465,"enrollment":496,"conditions":16466,"interventions":16467},"NCT00002380","The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children",[89],[33],[16468,16450],"Nelfinavir mesylate",{"trials":16470,"activeCount":101},[16471,16480,16489,16495],{"nctId":16472,"briefTitle":16473,"status":107,"phases":16474,"primaryCompletion":16475,"enrollment":4811,"conditions":16476,"interventions":16477},"NCT00001040","Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC",[90],"1994-05",[33],[16450,16478,16479],"Zidovudine","Zalcitabine",{"nctId":16481,"briefTitle":16482,"status":107,"phases":16483,"enrollment":1026,"conditions":16484,"interventions":16485},"NCT00002162","A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs",[90],[33],[16450,16486,16487,16478,16479,16488],"Lamivudine","Stavudine","Didanosine",{"nctId":16490,"briefTitle":16491,"status":107,"phases":16492,"enrollment":11202,"conditions":16493,"interventions":16494},"NCT00002333","A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine",[90],[33],[16450,16479],{"nctId":16496,"briefTitle":16497,"status":107,"phases":16498,"enrollment":1184,"conditions":16499,"interventions":16500},"NCT00002190","A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients",[90],[33],[16450,16486,16478],{"trials":16502,"activeCount":101},[16503,16511,16519,16526,16533,16540,16546,16553,16559],{"nctId":16504,"briefTitle":16505,"status":107,"phases":16506,"enrollment":16507,"conditions":16508,"interventions":16509},"NCT00002178","A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients",[91],375,[33],[11782,16468,16450,16510],"Delavirdine mesylate",{"nctId":16512,"briefTitle":16513,"status":107,"phases":16514,"start":16515,"enrollment":931,"conditions":16516,"interventions":16517},"NCT00002448","A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients",[91],"1999-10",[33],[11782,16518,16450],"Efavirenz",{"nctId":16520,"briefTitle":16521,"status":107,"phases":16522,"enrollment":425,"conditions":16523,"interventions":16525},"NCT00002397","A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease",[91],[33,16524],"AIDS-Associated Nephropathy",[16468,16450,16486,16487],{"nctId":16527,"briefTitle":16528,"status":107,"phases":16529,"enrollment":16530,"conditions":16531,"interventions":16532},"NCT00002382","A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients",[91],4000,[33],[16450],{"nctId":16534,"briefTitle":16535,"status":107,"phases":16536,"enrollment":16537,"conditions":16538,"interventions":16539},"NCT00002334","A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment",[91],3000,[33],[16450,16478,16479],{"nctId":16541,"briefTitle":16542,"status":107,"phases":16543,"start":16515,"enrollment":11543,"conditions":16544,"interventions":16545},"NCT00002447","A Study to Compare Two Anti-HIV Drug Combinations",[91],[33],[11782,16518,16450],{"nctId":16547,"briefTitle":16548,"status":107,"phases":16549,"enrollment":16550,"conditions":16551,"interventions":16552},"NCT00002378","A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients",[91],825,[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":16554,"briefTitle":16555,"status":107,"phases":16556,"enrollment":931,"conditions":16557,"interventions":16558},"NCT00002367","A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs",[91],[33],[16450,16486,16478],{"nctId":16560,"briefTitle":16561,"status":107,"phases":16562,"enrollment":1239,"conditions":16563,"interventions":16564},"NCT00002374","A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients",[91],[33],[11782,16468,16450,16487],{"trials":16566,"activeCount":101},[16567,16573],{"nctId":16568,"briefTitle":16569,"status":107,"phases":16570,"enrollment":4013,"conditions":16571,"interventions":16572},"NCT00002425","The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs",[92],[33],[16450],{"nctId":16574,"briefTitle":16575,"status":107,"phases":16576,"enrollment":920,"conditions":16577,"interventions":16578},"NCT00002229","Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients",[92],[33],[16450],{"trials":16580,"activeCount":101},[],{"intervention":4577,"totalTrials":13060,"cells":16582},{"EARLY_PHASE1":16583,"PHASE1":16585,"PHASE2":16591,"PHASE3":16636,"PHASE4":16642,"NA":16652},{"trials":16584,"activeCount":101},[],{"trials":16586,"activeCount":101},[16587],{"nctId":5373,"briefTitle":5374,"status":130,"phases":16588,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":16589,"interventions":16590},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":16592,"activeCount":101},[16593,16597,16601,16605,16609,16616,16620,16624,16628,16632],{"nctId":4092,"briefTitle":4093,"status":130,"phases":16594,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":16595,"interventions":16596},[90],[4098],[4089,4100,4101,4102,4103,4104],{"nctId":14720,"briefTitle":14721,"status":343,"phases":16598,"primaryCompletion":3213,"completion":3213,"start":4513,"enrollment":101,"conditions":16599,"interventions":16600},[90],[30],[5275,4577,1164,9036,1138],{"nctId":8931,"briefTitle":8932,"status":107,"phases":16602,"primaryCompletion":4454,"completion":4454,"start":8934,"enrollment":920,"conditions":16603,"interventions":16604},[90],[30],[1162,1162,1162,4577,1164,1164,1165,5275],{"nctId":8938,"briefTitle":8939,"status":130,"phases":16606,"primaryCompletion":3325,"completion":3325,"start":4281,"enrollment":2440,"conditions":16607,"interventions":16608},[90],[30],[5381,5381,5275,4104,4102],{"nctId":16610,"briefTitle":16611,"status":107,"phases":16612,"primaryCompletion":3182,"completion":3182,"start":4409,"enrollment":3015,"conditions":16613,"interventions":16615},"NCT00967330","A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma",[90],[16614],"Glioblastoma Multiforme",[5275,4102,5389],{"nctId":15883,"briefTitle":15884,"status":107,"phases":16617,"primaryCompletion":4563,"completion":4563,"start":15886,"enrollment":973,"conditions":16618,"interventions":16619},[90],[30],[4577,5381],{"nctId":8671,"briefTitle":8672,"status":107,"phases":16621,"primaryCompletion":4410,"completion":4410,"start":8674,"enrollment":6514,"conditions":16622,"interventions":16623},[90],[30],[1166,4577],{"nctId":15906,"briefTitle":15884,"status":107,"phases":16625,"primaryCompletion":8689,"completion":8689,"start":7930,"enrollment":2999,"conditions":16626,"interventions":16627},[90],[30],[4577,5381],{"nctId":8678,"briefTitle":8679,"status":107,"phases":16629,"primaryCompletion":8681,"completion":8681,"start":4563,"enrollment":2933,"conditions":16630,"interventions":16631},[90],[30],[8105,1166,4577],{"nctId":8987,"briefTitle":8988,"status":107,"phases":16633,"primaryCompletion":4682,"completion":4682,"start":2963,"enrollment":8990,"conditions":16634,"interventions":16635},[90],[30],[1162,5275,4102,8956,4104],{"trials":16637,"activeCount":101},[16638],{"nctId":13257,"briefTitle":13258,"status":107,"phases":16639,"primaryCompletion":4474,"completion":4474,"start":4315,"enrollment":1593,"conditions":16640,"interventions":16641},[91],[30],[5275,4102,8956,8955],{"trials":16643,"activeCount":101},[16644,16648],{"nctId":4568,"briefTitle":4569,"status":107,"phases":16645,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":16646,"interventions":16647},[92],[4098],[1165,1166,1015,1164,4576,4577],{"nctId":4579,"briefTitle":4580,"status":107,"phases":16649,"primaryCompletion":2965,"completion":4582,"start":122,"enrollment":931,"conditions":16650,"interventions":16651},[92],[30],[1597,1015,4577,1165],{"trials":16653,"activeCount":101},[],{"intervention":16655,"totalTrials":13060,"cells":16656},"Ibandronate",{"EARLY_PHASE1":16657,"PHASE1":16659,"PHASE2":16661,"PHASE3":16663,"PHASE4":16702,"NA":16767},{"trials":16658,"activeCount":101},[],{"trials":16660,"activeCount":101},[],{"trials":16662,"activeCount":101},[],{"trials":16664,"activeCount":101},[16665,16673,16681,16688,16695],{"nctId":16666,"briefTitle":16667,"status":107,"phases":16668,"primaryCompletion":8934,"completion":8934,"start":16669,"enrollment":3295,"conditions":16670,"interventions":16672},"NCT00397839","The Effect Of Oral Ibandronate In Male Osteoporosis",[91],"2007-01",[16671],"Male Osteoporosis",[16655],{"nctId":16674,"briefTitle":16675,"status":107,"phases":16676,"primaryCompletion":8934,"completion":8934,"start":14454,"enrollment":16677,"conditions":16678,"interventions":16680},"NCT00545779","BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.",[91],677,[16679],"Post-Menopausal Osteoporosis",[16655],{"nctId":16682,"briefTitle":16683,"status":107,"phases":16684,"primaryCompletion":4198,"completion":4198,"start":14454,"enrollment":8990,"conditions":16685,"interventions":16687},"NCT02561039","A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease",[91],[16686],"Pain; Bone Neoplasms; Neoplasm Metastasis",[16655],{"nctId":16689,"briefTitle":16690,"status":130,"phases":16691,"primaryCompletion":4322,"completion":4322,"start":4446,"enrollment":25,"conditions":16692,"interventions":16693},"NCT02739594","Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma",[91],[1305],[16655,16694],"Zoledronate",{"nctId":16696,"briefTitle":16697,"status":107,"phases":16698,"primaryCompletion":14572,"completion":3085,"start":8977,"enrollment":16699,"conditions":16700,"interventions":16701},"NCT02716792","A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer",[91],334,[16686],[16655],{"trials":16703,"activeCount":101},[16704,16710,16718,16725,16731,16738,16745,16752,16759],{"nctId":16705,"briefTitle":16706,"status":107,"phases":16707,"primaryCompletion":4562,"completion":4562,"start":9771,"enrollment":3015,"conditions":16708,"interventions":16709},"NCT02553707","A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer",[92],[16686],[16655],{"nctId":16711,"briefTitle":16712,"status":107,"phases":16713,"primaryCompletion":6277,"completion":6277,"start":8689,"enrollment":16714,"conditions":16715,"interventions":16717},"NCT02598453","PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia",[92],545,[16716],"Postmenopausal Osteoporosis",[16655],{"nctId":16719,"briefTitle":16720,"status":107,"phases":16721,"primaryCompletion":8810,"completion":8810,"start":11713,"enrollment":16722,"conditions":16723,"interventions":16724},"NCT02604836","A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia",[92],1711,[16716],[16655],{"nctId":16726,"briefTitle":16727,"status":107,"phases":16728,"primaryCompletion":8810,"completion":8810,"start":7054,"enrollment":123,"conditions":16729,"interventions":16730},"NCT02564107","A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease",[92],[16686],[16655],{"nctId":16732,"briefTitle":16733,"status":107,"phases":16734,"primaryCompletion":9596,"completion":9596,"start":4282,"enrollment":1026,"conditions":16735,"interventions":16736},"NCT00545051","A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.",[92],[16716],[16737],"ibandronate",{"nctId":16739,"briefTitle":16740,"status":107,"phases":16741,"primaryCompletion":122,"completion":122,"start":8605,"enrollment":1509,"conditions":16742,"interventions":16743},"NCT02598440","A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis",[92],[16716],[16744,16655],"Alendronate",{"nctId":16746,"briefTitle":16747,"status":107,"phases":16748,"primaryCompletion":6673,"completion":6673,"start":2923,"enrollment":1215,"conditions":16749,"interventions":16751},"NCT00148915","A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo",[92],[16750],"Osteoporosis",[16737],{"nctId":16753,"briefTitle":16754,"status":107,"phases":16755,"primaryCompletion":121,"completion":121,"start":8810,"enrollment":16756,"conditions":16757,"interventions":16758},"NCT00545363","A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)",[92],716,[16716],[16655],{"nctId":16760,"briefTitle":16761,"status":107,"phases":16762,"primaryCompletion":4282,"completion":4282,"start":6134,"enrollment":16763,"conditions":16764,"interventions":16766},"NCT02598934","A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis",[92],308,[16765],"Post Menopausal Osteoporosis",[16655],{"trials":16768,"activeCount":101},[],{"intervention":1164,"totalTrials":372,"cells":16770},{"EARLY_PHASE1":16771,"PHASE1":16773,"PHASE2":16779,"PHASE3":16809,"PHASE4":16827,"NA":16833},{"trials":16772,"activeCount":101},[],{"trials":16774,"activeCount":101},[16775],{"nctId":1153,"briefTitle":1154,"status":107,"phases":16776,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":16777,"interventions":16778},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"trials":16780,"activeCount":101},[16781,16785,16789,16793,16797,16801,16805],{"nctId":14720,"briefTitle":14721,"status":343,"phases":16782,"primaryCompletion":3213,"completion":3213,"start":4513,"enrollment":101,"conditions":16783,"interventions":16784},[90],[30],[5275,4577,1164,9036,1138],{"nctId":1504,"briefTitle":1505,"status":107,"phases":16786,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":16787,"interventions":16788},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":8931,"briefTitle":8932,"status":107,"phases":16790,"primaryCompletion":4454,"completion":4454,"start":8934,"enrollment":920,"conditions":16791,"interventions":16792},[90],[30],[1162,1162,1162,4577,1164,1164,1165,5275],{"nctId":8950,"briefTitle":8951,"status":107,"phases":16794,"primaryCompletion":3103,"completion":3103,"start":4488,"enrollment":817,"conditions":16795,"interventions":16796},[90],[30],[8955,8956,5275,5381,4104],{"nctId":15877,"briefTitle":15878,"status":107,"phases":16798,"primaryCompletion":7152,"completion":7152,"start":13164,"enrollment":1385,"conditions":16799,"interventions":16800},[90],[30],[5275,5381,5275,4089,8956],{"nctId":1588,"briefTitle":1589,"status":107,"phases":16802,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":16803,"interventions":16804},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"nctId":8987,"briefTitle":8988,"status":107,"phases":16806,"primaryCompletion":4682,"completion":4682,"start":2963,"enrollment":8990,"conditions":16807,"interventions":16808},[90],[30],[1162,5275,4102,8956,4104],{"trials":16810,"activeCount":101},[16811,16815,16819,16823],{"nctId":8723,"briefTitle":8724,"status":107,"phases":16812,"primaryCompletion":8726,"completion":8726,"start":8727,"enrollment":8728,"conditions":16813,"interventions":16814},[91],[30],[1166,1165,1164,1597],{"nctId":9030,"briefTitle":9031,"status":107,"phases":16816,"primaryCompletion":5457,"completion":5457,"start":6316,"enrollment":9033,"conditions":16817,"interventions":16818},[91],[30],[9036,1164,1165,1165,5381],{"nctId":15947,"briefTitle":15948,"status":107,"phases":16820,"primaryCompletion":15950,"completion":15950,"start":15951,"enrollment":15952,"conditions":16821,"interventions":16822},[91],[30],[1597,1164,8971],{"nctId":13257,"briefTitle":13258,"status":107,"phases":16824,"primaryCompletion":4474,"completion":4474,"start":4315,"enrollment":1593,"conditions":16825,"interventions":16826},[91],[30],[5275,4102,8956,8955],{"trials":16828,"activeCount":101},[16829],{"nctId":4568,"briefTitle":4569,"status":107,"phases":16830,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":16831,"interventions":16832},[92],[4098],[1165,1166,1015,1164,4576,4577],{"trials":16834,"activeCount":101},[],{"intervention":3482,"totalTrials":372,"cells":16836},{"EARLY_PHASE1":16837,"PHASE1":16839,"PHASE2":16849,"PHASE3":16875,"PHASE4":16889,"NA":16899},{"trials":16838,"activeCount":101},[],{"trials":16840,"activeCount":101},[16841,16845],{"nctId":3475,"briefTitle":3476,"status":107,"phases":16842,"primaryCompletion":3478,"completion":3478,"start":3479,"enrollment":2429,"conditions":16843,"interventions":16844},[89],[125],[1356,992,991,3482,1018,1357,1358],{"nctId":10038,"briefTitle":10039,"status":107,"phases":16846,"primaryCompletion":10041,"completion":10042,"start":10043,"enrollment":8028,"conditions":16847,"interventions":16848},[89],[3741],[992,3482,10046,10046,10046],{"trials":16850,"activeCount":101},[16851,16855,16859,16863,16867,16871],{"nctId":6058,"briefTitle":6059,"status":130,"phases":16852,"primaryCompletion":3246,"completion":3246,"start":4409,"enrollment":306,"conditions":16853,"interventions":16854},[90],[3826],[992,3482,6063,1359],{"nctId":10078,"briefTitle":10079,"status":130,"phases":16856,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":16857,"interventions":16858},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"nctId":6091,"briefTitle":6092,"status":107,"phases":16860,"primaryCompletion":3324,"completion":3324,"start":4446,"enrollment":1705,"conditions":16861,"interventions":16862},[90],[3741],[992,3482,1359],{"nctId":6105,"briefTitle":6106,"status":107,"phases":16864,"primaryCompletion":6108,"completion":6108,"start":6109,"enrollment":6110,"conditions":16865,"interventions":16866},[90],[6112],[992,3482,1359],{"nctId":6115,"briefTitle":6116,"status":107,"phases":16868,"primaryCompletion":6118,"completion":6118,"start":6119,"enrollment":1733,"conditions":16869,"interventions":16870},[90],[3741],[992,3482,1359],{"nctId":10115,"briefTitle":10116,"status":107,"phases":16872,"primaryCompletion":10118,"completion":10118,"start":10119,"enrollment":1385,"conditions":16873,"interventions":16874},[90],[3741],[5837,10122,10123],{"trials":16876,"activeCount":101},[16877,16881,16885],{"nctId":3799,"briefTitle":3800,"status":107,"phases":16878,"primaryCompletion":2549,"completion":3802,"start":3803,"enrollment":3804,"conditions":16879,"interventions":16880},[91],[3806],[1018,1073,3482,992,1359,1356],{"nctId":3841,"briefTitle":3842,"status":107,"phases":16882,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":3847,"conditions":16883,"interventions":16884},[91],[2431],[1356,2496,992,3482,1018],{"nctId":6365,"briefTitle":6366,"status":107,"phases":16886,"primaryCompletion":6368,"completion":6368,"start":3269,"enrollment":1103,"conditions":16887,"interventions":16888},[91],[2392],[1359,992,991,1358,1357,3482],{"trials":16890,"activeCount":101},[16891,16895],{"nctId":6390,"briefTitle":6391,"status":130,"phases":16892,"primaryCompletion":6393,"completion":6393,"start":6394,"enrollment":316,"conditions":16893,"interventions":16894},[92],[3741],[2496,992,3482,1359],{"nctId":6398,"briefTitle":6399,"status":130,"phases":16896,"primaryCompletion":6401,"completion":6401,"start":6402,"enrollment":25,"conditions":16897,"interventions":16898},[92],[3741],[992,3482,1359],{"trials":16900,"activeCount":101},[],{"intervention":16000,"totalTrials":709,"cells":16902},{"EARLY_PHASE1":16903,"PHASE1":16905,"PHASE2":16907,"PHASE3":16913,"PHASE4":16973,"NA":16993},{"trials":16904,"activeCount":101},[],{"trials":16906,"activeCount":101},[],{"trials":16908,"activeCount":101},[16909],{"nctId":15995,"briefTitle":15996,"status":107,"phases":16910,"primaryCompletion":6620,"completion":6620,"start":4282,"enrollment":1249,"conditions":16911,"interventions":16912},[90],[24],[16000,15973,15973,15973],{"trials":16914,"activeCount":101},[16915,16919,16923,16931,16938,16942,16952,16960,16969],{"nctId":16011,"briefTitle":16012,"status":107,"phases":16916,"primaryCompletion":4488,"completion":4488,"start":4513,"enrollment":3286,"conditions":16917,"interventions":16918},[91],[24],[16000,15973],{"nctId":16025,"briefTitle":16026,"status":107,"phases":16920,"primaryCompletion":8688,"completion":8688,"start":14454,"enrollment":1926,"conditions":16921,"interventions":16922},[91],[24],[16000,15973],{"nctId":16924,"briefTitle":16925,"status":107,"phases":16926,"primaryCompletion":2769,"completion":2769,"start":8811,"enrollment":16927,"conditions":16928,"interventions":16929},"NCT00090753","A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia",[91],1228,[24],[16930,16097,16023,16000],"Methoxy Polyethylene Glycol-Epoetin Beta",{"nctId":16932,"briefTitle":16933,"status":107,"phases":16934,"primaryCompletion":7152,"completion":7152,"start":3692,"enrollment":1148,"conditions":16935,"interventions":16936},"NCT00442702","A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.",[91],[24],[16937,16000],"Mircera",{"nctId":16059,"briefTitle":16060,"status":107,"phases":16939,"primaryCompletion":9771,"completion":9771,"start":11713,"enrollment":16062,"conditions":16940,"interventions":16941},[91],[24],[16065,15973],{"nctId":16943,"briefTitle":16944,"status":107,"phases":16945,"primaryCompletion":4314,"completion":4314,"start":3085,"enrollment":16946,"conditions":16947,"interventions":16948},"NCT00717821","A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.",[91],421,[24],[16949,16950,16951],"Methoxy Polyethylene Glycol-epoetin Beta","Epoetin Beta","Darbepoetin Alfa",{"nctId":16953,"briefTitle":16954,"status":130,"phases":16955,"primaryCompletion":4086,"completion":4086,"start":8484,"enrollment":2389,"conditions":16956,"interventions":16957},"NCT00454246","A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.",[91],[24],[16958,16959,16065],"methoxy polyethylene glycol-epoetin beta","epoetin alfa",{"nctId":16961,"briefTitle":16962,"status":107,"phases":16963,"primaryCompletion":3022,"completion":3022,"start":4513,"enrollment":16964,"conditions":16965,"interventions":16967},"NCT00559273","A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis",[91],307,[16966],"Renal Anemia, Chronic",[16968,16000],"Methoxy polyethylene glycol-epoetin beta",{"nctId":16099,"briefTitle":16086,"status":107,"phases":16970,"primaryCompletion":2923,"completion":2923,"start":8605,"enrollment":6307,"conditions":16971,"interventions":16972},[91],[24],[16000,15973],{"trials":16974,"activeCount":101},[16975,16986],{"nctId":16976,"briefTitle":16977,"status":107,"phases":16978,"primaryCompletion":16979,"completion":16979,"start":16980,"enrollment":16981,"conditions":16982,"interventions":16984},"NCT00773513","A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)",[92],"2017-07-27","2008-12-12",2825,[16983],"Chronic Renal Anemia",[16951,16985,16950,16958],"Epoetin Alfa",{"nctId":16987,"briefTitle":16988,"status":107,"phases":16989,"primaryCompletion":6377,"completion":6377,"start":6277,"enrollment":123,"conditions":16990,"interventions":16991},"NCT00377481","COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.",[92],[24],[16065,16992],"epoetin beta [NeoRecormon]",{"trials":16994,"activeCount":101},[],{"intervention":16996,"totalTrials":709,"cells":16997},"Copegus",{"EARLY_PHASE1":16998,"PHASE1":17000,"PHASE2":17002,"PHASE3":17061,"PHASE4":17063,"NA":17101},{"trials":16999,"activeCount":101},[],{"trials":17001,"activeCount":101},[],{"trials":17003,"activeCount":101},[17004,17013,17020,17027,17035,17044,17051],{"nctId":17005,"briefTitle":17006,"status":107,"phases":17007,"primaryCompletion":4206,"completion":4206,"start":4513,"enrollment":17008,"conditions":17009,"interventions":17010},"NCT00517439","A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.",[90],516,[27],[16996,17011,17011,17012,17012,17012],"Pegasys","RO4588161",{"nctId":17014,"briefTitle":17015,"status":107,"phases":17016,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":549,"conditions":17017,"interventions":17018},"NCT00963885","A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection",[90],[27],[16996,17011,17019,17019,17019,17019],"RO5190591",{"nctId":17021,"briefTitle":17022,"status":107,"phases":17023,"primaryCompletion":2948,"completion":2948,"start":5181,"enrollment":16946,"conditions":17024,"interventions":17025},"NCT01220947","A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection",[90],[27],[16996,17026,17026,17026,17011,11782],"Danoprevir",{"nctId":17028,"briefTitle":17029,"status":107,"phases":17030,"primaryCompletion":2768,"completion":2768,"start":6135,"enrollment":17031,"conditions":17032,"interventions":17033},"NCT00869661","A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4",[90],413,[27],[16996,16996,17011,17011,17034,17034,17034,17034],"RO5024048",{"nctId":17036,"briefTitle":17037,"status":107,"phases":17038,"primaryCompletion":3085,"completion":3085,"start":6277,"enrollment":15475,"conditions":17039,"interventions":17040},"NCT00377182","A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.",[90],[27],[16996,17041,17042,17043],"PEGASYS","RO5024048 1500mg","RO5024048 3000mg",{"nctId":17045,"briefTitle":17046,"status":107,"phases":17047,"primaryCompletion":4249,"completion":4249,"start":2931,"enrollment":17048,"conditions":17049,"interventions":17050},"NCT01331850","A Study of Danoprevir\u002FRitonavir and Copegus With RO5024048 and\u002For Pegasys in Patients With Chronic Hepatitis C",[90],381,[27],[16996,16996,17011,17011,17034,11967,11969],{"nctId":17052,"briefTitle":17053,"status":107,"phases":17054,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":17055,"interventions":17056},"NCT01482403","A Study of Mericitabine in Combination With Boceprevir and Pegasys\u002FCopegus in Patients With Chronic Hepatitis C",[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],"boceprevir","mericitabine","mericitabine placebo","boceprevir placebo",{"trials":17062,"activeCount":101},[],{"trials":17064,"activeCount":101},[17065,17073,17080,17088,17095],{"nctId":17066,"briefTitle":17067,"status":107,"phases":17068,"primaryCompletion":10332,"completion":10332,"start":2769,"enrollment":2572,"conditions":17069,"interventions":17070},"NCT01033448","A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response",[92],[27],[17071,17072],"COPEGUS","peginterferon alfa-2a [Pegasys]",{"nctId":17074,"briefTitle":17075,"status":107,"phases":17076,"primaryCompletion":3084,"completion":3084,"start":6306,"enrollment":17077,"conditions":17078,"interventions":17079},"NCT00940420","A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C",[92],2695,[27],[16996,16996,17072,17072],{"nctId":17081,"briefTitle":17082,"status":107,"phases":17083,"primaryCompletion":4455,"completion":4455,"start":17084,"enrollment":17085,"conditions":17086,"interventions":17087},"NCT00077636","ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.",[92],"2003-12",1469,[27],[16996,16996,17072,17072],{"nctId":17089,"briefTitle":17090,"status":107,"phases":17091,"primaryCompletion":8934,"completion":8934,"start":8811,"enrollment":17092,"conditions":17093,"interventions":17094},"NCT00087633","PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.",[92],115,[27],[17072,16996],{"nctId":17096,"briefTitle":17097,"status":107,"phases":17098,"primaryCompletion":2932,"completion":2932,"start":16669,"enrollment":5376,"conditions":17099,"interventions":17100},"NCT00412334","SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.",[92],[27],[16996,16996,17072,17072],{"trials":17102,"activeCount":101},[],{"intervention":7139,"totalTrials":2563,"cells":17104},{"EARLY_PHASE1":17105,"PHASE1":17107,"PHASE2":17115,"PHASE3":17143,"PHASE4":17178,"NA":17184},{"trials":17106,"activeCount":101},[],{"trials":17108,"activeCount":101},[17109],{"nctId":17110,"briefTitle":17111,"status":107,"phases":17112,"primaryCompletion":3022,"completion":3022,"start":8688,"enrollment":3497,"conditions":17113,"interventions":17114},"NCT00800436","A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females",[89],[18],[7139],{"trials":17116,"activeCount":101},[17117,17124,17131,17139],{"nctId":17118,"briefTitle":17119,"status":107,"phases":17120,"primaryCompletion":4455,"completion":121,"start":17121,"enrollment":8322,"conditions":17122,"interventions":17123},"NCT02748213","A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and\u002For Metastatic Breast Cancer",[90],"2002-02",[18],[9083,15945,7139],{"nctId":17125,"briefTitle":17126,"status":107,"phases":17127,"primaryCompletion":4445,"completion":2847,"start":6315,"enrollment":17128,"conditions":17129,"interventions":17130},"NCT01401166","Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer",[90],488,[4139],[7139,7139],{"nctId":17132,"briefTitle":17133,"status":107,"phases":17134,"primaryCompletion":4315,"completion":4315,"start":17135,"enrollment":11473,"conditions":17136,"interventions":17137},"NCT00337649","A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer",[89,90],"2004-05",[18],[17138,7139],"Epothilone D",{"nctId":9569,"briefTitle":9570,"status":107,"phases":17140,"primaryCompletion":9572,"completion":9572,"start":9573,"enrollment":9574,"conditions":17141,"interventions":17142},[90],[18],[7139,947,1221],{"trials":17144,"activeCount":101},[17145,17149,17156,17160,17170],{"nctId":7134,"briefTitle":7135,"status":130,"phases":17146,"primaryCompletion":3006,"completion":2955,"start":2905,"enrollment":4066,"conditions":17147,"interventions":17148},[91],[1735],[1166,1167,7139],{"nctId":17150,"briefTitle":17151,"status":107,"phases":17152,"primaryCompletion":3006,"completion":3006,"start":17153,"enrollment":1047,"conditions":17154,"interventions":17155},"NCT02721641","A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer",[91],"1999-06",[1241],[7139],{"nctId":9641,"briefTitle":9642,"status":107,"phases":17157,"primaryCompletion":3246,"completion":3246,"start":6277,"enrollment":9644,"conditions":17158,"interventions":17159},[91],[18],[5275,947,7139],{"nctId":17161,"briefTitle":17162,"status":107,"phases":17163,"primaryCompletion":17164,"completion":17165,"start":17166,"enrollment":17167,"conditions":17168,"interventions":17169},"NCT01566721","A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",[91],"2015-03-10","2020-02-19","2012-05-17",2577,[4139],[7139],{"nctId":17171,"briefTitle":17172,"status":107,"phases":17173,"primaryCompletion":8659,"completion":2800,"start":17174,"enrollment":17175,"conditions":17176,"interventions":17177},"NCT00045032","Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer",[91],"2001-11",5099,[18],[7139,7139],{"trials":17179,"activeCount":101},[17180],{"nctId":15958,"briefTitle":15959,"status":107,"phases":17181,"primaryCompletion":4322,"completion":4488,"start":2923,"enrollment":15961,"conditions":17182,"interventions":17183},[92],[18],[5381,15945,7139,5381,15945],{"trials":17185,"activeCount":101},[],{"intervention":3059,"totalTrials":462,"cells":17187},{"EARLY_PHASE1":17188,"PHASE1":17190,"PHASE2":17192,"PHASE3":17207,"PHASE4":17239,"NA":17253},{"trials":17189,"activeCount":101},[],{"trials":17191,"activeCount":101},[],{"trials":17193,"activeCount":101},[17194,17198],{"nctId":14443,"briefTitle":14444,"status":130,"phases":17195,"primaryCompletion":8689,"completion":8689,"start":14446,"enrollment":1796,"conditions":17196,"interventions":17197},[90],[14448],[3059,11717,5848],{"nctId":17199,"briefTitle":17200,"status":107,"phases":17201,"primaryCompletion":11437,"completion":11437,"start":2515,"enrollment":3574,"conditions":17202,"interventions":17204},"NCT01948401","A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma",[90],[17203],"Asthma",[17205,14484,17206],"LABA","prednisolone",{"trials":17208,"activeCount":101},[17209,17213,17217,17221,17231,17235],{"nctId":10139,"briefTitle":10140,"status":130,"phases":17210,"primaryCompletion":4582,"completion":4582,"start":7096,"enrollment":973,"conditions":17211,"interventions":17212},[91],[3597],[3707,3059,2820,992],{"nctId":15925,"briefTitle":15926,"status":107,"phases":17214,"primaryCompletion":14712,"completion":14712,"start":4562,"enrollment":15928,"conditions":17215,"interventions":17216},[91],[18],[3059,5381,15931],{"nctId":14478,"briefTitle":14479,"status":107,"phases":17218,"primaryCompletion":3479,"completion":3479,"start":5457,"enrollment":1058,"conditions":17219,"interventions":17220},[91],[5911],[5848,14483,14484],{"nctId":17222,"briefTitle":17223,"status":107,"phases":17224,"primaryCompletion":4455,"completion":4455,"start":17225,"enrollment":17226,"conditions":17227,"interventions":17228},"NCT00048152","A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients",[91],"2000-12",539,[5846],[3059,17229,17229,17230,11737],"Neoral","Zenapax",{"nctId":15587,"briefTitle":15588,"status":107,"phases":17232,"primaryCompletion":6004,"completion":3246,"start":4281,"enrollment":15590,"conditions":17233,"interventions":17234},[91],[2367],[5894,3035,5838,14484],{"nctId":3048,"briefTitle":3049,"status":107,"phases":17236,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":17237,"interventions":17238},[91],[2508],[1096,1357,3057,3058,3059,2824],{"trials":17240,"activeCount":101},[17241,17245],{"nctId":14528,"briefTitle":14529,"status":107,"phases":17242,"primaryCompletion":4233,"completion":4233,"start":4113,"enrollment":4701,"conditions":17243,"interventions":17244},[92],[5846],[5848,14533,14534,14484],{"nctId":17246,"briefTitle":17247,"status":107,"phases":17248,"primaryCompletion":3084,"completion":3084,"start":17249,"enrollment":1936,"conditions":17250,"interventions":17251},"NCT00121810","Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients",[92],"2003-08",[5846],[11737,3059,17252,11738],"Calcineurin inhibitors",{"trials":17254,"activeCount":101},[],{"intervention":11717,"totalTrials":1796,"cells":17256},{"EARLY_PHASE1":17257,"PHASE1":17259,"PHASE2":17271,"PHASE3":17281,"PHASE4":17296,"NA":17310},{"trials":17258,"activeCount":101},[],{"trials":17260,"activeCount":101},[17261,17267],{"nctId":17262,"briefTitle":17263,"status":107,"phases":17264,"primaryCompletion":2768,"completion":2768,"start":2905,"enrollment":5901,"conditions":17265,"interventions":17266},"NCT01514968","A Drug-Drug Interaction Study Between Danoprevir\u002FLow-Dose Ritonavir and Cyclosporine in Healthy Volunteers",[89],[21],[5850,11967,11969],{"nctId":12914,"briefTitle":12915,"status":107,"phases":17268,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1058,"conditions":17269,"interventions":17270},[89],[7754],[12889,398,12921,11717],{"trials":17272,"activeCount":101},[17273,17277],{"nctId":14443,"briefTitle":14444,"status":130,"phases":17274,"primaryCompletion":8689,"completion":8689,"start":14446,"enrollment":1796,"conditions":17275,"interventions":17276},[90],[14448],[3059,11717,5848],{"nctId":14451,"briefTitle":14452,"status":107,"phases":17278,"primaryCompletion":4113,"completion":4113,"start":14454,"enrollment":909,"conditions":17279,"interventions":17280},[90],[5846],[5848,14457,11717,14458],{"trials":17282,"activeCount":101},[17283,17292],{"nctId":17284,"briefTitle":17285,"status":107,"phases":17286,"primaryCompletion":5891,"completion":5891,"start":7054,"enrollment":2640,"conditions":17287,"interventions":17289},"NCT02686619","Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients",[91],[17288],"Renal Transplantation",[11717,5913,17290,17291,11738],"Mycophenoate Mofetil","Prednisolone",{"nctId":5841,"briefTitle":5842,"status":107,"phases":17293,"primaryCompletion":3325,"completion":3325,"start":4282,"enrollment":5844,"conditions":17294,"interventions":17295},[91],[5846],[5848,5848,5849,5839,5850],{"trials":17297,"activeCount":101},[17298,17302,17306],{"nctId":11710,"briefTitle":11711,"status":107,"phases":17299,"primaryCompletion":3692,"completion":3692,"start":11713,"enrollment":11714,"conditions":17300,"interventions":17301},[92],[5846],[5914,11717,3754],{"nctId":11731,"briefTitle":11732,"status":107,"phases":17303,"primaryCompletion":6343,"completion":4562,"start":2923,"enrollment":11734,"conditions":17304,"interventions":17305},[92],[11724],[11737,3754,11717,11738],{"nctId":5905,"briefTitle":5906,"status":107,"phases":17307,"primaryCompletion":5805,"completion":5805,"start":5908,"enrollment":5909,"conditions":17308,"interventions":17309},[92],[5911],[5913,274,5914,5850],{"trials":17311,"activeCount":101},[],{"intervention":17011,"totalTrials":1796,"cells":17313},{"EARLY_PHASE1":17314,"PHASE1":17316,"PHASE2":17318,"PHASE3":17348,"PHASE4":17358,"NA":17367},{"trials":17315,"activeCount":101},[],{"trials":17317,"activeCount":101},[],{"trials":17319,"activeCount":101},[17320,17324,17328,17332,17336,17340,17344],{"nctId":17005,"briefTitle":17006,"status":107,"phases":17321,"primaryCompletion":4206,"completion":4206,"start":4513,"enrollment":17008,"conditions":17322,"interventions":17323},[90],[27],[16996,17011,17011,17012,17012,17012],{"nctId":17014,"briefTitle":17015,"status":107,"phases":17325,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":549,"conditions":17326,"interventions":17327},[90],[27],[16996,17011,17019,17019,17019,17019],{"nctId":17021,"briefTitle":17022,"status":107,"phases":17329,"primaryCompletion":2948,"completion":2948,"start":5181,"enrollment":16946,"conditions":17330,"interventions":17331},[90],[27],[16996,17026,17026,17026,17011,11782],{"nctId":17028,"briefTitle":17029,"status":107,"phases":17333,"primaryCompletion":2768,"completion":2768,"start":6135,"enrollment":17031,"conditions":17334,"interventions":17335},[90],[27],[16996,16996,17011,17011,17034,17034,17034,17034],{"nctId":17036,"briefTitle":17037,"status":107,"phases":17337,"primaryCompletion":3085,"completion":3085,"start":6277,"enrollment":15475,"conditions":17338,"interventions":17339},[90],[27],[16996,17041,17042,17043],{"nctId":17045,"briefTitle":17046,"status":107,"phases":17341,"primaryCompletion":4249,"completion":4249,"start":2931,"enrollment":17048,"conditions":17342,"interventions":17343},[90],[27],[16996,16996,17011,17011,17034,11967,11969],{"nctId":17052,"briefTitle":17053,"status":107,"phases":17345,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":17346,"interventions":17347},[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],{"trials":17349,"activeCount":101},[17350],{"nctId":17351,"briefTitle":17352,"status":107,"phases":17353,"primaryCompletion":8811,"completion":8811,"start":17354,"enrollment":4447,"conditions":17355,"interventions":17357},"NCT00048945","Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B",[91],"2002-01",[17356],"Chronic Hepatitis B",[17041],{"trials":17359,"activeCount":101},[17360],{"nctId":17361,"briefTitle":17362,"status":107,"phases":17363,"primaryCompletion":2685,"completion":2685,"start":4198,"enrollment":4079,"conditions":17364,"interventions":17365},"NCT00560274","A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.",[92],[24],[17011,17366,16992],"Ribavirin",{"trials":17368,"activeCount":101},[],{"intervention":11737,"totalTrials":306,"cells":17370},{"EARLY_PHASE1":17371,"PHASE1":17373,"PHASE2":17375,"PHASE3":17377,"PHASE4":17390,"NA":17425},{"trials":17372,"activeCount":101},[],{"trials":17374,"activeCount":101},[],{"trials":17376,"activeCount":101},[],{"trials":17378,"activeCount":101},[17379,17386],{"nctId":17380,"briefTitle":17381,"status":107,"phases":17382,"completion":3692,"start":11713,"enrollment":846,"conditions":17383,"interventions":17385},"NCT00408213","A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.",[91],[17384],"Myasthenia Gravis Generalised",[11737],{"nctId":17222,"briefTitle":17223,"status":107,"phases":17387,"primaryCompletion":4455,"completion":4455,"start":17225,"enrollment":17226,"conditions":17388,"interventions":17389},[91],[5846],[3059,17229,17229,17230,11737],{"trials":17391,"activeCount":101},[17392,17399,17405,17409,17413,17419],{"nctId":17393,"briefTitle":17394,"status":107,"phases":17395,"primaryCompletion":121,"completion":121,"start":5469,"enrollment":1259,"conditions":17396,"interventions":17397},"NCT00337493","Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.",[92],[5846],[11737,11737,17398,17398],"Cyclosporine or tacrolimus",{"nctId":17400,"briefTitle":17401,"status":130,"phases":17402,"primaryCompletion":5457,"completion":5457,"start":133,"enrollment":709,"conditions":17403,"interventions":17404},"NCT00121784","Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients",[92],[5911],[11737],{"nctId":17246,"briefTitle":17247,"status":107,"phases":17406,"primaryCompletion":3084,"completion":3084,"start":17249,"enrollment":1936,"conditions":17407,"interventions":17408},[92],[5846],[11737,3059,17252,11738],{"nctId":11731,"briefTitle":11732,"status":107,"phases":17410,"primaryCompletion":6343,"completion":4562,"start":2923,"enrollment":11734,"conditions":17411,"interventions":17412},[92],[11724],[11737,3754,11717,11738],{"nctId":17414,"briefTitle":17415,"status":130,"phases":17416,"start":7096,"conditions":17417,"interventions":17418},"NCT00420472","A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.",[92],[5846],[11737],{"nctId":17420,"briefTitle":17421,"status":107,"phases":17422,"primaryCompletion":3103,"completion":3103,"start":3308,"enrollment":3497,"conditions":17423,"interventions":17424},"NCT00817687","A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation",[92],[5846],[11737,11737],{"trials":17426,"activeCount":101},[],{"intervention":17428,"totalTrials":306,"cells":17429},"Enfuvirtide",{"EARLY_PHASE1":17430,"PHASE1":17432,"PHASE2":17434,"PHASE3":17452,"PHASE4":17474,"NA":17496},{"trials":17431,"activeCount":101},[],{"trials":17433,"activeCount":101},[],{"trials":17435,"activeCount":101},[17436,17445],{"nctId":17437,"briefTitle":17438,"status":107,"phases":17439,"start":17440,"enrollment":4683,"conditions":17441,"interventions":17442},"NCT00002239","A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults",[90],"1999-05",[33],[17428,11782,17443,17444,16518],"Abacavir sulfate","Amprenavir",{"nctId":17446,"briefTitle":17447,"status":107,"phases":17448,"primaryCompletion":4410,"start":17449,"enrollment":973,"conditions":17450,"interventions":17451},"NCT00022763","T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents",[90],"2001-08",[33],[17428],{"trials":17453,"activeCount":101},[17454,17461,17468],{"nctId":17455,"briefTitle":17456,"status":107,"phases":17457,"enrollment":17458,"conditions":17459,"interventions":17460},"NCT00008528","T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and\u002For Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs",[91],525,[33],[17428],{"nctId":17462,"briefTitle":17463,"status":107,"phases":17464,"primaryCompletion":4198,"completion":4198,"start":4410,"enrollment":6821,"conditions":17465,"interventions":17466},"NCT02733419","Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection",[91],[33],[17428,17467],"Optimized background antiretroviral regimen",{"nctId":17469,"briefTitle":17470,"status":107,"phases":17471,"enrollment":17458,"conditions":17472,"interventions":17473},"NCT00021554","T-20 in HIV Patients With Prior Drug Treatment and\u002For Resistance to Each of the Three Classes of Anti-HIV Drugs",[91],[33],[17428],{"trials":17475,"activeCount":101},[17476,17482,17489],{"nctId":17477,"briefTitle":17478,"status":107,"phases":17479,"primaryCompletion":2769,"completion":2769,"start":9499,"enrollment":145,"conditions":17480,"interventions":17481},"NCT02582983","A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection",[92],[33],[17428],{"nctId":17483,"briefTitle":17484,"status":107,"phases":17485,"primaryCompletion":2965,"completion":2965,"start":11300,"enrollment":942,"conditions":17486,"interventions":17487},"NCT02569502","A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection",[92],[33],[17488],"enfuvirtide",{"nctId":17490,"briefTitle":17491,"status":107,"phases":17492,"primaryCompletion":5820,"completion":4582,"start":13164,"enrollment":1092,"conditions":17493,"interventions":17494},"NCT00487188","A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience",[92],[33],[17428,17495],"Highly active antiretroviral treatment",{"trials":17497,"activeCount":101},[],{"intervention":17499,"totalTrials":306,"cells":17500},"enfuvirtide [Fuzeon]",{"EARLY_PHASE1":17501,"PHASE1":17503,"PHASE2":17505,"PHASE3":17523,"PHASE4":17525,"NA":17569},{"trials":17502,"activeCount":101},[],{"trials":17504,"activeCount":101},[],{"trials":17506,"activeCount":101},[17507,17514],{"nctId":17508,"briefTitle":17509,"status":107,"phases":17510,"primaryCompletion":8320,"completion":8320,"start":121,"enrollment":1174,"conditions":17511,"interventions":17512},"NCT00615134","INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.",[90],[33],[17499,17513],"Optimized background ARV therapy",{"nctId":17515,"briefTitle":17516,"status":107,"phases":17517,"primaryCompletion":8751,"completion":8751,"start":17518,"enrollment":17519,"conditions":17520,"interventions":17521},"NCT00089492","A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients",[90],"2004-07",64,[33],[17522,17499,17499],"Optimized Background ARVs",{"trials":17524,"activeCount":101},[],{"trials":17526,"activeCount":101},[17527,17533,17540,17548,17556,17563],{"nctId":17528,"briefTitle":17529,"status":107,"phases":17530,"primaryCompletion":9771,"completion":9771,"start":2923,"enrollment":1724,"conditions":17531,"interventions":17532},"NCT00233883","WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.",[92],[33],[17499,17499],{"nctId":17534,"briefTitle":17535,"status":343,"phases":17536,"primaryCompletion":121,"completion":121,"start":8484,"enrollment":101,"conditions":17537,"interventions":17538},"NCT00461266","ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.",[92],[33],[17499,17539],"Antiretroviral therapy",{"nctId":17541,"briefTitle":17542,"status":107,"phases":17543,"primaryCompletion":8484,"completion":6620,"start":4455,"enrollment":3750,"conditions":17544,"interventions":17545},"NCT00326963","BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.",[92],[33],[17546,17547,17499],"Background ARVs","PI",{"nctId":17549,"briefTitle":17550,"status":130,"phases":17551,"primaryCompletion":8934,"completion":8934,"start":6377,"enrollment":1174,"conditions":17552,"interventions":17553},"NCT00488059","A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients",[92],[33],[17499,17554,17555,17499],"Optimized background ARV","Integrase inhibitor",{"nctId":17557,"briefTitle":17558,"status":107,"phases":17559,"primaryCompletion":133,"completion":133,"start":11713,"enrollment":4499,"conditions":17560,"interventions":17561},"NCT00232908","QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection",[92],[33],[17562,17499],"ARV regimen",{"nctId":17564,"briefTitle":17565,"status":107,"phases":17566,"primaryCompletion":16669,"completion":16669,"start":8751,"enrollment":3105,"conditions":17567,"interventions":17568},"NCT00337701","BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection",[92],[33],[17499,17499],{"trials":17570,"activeCount":101},[],{"intervention":16486,"totalTrials":306,"cells":17572},{"EARLY_PHASE1":17573,"PHASE1":17575,"PHASE2":17577,"PHASE3":17587,"PHASE4":17619,"NA":17629},{"trials":17574,"activeCount":101},[],{"trials":17576,"activeCount":101},[],{"trials":17578,"activeCount":101},[17579,17583],{"nctId":16481,"briefTitle":16482,"status":107,"phases":17580,"enrollment":1026,"conditions":17581,"interventions":17582},[90],[33],[16450,16486,16487,16478,16479,16488],{"nctId":16496,"briefTitle":16497,"status":107,"phases":17584,"enrollment":1184,"conditions":17585,"interventions":17586},[90],[33],[16450,16486,16478],{"trials":17588,"activeCount":101},[17589,17593,17601,17611,17615],{"nctId":16520,"briefTitle":16521,"status":107,"phases":17590,"enrollment":425,"conditions":17591,"interventions":17592},[91],[33,16524],[16468,16450,16486,16487],{"nctId":17594,"briefTitle":17595,"status":107,"phases":17596,"primaryCompletion":4206,"completion":4206,"start":6702,"enrollment":414,"conditions":17597,"interventions":17598},"NCT01095835","A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)",[91],[11790],[17599,17600,16486],"Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg","Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg",{"nctId":17602,"briefTitle":17603,"status":107,"phases":17604,"primaryCompletion":3413,"completion":3413,"start":17605,"enrollment":447,"conditions":17606,"interventions":17608},"NCT02263079","A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase",[91],"2014-06-16",[17607],"Pediatric Immuno-Tolerant Chronic Hepatitis B",[17609,16486,17610],"Entecavir","Pegylated Interferon Alfa-2A",{"nctId":16547,"briefTitle":16548,"status":107,"phases":17612,"enrollment":16550,"conditions":17613,"interventions":17614},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":16554,"briefTitle":16555,"status":107,"phases":17616,"enrollment":931,"conditions":17617,"interventions":17618},[91],[33],[16450,16486,16478],{"trials":17620,"activeCount":101},[17621],{"nctId":17622,"briefTitle":17623,"status":107,"phases":17624,"primaryCompletion":4322,"completion":4322,"start":133,"enrollment":17625,"conditions":17626,"interventions":17627},"NCT02598063","A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B",[92],255,[11790],[17628,16486,8692],"Adefovir dipivoxil",{"trials":17630,"activeCount":101},[],{"intervention":16097,"totalTrials":4548,"cells":17632},{"EARLY_PHASE1":17633,"PHASE1":17635,"PHASE2":17637,"PHASE3":17639,"PHASE4":17669,"NA":17675},{"trials":17634,"activeCount":101},[],{"trials":17636,"activeCount":101},[],{"trials":17638,"activeCount":101},[],{"trials":17640,"activeCount":101},[17641,17647,17651,17655,17659,17665],{"nctId":17642,"briefTitle":17643,"status":107,"phases":17644,"primaryCompletion":4206,"completion":4206,"start":121,"enrollment":1891,"conditions":17645,"interventions":17646},"NCT00605293","A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia",[91],[24],[16958,16097],{"nctId":16924,"briefTitle":16925,"status":107,"phases":17648,"primaryCompletion":2769,"completion":2769,"start":8811,"enrollment":16927,"conditions":17649,"interventions":17650},[91],[24],[16930,16097,16023,16000],{"nctId":16953,"briefTitle":16954,"status":130,"phases":17652,"primaryCompletion":4086,"completion":4086,"start":8484,"enrollment":2389,"conditions":17653,"interventions":17654},[91],[24],[16958,16959,16065],{"nctId":16091,"briefTitle":16092,"status":107,"phases":17656,"primaryCompletion":4474,"completion":4474,"start":4582,"enrollment":16094,"conditions":17657,"interventions":17658},[91],[24],[15973,16097],{"nctId":17660,"briefTitle":17661,"status":130,"phases":17662,"primaryCompletion":4513,"completion":4513,"start":7096,"enrollment":6507,"conditions":17663,"interventions":17664},"NCT00422513","A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.",[91],[24],[16958,16097],{"nctId":16110,"briefTitle":16111,"status":130,"phases":17666,"primaryCompletion":121,"completion":121,"start":6506,"enrollment":920,"conditions":17667,"interventions":17668},[91],[24],[16097,15973],{"trials":17670,"activeCount":101},[17671],{"nctId":16976,"briefTitle":16977,"status":107,"phases":17672,"primaryCompletion":16979,"completion":16979,"start":16980,"enrollment":16981,"conditions":17673,"interventions":17674},[92],[16983],[16951,16985,16950,16958],{"trials":17676,"activeCount":101},[],{"intervention":17609,"totalTrials":942,"cells":17678},{"EARLY_PHASE1":17679,"PHASE1":17681,"PHASE2":17683,"PHASE3":17695,"PHASE4":17701,"NA":17732},{"trials":17680,"activeCount":101},[],{"trials":17682,"activeCount":101},[],{"trials":17684,"activeCount":101},[17685],{"nctId":17686,"briefTitle":17687,"status":107,"phases":17688,"primaryCompletion":17689,"completion":17689,"start":17690,"enrollment":5013,"conditions":17691,"interventions":17692},"NCT02391805","A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection",[90],"2017-10-16","2015-05-17",[11790],[17609,17693,17694],"RO6864018","Tenofovir",{"trials":17696,"activeCount":101},[17697],{"nctId":17602,"briefTitle":17603,"status":107,"phases":17698,"primaryCompletion":3413,"completion":3413,"start":17605,"enrollment":447,"conditions":17699,"interventions":17700},[91],[17607],[17609,16486,17610],{"trials":17702,"activeCount":101},[17703,17710,17716,17725],{"nctId":17704,"briefTitle":17705,"status":107,"phases":17706,"primaryCompletion":2905,"completion":2905,"start":4322,"enrollment":2708,"conditions":17707,"interventions":17708},"NCT00940485","A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B",[92],[11790],[17709,17709,17072],"entecavir",{"nctId":17711,"briefTitle":17712,"status":107,"phases":17713,"primaryCompletion":3022,"completion":3022,"start":6673,"enrollment":14666,"conditions":17714,"interventions":17715},"NCT00614471","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.",[92],[11790],[17609,17609,17072,17072],{"nctId":17717,"briefTitle":17718,"status":107,"phases":17719,"primaryCompletion":17720,"completion":17720,"start":17721,"enrollment":571,"conditions":17722,"interventions":17723},"NCT00922207","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B",[92],"2014-09-29","2010-05-07",[11790],[17724,17609,17072],"Adefovir",{"nctId":17726,"briefTitle":17727,"status":343,"phases":17728,"primaryCompletion":11550,"completion":11550,"start":17729,"enrollment":101,"conditions":17730,"interventions":17731},"NCT01179594","A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.",[92],"2010-09-18",[11790],[17709,17072,17072],{"trials":17733,"activeCount":101},[],{"intervention":17735,"totalTrials":2631,"cells":17736},"valganciclovir [Valcyte]",{"EARLY_PHASE1":17737,"PHASE1":17739,"PHASE2":17755,"PHASE3":17757,"PHASE4":17765,"NA":17783},{"trials":17738,"activeCount":101},[],{"trials":17740,"activeCount":101},[17741,17748],{"nctId":17742,"briefTitle":17743,"status":107,"phases":17744,"primaryCompletion":2684,"completion":2684,"start":2931,"enrollment":510,"conditions":17745,"interventions":17747},"NCT01165580","A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age",[89],[17746],"Cytomegalovirus Infections, Heart Transplantation",[17735],{"nctId":17749,"briefTitle":17750,"status":107,"phases":17751,"primaryCompletion":8751,"completion":8751,"start":4410,"enrollment":5013,"conditions":17752,"interventions":17754},"NCT00377741","A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.",[89],[17753],"Cytomegalovirus Infections",[17735],{"trials":17756,"activeCount":101},[],{"trials":17758,"activeCount":101},[17759],{"nctId":17760,"briefTitle":17761,"status":107,"phases":17762,"primaryCompletion":122,"completion":122,"start":17135,"enrollment":6629,"conditions":17763,"interventions":17764},"NCT00090766","A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients",[90,91],[17753],[17735],{"trials":17766,"activeCount":101},[17767,17774],{"nctId":17768,"briefTitle":17769,"status":107,"phases":17770,"primaryCompletion":3085,"completion":3085,"start":15950,"enrollment":3414,"conditions":17771,"interventions":17772},"NCT00431353","VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients",[92],[17753],[17773,17735],"Ganciclovir",{"nctId":17775,"briefTitle":17776,"status":107,"phases":17777,"primaryCompletion":17778,"completion":17778,"start":17779,"enrollment":2999,"conditions":17780,"interventions":17782},"NCT01376804","A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients",[92],"2013-05-31","2011-07-31",[17781],"Kidney Transplantation, Cytomegalovirus Infections",[17735],{"trials":17784,"activeCount":101},[],{"intervention":2870,"totalTrials":2631,"cells":17786},{"EARLY_PHASE1":17787,"PHASE1":17789,"PHASE2":17791,"PHASE3":17793,"PHASE4":17807,"NA":17817},{"trials":17788,"activeCount":101},[],{"trials":17790,"activeCount":101},[],{"trials":17792,"activeCount":101},[],{"trials":17794,"activeCount":101},[17795,17799,17803],{"nctId":2861,"briefTitle":2862,"status":107,"phases":17796,"primaryCompletion":2864,"completion":2865,"start":2866,"enrollment":2867,"conditions":17797,"interventions":17798},[91],[15],[1096,2870],{"nctId":2988,"briefTitle":2989,"status":107,"phases":17800,"primaryCompletion":393,"completion":393,"start":2991,"enrollment":1395,"conditions":17801,"interventions":17802},[91],[15],[1096,2870,2994,2824],{"nctId":3019,"briefTitle":3020,"status":107,"phases":17804,"primaryCompletion":2793,"completion":2793,"start":3022,"enrollment":1724,"conditions":17805,"interventions":17806},[91],[15],[2870,1096],{"trials":17808,"activeCount":101},[17809,17813],{"nctId":15730,"briefTitle":15731,"status":107,"phases":17810,"primaryCompletion":15733,"completion":15733,"start":2975,"enrollment":4713,"conditions":17811,"interventions":17812},[92],[15],[5894,2870],{"nctId":3134,"briefTitle":3135,"status":107,"phases":17814,"primaryCompletion":3137,"completion":3137,"start":3138,"enrollment":316,"conditions":17815,"interventions":17816},[92],[3140],[2870,1096],{"trials":17818,"activeCount":101},[],{"intervention":17820,"totalTrials":5110,"cells":17821},"Omalizumab",{"EARLY_PHASE1":17822,"PHASE1":17824,"PHASE2":17826,"PHASE3":17828,"PHASE4":17853,"NA":17864},{"trials":17823,"activeCount":101},[],{"trials":17825,"activeCount":101},[],{"trials":17827,"activeCount":101},[],{"trials":17829,"activeCount":101},[17830,17839,17846],{"nctId":17831,"briefTitle":17832,"status":107,"phases":17833,"primaryCompletion":7568,"completion":7568,"start":17834,"enrollment":12,"conditions":17835,"interventions":17838},"NCT03478930","An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps",[91],"2018-05-09",[17836,17837],"Nasal Polyps","Chronic Rhinosinusitis",[17820],{"nctId":17840,"briefTitle":17841,"status":107,"phases":17842,"primaryCompletion":17843,"completion":17843,"start":8100,"enrollment":7408,"conditions":17844,"interventions":17845},"NCT03280537","A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps",[91],"2019-03-07",[17836,17837],[17820],{"nctId":17847,"briefTitle":17848,"status":107,"phases":17849,"primaryCompletion":581,"completion":581,"start":17850,"enrollment":897,"conditions":17851,"interventions":17852},"NCT03280550","A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps",[91],"2017-11-15",[17836,17837],[17820],{"trials":17854,"activeCount":101},[17855],{"nctId":17856,"briefTitle":17857,"status":107,"phases":17858,"primaryCompletion":17859,"completion":17859,"start":17860,"enrollment":17861,"conditions":17862,"interventions":17863},"NCT01922037","A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)",[92],"2016-03-31","2013-06-19",806,[17203],[17820],{"trials":17865,"activeCount":101},[],{"intervention":17867,"totalTrials":5110,"cells":17868},"oseltamivir [Tamiflu]",{"EARLY_PHASE1":17869,"PHASE1":17871,"PHASE2":17886,"PHASE3":17888,"PHASE4":17890,"NA":17904},{"trials":17870,"activeCount":101},[],{"trials":17872,"activeCount":101},[17873,17880],{"nctId":17874,"briefTitle":17875,"status":107,"phases":17876,"primaryCompletion":6578,"completion":6578,"start":5271,"enrollment":425,"conditions":17877,"interventions":17878},"NCT01172847","A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers",[89],[21],[17867,17879],"rimantadine",{"nctId":17881,"briefTitle":17882,"status":107,"phases":17883,"primaryCompletion":2948,"completion":2948,"start":4474,"enrollment":306,"conditions":17884,"interventions":17885},"NCT01033734","A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza",[89],[12770],[17867],{"trials":17887,"activeCount":101},[],{"trials":17889,"activeCount":101},[],{"trials":17891,"activeCount":101},[17892,17898],{"nctId":17893,"briefTitle":17894,"status":130,"phases":17895,"primaryCompletion":8484,"completion":8484,"start":16669,"conditions":17896,"interventions":17897},"NCT00436124","A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.",[92],[12770],[17867],{"nctId":17899,"briefTitle":17900,"status":107,"phases":17901,"primaryCompletion":6620,"completion":6620,"start":14454,"enrollment":973,"conditions":17902,"interventions":17903},"NCT00412555","A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.",[92],[12770],[17867],{"trials":17905,"activeCount":101},[],{"intervention":5913,"totalTrials":5110,"cells":17907},{"EARLY_PHASE1":17908,"PHASE1":17910,"PHASE2":17912,"PHASE3":17914,"PHASE4":17920,"NA":17938},{"trials":17909,"activeCount":101},[],{"trials":17911,"activeCount":101},[],{"trials":17913,"activeCount":101},[],{"trials":17915,"activeCount":101},[17916],{"nctId":17284,"briefTitle":17285,"status":107,"phases":17917,"primaryCompletion":5891,"completion":5891,"start":7054,"enrollment":2640,"conditions":17918,"interventions":17919},[91],[17288],[11717,5913,17290,17291,11738],{"trials":17921,"activeCount":101},[17922,17930,17934],{"nctId":17923,"briefTitle":17924,"status":107,"phases":17925,"primaryCompletion":8977,"completion":8977,"start":7153,"enrollment":2563,"conditions":17926,"interventions":17927},"NCT02576145","A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)",[92],[5846],[17928,5913,17929],"DT","KLH",{"nctId":14536,"briefTitle":14537,"status":107,"phases":17931,"primaryCompletion":4513,"completion":4513,"start":9499,"enrollment":1058,"conditions":17932,"interventions":17933},[92],[5911],[5913,5914,14541],{"nctId":5905,"briefTitle":5906,"status":107,"phases":17935,"primaryCompletion":5805,"completion":5805,"start":5908,"enrollment":5909,"conditions":17936,"interventions":17937},[92],[5911],[5913,274,5914,5850],{"trials":17939,"activeCount":101},[],{"intervention":13219,"totalTrials":5110,"cells":17941},{"EARLY_PHASE1":17942,"PHASE1":17944,"PHASE2":17946,"PHASE3":17955,"PHASE4":17968,"NA":17978},{"trials":17943,"activeCount":101},[],{"trials":17945,"activeCount":101},[],{"trials":17947,"activeCount":101},[17948],{"nctId":17949,"briefTitle":17950,"status":107,"phases":17951,"primaryCompletion":3007,"completion":3007,"start":3104,"enrollment":17952,"conditions":17953,"interventions":17954},"NCT01043029","A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment",[90],302,[36],[13182,13219],{"trials":17956,"activeCount":101},[17957,17964],{"nctId":17958,"briefTitle":17959,"status":107,"phases":17960,"primaryCompletion":5181,"completion":5181,"start":9596,"enrollment":17961,"conditions":17962,"interventions":17963},"NCT00909597","A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes",[91],756,[36],[13219,13206,13206],{"nctId":13214,"briefTitle":13215,"status":107,"phases":17965,"primaryCompletion":5181,"completion":5181,"start":8934,"enrollment":3105,"conditions":17966,"interventions":17967},[91],[36],[13131,13219,13206,13206],{"trials":17969,"activeCount":101},[17970],{"nctId":17971,"briefTitle":17972,"status":107,"phases":17973,"primaryCompletion":4474,"completion":4474,"start":121,"enrollment":1259,"conditions":17974,"interventions":17975},"NCT00545233","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.",[92],[27],[17072,17976,17977],"ribavirin [Copegus]","Pioglitazone",{"trials":17979,"activeCount":101},[],{"intervention":2994,"totalTrials":5110,"cells":17981},{"EARLY_PHASE1":17982,"PHASE1":17984,"PHASE2":17986,"PHASE3":17988,"PHASE4":18002,"NA":18016},{"trials":17983,"activeCount":101},[],{"trials":17985,"activeCount":101},[],{"trials":17987,"activeCount":101},[],{"trials":17989,"activeCount":101},[17990,17994,17998],{"nctId":7364,"briefTitle":7365,"status":107,"phases":17991,"primaryCompletion":1281,"completion":1281,"start":593,"enrollment":1651,"conditions":17992,"interventions":17993},[91],[7360],[7369,7370,5848,7371],{"nctId":2988,"briefTitle":2989,"status":107,"phases":17995,"primaryCompletion":393,"completion":393,"start":2991,"enrollment":1395,"conditions":17996,"interventions":17997},[91],[15],[1096,2870,2994,2824],{"nctId":3026,"briefTitle":3027,"status":107,"phases":17999,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":3031,"conditions":18000,"interventions":18001},[91],[15],[1096,3034,3035,3036],{"trials":18003,"activeCount":101},[18004],{"nctId":18005,"briefTitle":18006,"status":107,"phases":18007,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":18010,"interventions":18011},"NCT02537691","Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers",[92],"2015-08-28",483,[17203],[18012,17205,18013,18014,18015,2994],"FP","LTRA","LAMA","Theophylline",{"trials":18017,"activeCount":101},[],{"intervention":11738,"totalTrials":706,"cells":18019},{"EARLY_PHASE1":18020,"PHASE1":18022,"PHASE2":18024,"PHASE3":18026,"PHASE4":18032,"NA":18042},{"trials":18021,"activeCount":101},[],{"trials":18023,"activeCount":101},[],{"trials":18025,"activeCount":101},[],{"trials":18027,"activeCount":101},[18028],{"nctId":17284,"briefTitle":17285,"status":107,"phases":18029,"primaryCompletion":5891,"completion":5891,"start":7054,"enrollment":2640,"conditions":18030,"interventions":18031},[91],[17288],[11717,5913,17290,17291,11738],{"trials":18033,"activeCount":101},[18034,18038],{"nctId":17246,"briefTitle":17247,"status":107,"phases":18035,"primaryCompletion":3084,"completion":3084,"start":17249,"enrollment":1936,"conditions":18036,"interventions":18037},[92],[5846],[11737,3059,17252,11738],{"nctId":11731,"briefTitle":11732,"status":107,"phases":18039,"primaryCompletion":6343,"completion":4562,"start":2923,"enrollment":11734,"conditions":18040,"interventions":18041},[92],[11724],[11737,3754,11717,11738],{"trials":18043,"activeCount":101},[],{"intervention":15945,"totalTrials":706,"cells":18045},{"EARLY_PHASE1":18046,"PHASE1":18048,"PHASE2":18050,"PHASE3":18056,"PHASE4":18062,"NA":18068},{"trials":18047,"activeCount":101},[],{"trials":18049,"activeCount":101},[],{"trials":18051,"activeCount":101},[18052],{"nctId":17118,"briefTitle":17119,"status":107,"phases":18053,"primaryCompletion":4455,"completion":121,"start":17121,"enrollment":8322,"conditions":18054,"interventions":18055},[90],[18],[9083,15945,7139],{"trials":18057,"activeCount":101},[18058],{"nctId":15939,"briefTitle":15940,"status":107,"phases":18059,"primaryCompletion":4409,"completion":2801,"start":5805,"enrollment":15942,"conditions":18060,"interventions":18061},[91],[18],[5381,15945,15945],{"trials":18063,"activeCount":101},[18064],{"nctId":15958,"briefTitle":15959,"status":107,"phases":18065,"primaryCompletion":4322,"completion":4488,"start":2923,"enrollment":15961,"conditions":18066,"interventions":18067},[92],[18],[5381,15945,7139,5381,15945],{"trials":18069,"activeCount":101},[],{"intervention":17724,"totalTrials":162,"cells":18071},{"EARLY_PHASE1":18072,"PHASE1":18074,"PHASE2":18076,"PHASE3":18078,"PHASE4":18080,"NA":18093},{"trials":18073,"activeCount":101},[],{"trials":18075,"activeCount":101},[],{"trials":18077,"activeCount":101},[],{"trials":18079,"activeCount":101},[],{"trials":18081,"activeCount":101},[18082,18089],{"nctId":18083,"briefTitle":18084,"status":107,"phases":18085,"primaryCompletion":3674,"completion":3674,"start":8826,"enrollment":16020,"conditions":18086,"interventions":18087},"NCT01086085","A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive",[92],[11790],[17724,18088,18088,18088],"peginterferon alfa-2a [PEGASYS]",{"nctId":17717,"briefTitle":17718,"status":107,"phases":18090,"primaryCompletion":17720,"completion":17720,"start":17721,"enrollment":571,"conditions":18091,"interventions":18092},[92],[11790],[17724,17609,17072],{"trials":18094,"activeCount":101},[],{"intervention":10182,"totalTrials":162,"cells":18096},{"EARLY_PHASE1":18097,"PHASE1":18099,"PHASE2":18101,"PHASE3":18103,"PHASE4":18109,"NA":18115},{"trials":18098,"activeCount":101},[],{"trials":18100,"activeCount":101},[],{"trials":18102,"activeCount":101},[],{"trials":18104,"activeCount":101},[18105],{"nctId":10173,"briefTitle":10174,"status":107,"phases":18106,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":18107,"interventions":18108},[91],[10179],[8041,989,991,992,10181,10182],{"trials":18110,"activeCount":101},[18111],{"nctId":14622,"briefTitle":14623,"status":107,"phases":18112,"primaryCompletion":2965,"completion":2965,"start":8751,"enrollment":2532,"conditions":18113,"interventions":18114},[92],[125],[1572,14627,10182],{"trials":18116,"activeCount":101},[],{"intervention":2891,"totalTrials":162,"cells":18118},{"EARLY_PHASE1":18119,"PHASE1":18121,"PHASE2":18123,"PHASE3":18125,"PHASE4":18131,"NA":18137},{"trials":18120,"activeCount":101},[],{"trials":18122,"activeCount":101},[],{"trials":18124,"activeCount":101},[],{"trials":18126,"activeCount":101},[18127],{"nctId":2883,"briefTitle":2884,"status":107,"phases":18128,"primaryCompletion":2886,"completion":2886,"start":2887,"enrollment":2888,"conditions":18129,"interventions":18130},[91],[15],[1096,2891],{"trials":18132,"activeCount":101},[18133],{"nctId":3109,"briefTitle":3110,"status":107,"phases":18134,"primaryCompletion":3112,"completion":3113,"start":754,"enrollment":447,"conditions":18135,"interventions":18136},[92],[2367],[1096,3116,3117,2891],{"trials":18138,"activeCount":101},[],{"intervention":17929,"totalTrials":162,"cells":18140},{"EARLY_PHASE1":18141,"PHASE1":18143,"PHASE2":18145,"PHASE3":18147,"PHASE4":18163,"NA":18169},{"trials":18142,"activeCount":101},[],{"trials":18144,"activeCount":101},[],{"trials":18146,"activeCount":101},[],{"trials":18148,"activeCount":101},[18149],{"nctId":18150,"briefTitle":18151,"status":107,"phases":18152,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":18156,"interventions":18157},"NCT02545868","A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis",[91],"2017-02-14","2021-09-21","2015-10-27",[193],[18158,18159,18160,17929,18161,18162],"23-PPV","13-PCV Booster","Influenza Vaccine","OCR","TT Vaccine",{"trials":18164,"activeCount":101},[18165],{"nctId":17923,"briefTitle":17924,"status":107,"phases":18166,"primaryCompletion":8977,"completion":8977,"start":7153,"enrollment":2563,"conditions":18167,"interventions":18168},[92],[5846],[17928,5913,17929],{"trials":18170,"activeCount":101},[],{"intervention":18172,"totalTrials":162,"cells":18173},"Platinum-based chemotherapy",{"EARLY_PHASE1":18174,"PHASE1":18176,"PHASE2":18178,"PHASE3":18186,"PHASE4":18188,"NA":18197},{"trials":18175,"activeCount":101},[],{"trials":18177,"activeCount":101},[],{"trials":18179,"activeCount":101},[18180],{"nctId":18181,"briefTitle":18182,"status":130,"phases":18183,"primaryCompletion":4086,"completion":4086,"start":5457,"enrollment":15799,"conditions":18184,"interventions":18185},"NCT00404703","A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer",[90],[975],[5275,18172],{"trials":18187,"activeCount":101},[],{"trials":18189,"activeCount":101},[18190],{"nctId":18191,"briefTitle":18192,"status":107,"phases":18193,"primaryCompletion":2963,"completion":2963,"start":5457,"enrollment":18194,"conditions":18195,"interventions":18196},"NCT00451906","A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.",[92],2252,[2257],[18172,8105],{"trials":18198,"activeCount":101},[],{"intervention":17628,"totalTrials":162,"cells":18200},{"EARLY_PHASE1":18201,"PHASE1":18203,"PHASE2":18205,"PHASE3":18207,"PHASE4":18216,"NA":18222},{"trials":18202,"activeCount":101},[],{"trials":18204,"activeCount":101},[],{"trials":18206,"activeCount":101},[],{"trials":18208,"activeCount":101},[18209],{"nctId":18210,"briefTitle":18211,"status":107,"phases":18212,"primaryCompletion":2931,"completion":2931,"start":3085,"enrollment":462,"conditions":18213,"interventions":18214},"NCT00661076","ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B",[91],[11790],[18215,17072],"adefovir dipivoxil",{"trials":18217,"activeCount":101},[18218],{"nctId":17622,"briefTitle":17623,"status":107,"phases":18219,"primaryCompletion":4322,"completion":4322,"start":133,"enrollment":17625,"conditions":18220,"interventions":18221},[92],[11790],[17628,16486,8692],{"trials":18223,"activeCount":101},[],{"intervention":15612,"totalTrials":162,"cells":18225},{"EARLY_PHASE1":18226,"PHASE1":18228,"PHASE2":18230,"PHASE3":18232,"PHASE4":18238,"NA":18244},{"trials":18227,"activeCount":101},[],{"trials":18229,"activeCount":101},[],{"trials":18231,"activeCount":101},[],{"trials":18233,"activeCount":101},[18234],{"nctId":15607,"briefTitle":15608,"status":107,"phases":18235,"primaryCompletion":2792,"completion":5417,"start":2684,"enrollment":7923,"conditions":18236,"interventions":18237},[91],[15],[15612,5838,5894,5894,5894],{"trials":18239,"activeCount":101},[18240],{"nctId":15756,"briefTitle":15757,"status":130,"phases":18241,"primaryCompletion":4249,"completion":4249,"start":2685,"enrollment":162,"conditions":18242,"interventions":18243},[92],[15],[5894,15612],{"trials":18245,"activeCount":101},[],{"intervention":17205,"totalTrials":162,"cells":18247},{"EARLY_PHASE1":18248,"PHASE1":18250,"PHASE2":18252,"PHASE3":18258,"PHASE4":18260,"NA":18266},{"trials":18249,"activeCount":101},[],{"trials":18251,"activeCount":101},[],{"trials":18253,"activeCount":101},[18254],{"nctId":17199,"briefTitle":17200,"status":107,"phases":18255,"primaryCompletion":11437,"completion":11437,"start":2515,"enrollment":3574,"conditions":18256,"interventions":18257},[90],[17203],[17205,14484,17206],{"trials":18259,"activeCount":101},[],{"trials":18261,"activeCount":101},[18262],{"nctId":18005,"briefTitle":18006,"status":107,"phases":18263,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":18264,"interventions":18265},[92],[17203],[18012,17205,18013,18014,18015,2994],{"trials":18267,"activeCount":101},[],{"intervention":18269,"totalTrials":350,"cells":18270},"XELODA [capecitabine]",{"EARLY_PHASE1":18271,"PHASE1":18273,"PHASE2":18275,"PHASE3":18277,"PHASE4":18279,"NA":18288},{"trials":18272,"activeCount":101},[],{"trials":18274,"activeCount":101},[],{"trials":18276,"activeCount":101},[],{"trials":18278,"activeCount":101},[],{"trials":18280,"activeCount":101},[18281],{"nctId":18282,"briefTitle":18283,"status":130,"phases":18284,"primaryCompletion":8811,"completion":8811,"start":18285,"conditions":18286,"interventions":18287},"NCT00087620","A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer",[92],"2004-09",[18],[18269],{"trials":18289,"activeCount":101},[],{"intervention":11726,"totalTrials":350,"cells":18291},{"EARLY_PHASE1":18292,"PHASE1":18294,"PHASE2":18296,"PHASE3":18298,"PHASE4":18300,"NA":18306},{"trials":18293,"activeCount":101},[],{"trials":18295,"activeCount":101},[],{"trials":18297,"activeCount":101},[],{"trials":18299,"activeCount":101},[],{"trials":18301,"activeCount":101},[18302],{"nctId":11719,"briefTitle":11720,"status":107,"phases":18303,"primaryCompletion":4314,"completion":4314,"start":5820,"enrollment":11722,"conditions":18304,"interventions":18305},[92],[11724],[11726,3754,11727,11728,11729],{"trials":18307,"activeCount":101},[],{"intervention":11727,"totalTrials":350,"cells":18309},{"EARLY_PHASE1":18310,"PHASE1":18312,"PHASE2":18314,"PHASE3":18316,"PHASE4":18318,"NA":18324},{"trials":18311,"activeCount":101},[],{"trials":18313,"activeCount":101},[],{"trials":18315,"activeCount":101},[],{"trials":18317,"activeCount":101},[],{"trials":18319,"activeCount":101},[18320],{"nctId":11719,"briefTitle":11720,"status":107,"phases":18321,"primaryCompletion":4314,"completion":4314,"start":5820,"enrollment":11722,"conditions":18322,"interventions":18323},[92],[11724],[11726,3754,11727,11728,11729],{"trials":18325,"activeCount":101},[],{"intervention":11728,"totalTrials":350,"cells":18327},{"EARLY_PHASE1":18328,"PHASE1":18330,"PHASE2":18332,"PHASE3":18334,"PHASE4":18336,"NA":18342},{"trials":18329,"activeCount":101},[],{"trials":18331,"activeCount":101},[],{"trials":18333,"activeCount":101},[],{"trials":18335,"activeCount":101},[],{"trials":18337,"activeCount":101},[18338],{"nctId":11719,"briefTitle":11720,"status":107,"phases":18339,"primaryCompletion":4314,"completion":4314,"start":5820,"enrollment":11722,"conditions":18340,"interventions":18341},[92],[11724],[11726,3754,11727,11728,11729],{"trials":18343,"activeCount":101},[],{"intervention":11729,"totalTrials":350,"cells":18345},{"EARLY_PHASE1":18346,"PHASE1":18348,"PHASE2":18350,"PHASE3":18352,"PHASE4":18354,"NA":18360},{"trials":18347,"activeCount":101},[],{"trials":18349,"activeCount":101},[],{"trials":18351,"activeCount":101},[],{"trials":18353,"activeCount":101},[],{"trials":18355,"activeCount":101},[18356],{"nctId":11719,"briefTitle":11720,"status":107,"phases":18357,"primaryCompletion":4314,"completion":4314,"start":5820,"enrollment":11722,"conditions":18358,"interventions":18359},[92],[11724],[11726,3754,11727,11728,11729],{"trials":18361,"activeCount":101},[],{"intervention":6380,"totalTrials":350,"cells":18363},{"EARLY_PHASE1":18364,"PHASE1":18366,"PHASE2":18368,"PHASE3":18370,"PHASE4":18372,"NA":18378},{"trials":18365,"activeCount":101},[],{"trials":18367,"activeCount":101},[],{"trials":18369,"activeCount":101},[],{"trials":18371,"activeCount":101},[],{"trials":18373,"activeCount":101},[18374],{"nctId":6374,"briefTitle":6375,"status":107,"phases":18375,"primaryCompletion":4488,"completion":4488,"start":6377,"enrollment":931,"conditions":18376,"interventions":18377},[92],[15],[3677,2824,6380],{"trials":18379,"activeCount":101},[],{"intervention":15699,"totalTrials":350,"cells":18381},{"EARLY_PHASE1":18382,"PHASE1":18384,"PHASE2":18386,"PHASE3":18388,"PHASE4":18390,"NA":18396},{"trials":18383,"activeCount":101},[],{"trials":18385,"activeCount":101},[],{"trials":18387,"activeCount":101},[],{"trials":18389,"activeCount":101},[],{"trials":18391,"activeCount":101},[18392],{"nctId":15692,"briefTitle":15693,"status":130,"phases":18393,"primaryCompletion":15695,"completion":15695,"start":2931,"enrollment":1036,"conditions":18394,"interventions":18395},[92],[15],[5894,15698,5838,15699],{"trials":18397,"activeCount":101},[],{"intervention":17398,"totalTrials":350,"cells":18399},{"EARLY_PHASE1":18400,"PHASE1":18402,"PHASE2":18404,"PHASE3":18406,"PHASE4":18408,"NA":18414},{"trials":18401,"activeCount":101},[],{"trials":18403,"activeCount":101},[],{"trials":18405,"activeCount":101},[],{"trials":18407,"activeCount":101},[],{"trials":18409,"activeCount":101},[18410],{"nctId":17393,"briefTitle":17394,"status":107,"phases":18411,"primaryCompletion":121,"completion":121,"start":5469,"enrollment":1259,"conditions":18412,"interventions":18413},[92],[5846],[11737,11737,17398,17398],{"trials":18415,"activeCount":101},[],{"intervention":9212,"totalTrials":350,"cells":18417},{"EARLY_PHASE1":18418,"PHASE1":18420,"PHASE2":18422,"PHASE3":18424,"PHASE4":18426,"NA":18432},{"trials":18419,"activeCount":101},[],{"trials":18421,"activeCount":101},[],{"trials":18423,"activeCount":101},[],{"trials":18425,"activeCount":101},[],{"trials":18427,"activeCount":101},[18428],{"nctId":9207,"briefTitle":9208,"status":107,"phases":18429,"primaryCompletion":4409,"completion":4409,"start":3084,"enrollment":145,"conditions":18430,"interventions":18431},[92],[5846],[3773,9212,1357],{"trials":18433,"activeCount":101},[],{"intervention":18435,"totalTrials":350,"cells":18436},"ribavirin (Copegus]",{"EARLY_PHASE1":18437,"PHASE1":18439,"PHASE2":18441,"PHASE3":18443,"PHASE4":18445,"NA":18454},{"trials":18438,"activeCount":101},[],{"trials":18440,"activeCount":101},[],{"trials":18442,"activeCount":101},[],{"trials":18444,"activeCount":101},[],{"trials":18446,"activeCount":101},[18447],{"nctId":18448,"briefTitle":18449,"status":107,"phases":18450,"primaryCompletion":3174,"completion":3174,"start":15695,"enrollment":18451,"conditions":18452,"interventions":18453},"NCT01591460","A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C",[92],165,[27],[17057,17072,17072,18435,18435],{"trials":18455,"activeCount":101},[],{"intervention":4576,"totalTrials":350,"cells":18457},{"EARLY_PHASE1":18458,"PHASE1":18460,"PHASE2":18462,"PHASE3":18464,"PHASE4":18466,"NA":18472},{"trials":18459,"activeCount":101},[],{"trials":18461,"activeCount":101},[],{"trials":18463,"activeCount":101},[],{"trials":18465,"activeCount":101},[],{"trials":18467,"activeCount":101},[18468],{"nctId":4568,"briefTitle":4569,"status":107,"phases":18469,"primaryCompletion":4571,"completion":1114,"start":4572,"enrollment":4573,"conditions":18470,"interventions":18471},[92],[4098],[1165,1166,1015,1164,4576,4577],{"trials":18473,"activeCount":101},[],{"intervention":14533,"totalTrials":350,"cells":18475},{"EARLY_PHASE1":18476,"PHASE1":18478,"PHASE2":18480,"PHASE3":18482,"PHASE4":18484,"NA":18490},{"trials":18477,"activeCount":101},[],{"trials":18479,"activeCount":101},[],{"trials":18481,"activeCount":101},[],{"trials":18483,"activeCount":101},[],{"trials":18485,"activeCount":101},[18486],{"nctId":14528,"briefTitle":14529,"status":107,"phases":18487,"primaryCompletion":4233,"completion":4233,"start":4113,"enrollment":4701,"conditions":18488,"interventions":18489},[92],[5846],[5848,14533,14534,14484],{"trials":18491,"activeCount":101},[],{"intervention":14534,"totalTrials":350,"cells":18493},{"EARLY_PHASE1":18494,"PHASE1":18496,"PHASE2":18498,"PHASE3":18500,"PHASE4":18502,"NA":18508},{"trials":18495,"activeCount":101},[],{"trials":18497,"activeCount":101},[],{"trials":18499,"activeCount":101},[],{"trials":18501,"activeCount":101},[],{"trials":18503,"activeCount":101},[18504],{"nctId":14528,"briefTitle":14529,"status":107,"phases":18505,"primaryCompletion":4233,"completion":4233,"start":4113,"enrollment":4701,"conditions":18506,"interventions":18507},[92],[5846],[5848,14533,14534,14484],{"trials":18509,"activeCount":101},[],{"intervention":18511,"totalTrials":350,"cells":18512},"Satralizumab 120 mg",{"EARLY_PHASE1":18513,"PHASE1":18515,"PHASE2":18517,"PHASE3":18519,"PHASE4":18521,"NA":18530},{"trials":18514,"activeCount":101},[],{"trials":18516,"activeCount":101},[],{"trials":18518,"activeCount":101},[],{"trials":18520,"activeCount":101},[],{"trials":18522,"activeCount":101},[18523],{"nctId":18524,"briefTitle":18525,"status":130,"phases":18526,"primaryCompletion":7386,"completion":7386,"start":18527,"enrollment":5110,"conditions":18528,"interventions":18529},"NCT05269667","A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention",[92],"2022-08-02",[7360,7361],[18511],{"trials":18531,"activeCount":101},[],{"intervention":18533,"totalTrials":350,"cells":18534},"peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]",{"EARLY_PHASE1":18535,"PHASE1":18537,"PHASE2":18539,"PHASE3":18541,"PHASE4":18543,"NA":18551},{"trials":18536,"activeCount":101},[],{"trials":18538,"activeCount":101},[],{"trials":18540,"activeCount":101},[],{"trials":18542,"activeCount":101},[],{"trials":18544,"activeCount":101},[18545],{"nctId":18546,"briefTitle":18547,"status":107,"phases":18548,"primaryCompletion":5469,"completion":5469,"start":8260,"enrollment":291,"conditions":18549,"interventions":18550},"NCT00077649","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).",[92],[27],[17976,17976,18533,18533],{"trials":18552,"activeCount":101},[],{"intervention":17539,"totalTrials":350,"cells":18554},{"EARLY_PHASE1":18555,"PHASE1":18557,"PHASE2":18559,"PHASE3":18561,"PHASE4":18563,"NA":18569},{"trials":18556,"activeCount":101},[],{"trials":18558,"activeCount":101},[],{"trials":18560,"activeCount":101},[],{"trials":18562,"activeCount":101},[],{"trials":18564,"activeCount":101},[18565],{"nctId":17534,"briefTitle":17535,"status":343,"phases":18566,"primaryCompletion":121,"completion":121,"start":8484,"enrollment":101,"conditions":18567,"interventions":18568},[92],[33],[17499,17539],{"trials":18570,"activeCount":101},[],{"intervention":18572,"totalTrials":350,"cells":18573},"granisetron",{"EARLY_PHASE1":18574,"PHASE1":18576,"PHASE2":18578,"PHASE3":18580,"PHASE4":18582,"NA":18591},{"trials":18575,"activeCount":101},[],{"trials":18577,"activeCount":101},[],{"trials":18579,"activeCount":101},[],{"trials":18581,"activeCount":101},[],{"trials":18583,"activeCount":101},[18584],{"nctId":18585,"briefTitle":18586,"status":107,"phases":18587,"primaryCompletion":4513,"completion":4513,"start":8484,"enrollment":16260,"conditions":18588,"interventions":18590},"NCT00231478","A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy",[92],[18589],"Post-Operative Nausea and Vomiting",[18572,18572],{"trials":18592,"activeCount":101},[],{"intervention":17252,"totalTrials":350,"cells":18594},{"EARLY_PHASE1":18595,"PHASE1":18597,"PHASE2":18599,"PHASE3":18601,"PHASE4":18603,"NA":18609},{"trials":18596,"activeCount":101},[],{"trials":18598,"activeCount":101},[],{"trials":18600,"activeCount":101},[],{"trials":18602,"activeCount":101},[],{"trials":18604,"activeCount":101},[18605],{"nctId":17246,"briefTitle":17247,"status":107,"phases":18606,"primaryCompletion":3084,"completion":3084,"start":17249,"enrollment":1936,"conditions":18607,"interventions":18608},[92],[5846],[11737,3059,17252,11738],{"trials":18610,"activeCount":101},[],{"intervention":15722,"totalTrials":350,"cells":18612},{"EARLY_PHASE1":18613,"PHASE1":18615,"PHASE2":18617,"PHASE3":18619,"PHASE4":18621,"NA":18627},{"trials":18614,"activeCount":101},[],{"trials":18616,"activeCount":101},[],{"trials":18618,"activeCount":101},[],{"trials":18620,"activeCount":101},[],{"trials":18622,"activeCount":101},[18623],{"nctId":15717,"briefTitle":15718,"status":107,"phases":18624,"primaryCompletion":3189,"completion":3189,"start":4555,"enrollment":3574,"conditions":18625,"interventions":18626},[92],[15],[5894,15722],{"trials":18628,"activeCount":101},[],{"intervention":3117,"totalTrials":350,"cells":18630},{"EARLY_PHASE1":18631,"PHASE1":18633,"PHASE2":18635,"PHASE3":18637,"PHASE4":18639,"NA":18645},{"trials":18632,"activeCount":101},[],{"trials":18634,"activeCount":101},[],{"trials":18636,"activeCount":101},[],{"trials":18638,"activeCount":101},[],{"trials":18640,"activeCount":101},[18641],{"nctId":3109,"briefTitle":3110,"status":107,"phases":18642,"primaryCompletion":3112,"completion":3113,"start":754,"enrollment":447,"conditions":18643,"interventions":18644},[92],[2367],[1096,3116,3117,2891],{"trials":18646,"activeCount":101},[],{"intervention":18648,"totalTrials":350,"cells":18649},"Warfarin",{"EARLY_PHASE1":18650,"PHASE1":18652,"PHASE2":18654,"PHASE3":18656,"PHASE4":18658,"NA":18667},{"trials":18651,"activeCount":101},[],{"trials":18653,"activeCount":101},[],{"trials":18655,"activeCount":101},[],{"trials":18657,"activeCount":101},[],{"trials":18659,"activeCount":101},[18660],{"nctId":18661,"briefTitle":18662,"status":107,"phases":18663,"primaryCompletion":6343,"completion":6343,"start":4086,"enrollment":2375,"conditions":18664,"interventions":18666},"NCT02780622","A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)",[92],[18665],"Drug Therapy, Combination",[12796,18648],{"trials":18668,"activeCount":101},[],{"intervention":14627,"totalTrials":350,"cells":18670},{"EARLY_PHASE1":18671,"PHASE1":18673,"PHASE2":18675,"PHASE3":18677,"PHASE4":18679,"NA":18685},{"trials":18672,"activeCount":101},[],{"trials":18674,"activeCount":101},[],{"trials":18676,"activeCount":101},[],{"trials":18678,"activeCount":101},[],{"trials":18680,"activeCount":101},[18681],{"nctId":14622,"briefTitle":14623,"status":107,"phases":18682,"primaryCompletion":2965,"completion":2965,"start":8751,"enrollment":2532,"conditions":18683,"interventions":18684},[92],[125],[1572,14627,10182],{"trials":18686,"activeCount":101},[],{"intervention":17546,"totalTrials":350,"cells":18688},{"EARLY_PHASE1":18689,"PHASE1":18691,"PHASE2":18693,"PHASE3":18695,"PHASE4":18697,"NA":18703},{"trials":18690,"activeCount":101},[],{"trials":18692,"activeCount":101},[],{"trials":18694,"activeCount":101},[],{"trials":18696,"activeCount":101},[],{"trials":18698,"activeCount":101},[18699],{"nctId":17541,"briefTitle":17542,"status":107,"phases":18700,"primaryCompletion":8484,"completion":6620,"start":4455,"enrollment":3750,"conditions":18701,"interventions":18702},[92],[33],[17546,17547,17499],{"trials":18704,"activeCount":101},[],{"intervention":17547,"totalTrials":350,"cells":18706},{"EARLY_PHASE1":18707,"PHASE1":18709,"PHASE2":18711,"PHASE3":18713,"PHASE4":18715,"NA":18721},{"trials":18708,"activeCount":101},[],{"trials":18710,"activeCount":101},[],{"trials":18712,"activeCount":101},[],{"trials":18714,"activeCount":101},[],{"trials":18716,"activeCount":101},[18717],{"nctId":17541,"briefTitle":17542,"status":107,"phases":18718,"primaryCompletion":8484,"completion":6620,"start":4455,"enrollment":3750,"conditions":18719,"interventions":18720},[92],[33],[17546,17547,17499],{"trials":18722,"activeCount":101},[],{"intervention":18724,"totalTrials":350,"cells":18725},"peginterferon alfa-2a (40KD) [PEGASYS]",{"EARLY_PHASE1":18726,"PHASE1":18728,"PHASE2":18730,"PHASE3":18732,"PHASE4":18734,"NA":18742},{"trials":18727,"activeCount":101},[],{"trials":18729,"activeCount":101},[],{"trials":18731,"activeCount":101},[],{"trials":18733,"activeCount":101},[],{"trials":18735,"activeCount":101},[18736],{"nctId":18737,"briefTitle":18738,"status":130,"phases":18739,"completion":14572,"start":3692,"enrollment":336,"conditions":18740,"interventions":18741},"NCT00460850","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.",[92],[11790],[18724],{"trials":18743,"activeCount":101},[],{"intervention":18745,"totalTrials":350,"cells":18746},"Ocrelizumab 300 mg",{"EARLY_PHASE1":18747,"PHASE1":18749,"PHASE2":18751,"PHASE3":18753,"PHASE4":18755,"NA":18767},{"trials":18748,"activeCount":101},[],{"trials":18750,"activeCount":101},[],{"trials":18752,"activeCount":101},[],{"trials":18754,"activeCount":101},[],{"trials":18756,"activeCount":101},[18757],{"nctId":18758,"briefTitle":18759,"status":107,"phases":18760,"primaryCompletion":18761,"completion":18761,"start":18762,"enrollment":18763,"conditions":18764,"interventions":18765},"NCT03589105","A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting",[92],"2021-02-15","2018-08-06",423,[147],[18745,18766],"Ocrelizumab 600 mg",{"trials":18768,"activeCount":101},[],{"intervention":18766,"totalTrials":350,"cells":18770},{"EARLY_PHASE1":18771,"PHASE1":18773,"PHASE2":18775,"PHASE3":18777,"PHASE4":18779,"NA":18785},{"trials":18772,"activeCount":101},[],{"trials":18774,"activeCount":101},[],{"trials":18776,"activeCount":101},[],{"trials":18778,"activeCount":101},[],{"trials":18780,"activeCount":101},[18781],{"nctId":18758,"briefTitle":18759,"status":107,"phases":18782,"primaryCompletion":18761,"completion":18761,"start":18762,"enrollment":18763,"conditions":18783,"interventions":18784},[92],[147],[18745,18766],{"trials":18786,"activeCount":101},[],{"intervention":17495,"totalTrials":350,"cells":18788},{"EARLY_PHASE1":18789,"PHASE1":18791,"PHASE2":18793,"PHASE3":18795,"PHASE4":18797,"NA":18803},{"trials":18790,"activeCount":101},[],{"trials":18792,"activeCount":101},[],{"trials":18794,"activeCount":101},[],{"trials":18796,"activeCount":101},[],{"trials":18798,"activeCount":101},[18799],{"nctId":17490,"briefTitle":17491,"status":107,"phases":18800,"primaryCompletion":5820,"completion":4582,"start":13164,"enrollment":1092,"conditions":18801,"interventions":18802},[92],[33],[17428,17495],{"trials":18804,"activeCount":101},[],{"intervention":17928,"totalTrials":350,"cells":18806},{"EARLY_PHASE1":18807,"PHASE1":18809,"PHASE2":18811,"PHASE3":18813,"PHASE4":18815,"NA":18821},{"trials":18808,"activeCount":101},[],{"trials":18810,"activeCount":101},[],{"trials":18812,"activeCount":101},[],{"trials":18814,"activeCount":101},[],{"trials":18816,"activeCount":101},[18817],{"nctId":17923,"briefTitle":17924,"status":107,"phases":18818,"primaryCompletion":8977,"completion":8977,"start":7153,"enrollment":2563,"conditions":18819,"interventions":18820},[92],[5846],[17928,5913,17929],{"trials":18822,"activeCount":101},[],{"intervention":14541,"totalTrials":350,"cells":18824},{"EARLY_PHASE1":18825,"PHASE1":18827,"PHASE2":18829,"PHASE3":18831,"PHASE4":18833,"NA":18839},{"trials":18826,"activeCount":101},[],{"trials":18828,"activeCount":101},[],{"trials":18830,"activeCount":101},[],{"trials":18832,"activeCount":101},[],{"trials":18834,"activeCount":101},[18835],{"nctId":14536,"briefTitle":14537,"status":107,"phases":18836,"primaryCompletion":4513,"completion":4513,"start":9499,"enrollment":1058,"conditions":18837,"interventions":18838},[92],[5911],[5913,5914,14541],{"trials":18840,"activeCount":101},[],{"intervention":18842,"totalTrials":350,"cells":18843},"Vitamin D and calcium supplementation",{"EARLY_PHASE1":18844,"PHASE1":18846,"PHASE2":18848,"PHASE3":18850,"PHASE4":18852,"NA":18861},{"trials":18845,"activeCount":101},[],{"trials":18847,"activeCount":101},[],{"trials":18849,"activeCount":101},[],{"trials":18851,"activeCount":101},[],{"trials":18853,"activeCount":101},[18854],{"nctId":18855,"briefTitle":18856,"status":107,"phases":18857,"primaryCompletion":6377,"completion":6377,"start":4446,"enrollment":6514,"conditions":18858,"interventions":18859},"NCT00303485","A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)",[92],[16765],[18842,18860],"ibandronate [Bonviva\u002FBoniva]",{"trials":18862,"activeCount":101},[],{"intervention":18864,"totalTrials":350,"cells":18865},"Nintedanib",{"EARLY_PHASE1":18866,"PHASE1":18868,"PHASE2":18870,"PHASE3":18872,"PHASE4":18874,"NA":18886},{"trials":18867,"activeCount":101},[],{"trials":18869,"activeCount":101},[],{"trials":18871,"activeCount":101},[],{"trials":18873,"activeCount":101},[],{"trials":18875,"activeCount":101},[18876],{"nctId":18877,"briefTitle":18878,"status":107,"phases":18879,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":25,"conditions":18882,"interventions":18884},"NCT02598193","Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)",[92],"2017-05-16","2016-01-14",[18883],"Idiopathic Pulmonary Fibrosis",[18864,18885],"Pirfenidone",{"trials":18887,"activeCount":101},[],{"intervention":17554,"totalTrials":350,"cells":18889},{"EARLY_PHASE1":18890,"PHASE1":18892,"PHASE2":18894,"PHASE3":18896,"PHASE4":18898,"NA":18904},{"trials":18891,"activeCount":101},[],{"trials":18893,"activeCount":101},[],{"trials":18895,"activeCount":101},[],{"trials":18897,"activeCount":101},[],{"trials":18899,"activeCount":101},[18900],{"nctId":17549,"briefTitle":17550,"status":130,"phases":18901,"primaryCompletion":8934,"completion":8934,"start":6377,"enrollment":1174,"conditions":18902,"interventions":18903},[92],[33],[17499,17554,17555,17499],{"trials":18905,"activeCount":101},[],{"intervention":17555,"totalTrials":350,"cells":18907},{"EARLY_PHASE1":18908,"PHASE1":18910,"PHASE2":18912,"PHASE3":18914,"PHASE4":18916,"NA":18922},{"trials":18909,"activeCount":101},[],{"trials":18911,"activeCount":101},[],{"trials":18913,"activeCount":101},[],{"trials":18915,"activeCount":101},[],{"trials":18917,"activeCount":101},[18918],{"nctId":17549,"briefTitle":17550,"status":130,"phases":18919,"primaryCompletion":8934,"completion":8934,"start":6377,"enrollment":1174,"conditions":18920,"interventions":18921},[92],[33],[17499,17554,17555,17499],{"trials":18923,"activeCount":101},[],{"intervention":18925,"totalTrials":350,"cells":18926},"Peg-Interferon Alpha-2A",{"EARLY_PHASE1":18927,"PHASE1":18929,"PHASE2":18931,"PHASE3":18933,"PHASE4":18935,"NA":18943},{"trials":18928,"activeCount":101},[],{"trials":18930,"activeCount":101},[],{"trials":18932,"activeCount":101},[],{"trials":18934,"activeCount":101},[],{"trials":18936,"activeCount":101},[18937],{"nctId":18938,"briefTitle":18939,"status":107,"phases":18940,"primaryCompletion":4281,"completion":4281,"start":11300,"enrollment":11722,"conditions":18941,"interventions":18942},"NCT02761629","Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus",[92],[27],[18925,17366],{"trials":18944,"activeCount":101},[],{"intervention":17562,"totalTrials":350,"cells":18946},{"EARLY_PHASE1":18947,"PHASE1":18949,"PHASE2":18951,"PHASE3":18953,"PHASE4":18955,"NA":18961},{"trials":18948,"activeCount":101},[],{"trials":18950,"activeCount":101},[],{"trials":18952,"activeCount":101},[],{"trials":18954,"activeCount":101},[],{"trials":18956,"activeCount":101},[18957],{"nctId":17557,"briefTitle":17558,"status":107,"phases":18958,"primaryCompletion":133,"completion":133,"start":11713,"enrollment":4499,"conditions":18959,"interventions":18960},[92],[33],[17562,17499],{"trials":18962,"activeCount":101},[],{"intervention":18012,"totalTrials":350,"cells":18964},{"EARLY_PHASE1":18965,"PHASE1":18967,"PHASE2":18969,"PHASE3":18971,"PHASE4":18973,"NA":18979},{"trials":18966,"activeCount":101},[],{"trials":18968,"activeCount":101},[],{"trials":18970,"activeCount":101},[],{"trials":18972,"activeCount":101},[],{"trials":18974,"activeCount":101},[18975],{"nctId":18005,"briefTitle":18006,"status":107,"phases":18976,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":18977,"interventions":18978},[92],[17203],[18012,17205,18013,18014,18015,2994],{"trials":18980,"activeCount":101},[],{"intervention":18013,"totalTrials":350,"cells":18982},{"EARLY_PHASE1":18983,"PHASE1":18985,"PHASE2":18987,"PHASE3":18989,"PHASE4":18991,"NA":18997},{"trials":18984,"activeCount":101},[],{"trials":18986,"activeCount":101},[],{"trials":18988,"activeCount":101},[],{"trials":18990,"activeCount":101},[],{"trials":18992,"activeCount":101},[18993],{"nctId":18005,"briefTitle":18006,"status":107,"phases":18994,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":18995,"interventions":18996},[92],[17203],[18012,17205,18013,18014,18015,2994],{"trials":18998,"activeCount":101},[],{"intervention":18014,"totalTrials":350,"cells":19000},{"EARLY_PHASE1":19001,"PHASE1":19003,"PHASE2":19005,"PHASE3":19007,"PHASE4":19009,"NA":19015},{"trials":19002,"activeCount":101},[],{"trials":19004,"activeCount":101},[],{"trials":19006,"activeCount":101},[],{"trials":19008,"activeCount":101},[],{"trials":19010,"activeCount":101},[19011],{"nctId":18005,"briefTitle":18006,"status":107,"phases":19012,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":19013,"interventions":19014},[92],[17203],[18012,17205,18013,18014,18015,2994],{"trials":19016,"activeCount":101},[],{"intervention":18015,"totalTrials":350,"cells":19018},{"EARLY_PHASE1":19019,"PHASE1":19021,"PHASE2":19023,"PHASE3":19025,"PHASE4":19027,"NA":19033},{"trials":19020,"activeCount":101},[],{"trials":19022,"activeCount":101},[],{"trials":19024,"activeCount":101},[],{"trials":19026,"activeCount":101},[],{"trials":19028,"activeCount":101},[19029],{"nctId":18005,"briefTitle":18006,"status":107,"phases":19030,"primaryCompletion":4885,"completion":4885,"start":18008,"enrollment":18009,"conditions":19031,"interventions":19032},[92],[17203],[18012,17205,18013,18014,18015,2994],{"trials":19034,"activeCount":101},[],{"intervention":19036,"totalTrials":350,"cells":19037},"Orlistat",{"EARLY_PHASE1":19038,"PHASE1":19040,"PHASE2":19042,"PHASE3":19044,"PHASE4":19046,"NA":19055},{"trials":19039,"activeCount":101},[],{"trials":19041,"activeCount":101},[],{"trials":19043,"activeCount":101},[],{"trials":19045,"activeCount":101},[],{"trials":19047,"activeCount":101},[19048],{"nctId":19049,"briefTitle":19050,"status":107,"phases":19051,"primaryCompletion":3325,"completion":3325,"start":19052,"enrollment":37,"conditions":19053,"interventions":19054},"NCT02706067","Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults",[92],"2002-07",[9440],[19036],{"trials":19056,"activeCount":101},[],{"intervention":19058,"totalTrials":350,"cells":19059},"FUZEON [enfuvirtide]",{"EARLY_PHASE1":19060,"PHASE1":19062,"PHASE2":19064,"PHASE3":19066,"PHASE4":19068,"NA":19079},{"trials":19061,"activeCount":101},[],{"trials":19063,"activeCount":101},[],{"trials":19065,"activeCount":101},[],{"trials":19067,"activeCount":101},[],{"trials":19069,"activeCount":101},[19070],{"nctId":19071,"briefTitle":19072,"status":130,"phases":19073,"primaryCompletion":19074,"completion":19074,"start":19075,"enrollment":306,"conditions":19076,"interventions":19078},"NCT00100984","A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir\u002FRitonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir\u002FRitonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1",[92],"2005-07-16","2004-07-21",[19077],"HIV Infection",[19058],{"trials":19080,"activeCount":101},[],{"intervention":19082,"totalTrials":350,"cells":19083},"Risedronate",{"EARLY_PHASE1":19084,"PHASE1":19086,"PHASE2":19088,"PHASE3":19090,"PHASE4":19092,"NA":19101},{"trials":19085,"activeCount":101},[],{"trials":19087,"activeCount":101},[],{"trials":19089,"activeCount":101},[],{"trials":19091,"activeCount":101},[],{"trials":19093,"activeCount":101},[19094],{"nctId":19095,"briefTitle":19096,"status":107,"phases":19097,"primaryCompletion":3085,"completion":3085,"start":4282,"enrollment":19098,"conditions":19099,"interventions":19100},"NCT00377234","A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.",[92],356,[16765],[19082,18860],{"trials":19102,"activeCount":101},[],{"intervention":19104,"totalTrials":350,"cells":19105},"calcipotriol hydrate [Daivonex]",{"EARLY_PHASE1":19106,"PHASE1":19108,"PHASE2":19110,"PHASE3":19112,"PHASE4":19114,"NA":19123},{"trials":19107,"activeCount":101},[],{"trials":19109,"activeCount":101},[],{"trials":19111,"activeCount":101},[],{"trials":19113,"activeCount":101},[],{"trials":19115,"activeCount":101},[19116],{"nctId":19117,"briefTitle":19118,"status":107,"phases":19119,"primaryCompletion":5271,"completion":5271,"start":6506,"enrollment":2708,"conditions":19120,"interventions":19122},"NCT00437619","A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.",[92],[19121],"Psoriasis",[19104],{"trials":19124,"activeCount":101},[],{"intervention":3871,"totalTrials":350,"cells":19126},{"EARLY_PHASE1":19127,"PHASE1":19129,"PHASE2":19131,"PHASE3":19133,"PHASE4":19135,"NA":19141},{"trials":19128,"activeCount":101},[],{"trials":19130,"activeCount":101},[],{"trials":19132,"activeCount":101},[],{"trials":19134,"activeCount":101},[],{"trials":19136,"activeCount":101},[19137],{"nctId":3863,"briefTitle":3864,"status":107,"phases":19138,"primaryCompletion":3866,"completion":3867,"start":1056,"enrollment":22,"conditions":19139,"interventions":19140},[92],[3869],[1018,1356,992,991,3871,1358],{"trials":19142,"activeCount":101},[],{"intervention":19144,"totalTrials":350,"cells":19145},"Zelboraf",{"EARLY_PHASE1":19146,"PHASE1":19148,"PHASE2":19150,"PHASE3":19152,"PHASE4":19154,"NA":19164},{"trials":19147,"activeCount":101},[],{"trials":19149,"activeCount":101},[],{"trials":19151,"activeCount":101},[],{"trials":19153,"activeCount":101},[],{"trials":19155,"activeCount":101},[19156],{"nctId":19157,"briefTitle":19158,"status":107,"phases":19159,"primaryCompletion":19160,"completion":19160,"start":19161,"enrollment":336,"conditions":19162,"interventions":19163},"NCT01898585","An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma",[92],"2019-05-22","2013-10-17",[1261],[19144],{"trials":19165,"activeCount":101},[],{"intervention":14548,"totalTrials":350,"cells":19167},{"EARLY_PHASE1":19168,"PHASE1":19170,"PHASE2":19172,"PHASE3":19174,"PHASE4":19176,"NA":19182},{"trials":19169,"activeCount":101},[],{"trials":19171,"activeCount":101},[],{"trials":19173,"activeCount":101},[],{"trials":19175,"activeCount":101},[],{"trials":19177,"activeCount":101},[19178],{"nctId":14543,"briefTitle":14544,"status":107,"phases":19179,"primaryCompletion":4314,"completion":4314,"start":4281,"enrollment":1296,"conditions":19180,"interventions":19181},[92],[11724],[5914,14548,14548],{"trials":19183,"activeCount":101},[],{"intervention":4611,"totalTrials":350,"cells":19185},{"EARLY_PHASE1":19186,"PHASE1":19188,"PHASE2":19190,"PHASE3":19192,"PHASE4":19194,"NA":19200},{"trials":19187,"activeCount":101},[],{"trials":19189,"activeCount":101},[],{"trials":19191,"activeCount":101},[],{"trials":19193,"activeCount":101},[],{"trials":19195,"activeCount":101},[19196],{"nctId":4603,"briefTitle":4604,"status":107,"phases":19197,"primaryCompletion":4606,"completion":4607,"start":4608,"enrollment":37,"conditions":19198,"interventions":19199},[92],[30],[4611,4100],{"trials":19201,"activeCount":101},[],{"intervention":16188,"totalTrials":350,"cells":19203},{"EARLY_PHASE1":19204,"PHASE1":19206,"PHASE2":19208,"PHASE3":19210,"PHASE4":19212,"NA":19218},{"trials":19205,"activeCount":101},[],{"trials":19207,"activeCount":101},[],{"trials":19209,"activeCount":101},[],{"trials":19211,"activeCount":101},[],{"trials":19213,"activeCount":101},[19214],{"nctId":16183,"briefTitle":16184,"status":130,"phases":19215,"primaryCompletion":6343,"completion":6343,"start":4513,"enrollment":350,"conditions":19216,"interventions":19217},[92],[24],[15973,16188],{"trials":19219,"activeCount":101},[],{"intervention":11969,"totalTrials":1705,"cells":19221},{"EARLY_PHASE1":19222,"PHASE1":19224,"PHASE2":19357,"PHASE3":19403,"PHASE4":19434,"NA":19436},{"trials":19223,"activeCount":101},[],{"trials":19225,"activeCount":101},[19226,19232,19236,19242,19249,19257,19264,19268,19274,19281,19288,19295,19301,19308,19315,19319,19327,19334,19340,19347],{"nctId":19227,"briefTitle":19228,"status":107,"phases":19229,"primaryCompletion":7152,"completion":7152,"start":7095,"enrollment":5901,"conditions":19230,"interventions":19231},"NCT01164488","A Study of RO5190591 (Danoprevir) in Healthy Volunteers",[89],[21],[11967,11483,11969],{"nctId":11962,"briefTitle":11963,"status":107,"phases":19233,"primaryCompletion":3189,"completion":3189,"start":4314,"enrollment":8206,"conditions":19234,"interventions":19235},[89],[21],[11967,418,11968,11969],{"nctId":19237,"briefTitle":19238,"status":107,"phases":19239,"primaryCompletion":8681,"completion":8681,"start":3007,"enrollment":395,"conditions":19240,"interventions":19241},"NCT01654211","A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers",[89],[21],[11967,11967,11969],{"nctId":19243,"briefTitle":19244,"status":107,"phases":19245,"primaryCompletion":3213,"completion":3213,"start":2793,"enrollment":931,"conditions":19246,"interventions":19247},"NCT01588002","A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers",[89],[21],[11967,19248,11969],"efavirenz",{"nctId":19250,"briefTitle":19251,"status":107,"phases":19252,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":931,"conditions":19253,"interventions":19254},"NCT01592305","A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir",[89],[21],[19255,11967,11969,19256],"atazanavir","tenofovir disoproxil fumarate",{"nctId":19258,"briefTitle":19259,"status":107,"phases":19260,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":2572,"conditions":19261,"interventions":19262},"NCT01185860","A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1",[89],[27],[11967,17072,19263,11969],"ribavirin",{"nctId":17262,"briefTitle":17263,"status":107,"phases":19265,"primaryCompletion":2768,"completion":2768,"start":2905,"enrollment":5901,"conditions":19266,"interventions":19267},[89],[21],[5850,11967,11969],{"nctId":19269,"briefTitle":19270,"status":107,"phases":19271,"primaryCompletion":3103,"completion":3103,"start":2905,"enrollment":1058,"conditions":19272,"interventions":19273},"NCT01483729","A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers",[89],[21],[11967,11967,11967,11969,11969,11969],{"nctId":19275,"briefTitle":19276,"status":107,"phases":19277,"primaryCompletion":4445,"completion":4445,"start":8681,"enrollment":5901,"conditions":19278,"interventions":19279},"NCT01714154","A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls",[89],[21],[11967,11969,19280],"setrobuvir",{"nctId":19282,"briefTitle":19283,"status":107,"phases":19284,"primaryCompletion":3175,"completion":3175,"start":2768,"enrollment":931,"conditions":19285,"interventions":19286},"NCT01519336","A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers",[89],[21],[11967,19287,11969],"darunavir",{"nctId":19289,"briefTitle":19290,"status":107,"phases":19291,"primaryCompletion":3084,"completion":3084,"start":6277,"enrollment":721,"conditions":19292,"interventions":19293},"NCT00435929","A Study of Saquinavir\u002FRitonavir in Liver-Impaired Patients With HIV Infection.",[89],[33],[11782,19294],"saquinavir [Invirase]",{"nctId":19296,"briefTitle":19297,"status":107,"phases":19298,"primaryCompletion":3212,"completion":3212,"start":4233,"enrollment":6432,"conditions":19299,"interventions":19300},"NCT01185873","A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment",[89],[21],[11967,11969],{"nctId":19302,"briefTitle":19303,"status":107,"phases":19304,"primaryCompletion":3213,"completion":3213,"start":3103,"enrollment":145,"conditions":19305,"interventions":19306},"NCT01638650","A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients",[89],[33],[19307,11969,19294],"Nucleoside Reverse Transcriptase Inhibitor",{"nctId":19309,"briefTitle":19310,"status":107,"phases":19311,"primaryCompletion":3189,"completion":3189,"start":9079,"enrollment":2375,"conditions":19312,"interventions":19313},"NCT01418274","A Study to Evaluate the Effect of Danoprevir\u002FRitonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers",[89],[21],[11967,19314,11969],"escitalopram",{"nctId":11775,"briefTitle":11776,"status":130,"phases":19316,"primaryCompletion":11778,"completion":11778,"start":10316,"enrollment":1847,"conditions":19317,"interventions":19318},[89],[21],[11781,388,11782],{"nctId":19320,"briefTitle":19321,"status":107,"phases":19322,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":1115,"conditions":19323,"interventions":19324},"NCT01591850","A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers",[89],[21],[19325,19255,11483,19326,11969],"RO5093151","rifampicin",{"nctId":19328,"briefTitle":19329,"status":107,"phases":19330,"primaryCompletion":3175,"completion":3175,"start":3103,"enrollment":2375,"conditions":19331,"interventions":19332},"NCT01531647","A Study of Drug-Drug Interaction Between Danoprevir\u002FLow-Dose Ritonavir and Raltegravir in Healthy Volunteers",[89],[21],[11967,19333,11969],"raltegravir",{"nctId":19335,"briefTitle":19336,"status":107,"phases":19337,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":1733,"conditions":19338,"interventions":19339},"NCT01592318","A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers",[89],[21],[11967,11967,11969,11969],{"nctId":19341,"briefTitle":19342,"status":107,"phases":19343,"primaryCompletion":4314,"completion":4314,"start":8320,"enrollment":5901,"conditions":19344,"interventions":19345},"NCT01389544","A Study on the Interaction Between Danoprevir\u002FRitonavir and Methadone",[89],[21],[11967,19346,11969],"methadone",{"nctId":19348,"briefTitle":19349,"status":107,"phases":19350,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":19351,"interventions":19352},"NCT01398293","A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects",[89],[21],[11967,11967,19353,19354,19355,11969,19356],"danoprevir placebo","moxifloxacin","moxifloxacin placebo","ritonavir placebo",{"trials":19358,"activeCount":101},[19359,19365,19369,19375,19379,19386,19393,19397],{"nctId":19360,"briefTitle":19361,"status":343,"phases":19362,"primaryCompletion":3197,"completion":3197,"start":3007,"enrollment":101,"conditions":19363,"interventions":19364},"NCT01579019","A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys\u002FCopegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment",[90],[27],[17034,17034,11967,17072,17976,11969],{"nctId":17437,"briefTitle":17438,"status":107,"phases":19366,"start":17440,"enrollment":4683,"conditions":19367,"interventions":19368},[90],[33],[17428,11782,17443,17444,16518],{"nctId":19370,"briefTitle":19371,"status":107,"phases":19372,"primaryCompletion":4555,"completion":4555,"start":14572,"enrollment":5901,"conditions":19373,"interventions":19374},"NCT00623597","A Study of Invirase (Saquinavir)\u002FRitonavir in HIV-Infected Infants and Children.",[90],[33],[11969,19294],{"nctId":17021,"briefTitle":17022,"status":107,"phases":19376,"primaryCompletion":2948,"completion":2948,"start":5181,"enrollment":16946,"conditions":19377,"interventions":19378},[90],[27],[16996,17026,17026,17026,17011,11782],{"nctId":19380,"briefTitle":19381,"status":107,"phases":19382,"primaryCompletion":2956,"completion":2956,"start":3213,"enrollment":1283,"conditions":19383,"interventions":19384},"NCT01628094","ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment",[90],[27],[17034,17019,19385,17976,11969],"RO5466731",{"nctId":19387,"briefTitle":19388,"status":107,"phases":19389,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":19390,"interventions":19391},"NCT01278134","A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)",[90],[27],[19392,17034,11967,17072,17976,11969],"Copegus placebo",{"nctId":17045,"briefTitle":17046,"status":107,"phases":19394,"primaryCompletion":4249,"completion":4249,"start":2931,"enrollment":17048,"conditions":19395,"interventions":19396},[90],[27],[16996,16996,17011,17011,17034,11967,11969],{"nctId":19398,"briefTitle":19399,"status":107,"phases":19400,"primaryCompletion":2684,"completion":2684,"start":2793,"enrollment":1385,"conditions":19401,"interventions":19402},"NCT01483742","A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis",[90],[27],[17034,11967,17072,19263,11969],{"trials":19404,"activeCount":101},[19405,19409,19413,19422,19426,19430],{"nctId":16504,"briefTitle":16505,"status":107,"phases":19406,"enrollment":16507,"conditions":19407,"interventions":19408},[91],[33],[11782,16468,16450,16510],{"nctId":16512,"briefTitle":16513,"status":107,"phases":19410,"start":16515,"enrollment":931,"conditions":19411,"interventions":19412},[91],[33],[11782,16518,16450],{"nctId":19414,"briefTitle":19415,"status":107,"phases":19416,"primaryCompletion":6673,"completion":6343,"start":11300,"enrollment":19417,"conditions":19418,"interventions":19419},"NCT00105079","GEMINI Study - A Study of Saquinavir\u002FRitonavir in Treatment-Naive Patients With HIV-1 Infection",[91],337,[33],[19294,19420,19421,11782],"Lopinavir\u002Fritonavir","Emtricitabine\u002Ftenofovir disoproxil fumarate",{"nctId":16541,"briefTitle":16542,"status":107,"phases":19423,"start":16515,"enrollment":11543,"conditions":19424,"interventions":19425},[91],[33],[11782,16518,16450],{"nctId":16547,"briefTitle":16548,"status":107,"phases":19427,"enrollment":16550,"conditions":19428,"interventions":19429},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":16560,"briefTitle":16561,"status":107,"phases":19431,"enrollment":1239,"conditions":19432,"interventions":19433},[91],[33],[11782,16468,16450,16487],{"trials":19435,"activeCount":101},[],{"trials":19437,"activeCount":101},[],{"intervention":13182,"totalTrials":3939,"cells":19439},{"EARLY_PHASE1":19440,"PHASE1":19442,"PHASE2":19498,"PHASE3":19534,"PHASE4":19581,"NA":19583},{"trials":19441,"activeCount":101},[],{"trials":19443,"activeCount":101},[19444,19451,19459,19465,19471,19478,19485,19491],{"nctId":19445,"briefTitle":19446,"status":107,"phases":19447,"primaryCompletion":2906,"completion":2906,"start":7095,"enrollment":4886,"conditions":19448,"interventions":19449},"NCT01188304","A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers",[89],[21],[13182,19450],"aspirin",{"nctId":19452,"briefTitle":19453,"status":107,"phases":19454,"primaryCompletion":4249,"completion":4249,"start":3007,"enrollment":5901,"conditions":19455,"interventions":19456},"NCT01615354","A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers",[89],[21],[19457,19458],"Aleglitazar","Microgynon®",{"nctId":19460,"briefTitle":19461,"status":107,"phases":19462,"primaryCompletion":9079,"completion":9079,"start":2932,"enrollment":2492,"conditions":19463,"interventions":19464},"NCT01197911","A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar",[89],[21],[13182],{"nctId":19466,"briefTitle":19467,"status":107,"phases":19468,"primaryCompletion":2948,"completion":2948,"start":15695,"enrollment":425,"conditions":19469,"interventions":19470},"NCT01679639","A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers",[89],[21],[13182,19326],{"nctId":19472,"briefTitle":19473,"status":107,"phases":19474,"primaryCompletion":2809,"completion":2809,"start":9079,"enrollment":786,"conditions":19475,"interventions":19476},"NCT01398267","A Pharmacodynamic\u002FPharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril",[89],[36],[13182,19477],"lisinopril",{"nctId":19479,"briefTitle":19480,"status":107,"phases":19481,"primaryCompletion":4249,"completion":4249,"start":2809,"enrollment":496,"conditions":19482,"interventions":19483},"NCT01701739","A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers",[89],[21],[13182,19484],"digoxin",{"nctId":19486,"briefTitle":19487,"status":107,"phases":19488,"primaryCompletion":2948,"completion":2948,"start":8681,"enrollment":721,"conditions":19489,"interventions":19490},"NCT01711775","A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers",[89],[21],[13182],{"nctId":19492,"briefTitle":19493,"status":107,"phases":19494,"completion":3189,"start":4409,"enrollment":4886,"conditions":19495,"interventions":19496},"NCT01188317","A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers",[89],[21],[13182,19497],"ibuprofen",{"trials":19499,"activeCount":101},[19500,19507,19513,19517,19523,19527],{"nctId":19501,"briefTitle":19502,"status":107,"phases":19503,"primaryCompletion":4513,"completion":4513,"start":6620,"enrollment":13060,"conditions":19504,"interventions":19505},"NCT00461058","A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.",[90],[36],[19506,13182],"Actos",{"nctId":19508,"briefTitle":19509,"status":107,"phases":19510,"primaryCompletion":4113,"completion":4113,"start":6377,"enrollment":1415,"conditions":19511,"interventions":19512},"NCT00461006","A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.",[90],[36],[19506,13182],{"nctId":13177,"briefTitle":13178,"status":107,"phases":19514,"primaryCompletion":2684,"completion":2684,"start":2948,"enrollment":2999,"conditions":19515,"interventions":19516},[90],[36],[13182,13131],{"nctId":19518,"briefTitle":19519,"status":107,"phases":19520,"primaryCompletion":2684,"completion":2684,"start":2809,"enrollment":5901,"conditions":19521,"interventions":19522},"NCT01680978","A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease",[90],[36],[13182],{"nctId":17949,"briefTitle":17950,"status":107,"phases":19524,"primaryCompletion":3007,"completion":3007,"start":3104,"enrollment":17952,"conditions":19525,"interventions":19526},[90],[36],[13182,13219],{"nctId":19528,"briefTitle":19529,"status":107,"phases":19530,"primaryCompletion":4198,"completion":4198,"start":8658,"enrollment":19531,"conditions":19532,"interventions":19533},"NCT00388518","A Study of Aleglitazar in Patients With Type 2 Diabetes",[90],332,[36],[19506,13182],{"trials":19535,"activeCount":101},[19536,19544,19550,19554,19560,19568,19574],{"nctId":19537,"briefTitle":19538,"status":343,"phases":19539,"primaryCompletion":19540,"completion":19540,"start":3212,"enrollment":101,"conditions":19541,"interventions":19543},"NCT01893242","A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)",[91],"2019-01",[19542],"Diabetes Mellitus Type 2, Kidney Disease, Chronic",[19457],{"nctId":19545,"briefTitle":19546,"status":107,"phases":19547,"primaryCompletion":2684,"completion":2684,"start":2948,"enrollment":4269,"conditions":19548,"interventions":19549},"NCT01691989","A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy",[91],[36],[13182],{"nctId":13208,"briefTitle":13209,"status":107,"phases":19551,"primaryCompletion":6157,"completion":6157,"start":4445,"enrollment":4548,"conditions":19552,"interventions":19553},[91],[36],[13182,13131],{"nctId":19555,"briefTitle":19556,"status":107,"phases":19557,"primaryCompletion":2956,"completion":2956,"start":10332,"enrollment":372,"conditions":19558,"interventions":19559},"NCT01871428","A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy",[91],[36],[13182],{"nctId":19561,"briefTitle":19562,"status":107,"phases":19563,"primaryCompletion":2956,"completion":2956,"start":2948,"enrollment":19564,"conditions":19565,"interventions":19567},"NCT01715818","A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities",[91],1999,[19566],"Cardiovascular Disease, Diabetes Mellitus Type 2",[13182],{"nctId":19569,"briefTitle":19570,"status":107,"phases":19571,"primaryCompletion":2684,"completion":2684,"start":8681,"enrollment":14916,"conditions":19572,"interventions":19573},"NCT01691755","A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy",[91],[36],[13182],{"nctId":19575,"briefTitle":19576,"status":107,"phases":19577,"primaryCompletion":2956,"completion":2956,"start":6578,"enrollment":19578,"conditions":19579,"interventions":19580},"NCT01042769","A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus",[91],7226,[36],[19457],{"trials":19582,"activeCount":101},[],{"trials":19584,"activeCount":101},[],{"intervention":19586,"totalTrials":13060,"cells":19587},"Gantenerumab",{"EARLY_PHASE1":19588,"PHASE1":19590,"PHASE2":19632,"PHASE3":19643,"PHASE4":19703,"NA":19705},{"trials":19589,"activeCount":101},[],{"trials":19591,"activeCount":101},[19592,19599,19605,19612,19619,19625],{"nctId":19593,"briefTitle":19594,"status":107,"phases":19595,"primaryCompletion":2809,"completion":2809,"start":2801,"enrollment":1239,"conditions":19596,"interventions":19597},"NCT01636531","A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers",[89],[21],[19598,19598],"gantenerumab",{"nctId":19600,"briefTitle":19601,"status":107,"phases":19602,"primaryCompletion":2932,"completion":2932,"start":14454,"enrollment":336,"conditions":19603,"interventions":19604},"NCT00531804","A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.",[89],[14384],[19598],{"nctId":19606,"briefTitle":19607,"status":107,"phases":19608,"primaryCompletion":19609,"completion":19609,"start":17859,"enrollment":5901,"conditions":19610,"interventions":19611},"NCT02711423","A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers",[89],"2016-09-28",[21],[19586],{"nctId":19613,"briefTitle":19614,"status":107,"phases":19615,"primaryCompletion":743,"completion":743,"start":19616,"enrollment":22,"conditions":19617,"interventions":19618},"NCT03236844","Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants",[89],"2017-08-01",[7754],[19586],{"nctId":19620,"briefTitle":19621,"status":107,"phases":19622,"primaryCompletion":3182,"completion":3182,"start":11437,"enrollment":5013,"conditions":19623,"interventions":19624},"NCT02133937","A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers",[89],[21],[19598,19598],{"nctId":19626,"briefTitle":19627,"status":107,"phases":19628,"primaryCompletion":424,"completion":424,"start":19629,"enrollment":123,"conditions":19630,"interventions":19631},"NCT02882009","A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants",[89],"2016-08-31",[21],[19586],{"trials":19633,"activeCount":101},[19634],{"nctId":19635,"briefTitle":19636,"status":130,"phases":19637,"primaryCompletion":19638,"completion":5194,"start":19639,"enrollment":11788,"conditions":19640,"interventions":19642},"NCT04592341","A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)",[90],"2023-01-11","2020-11-18",[19641],"Alzheimer Disease",[19586],{"trials":19644,"activeCount":101},[19645,19654,19663,19671,19680,19687,19695],{"nctId":19646,"briefTitle":19647,"status":130,"phases":19648,"primaryCompletion":19649,"completion":19649,"start":19650,"enrollment":19651,"conditions":19652,"interventions":19653},"NCT04374253","A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)",[91],"2023-03-06","2021-01-26",1382,[19641],[19586,19586],{"nctId":19655,"briefTitle":19656,"status":130,"phases":19657,"primaryCompletion":19658,"completion":19659,"start":7345,"enrollment":19660,"conditions":19661,"interventions":19662},"NCT03444870","Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)",[91],"2022-12-28","2023-02-17",1053,[19641],[19586],{"nctId":19664,"briefTitle":19665,"status":107,"phases":19666,"primaryCompletion":19667,"completion":19667,"start":19668,"enrollment":6208,"conditions":19669,"interventions":19670},"NCT02051608","A Study of Gantenerumab in Participants With Mild Alzheimer Disease",[91],"2021-04-16","2014-03-27",[14384],[19586],{"nctId":19672,"briefTitle":19673,"status":130,"phases":19674,"primaryCompletion":19675,"completion":19676,"start":10594,"enrollment":19677,"conditions":19678,"interventions":19679},"NCT03443973","Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)",[91],"2022-09-23","2022-11-28",975,[19641],[19586],{"nctId":19681,"briefTitle":19682,"status":130,"phases":19683,"primaryCompletion":7580,"completion":7580,"start":19684,"enrollment":5355,"conditions":19685,"interventions":19686},"NCT04339413","A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)",[91],"2020-05-22",[19641],[19586],{"nctId":19688,"briefTitle":19689,"status":130,"phases":19690,"primaryCompletion":19691,"completion":19691,"start":19692,"enrollment":97,"conditions":19693,"interventions":19694},"NCT05256134","A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)",[91],"2023-03-13","2022-04-19",[11117],[19586],{"nctId":19696,"briefTitle":19697,"status":107,"phases":19698,"primaryCompletion":19699,"completion":19699,"start":16141,"enrollment":19700,"conditions":19701,"interventions":19702},"NCT01224106","A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease",[91],"2020-09-10",799,[14384],[19586],{"trials":19704,"activeCount":101},[],{"trials":19706,"activeCount":101},[],{"intervention":19708,"totalTrials":372,"cells":19709},"RO4917838",{"EARLY_PHASE1":19710,"PHASE1":19712,"PHASE2":19784,"PHASE3":19794,"PHASE4":19812,"NA":19814},{"trials":19711,"activeCount":101},[],{"trials":19713,"activeCount":101},[19714,19721,19728,19735,19741,19747,19755,19763,19770,19778],{"nctId":19715,"briefTitle":19716,"status":107,"phases":19717,"primaryCompletion":8681,"completion":8681,"start":15695,"enrollment":721,"conditions":19718,"interventions":19719},"NCT01665976","A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers",[89],[21],[19708,19708,19720],"RO4927838",{"nctId":19722,"briefTitle":19723,"status":107,"phases":19724,"primaryCompletion":4314,"completion":4314,"start":14712,"enrollment":721,"conditions":19725,"interventions":19726},"NCT01365403","A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers",[89],[21],[19708,19727],"carbamazepine",{"nctId":19729,"briefTitle":19730,"status":107,"phases":19731,"primaryCompletion":2801,"completion":2801,"start":6315,"enrollment":7619,"conditions":19732,"interventions":19733},"NCT01438749","A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users",[89],[21],[19708,19734],"diazepam",{"nctId":19736,"briefTitle":19737,"status":107,"phases":19738,"primaryCompletion":6315,"completion":6315,"start":8320,"enrollment":384,"conditions":19739,"interventions":19740},"NCT01356550","A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838",[89],[21],[19708],{"nctId":19742,"briefTitle":19743,"status":107,"phases":19744,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":721,"conditions":19745,"interventions":19746},"NCT01433575","A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers",[89],[21],[19708,19708],{"nctId":19748,"briefTitle":19749,"status":107,"phases":19750,"primaryCompletion":4682,"completion":4682,"start":5181,"enrollment":1174,"conditions":19751,"interventions":19753},"NCT01116830","A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder",[89],[19752],"Schizophrenia",[19708,19754],"Standard Antipsychotic Therapy",{"nctId":19756,"briefTitle":19757,"status":107,"phases":19758,"primaryCompletion":4488,"completion":4488,"start":3308,"enrollment":1406,"conditions":19759,"interventions":19760},"NCT01613040","A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers",[89],[21],[19761,19761,19708,19708,19762],"Moxifloxacin","RO4917838 placebo",{"nctId":19764,"briefTitle":19765,"status":107,"phases":19766,"primaryCompletion":3103,"completion":3103,"start":6315,"enrollment":5901,"conditions":19767,"interventions":19768},"NCT01495104","A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers",[89],[21],[19708,19769],"valproate",{"nctId":19771,"briefTitle":19772,"status":107,"phases":19773,"primaryCompletion":19774,"completion":19774,"start":19775,"enrollment":97,"conditions":19776,"interventions":19777},"NCT01543529","A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers",[89],"2012-06-04","2012-02-28",[21],[19708],{"nctId":19779,"briefTitle":19780,"status":107,"phases":19781,"primaryCompletion":3175,"completion":3175,"start":6315,"enrollment":709,"conditions":19782,"interventions":19783},"NCT01510899","A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838",[89],[21],[19708,19708],{"trials":19785,"activeCount":101},[19786],{"nctId":19787,"briefTitle":19788,"status":107,"phases":19789,"primaryCompletion":6578,"completion":6578,"start":4198,"enrollment":19790,"conditions":19791,"interventions":19792},"NCT00616798","A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.",[90],323,[19752],[19708,19708,19708,19793],"Standard antipsychotic therapy",{"trials":19795,"activeCount":101},[19796,19806],{"nctId":19797,"briefTitle":19798,"status":107,"phases":19799,"primaryCompletion":19800,"completion":19800,"start":19801,"enrollment":19802,"conditions":19803,"interventions":19804},"NCT01192867","A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)",[91],"2014-05-26","2010-12-11",629,[19752],[19708,19805],"Antipshychotics",{"nctId":19807,"briefTitle":19808,"status":107,"phases":19809,"primaryCompletion":5364,"completion":5364,"start":5891,"enrollment":2107,"conditions":19810,"interventions":19811},"NCT01235520","A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)",[91],[19752],[19708,19708],{"trials":19813,"activeCount":101},[],{"trials":19815,"activeCount":101},[],{"intervention":13206,"totalTrials":709,"cells":19817},{"EARLY_PHASE1":19818,"PHASE1":19820,"PHASE2":19828,"PHASE3":19836,"PHASE4":19892,"NA":19894},{"trials":19819,"activeCount":101},[],{"trials":19821,"activeCount":101},[19822],{"nctId":19823,"briefTitle":19824,"status":107,"phases":19825,"primaryCompletion":5271,"completion":5271,"start":8688,"enrollment":5901,"conditions":19826,"interventions":19827},"NCT00811460","A Study of Taspoglutide in Type 2 Diabetic Patients",[89],[36],[13206,13206],{"trials":19829,"activeCount":101},[19830],{"nctId":19831,"briefTitle":19832,"status":107,"phases":19833,"primaryCompletion":5820,"completion":5820,"start":6506,"enrollment":2933,"conditions":19834,"interventions":19835},"NCT00423501","A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.",[90],[36],[13206,13206,13206,13206,13206],{"trials":19837,"activeCount":101},[19838,19842,19846,19852,19856,19862,19869,19876,19884,19888],{"nctId":13190,"briefTitle":13191,"status":107,"phases":19839,"primaryCompletion":2964,"completion":2964,"start":8934,"enrollment":13193,"conditions":19840,"interventions":19841},[91],[36],[1576,13196,13197],{"nctId":13199,"briefTitle":13200,"status":107,"phases":19843,"primaryCompletion":4474,"completion":4474,"start":8688,"enrollment":13202,"conditions":19844,"interventions":19845},[91],[36],[13205,13131,13206,13206],{"nctId":19847,"briefTitle":19848,"status":107,"phases":19849,"primaryCompletion":3104,"completion":3104,"start":3308,"enrollment":1936,"conditions":19850,"interventions":19851},"NCT00823992","A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy",[91],[36],[13206],{"nctId":17958,"briefTitle":17959,"status":107,"phases":19853,"primaryCompletion":5181,"completion":5181,"start":9596,"enrollment":17961,"conditions":19854,"interventions":19855},[91],[36],[13219,13206,13206],{"nctId":19857,"briefTitle":19858,"status":107,"phases":19859,"primaryCompletion":3022,"completion":3022,"start":4562,"enrollment":336,"conditions":19860,"interventions":19861},"NCT00809705","A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes",[91],[36],[13206,13206],{"nctId":19863,"briefTitle":19864,"status":107,"phases":19865,"primaryCompletion":8826,"completion":8826,"start":3085,"enrollment":19866,"conditions":19867,"interventions":19868},"NCT00744926","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.",[91],373,[36],[13206,13206],{"nctId":19870,"briefTitle":19871,"status":107,"phases":19872,"primaryCompletion":5891,"completion":5891,"start":4206,"enrollment":19873,"conditions":19874,"interventions":19875},"NCT01018173","A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease",[91],2118,[36],[13206],{"nctId":19877,"briefTitle":19878,"status":107,"phases":19879,"primaryCompletion":2964,"completion":2964,"start":6343,"enrollment":19880,"conditions":19881,"interventions":19882},"NCT00717457","A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.",[91],1189,[36],[19883,13206,13206],"exenatide",{"nctId":13214,"briefTitle":13215,"status":107,"phases":19885,"primaryCompletion":5181,"completion":5181,"start":8934,"enrollment":3105,"conditions":19886,"interventions":19887},[91],[36],[13131,13219,13206,13206],{"nctId":13221,"briefTitle":13222,"status":130,"phases":19889,"primaryCompletion":4474,"completion":4474,"start":4206,"enrollment":10152,"conditions":19890,"interventions":19891},[91],[36],[13205,13131,13206,13206],{"trials":19893,"activeCount":101},[],{"trials":19895,"activeCount":101},[],{"intervention":19897,"totalTrials":2563,"cells":19898},"dalcetrapib",{"EARLY_PHASE1":19899,"PHASE1":19901,"PHASE2":19916,"PHASE3":19954,"PHASE4":19986,"NA":19988},{"trials":19900,"activeCount":101},[],{"trials":19902,"activeCount":101},[19903,19910],{"nctId":19904,"briefTitle":19905,"status":107,"phases":19906,"primaryCompletion":4314,"completion":4314,"start":8320,"enrollment":425,"conditions":19907,"interventions":19908},"NCT01363999","A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers",[89],[21],[19909,19897],"atorvastatin",{"nctId":19911,"briefTitle":19912,"status":107,"phases":19913,"primaryCompletion":2685,"completion":2685,"start":6315,"enrollment":942,"conditions":19914,"interventions":19915},"NCT01476267","A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers",[89],[21],[19897],{"trials":19917,"activeCount":101},[19918,19925,19931,19938,19945],{"nctId":19919,"briefTitle":19920,"status":107,"phases":19921,"primaryCompletion":8934,"completion":8934,"start":9771,"enrollment":3295,"conditions":19922,"interventions":19924},"NCT00353522","A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.",[90],[19923],"Coronary Heart Disease",[19897],{"nctId":19926,"briefTitle":19927,"status":107,"phases":19928,"primaryCompletion":121,"completion":121,"start":16669,"enrollment":1080,"conditions":19929,"interventions":19930},"NCT00400439","A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381",[90],[19923],[19897],{"nctId":19932,"briefTitle":19933,"status":107,"phases":19934,"primaryCompletion":3104,"completion":3104,"start":4086,"enrollment":19935,"conditions":19936,"interventions":19937},"NCT00655538","A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients",[90],476,[19923],[19897],{"nctId":19939,"briefTitle":19940,"status":107,"phases":19941,"primaryCompletion":5181,"completion":5181,"start":4198,"enrollment":6418,"conditions":19942,"interventions":19943},"NCT00655473","A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease",[90],[19923],[19944],"Dalcetrapib",{"nctId":19946,"briefTitle":19947,"status":107,"phases":19948,"primaryCompletion":4282,"completion":4282,"start":4323,"enrollment":19949,"conditions":19950,"interventions":19952},"NCT00697203","A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)",[90],292,[19951],"Dyslipidemia",[19953,19944,19944,19944],"Pravastatin",{"trials":19955,"activeCount":101},[19956,19964,19972,19980],{"nctId":19957,"briefTitle":19958,"status":107,"phases":19959,"primaryCompletion":3146,"completion":3146,"start":4582,"enrollment":19960,"conditions":19961,"interventions":19962},"NCT00658515","A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome",[91],15871,[19923],[19944,19963],"Evidence-based medical care for Acute Coronary Syndrome",{"nctId":19965,"briefTitle":19966,"status":107,"phases":19967,"primaryCompletion":3007,"completion":3007,"start":3103,"enrollment":19968,"conditions":19969,"interventions":19971},"NCT01516541","A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease",[91],2220,[19970],"Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)",[19897],{"nctId":19973,"briefTitle":19974,"status":130,"phases":19975,"primaryCompletion":3189,"completion":3189,"start":4206,"enrollment":19976,"conditions":19977,"interventions":19979},"NCT01059682","A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease",[91],936,[19978],"Cardiovascular Disease",[19944],{"nctId":19981,"briefTitle":19982,"status":107,"phases":19983,"primaryCompletion":3175,"completion":3175,"start":2964,"enrollment":4811,"conditions":19984,"interventions":19985},"NCT01323153","A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)",[91],[19923],[19897],{"trials":19987,"activeCount":101},[],{"trials":19989,"activeCount":101},[],{"intervention":19991,"totalTrials":2563,"cells":19992},"Lebrikizumab",{"EARLY_PHASE1":19993,"PHASE1":19995,"PHASE2":19997,"PHASE3":20050,"PHASE4":20091,"NA":20093},{"trials":19994,"activeCount":101},[],{"trials":19996,"activeCount":101},[],{"trials":19998,"activeCount":101},[19999,20007,20016,20025,20033,20043],{"nctId":20000,"briefTitle":20001,"status":107,"phases":20002,"primaryCompletion":20003,"completion":20003,"start":1203,"enrollment":20004,"conditions":20005,"interventions":20006},"NCT02546700","A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[90],"2016-11-25",309,[11072],[19991],{"nctId":20008,"briefTitle":20009,"status":107,"phases":20010,"primaryCompletion":20011,"completion":20012,"start":20013,"enrollment":6425,"conditions":20014,"interventions":20015},"NCT01872689","A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)",[90],"2017-07-28","2017-11-06","2013-10-13",[18883],[19991,18885],{"nctId":20017,"briefTitle":20018,"status":107,"phases":20019,"primaryCompletion":20020,"completion":20020,"start":20021,"enrollment":786,"conditions":20022,"interventions":20023},"NCT02465606","A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis",[90],"2016-05-30","2015-07-30",[3925],[19991,20024],"Topical Corticosteroid Creams",{"nctId":20026,"briefTitle":20027,"status":107,"phases":20028,"primaryCompletion":20029,"completion":20029,"start":2947,"enrollment":2878,"conditions":20030,"interventions":20031},"NCT02340234","A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis",[90],"2016-04",[3925],[19991,20032],"TCS Cream",{"nctId":20034,"briefTitle":20035,"status":107,"phases":20036,"primaryCompletion":20037,"completion":20037,"start":20038,"enrollment":17519,"conditions":20039,"interventions":20040},"NCT02099656","A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma",[90],"2016-10-13","2014-11-06",[17203],[19991,20041,20042],"Inhaled corticposteroids","Second Asthma Controller Medication",{"nctId":20044,"briefTitle":20045,"status":107,"phases":20046,"primaryCompletion":16280,"completion":16280,"start":20047,"enrollment":3423,"conditions":20048,"interventions":20049},"NCT01987492","A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma",[90],"2014-02-28",[17203],[19991],{"trials":20051,"activeCount":101},[20052,20060,20068,20076,20083],{"nctId":20053,"briefTitle":20054,"status":343,"phases":20055,"primaryCompletion":20056,"completion":20056,"start":20057,"enrollment":101,"conditions":20058,"interventions":20059},"NCT02546869","A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting",[91],"2016-06-29","2015-09-29",[17203],[19991],{"nctId":20061,"briefTitle":20062,"status":107,"phases":20063,"primaryCompletion":20064,"completion":20064,"start":3736,"enrollment":20065,"conditions":20066,"interventions":20067},"NCT01875003","A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",[91],"2016-12-28",348,[17203],[19991,8649],{"nctId":20069,"briefTitle":20070,"status":107,"phases":20071,"primaryCompletion":20072,"completion":20072,"start":6187,"enrollment":20073,"conditions":20074,"interventions":20075},"NCT01868061","A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication",[91],"2017-01-02",1068,[17203],[19991],{"nctId":20077,"briefTitle":20078,"status":107,"phases":20079,"primaryCompletion":20072,"completion":20072,"start":6187,"enrollment":20080,"conditions":20081,"interventions":20082},"NCT01867125","A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",[91],1081,[17203],[19991],{"nctId":20084,"briefTitle":20085,"status":107,"phases":20086,"primaryCompletion":2514,"completion":2514,"start":3174,"enrollment":6307,"conditions":20087,"interventions":20088},"NCT02104674","A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma",[91],[17203],[20089,20090],"lebrikizumab","montelukast [Singulair]",{"trials":20092,"activeCount":101},[],{"trials":20094,"activeCount":101},[],{"intervention":4468,"totalTrials":462,"cells":20096},{"EARLY_PHASE1":20097,"PHASE1":20099,"PHASE2":20105,"PHASE3":20115,"PHASE4":20145,"NA":20147},{"trials":20098,"activeCount":101},[],{"trials":20100,"activeCount":101},[20101],{"nctId":9315,"briefTitle":9316,"status":107,"phases":20102,"primaryCompletion":9318,"completion":9318,"start":9319,"enrollment":755,"conditions":20103,"interventions":20104},[89],[1305],[4468,9322,2644,9323,2577],{"trials":20106,"activeCount":101},[20107,20111],{"nctId":6558,"briefTitle":6559,"status":130,"phases":20108,"primaryCompletion":6561,"completion":6561,"start":6562,"enrollment":6563,"conditions":20109,"interventions":20110},[90],[6565],[6567,4219,1163,1983],{"nctId":4211,"briefTitle":4212,"status":107,"phases":20112,"primaryCompletion":4214,"completion":4215,"start":4216,"enrollment":1936,"conditions":20113,"interventions":20114},[90],[1049],[4219,1015,2152],{"trials":20116,"activeCount":101},[20117,20121,20125,20129,20133,20137,20141],{"nctId":9620,"briefTitle":9621,"status":107,"phases":20118,"primaryCompletion":9623,"completion":9624,"start":4635,"enrollment":9625,"conditions":20119,"interventions":20120},[91],[1316],[4468,947],{"nctId":5522,"briefTitle":5523,"status":107,"phases":20122,"primaryCompletion":5245,"completion":5525,"start":5526,"enrollment":5527,"conditions":20123,"interventions":20124},[91],[2038],[4468,990,1074],{"nctId":5240,"briefTitle":5241,"status":107,"phases":20126,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":5246,"conditions":20127,"interventions":20128},[91],[5248],[4468,989,1319,990,1167,1163],{"nctId":6731,"briefTitle":6732,"status":107,"phases":20130,"primaryCompletion":6734,"completion":6735,"start":6736,"enrollment":5246,"conditions":20131,"interventions":20132},[91],[975],[4468,1983,1163],{"nctId":4460,"briefTitle":4461,"status":107,"phases":20134,"primaryCompletion":4463,"completion":4464,"start":3277,"enrollment":4465,"conditions":20135,"interventions":20136},[91],[1049],[4468,1015,2152],{"nctId":5251,"briefTitle":5252,"status":107,"phases":20138,"primaryCompletion":2007,"completion":1691,"start":5254,"enrollment":5255,"conditions":20139,"interventions":20140},[91],[5257],[4468,990,1107,1319],{"nctId":4523,"briefTitle":4524,"status":107,"phases":20142,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":4529,"conditions":20143,"interventions":20144},[91],[1316],[4468,1015,990,1106],{"trials":20146,"activeCount":101},[],{"trials":20148,"activeCount":101},[],{"intervention":1500,"totalTrials":462,"cells":20150},{"EARLY_PHASE1":20151,"PHASE1":20153,"PHASE2":20176,"PHASE3":20211,"PHASE4":20222,"NA":20224},{"trials":20152,"activeCount":101},[],{"trials":20154,"activeCount":101},[20155,20165,20172],{"nctId":20156,"briefTitle":20157,"status":107,"phases":20158,"primaryCompletion":20159,"completion":20159,"start":20160,"enrollment":306,"conditions":20161,"interventions":20162},"NCT02828930","A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)",[89],"2017-06-19","2016-09-08",[922],[1500,20163,20164],"[13C]-radiolabeled Idasanutlin","[14C]-radiolabeled Idasanutlin",{"nctId":20166,"briefTitle":20167,"status":107,"phases":20168,"primaryCompletion":20169,"completion":20169,"start":6452,"enrollment":123,"conditions":20170,"interventions":20171},"NCT03362723","A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors",[89],"2019-06-11",[922],[1500],{"nctId":10476,"briefTitle":10477,"status":107,"phases":20173,"primaryCompletion":10479,"completion":10479,"start":3585,"enrollment":736,"conditions":20174,"interventions":20175},[89],[10481],[1084,1500,1073],{"trials":20177,"activeCount":101},[20178,20187,20191,20195,20203,20207],{"nctId":20179,"briefTitle":20180,"status":130,"phases":20181,"primaryCompletion":20182,"completion":20182,"start":20183,"enrollment":11473,"conditions":20184,"interventions":20186},"NCT03287245","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant\u002FIntolerant Polycythemia Vera",[90],"2020-03-03","2018-02-21",[20185],"Polycythemia Vera",[1500],{"nctId":3638,"briefTitle":3639,"status":130,"phases":20188,"primaryCompletion":3641,"completion":3641,"start":3642,"enrollment":1174,"conditions":20189,"interventions":20190},[89,90],[2642,3644],[1500,1018,1073,1359],{"nctId":10078,"briefTitle":10079,"status":130,"phases":20192,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":20193,"interventions":20194},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"nctId":20196,"briefTitle":20197,"status":130,"phases":20198,"primaryCompletion":19699,"completion":19699,"start":20199,"enrollment":425,"conditions":20200,"interventions":20201},"NCT03850535","A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission",[89,90],"2019-03-25",[933],[1500,10088,20202],"Daunorubicin",{"nctId":1490,"briefTitle":1491,"status":130,"phases":20204,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":20205,"interventions":20206},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"nctId":3711,"briefTitle":3712,"status":130,"phases":20208,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":97,"conditions":20209,"interventions":20210},[89,90],[125],[1500,1018,1359],{"trials":20212,"activeCount":101},[20213],{"nctId":20214,"briefTitle":20215,"status":130,"phases":20216,"primaryCompletion":20217,"completion":20217,"start":20218,"enrollment":20219,"conditions":20220,"interventions":20221},"NCT02545283","A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[91],"2020-04-24","2015-12-30",447,[10481],[10088,1500],{"trials":20223,"activeCount":101},[],{"trials":20225,"activeCount":101},[],{"intervention":10088,"totalTrials":306,"cells":20227},{"EARLY_PHASE1":20228,"PHASE1":20230,"PHASE2":20257,"PHASE3":20281,"PHASE4":20287,"NA":20289},{"trials":20229,"activeCount":101},[],{"trials":20231,"activeCount":101},[20232,20241,20250],{"nctId":20233,"briefTitle":20234,"status":107,"phases":20235,"primaryCompletion":4454,"completion":4454,"start":3007,"enrollment":1385,"conditions":20236,"interventions":20238},"NCT01635296","A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia",[89],[20237],"Myelogenous Leukemia, Acute",[20239,20239,20240,20240],"RO5045377","cytarabine",{"nctId":20242,"briefTitle":20243,"status":107,"phases":20244,"primaryCompletion":2601,"completion":2601,"start":132,"enrollment":3190,"conditions":20245,"interventions":20246},"NCT01773408","A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia",[89],[20237],[20247,20248,20249,20202,10088],"RO5503781 MBP","RO5503781 SDP","Idarubicin",{"nctId":20251,"briefTitle":20252,"status":107,"phases":20253,"primaryCompletion":3006,"completion":3006,"start":15695,"enrollment":4886,"conditions":20254,"interventions":20255},"NCT01641250","A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia",[89],[20237],[20256,20240],"RO5429083",{"trials":20258,"activeCount":101},[20259,20263,20267,20273],{"nctId":10078,"briefTitle":10079,"status":130,"phases":20260,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":20261,"interventions":20262},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"nctId":20196,"briefTitle":20197,"status":130,"phases":20264,"primaryCompletion":19699,"completion":19699,"start":20199,"enrollment":425,"conditions":20265,"interventions":20266},[89,90],[933],[1500,10088,20202],{"nctId":20268,"briefTitle":20269,"status":130,"phases":20270,"primaryCompletion":3325,"completion":3325,"start":3692,"enrollment":2631,"conditions":20271,"interventions":20272},"NCT00517699","A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.",[90],[1038],[5837,2824,10088],{"nctId":20274,"briefTitle":20275,"status":130,"phases":20276,"primaryCompletion":11550,"completion":11550,"start":2684,"enrollment":2492,"conditions":20277,"interventions":20279},"NCT01880437","A Study of Vismodegib in Patients With Relapsed\u002FRefractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome",[90],[20278],"Myelodysplastic Syndromes, Myelogenous Leukemia, Acute",[20240,20280],"vismodegib",{"trials":20282,"activeCount":101},[20283],{"nctId":20214,"briefTitle":20215,"status":130,"phases":20284,"primaryCompletion":20217,"completion":20217,"start":20218,"enrollment":20219,"conditions":20285,"interventions":20286},[91],[10481],[10088,1500],{"trials":20288,"activeCount":101},[],{"trials":20290,"activeCount":101},[],{"intervention":20292,"totalTrials":306,"cells":20293},"Balovaptan",{"EARLY_PHASE1":20294,"PHASE1":20296,"PHASE2":20342,"PHASE3":20359,"PHASE4":20370,"NA":20372},{"trials":20295,"activeCount":101},[],{"trials":20297,"activeCount":101},[20298,20305,20315,20324,20333],{"nctId":20299,"briefTitle":20300,"status":107,"phases":20301,"primaryCompletion":20302,"completion":20302,"start":1765,"enrollment":2619,"conditions":20303,"interventions":20304},"NCT03579719","A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers",[89],"2018-11-09",[427],[20292,398],{"nctId":20306,"briefTitle":20307,"status":107,"phases":20308,"primaryCompletion":20309,"completion":20310,"start":20311,"enrollment":721,"conditions":20312,"interventions":20313},"NCT03586726","A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers",[89],"2018-11-02","2018-11-15","2018-07-24",[427],[20292,20314],"Rifampicin",{"nctId":20316,"briefTitle":20317,"status":343,"phases":20318,"primaryCompletion":20319,"completion":20320,"start":20321,"enrollment":101,"conditions":20322,"interventions":20323},"NCT03912350","The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan",[89],"2022-09-24","2022-10-13","2022-06-26",[11768],[20292],{"nctId":20325,"briefTitle":20326,"status":130,"phases":20327,"primaryCompletion":20328,"completion":20329,"start":20330,"enrollment":162,"conditions":20331,"interventions":20332},"NCT04049578","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder",[89],"2020-04-23","2020-05-06","2019-12-19",[11768],[20292],{"nctId":20334,"briefTitle":20335,"status":107,"phases":20336,"primaryCompletion":20337,"completion":20338,"start":20339,"enrollment":721,"conditions":20340,"interventions":20341},"NCT04156646","A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers",[89],"2019-12-24","2020-01-06","2019-11-19",[11768],[20292,4846],{"trials":20343,"activeCount":101},[20344,20351],{"nctId":20345,"briefTitle":20346,"status":107,"phases":20347,"primaryCompletion":142,"completion":142,"start":18527,"enrollment":1174,"conditions":20348,"interventions":20350},"NCT05401565","Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)",[90],[20349],"Stress Disorders, Post-Traumatic",[20292],{"nctId":20352,"briefTitle":20353,"status":343,"phases":20354,"primaryCompletion":2006,"completion":2006,"start":20355,"enrollment":101,"conditions":20356,"interventions":20358},"NCT05399550","Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema",[90],"2022-06-22",[20357],"Acute Ischemic Stroke",[20292],{"trials":20360,"activeCount":101},[20361],{"nctId":20362,"briefTitle":20363,"status":130,"phases":20364,"primaryCompletion":1871,"completion":20365,"start":20366,"enrollment":20367,"conditions":20368,"interventions":20369},"NCT03504917","A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension",[91],"2020-07-01","2018-08-08",322,[11768],[20292],{"trials":20371,"activeCount":101},[],{"trials":20373,"activeCount":101},[],{"intervention":20375,"totalTrials":306,"cells":20376},"Etrolizumab",{"EARLY_PHASE1":20377,"PHASE1":20379,"PHASE2":20390,"PHASE3":20392,"PHASE4":20455,"NA":20457},{"trials":20378,"activeCount":101},[],{"trials":20380,"activeCount":101},[20381],{"nctId":20382,"briefTitle":20383,"status":130,"phases":20384,"primaryCompletion":20385,"completion":2168,"start":8026,"enrollment":425,"conditions":20386,"interventions":20389},"NCT03478956","A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease",[89],"2019-12-02",[20387,20388],"Ulcerative Colitis","Crohn's Disease",[20375],{"trials":20391,"activeCount":101},[],{"trials":20393,"activeCount":101},[20394,20403,20411,20419,20428,20437,20447],{"nctId":20395,"briefTitle":20396,"status":107,"phases":20397,"primaryCompletion":20398,"completion":20398,"start":20399,"enrollment":20400,"conditions":20401,"interventions":20402},"NCT02136069","A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors",[91],"2020-06-23","2014-12-24",397,[20387],[20375,6447],{"nctId":20404,"briefTitle":20405,"status":107,"phases":20406,"primaryCompletion":17165,"completion":20407,"start":20408,"enrollment":2323,"conditions":20409,"interventions":20410},"NCT02163759","A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors",[91],"2020-03-19","2014-11-04",[20387],[2382,20375],{"nctId":20412,"briefTitle":20405,"status":107,"phases":20413,"primaryCompletion":20414,"completion":20415,"start":20416,"enrollment":2323,"conditions":20417,"interventions":20418},"NCT02171429",[91],"2020-03-02","2020-05-25","2014-11-14",[20387],[2382,20375],{"nctId":20420,"briefTitle":20421,"status":107,"phases":20422,"primaryCompletion":20423,"completion":20423,"start":20424,"enrollment":8752,"conditions":20425,"interventions":20427},"NCT02394028","A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease",[91],"2021-09-07","2015-03-20",[20426],"Crohn Disease",[20375],{"nctId":20429,"briefTitle":20430,"status":130,"phases":20431,"primaryCompletion":20432,"completion":20432,"start":20433,"enrollment":20434,"conditions":20435,"interventions":20436},"NCT02403323","Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144",[91],"2023-10-09","2015-06-08",790,[20426],[20375],{"nctId":20438,"briefTitle":20439,"status":107,"phases":20440,"primaryCompletion":20441,"completion":20441,"start":20442,"enrollment":20443,"conditions":20444,"interventions":20446},"NCT02165215","A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors",[91],"2020-04-06","2014-08-12",359,[20445],"Colitis, Ulcerative",[20375],{"nctId":20448,"briefTitle":20449,"status":130,"phases":20450,"primaryCompletion":142,"completion":142,"start":20451,"enrollment":20452,"conditions":20453,"interventions":20454},"NCT02118584","Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II\u002FIII Studies",[91],"2014-09-15",1822,[20387],[20375],{"trials":20456,"activeCount":101},[],{"trials":20458,"activeCount":101},[],{"intervention":4244,"totalTrials":4548,"cells":20460},{"EARLY_PHASE1":20461,"PHASE1":20463,"PHASE2":20473,"PHASE3":20483,"PHASE4":20500,"NA":20502},{"trials":20462,"activeCount":101},[],{"trials":20464,"activeCount":101},[20465,20469],{"nctId":11812,"briefTitle":11813,"status":107,"phases":20466,"primaryCompletion":4473,"completion":4473,"start":2684,"enrollment":1796,"conditions":20467,"interventions":20468},[89],[1443],[4244,2011],{"nctId":10452,"briefTitle":10453,"status":343,"phases":20470,"primaryCompletion":5364,"completion":5364,"start":4682,"enrollment":101,"conditions":20471,"interventions":20472},[89],[1241],[1084,1084,4244,1479],{"trials":20474,"activeCount":101},[20475,20479],{"nctId":4237,"briefTitle":4238,"status":107,"phases":20476,"primaryCompletion":4240,"completion":4240,"start":4241,"enrollment":3295,"conditions":20477,"interventions":20478},[90],[4068],[1015,4244],{"nctId":8998,"briefTitle":8999,"status":107,"phases":20480,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":1548,"conditions":20481,"interventions":20482},[90],[1735],[4244,1165,4272,4131,1597],{"trials":20484,"activeCount":101},[20485,20489,20496],{"nctId":4430,"briefTitle":4431,"status":107,"phases":20486,"primaryCompletion":4433,"completion":4433,"start":4434,"enrollment":709,"conditions":20487,"interventions":20488},[91],[1160],[4244,1015,977],{"nctId":20490,"briefTitle":20491,"status":107,"phases":20492,"primaryCompletion":3006,"completion":3006,"start":3212,"enrollment":462,"conditions":20493,"interventions":20494},"NCT01887886","A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation",[91],[2257],[4201,20495],"onartuzumab",{"nctId":9058,"briefTitle":9059,"status":107,"phases":20497,"primaryCompletion":2847,"completion":2847,"start":8681,"enrollment":9061,"conditions":20498,"interventions":20499},[91],[1735],[9064,4272,4244,1165],{"trials":20501,"activeCount":101},[],{"trials":20503,"activeCount":101},[],{"intervention":586,"totalTrials":4548,"cells":20505},{"EARLY_PHASE1":20506,"PHASE1":20508,"PHASE2":20510,"PHASE3":20512,"PHASE4":20542,"NA":20544},{"trials":20507,"activeCount":101},[],{"trials":20509,"activeCount":101},[],{"trials":20511,"activeCount":101},[],{"trials":20513,"activeCount":101},[20514,20518,20522,20526,20530,20534,20538],{"nctId":7662,"briefTitle":7663,"status":343,"phases":20515,"primaryCompletion":345,"completion":5706,"start":7665,"enrollment":101,"conditions":20516,"interventions":20517},[91],[7667],[528,586],{"nctId":576,"briefTitle":577,"status":107,"phases":20519,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":20520,"interventions":20521},[91],[584],[509,586],{"nctId":588,"briefTitle":589,"status":107,"phases":20523,"primaryCompletion":591,"completion":592,"start":593,"enrollment":594,"conditions":20524,"interventions":20525},[91],[596,597,598],[509,586],{"nctId":601,"briefTitle":602,"status":107,"phases":20527,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":20528,"interventions":20529},[91],[551],[586,509],{"nctId":611,"briefTitle":612,"status":107,"phases":20531,"primaryCompletion":614,"completion":615,"start":593,"enrollment":616,"conditions":20532,"interventions":20533},[91],[596,618],[509,586],{"nctId":621,"briefTitle":622,"status":107,"phases":20535,"primaryCompletion":220,"completion":624,"start":625,"enrollment":626,"conditions":20536,"interventions":20537},[91],[584],[509,586],{"nctId":630,"briefTitle":631,"status":107,"phases":20539,"primaryCompletion":633,"completion":634,"start":635,"enrollment":636,"conditions":20540,"interventions":20541},[91],[551],[586,509],{"trials":20543,"activeCount":101},[],{"trials":20545,"activeCount":101},[],{"intervention":4071,"totalTrials":942,"cells":20547},{"EARLY_PHASE1":20548,"PHASE1":20550,"PHASE2":20556,"PHASE3":20576,"PHASE4":20582,"NA":20584},{"trials":20549,"activeCount":101},[],{"trials":20551,"activeCount":101},[20552],{"nctId":5373,"briefTitle":5374,"status":130,"phases":20553,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":20554,"interventions":20555},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":20557,"activeCount":101},[20558,20562,20566,20572],{"nctId":4061,"briefTitle":4062,"status":107,"phases":20559,"primaryCompletion":2089,"completion":4064,"start":4065,"enrollment":4066,"conditions":20560,"interventions":20561},[90],[4068],[1015,4070,4071,4072],{"nctId":4154,"briefTitle":4155,"status":107,"phases":20563,"primaryCompletion":4157,"completion":3413,"start":4158,"enrollment":4159,"conditions":20564,"interventions":20565},[90],[4161],[1015,4071],{"nctId":20567,"briefTitle":20568,"status":107,"phases":20569,"primaryCompletion":3007,"completion":3007,"start":4409,"enrollment":8206,"conditions":20570,"interventions":20571},"NCT01115491","A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme",[90],[16614],[5275,5389],{"nctId":16610,"briefTitle":16611,"status":107,"phases":20573,"primaryCompletion":3182,"completion":3182,"start":4409,"enrollment":3015,"conditions":20574,"interventions":20575},[90],[16614],[5275,4102,5389],{"trials":20577,"activeCount":101},[20578],{"nctId":4393,"briefTitle":4394,"status":107,"phases":20579,"primaryCompletion":4396,"completion":2864,"start":4397,"enrollment":4398,"conditions":20580,"interventions":20581},[91],[4068],[1015,4071],{"trials":20583,"activeCount":101},[],{"trials":20585,"activeCount":101},[],{"intervention":20587,"totalTrials":942,"cells":20588},"Olesoxime",{"EARLY_PHASE1":20589,"PHASE1":20591,"PHASE2":20607,"PHASE3":20632,"PHASE4":20643,"NA":20645},{"trials":20590,"activeCount":101},[],{"trials":20592,"activeCount":101},[20593,20601],{"nctId":20594,"briefTitle":20595,"status":107,"phases":20596,"primaryCompletion":2830,"completion":2830,"start":3029,"enrollment":4886,"conditions":20597,"interventions":20599},"NCT01808885","Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.",[89],[20598],"Relapsing Remitting Multiple Sclerosis",[20600],"olesoxime",{"nctId":20602,"briefTitle":20603,"status":107,"phases":20604,"primaryCompletion":3182,"completion":3182,"start":5364,"enrollment":942,"conditions":20605,"interventions":20606},"NCT02835976","A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)",[89],[21],[20587],{"trials":20608,"activeCount":101},[20609,20616,20624],{"nctId":20610,"briefTitle":20611,"status":107,"phases":20612,"primaryCompletion":2932,"completion":2932,"start":3325,"enrollment":510,"conditions":20613,"interventions":20615},"NCT00876538","Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy",[90],[20614],"Chemotherapy-Induced Peripheral Neuropathy",[20587],{"nctId":20617,"briefTitle":20618,"status":107,"phases":20619,"primaryCompletion":20620,"completion":20620,"start":20621,"enrollment":414,"conditions":20622,"interventions":20623},"NCT02628743","A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)",[90],"2018-12-18","2016-01-20",[406],[20587],{"nctId":20625,"briefTitle":20626,"status":107,"phases":20627,"primaryCompletion":4454,"completion":4454,"start":5181,"enrollment":18451,"conditions":20628,"interventions":20631},"NCT01302600","Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.",[90],[20629,20630],"Spinal Muscular Atrophy Type II","Spinal Muscular Atrophy Type III Non Ambulant",[20587],{"trials":20633,"activeCount":101},[20634],{"nctId":20635,"briefTitle":20636,"status":107,"phases":20637,"primaryCompletion":16165,"completion":16165,"start":16142,"enrollment":20638,"conditions":20639,"interventions":20641},"NCT00868166","Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS",[91],512,[20640],"Amyotrophic Lateral Sclerosis",[20587,20642],"Riluzole",{"trials":20644,"activeCount":101},[],{"trials":20646,"activeCount":101},[],{"intervention":5619,"totalTrials":942,"cells":20648},{"EARLY_PHASE1":20649,"PHASE1":20651,"PHASE2":20653,"PHASE3":20667,"PHASE4":20681,"NA":20683},{"trials":20650,"activeCount":101},[],{"trials":20652,"activeCount":101},[],{"trials":20654,"activeCount":101},[20655,20659,20663],{"nctId":8602,"briefTitle":8603,"status":107,"phases":20656,"primaryCompletion":2905,"completion":2905,"start":8605,"enrollment":3015,"conditions":20657,"interventions":20658},[90],[18],[1597,1166,992,947,5619],{"nctId":7918,"briefTitle":7919,"status":107,"phases":20660,"primaryCompletion":7921,"completion":1811,"start":7922,"enrollment":7923,"conditions":20661,"interventions":20662},[90],[18],[1597,992,947,991,5619,1106,1221,1222],{"nctId":7092,"briefTitle":7093,"status":107,"phases":20664,"primaryCompletion":7095,"completion":7095,"start":7096,"enrollment":1011,"conditions":20665,"interventions":20666},[90],[1735],[1167,1166,5619,1167,1166,1165,947,1166],{"trials":20668,"activeCount":101},[20669,20673,20677],{"nctId":8075,"briefTitle":8076,"status":107,"phases":20670,"primaryCompletion":47,"completion":8078,"start":8079,"enrollment":8080,"conditions":20671,"interventions":20672},[91],[18],[1419,1222,1221,1106,5619,991,947,992,1597],{"nctId":9714,"briefTitle":9715,"status":107,"phases":20674,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":20675,"interventions":20676},[91],[18],[1597,992,947,5619,9723,9724],{"nctId":5610,"briefTitle":5611,"status":107,"phases":20678,"primaryCompletion":5613,"completion":5614,"start":5615,"enrollment":5616,"conditions":20679,"interventions":20680},[91],[18],[1597,990,992,947,991,5619,1106,1221,1222],{"trials":20682,"activeCount":101},[],{"trials":20684,"activeCount":101},[],{"intervention":4272,"totalTrials":2631,"cells":20686},{"EARLY_PHASE1":20687,"PHASE1":20689,"PHASE2":20691,"PHASE3":20709,"PHASE4":20715,"NA":20717},{"trials":20688,"activeCount":101},[],{"trials":20690,"activeCount":101},[],{"trials":20692,"activeCount":101},[20693,20697,20701,20705],{"nctId":4092,"briefTitle":4093,"status":130,"phases":20694,"primaryCompletion":4095,"completion":4095,"start":4096,"enrollment":571,"conditions":20695,"interventions":20696},[90],[4098],[4089,4100,4101,4102,4103,4104],{"nctId":4264,"briefTitle":4265,"status":130,"phases":20698,"primaryCompletion":3122,"completion":4267,"start":4268,"enrollment":4269,"conditions":20699,"interventions":20700},[90],[30],[1162,1015,4272,1165,4037],{"nctId":4302,"briefTitle":4303,"status":107,"phases":20702,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":1352,"conditions":20703,"interventions":20704},[90],[1727],[1015,1165,4309,4089],{"nctId":8998,"briefTitle":8999,"status":107,"phases":20706,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":1548,"conditions":20707,"interventions":20708},[90],[1735],[4244,1165,4272,4131,1597],{"trials":20710,"activeCount":101},[20711],{"nctId":9058,"briefTitle":9059,"status":107,"phases":20712,"primaryCompletion":2847,"completion":2847,"start":8681,"enrollment":9061,"conditions":20713,"interventions":20714},[91],[1735],[9064,4272,4244,1165],{"trials":20716,"activeCount":101},[],{"trials":20718,"activeCount":101},[],{"intervention":16468,"totalTrials":2631,"cells":20720},{"EARLY_PHASE1":20721,"PHASE1":20723,"PHASE2":20729,"PHASE3":20731,"PHASE4":20749,"NA":20751},{"trials":20722,"activeCount":101},[],{"trials":20724,"activeCount":101},[20725],{"nctId":16463,"briefTitle":16464,"status":107,"phases":20726,"enrollment":496,"conditions":20727,"interventions":20728},[89],[33],[16468,16450],{"trials":20730,"activeCount":101},[],{"trials":20732,"activeCount":101},[20733,20737,20741,20745],{"nctId":16504,"briefTitle":16505,"status":107,"phases":20734,"enrollment":16507,"conditions":20735,"interventions":20736},[91],[33],[11782,16468,16450,16510],{"nctId":16520,"briefTitle":16521,"status":107,"phases":20738,"enrollment":425,"conditions":20739,"interventions":20740},[91],[33,16524],[16468,16450,16486,16487],{"nctId":16547,"briefTitle":16548,"status":107,"phases":20742,"enrollment":16550,"conditions":20743,"interventions":20744},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":16560,"briefTitle":16561,"status":107,"phases":20746,"enrollment":1239,"conditions":20747,"interventions":20748},[91],[33],[11782,16468,16450,16487],{"trials":20750,"activeCount":101},[],{"trials":20752,"activeCount":101},[],{"intervention":20754,"totalTrials":2631,"cells":20755},"PRM-151",{"EARLY_PHASE1":20756,"PHASE1":20758,"PHASE2":20768,"PHASE3":20788,"PHASE4":20804,"NA":20806},{"trials":20757,"activeCount":101},[],{"trials":20759,"activeCount":101},[20760],{"nctId":20761,"briefTitle":20762,"status":107,"phases":20763,"primaryCompletion":20764,"completion":20764,"start":20765,"enrollment":3939,"conditions":20766,"interventions":20767},"NCT01254409","A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[89],"2012-07-02","2011-03-29",[18883],[20754],{"trials":20769,"activeCount":101},[20770,20778],{"nctId":20771,"briefTitle":20772,"status":107,"phases":20773,"primaryCompletion":20774,"completion":20774,"start":20775,"enrollment":2733,"conditions":20776,"interventions":20777},"NCT02550873","A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)",[90],"2017-05-02","2015-09-01",[18883],[20754],{"nctId":20779,"briefTitle":20780,"status":107,"phases":20781,"primaryCompletion":20782,"completion":20783,"start":20784,"enrollment":4159,"conditions":20785,"interventions":20787},"NCT01064817","PRM-151 in the Prevention of Scarring Following Trabeculectomy",[90],"2012-04-30","2012-11-14","2010-06-14",[20786],"Glaucoma",[20754],{"trials":20789,"activeCount":101},[20790,20797],{"nctId":20791,"briefTitle":20792,"status":130,"phases":20793,"primaryCompletion":1634,"completion":1634,"start":20794,"enrollment":2733,"conditions":20795,"interventions":20796},"NCT04594707","A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis",[91],"2021-08-30",[18883],[20754],{"nctId":20798,"briefTitle":20799,"status":130,"phases":20800,"primaryCompletion":1634,"completion":1634,"start":9318,"enrollment":20801,"conditions":20802,"interventions":20803},"NCT04552899","A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis",[91],665,[18883],[20754],{"trials":20805,"activeCount":101},[],{"trials":20807,"activeCount":101},[],{"intervention":9587,"totalTrials":2631,"cells":20809},{"EARLY_PHASE1":20810,"PHASE1":20812,"PHASE2":20814,"PHASE3":20841,"PHASE4":20850,"NA":20852},{"trials":20811,"activeCount":101},[],{"trials":20813,"activeCount":101},[],{"trials":20815,"activeCount":101},[20816,20822,20828,20837],{"nctId":20817,"briefTitle":20818,"status":130,"phases":20819,"primaryCompletion":2769,"completion":2769,"start":6620,"enrollment":706,"conditions":20820,"interventions":20821},"NCT00642824","A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.",[90],[2257],[9587,5275],{"nctId":20823,"briefTitle":20824,"status":107,"phases":20825,"primaryCompletion":8826,"completion":5418,"start":8934,"enrollment":973,"conditions":20826,"interventions":20827},"NCT00717405","A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.",[90],[18],[9587,5275,5390],{"nctId":20829,"briefTitle":20830,"status":107,"phases":20831,"primaryCompletion":20832,"completion":20833,"start":20834,"enrollment":5458,"conditions":20835,"interventions":20836},"NCT00643565","A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.",[90],"2015-05-31","2019-04-30","2008-07-29",[4856],[9587,5275],{"nctId":9582,"briefTitle":9583,"status":107,"phases":20838,"primaryCompletion":2932,"completion":2932,"start":4513,"enrollment":3665,"conditions":20839,"interventions":20840},[90],[18],[5275,947,9587],{"trials":20842,"activeCount":101},[20843],{"nctId":20844,"briefTitle":20845,"status":107,"phases":20846,"primaryCompletion":4322,"completion":4322,"start":20847,"enrollment":157,"conditions":20848,"interventions":20849},"NCT00269113","A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma",[91],"1998-09",[125],[5837,9587],{"trials":20851,"activeCount":101},[],{"trials":20853,"activeCount":101},[],{"intervention":20855,"totalTrials":2631,"cells":20856},"Bitopertin",{"EARLY_PHASE1":20857,"PHASE1":20859,"PHASE2":20871,"PHASE3":20891,"PHASE4":20901,"NA":20903},{"trials":20858,"activeCount":101},[],{"trials":20860,"activeCount":101},[20861,20865],{"nctId":11752,"briefTitle":11753,"status":343,"phases":20862,"primaryCompletion":11755,"completion":11755,"start":11756,"enrollment":101,"conditions":20863,"interventions":20864},[89],[21],[388,11759],{"nctId":20866,"briefTitle":20867,"status":107,"phases":20868,"primaryCompletion":5457,"completion":5457,"start":13164,"enrollment":3286,"conditions":20869,"interventions":20870},"NCT01636492","A Study of Bitopertin (RO4917838) in Healthy Male Volunteers",[89],[21],[11759],{"trials":20872,"activeCount":101},[20873,20883],{"nctId":20874,"briefTitle":20875,"status":107,"phases":20876,"primaryCompletion":20877,"completion":20877,"start":20878,"enrollment":559,"conditions":20879,"interventions":20881},"NCT01674361","A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)",[90],"2015-04-30","2012-12-31",[20880],"Obsessive-Compulsive Disorder",[20855,20882],"SSRI",{"nctId":20884,"briefTitle":20885,"status":107,"phases":20886,"primaryCompletion":4433,"completion":4433,"start":20887,"enrollment":709,"conditions":20888,"interventions":20890},"NCT03271541","A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia",[90],"2017-10-26",[20889],"Beta-Thalassemia",[20855],{"trials":20892,"activeCount":101},[20893],{"nctId":20894,"briefTitle":20895,"status":107,"phases":20896,"primaryCompletion":5364,"completion":5364,"start":5181,"enrollment":20897,"conditions":20898,"interventions":20899},"NCT01192880","A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia",[91],625,[19752],[20855,20900],"Antipsychotics",{"trials":20902,"activeCount":101},[],{"trials":20904,"activeCount":101},[],{"intervention":20906,"totalTrials":5110,"cells":20907},"RO7234292",{"EARLY_PHASE1":20908,"PHASE1":20910,"PHASE2":20919,"PHASE3":20928,"PHASE4":20948,"NA":20950},{"trials":20909,"activeCount":101},[],{"trials":20911,"activeCount":101},[20912],{"nctId":20913,"briefTitle":20914,"status":107,"phases":20915,"primaryCompletion":624,"completion":624,"start":3879,"enrollment":709,"conditions":20916,"interventions":20918},"NCT04000594","A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease",[89],[20917],"Huntingtons Disease",[20906],{"trials":20920,"activeCount":101},[20921],{"nctId":20922,"briefTitle":20923,"status":107,"phases":20924,"primaryCompletion":1229,"completion":1229,"start":20925,"enrollment":1204,"conditions":20926,"interventions":20927},"NCT03342053","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)",[90],"2018-01-02",[15093],[20906],{"trials":20929,"activeCount":101},[20930,20938],{"nctId":20931,"briefTitle":20932,"status":107,"phases":20933,"primaryCompletion":20934,"completion":20934,"start":12777,"enrollment":20935,"conditions":20936,"interventions":20937},"NCT03761849","A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease",[91],"2022-03-24",899,[20917],[20906],{"nctId":20939,"briefTitle":20940,"status":107,"phases":20941,"primaryCompletion":20942,"completion":20943,"start":20944,"enrollment":20945,"conditions":20946,"interventions":20947},"NCT03842969","An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies",[91],"2022-03-25","2022-03-30","2019-04-23",236,[13586],[20906],{"trials":20949,"activeCount":101},[],{"trials":20951,"activeCount":101},[],{"intervention":20953,"totalTrials":5110,"cells":20954},"ibandronate [Bondronat]",{"EARLY_PHASE1":20955,"PHASE1":20957,"PHASE2":20959,"PHASE3":20976,"PHASE4":20991,"NA":20993},{"trials":20956,"activeCount":101},[],{"trials":20958,"activeCount":101},[],{"trials":20960,"activeCount":101},[20961,20970],{"nctId":20962,"briefTitle":20963,"status":343,"phases":20964,"primaryCompletion":4086,"completion":4086,"start":6377,"enrollment":101,"conditions":20965,"interventions":20969},"NCT00478270","A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.",[90],[20966,20967,20968],"Pain","Bone Neoplasm","Neoplasm Metastasis",[20953],{"nctId":20971,"briefTitle":20972,"status":107,"phases":20973,"primaryCompletion":3325,"completion":3325,"start":121,"enrollment":372,"conditions":20974,"interventions":20975},"NCT00502736","A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.",[90],[16686],[20953],{"trials":20977,"activeCount":101},[20978,20985],{"nctId":20979,"briefTitle":20980,"status":130,"phases":20981,"primaryCompletion":4513,"completion":4513,"start":2923,"enrollment":1036,"conditions":20982,"interventions":20983},"NCT00099177","A Study to Assess the Efficacy of Intravenous\u002FOral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain",[91],[20966,20967,20968],[20953,20984],"zoledronic acid",{"nctId":20986,"briefTitle":20987,"status":130,"phases":20988,"primaryCompletion":4513,"completion":4513,"start":4323,"enrollment":6037,"conditions":20989,"interventions":20990},"NCT00099203","A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease",[91],[20966,20967,20968],[20953,20984],{"trials":20992,"activeCount":101},[],{"trials":20994,"activeCount":101},[],{"intervention":2820,"totalTrials":5110,"cells":20996},{"EARLY_PHASE1":20997,"PHASE1":20999,"PHASE2":21001,"PHASE3":21003,"PHASE4":21021,"NA":21023},{"trials":20998,"activeCount":101},[],{"trials":21000,"activeCount":101},[],{"trials":21002,"activeCount":101},[],{"trials":21004,"activeCount":101},[21005,21009,21013,21017],{"nctId":10139,"briefTitle":10140,"status":130,"phases":21006,"primaryCompletion":4582,"completion":4582,"start":7096,"enrollment":973,"conditions":21007,"interventions":21008},[91],[3597],[3707,3059,2820,992],{"nctId":2813,"briefTitle":2814,"status":107,"phases":21010,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":21011,"interventions":21012},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"nctId":10149,"briefTitle":10150,"status":107,"phases":21014,"primaryCompletion":7096,"completion":4555,"start":4323,"enrollment":10152,"conditions":21015,"interventions":21016},[91],[3597],[5914,992,2820,10155],{"nctId":7364,"briefTitle":7365,"status":107,"phases":21018,"primaryCompletion":1281,"completion":1281,"start":593,"enrollment":1651,"conditions":21019,"interventions":21020},[91],[7360],[7369,7370,5848,7371],{"trials":21022,"activeCount":101},[],{"trials":21024,"activeCount":101},[],{"intervention":21026,"totalTrials":5110,"cells":21027},"Crenezumab",{"EARLY_PHASE1":21028,"PHASE1":21030,"PHASE2":21032,"PHASE3":21040,"PHASE4":21063,"NA":21065},{"trials":21029,"activeCount":101},[],{"trials":21031,"activeCount":101},[],{"trials":21033,"activeCount":101},[21034],{"nctId":21035,"briefTitle":21036,"status":107,"phases":21037,"primaryCompletion":19692,"completion":19692,"start":1202,"enrollment":22,"conditions":21038,"interventions":21039},"NCT03977584","Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease",[90],[19641],[21026],{"trials":21041,"activeCount":101},[21042,21048,21056],{"nctId":21043,"briefTitle":21044,"status":130,"phases":21045,"primaryCompletion":1520,"completion":1520,"start":1349,"enrollment":2524,"conditions":21046,"interventions":21047},"NCT03491150","An Open-Label Crenezumab Study in Participants With Alzheimer's Disease",[91],[14384],[21026],{"nctId":21049,"briefTitle":21050,"status":130,"phases":21051,"primaryCompletion":1520,"completion":1520,"start":21052,"enrollment":21053,"conditions":21054,"interventions":21055},"NCT02670083","A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).",[91],"2016-03-22",813,[14384],[21026],{"nctId":21057,"briefTitle":21058,"status":130,"phases":21059,"primaryCompletion":20169,"completion":20169,"start":21060,"enrollment":17861,"conditions":21061,"interventions":21062},"NCT03114657","A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)",[91],"2017-03-29",[14384],[21026],{"trials":21064,"activeCount":101},[],{"trials":21066,"activeCount":101},[],{"intervention":16518,"totalTrials":5110,"cells":21068},{"EARLY_PHASE1":21069,"PHASE1":21071,"PHASE2":21077,"PHASE3":21083,"PHASE4":21093,"NA":21095},{"trials":21070,"activeCount":101},[],{"trials":21072,"activeCount":101},[21073],{"nctId":19243,"briefTitle":19244,"status":107,"phases":21074,"primaryCompletion":3213,"completion":3213,"start":2793,"enrollment":931,"conditions":21075,"interventions":21076},[89],[21],[11967,19248,11969],{"trials":21078,"activeCount":101},[21079],{"nctId":17437,"briefTitle":17438,"status":107,"phases":21080,"start":17440,"enrollment":4683,"conditions":21081,"interventions":21082},[90],[33],[17428,11782,17443,17444,16518],{"trials":21084,"activeCount":101},[21085,21089],{"nctId":16512,"briefTitle":16513,"status":107,"phases":21086,"start":16515,"enrollment":931,"conditions":21087,"interventions":21088},[91],[33],[11782,16518,16450],{"nctId":16541,"briefTitle":16542,"status":107,"phases":21090,"start":16515,"enrollment":11543,"conditions":21091,"interventions":21092},[91],[33],[11782,16518,16450],{"trials":21094,"activeCount":101},[],{"trials":21096,"activeCount":101},[],{"intervention":8041,"totalTrials":5110,"cells":21098},{"EARLY_PHASE1":21099,"PHASE1":21101,"PHASE2":21103,"PHASE3":21105,"PHASE4":21123,"NA":21125},{"trials":21100,"activeCount":101},[],{"trials":21102,"activeCount":101},[],{"trials":21104,"activeCount":101},[],{"trials":21106,"activeCount":101},[21107,21111,21115,21119],{"nctId":8032,"briefTitle":8033,"status":107,"phases":21108,"primaryCompletion":8035,"completion":8036,"start":8037,"enrollment":8038,"conditions":21109,"interventions":21110},[91],[986],[8041,2093,1106],{"nctId":10173,"briefTitle":10174,"status":107,"phases":21112,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":21113,"interventions":21114},[91],[10179],[8041,989,991,992,10181,10182],{"nctId":10574,"briefTitle":10575,"status":107,"phases":21116,"primaryCompletion":3896,"completion":10577,"start":2865,"enrollment":10578,"conditions":21117,"interventions":21118},[91],[30],[10581,1084,1497],{"nctId":13024,"briefTitle":13025,"status":107,"phases":21120,"primaryCompletion":13027,"completion":13028,"start":13029,"enrollment":13030,"conditions":21121,"interventions":21122},[91],[1061],[8041,1107],{"trials":21124,"activeCount":101},[],{"trials":21126,"activeCount":101},[],{"intervention":19294,"totalTrials":5110,"cells":21128},{"EARLY_PHASE1":21129,"PHASE1":21131,"PHASE2":21141,"PHASE3":21147,"PHASE4":21153,"NA":21155},{"trials":21130,"activeCount":101},[],{"trials":21132,"activeCount":101},[21133,21137],{"nctId":19289,"briefTitle":19290,"status":107,"phases":21134,"primaryCompletion":3084,"completion":3084,"start":6277,"enrollment":721,"conditions":21135,"interventions":21136},[89],[33],[11782,19294],{"nctId":19302,"briefTitle":19303,"status":107,"phases":21138,"primaryCompletion":3213,"completion":3213,"start":3103,"enrollment":145,"conditions":21139,"interventions":21140},[89],[33],[19307,11969,19294],{"trials":21142,"activeCount":101},[21143],{"nctId":19370,"briefTitle":19371,"status":107,"phases":21144,"primaryCompletion":4555,"completion":4555,"start":14572,"enrollment":5901,"conditions":21145,"interventions":21146},[90],[33],[11969,19294],{"trials":21148,"activeCount":101},[21149],{"nctId":19414,"briefTitle":19415,"status":107,"phases":21150,"primaryCompletion":6673,"completion":6343,"start":11300,"enrollment":19417,"conditions":21151,"interventions":21152},[91],[33],[19294,19420,19421,11782],{"trials":21154,"activeCount":101},[],{"trials":21156,"activeCount":101},[],{"intervention":16487,"totalTrials":5110,"cells":21158},{"EARLY_PHASE1":21159,"PHASE1":21161,"PHASE2":21163,"PHASE3":21169,"PHASE4":21183,"NA":21185},{"trials":21160,"activeCount":101},[],{"trials":21162,"activeCount":101},[],{"trials":21164,"activeCount":101},[21165],{"nctId":16481,"briefTitle":16482,"status":107,"phases":21166,"enrollment":1026,"conditions":21167,"interventions":21168},[90],[33],[16450,16486,16487,16478,16479,16488],{"trials":21170,"activeCount":101},[21171,21175,21179],{"nctId":16520,"briefTitle":16521,"status":107,"phases":21172,"enrollment":425,"conditions":21173,"interventions":21174},[91],[33,16524],[16468,16450,16486,16487],{"nctId":16547,"briefTitle":16548,"status":107,"phases":21176,"enrollment":16550,"conditions":21177,"interventions":21178},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":16560,"briefTitle":16561,"status":107,"phases":21180,"enrollment":1239,"conditions":21181,"interventions":21182},[91],[33],[11782,16468,16450,16487],{"trials":21184,"activeCount":101},[],{"trials":21186,"activeCount":101},[],{"intervention":8162,"totalTrials":5110,"cells":21188},{"EARLY_PHASE1":21189,"PHASE1":21191,"PHASE2":21193,"PHASE3":21206,"PHASE4":21220,"NA":21222},{"trials":21190,"activeCount":101},[],{"trials":21192,"activeCount":101},[],{"trials":21194,"activeCount":101},[21195],{"nctId":21196,"briefTitle":21197,"status":107,"phases":21198,"primaryCompletion":21199,"completion":21200,"start":21201,"enrollment":3923,"conditions":21202,"interventions":21204},"NCT03674112","A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer",[90],"2020-02-24","2022-10-12","2018-12-19",[21203],"HER2-Positive Early Breast Cancer",[21205,8162,8164],"Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration",{"trials":21207,"activeCount":101},[21208,21212,21216],{"nctId":10354,"briefTitle":10355,"status":107,"phases":21209,"primaryCompletion":10357,"completion":10358,"start":10359,"enrollment":10360,"conditions":21210,"interventions":21211},[91],[5655,3466,10362],[10364,8162,8164,1419,10365],{"nctId":9633,"briefTitle":9634,"status":107,"phases":21213,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":21214,"interventions":21215},[91],[9637],[8162,8164,9639,991,992,947,8166],{"nctId":8154,"briefTitle":8155,"status":107,"phases":21217,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":21218,"interventions":21219},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"trials":21221,"activeCount":101},[],{"trials":21223,"activeCount":101},[],{"intervention":8164,"totalTrials":5110,"cells":21225},{"EARLY_PHASE1":21226,"PHASE1":21228,"PHASE2":21230,"PHASE3":21236,"PHASE4":21250,"NA":21252},{"trials":21227,"activeCount":101},[],{"trials":21229,"activeCount":101},[],{"trials":21231,"activeCount":101},[21232],{"nctId":21196,"briefTitle":21197,"status":107,"phases":21233,"primaryCompletion":21199,"completion":21200,"start":21201,"enrollment":3923,"conditions":21234,"interventions":21235},[90],[21203],[21205,8162,8164],{"trials":21237,"activeCount":101},[21238,21242,21246],{"nctId":10354,"briefTitle":10355,"status":107,"phases":21239,"primaryCompletion":10357,"completion":10358,"start":10359,"enrollment":10360,"conditions":21240,"interventions":21241},[91],[5655,3466,10362],[10364,8162,8164,1419,10365],{"nctId":9633,"briefTitle":9634,"status":107,"phases":21243,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":21244,"interventions":21245},[91],[9637],[8162,8164,9639,991,992,947,8166],{"nctId":8154,"briefTitle":8155,"status":107,"phases":21247,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":21248,"interventions":21249},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"trials":21251,"activeCount":101},[],{"trials":21253,"activeCount":101},[],{"intervention":7641,"totalTrials":5110,"cells":21255},{"EARLY_PHASE1":21256,"PHASE1":21258,"PHASE2":21260,"PHASE3":21270,"PHASE4":21288,"NA":21290},{"trials":21257,"activeCount":101},[],{"trials":21259,"activeCount":101},[],{"trials":21261,"activeCount":101},[21262,21266],{"nctId":7633,"briefTitle":7634,"status":107,"phases":21263,"primaryCompletion":7636,"completion":7637,"start":52,"enrollment":7638,"conditions":21264,"interventions":21265},[90],[551],[7641,528],{"nctId":7647,"briefTitle":7648,"status":107,"phases":21267,"primaryCompletion":7650,"completion":7651,"start":7652,"enrollment":4961,"conditions":21268,"interventions":21269},[90],[551],[7641,528],{"trials":21271,"activeCount":101},[21272,21279],{"nctId":21273,"briefTitle":21274,"status":107,"phases":21275,"primaryCompletion":11000,"completion":870,"start":2449,"enrollment":21276,"conditions":21277,"interventions":21278},"NCT05642312","A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema",[91],245,[7609],[7641],{"nctId":21280,"briefTitle":21281,"status":107,"phases":21282,"primaryCompletion":21283,"completion":21284,"start":21285,"enrollment":6563,"conditions":21286,"interventions":21287},"NCT05642325","Vamikibart in Participants With Uveitic Macular Edema",[91],"2025-05-07","2025-12-24","2023-03-23",[7609],[7641],{"trials":21289,"activeCount":101},[],{"trials":21291,"activeCount":101},[],{"intervention":21293,"totalTrials":706,"cells":21294},"tenofovir",{"EARLY_PHASE1":21295,"PHASE1":21297,"PHASE2":21305,"PHASE3":21311,"PHASE4":21321,"NA":21323},{"trials":21296,"activeCount":101},[],{"trials":21298,"activeCount":101},[21299],{"nctId":21300,"briefTitle":21301,"status":107,"phases":21302,"primaryCompletion":2768,"completion":2768,"start":5271,"enrollment":1184,"conditions":21303,"interventions":21304},"NCT00962871","A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both",[89],[11790],[17072,21293],{"trials":21306,"activeCount":101},[21307],{"nctId":17686,"briefTitle":17687,"status":107,"phases":21308,"primaryCompletion":17689,"completion":17689,"start":17690,"enrollment":5013,"conditions":21309,"interventions":21310},[90],[11790],[17609,17693,17694],{"trials":21312,"activeCount":101},[21313],{"nctId":21314,"briefTitle":21315,"status":107,"phases":21316,"primaryCompletion":14644,"completion":14644,"start":21317,"enrollment":37,"conditions":21318,"interventions":21320},"NCT01088659","A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.",[91],"2010-02-16",[21319],"Hepatitis D, Chronic",[17072,21293],{"trials":21322,"activeCount":101},[],{"trials":21324,"activeCount":101},[],{"intervention":21326,"totalTrials":706,"cells":21327},"Lampalizumab",{"EARLY_PHASE1":21328,"PHASE1":21330,"PHASE2":21332,"PHASE3":21334,"PHASE4":21361,"NA":21363},{"trials":21329,"activeCount":101},[],{"trials":21331,"activeCount":101},[],{"trials":21333,"activeCount":101},[],{"trials":21335,"activeCount":101},[21336,21344,21352],{"nctId":21337,"briefTitle":21338,"status":130,"phases":21339,"primaryCompletion":3822,"completion":3822,"start":21340,"enrollment":21341,"conditions":21342,"interventions":21343},"NCT02745119","Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)",[91],"2016-07-21",994,[15187],[21326],{"nctId":21345,"briefTitle":21346,"status":130,"phases":21347,"primaryCompletion":21348,"completion":21348,"start":21349,"enrollment":19677,"conditions":21350,"interventions":21351},"NCT02247531","A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",[91],"2018-01-23","2014-10-06",[15187],[21326],{"nctId":21353,"briefTitle":21354,"status":130,"phases":21355,"primaryCompletion":21356,"completion":21356,"start":21357,"enrollment":21358,"conditions":21359,"interventions":21360},"NCT02247479","A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",[91],"2018-01-29","2014-09-18",906,[15187],[21326],{"trials":21362,"activeCount":101},[],{"trials":21364,"activeCount":101},[],{"intervention":16050,"totalTrials":706,"cells":21366},{"EARLY_PHASE1":21367,"PHASE1":21369,"PHASE2":21371,"PHASE3":21373,"PHASE4":21393,"NA":21395},{"trials":21368,"activeCount":101},[],{"trials":21370,"activeCount":101},[],{"trials":21372,"activeCount":101},[],{"trials":21374,"activeCount":101},[21375,21381,21385],{"nctId":21376,"briefTitle":21377,"status":107,"phases":21378,"primaryCompletion":3030,"completion":3030,"start":8605,"enrollment":5293,"conditions":21379,"interventions":21380},"NCT00077623","A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.",[91],[24],[16050,16958,16958],{"nctId":16044,"briefTitle":16045,"status":107,"phases":21382,"primaryCompletion":4455,"completion":4455,"start":11713,"enrollment":16047,"conditions":21383,"interventions":21384},[91],[24],[16050,15973],{"nctId":21386,"briefTitle":21387,"status":107,"phases":21388,"primaryCompletion":2923,"completion":2923,"start":9499,"enrollment":15617,"conditions":21389,"interventions":21390},"NCT00077610","A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients",[91],[24],[21391,21392,21392],"Epoetin alfa or beta","RO0503821",{"trials":21394,"activeCount":101},[],{"trials":21396,"activeCount":101},[],{"intervention":9036,"totalTrials":706,"cells":21398},{"EARLY_PHASE1":21399,"PHASE1":21401,"PHASE2":21403,"PHASE3":21416,"PHASE4":21422,"NA":21424},{"trials":21400,"activeCount":101},[],{"trials":21402,"activeCount":101},[],{"trials":21404,"activeCount":101},[21405,21412],{"nctId":21406,"briefTitle":21407,"status":107,"phases":21408,"primaryCompletion":2685,"completion":2685,"start":4315,"enrollment":984,"conditions":21409,"interventions":21410},"NCT00448136","A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.",[90],[1241],[5275,9036,21411,9083],"Streptozotocin",{"nctId":14720,"briefTitle":14721,"status":343,"phases":21413,"primaryCompletion":3213,"completion":3213,"start":4513,"enrollment":101,"conditions":21414,"interventions":21415},[90],[30],[5275,4577,1164,9036,1138],{"trials":21417,"activeCount":101},[21418],{"nctId":9030,"briefTitle":9031,"status":107,"phases":21419,"primaryCompletion":5457,"completion":5457,"start":6316,"enrollment":9033,"conditions":21420,"interventions":21421},[91],[30],[9036,1164,1165,1165,5381],{"trials":21423,"activeCount":101},[],{"trials":21425,"activeCount":101},[],{"intervention":2093,"totalTrials":706,"cells":21427},{"EARLY_PHASE1":21428,"PHASE1":21430,"PHASE2":21432,"PHASE3":21434,"PHASE4":21448,"NA":21450},{"trials":21429,"activeCount":101},[],{"trials":21431,"activeCount":101},[],{"trials":21433,"activeCount":101},[],{"trials":21435,"activeCount":101},[21436,21440,21444],{"nctId":8032,"briefTitle":8033,"status":107,"phases":21437,"primaryCompletion":8035,"completion":8036,"start":8037,"enrollment":8038,"conditions":21438,"interventions":21439},[91],[986],[8041,2093,1106],{"nctId":2084,"briefTitle":2085,"status":107,"phases":21441,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":2090,"conditions":21442,"interventions":21443},[91],[1285],[68,2093,1084,1479,2094],{"nctId":2203,"briefTitle":2204,"status":107,"phases":21445,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":21446,"interventions":21447},[91],[1417,2211,2212],[1106,990,68,1015,2093],{"trials":21449,"activeCount":101},[],{"trials":21451,"activeCount":101},[],{"intervention":21453,"totalTrials":706,"cells":21454},"RO7239361",{"EARLY_PHASE1":21455,"PHASE1":21457,"PHASE2":21468,"PHASE3":21480,"PHASE4":21490,"NA":21492},{"trials":21456,"activeCount":101},[],{"trials":21458,"activeCount":101},[21459],{"nctId":21460,"briefTitle":21461,"status":107,"phases":21462,"primaryCompletion":21463,"completion":21463,"start":21464,"enrollment":559,"conditions":21465,"interventions":21467},"NCT03100630","Compare Bioavailability of RO7239361 After Subcutaneous Injection",[89],"2017-10-17","2017-05-09",[21466],"Healthy",[21453],{"trials":21469,"activeCount":101},[21470],{"nctId":21471,"briefTitle":21472,"status":130,"phases":21473,"primaryCompletion":21474,"completion":21475,"start":21476,"enrollment":1385,"conditions":21477,"interventions":21479},"NCT02515669","Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD",[89,90],"2018-02-08","2020-04-15","2015-12-02",[21478],"Muscular Dystrophy (DMD)",[21453],{"trials":21481,"activeCount":101},[21482],{"nctId":21483,"briefTitle":21484,"status":107,"phases":21485,"primaryCompletion":21486,"completion":21486,"start":21487,"enrollment":3804,"conditions":21488,"interventions":21489},"NCT03039686","Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy",[90,91],"2020-04-28","2017-07-06",[7337],[21453],{"trials":21491,"activeCount":101},[],{"trials":21493,"activeCount":101},[],{"intervention":6713,"totalTrials":706,"cells":21495},{"EARLY_PHASE1":21496,"PHASE1":21498,"PHASE2":21500,"PHASE3":21506,"PHASE4":21516,"NA":21518},{"trials":21497,"activeCount":101},[],{"trials":21499,"activeCount":101},[],{"trials":21501,"activeCount":101},[21502],{"nctId":10078,"briefTitle":10079,"status":130,"phases":21503,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":21504,"interventions":21505},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"trials":21507,"activeCount":101},[21508,21512],{"nctId":6706,"briefTitle":6707,"status":107,"phases":21509,"primaryCompletion":6709,"completion":6710,"start":6453,"enrollment":8,"conditions":21510,"interventions":21511},[91],[1417],[1163,1106,1221,6713],{"nctId":4494,"briefTitle":4495,"status":107,"phases":21513,"primaryCompletion":4497,"completion":4497,"start":4498,"enrollment":4499,"conditions":21514,"interventions":21515},[91],[1417],[1015,4502,4503,4504],{"trials":21517,"activeCount":101},[],{"trials":21519,"activeCount":101},[],{"intervention":21521,"totalTrials":706,"cells":21522},"bitopertin [RO4917838]",{"EARLY_PHASE1":21523,"PHASE1":21525,"PHASE2":21527,"PHASE3":21536,"PHASE4":21552,"NA":21554},{"trials":21524,"activeCount":101},[],{"trials":21526,"activeCount":101},[],{"trials":21528,"activeCount":101},[21529],{"nctId":21530,"briefTitle":21531,"status":107,"phases":21532,"primaryCompletion":3146,"completion":3146,"start":4233,"enrollment":13839,"conditions":21533,"interventions":21534},"NCT01234779","A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia",[90],[19752],[21521,21521,21535],"olanzapine",{"trials":21537,"activeCount":101},[21538,21545],{"nctId":21539,"briefTitle":21540,"status":107,"phases":21541,"primaryCompletion":5364,"completion":5364,"start":4474,"enrollment":21542,"conditions":21543,"interventions":21544},"NCT01192906","A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)",[91],624,[19752],[21521,21521],{"nctId":21546,"briefTitle":21547,"status":107,"phases":21548,"primaryCompletion":3182,"completion":3182,"start":4474,"enrollment":21549,"conditions":21550,"interventions":21551},"NCT01235585","A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)",[91],597,[19752],[21521,21521],{"trials":21553,"activeCount":101},[],{"trials":21555,"activeCount":101},[],{"intervention":21557,"totalTrials":162,"cells":21558},"methoxy polyethylene glycol-epoetin beta [C.E.R.A.]",{"EARLY_PHASE1":21559,"PHASE1":21561,"PHASE2":21563,"PHASE3":21565,"PHASE4":21581,"NA":21583},{"trials":21560,"activeCount":101},[],{"trials":21562,"activeCount":101},[],{"trials":21564,"activeCount":101},[],{"trials":21566,"activeCount":101},[21567,21573],{"nctId":21568,"briefTitle":21569,"status":107,"phases":21570,"primaryCompletion":4555,"completion":4555,"start":4281,"enrollment":2857,"conditions":21571,"interventions":21572},"NCT00576628","A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.",[91],[24],[21557],{"nctId":21574,"briefTitle":21575,"status":107,"phases":21576,"primaryCompletion":21577,"completion":21577,"start":21578,"enrollment":2375,"conditions":21579,"interventions":21580},"NCT00642304","A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.",[91],"2009-12-09","2008-03-27",[24],[21557],{"trials":21582,"activeCount":101},[],{"trials":21584,"activeCount":101},[],{"intervention":21586,"totalTrials":162,"cells":21587},"Pegylated Interferon (PEG-IFN) alfa-2a",{"EARLY_PHASE1":21588,"PHASE1":21590,"PHASE2":21592,"PHASE3":21600,"PHASE4":21608,"NA":21610},{"trials":21589,"activeCount":101},[],{"trials":21591,"activeCount":101},[],{"trials":21593,"activeCount":101},[21594],{"nctId":21595,"briefTitle":21596,"status":107,"phases":21597,"primaryCompletion":8826,"completion":8826,"start":8484,"enrollment":4683,"conditions":21598,"interventions":21599},"NCT02716779","Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection",[90],[27],[21586,17366],{"trials":21601,"activeCount":101},[21602],{"nctId":21603,"briefTitle":21604,"status":107,"phases":21605,"primaryCompletion":4562,"completion":4562,"start":133,"enrollment":5013,"conditions":21606,"interventions":21607},"NCT02732639","A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)",[91],[21319],[21586],{"trials":21609,"activeCount":101},[],{"trials":21611,"activeCount":101},[],{"intervention":20984,"totalTrials":162,"cells":21613},{"EARLY_PHASE1":21614,"PHASE1":21616,"PHASE2":21618,"PHASE3":21620,"PHASE4":21630,"NA":21632},{"trials":21615,"activeCount":101},[],{"trials":21617,"activeCount":101},[],{"trials":21619,"activeCount":101},[],{"trials":21621,"activeCount":101},[21622,21626],{"nctId":20979,"briefTitle":20980,"status":130,"phases":21623,"primaryCompletion":4513,"completion":4513,"start":2923,"enrollment":1036,"conditions":21624,"interventions":21625},[91],[20966,20967,20968],[20953,20984],{"nctId":20986,"briefTitle":20987,"status":130,"phases":21627,"primaryCompletion":4513,"completion":4513,"start":4323,"enrollment":6037,"conditions":21628,"interventions":21629},[91],[20966,20967,20968],[20953,20984],{"trials":21631,"activeCount":101},[],{"trials":21633,"activeCount":101},[],{"intervention":16510,"totalTrials":162,"cells":21635},{"EARLY_PHASE1":21636,"PHASE1":21638,"PHASE2":21640,"PHASE3":21642,"PHASE4":21652,"NA":21654},{"trials":21637,"activeCount":101},[],{"trials":21639,"activeCount":101},[],{"trials":21641,"activeCount":101},[],{"trials":21643,"activeCount":101},[21644,21648],{"nctId":16504,"briefTitle":16505,"status":107,"phases":21645,"enrollment":16507,"conditions":21646,"interventions":21647},[91],[33],[11782,16468,16450,16510],{"nctId":16547,"briefTitle":16548,"status":107,"phases":21649,"enrollment":16550,"conditions":21650,"interventions":21651},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"trials":21653,"activeCount":101},[],{"trials":21655,"activeCount":101},[],{"intervention":8649,"totalTrials":162,"cells":21657},{"EARLY_PHASE1":21658,"PHASE1":21660,"PHASE2":21662,"PHASE3":21668,"PHASE4":21674,"NA":21676},{"trials":21659,"activeCount":101},[],{"trials":21661,"activeCount":101},[],{"trials":21663,"activeCount":101},[21664],{"nctId":8644,"briefTitle":8645,"status":130,"phases":21665,"primaryCompletion":4233,"completion":4233,"start":5271,"enrollment":425,"conditions":21666,"interventions":21667},[90],[18],[1166,8649],{"trials":21669,"activeCount":101},[21670],{"nctId":20061,"briefTitle":20062,"status":107,"phases":21671,"primaryCompletion":20064,"completion":20064,"start":3736,"enrollment":20065,"conditions":21672,"interventions":21673},[91],[17203],[19991,8649],{"trials":21675,"activeCount":101},[],{"trials":21677,"activeCount":101},[],{"intervention":17291,"totalTrials":162,"cells":21679},{"EARLY_PHASE1":21680,"PHASE1":21682,"PHASE2":21684,"PHASE3":21690,"PHASE4":21696,"NA":21698},{"trials":21681,"activeCount":101},[],{"trials":21683,"activeCount":101},[],{"trials":21685,"activeCount":101},[21686],{"nctId":17199,"briefTitle":17200,"status":107,"phases":21687,"primaryCompletion":11437,"completion":11437,"start":2515,"enrollment":3574,"conditions":21688,"interventions":21689},[90],[17203],[17205,14484,17206],{"trials":21691,"activeCount":101},[21692],{"nctId":17284,"briefTitle":17285,"status":107,"phases":21693,"primaryCompletion":5891,"completion":5891,"start":7054,"enrollment":2640,"conditions":21694,"interventions":21695},[91],[17288],[11717,5913,17290,17291,11738],{"trials":21697,"activeCount":101},[],{"trials":21699,"activeCount":101},[],{"intervention":8284,"totalTrials":162,"cells":21701},{"EARLY_PHASE1":21702,"PHASE1":21704,"PHASE2":21706,"PHASE3":21712,"PHASE4":21718,"NA":21720},{"trials":21703,"activeCount":101},[],{"trials":21705,"activeCount":101},[],{"trials":21707,"activeCount":101},[21708],{"nctId":8279,"briefTitle":8280,"status":107,"phases":21709,"primaryCompletion":3213,"completion":3213,"start":133,"enrollment":4886,"conditions":21710,"interventions":21711},[90],[18],[1222,8284],{"trials":21713,"activeCount":101},[21714],{"nctId":10416,"briefTitle":10417,"status":130,"phases":21715,"primaryCompletion":4699,"completion":2139,"start":10419,"enrollment":10420,"conditions":21716,"interventions":21717},[90,91],[1735],[8284,8133,8133],{"trials":21719,"activeCount":101},[],{"trials":21721,"activeCount":101},[],{"intervention":13205,"totalTrials":162,"cells":21723},{"EARLY_PHASE1":21724,"PHASE1":21726,"PHASE2":21728,"PHASE3":21730,"PHASE4":21740,"NA":21742},{"trials":21725,"activeCount":101},[],{"trials":21727,"activeCount":101},[],{"trials":21729,"activeCount":101},[],{"trials":21731,"activeCount":101},[21732,21736],{"nctId":13199,"briefTitle":13200,"status":107,"phases":21733,"primaryCompletion":4474,"completion":4474,"start":8688,"enrollment":13202,"conditions":21734,"interventions":21735},[91],[36],[13205,13131,13206,13206],{"nctId":13221,"briefTitle":13222,"status":130,"phases":21737,"primaryCompletion":4474,"completion":4474,"start":4206,"enrollment":10152,"conditions":21738,"interventions":21739},[91],[36],[13205,13131,13206,13206],{"trials":21741,"activeCount":101},[],{"trials":21743,"activeCount":101},[],{"intervention":10155,"totalTrials":162,"cells":21745},{"EARLY_PHASE1":21746,"PHASE1":21748,"PHASE2":21750,"PHASE3":21756,"PHASE4":21762,"NA":21764},{"trials":21747,"activeCount":101},[],{"trials":21749,"activeCount":101},[],{"trials":21751,"activeCount":101},[21752],{"nctId":14451,"briefTitle":14452,"status":107,"phases":21753,"primaryCompletion":4113,"completion":4113,"start":14454,"enrollment":909,"conditions":21754,"interventions":21755},[90],[5846],[5848,14457,11717,14458],{"trials":21757,"activeCount":101},[21758],{"nctId":10149,"briefTitle":10150,"status":107,"phases":21759,"primaryCompletion":7096,"completion":4555,"start":4323,"enrollment":10152,"conditions":21760,"interventions":21761},[91],[3597],[5914,992,2820,10155],{"trials":21763,"activeCount":101},[],{"trials":21765,"activeCount":101},[],{"intervention":10046,"totalTrials":162,"cells":21767},{"EARLY_PHASE1":21768,"PHASE1":21770,"PHASE2":21776,"PHASE3":21778,"PHASE4":21786,"NA":21788},{"trials":21769,"activeCount":101},[],{"trials":21771,"activeCount":101},[21772],{"nctId":10038,"briefTitle":10039,"status":107,"phases":21773,"primaryCompletion":10041,"completion":10042,"start":10043,"enrollment":8028,"conditions":21774,"interventions":21775},[89],[3741],[992,3482,10046,10046,10046],{"trials":21777,"activeCount":101},[],{"trials":21779,"activeCount":101},[21780],{"nctId":21781,"briefTitle":21782,"status":107,"phases":21783,"primaryCompletion":5181,"completion":5181,"start":8658,"enrollment":17952,"conditions":21784,"interventions":21785},"NCT02079532","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor",[91],[15],[10046],{"trials":21787,"activeCount":101},[],{"trials":21789,"activeCount":101},[],{"intervention":7575,"totalTrials":162,"cells":21791},{"EARLY_PHASE1":21792,"PHASE1":21794,"PHASE2":21796,"PHASE3":21798,"PHASE4":21808,"NA":21810},{"trials":21793,"activeCount":101},[],{"trials":21795,"activeCount":101},[],{"trials":21797,"activeCount":101},[],{"trials":21799,"activeCount":101},[21800,21804],{"nctId":7565,"briefTitle":7566,"status":107,"phases":21801,"primaryCompletion":7568,"completion":7569,"start":7570,"enrollment":7571,"conditions":21802,"interventions":21803},[91],[7573],[946,3371,7575],{"nctId":10216,"briefTitle":10217,"status":107,"phases":21805,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":21806,"interventions":21807},[91],[125],[9132,9131,992,991,1358,7575],{"trials":21809,"activeCount":101},[],{"trials":21811,"activeCount":101},[],{"intervention":21813,"totalTrials":162,"cells":21814},"Pegylated-interferon alfa-2a",{"EARLY_PHASE1":21815,"PHASE1":21817,"PHASE2":21819,"PHASE3":21821,"PHASE4":21836,"NA":21838},{"trials":21816,"activeCount":101},[],{"trials":21818,"activeCount":101},[],{"trials":21820,"activeCount":101},[],{"trials":21822,"activeCount":101},[21823,21829],{"nctId":21824,"briefTitle":21825,"status":107,"phases":21826,"primaryCompletion":3175,"completion":3175,"start":4322,"enrollment":1184,"conditions":21827,"interventions":21828},"NCT00800735","A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols",[91],[27],[21813,17366],{"nctId":21830,"briefTitle":21831,"status":107,"phases":21832,"primaryCompletion":3104,"completion":3104,"start":6377,"enrollment":20945,"conditions":21833,"interventions":21834},"NCT00483938","The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2\u002F3 (IMPROVE)",[91],[27],[21835,17366],"Pegylated-interferon Alfa-2a",{"trials":21837,"activeCount":101},[],{"trials":21839,"activeCount":101},[],{"intervention":8166,"totalTrials":162,"cells":21841},{"EARLY_PHASE1":21842,"PHASE1":21844,"PHASE2":21846,"PHASE3":21848,"PHASE4":21858,"NA":21860},{"trials":21843,"activeCount":101},[],{"trials":21845,"activeCount":101},[],{"trials":21847,"activeCount":101},[],{"trials":21849,"activeCount":101},[21850,21854],{"nctId":9633,"briefTitle":9634,"status":107,"phases":21851,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":21852,"interventions":21853},[91],[9637],[8162,8164,9639,991,992,947,8166],{"nctId":8154,"briefTitle":8155,"status":107,"phases":21855,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":21856,"interventions":21857},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"trials":21859,"activeCount":101},[],{"trials":21861,"activeCount":101},[],{"intervention":16057,"totalTrials":162,"cells":21863},{"EARLY_PHASE1":21864,"PHASE1":21866,"PHASE2":21868,"PHASE3":21870,"PHASE4":21884,"NA":21886},{"trials":21865,"activeCount":101},[],{"trials":21867,"activeCount":101},[],{"trials":21869,"activeCount":101},[],{"trials":21871,"activeCount":101},[21872,21876],{"nctId":16052,"briefTitle":16053,"status":107,"phases":21873,"primaryCompletion":8751,"completion":8751,"start":9499,"enrollment":3015,"conditions":21874,"interventions":21875},[91],[24],[16057,15973],{"nctId":21877,"briefTitle":21878,"status":107,"phases":21879,"primaryCompletion":2769,"completion":2769,"start":5820,"enrollment":920,"conditions":21880,"interventions":21881},"NCT00546481","A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.",[91],[24],[21882,21883],"methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]","Epoetin",{"trials":21885,"activeCount":101},[],{"trials":21887,"activeCount":101},[],{"intervention":8772,"totalTrials":162,"cells":21889},{"EARLY_PHASE1":21890,"PHASE1":21892,"PHASE2":21894,"PHASE3":21896,"PHASE4":21906,"NA":21908},{"trials":21891,"activeCount":101},[],{"trials":21893,"activeCount":101},[],{"trials":21895,"activeCount":101},[],{"trials":21897,"activeCount":101},[21898,21902],{"nctId":8764,"briefTitle":8765,"status":107,"phases":21899,"primaryCompletion":8767,"completion":8768,"start":8769,"enrollment":4637,"conditions":21900,"interventions":21901},[91],[18],[1419,8772,1166],{"nctId":8778,"briefTitle":8779,"status":107,"phases":21903,"primaryCompletion":3007,"completion":2808,"start":3479,"enrollment":8781,"conditions":21904,"interventions":21905},[91],[18],[1223,8772,1166],{"trials":21907,"activeCount":101},[],{"trials":21909,"activeCount":101},[],{"intervention":4292,"totalTrials":162,"cells":21911},{"EARLY_PHASE1":21912,"PHASE1":21914,"PHASE2":21916,"PHASE3":21922,"PHASE4":21928,"NA":21930},{"trials":21913,"activeCount":101},[],{"trials":21915,"activeCount":101},[],{"trials":21917,"activeCount":101},[21918],{"nctId":4286,"briefTitle":4287,"status":107,"phases":21919,"primaryCompletion":2973,"completion":2973,"start":4289,"enrollment":931,"conditions":21920,"interventions":21921},[90],[1261],[1015,4292],{"trials":21923,"activeCount":101},[21924],{"nctId":11569,"briefTitle":11570,"status":107,"phases":21925,"primaryCompletion":4474,"completion":2792,"start":4206,"enrollment":11572,"conditions":21926,"interventions":21927},[91],[1261],[1479,4292],{"trials":21929,"activeCount":101},[],{"trials":21931,"activeCount":101},[],{"intervention":1497,"totalTrials":162,"cells":21933},{"EARLY_PHASE1":21934,"PHASE1":21936,"PHASE2":21938,"PHASE3":21944,"PHASE4":21950,"NA":21952},{"trials":21935,"activeCount":101},[],{"trials":21937,"activeCount":101},[],{"trials":21939,"activeCount":101},[21940],{"nctId":1490,"briefTitle":1491,"status":130,"phases":21941,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":21942,"interventions":21943},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"trials":21945,"activeCount":101},[21946],{"nctId":10574,"briefTitle":10575,"status":107,"phases":21947,"primaryCompletion":3896,"completion":10577,"start":2865,"enrollment":10578,"conditions":21948,"interventions":21949},[91],[30],[10581,1084,1497],{"trials":21951,"activeCount":101},[],{"trials":21953,"activeCount":101},[],{"intervention":9131,"totalTrials":162,"cells":21955},{"EARLY_PHASE1":21956,"PHASE1":21958,"PHASE2":21960,"PHASE3":21966,"PHASE4":21972,"NA":21974},{"trials":21957,"activeCount":101},[],{"trials":21959,"activeCount":101},[],{"trials":21961,"activeCount":101},[21962],{"nctId":9123,"briefTitle":9124,"status":107,"phases":21963,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":21964,"interventions":21965},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"trials":21967,"activeCount":101},[21968],{"nctId":10216,"briefTitle":10217,"status":107,"phases":21969,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":21970,"interventions":21971},[91],[125],[9132,9131,992,991,1358,7575],{"trials":21973,"activeCount":101},[],{"trials":21975,"activeCount":101},[],{"intervention":9132,"totalTrials":162,"cells":21977},{"EARLY_PHASE1":21978,"PHASE1":21980,"PHASE2":21982,"PHASE3":21988,"PHASE4":21994,"NA":21996},{"trials":21979,"activeCount":101},[],{"trials":21981,"activeCount":101},[],{"trials":21983,"activeCount":101},[21984],{"nctId":9123,"briefTitle":9124,"status":107,"phases":21985,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":21986,"interventions":21987},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"trials":21989,"activeCount":101},[21990],{"nctId":10216,"briefTitle":10217,"status":107,"phases":21991,"primaryCompletion":10219,"completion":7067,"start":10220,"enrollment":10221,"conditions":21992,"interventions":21993},[91],[125],[9132,9131,992,991,1358,7575],{"trials":21995,"activeCount":101},[],{"trials":21997,"activeCount":101},[],{"intervention":3035,"totalTrials":162,"cells":21999},{"EARLY_PHASE1":22000,"PHASE1":22002,"PHASE2":22004,"PHASE3":22006,"PHASE4":22016,"NA":22018},{"trials":22001,"activeCount":101},[],{"trials":22003,"activeCount":101},[],{"trials":22005,"activeCount":101},[],{"trials":22007,"activeCount":101},[22008,22012],{"nctId":15587,"briefTitle":15588,"status":107,"phases":22009,"primaryCompletion":6004,"completion":3246,"start":4281,"enrollment":15590,"conditions":22010,"interventions":22011},[91],[2367],[5894,3035,5838,14484],{"nctId":3026,"briefTitle":3027,"status":107,"phases":22013,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":3031,"conditions":22014,"interventions":22015},[91],[15],[1096,3034,3035,3036],{"trials":22017,"activeCount":101},[],{"trials":22019,"activeCount":101},[],{"intervention":6264,"totalTrials":162,"cells":22021},{"EARLY_PHASE1":22022,"PHASE1":22024,"PHASE2":22026,"PHASE3":22028,"PHASE4":22038,"NA":22040},{"trials":22023,"activeCount":101},[],{"trials":22025,"activeCount":101},[],{"trials":22027,"activeCount":101},[],{"trials":22029,"activeCount":101},[22030,22034],{"nctId":6256,"briefTitle":6257,"status":107,"phases":22031,"primaryCompletion":6259,"completion":2973,"start":6260,"enrollment":6261,"conditions":22032,"interventions":22033},[91],[2431],[1359,6264,992],{"nctId":6312,"briefTitle":6313,"status":107,"phases":22035,"primaryCompletion":4315,"completion":6315,"start":6316,"enrollment":6317,"conditions":22036,"interventions":22037},[91],[6319],[1359,992,6264],{"trials":22039,"activeCount":101},[],{"trials":22041,"activeCount":101},[],{"intervention":22043,"totalTrials":162,"cells":22044},"TRO19622",{"EARLY_PHASE1":22045,"PHASE1":22047,"PHASE2":22049,"PHASE3":22060,"PHASE4":22068,"NA":22070},{"trials":22046,"activeCount":101},[],{"trials":22048,"activeCount":101},[],{"trials":22050,"activeCount":101},[22051],{"nctId":22052,"briefTitle":22053,"status":107,"phases":22054,"primaryCompletion":22055,"completion":22055,"start":22056,"enrollment":2289,"conditions":22057,"interventions":22059},"NCT00666016","Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)",[90],"2009-02-05","2008-04-15",[22058],"Non-Alcoholic Steatohepatitis (NASH)",[22043],{"trials":22061,"activeCount":101},[22062],{"nctId":22063,"briefTitle":22064,"status":107,"phases":22065,"primaryCompletion":3175,"completion":3175,"start":2906,"enrollment":3814,"conditions":22066,"interventions":22067},"NCT01285583","Safety Extension Study of TRO19622 in ALS",[90,91],[20640],[22043],{"trials":22069,"activeCount":101},[],{"trials":22071,"activeCount":101},[],{"intervention":234,"totalTrials":162,"cells":22073},{"EARLY_PHASE1":22074,"PHASE1":22076,"PHASE2":22078,"PHASE3":22080,"PHASE4":22090,"NA":22092},{"trials":22075,"activeCount":101},[],{"trials":22077,"activeCount":101},[],{"trials":22079,"activeCount":101},[],{"trials":22081,"activeCount":101},[22082,22086],{"nctId":225,"briefTitle":226,"status":107,"phases":22083,"primaryCompletion":228,"completion":170,"start":229,"enrollment":230,"conditions":22084,"interventions":22085},[91],[232],[234,96],{"nctId":236,"briefTitle":226,"status":107,"phases":22087,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":22088,"interventions":22089},[91],[232],[234,96],{"trials":22091,"activeCount":101},[],{"trials":22093,"activeCount":101},[],{"intervention":5386,"totalTrials":162,"cells":22095},{"EARLY_PHASE1":22096,"PHASE1":22098,"PHASE2":22104,"PHASE3":22106,"PHASE4":22112,"NA":22114},{"trials":22097,"activeCount":101},[],{"trials":22099,"activeCount":101},[22100],{"nctId":5373,"briefTitle":5374,"status":130,"phases":22101,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":22102,"interventions":22103},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":22105,"activeCount":101},[],{"trials":22107,"activeCount":101},[22108],{"nctId":14732,"briefTitle":14733,"status":343,"phases":22109,"primaryCompletion":2947,"completion":2947,"start":8320,"enrollment":101,"conditions":22110,"interventions":22111},[91],[30],[5275,5382,5386],{"trials":22113,"activeCount":101},[],{"trials":22115,"activeCount":101},[],{"intervention":5297,"totalTrials":162,"cells":22117},{"EARLY_PHASE1":22118,"PHASE1":22120,"PHASE2":22122,"PHASE3":22124,"PHASE4":22134,"NA":22136},{"trials":22119,"activeCount":101},[],{"trials":22121,"activeCount":101},[],{"trials":22123,"activeCount":101},[],{"trials":22125,"activeCount":101},[22126,22130],{"nctId":8135,"briefTitle":8136,"status":107,"phases":22127,"primaryCompletion":8138,"completion":8139,"start":8140,"enrollment":8141,"conditions":22128,"interventions":22129},[91],[1539],[5297,947,1106,8144],{"nctId":5288,"briefTitle":5289,"status":107,"phases":22131,"primaryCompletion":1925,"completion":5291,"start":5292,"enrollment":5293,"conditions":22132,"interventions":22133},[91],[5295],[5297,990,1167,1163,1319],{"trials":22135,"activeCount":101},[],{"trials":22137,"activeCount":101},[],{"intervention":114,"totalTrials":162,"cells":22139},{"EARLY_PHASE1":22140,"PHASE1":22142,"PHASE2":22148,"PHASE3":22150,"PHASE4":22156,"NA":22158},{"trials":22141,"activeCount":101},[],{"trials":22143,"activeCount":101},[22144],{"nctId":105,"briefTitle":106,"status":107,"phases":22145,"primaryCompletion":109,"completion":109,"start":110,"enrollment":19,"conditions":22146,"interventions":22147},[89],[112],[96,96,114],{"trials":22149,"activeCount":101},[],{"trials":22151,"activeCount":101},[22152],{"nctId":2215,"briefTitle":2216,"status":107,"phases":22153,"primaryCompletion":2218,"completion":2219,"start":2220,"enrollment":2221,"conditions":22154,"interventions":22155},[91],[975],[68,114],{"trials":22157,"activeCount":101},[],{"trials":22159,"activeCount":101},[],{"intervention":4539,"totalTrials":162,"cells":22161},{"EARLY_PHASE1":22162,"PHASE1":22164,"PHASE2":22166,"PHASE3":22168,"PHASE4":22182,"NA":22184},{"trials":22163,"activeCount":101},[],{"trials":22165,"activeCount":101},[],{"trials":22167,"activeCount":101},[],{"trials":22169,"activeCount":101},[22170,22174],{"nctId":4533,"briefTitle":4534,"status":130,"phases":22171,"primaryCompletion":2914,"completion":2914,"start":4536,"enrollment":3739,"conditions":22172,"interventions":22173},[91],[2543],[1015,1359,4539],{"nctId":22175,"briefTitle":22176,"status":107,"phases":22177,"primaryCompletion":22178,"completion":8127,"start":22179,"enrollment":5293,"conditions":22180,"interventions":22181},"NCT01649856","A Study of Subcutaneous Versus Intravenous MabThera\u002FRituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma",[91],"2014-10-21","2012-08-24",[3644],[4539,5837,5837],{"trials":22183,"activeCount":101},[],{"trials":22185,"activeCount":101},[],{"intervention":8008,"totalTrials":350,"cells":22187},{"EARLY_PHASE1":22188,"PHASE1":22190,"PHASE2":22192,"PHASE3":22194,"PHASE4":22200,"NA":22202},{"trials":22189,"activeCount":101},[],{"trials":22191,"activeCount":101},[],{"trials":22193,"activeCount":101},[],{"trials":22195,"activeCount":101},[22196],{"nctId":8001,"briefTitle":8002,"status":107,"phases":22197,"primaryCompletion":3007,"completion":3007,"start":8004,"enrollment":8005,"conditions":22198,"interventions":22199},[91],[18],[1222,991,1106,8008],{"trials":22201,"activeCount":101},[],{"trials":22203,"activeCount":101},[],{"intervention":19963,"totalTrials":350,"cells":22205},{"EARLY_PHASE1":22206,"PHASE1":22208,"PHASE2":22210,"PHASE3":22212,"PHASE4":22218,"NA":22220},{"trials":22207,"activeCount":101},[],{"trials":22209,"activeCount":101},[],{"trials":22211,"activeCount":101},[],{"trials":22213,"activeCount":101},[22214],{"nctId":19957,"briefTitle":19958,"status":107,"phases":22215,"primaryCompletion":3146,"completion":3146,"start":4582,"enrollment":19960,"conditions":22216,"interventions":22217},[91],[19923],[19944,19963],{"trials":22219,"activeCount":101},[],{"trials":22221,"activeCount":101},[],{"intervention":22223,"totalTrials":350,"cells":22224},"aleglitazar+metformin",{"EARLY_PHASE1":22225,"PHASE1":22227,"PHASE2":22229,"PHASE3":22231,"PHASE4":22239,"NA":22241},{"trials":22226,"activeCount":101},[],{"trials":22228,"activeCount":101},[],{"trials":22230,"activeCount":101},[],{"trials":22232,"activeCount":101},[22233],{"nctId":22234,"briefTitle":22235,"status":107,"phases":22236,"primaryCompletion":2684,"completion":2684,"start":2809,"enrollment":2708,"conditions":22237,"interventions":22238},"NCT01691846","A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone",[91],[36],[22223],{"trials":22240,"activeCount":101},[],{"trials":22242,"activeCount":101},[],{"intervention":1823,"totalTrials":350,"cells":22244},{"EARLY_PHASE1":22245,"PHASE1":22247,"PHASE2":22249,"PHASE3":22251,"PHASE4":22257,"NA":22259},{"trials":22246,"activeCount":101},[],{"trials":22248,"activeCount":101},[],{"trials":22250,"activeCount":101},[],{"trials":22252,"activeCount":101},[22253],{"nctId":1815,"briefTitle":1816,"status":130,"phases":22254,"primaryCompletion":1818,"completion":1818,"start":1819,"enrollment":1820,"conditions":22255,"interventions":22256},[91],[1061],[68,1106,1823,992],{"trials":22258,"activeCount":101},[],{"trials":22260,"activeCount":101},[],{"intervention":2772,"totalTrials":350,"cells":22262},{"EARLY_PHASE1":22263,"PHASE1":22265,"PHASE2":22267,"PHASE3":22269,"PHASE4":22275,"NA":22277},{"trials":22264,"activeCount":101},[],{"trials":22266,"activeCount":101},[],{"trials":22268,"activeCount":101},[],{"trials":22270,"activeCount":101},[22271],{"nctId":2765,"briefTitle":2766,"status":107,"phases":22272,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":1204,"conditions":22273,"interventions":22274},[91],[15],[1096,2772],{"trials":22276,"activeCount":101},[],{"trials":22278,"activeCount":101},[],{"intervention":22280,"totalTrials":350,"cells":22281},"Recombinant Interferon Alfa 2a",{"EARLY_PHASE1":22282,"PHASE1":22284,"PHASE2":22286,"PHASE3":22288,"PHASE4":22298,"NA":22300},{"trials":22283,"activeCount":101},[],{"trials":22285,"activeCount":101},[],{"trials":22287,"activeCount":101},[],{"trials":22289,"activeCount":101},[22290],{"nctId":22291,"briefTitle":22292,"status":107,"phases":22293,"primaryCompletion":121,"completion":121,"start":8260,"enrollment":1796,"conditions":22294,"interventions":22296},"NCT02829775","A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies",[90,91],[22295,1261,1049],"Chronic Myelogenous Leukemia",[22297,22280],"Pegylated Interferon Alfa-2a",{"trials":22299,"activeCount":101},[],{"trials":22301,"activeCount":101},[],{"intervention":6942,"totalTrials":350,"cells":22303},{"EARLY_PHASE1":22304,"PHASE1":22306,"PHASE2":22308,"PHASE3":22310,"PHASE4":22316,"NA":22318},{"trials":22305,"activeCount":101},[],{"trials":22307,"activeCount":101},[],{"trials":22309,"activeCount":101},[],{"trials":22311,"activeCount":101},[22312],{"nctId":6934,"briefTitle":6935,"status":130,"phases":22313,"primaryCompletion":6937,"completion":6937,"start":6938,"enrollment":6939,"conditions":22314,"interventions":22315},[91],[18],[6942,1573],{"trials":22317,"activeCount":101},[],{"trials":22319,"activeCount":101},[],{"intervention":11903,"totalTrials":350,"cells":22321},{"EARLY_PHASE1":22322,"PHASE1":22324,"PHASE2":22326,"PHASE3":22328,"PHASE4":22334,"NA":22336},{"trials":22323,"activeCount":101},[],{"trials":22325,"activeCount":101},[],{"trials":22327,"activeCount":101},[],{"trials":22329,"activeCount":101},[22330],{"nctId":11894,"briefTitle":11895,"status":343,"phases":22331,"primaryCompletion":11897,"completion":11898,"start":11899,"enrollment":101,"conditions":22332,"interventions":22333},[91],[11901],[1697,2121,11903],{"trials":22335,"activeCount":101},[],{"trials":22337,"activeCount":101},[],{"intervention":13196,"totalTrials":350,"cells":22339},{"EARLY_PHASE1":22340,"PHASE1":22342,"PHASE2":22344,"PHASE3":22346,"PHASE4":22352,"NA":22354},{"trials":22341,"activeCount":101},[],{"trials":22343,"activeCount":101},[],{"trials":22345,"activeCount":101},[],{"trials":22347,"activeCount":101},[22348],{"nctId":13190,"briefTitle":13191,"status":107,"phases":22349,"primaryCompletion":2964,"completion":2964,"start":8934,"enrollment":13193,"conditions":22350,"interventions":22351},[91],[36],[1576,13196,13197],{"trials":22353,"activeCount":101},[],{"trials":22355,"activeCount":101},[],{"intervention":15931,"totalTrials":350,"cells":22357},{"EARLY_PHASE1":22358,"PHASE1":22360,"PHASE2":22362,"PHASE3":22364,"PHASE4":22370,"NA":22372},{"trials":22359,"activeCount":101},[],{"trials":22361,"activeCount":101},[],{"trials":22363,"activeCount":101},[],{"trials":22365,"activeCount":101},[22366],{"nctId":15925,"briefTitle":15926,"status":107,"phases":22367,"primaryCompletion":14712,"completion":14712,"start":4562,"enrollment":15928,"conditions":22368,"interventions":22369},[91],[18],[3059,5381,15931],{"trials":22371,"activeCount":101},[],{"trials":22373,"activeCount":101},[],{"intervention":9170,"totalTrials":350,"cells":22375},{"EARLY_PHASE1":22376,"PHASE1":22378,"PHASE2":22380,"PHASE3":22382,"PHASE4":22388,"NA":22390},{"trials":22377,"activeCount":101},[],{"trials":22379,"activeCount":101},[],{"trials":22381,"activeCount":101},[],{"trials":22383,"activeCount":101},[22384],{"nctId":9165,"briefTitle":9166,"status":130,"phases":22385,"primaryCompletion":4562,"completion":4562,"start":4455,"enrollment":721,"conditions":22386,"interventions":22387},[91],[3597],[5914,9170,9171,1357],{"trials":22389,"activeCount":101},[],{"trials":22391,"activeCount":101},[],{"intervention":9171,"totalTrials":350,"cells":22393},{"EARLY_PHASE1":22394,"PHASE1":22396,"PHASE2":22398,"PHASE3":22400,"PHASE4":22406,"NA":22408},{"trials":22395,"activeCount":101},[],{"trials":22397,"activeCount":101},[],{"trials":22399,"activeCount":101},[],{"trials":22401,"activeCount":101},[22402],{"nctId":9165,"briefTitle":9166,"status":130,"phases":22403,"primaryCompletion":4562,"completion":4562,"start":4455,"enrollment":721,"conditions":22404,"interventions":22405},[91],[3597],[5914,9170,9171,1357],{"trials":22407,"activeCount":101},[],{"trials":22409,"activeCount":101},[],{"intervention":16298,"totalTrials":350,"cells":22411},{"EARLY_PHASE1":22412,"PHASE1":22414,"PHASE2":22416,"PHASE3":22418,"PHASE4":22424,"NA":22426},{"trials":22413,"activeCount":101},[],{"trials":22415,"activeCount":101},[],{"trials":22417,"activeCount":101},[],{"trials":22419,"activeCount":101},[22420],{"nctId":16293,"briefTitle":16294,"status":107,"phases":22421,"primaryCompletion":3213,"completion":3213,"start":4322,"enrollment":4713,"conditions":22422,"interventions":22423},[91],[975],[5384,16298,16299,16300],{"trials":22425,"activeCount":101},[],{"trials":22427,"activeCount":101},[],{"intervention":16299,"totalTrials":350,"cells":22429},{"EARLY_PHASE1":22430,"PHASE1":22432,"PHASE2":22434,"PHASE3":22436,"PHASE4":22442,"NA":22444},{"trials":22431,"activeCount":101},[],{"trials":22433,"activeCount":101},[],{"trials":22435,"activeCount":101},[],{"trials":22437,"activeCount":101},[22438],{"nctId":16293,"briefTitle":16294,"status":107,"phases":22439,"primaryCompletion":3213,"completion":3213,"start":4322,"enrollment":4713,"conditions":22440,"interventions":22441},[91],[975],[5384,16298,16299,16300],{"trials":22443,"activeCount":101},[],{"trials":22445,"activeCount":101},[],{"intervention":16300,"totalTrials":350,"cells":22447},{"EARLY_PHASE1":22448,"PHASE1":22450,"PHASE2":22452,"PHASE3":22454,"PHASE4":22460,"NA":22462},{"trials":22449,"activeCount":101},[],{"trials":22451,"activeCount":101},[],{"trials":22453,"activeCount":101},[],{"trials":22455,"activeCount":101},[22456],{"nctId":16293,"briefTitle":16294,"status":107,"phases":22457,"primaryCompletion":3213,"completion":3213,"start":4322,"enrollment":4713,"conditions":22458,"interventions":22459},[91],[975],[5384,16298,16299,16300],{"trials":22461,"activeCount":101},[],{"trials":22463,"activeCount":101},[],{"intervention":22465,"totalTrials":350,"cells":22466},"bitopertin [RO4917838] level 1",{"EARLY_PHASE1":22467,"PHASE1":22469,"PHASE2":22471,"PHASE3":22473,"PHASE4":22483,"NA":22485},{"trials":22468,"activeCount":101},[],{"trials":22470,"activeCount":101},[],{"trials":22472,"activeCount":101},[],{"trials":22474,"activeCount":101},[22475],{"nctId":22476,"briefTitle":22477,"status":107,"phases":22478,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":22479,"conditions":22480,"interventions":22481},"NCT01235559","A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)",[91],604,[19752],[22465,22482],"bitopertin [RO4917838] level 2",{"trials":22484,"activeCount":101},[],{"trials":22486,"activeCount":101},[],{"intervention":22482,"totalTrials":350,"cells":22488},{"EARLY_PHASE1":22489,"PHASE1":22491,"PHASE2":22493,"PHASE3":22495,"PHASE4":22501,"NA":22503},{"trials":22490,"activeCount":101},[],{"trials":22492,"activeCount":101},[],{"trials":22494,"activeCount":101},[],{"trials":22496,"activeCount":101},[22497],{"nctId":22476,"briefTitle":22477,"status":107,"phases":22498,"primaryCompletion":4473,"completion":4473,"start":4474,"enrollment":22479,"conditions":22499,"interventions":22500},[91],[19752],[22465,22482],{"trials":22502,"activeCount":101},[],{"trials":22504,"activeCount":101},[],{"intervention":6200,"totalTrials":350,"cells":22506},{"EARLY_PHASE1":22507,"PHASE1":22509,"PHASE2":22511,"PHASE3":22513,"PHASE4":22519,"NA":22521},{"trials":22508,"activeCount":101},[],{"trials":22510,"activeCount":101},[],{"trials":22512,"activeCount":101},[],{"trials":22514,"activeCount":101},[22515],{"nctId":6192,"briefTitle":6193,"status":107,"phases":22516,"primaryCompletion":6195,"completion":6195,"start":2948,"enrollment":6196,"conditions":22517,"interventions":22518},[91],[6198],[6200,6201,1356,1359,1359,1359,1359],{"trials":22520,"activeCount":101},[],{"trials":22522,"activeCount":101},[],{"intervention":6201,"totalTrials":350,"cells":22524},{"EARLY_PHASE1":22525,"PHASE1":22527,"PHASE2":22529,"PHASE3":22531,"PHASE4":22537,"NA":22539},{"trials":22526,"activeCount":101},[],{"trials":22528,"activeCount":101},[],{"trials":22530,"activeCount":101},[],{"trials":22532,"activeCount":101},[22533],{"nctId":6192,"briefTitle":6193,"status":107,"phases":22534,"primaryCompletion":6195,"completion":6195,"start":2948,"enrollment":6196,"conditions":22535,"interventions":22536},[91],[6198],[6200,6201,1356,1359,1359,1359,1359],{"trials":22538,"activeCount":101},[],{"trials":22540,"activeCount":101},[],{"intervention":14483,"totalTrials":350,"cells":22542},{"EARLY_PHASE1":22543,"PHASE1":22545,"PHASE2":22547,"PHASE3":22549,"PHASE4":22555,"NA":22557},{"trials":22544,"activeCount":101},[],{"trials":22546,"activeCount":101},[],{"trials":22548,"activeCount":101},[],{"trials":22550,"activeCount":101},[22551],{"nctId":14478,"briefTitle":14479,"status":107,"phases":22552,"primaryCompletion":3479,"completion":3479,"start":5457,"enrollment":1058,"conditions":22553,"interventions":22554},[91],[5911],[5848,14483,14484],{"trials":22556,"activeCount":101},[],{"trials":22558,"activeCount":101},[],{"intervention":17290,"totalTrials":350,"cells":22560},{"EARLY_PHASE1":22561,"PHASE1":22563,"PHASE2":22565,"PHASE3":22567,"PHASE4":22573,"NA":22575},{"trials":22562,"activeCount":101},[],{"trials":22564,"activeCount":101},[],{"trials":22566,"activeCount":101},[],{"trials":22568,"activeCount":101},[22569],{"nctId":17284,"briefTitle":17285,"status":107,"phases":22570,"primaryCompletion":5891,"completion":5891,"start":7054,"enrollment":2640,"conditions":22571,"interventions":22572},[91],[17288],[11717,5913,17290,17291,11738],{"trials":22574,"activeCount":101},[],{"trials":22576,"activeCount":101},[],{"intervention":2821,"totalTrials":350,"cells":22578},{"EARLY_PHASE1":22579,"PHASE1":22581,"PHASE2":22583,"PHASE3":22585,"PHASE4":22591,"NA":22593},{"trials":22580,"activeCount":101},[],{"trials":22582,"activeCount":101},[],{"trials":22584,"activeCount":101},[],{"trials":22586,"activeCount":101},[22587],{"nctId":2813,"briefTitle":2814,"status":107,"phases":22588,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":22589,"interventions":22590},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"trials":22592,"activeCount":101},[],{"trials":22594,"activeCount":101},[],{"intervention":2822,"totalTrials":350,"cells":22596},{"EARLY_PHASE1":22597,"PHASE1":22599,"PHASE2":22601,"PHASE3":22603,"PHASE4":22609,"NA":22611},{"trials":22598,"activeCount":101},[],{"trials":22600,"activeCount":101},[],{"trials":22602,"activeCount":101},[],{"trials":22604,"activeCount":101},[22605],{"nctId":2813,"briefTitle":2814,"status":107,"phases":22606,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":22607,"interventions":22608},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"trials":22610,"activeCount":101},[],{"trials":22612,"activeCount":101},[],{"intervention":2823,"totalTrials":350,"cells":22614},{"EARLY_PHASE1":22615,"PHASE1":22617,"PHASE2":22619,"PHASE3":22621,"PHASE4":22627,"NA":22629},{"trials":22616,"activeCount":101},[],{"trials":22618,"activeCount":101},[],{"trials":22620,"activeCount":101},[],{"trials":22622,"activeCount":101},[22623],{"nctId":2813,"briefTitle":2814,"status":107,"phases":22624,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":22625,"interventions":22626},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"trials":22628,"activeCount":101},[],{"trials":22630,"activeCount":101},[],{"intervention":2825,"totalTrials":350,"cells":22632},{"EARLY_PHASE1":22633,"PHASE1":22635,"PHASE2":22637,"PHASE3":22639,"PHASE4":22645,"NA":22647},{"trials":22634,"activeCount":101},[],{"trials":22636,"activeCount":101},[],{"trials":22638,"activeCount":101},[],{"trials":22640,"activeCount":101},[22641],{"nctId":2813,"briefTitle":2814,"status":107,"phases":22642,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":22643,"interventions":22644},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"trials":22646,"activeCount":101},[],{"trials":22648,"activeCount":101},[],{"intervention":22650,"totalTrials":350,"cells":22651},"r-HuEPO",{"EARLY_PHASE1":22652,"PHASE1":22654,"PHASE2":22656,"PHASE3":22658,"PHASE4":22667,"NA":22669},{"trials":22653,"activeCount":101},[],{"trials":22655,"activeCount":101},[],{"trials":22657,"activeCount":101},[],{"trials":22659,"activeCount":101},[22660],{"nctId":22661,"briefTitle":22662,"status":107,"phases":22663,"primaryCompletion":13171,"completion":13171,"start":22664,"enrollment":34,"conditions":22665,"interventions":22666},"NCT02767765","A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy",[91],"2003-06",[24],[22650],{"trials":22668,"activeCount":101},[],{"trials":22670,"activeCount":101},[],{"intervention":22672,"totalTrials":350,"cells":22673},"Oseltamivir IV",{"EARLY_PHASE1":22674,"PHASE1":22676,"PHASE2":22678,"PHASE3":22680,"PHASE4":22689,"NA":22691},{"trials":22675,"activeCount":101},[],{"trials":22677,"activeCount":101},[],{"trials":22679,"activeCount":101},[],{"trials":22681,"activeCount":101},[22682],{"nctId":22683,"briefTitle":22684,"status":107,"phases":22685,"primaryCompletion":3146,"completion":3146,"start":4206,"enrollment":22686,"conditions":22687,"interventions":22688},"NCT01050257","A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza",[91],118,[12770],[22672,12796],{"trials":22690,"activeCount":101},[],{"trials":22692,"activeCount":101},[],{"intervention":22694,"totalTrials":350,"cells":22695},"Etrozulimab",{"EARLY_PHASE1":22696,"PHASE1":22698,"PHASE2":22700,"PHASE3":22702,"PHASE4":22713,"NA":22715},{"trials":22697,"activeCount":101},[],{"trials":22699,"activeCount":101},[],{"trials":22701,"activeCount":101},[],{"trials":22703,"activeCount":101},[22704],{"nctId":22705,"briefTitle":22706,"status":107,"phases":22707,"primaryCompletion":22708,"completion":22708,"start":22709,"enrollment":22710,"conditions":22711,"interventions":22712},"NCT02100696","A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors",[91],"2020-04-16","2014-05-21",609,[20387],[22694],{"trials":22714,"activeCount":101},[],{"trials":22716,"activeCount":101},[],{"intervention":2850,"totalTrials":350,"cells":22718},{"EARLY_PHASE1":22719,"PHASE1":22721,"PHASE2":22723,"PHASE3":22725,"PHASE4":22731,"NA":22733},{"trials":22720,"activeCount":101},[],{"trials":22722,"activeCount":101},[],{"trials":22724,"activeCount":101},[],{"trials":22726,"activeCount":101},[22727],{"nctId":2844,"briefTitle":2845,"status":107,"phases":22728,"primaryCompletion":2847,"completion":2847,"start":2830,"enrollment":1103,"conditions":22729,"interventions":22730},[91],[15],[1096,2824,2850],{"trials":22732,"activeCount":101},[],{"trials":22734,"activeCount":101},[],{"intervention":22736,"totalTrials":350,"cells":22737},"tocilizumab [RoActemra]",{"EARLY_PHASE1":22738,"PHASE1":22740,"PHASE2":22742,"PHASE3":22744,"PHASE4":22752,"NA":22754},{"trials":22739,"activeCount":101},[],{"trials":22741,"activeCount":101},[],{"trials":22743,"activeCount":101},[],{"trials":22745,"activeCount":101},[22746],{"nctId":22747,"briefTitle":22748,"status":107,"phases":22749,"primaryCompletion":132,"completion":132,"start":4233,"enrollment":1115,"conditions":22750,"interventions":22751},"NCT01254331","An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment",[91],[15],[22736],{"trials":22753,"activeCount":101},[],{"trials":22755,"activeCount":101},[],{"intervention":5824,"totalTrials":350,"cells":22757},{"EARLY_PHASE1":22758,"PHASE1":22760,"PHASE2":22762,"PHASE3":22764,"PHASE4":22770,"NA":22772},{"trials":22759,"activeCount":101},[],{"trials":22761,"activeCount":101},[],{"trials":22763,"activeCount":101},[],{"trials":22765,"activeCount":101},[22766],{"nctId":5817,"briefTitle":5818,"status":107,"phases":22767,"primaryCompletion":3084,"completion":4445,"start":5820,"enrollment":5821,"conditions":22768,"interventions":22769},[91],[15],[1359,274,2824,5824],{"trials":22771,"activeCount":101},[],{"trials":22773,"activeCount":101},[],{"intervention":22775,"totalTrials":350,"cells":22776},"Mycophenolate Mofetil 2 g\u002FDay",{"EARLY_PHASE1":22777,"PHASE1":22779,"PHASE2":22781,"PHASE3":22783,"PHASE4":22793,"NA":22795},{"trials":22778,"activeCount":101},[],{"trials":22780,"activeCount":101},[],{"trials":22782,"activeCount":101},[],{"trials":22784,"activeCount":101},[22785],{"nctId":22786,"briefTitle":22787,"status":107,"phases":22788,"primaryCompletion":8934,"completion":8934,"start":17135,"enrollment":1036,"conditions":22789,"interventions":22791},"NCT00683930","A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)",[91],[22790],"Pemphigus Vulgaris (PV)",[22775,22792],"Mycophenolate Mofetil (MMF) 3 g\u002FDay",{"trials":22794,"activeCount":101},[],{"trials":22796,"activeCount":101},[],{"intervention":22792,"totalTrials":350,"cells":22798},{"EARLY_PHASE1":22799,"PHASE1":22801,"PHASE2":22803,"PHASE3":22805,"PHASE4":22811,"NA":22813},{"trials":22800,"activeCount":101},[],{"trials":22802,"activeCount":101},[],{"trials":22804,"activeCount":101},[],{"trials":22806,"activeCount":101},[22807],{"nctId":22786,"briefTitle":22787,"status":107,"phases":22808,"primaryCompletion":8934,"completion":8934,"start":17135,"enrollment":1036,"conditions":22809,"interventions":22810},[91],[22790],[22775,22792],{"trials":22812,"activeCount":101},[],{"trials":22814,"activeCount":101},[],{"intervention":22816,"totalTrials":350,"cells":22817},"Tocilizumab 162 mg",{"EARLY_PHASE1":22818,"PHASE1":22820,"PHASE2":22822,"PHASE3":22824,"PHASE4":22833,"NA":22835},{"trials":22819,"activeCount":101},[],{"trials":22821,"activeCount":101},[],{"trials":22823,"activeCount":101},[],{"trials":22825,"activeCount":101},[22826],{"nctId":22827,"briefTitle":22828,"status":107,"phases":22829,"primaryCompletion":2801,"completion":2956,"start":2964,"enrollment":22830,"conditions":22831,"interventions":22832},"NCT01232569","A Study of RoActemra\u002FActemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis",[91],656,[15],[22816],{"trials":22834,"activeCount":101},[],{"trials":22836,"activeCount":101},[],{"intervention":17229,"totalTrials":350,"cells":22838},{"EARLY_PHASE1":22839,"PHASE1":22841,"PHASE2":22843,"PHASE3":22845,"PHASE4":22851,"NA":22853},{"trials":22840,"activeCount":101},[],{"trials":22842,"activeCount":101},[],{"trials":22844,"activeCount":101},[],{"trials":22846,"activeCount":101},[22847],{"nctId":17222,"briefTitle":17223,"status":107,"phases":22848,"primaryCompletion":4455,"completion":4455,"start":17225,"enrollment":17226,"conditions":22849,"interventions":22850},[91],[5846],[3059,17229,17229,17230,11737],{"trials":22852,"activeCount":101},[],{"trials":22854,"activeCount":101},[],{"intervention":17230,"totalTrials":350,"cells":22856},{"EARLY_PHASE1":22857,"PHASE1":22859,"PHASE2":22861,"PHASE3":22863,"PHASE4":22869,"NA":22871},{"trials":22858,"activeCount":101},[],{"trials":22860,"activeCount":101},[],{"trials":22862,"activeCount":101},[],{"trials":22864,"activeCount":101},[22865],{"nctId":17222,"briefTitle":17223,"status":107,"phases":22866,"primaryCompletion":4455,"completion":4455,"start":17225,"enrollment":17226,"conditions":22867,"interventions":22868},[91],[5846],[3059,17229,17229,17230,11737],{"trials":22870,"activeCount":101},[],{"trials":22872,"activeCount":101},[],{"intervention":22874,"totalTrials":350,"cells":22875},"Faricimab PFS Configuration",{"EARLY_PHASE1":22876,"PHASE1":22878,"PHASE2":22880,"PHASE3":22882,"PHASE4":22890,"NA":22892},{"trials":22877,"activeCount":101},[],{"trials":22879,"activeCount":101},[],{"trials":22881,"activeCount":101},[],{"trials":22883,"activeCount":101},[22884],{"nctId":22885,"briefTitle":22886,"status":107,"phases":22887,"primaryCompletion":3895,"completion":3895,"start":2742,"enrollment":384,"conditions":22888,"interventions":22889},"NCT05569148","A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe",[91],[647,551],[22874],{"trials":22891,"activeCount":101},[],{"trials":22893,"activeCount":101},[],{"intervention":10364,"totalTrials":350,"cells":22895},{"EARLY_PHASE1":22896,"PHASE1":22898,"PHASE2":22900,"PHASE3":22902,"PHASE4":22908,"NA":22910},{"trials":22897,"activeCount":101},[],{"trials":22899,"activeCount":101},[],{"trials":22901,"activeCount":101},[],{"trials":22903,"activeCount":101},[22904],{"nctId":10354,"briefTitle":10355,"status":107,"phases":22905,"primaryCompletion":10357,"completion":10358,"start":10359,"enrollment":10360,"conditions":22906,"interventions":22907},[91],[5655,3466,10362],[10364,8162,8164,1419,10365],{"trials":22909,"activeCount":101},[],{"trials":22911,"activeCount":101},[],{"intervention":10365,"totalTrials":350,"cells":22913},{"EARLY_PHASE1":22914,"PHASE1":22916,"PHASE2":22918,"PHASE3":22920,"PHASE4":22926,"NA":22928},{"trials":22915,"activeCount":101},[],{"trials":22917,"activeCount":101},[],{"trials":22919,"activeCount":101},[],{"trials":22921,"activeCount":101},[22922],{"nctId":10354,"briefTitle":10355,"status":107,"phases":22923,"primaryCompletion":10357,"completion":10358,"start":10359,"enrollment":10360,"conditions":22924,"interventions":22925},[91],[5655,3466,10362],[10364,8162,8164,1419,10365],{"trials":22927,"activeCount":101},[],{"trials":22929,"activeCount":101},[],{"intervention":6227,"totalTrials":350,"cells":22931},{"EARLY_PHASE1":22932,"PHASE1":22934,"PHASE2":22936,"PHASE3":22938,"PHASE4":22944,"NA":22946},{"trials":22933,"activeCount":101},[],{"trials":22935,"activeCount":101},[],{"trials":22937,"activeCount":101},[],{"trials":22939,"activeCount":101},[22940],{"nctId":6220,"briefTitle":6221,"status":107,"phases":22941,"primaryCompletion":6223,"completion":6223,"start":6224,"enrollment":4573,"conditions":22942,"interventions":22943},[91],[3741],[6227,992,1359],{"trials":22945,"activeCount":101},[],{"trials":22947,"activeCount":101},[],{"intervention":7352,"totalTrials":350,"cells":22949},{"EARLY_PHASE1":22950,"PHASE1":22952,"PHASE2":22954,"PHASE3":22956,"PHASE4":22962,"NA":22964},{"trials":22951,"activeCount":101},[],{"trials":22953,"activeCount":101},[],{"trials":22955,"activeCount":101},[],{"trials":22957,"activeCount":101},[22958],{"nctId":7342,"briefTitle":7343,"status":107,"phases":22959,"primaryCompletion":7345,"completion":7346,"start":7347,"enrollment":755,"conditions":22960,"interventions":22961},[91],[7349,7350],[7321,7352],{"trials":22963,"activeCount":101},[],{"trials":22965,"activeCount":101},[],{"intervention":16307,"totalTrials":350,"cells":22967},{"EARLY_PHASE1":22968,"PHASE1":22970,"PHASE2":22972,"PHASE3":22974,"PHASE4":22980,"NA":22982},{"trials":22969,"activeCount":101},[],{"trials":22971,"activeCount":101},[],{"trials":22973,"activeCount":101},[],{"trials":22975,"activeCount":101},[22976],{"nctId":16302,"briefTitle":16303,"status":107,"phases":22977,"primaryCompletion":3213,"completion":3213,"start":4455,"enrollment":9644,"conditions":22978,"interventions":22979},[91],[975],[16307,5384],{"trials":22981,"activeCount":101},[],{"trials":22983,"activeCount":101},[],{"intervention":9639,"totalTrials":350,"cells":22985},{"EARLY_PHASE1":22986,"PHASE1":22988,"PHASE2":22990,"PHASE3":22992,"PHASE4":22998,"NA":23000},{"trials":22987,"activeCount":101},[],{"trials":22989,"activeCount":101},[],{"trials":22991,"activeCount":101},[],{"trials":22993,"activeCount":101},[22994],{"nctId":9633,"briefTitle":9634,"status":107,"phases":22995,"primaryCompletion":4464,"completion":357,"start":971,"enrollment":2708,"conditions":22996,"interventions":22997},[91],[9637],[8162,8164,9639,991,992,947,8166],{"trials":22999,"activeCount":101},[],{"trials":23001,"activeCount":101},[],{"intervention":15550,"totalTrials":350,"cells":23003},{"EARLY_PHASE1":23004,"PHASE1":23006,"PHASE2":23008,"PHASE3":23010,"PHASE4":23016,"NA":23018},{"trials":23005,"activeCount":101},[],{"trials":23007,"activeCount":101},[],{"trials":23009,"activeCount":101},[],{"trials":23011,"activeCount":101},[23012],{"nctId":15544,"briefTitle":15545,"status":107,"phases":23013,"primaryCompletion":7095,"completion":2964,"start":9596,"enrollment":15547,"conditions":23014,"interventions":23015},[91],[15],[5894,5894,15550],{"trials":23017,"activeCount":101},[],{"trials":23019,"activeCount":101},[],{"intervention":5508,"totalTrials":350,"cells":23021},{"EARLY_PHASE1":23022,"PHASE1":23024,"PHASE2":23026,"PHASE3":23028,"PHASE4":23034,"NA":23036},{"trials":23023,"activeCount":101},[],{"trials":23025,"activeCount":101},[],{"trials":23027,"activeCount":101},[],{"trials":23029,"activeCount":101},[23030],{"nctId":5500,"briefTitle":5501,"status":107,"phases":23031,"primaryCompletion":5503,"completion":5504,"start":5505,"enrollment":437,"conditions":23032,"interventions":23033},[91],[18],[1222,991,992,1106,947,990,5508],{"trials":23035,"activeCount":101},[],{"trials":23037,"activeCount":101},[],{"intervention":4414,"totalTrials":350,"cells":23039},{"EARLY_PHASE1":23040,"PHASE1":23042,"PHASE2":23044,"PHASE3":23046,"PHASE4":23052,"NA":23054},{"trials":23041,"activeCount":101},[],{"trials":23043,"activeCount":101},[],{"trials":23045,"activeCount":101},[],{"trials":23047,"activeCount":101},[23048],{"nctId":4406,"briefTitle":4407,"status":107,"phases":23049,"primaryCompletion":4409,"completion":3213,"start":4410,"enrollment":4411,"conditions":23050,"interventions":23051},[91],[30],[1015,1166,1597,4414,1165],{"trials":23053,"activeCount":101},[],{"trials":23055,"activeCount":101},[],{"intervention":10181,"totalTrials":350,"cells":23057},{"EARLY_PHASE1":23058,"PHASE1":23060,"PHASE2":23062,"PHASE3":23064,"PHASE4":23070,"NA":23072},{"trials":23059,"activeCount":101},[],{"trials":23061,"activeCount":101},[],{"trials":23063,"activeCount":101},[],{"trials":23065,"activeCount":101},[23066],{"nctId":10173,"briefTitle":10174,"status":107,"phases":23067,"primaryCompletion":3076,"completion":2115,"start":10176,"enrollment":10177,"conditions":23068,"interventions":23069},[91],[10179],[8041,989,991,992,10181,10182],{"trials":23071,"activeCount":101},[],{"trials":23073,"activeCount":101},[],{"intervention":17599,"totalTrials":350,"cells":23075},{"EARLY_PHASE1":23076,"PHASE1":23078,"PHASE2":23080,"PHASE3":23082,"PHASE4":23088,"NA":23090},{"trials":23077,"activeCount":101},[],{"trials":23079,"activeCount":101},[],{"trials":23081,"activeCount":101},[],{"trials":23083,"activeCount":101},[23084],{"nctId":17594,"briefTitle":17595,"status":107,"phases":23085,"primaryCompletion":4206,"completion":4206,"start":6702,"enrollment":414,"conditions":23086,"interventions":23087},[91],[11790],[17599,17600,16486],{"trials":23089,"activeCount":101},[],{"trials":23091,"activeCount":101},[],{"intervention":17600,"totalTrials":350,"cells":23093},{"EARLY_PHASE1":23094,"PHASE1":23096,"PHASE2":23098,"PHASE3":23100,"PHASE4":23106,"NA":23108},{"trials":23095,"activeCount":101},[],{"trials":23097,"activeCount":101},[],{"trials":23099,"activeCount":101},[],{"trials":23101,"activeCount":101},[23102],{"nctId":17594,"briefTitle":17595,"status":107,"phases":23103,"primaryCompletion":4206,"completion":4206,"start":6702,"enrollment":414,"conditions":23104,"interventions":23105},[91],[11790],[17599,17600,16486],{"trials":23107,"activeCount":101},[],{"trials":23109,"activeCount":101},[],{"intervention":8417,"totalTrials":350,"cells":23111},{"EARLY_PHASE1":23112,"PHASE1":23114,"PHASE2":23116,"PHASE3":23118,"PHASE4":23124,"NA":23126},{"trials":23113,"activeCount":101},[],{"trials":23115,"activeCount":101},[],{"trials":23117,"activeCount":101},[],{"trials":23119,"activeCount":101},[23120],{"nctId":8410,"briefTitle":8411,"status":107,"phases":23121,"primaryCompletion":3254,"completion":8413,"start":4095,"enrollment":8414,"conditions":23122,"interventions":23123},[91],[18],[8417,947,1221,1222],{"trials":23125,"activeCount":101},[],{"trials":23127,"activeCount":101},[],{"intervention":19420,"totalTrials":350,"cells":23129},{"EARLY_PHASE1":23130,"PHASE1":23132,"PHASE2":23134,"PHASE3":23136,"PHASE4":23142,"NA":23144},{"trials":23131,"activeCount":101},[],{"trials":23133,"activeCount":101},[],{"trials":23135,"activeCount":101},[],{"trials":23137,"activeCount":101},[23138],{"nctId":19414,"briefTitle":19415,"status":107,"phases":23139,"primaryCompletion":6673,"completion":6343,"start":11300,"enrollment":19417,"conditions":23140,"interventions":23141},[91],[33],[19294,19420,19421,11782],{"trials":23143,"activeCount":101},[],{"trials":23145,"activeCount":101},[],{"intervention":19421,"totalTrials":350,"cells":23147},{"EARLY_PHASE1":23148,"PHASE1":23150,"PHASE2":23152,"PHASE3":23154,"PHASE4":23160,"NA":23162},{"trials":23149,"activeCount":101},[],{"trials":23151,"activeCount":101},[],{"trials":23153,"activeCount":101},[],{"trials":23155,"activeCount":101},[23156],{"nctId":19414,"briefTitle":19415,"status":107,"phases":23157,"primaryCompletion":6673,"completion":6343,"start":11300,"enrollment":19417,"conditions":23158,"interventions":23159},[91],[33],[19294,19420,19421,11782],{"trials":23161,"activeCount":101},[],{"trials":23163,"activeCount":101},[],{"intervention":23165,"totalTrials":350,"cells":23166},"Atezolizumab SC",{"EARLY_PHASE1":23167,"PHASE1":23169,"PHASE2":23171,"PHASE3":23173,"PHASE4":23182,"NA":23184},{"trials":23168,"activeCount":101},[],{"trials":23170,"activeCount":101},[],{"trials":23172,"activeCount":101},[],{"trials":23174,"activeCount":101},[23175],{"nctId":23176,"briefTitle":23177,"status":130,"phases":23178,"primaryCompletion":1270,"completion":1270,"start":23179,"enrollment":1001,"conditions":23180,"interventions":23181},"NCT05694013","Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice",[90,91],"2023-02-27",[1883],[23165],{"trials":23183,"activeCount":101},[],{"trials":23185,"activeCount":101},[],{"intervention":5849,"totalTrials":350,"cells":23187},{"EARLY_PHASE1":23188,"PHASE1":23190,"PHASE2":23192,"PHASE3":23194,"PHASE4":23200,"NA":23202},{"trials":23189,"activeCount":101},[],{"trials":23191,"activeCount":101},[],{"trials":23193,"activeCount":101},[],{"trials":23195,"activeCount":101},[23196],{"nctId":5841,"briefTitle":5842,"status":107,"phases":23197,"primaryCompletion":3325,"completion":3325,"start":4282,"enrollment":5844,"conditions":23198,"interventions":23199},[91],[5846],[5848,5848,5849,5839,5850],{"trials":23201,"activeCount":101},[],{"trials":23203,"activeCount":101},[],{"intervention":21882,"totalTrials":350,"cells":23205},{"EARLY_PHASE1":23206,"PHASE1":23208,"PHASE2":23210,"PHASE3":23212,"PHASE4":23218,"NA":23220},{"trials":23207,"activeCount":101},[],{"trials":23209,"activeCount":101},[],{"trials":23211,"activeCount":101},[],{"trials":23213,"activeCount":101},[23214],{"nctId":21877,"briefTitle":21878,"status":107,"phases":23215,"primaryCompletion":2769,"completion":2769,"start":5820,"enrollment":920,"conditions":23216,"interventions":23217},[91],[24],[21882,21883],{"trials":23219,"activeCount":101},[],{"trials":23221,"activeCount":101},[],{"intervention":16694,"totalTrials":350,"cells":23223},{"EARLY_PHASE1":23224,"PHASE1":23226,"PHASE2":23228,"PHASE3":23230,"PHASE4":23236,"NA":23238},{"trials":23225,"activeCount":101},[],{"trials":23227,"activeCount":101},[],{"trials":23229,"activeCount":101},[],{"trials":23231,"activeCount":101},[23232],{"nctId":16689,"briefTitle":16690,"status":130,"phases":23233,"primaryCompletion":4322,"completion":4322,"start":4446,"enrollment":25,"conditions":23234,"interventions":23235},[91],[1305],[16655,16694],{"trials":23237,"activeCount":101},[],{"trials":23239,"activeCount":101},[],{"intervention":20642,"totalTrials":350,"cells":23241},{"EARLY_PHASE1":23242,"PHASE1":23244,"PHASE2":23246,"PHASE3":23248,"PHASE4":23254,"NA":23256},{"trials":23243,"activeCount":101},[],{"trials":23245,"activeCount":101},[],{"trials":23247,"activeCount":101},[],{"trials":23249,"activeCount":101},[23250],{"nctId":20635,"briefTitle":20636,"status":107,"phases":23251,"primaryCompletion":16165,"completion":16165,"start":16142,"enrollment":20638,"conditions":23252,"interventions":23253},[91],[20640],[20587,20642],{"trials":23255,"activeCount":101},[],{"trials":23257,"activeCount":101},[],{"intervention":10389,"totalTrials":350,"cells":23259},{"EARLY_PHASE1":23260,"PHASE1":23262,"PHASE2":23264,"PHASE3":23266,"PHASE4":23272,"NA":23274},{"trials":23261,"activeCount":101},[],{"trials":23263,"activeCount":101},[],{"trials":23265,"activeCount":101},[],{"trials":23267,"activeCount":101},[23268],{"nctId":10383,"briefTitle":10384,"status":107,"phases":23269,"primaryCompletion":132,"completion":2955,"start":3189,"enrollment":10386,"conditions":23270,"interventions":23271},[91],[18],[1223,10389],{"trials":23273,"activeCount":101},[],{"trials":23275,"activeCount":101},[],{"intervention":23277,"totalTrials":350,"cells":23278},"Ocrelizumab IV",{"EARLY_PHASE1":23279,"PHASE1":23281,"PHASE2":23283,"PHASE3":23285,"PHASE4":23300,"NA":23302},{"trials":23280,"activeCount":101},[],{"trials":23282,"activeCount":101},[],{"trials":23284,"activeCount":101},[],{"trials":23286,"activeCount":101},[23287],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23290,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23293,"interventions":23294},"NCT05232825","A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis",[91],"2023-03-10","2025-06-06",[232,338],[23277,23295,23296,23297,23298,23299],"Ocrelizumab SC","Methylprednisolone IV","Diphenhydramine IV","Dexamethasone given orally","Desloratadine given orally",{"trials":23301,"activeCount":101},[],{"trials":23303,"activeCount":101},[],{"intervention":23295,"totalTrials":350,"cells":23305},{"EARLY_PHASE1":23306,"PHASE1":23308,"PHASE2":23310,"PHASE3":23312,"PHASE4":23318,"NA":23320},{"trials":23307,"activeCount":101},[],{"trials":23309,"activeCount":101},[],{"trials":23311,"activeCount":101},[],{"trials":23313,"activeCount":101},[23314],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23315,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23316,"interventions":23317},[91],[232,338],[23277,23295,23296,23297,23298,23299],{"trials":23319,"activeCount":101},[],{"trials":23321,"activeCount":101},[],{"intervention":23296,"totalTrials":350,"cells":23323},{"EARLY_PHASE1":23324,"PHASE1":23326,"PHASE2":23328,"PHASE3":23330,"PHASE4":23336,"NA":23338},{"trials":23325,"activeCount":101},[],{"trials":23327,"activeCount":101},[],{"trials":23329,"activeCount":101},[],{"trials":23331,"activeCount":101},[23332],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23333,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23334,"interventions":23335},[91],[232,338],[23277,23295,23296,23297,23298,23299],{"trials":23337,"activeCount":101},[],{"trials":23339,"activeCount":101},[],{"intervention":23297,"totalTrials":350,"cells":23341},{"EARLY_PHASE1":23342,"PHASE1":23344,"PHASE2":23346,"PHASE3":23348,"PHASE4":23354,"NA":23356},{"trials":23343,"activeCount":101},[],{"trials":23345,"activeCount":101},[],{"trials":23347,"activeCount":101},[],{"trials":23349,"activeCount":101},[23350],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23351,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23352,"interventions":23353},[91],[232,338],[23277,23295,23296,23297,23298,23299],{"trials":23355,"activeCount":101},[],{"trials":23357,"activeCount":101},[],{"intervention":23298,"totalTrials":350,"cells":23359},{"EARLY_PHASE1":23360,"PHASE1":23362,"PHASE2":23364,"PHASE3":23366,"PHASE4":23372,"NA":23374},{"trials":23361,"activeCount":101},[],{"trials":23363,"activeCount":101},[],{"trials":23365,"activeCount":101},[],{"trials":23367,"activeCount":101},[23368],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23369,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23370,"interventions":23371},[91],[232,338],[23277,23295,23296,23297,23298,23299],{"trials":23373,"activeCount":101},[],{"trials":23375,"activeCount":101},[],{"intervention":23299,"totalTrials":350,"cells":23377},{"EARLY_PHASE1":23378,"PHASE1":23380,"PHASE2":23382,"PHASE3":23384,"PHASE4":23390,"NA":23392},{"trials":23379,"activeCount":101},[],{"trials":23381,"activeCount":101},[],{"trials":23383,"activeCount":101},[],{"trials":23385,"activeCount":101},[23386],{"nctId":23288,"briefTitle":23289,"status":107,"phases":23387,"primaryCompletion":23291,"completion":23292,"start":259,"enrollment":20945,"conditions":23388,"interventions":23389},[91],[232,338],[23277,23295,23296,23297,23298,23299],{"trials":23391,"activeCount":101},[],{"trials":23393,"activeCount":101},[],{"intervention":23395,"totalTrials":350,"cells":23396},"Peginterferon Alfa-2",{"EARLY_PHASE1":23397,"PHASE1":23399,"PHASE2":23401,"PHASE3":23403,"PHASE4":23412,"NA":23414},{"trials":23398,"activeCount":101},[],{"trials":23400,"activeCount":101},[],{"trials":23402,"activeCount":101},[],{"trials":23404,"activeCount":101},[23405],{"nctId":23406,"briefTitle":23407,"status":130,"phases":23408,"primaryCompletion":2963,"completion":2963,"start":8659,"enrollment":8583,"conditions":23409,"interventions":23411},"NCT02762383","Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)",[91],[23410],"HIV\u002FHCV Coinfection",[23395],{"trials":23413,"activeCount":101},[],{"trials":23415,"activeCount":101},[],{"intervention":6746,"totalTrials":350,"cells":23417},{"EARLY_PHASE1":23418,"PHASE1":23420,"PHASE2":23422,"PHASE3":23424,"PHASE4":23430,"NA":23432},{"trials":23419,"activeCount":101},[],{"trials":23421,"activeCount":101},[],{"trials":23423,"activeCount":101},[],{"trials":23425,"activeCount":101},[23426],{"nctId":6740,"briefTitle":6741,"status":107,"phases":23427,"primaryCompletion":3324,"completion":3324,"start":4322,"enrollment":6743,"conditions":23428,"interventions":23429},[91],[2257],[6746,5384,5186],{"trials":23431,"activeCount":101},[],{"trials":23433,"activeCount":101},[],{"intervention":23435,"totalTrials":350,"cells":23436},"RoActemra\u002FActemra",{"EARLY_PHASE1":23437,"PHASE1":23439,"PHASE2":23441,"PHASE3":23443,"PHASE4":23453,"NA":23455},{"trials":23438,"activeCount":101},[],{"trials":23440,"activeCount":101},[],{"trials":23442,"activeCount":101},[],{"trials":23444,"activeCount":101},[23445],{"nctId":23446,"briefTitle":23447,"status":130,"phases":23448,"primaryCompletion":23449,"completion":23449,"start":23450,"enrollment":2440,"conditions":23451,"interventions":23452},"NCT01575769","An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis",[91],"2013-12-03","2012-01-19",[2367],[23435],{"trials":23454,"activeCount":101},[],{"trials":23456,"activeCount":101},[],{"intervention":23458,"totalTrials":350,"cells":23459},"Second-Line Chemotherapy",{"EARLY_PHASE1":23460,"PHASE1":23462,"PHASE2":23464,"PHASE3":23466,"PHASE4":23475,"NA":23477},{"trials":23461,"activeCount":101},[],{"trials":23463,"activeCount":101},[],{"trials":23465,"activeCount":101},[],{"trials":23467,"activeCount":101},[23468],{"nctId":23469,"briefTitle":23470,"status":107,"phases":23471,"primaryCompletion":2847,"completion":8321,"start":3189,"enrollment":23472,"conditions":23473,"interventions":23474},"NCT01328951","A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy",[91],643,[2257],[977,23458],{"trials":23476,"activeCount":101},[],{"trials":23478,"activeCount":101},[],{"intervention":23480,"totalTrials":350,"cells":23481},"Interferon alfa 2a [Roferon]",{"EARLY_PHASE1":23482,"PHASE1":23484,"PHASE2":23486,"PHASE3":23488,"PHASE4":23496,"NA":23498},{"trials":23483,"activeCount":101},[],{"trials":23485,"activeCount":101},[],{"trials":23487,"activeCount":101},[],{"trials":23489,"activeCount":101},[23490],{"nctId":23491,"briefTitle":23492,"status":107,"phases":23493,"primaryCompletion":4113,"completion":4113,"start":11713,"enrollment":3066,"conditions":23494,"interventions":23495},"NCT00738530","A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy",[91],[4692],[8105,23480],{"trials":23497,"activeCount":101},[],{"trials":23499,"activeCount":101},[],{"intervention":19805,"totalTrials":350,"cells":23501},{"EARLY_PHASE1":23502,"PHASE1":23504,"PHASE2":23506,"PHASE3":23508,"PHASE4":23514,"NA":23516},{"trials":23503,"activeCount":101},[],{"trials":23505,"activeCount":101},[],{"trials":23507,"activeCount":101},[],{"trials":23509,"activeCount":101},[23510],{"nctId":19797,"briefTitle":19798,"status":107,"phases":23511,"primaryCompletion":19800,"completion":19800,"start":19801,"enrollment":19802,"conditions":23512,"interventions":23513},[91],[19752],[19708,19805],{"trials":23515,"activeCount":101},[],{"trials":23517,"activeCount":101},[],{"intervention":23519,"totalTrials":350,"cells":23520},"RO7496998",{"EARLY_PHASE1":23521,"PHASE1":23523,"PHASE2":23525,"PHASE3":23527,"PHASE4":23538,"NA":23540},{"trials":23522,"activeCount":101},[],{"trials":23524,"activeCount":101},[],{"trials":23526,"activeCount":101},[],{"trials":23528,"activeCount":101},[23529],{"nctId":23530,"briefTitle":23531,"status":130,"phases":23532,"primaryCompletion":23533,"completion":23533,"start":23534,"enrollment":23535,"conditions":23536,"interventions":23537},"NCT04889040","Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19",[91],"2021-12-02","2021-04-28",216,[2476],[23519],{"trials":23539,"activeCount":101},[],{"trials":23541,"activeCount":101},[],{"intervention":9688,"totalTrials":350,"cells":23543},{"EARLY_PHASE1":23544,"PHASE1":23546,"PHASE2":23548,"PHASE3":23550,"PHASE4":23556,"NA":23558},{"trials":23545,"activeCount":101},[],{"trials":23547,"activeCount":101},[],{"trials":23549,"activeCount":101},[],{"trials":23551,"activeCount":101},[23552],{"nctId":9680,"briefTitle":9681,"status":107,"phases":23553,"primaryCompletion":9683,"completion":9683,"start":9684,"enrollment":9685,"conditions":23554,"interventions":23555},[91],[18],[947,9688,5390],{"trials":23557,"activeCount":101},[],{"trials":23559,"activeCount":101},[],{"intervention":2094,"totalTrials":350,"cells":23561},{"EARLY_PHASE1":23562,"PHASE1":23564,"PHASE2":23566,"PHASE3":23568,"PHASE4":23574,"NA":23576},{"trials":23563,"activeCount":101},[],{"trials":23565,"activeCount":101},[],{"trials":23567,"activeCount":101},[],{"trials":23569,"activeCount":101},[23570],{"nctId":2084,"briefTitle":2085,"status":107,"phases":23571,"primaryCompletion":2087,"completion":2088,"start":2089,"enrollment":2090,"conditions":23572,"interventions":23573},[91],[1285],[68,2093,1084,1479,2094],{"trials":23575,"activeCount":101},[],{"trials":23577,"activeCount":101},[],{"intervention":2968,"totalTrials":350,"cells":23579},{"EARLY_PHASE1":23580,"PHASE1":23582,"PHASE2":23584,"PHASE3":23586,"PHASE4":23592,"NA":23594},{"trials":23581,"activeCount":101},[],{"trials":23583,"activeCount":101},[],{"trials":23585,"activeCount":101},[],{"trials":23587,"activeCount":101},[23588],{"nctId":2960,"briefTitle":2961,"status":107,"phases":23589,"primaryCompletion":2963,"completion":2964,"start":2965,"enrollment":2277,"conditions":23590,"interventions":23591},[91],[15],[1096,2968],{"trials":23593,"activeCount":101},[],{"trials":23595,"activeCount":101},[],{"intervention":23597,"totalTrials":350,"cells":23598},"PDS Implant filled with 100 mg\u002FmL Ranibizumab",{"EARLY_PHASE1":23599,"PHASE1":23601,"PHASE2":23603,"PHASE3":23605,"PHASE4":23616,"NA":23618},{"trials":23600,"activeCount":101},[],{"trials":23602,"activeCount":101},[],{"trials":23604,"activeCount":101},[],{"trials":23606,"activeCount":101},[23607],{"nctId":23608,"briefTitle":23609,"status":107,"phases":23610,"primaryCompletion":19684,"completion":23611,"start":23612,"enrollment":10420,"conditions":23613,"interventions":23614},"NCT03677934","A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration",[91],"2021-06-09","2018-09-12",[7667],[23597,23615],"Intravitreal Injections of 10 mg\u002FmL Ranibizumab",{"trials":23617,"activeCount":101},[],{"trials":23619,"activeCount":101},[],{"intervention":23615,"totalTrials":350,"cells":23621},{"EARLY_PHASE1":23622,"PHASE1":23624,"PHASE2":23626,"PHASE3":23628,"PHASE4":23634,"NA":23636},{"trials":23623,"activeCount":101},[],{"trials":23625,"activeCount":101},[],{"trials":23627,"activeCount":101},[],{"trials":23629,"activeCount":101},[23630],{"nctId":23608,"briefTitle":23609,"status":107,"phases":23631,"primaryCompletion":19684,"completion":23611,"start":23612,"enrollment":10420,"conditions":23632,"interventions":23633},[91],[7667],[23597,23615],{"trials":23635,"activeCount":101},[],{"trials":23637,"activeCount":101},[],{"intervention":19883,"totalTrials":350,"cells":23639},{"EARLY_PHASE1":23640,"PHASE1":23642,"PHASE2":23644,"PHASE3":23646,"PHASE4":23652,"NA":23654},{"trials":23641,"activeCount":101},[],{"trials":23643,"activeCount":101},[],{"trials":23645,"activeCount":101},[],{"trials":23647,"activeCount":101},[23648],{"nctId":19877,"briefTitle":19878,"status":107,"phases":23649,"primaryCompletion":2964,"completion":2964,"start":6343,"enrollment":19880,"conditions":23650,"interventions":23651},[91],[36],[19883,13206,13206],{"trials":23653,"activeCount":101},[],{"trials":23655,"activeCount":101},[],{"intervention":6310,"totalTrials":350,"cells":23657},{"EARLY_PHASE1":23658,"PHASE1":23660,"PHASE2":23662,"PHASE3":23664,"PHASE4":23670,"NA":23672},{"trials":23659,"activeCount":101},[],{"trials":23661,"activeCount":101},[],{"trials":23663,"activeCount":101},[],{"trials":23665,"activeCount":101},[23666],{"nctId":6303,"briefTitle":6304,"status":107,"phases":23667,"primaryCompletion":4314,"completion":4314,"start":6306,"enrollment":6307,"conditions":23668,"interventions":23669},[91],[1038],[3677,6310],{"trials":23671,"activeCount":101},[],{"trials":23673,"activeCount":101},[],{"intervention":4492,"totalTrials":350,"cells":23675},{"EARLY_PHASE1":23676,"PHASE1":23678,"PHASE2":23680,"PHASE3":23682,"PHASE4":23688,"NA":23690},{"trials":23677,"activeCount":101},[],{"trials":23679,"activeCount":101},[],{"trials":23681,"activeCount":101},[],{"trials":23683,"activeCount":101},[23684],{"nctId":4485,"briefTitle":4486,"status":107,"phases":23685,"primaryCompletion":4488,"completion":4488,"start":4282,"enrollment":4489,"conditions":23686,"interventions":23687},[91],[30],[1015,4492],{"trials":23689,"activeCount":101},[],{"trials":23691,"activeCount":101},[],{"intervention":20090,"totalTrials":350,"cells":23693},{"EARLY_PHASE1":23694,"PHASE1":23696,"PHASE2":23698,"PHASE3":23700,"PHASE4":23706,"NA":23708},{"trials":23695,"activeCount":101},[],{"trials":23697,"activeCount":101},[],{"trials":23699,"activeCount":101},[],{"trials":23701,"activeCount":101},[23702],{"nctId":20084,"briefTitle":20085,"status":107,"phases":23703,"primaryCompletion":2514,"completion":2514,"start":3174,"enrollment":6307,"conditions":23704,"interventions":23705},[91],[17203],[20089,20090],{"trials":23707,"activeCount":101},[],{"trials":23709,"activeCount":101},[],{"intervention":4502,"totalTrials":350,"cells":23711},{"EARLY_PHASE1":23712,"PHASE1":23714,"PHASE2":23716,"PHASE3":23718,"PHASE4":23724,"NA":23726},{"trials":23713,"activeCount":101},[],{"trials":23715,"activeCount":101},[],{"trials":23717,"activeCount":101},[],{"trials":23719,"activeCount":101},[23720],{"nctId":4494,"briefTitle":4495,"status":107,"phases":23721,"primaryCompletion":4497,"completion":4497,"start":4498,"enrollment":4499,"conditions":23722,"interventions":23723},[91],[1417],[1015,4502,4503,4504],{"trials":23725,"activeCount":101},[],{"trials":23727,"activeCount":101},[],{"intervention":8132,"totalTrials":350,"cells":23729},{"EARLY_PHASE1":23730,"PHASE1":23732,"PHASE2":23734,"PHASE3":23736,"PHASE4":23742,"NA":23744},{"trials":23731,"activeCount":101},[],{"trials":23733,"activeCount":101},[],{"trials":23735,"activeCount":101},[],{"trials":23737,"activeCount":101},[23738],{"nctId":8123,"briefTitle":8124,"status":107,"phases":23739,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":23740,"interventions":23741},[91],[18],[5383,4503,5472,8132,5390,8133],{"trials":23743,"activeCount":101},[],{"trials":23745,"activeCount":101},[],{"intervention":15634,"totalTrials":350,"cells":23747},{"EARLY_PHASE1":23748,"PHASE1":23750,"PHASE2":23752,"PHASE3":23754,"PHASE4":23760,"NA":23762},{"trials":23749,"activeCount":101},[],{"trials":23751,"activeCount":101},[],{"trials":23753,"activeCount":101},[],{"trials":23755,"activeCount":101},[23756],{"nctId":15627,"briefTitle":15628,"status":107,"phases":23757,"primaryCompletion":15630,"completion":15630,"start":2975,"enrollment":15631,"conditions":23758,"interventions":23759},[91],[15],[5894,15634],{"trials":23761,"activeCount":101},[],{"trials":23763,"activeCount":101},[],{"intervention":17467,"totalTrials":350,"cells":23765},{"EARLY_PHASE1":23766,"PHASE1":23768,"PHASE2":23770,"PHASE3":23772,"PHASE4":23778,"NA":23780},{"trials":23767,"activeCount":101},[],{"trials":23769,"activeCount":101},[],{"trials":23771,"activeCount":101},[],{"trials":23773,"activeCount":101},[23774],{"nctId":17462,"briefTitle":17463,"status":107,"phases":23775,"primaryCompletion":4198,"completion":4198,"start":4410,"enrollment":6821,"conditions":23776,"interventions":23777},[91],[33],[17428,17467],{"trials":23779,"activeCount":101},[],{"trials":23781,"activeCount":101},[],{"intervention":23783,"totalTrials":350,"cells":23784},"XELOX",{"EARLY_PHASE1":23785,"PHASE1":23787,"PHASE2":23789,"PHASE3":23791,"PHASE4":23800,"NA":23802},{"trials":23786,"activeCount":101},[],{"trials":23788,"activeCount":101},[],{"trials":23790,"activeCount":101},[],{"trials":23792,"activeCount":101},[23793],{"nctId":23794,"briefTitle":23795,"status":107,"phases":23796,"primaryCompletion":8688,"completion":8688,"start":5457,"enrollment":17519,"conditions":23797,"interventions":23798},"NCT00349336","A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.",[91],[30],[5275,23783,5275,23799],"FOLFOX-4",{"trials":23801,"activeCount":101},[],{"trials":23803,"activeCount":101},[],{"intervention":23799,"totalTrials":350,"cells":23805},{"EARLY_PHASE1":23806,"PHASE1":23808,"PHASE2":23810,"PHASE3":23812,"PHASE4":23818,"NA":23820},{"trials":23807,"activeCount":101},[],{"trials":23809,"activeCount":101},[],{"trials":23811,"activeCount":101},[],{"trials":23813,"activeCount":101},[23814],{"nctId":23794,"briefTitle":23795,"status":107,"phases":23815,"primaryCompletion":8688,"completion":8688,"start":5457,"enrollment":17519,"conditions":23816,"interventions":23817},[91],[30],[5275,23783,5275,23799],{"trials":23819,"activeCount":101},[],{"trials":23821,"activeCount":101},[],{"intervention":8144,"totalTrials":350,"cells":23823},{"EARLY_PHASE1":23824,"PHASE1":23826,"PHASE2":23828,"PHASE3":23830,"PHASE4":23836,"NA":23838},{"trials":23825,"activeCount":101},[],{"trials":23827,"activeCount":101},[],{"trials":23829,"activeCount":101},[],{"trials":23831,"activeCount":101},[23832],{"nctId":8135,"briefTitle":8136,"status":107,"phases":23833,"primaryCompletion":8138,"completion":8139,"start":8140,"enrollment":8141,"conditions":23834,"interventions":23835},[91],[1539],[5297,947,1106,8144],{"trials":23837,"activeCount":101},[],{"trials":23839,"activeCount":101},[],{"intervention":5576,"totalTrials":350,"cells":23841},{"EARLY_PHASE1":23842,"PHASE1":23844,"PHASE2":23846,"PHASE3":23848,"PHASE4":23854,"NA":23856},{"trials":23843,"activeCount":101},[],{"trials":23845,"activeCount":101},[],{"trials":23847,"activeCount":101},[],{"trials":23849,"activeCount":101},[23850],{"nctId":5568,"briefTitle":5569,"status":107,"phases":23851,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":4475,"conditions":23852,"interventions":23853},[91],[5420],[5576,990,1107,1106],{"trials":23855,"activeCount":101},[],{"trials":23857,"activeCount":101},[],{"intervention":4517,"totalTrials":350,"cells":23859},{"EARLY_PHASE1":23860,"PHASE1":23862,"PHASE2":23864,"PHASE3":23866,"PHASE4":23872,"NA":23874},{"trials":23861,"activeCount":101},[],{"trials":23863,"activeCount":101},[],{"trials":23865,"activeCount":101},[],{"trials":23867,"activeCount":101},[23868],{"nctId":4510,"briefTitle":4511,"status":107,"phases":23869,"primaryCompletion":2768,"completion":3174,"start":4513,"enrollment":4514,"conditions":23870,"interventions":23871},[91],[18],[1015,4517],{"trials":23873,"activeCount":101},[],{"trials":23875,"activeCount":101},[],{"intervention":23877,"totalTrials":350,"cells":23878},"tocilizumab SC",{"EARLY_PHASE1":23879,"PHASE1":23881,"PHASE2":23883,"PHASE3":23885,"PHASE4":23896,"NA":23898},{"trials":23880,"activeCount":101},[],{"trials":23882,"activeCount":101},[],{"trials":23884,"activeCount":101},[],{"trials":23886,"activeCount":101},[23887],{"nctId":23888,"briefTitle":23889,"status":107,"phases":23890,"primaryCompletion":3103,"completion":6157,"start":2932,"enrollment":23891,"conditions":23892,"interventions":23893},"NCT01194414","A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra\u002FActemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis",[91],1262,[15],[23877,23894,23895],"tocilizumab IV","Disease-modifying antirheumatic drugs",{"trials":23897,"activeCount":101},[],{"trials":23899,"activeCount":101},[],{"intervention":23894,"totalTrials":350,"cells":23901},{"EARLY_PHASE1":23902,"PHASE1":23904,"PHASE2":23906,"PHASE3":23908,"PHASE4":23914,"NA":23916},{"trials":23903,"activeCount":101},[],{"trials":23905,"activeCount":101},[],{"trials":23907,"activeCount":101},[],{"trials":23909,"activeCount":101},[23910],{"nctId":23888,"briefTitle":23889,"status":107,"phases":23911,"primaryCompletion":3103,"completion":6157,"start":2932,"enrollment":23891,"conditions":23912,"interventions":23913},[91],[15],[23877,23894,23895],{"trials":23915,"activeCount":101},[],{"trials":23917,"activeCount":101},[],{"intervention":23895,"totalTrials":350,"cells":23919},{"EARLY_PHASE1":23920,"PHASE1":23922,"PHASE2":23924,"PHASE3":23926,"PHASE4":23932,"NA":23934},{"trials":23921,"activeCount":101},[],{"trials":23923,"activeCount":101},[],{"trials":23925,"activeCount":101},[],{"trials":23927,"activeCount":101},[23928],{"nctId":23888,"briefTitle":23889,"status":107,"phases":23929,"primaryCompletion":3103,"completion":6157,"start":2932,"enrollment":23891,"conditions":23930,"interventions":23931},[91],[15],[23877,23894,23895],{"trials":23933,"activeCount":101},[],{"trials":23935,"activeCount":101},[],{"intervention":6333,"totalTrials":350,"cells":23937},{"EARLY_PHASE1":23938,"PHASE1":23940,"PHASE2":23942,"PHASE3":23944,"PHASE4":23950,"NA":23952},{"trials":23939,"activeCount":101},[],{"trials":23941,"activeCount":101},[],{"trials":23943,"activeCount":101},[],{"trials":23945,"activeCount":101},[23946],{"nctId":6326,"briefTitle":6327,"status":107,"phases":23947,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":23948,"interventions":23949},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"trials":23951,"activeCount":101},[],{"trials":23953,"activeCount":101},[],{"intervention":6334,"totalTrials":350,"cells":23955},{"EARLY_PHASE1":23956,"PHASE1":23958,"PHASE2":23960,"PHASE3":23962,"PHASE4":23968,"NA":23970},{"trials":23957,"activeCount":101},[],{"trials":23959,"activeCount":101},[],{"trials":23961,"activeCount":101},[],{"trials":23963,"activeCount":101},[23964],{"nctId":6326,"briefTitle":6327,"status":107,"phases":23965,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":703,"conditions":23966,"interventions":23967},[91],[3826],[1785,1359,992,991,1358,6333,1357,6334],{"trials":23969,"activeCount":101},[],{"trials":23971,"activeCount":101},[],{"intervention":18158,"totalTrials":350,"cells":23973},{"EARLY_PHASE1":23974,"PHASE1":23976,"PHASE2":23978,"PHASE3":23980,"PHASE4":23986,"NA":23988},{"trials":23975,"activeCount":101},[],{"trials":23977,"activeCount":101},[],{"trials":23979,"activeCount":101},[],{"trials":23981,"activeCount":101},[23982],{"nctId":18150,"briefTitle":18151,"status":107,"phases":23983,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":23984,"interventions":23985},[91],[193],[18158,18159,18160,17929,18161,18162],{"trials":23987,"activeCount":101},[],{"trials":23989,"activeCount":101},[],{"intervention":18159,"totalTrials":350,"cells":23991},{"EARLY_PHASE1":23992,"PHASE1":23994,"PHASE2":23996,"PHASE3":23998,"PHASE4":24004,"NA":24006},{"trials":23993,"activeCount":101},[],{"trials":23995,"activeCount":101},[],{"trials":23997,"activeCount":101},[],{"trials":23999,"activeCount":101},[24000],{"nctId":18150,"briefTitle":18151,"status":107,"phases":24001,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":24002,"interventions":24003},[91],[193],[18158,18159,18160,17929,18161,18162],{"trials":24005,"activeCount":101},[],{"trials":24007,"activeCount":101},[],{"intervention":18160,"totalTrials":350,"cells":24009},{"EARLY_PHASE1":24010,"PHASE1":24012,"PHASE2":24014,"PHASE3":24016,"PHASE4":24022,"NA":24024},{"trials":24011,"activeCount":101},[],{"trials":24013,"activeCount":101},[],{"trials":24015,"activeCount":101},[],{"trials":24017,"activeCount":101},[24018],{"nctId":18150,"briefTitle":18151,"status":107,"phases":24019,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":24020,"interventions":24021},[91],[193],[18158,18159,18160,17929,18161,18162],{"trials":24023,"activeCount":101},[],{"trials":24025,"activeCount":101},[],{"intervention":18161,"totalTrials":350,"cells":24027},{"EARLY_PHASE1":24028,"PHASE1":24030,"PHASE2":24032,"PHASE3":24034,"PHASE4":24040,"NA":24042},{"trials":24029,"activeCount":101},[],{"trials":24031,"activeCount":101},[],{"trials":24033,"activeCount":101},[],{"trials":24035,"activeCount":101},[24036],{"nctId":18150,"briefTitle":18151,"status":107,"phases":24037,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":24038,"interventions":24039},[91],[193],[18158,18159,18160,17929,18161,18162],{"trials":24041,"activeCount":101},[],{"trials":24043,"activeCount":101},[],{"intervention":18162,"totalTrials":350,"cells":24045},{"EARLY_PHASE1":24046,"PHASE1":24048,"PHASE2":24050,"PHASE3":24052,"PHASE4":24058,"NA":24060},{"trials":24047,"activeCount":101},[],{"trials":24049,"activeCount":101},[],{"trials":24051,"activeCount":101},[],{"trials":24053,"activeCount":101},[24054],{"nctId":18150,"briefTitle":18151,"status":107,"phases":24055,"primaryCompletion":18153,"completion":18154,"start":18155,"enrollment":3247,"conditions":24056,"interventions":24057},[91],[193],[18158,18159,18160,17929,18161,18162],{"trials":24059,"activeCount":101},[],{"trials":24061,"activeCount":101},[],{"intervention":3034,"totalTrials":350,"cells":24063},{"EARLY_PHASE1":24064,"PHASE1":24066,"PHASE2":24068,"PHASE3":24070,"PHASE4":24076,"NA":24078},{"trials":24065,"activeCount":101},[],{"trials":24067,"activeCount":101},[],{"trials":24069,"activeCount":101},[],{"trials":24071,"activeCount":101},[24072],{"nctId":3026,"briefTitle":3027,"status":107,"phases":24073,"primaryCompletion":3029,"completion":3029,"start":3030,"enrollment":3031,"conditions":24074,"interventions":24075},[91],[15],[1096,3034,3035,3036],{"trials":24077,"activeCount":101},[],{"trials":24079,"activeCount":101},[],{"intervention":20900,"totalTrials":350,"cells":24081},{"EARLY_PHASE1":24082,"PHASE1":24084,"PHASE2":24086,"PHASE3":24088,"PHASE4":24094,"NA":24096},{"trials":24083,"activeCount":101},[],{"trials":24085,"activeCount":101},[],{"trials":24087,"activeCount":101},[],{"trials":24089,"activeCount":101},[24090],{"nctId":20894,"briefTitle":20895,"status":107,"phases":24091,"primaryCompletion":5364,"completion":5364,"start":5181,"enrollment":20897,"conditions":24092,"interventions":24093},[91],[19752],[20855,20900],{"trials":24095,"activeCount":101},[],{"trials":24097,"activeCount":101},[],{"intervention":7300,"totalTrials":350,"cells":24099},{"EARLY_PHASE1":24100,"PHASE1":24102,"PHASE2":24104,"PHASE3":24106,"PHASE4":24112,"NA":24114},{"trials":24101,"activeCount":101},[],{"trials":24103,"activeCount":101},[],{"trials":24105,"activeCount":101},[],{"trials":24107,"activeCount":101},[24108],{"nctId":7292,"briefTitle":7293,"status":343,"phases":24109,"primaryCompletion":7295,"completion":2754,"start":7296,"enrollment":101,"conditions":24110,"interventions":24111},[91],[7298],[58,7300],{"trials":24113,"activeCount":101},[],{"trials":24115,"activeCount":101},[],{"intervention":8163,"totalTrials":350,"cells":24117},{"EARLY_PHASE1":24118,"PHASE1":24120,"PHASE2":24122,"PHASE3":24124,"PHASE4":24130,"NA":24132},{"trials":24119,"activeCount":101},[],{"trials":24121,"activeCount":101},[],{"trials":24123,"activeCount":101},[],{"trials":24125,"activeCount":101},[24126],{"nctId":8154,"briefTitle":8155,"status":107,"phases":24127,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":24128,"interventions":24129},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"trials":24131,"activeCount":101},[],{"trials":24133,"activeCount":101},[],{"intervention":8165,"totalTrials":350,"cells":24135},{"EARLY_PHASE1":24136,"PHASE1":24138,"PHASE2":24140,"PHASE3":24142,"PHASE4":24148,"NA":24150},{"trials":24137,"activeCount":101},[],{"trials":24139,"activeCount":101},[],{"trials":24141,"activeCount":101},[],{"trials":24143,"activeCount":101},[24144],{"nctId":8154,"briefTitle":8155,"status":107,"phases":24145,"primaryCompletion":8157,"completion":8158,"start":8159,"enrollment":211,"conditions":24146,"interventions":24147},[91],[5655],[992,991,947,1106,8162,8163,8164,8165,8166],{"trials":24149,"activeCount":101},[],{"trials":24151,"activeCount":101},[],{"intervention":24153,"totalTrials":350,"cells":24154},"Valganciclovir CMV Prophylaxis",{"EARLY_PHASE1":24155,"PHASE1":24157,"PHASE2":24159,"PHASE3":24161,"PHASE4":24170,"NA":24172},{"trials":24156,"activeCount":101},[],{"trials":24158,"activeCount":101},[],{"trials":24160,"activeCount":101},[],{"trials":24162,"activeCount":101},[24163],{"nctId":24164,"briefTitle":24165,"status":107,"phases":24166,"primaryCompletion":8341,"completion":8341,"start":4282,"enrollment":3880,"conditions":24167,"interventions":24168},"NCT00372229","A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation",[91],[17753],[24153,24169,17773],"Valganciclovir",{"trials":24171,"activeCount":101},[],{"trials":24173,"activeCount":101},[],{"intervention":3057,"totalTrials":350,"cells":24175},{"EARLY_PHASE1":24176,"PHASE1":24178,"PHASE2":24180,"PHASE3":24182,"PHASE4":24188,"NA":24190},{"trials":24177,"activeCount":101},[],{"trials":24179,"activeCount":101},[],{"trials":24181,"activeCount":101},[],{"trials":24183,"activeCount":101},[24184],{"nctId":3048,"briefTitle":3049,"status":107,"phases":24185,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":24186,"interventions":24187},[91],[2508],[1096,1357,3057,3058,3059,2824],{"trials":24189,"activeCount":101},[],{"trials":24191,"activeCount":101},[],{"intervention":3058,"totalTrials":350,"cells":24193},{"EARLY_PHASE1":24194,"PHASE1":24196,"PHASE2":24198,"PHASE3":24200,"PHASE4":24206,"NA":24208},{"trials":24195,"activeCount":101},[],{"trials":24197,"activeCount":101},[],{"trials":24199,"activeCount":101},[],{"trials":24201,"activeCount":101},[24202],{"nctId":3048,"briefTitle":3049,"status":107,"phases":24203,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":24204,"interventions":24205},[91],[2508],[1096,1357,3057,3058,3059,2824],{"trials":24207,"activeCount":101},[],{"trials":24209,"activeCount":101},[],{"intervention":3070,"totalTrials":350,"cells":24211},{"EARLY_PHASE1":24212,"PHASE1":24214,"PHASE2":24216,"PHASE3":24218,"PHASE4":24224,"NA":24226},{"trials":24213,"activeCount":101},[],{"trials":24215,"activeCount":101},[],{"trials":24217,"activeCount":101},[],{"trials":24219,"activeCount":101},[24220],{"nctId":3061,"briefTitle":3062,"status":107,"phases":24221,"primaryCompletion":413,"completion":3064,"start":3065,"enrollment":3066,"conditions":24222,"interventions":24223},[91],[3068],[3070,1096],{"trials":24225,"activeCount":101},[],{"trials":24227,"activeCount":101},[],{"intervention":9723,"totalTrials":350,"cells":24229},{"EARLY_PHASE1":24230,"PHASE1":24232,"PHASE2":24234,"PHASE3":24236,"PHASE4":24242,"NA":24244},{"trials":24231,"activeCount":101},[],{"trials":24233,"activeCount":101},[],{"trials":24235,"activeCount":101},[],{"trials":24237,"activeCount":101},[24238],{"nctId":9714,"briefTitle":9715,"status":107,"phases":24239,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":24240,"interventions":24241},[91],[18],[1597,992,947,5619,9723,9724],{"trials":24243,"activeCount":101},[],{"trials":24245,"activeCount":101},[],{"intervention":9724,"totalTrials":350,"cells":24247},{"EARLY_PHASE1":24248,"PHASE1":24250,"PHASE2":24252,"PHASE3":24254,"PHASE4":24260,"NA":24262},{"trials":24249,"activeCount":101},[],{"trials":24251,"activeCount":101},[],{"trials":24253,"activeCount":101},[],{"trials":24255,"activeCount":101},[24256],{"nctId":9714,"briefTitle":9715,"status":107,"phases":24257,"primaryCompletion":9717,"completion":9718,"start":9719,"enrollment":9720,"conditions":24258,"interventions":24259},[91],[18],[1597,992,947,5619,9723,9724],{"trials":24261,"activeCount":101},[],{"trials":24263,"activeCount":101},[],{"intervention":809,"totalTrials":350,"cells":24265},{"EARLY_PHASE1":24266,"PHASE1":24268,"PHASE2":24270,"PHASE3":24272,"PHASE4":24278,"NA":24280},{"trials":24267,"activeCount":101},[],{"trials":24269,"activeCount":101},[],{"trials":24271,"activeCount":101},[],{"trials":24273,"activeCount":101},[24274],{"nctId":801,"briefTitle":802,"status":107,"phases":24275,"primaryCompletion":546,"completion":804,"start":805,"enrollment":806,"conditions":24276,"interventions":24277},[91],[723],[708,809],{"trials":24279,"activeCount":101},[],{"trials":24281,"activeCount":101},[],{"intervention":24283,"totalTrials":350,"cells":24284},"Acitretin",{"EARLY_PHASE1":24285,"PHASE1":24287,"PHASE2":24289,"PHASE3":24291,"PHASE4":24299,"NA":24301},{"trials":24286,"activeCount":101},[],{"trials":24288,"activeCount":101},[],{"trials":24290,"activeCount":101},[],{"trials":24292,"activeCount":101},[24293],{"nctId":24294,"briefTitle":24295,"status":107,"phases":24296,"enrollment":1184,"conditions":24297,"interventions":24298},"NCT00002143","Treatment of Psoriasis Using Acitretin in HIV-Positive Patients",[91],[33,19121],[24283],{"trials":24300,"activeCount":101},[],{"trials":24302,"activeCount":101},[],{"intervention":8467,"totalTrials":350,"cells":24304},{"EARLY_PHASE1":24305,"PHASE1":24307,"PHASE2":24309,"PHASE3":24311,"PHASE4":24317,"NA":24319},{"trials":24306,"activeCount":101},[],{"trials":24308,"activeCount":101},[],{"trials":24310,"activeCount":101},[],{"trials":24312,"activeCount":101},[24313],{"nctId":8462,"briefTitle":8463,"status":107,"phases":24314,"primaryCompletion":3022,"completion":3022,"start":6644,"enrollment":8,"conditions":24315,"interventions":24316},[91],[18],[6647,8467],{"trials":24318,"activeCount":101},[],{"trials":24320,"activeCount":101},[],{"intervention":24322,"totalTrials":350,"cells":24323},"orlistat [Xenical]",{"EARLY_PHASE1":24324,"PHASE1":24326,"PHASE2":24328,"PHASE3":24330,"PHASE4":24338,"NA":24340},{"trials":24325,"activeCount":101},[],{"trials":24327,"activeCount":101},[],{"trials":24329,"activeCount":101},[],{"trials":24331,"activeCount":101},[24332],{"nctId":24333,"briefTitle":24334,"status":107,"phases":24335,"primaryCompletion":2932,"completion":2932,"start":4582,"enrollment":336,"conditions":24336,"interventions":24337},"NCT00940628","A Study of Xenical (Orlistat) in Overweight and Obese Adolescents",[91],[9440],[24322],{"trials":24339,"activeCount":101},[],{"trials":24341,"activeCount":101},[],{"intervention":9064,"totalTrials":350,"cells":24343},{"EARLY_PHASE1":24344,"PHASE1":24346,"PHASE2":24348,"PHASE3":24350,"PHASE4":24356,"NA":24358},{"trials":24345,"activeCount":101},[],{"trials":24347,"activeCount":101},[],{"trials":24349,"activeCount":101},[],{"trials":24351,"activeCount":101},[24352],{"nctId":9058,"briefTitle":9059,"status":107,"phases":24353,"primaryCompletion":2847,"completion":2847,"start":8681,"enrollment":9061,"conditions":24354,"interventions":24355},[91],[1735],[9064,4272,4244,1165],{"trials":24357,"activeCount":101},[],{"trials":24359,"activeCount":101},[],{"intervention":24361,"totalTrials":350,"cells":24362},"MabThera\u002FRituxan",{"EARLY_PHASE1":24363,"PHASE1":24365,"PHASE2":24367,"PHASE3":24369,"PHASE4":24378,"NA":24380},{"trials":24364,"activeCount":101},[],{"trials":24366,"activeCount":101},[],{"trials":24368,"activeCount":101},[],{"trials":24370,"activeCount":101},[24371],{"nctId":24372,"briefTitle":24373,"status":107,"phases":24374,"primaryCompletion":8689,"completion":3007,"start":14446,"enrollment":24375,"conditions":24376,"interventions":24377},"NCT00468546","A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy",[91],520,[15],[24361,2824],{"trials":24379,"activeCount":101},[],{"trials":24381,"activeCount":101},[],{"intervention":21392,"totalTrials":350,"cells":24383},{"EARLY_PHASE1":24384,"PHASE1":24386,"PHASE2":24388,"PHASE3":24390,"PHASE4":24396,"NA":24398},{"trials":24385,"activeCount":101},[],{"trials":24387,"activeCount":101},[],{"trials":24389,"activeCount":101},[],{"trials":24391,"activeCount":101},[24392],{"nctId":21386,"briefTitle":21387,"status":107,"phases":24393,"primaryCompletion":2923,"completion":2923,"start":9499,"enrollment":15617,"conditions":24394,"interventions":24395},[91],[24],[21391,21392,21392],{"trials":24397,"activeCount":101},[],{"trials":24399,"activeCount":101},[],{"intervention":16328,"totalTrials":350,"cells":24401},{"EARLY_PHASE1":24402,"PHASE1":24404,"PHASE2":24406,"PHASE3":24408,"PHASE4":24414,"NA":24416},{"trials":24403,"activeCount":101},[],{"trials":24405,"activeCount":101},[],{"trials":24407,"activeCount":101},[],{"trials":24409,"activeCount":101},[24410],{"nctId":16321,"briefTitle":16322,"status":107,"phases":24411,"primaryCompletion":16324,"completion":16324,"start":1341,"enrollment":16325,"conditions":24412,"interventions":24413},[91],[975],[5384,16328],{"trials":24415,"activeCount":101},[],{"trials":24417,"activeCount":101},[],{"intervention":649,"totalTrials":350,"cells":24419},{"EARLY_PHASE1":24420,"PHASE1":24422,"PHASE2":24424,"PHASE3":24426,"PHASE4":24432,"NA":24434},{"trials":24421,"activeCount":101},[],{"trials":24423,"activeCount":101},[],{"trials":24425,"activeCount":101},[],{"trials":24427,"activeCount":101},[24428],{"nctId":640,"briefTitle":641,"status":107,"phases":24429,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":24430,"interventions":24431},[91],[647],[509,649],{"trials":24433,"activeCount":101},[],{"trials":24435,"activeCount":101},[],{"intervention":6362,"totalTrials":350,"cells":24437},{"EARLY_PHASE1":24438,"PHASE1":24440,"PHASE2":24442,"PHASE3":24444,"PHASE4":24450,"NA":24452},{"trials":24439,"activeCount":101},[],{"trials":24441,"activeCount":101},[],{"trials":24443,"activeCount":101},[],{"trials":24445,"activeCount":101},[24446],{"nctId":6353,"briefTitle":6354,"status":107,"phases":24447,"primaryCompletion":6356,"completion":6357,"start":6358,"enrollment":3295,"conditions":24448,"interventions":24449},[91],[6360],[6362,3707,1359,6363],{"trials":24451,"activeCount":101},[],{"trials":24453,"activeCount":101},[],{"intervention":6363,"totalTrials":350,"cells":24455},{"EARLY_PHASE1":24456,"PHASE1":24458,"PHASE2":24460,"PHASE3":24462,"PHASE4":24468,"NA":24470},{"trials":24457,"activeCount":101},[],{"trials":24459,"activeCount":101},[],{"trials":24461,"activeCount":101},[],{"trials":24463,"activeCount":101},[24464],{"nctId":6353,"briefTitle":6354,"status":107,"phases":24465,"primaryCompletion":6356,"completion":6357,"start":6358,"enrollment":3295,"conditions":24466,"interventions":24467},[91],[6360],[6362,3707,1359,6363],{"trials":24469,"activeCount":101},[],{"trials":24471,"activeCount":101},[],{"intervention":24473,"totalTrials":350,"cells":24474},"Oxaliplatin 130 mg\u002Fm^2",{"EARLY_PHASE1":24475,"PHASE1":24477,"PHASE2":24479,"PHASE3":24481,"PHASE4":24496,"NA":24498},{"trials":24476,"activeCount":101},[],{"trials":24478,"activeCount":101},[],{"trials":24480,"activeCount":101},[],{"trials":24482,"activeCount":101},[24483],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24486,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24488,"interventions":24489},"NCT00069095","A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer",[91],2035,[30],[24473,24490,24491,24492,24493,24494,24495],"Capecitabine 1000 mg\u002Fm^2","Bevacizumab 7.5 mg\u002Fkg","Oxaliplatin 85 mg\u002Fm^2","Leucovorin 200 mg\u002Fm^2","Fluorouracil 400 mg\u002Fm^2","Bevacizumab 5 mg\u002Fkg",{"trials":24497,"activeCount":101},[],{"trials":24499,"activeCount":101},[],{"intervention":24490,"totalTrials":350,"cells":24501},{"EARLY_PHASE1":24502,"PHASE1":24504,"PHASE2":24506,"PHASE3":24508,"PHASE4":24514,"NA":24516},{"trials":24503,"activeCount":101},[],{"trials":24505,"activeCount":101},[],{"trials":24507,"activeCount":101},[],{"trials":24509,"activeCount":101},[24510],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24511,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24512,"interventions":24513},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24515,"activeCount":101},[],{"trials":24517,"activeCount":101},[],{"intervention":24491,"totalTrials":350,"cells":24519},{"EARLY_PHASE1":24520,"PHASE1":24522,"PHASE2":24524,"PHASE3":24526,"PHASE4":24532,"NA":24534},{"trials":24521,"activeCount":101},[],{"trials":24523,"activeCount":101},[],{"trials":24525,"activeCount":101},[],{"trials":24527,"activeCount":101},[24528],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24529,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24530,"interventions":24531},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24533,"activeCount":101},[],{"trials":24535,"activeCount":101},[],{"intervention":24492,"totalTrials":350,"cells":24537},{"EARLY_PHASE1":24538,"PHASE1":24540,"PHASE2":24542,"PHASE3":24544,"PHASE4":24550,"NA":24552},{"trials":24539,"activeCount":101},[],{"trials":24541,"activeCount":101},[],{"trials":24543,"activeCount":101},[],{"trials":24545,"activeCount":101},[24546],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24547,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24548,"interventions":24549},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24551,"activeCount":101},[],{"trials":24553,"activeCount":101},[],{"intervention":24493,"totalTrials":350,"cells":24555},{"EARLY_PHASE1":24556,"PHASE1":24558,"PHASE2":24560,"PHASE3":24562,"PHASE4":24568,"NA":24570},{"trials":24557,"activeCount":101},[],{"trials":24559,"activeCount":101},[],{"trials":24561,"activeCount":101},[],{"trials":24563,"activeCount":101},[24564],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24565,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24566,"interventions":24567},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24569,"activeCount":101},[],{"trials":24571,"activeCount":101},[],{"intervention":24494,"totalTrials":350,"cells":24573},{"EARLY_PHASE1":24574,"PHASE1":24576,"PHASE2":24578,"PHASE3":24580,"PHASE4":24586,"NA":24588},{"trials":24575,"activeCount":101},[],{"trials":24577,"activeCount":101},[],{"trials":24579,"activeCount":101},[],{"trials":24581,"activeCount":101},[24582],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24583,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24584,"interventions":24585},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24587,"activeCount":101},[],{"trials":24589,"activeCount":101},[],{"intervention":24495,"totalTrials":350,"cells":24591},{"EARLY_PHASE1":24592,"PHASE1":24594,"PHASE2":24596,"PHASE3":24598,"PHASE4":24604,"NA":24606},{"trials":24593,"activeCount":101},[],{"trials":24595,"activeCount":101},[],{"trials":24597,"activeCount":101},[],{"trials":24599,"activeCount":101},[24600],{"nctId":24484,"briefTitle":24485,"status":107,"phases":24601,"primaryCompletion":8977,"completion":4322,"start":6316,"enrollment":24487,"conditions":24602,"interventions":24603},[91],[30],[24473,24490,24491,24492,24493,24494,24495],{"trials":24605,"activeCount":101},[],{"trials":24607,"activeCount":101},[],{"intervention":835,"totalTrials":350,"cells":24609},{"EARLY_PHASE1":24610,"PHASE1":24612,"PHASE2":24614,"PHASE3":24616,"PHASE4":24622,"NA":24624},{"trials":24611,"activeCount":101},[],{"trials":24613,"activeCount":101},[],{"trials":24615,"activeCount":101},[],{"trials":24617,"activeCount":101},[24618],{"nctId":826,"briefTitle":827,"status":107,"phases":24619,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":24620,"interventions":24621},[91],[723],[708,835,836],{"trials":24623,"activeCount":101},[],{"trials":24625,"activeCount":101},[],{"intervention":836,"totalTrials":350,"cells":24627},{"EARLY_PHASE1":24628,"PHASE1":24630,"PHASE2":24632,"PHASE3":24634,"PHASE4":24640,"NA":24642},{"trials":24629,"activeCount":101},[],{"trials":24631,"activeCount":101},[],{"trials":24633,"activeCount":101},[],{"trials":24635,"activeCount":101},[24636],{"nctId":826,"briefTitle":827,"status":107,"phases":24637,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":24638,"interventions":24639},[91],[723],[708,835,836],{"trials":24641,"activeCount":101},[],{"trials":24643,"activeCount":101},[],{"intervention":11967,"totalTrials":2289,"cells":24645},{"EARLY_PHASE1":24646,"PHASE1":24648,"PHASE2":24720,"PHASE3":24742,"PHASE4":24744,"NA":24746},{"trials":24647,"activeCount":101},[],{"trials":24649,"activeCount":101},[24650,24654,24658,24662,24666,24670,24674,24678,24682,24688,24692,24696,24700,24704,24708,24712,24716],{"nctId":19227,"briefTitle":19228,"status":107,"phases":24651,"primaryCompletion":7152,"completion":7152,"start":7095,"enrollment":5901,"conditions":24652,"interventions":24653},[89],[21],[11967,11483,11969],{"nctId":11962,"briefTitle":11963,"status":107,"phases":24655,"primaryCompletion":3189,"completion":3189,"start":4314,"enrollment":8206,"conditions":24656,"interventions":24657},[89],[21],[11967,418,11968,11969],{"nctId":19237,"briefTitle":19238,"status":107,"phases":24659,"primaryCompletion":8681,"completion":8681,"start":3007,"enrollment":395,"conditions":24660,"interventions":24661},[89],[21],[11967,11967,11969],{"nctId":19243,"briefTitle":19244,"status":107,"phases":24663,"primaryCompletion":3213,"completion":3213,"start":2793,"enrollment":931,"conditions":24664,"interventions":24665},[89],[21],[11967,19248,11969],{"nctId":19250,"briefTitle":19251,"status":107,"phases":24667,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":931,"conditions":24668,"interventions":24669},[89],[21],[19255,11967,11969,19256],{"nctId":19258,"briefTitle":19259,"status":107,"phases":24671,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":2572,"conditions":24672,"interventions":24673},[89],[27],[11967,17072,19263,11969],{"nctId":17262,"briefTitle":17263,"status":107,"phases":24675,"primaryCompletion":2768,"completion":2768,"start":2905,"enrollment":5901,"conditions":24676,"interventions":24677},[89],[21],[5850,11967,11969],{"nctId":19269,"briefTitle":19270,"status":107,"phases":24679,"primaryCompletion":3103,"completion":3103,"start":2905,"enrollment":1058,"conditions":24680,"interventions":24681},[89],[21],[11967,11967,11967,11969,11969,11969],{"nctId":24683,"briefTitle":24684,"status":107,"phases":24685,"primaryCompletion":4555,"completion":4555,"start":8688,"enrollment":736,"conditions":24686,"interventions":24687},"NCT00801255","A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591\u002FDanoprevir) in Genotype 1 Chronic Hepatitis C Patients",[89],[27],[17034,11967,11967,11967,11967,11967],{"nctId":19275,"briefTitle":19276,"status":107,"phases":24689,"primaryCompletion":4445,"completion":4445,"start":8681,"enrollment":5901,"conditions":24690,"interventions":24691},[89],[21],[11967,11969,19280],{"nctId":19282,"briefTitle":19283,"status":107,"phases":24693,"primaryCompletion":3175,"completion":3175,"start":2768,"enrollment":931,"conditions":24694,"interventions":24695},[89],[21],[11967,19287,11969],{"nctId":19296,"briefTitle":19297,"status":107,"phases":24697,"primaryCompletion":3212,"completion":3212,"start":4233,"enrollment":6432,"conditions":24698,"interventions":24699},[89],[21],[11967,11969],{"nctId":19309,"briefTitle":19310,"status":107,"phases":24701,"primaryCompletion":3189,"completion":3189,"start":9079,"enrollment":2375,"conditions":24702,"interventions":24703},[89],[21],[11967,19314,11969],{"nctId":19328,"briefTitle":19329,"status":107,"phases":24705,"primaryCompletion":3175,"completion":3175,"start":3103,"enrollment":2375,"conditions":24706,"interventions":24707},[89],[21],[11967,19333,11969],{"nctId":19335,"briefTitle":19336,"status":107,"phases":24709,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":1733,"conditions":24710,"interventions":24711},[89],[21],[11967,11967,11969,11969],{"nctId":19341,"briefTitle":19342,"status":107,"phases":24713,"primaryCompletion":4314,"completion":4314,"start":8320,"enrollment":5901,"conditions":24714,"interventions":24715},[89],[21],[11967,19346,11969],{"nctId":19348,"briefTitle":19349,"status":107,"phases":24717,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":24718,"interventions":24719},[89],[21],[11967,11967,19353,19354,19355,11969,19356],{"trials":24721,"activeCount":101},[24722,24726,24730,24734,24738],{"nctId":19360,"briefTitle":19361,"status":343,"phases":24723,"primaryCompletion":3197,"completion":3197,"start":3007,"enrollment":101,"conditions":24724,"interventions":24725},[90],[27],[17034,17034,11967,17072,17976,11969],{"nctId":17021,"briefTitle":17022,"status":107,"phases":24727,"primaryCompletion":2948,"completion":2948,"start":5181,"enrollment":16946,"conditions":24728,"interventions":24729},[90],[27],[16996,17026,17026,17026,17011,11782],{"nctId":19387,"briefTitle":19388,"status":107,"phases":24731,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":24732,"interventions":24733},[90],[27],[19392,17034,11967,17072,17976,11969],{"nctId":17045,"briefTitle":17046,"status":107,"phases":24735,"primaryCompletion":4249,"completion":4249,"start":2931,"enrollment":17048,"conditions":24736,"interventions":24737},[90],[27],[16996,16996,17011,17011,17034,11967,11969],{"nctId":19398,"briefTitle":19399,"status":107,"phases":24739,"primaryCompletion":2684,"completion":2684,"start":2793,"enrollment":1385,"conditions":24740,"interventions":24741},[90],[27],[17034,11967,17072,19263,11969],{"trials":24743,"activeCount":101},[],{"trials":24745,"activeCount":101},[],{"trials":24747,"activeCount":101},[],{"intervention":24749,"totalTrials":462,"cells":24750},"RO4917523",{"EARLY_PHASE1":24751,"PHASE1":24753,"PHASE2":24801,"PHASE3":24823,"PHASE4":24825,"NA":24827},{"trials":24752,"activeCount":101},[],{"trials":24754,"activeCount":101},[24755,24762,24768,24775,24781,24788,24794],{"nctId":24756,"briefTitle":24757,"status":107,"phases":24758,"primaryCompletion":4454,"completion":4454,"start":2905,"enrollment":1272,"conditions":24759,"interventions":24760},"NCT01483469","A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers",[89],[21],[24749,24761],"RO5011232",{"nctId":24763,"briefTitle":24764,"status":107,"phases":24765,"primaryCompletion":2801,"completion":2801,"start":2793,"enrollment":942,"conditions":24766,"interventions":24767},"NCT01592890","A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers",[89],[21],[24749,24749],{"nctId":24769,"briefTitle":24770,"status":107,"phases":24771,"primaryCompletion":8320,"completion":8320,"start":4206,"enrollment":97,"conditions":24772,"interventions":24773},"NCT01045083","A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers",[89],[21],[24749,19314,24774],"methylphenidate",{"nctId":24776,"briefTitle":24777,"status":107,"phases":24778,"primaryCompletion":2685,"completion":2685,"start":8320,"enrollment":1733,"conditions":24779,"interventions":24780},"NCT01368926","A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects",[89],[21],[24749,24749],{"nctId":24782,"briefTitle":24783,"status":107,"phases":24784,"primaryCompletion":3146,"completion":3146,"start":3213,"enrollment":721,"conditions":24785,"interventions":24786},"NCT01629368","A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers",[89],[21],[24787,24749],"Carbamazepine",{"nctId":24789,"briefTitle":24790,"status":107,"phases":24791,"primaryCompletion":6157,"completion":6157,"start":10332,"enrollment":425,"conditions":24792,"interventions":24793},"NCT01873508","A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers",[89],[21],[24749,24749,24749,24749],{"nctId":24795,"briefTitle":24796,"status":107,"phases":24797,"primaryCompletion":3146,"completion":3146,"start":3007,"enrollment":721,"conditions":24798,"interventions":24799},"NCT01665404","A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers",[89],[21],[24800,24749],"Fluvoxamine",{"trials":24802,"activeCount":101},[24803,24810,24816],{"nctId":24804,"briefTitle":24805,"status":107,"phases":24806,"primaryCompletion":5891,"completion":5891,"start":3084,"enrollment":931,"conditions":24807,"interventions":24809},"NCT01015430","A Study With RO4917523 in Patients With Fragile X Syndrome",[90],[24808],"Fragile X Syndrome",[24749,24749],{"nctId":24811,"briefTitle":24812,"status":107,"phases":24813,"primaryCompletion":11437,"completion":11437,"start":132,"enrollment":1092,"conditions":24814,"interventions":24815},"NCT01750957","A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome",[90],[24808],[24749,24749],{"nctId":24817,"briefTitle":24818,"status":107,"phases":24819,"primaryCompletion":4233,"completion":4233,"start":3325,"enrollment":1204,"conditions":24820,"interventions":24822},"NCT00809562","A Study of RO4917523 in Patients With Treatment Resistant Depression",[90],[24821],"Depression",[24749],{"trials":24824,"activeCount":101},[],{"trials":24826,"activeCount":101},[],{"trials":24828,"activeCount":101},[],{"intervention":17034,"totalTrials":462,"cells":24830},{"EARLY_PHASE1":24831,"PHASE1":24833,"PHASE2":24851,"PHASE3":24884,"PHASE4":24886,"NA":24888},{"trials":24832,"activeCount":101},[],{"trials":24834,"activeCount":101},[24835,24841,24845],{"nctId":24836,"briefTitle":24837,"status":107,"phases":24838,"primaryCompletion":2932,"completion":2932,"start":4555,"enrollment":1184,"conditions":24839,"interventions":24840},"NCT01099904","A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048",[89],[21],[17034],{"nctId":24683,"briefTitle":24684,"status":107,"phases":24842,"primaryCompletion":4555,"completion":4555,"start":8688,"enrollment":736,"conditions":24843,"interventions":24844},[89],[27],[17034,11967,11967,11967,11967,11967],{"nctId":24846,"briefTitle":24847,"status":107,"phases":24848,"completion":7152,"start":4409,"enrollment":8990,"conditions":24849,"interventions":24850},"NCT01152671","A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers",[89],[21],[17034],{"trials":24852,"activeCount":101},[24853,24857,24861,24865,24869,24873,24880],{"nctId":19360,"briefTitle":19361,"status":343,"phases":24854,"primaryCompletion":3197,"completion":3197,"start":3007,"enrollment":101,"conditions":24855,"interventions":24856},[90],[27],[17034,17034,11967,17072,17976,11969],{"nctId":17028,"briefTitle":17029,"status":107,"phases":24858,"primaryCompletion":2768,"completion":2768,"start":6135,"enrollment":17031,"conditions":24859,"interventions":24860},[90],[27],[16996,16996,17011,17011,17034,17034,17034,17034],{"nctId":19380,"briefTitle":19381,"status":107,"phases":24862,"primaryCompletion":2956,"completion":2956,"start":3213,"enrollment":1283,"conditions":24863,"interventions":24864},[90],[27],[17034,17019,19385,17976,11969],{"nctId":19387,"briefTitle":19388,"status":107,"phases":24866,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":24867,"interventions":24868},[90],[27],[19392,17034,11967,17072,17976,11969],{"nctId":17045,"briefTitle":17046,"status":107,"phases":24870,"primaryCompletion":4249,"completion":4249,"start":2931,"enrollment":17048,"conditions":24871,"interventions":24872},[90],[27],[16996,16996,17011,17011,17034,11967,11969],{"nctId":24874,"briefTitle":24875,"status":107,"phases":24876,"primaryCompletion":2793,"completion":2793,"start":6578,"enrollment":4489,"conditions":24877,"interventions":24878},"NCT01057667","A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4",[90],[27],[17034,24879,17072],"Ribavirin [Copegus]",{"nctId":19398,"briefTitle":19399,"status":107,"phases":24881,"primaryCompletion":2684,"completion":2684,"start":2793,"enrollment":1385,"conditions":24882,"interventions":24883},[90],[27],[17034,11967,17072,19263,11969],{"trials":24885,"activeCount":101},[],{"trials":24887,"activeCount":101},[],{"trials":24889,"activeCount":101},[],{"intervention":5379,"totalTrials":1796,"cells":24891},{"EARLY_PHASE1":24892,"PHASE1":24894,"PHASE2":24925,"PHASE3":24947,"PHASE4":24949,"NA":24951},{"trials":24893,"activeCount":101},[],{"trials":24895,"activeCount":101},[24896,24902,24908,24914,24918],{"nctId":24897,"briefTitle":24898,"status":107,"phases":24899,"primaryCompletion":4474,"completion":4474,"start":4488,"enrollment":306,"conditions":24900,"interventions":24901},"NCT00882674","A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer",[89],[18],[5379],{"nctId":24903,"briefTitle":24904,"status":107,"phases":24905,"primaryCompletion":14712,"completion":14712,"start":8810,"enrollment":1215,"conditions":24906,"interventions":24907},"NCT00400361","A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.",[89],[1241],[5379],{"nctId":24909,"briefTitle":24910,"status":107,"phases":24911,"primaryCompletion":2905,"completion":2905,"start":4513,"enrollment":1705,"conditions":24912,"interventions":24913},"NCT00560144","A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.",[89],[1241],[5379,5379,5379],{"nctId":5373,"briefTitle":5374,"status":130,"phases":24915,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":24916,"interventions":24917},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"nctId":24919,"briefTitle":24920,"status":130,"phases":24921,"primaryCompletion":10332,"completion":10332,"start":3084,"enrollment":2563,"conditions":24922,"interventions":24923},"NCT00985374","A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors",[89],[1241],[24924,5379],"RAD001",{"trials":24926,"activeCount":101},[24927,24931,24935,24939],{"nctId":16208,"briefTitle":16209,"status":130,"phases":24928,"primaryCompletion":6578,"completion":6578,"start":8688,"enrollment":384,"conditions":24929,"interventions":24930},[90],[975],[5379,5384],{"nctId":16255,"briefTitle":16256,"status":130,"phases":24932,"primaryCompletion":16258,"completion":16258,"start":16259,"enrollment":16260,"conditions":24933,"interventions":24934},[90],[2257],[5379,5379,5384],{"nctId":7720,"briefTitle":7721,"status":130,"phases":24936,"primaryCompletion":7723,"completion":7723,"start":7724,"enrollment":942,"conditions":24937,"interventions":24938},[90],[18],[5379,1422],{"nctId":24940,"briefTitle":24941,"status":130,"phases":24942,"primaryCompletion":24943,"completion":24943,"start":24944,"enrollment":15639,"conditions":24945,"interventions":24946},"NCT00642941","A Study of R1507 in Participants With Recurrent or Refractory Sarcoma",[90],"2014-02-19","2007-12-18",[4856],[5379],{"trials":24948,"activeCount":101},[],{"trials":24950,"activeCount":101},[],{"trials":24952,"activeCount":101},[],{"intervention":13159,"totalTrials":306,"cells":24954},{"EARLY_PHASE1":24955,"PHASE1":24957,"PHASE2":24986,"PHASE3":25008,"PHASE4":25010,"NA":25012},{"trials":24956,"activeCount":101},[],{"trials":24958,"activeCount":101},[24959,24965,24972,24980],{"nctId":24960,"briefTitle":24961,"status":107,"phases":24962,"primaryCompletion":8484,"completion":8484,"start":5457,"enrollment":395,"conditions":24963,"interventions":24964},"NCT00377442","A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.",[89],[36],[13159,15424],{"nctId":24966,"briefTitle":24967,"status":107,"phases":24968,"primaryCompletion":4315,"completion":4315,"start":13171,"enrollment":5901,"conditions":24969,"interventions":24970},"NCT00388986","A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.",[89],[36],[13159,24971],"Glyburide",{"nctId":24973,"briefTitle":24974,"status":130,"phases":24975,"primaryCompletion":6377,"completion":6377,"start":7096,"enrollment":162,"conditions":24976,"interventions":24978},"NCT00437606","A Study of the Pharmacokinetics\u002FPharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.",[89],[24977],"Diabetes Mellitus, Type 2",[13159,24979],"Ethanol",{"nctId":24981,"briefTitle":24982,"status":107,"phases":24983,"primaryCompletion":6673,"completion":6673,"start":8977,"enrollment":2631,"conditions":24984,"interventions":24985},"NCT00368368","A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.",[89],[36],[13159],{"trials":24987,"activeCount":101},[24988,24992,24996,25002],{"nctId":13154,"briefTitle":13155,"status":107,"phases":24989,"primaryCompletion":2965,"completion":2965,"start":4446,"enrollment":483,"conditions":24990,"interventions":24991},[90],[36],[13159,1576],{"nctId":13161,"briefTitle":13162,"status":107,"phases":24993,"primaryCompletion":7096,"completion":7096,"start":13164,"enrollment":6872,"conditions":24994,"interventions":24995},[90],[36],[13159,1576],{"nctId":24997,"briefTitle":24998,"status":107,"phases":24999,"primaryCompletion":6620,"completion":6620,"start":13164,"enrollment":3685,"conditions":25000,"interventions":25001},"NCT00266240","A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus",[90],[36],[13159],{"nctId":25003,"briefTitle":25004,"status":107,"phases":25005,"primaryCompletion":6377,"completion":6377,"start":9771,"enrollment":7408,"conditions":25006,"interventions":25007},"NCT00366379","A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.",[90],[36],[13159],{"trials":25009,"activeCount":101},[],{"trials":25011,"activeCount":101},[],{"trials":25013,"activeCount":101},[],{"intervention":13150,"totalTrials":4548,"cells":25015},{"EARLY_PHASE1":25016,"PHASE1":25018,"PHASE2":25059,"PHASE3":25068,"PHASE4":25070,"NA":25072},{"trials":25017,"activeCount":101},[],{"trials":25019,"activeCount":101},[25020,25027,25034,25041,25047,25051],{"nctId":25021,"briefTitle":25022,"status":107,"phases":25023,"primaryCompletion":4454,"completion":4454,"start":15695,"enrollment":372,"conditions":25024,"interventions":25026},"NCT01667367","A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662",[89],[25025],"Healthy Volunteer, Down Syndrome",[13150],{"nctId":25028,"briefTitle":25029,"status":107,"phases":25030,"primaryCompletion":3246,"completion":3246,"start":3246,"enrollment":5901,"conditions":25031,"interventions":25032},"NCT02194244","Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662",[89],[21],[25033,13150],"RG1662 granules",{"nctId":25035,"briefTitle":25036,"status":107,"phases":25037,"primaryCompletion":2684,"completion":2684,"start":2685,"enrollment":384,"conditions":25038,"interventions":25040},"NCT01436955","A Study of RG1662 in Individuals With Down Syndrome",[89],[25039],"Down Syndrome",[13150],{"nctId":25042,"briefTitle":25043,"status":107,"phases":25044,"primaryCompletion":2809,"completion":2809,"start":3146,"enrollment":942,"conditions":25045,"interventions":25046},"NCT01684891","A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers",[89],[21],[13150],{"nctId":13145,"briefTitle":13146,"status":107,"phases":25048,"primaryCompletion":2947,"completion":2947,"start":3006,"enrollment":510,"conditions":25049,"interventions":25050},[89],[21],[13150,13131],{"nctId":25052,"briefTitle":25053,"status":107,"phases":25054,"primaryCompletion":2792,"completion":2792,"start":2947,"enrollment":709,"conditions":25055,"interventions":25057},"NCT02470832","A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects",[89],[25056],"Healthy Patient Study",[13150,25058],"itraconazole",{"trials":25060,"activeCount":101},[25061],{"nctId":25062,"briefTitle":25063,"status":107,"phases":25064,"primaryCompletion":6401,"completion":6401,"start":25065,"enrollment":12803,"conditions":25066,"interventions":25067},"NCT02024789","A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)",[90],"2014-05-05",[25039],[13150,13150],{"trials":25069,"activeCount":101},[],{"trials":25071,"activeCount":101},[],{"trials":25073,"activeCount":101},[],{"intervention":25075,"totalTrials":942,"cells":25076},"RO5185426",{"EARLY_PHASE1":25077,"PHASE1":25079,"PHASE2":25107,"PHASE3":25124,"PHASE4":25126,"NA":25128},{"trials":25078,"activeCount":101},[],{"trials":25080,"activeCount":101},[25081,25087,25093,25099],{"nctId":25082,"briefTitle":25083,"status":107,"phases":25084,"primaryCompletion":4445,"completion":4445,"start":5891,"enrollment":721,"conditions":25085,"interventions":25086},"NCT01264380","A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma",[89],[1261],[25075,25075,25075],{"nctId":25088,"briefTitle":25089,"status":107,"phases":25090,"primaryCompletion":2948,"completion":2948,"start":7095,"enrollment":4548,"conditions":25091,"interventions":25092},"NCT01164891","A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma",[89],[1261],[25075],{"nctId":25094,"briefTitle":25095,"status":107,"phases":25096,"primaryCompletion":132,"completion":132,"start":3104,"enrollment":973,"conditions":25097,"interventions":25098},"NCT01107418","A Pharmacokinetic\u002FPharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma",[89],[1261],[25075,25075,25075,25075,25075],{"nctId":25100,"briefTitle":25101,"status":107,"phases":25102,"primaryCompletion":25103,"completion":25103,"start":2916,"enrollment":97,"conditions":25104,"interventions":25105},"NCT01001299","A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma",[89],"2012-02-29",[1261],[25106,25075],"Drug cocktail",{"trials":25108,"activeCount":101},[25109,25117],{"nctId":25110,"briefTitle":25111,"status":107,"phases":25112,"primaryCompletion":25113,"completion":25113,"start":25114,"enrollment":425,"conditions":25115,"interventions":25116},"NCT01253564","A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases",[90],"2012-03-14","2010-11-22",[1261],[25075],{"nctId":25118,"briefTitle":25119,"status":107,"phases":25120,"primaryCompletion":6315,"completion":6315,"start":4474,"enrollment":25121,"conditions":25122,"interventions":25123},"NCT01248936","A Study of RO5185426 in Patients With Metastatic Melanoma",[90],374,[1261],[25075],{"trials":25125,"activeCount":101},[],{"trials":25127,"activeCount":101},[],{"trials":25129,"activeCount":101},[],{"intervention":5184,"totalTrials":2631,"cells":25131},{"EARLY_PHASE1":25132,"PHASE1":25134,"PHASE2":25150,"PHASE3":25160,"PHASE4":25162,"NA":25164},{"trials":25133,"activeCount":101},[],{"trials":25135,"activeCount":101},[25136,25140,25144],{"nctId":5361,"briefTitle":5362,"status":343,"phases":25137,"primaryCompletion":2602,"completion":2602,"start":5364,"enrollment":101,"conditions":25138,"interventions":25139},[89],[2257],[5184,5367,5185,5186,4503],{"nctId":14700,"briefTitle":14701,"status":107,"phases":25141,"primaryCompletion":3213,"completion":3213,"start":3084,"enrollment":447,"conditions":25142,"interventions":25143},[89],[14704],[5184,5382],{"nctId":25145,"briefTitle":25146,"status":107,"phases":25147,"primaryCompletion":8320,"completion":8320,"start":14572,"enrollment":3247,"conditions":25148,"interventions":25149},"NCT00721266","A Dose-Escalation Study of RO5083945 in Patients With Metastatic and\u002For Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.",[89],[1241],[5184],{"trials":25151,"activeCount":101},[25152,25156],{"nctId":14709,"briefTitle":14710,"status":107,"phases":25153,"primaryCompletion":3212,"completion":3212,"start":14712,"enrollment":1406,"conditions":25154,"interventions":25155},[90],[30],[1142,5184,5382],{"nctId":5178,"briefTitle":5179,"status":107,"phases":25157,"primaryCompletion":3146,"completion":3146,"start":5181,"enrollment":2743,"conditions":25158,"interventions":25159},[90],[2257],[5184,5185,5186,5187],{"trials":25161,"activeCount":101},[],{"trials":25163,"activeCount":101},[],{"trials":25165,"activeCount":101},[],{"intervention":25167,"totalTrials":2631,"cells":25168},"RO4995819",{"EARLY_PHASE1":25169,"PHASE1":25171,"PHASE2":25199,"PHASE3":25208,"PHASE4":25210,"NA":25212},{"trials":25170,"activeCount":101},[],{"trials":25172,"activeCount":101},[25173,25180,25187,25193],{"nctId":25174,"briefTitle":25175,"status":107,"phases":25176,"primaryCompletion":3189,"completion":3189,"start":2931,"enrollment":8206,"conditions":25177,"interventions":25178},"NCT01367756","A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers",[89],[21],[25167,25179],"citalopram",{"nctId":25181,"briefTitle":25182,"status":107,"phases":25183,"primaryCompletion":2768,"completion":2768,"start":9079,"enrollment":316,"conditions":25184,"interventions":25185},"NCT01409369","A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819",[89],[21],[25167,25186],"activated charcoal",{"nctId":25188,"briefTitle":25189,"status":107,"phases":25190,"primaryCompletion":2905,"completion":2905,"start":4314,"enrollment":1184,"conditions":25191,"interventions":25192},"NCT01457664","A Study of RO4995819 in Healthy Elderly Volunteers",[89],[21],[25167],{"nctId":25194,"briefTitle":25195,"status":107,"phases":25196,"primaryCompletion":2956,"completion":2956,"start":10332,"enrollment":973,"conditions":25197,"interventions":25198},"NCT01901159","A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers",[89],[21],[25167,25167],{"trials":25200,"activeCount":101},[25201],{"nctId":25202,"briefTitle":25203,"status":107,"phases":25204,"primaryCompletion":3174,"completion":3174,"start":2905,"enrollment":11684,"conditions":25205,"interventions":25207},"NCT01457677","ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment",[90],[25206],"Major Depressive Disorder",[25167,25167,25167],{"trials":25209,"activeCount":101},[],{"trials":25211,"activeCount":101},[],{"trials":25213,"activeCount":101},[],{"intervention":25215,"totalTrials":2631,"cells":25216},"RO4602522",{"EARLY_PHASE1":25217,"PHASE1":25219,"PHASE2":25248,"PHASE3":25262,"PHASE4":25264,"NA":25266},{"trials":25218,"activeCount":101},[],{"trials":25220,"activeCount":101},[25221,25227,25233,25240],{"nctId":25222,"briefTitle":25223,"status":107,"phases":25224,"primaryCompletion":3213,"completion":3213,"start":3213,"enrollment":942,"conditions":25225,"interventions":25226},"NCT01631422","A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers",[89],[21],[25215],{"nctId":25228,"briefTitle":25229,"status":107,"phases":25230,"primaryCompletion":2948,"completion":2948,"start":3007,"enrollment":1705,"conditions":25231,"interventions":25232},"NCT01625806","A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers",[89],[21],[25215,11483],{"nctId":25234,"briefTitle":25235,"status":107,"phases":25236,"primaryCompletion":3246,"completion":3246,"start":11437,"enrollment":25237,"conditions":25238,"interventions":25239},"NCT02104648","A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval",[89],203,[21],[25215,25215,19354],{"nctId":25241,"briefTitle":25242,"status":107,"phases":25243,"primaryCompletion":4445,"completion":4445,"start":3146,"enrollment":510,"conditions":25244,"interventions":25246},"NCT01701089","A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers",[89],[25245],"Healthy Volunteer, Alzheimer's Disease",[25247,25215,25215],"11C-L-deprenyl-D2",{"trials":25249,"activeCount":101},[25250],{"nctId":25251,"briefTitle":25252,"status":107,"phases":25253,"primaryCompletion":25254,"completion":25254,"start":25255,"enrollment":1133,"conditions":25256,"interventions":25257},"NCT01677754","A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy",[90],"2015-06-12","2012-10-24",[14384],[25215,25258,25259,25260,25261],"Donepezil","Memantine","Rivastigmine","Galantamine",{"trials":25263,"activeCount":101},[],{"trials":25265,"activeCount":101},[],{"trials":25267,"activeCount":101},[],{"intervention":19325,"totalTrials":2631,"cells":25269},{"EARLY_PHASE1":25270,"PHASE1":25272,"PHASE2":25293,"PHASE3":25309,"PHASE4":25311,"NA":25313},{"trials":25271,"activeCount":101},[],{"trials":25273,"activeCount":101},[25274,25282,25286],{"nctId":25275,"briefTitle":25276,"status":107,"phases":25277,"primaryCompletion":2560,"completion":2560,"start":25278,"enrollment":909,"conditions":25279,"interventions":25280},"NCT02622334","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).",[89],"2015-12-29",[20786],[25281,19325],"Latanoprost",{"nctId":19320,"briefTitle":19321,"status":107,"phases":25283,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":1115,"conditions":25284,"interventions":25285},[89],[21],[19325,19255,11483,19326,11969],{"nctId":25287,"briefTitle":25288,"status":107,"phases":25289,"primaryCompletion":3175,"completion":3175,"start":14712,"enrollment":2365,"conditions":25290,"interventions":25292},"NCT01277094","A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease",[89],[25291],"Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD",[19325],{"trials":25294,"activeCount":101},[25295,25302],{"nctId":25296,"briefTitle":25297,"status":107,"phases":25298,"primaryCompletion":5271,"completion":5271,"start":4322,"enrollment":1283,"conditions":25299,"interventions":25300},"NCT00823680","A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin",[90],[36],[25301,25301,19325,19325],"RO5027838",{"nctId":25303,"briefTitle":25304,"status":107,"phases":25305,"primaryCompletion":8681,"completion":8681,"start":2905,"enrollment":5013,"conditions":25306,"interventions":25308},"NCT01493271","A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma",[90],[25307],"Hypertension, Glaucoma, Open-Angle",[19325],{"trials":25310,"activeCount":101},[],{"trials":25312,"activeCount":101},[],{"trials":25314,"activeCount":101},[],{"intervention":25316,"totalTrials":2631,"cells":25317},"RO5285119",{"EARLY_PHASE1":25318,"PHASE1":25320,"PHASE2":25350,"PHASE3":25360,"PHASE4":25362,"NA":25364},{"trials":25319,"activeCount":101},[],{"trials":25321,"activeCount":101},[25322,25328,25335,25341],{"nctId":25323,"briefTitle":25324,"status":107,"phases":25325,"primaryCompletion":3007,"completion":3007,"start":4314,"enrollment":1080,"conditions":25326,"interventions":25327},"NCT01418963","A Study of RO5285119 in Healthy Volunteers",[89],[21],[25316],{"nctId":25329,"briefTitle":25330,"status":107,"phases":25331,"primaryCompletion":3212,"completion":3212,"start":4454,"enrollment":496,"conditions":25332,"interventions":25333},"NCT01967979","A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects",[89],[21],[25316,25334,25058],"fluoxetine",{"nctId":25336,"briefTitle":25337,"status":107,"phases":25338,"primaryCompletion":5364,"completion":5364,"start":3174,"enrollment":942,"conditions":25339,"interventions":25340},"NCT02179866","A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers",[89],[21],[25316],{"nctId":25342,"briefTitle":25343,"status":107,"phases":25344,"primaryCompletion":132,"completion":132,"start":8681,"enrollment":425,"conditions":25345,"interventions":25346},"NCT01708616","A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers",[89],[21],[25316,25347,25348,25349],"RO5285119 placebo","risperidone","risperidone placebo",{"trials":25351,"activeCount":101},[25352],{"nctId":25353,"briefTitle":25354,"status":130,"phases":25355,"primaryCompletion":21475,"completion":1660,"start":25356,"enrollment":25357,"conditions":25358,"interventions":25359},"NCT02901431","A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)",[90],"2016-11-21",339,[11768],[25316],{"trials":25361,"activeCount":101},[],{"trials":25363,"activeCount":101},[],{"trials":25365,"activeCount":101},[],{"intervention":25367,"totalTrials":5110,"cells":25368},"RO4998452",{"EARLY_PHASE1":25369,"PHASE1":25371,"PHASE2":25391,"PHASE3":25401,"PHASE4":25403,"NA":25405},{"trials":25370,"activeCount":101},[],{"trials":25372,"activeCount":101},[25373,25379,25385],{"nctId":25374,"briefTitle":25375,"status":107,"phases":25376,"primaryCompletion":2932,"completion":2932,"start":2963,"enrollment":1058,"conditions":25377,"interventions":25378},"NCT00933972","A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment",[89],[36],[25367],{"nctId":25380,"briefTitle":25381,"status":107,"phases":25382,"primaryCompletion":7152,"completion":7152,"start":2769,"enrollment":2289,"conditions":25383,"interventions":25384},"NCT01044017","A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes",[89],[36],[25367],{"nctId":25386,"briefTitle":25387,"status":107,"phases":25388,"primaryCompletion":3325,"completion":3325,"start":4281,"enrollment":786,"conditions":25389,"interventions":25390},"NCT00682097","A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.",[89],[36],[25367],{"trials":25392,"activeCount":101},[25393],{"nctId":25394,"briefTitle":25395,"status":107,"phases":25396,"primaryCompletion":25397,"completion":25397,"start":25398,"enrollment":7638,"conditions":25399,"interventions":25400},"NCT00800176","A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus",[90],"2009-10-28","2009-01-22",[36],[25367,25367,25367,25367,25367],{"trials":25402,"activeCount":101},[],{"trials":25404,"activeCount":101},[],{"trials":25406,"activeCount":101},[],{"intervention":25408,"totalTrials":5110,"cells":25409},"Basmisanil",{"EARLY_PHASE1":25410,"PHASE1":25412,"PHASE2":25420,"PHASE3":25446,"PHASE4":25448,"NA":25450},{"trials":25411,"activeCount":101},[],{"trials":25413,"activeCount":101},[25414],{"nctId":25415,"briefTitle":25416,"status":107,"phases":25417,"primaryCompletion":8341,"completion":3478,"start":2955,"enrollment":942,"conditions":25418,"interventions":25419},"NCT02534207","Basmisanil Positron Emission Tomography Study in Japanese Volunteers",[89],[21],[25408],{"trials":25421,"activeCount":101},[25422,25428,25437],{"nctId":25423,"briefTitle":25424,"status":107,"phases":25425,"primaryCompletion":929,"completion":929,"start":2229,"enrollment":1593,"conditions":25426,"interventions":25427},"NCT02953639","A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics",[90],[19752],[25408],{"nctId":25429,"briefTitle":25430,"status":130,"phases":25431,"primaryCompletion":25432,"completion":25432,"start":25433,"enrollment":4548,"conditions":25434,"interventions":25436},"NCT05307679","A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome",[90],"2024-03-04","2022-12-16",[25435],"Dup15q Syndrome",[25408],{"nctId":25438,"briefTitle":25439,"status":130,"phases":25440,"primaryCompletion":25441,"completion":25441,"start":25442,"enrollment":2631,"conditions":25443,"interventions":25445},"NCT02928393","A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke",[90],"2017-11-03","2017-02-20",[25444],"Stroke",[25408],{"trials":25447,"activeCount":101},[],{"trials":25449,"activeCount":101},[],{"trials":25451,"activeCount":101},[],{"intervention":1051,"totalTrials":5110,"cells":25453},{"EARLY_PHASE1":25454,"PHASE1":25456,"PHASE2":25470,"PHASE3":25476,"PHASE4":25478,"NA":25480},{"trials":25455,"activeCount":101},[],{"trials":25457,"activeCount":101},[25458,25462,25466],{"nctId":8230,"briefTitle":8231,"status":107,"phases":25459,"primaryCompletion":3895,"completion":3895,"start":8233,"enrollment":19,"conditions":25460,"interventions":25461},[89],[1160,18,8235],[1051,1222,1138],{"nctId":1042,"briefTitle":1043,"status":107,"phases":25463,"primaryCompletion":1045,"completion":1045,"start":1046,"enrollment":1047,"conditions":25464,"interventions":25465},[89],[1049],[68,1015,1051],{"nctId":5924,"briefTitle":5925,"status":107,"phases":25467,"primaryCompletion":5927,"completion":5927,"start":1835,"enrollment":984,"conditions":25468,"interventions":25469},[89],[1477],[1051,1957],{"trials":25471,"activeCount":101},[25472],{"nctId":1504,"briefTitle":1505,"status":107,"phases":25473,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":25474,"interventions":25475},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"trials":25477,"activeCount":101},[],{"trials":25479,"activeCount":101},[],{"trials":25481,"activeCount":101},[],{"intervention":25483,"totalTrials":5110,"cells":25484},"RO6811135",{"EARLY_PHASE1":25485,"PHASE1":25487,"PHASE2":25507,"PHASE3":25515,"PHASE4":25517,"NA":25519},{"trials":25486,"activeCount":101},[],{"trials":25488,"activeCount":101},[25489,25495,25501],{"nctId":25490,"briefTitle":25491,"status":107,"phases":25492,"primaryCompletion":2684,"completion":2684,"start":3674,"enrollment":1272,"conditions":25493,"interventions":25494},"NCT01789788","A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus",[89],[36],[25483],{"nctId":25496,"briefTitle":25497,"status":107,"phases":25498,"primaryCompletion":10332,"completion":10332,"start":4445,"enrollment":709,"conditions":25499,"interventions":25500},"NCT01802853","A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers",[89],[21],[25483,25483],{"nctId":25502,"briefTitle":25503,"status":107,"phases":25504,"primaryCompletion":2948,"completion":2948,"start":3146,"enrollment":1272,"conditions":25505,"interventions":25506},"NCT01676584","A Study of Single Dose RO6811135 in Healthy Volunteers",[89],[21],[25483],{"trials":25508,"activeCount":101},[25509],{"nctId":25510,"briefTitle":25511,"status":343,"phases":25512,"primaryCompletion":3212,"completion":3212,"start":3212,"enrollment":101,"conditions":25513,"interventions":25514},"NCT01951183","A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin",[90],[36],[25483],{"trials":25516,"activeCount":101},[],{"trials":25518,"activeCount":101},[],{"trials":25520,"activeCount":101},[],{"intervention":1162,"totalTrials":5110,"cells":25522},{"EARLY_PHASE1":25523,"PHASE1":25525,"PHASE2":25531,"PHASE3":25545,"PHASE4":25547,"NA":25549},{"trials":25524,"activeCount":101},[],{"trials":25526,"activeCount":101},[25527],{"nctId":1153,"briefTitle":1154,"status":107,"phases":25528,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":1158,"conditions":25529,"interventions":25530},[89],[1160],[1162,68,1015,1163,1164,1107,1165,1166,1167],{"trials":25532,"activeCount":101},[25533,25537,25541],{"nctId":8931,"briefTitle":8932,"status":107,"phases":25534,"primaryCompletion":4454,"completion":4454,"start":8934,"enrollment":920,"conditions":25535,"interventions":25536},[90],[30],[1162,1162,1162,4577,1164,1164,1165,5275],{"nctId":4264,"briefTitle":4265,"status":130,"phases":25538,"primaryCompletion":3122,"completion":4267,"start":4268,"enrollment":4269,"conditions":25539,"interventions":25540},[90],[30],[1162,1015,4272,1165,4037],{"nctId":8987,"briefTitle":8988,"status":107,"phases":25542,"primaryCompletion":4682,"completion":4682,"start":2963,"enrollment":8990,"conditions":25543,"interventions":25544},[90],[30],[1162,5275,4102,8956,4104],{"trials":25546,"activeCount":101},[],{"trials":25548,"activeCount":101},[],{"trials":25550,"activeCount":101},[],{"intervention":25552,"totalTrials":706,"cells":25553},"RO4905417",{"EARLY_PHASE1":25554,"PHASE1":25556,"PHASE2":25565,"PHASE3":25583,"PHASE4":25585,"NA":25587},{"trials":25555,"activeCount":101},[],{"trials":25557,"activeCount":101},[25558],{"nctId":25559,"briefTitle":25560,"status":107,"phases":25561,"primaryCompletion":8320,"completion":8320,"start":4113,"enrollment":3665,"conditions":25562,"interventions":25564},"NCT00760565","A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).",[89],[25563],"Peripheral Arterial Disease (PAD)",[25552,25552,25552],{"trials":25566,"activeCount":101},[25567,25575],{"nctId":25568,"briefTitle":25569,"status":107,"phases":25570,"primaryCompletion":4445,"completion":4445,"start":4474,"enrollment":25571,"conditions":25572,"interventions":25574},"NCT01245634","A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery",[90],384,[25573],"Coronary Heart Disease, Graft Occlusion, Vascular",[25552],{"nctId":25576,"briefTitle":25577,"status":107,"phases":25578,"primaryCompletion":2809,"completion":2809,"start":2931,"enrollment":25579,"conditions":25580,"interventions":25582},"NCT01327183","A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention",[90],532,[25581],"Myocardial Infarction",[25552,25552],{"trials":25584,"activeCount":101},[],{"trials":25586,"activeCount":101},[],{"trials":25588,"activeCount":101},[],{"intervention":19280,"totalTrials":706,"cells":25590},{"EARLY_PHASE1":25591,"PHASE1":25593,"PHASE2":25605,"PHASE3":25614,"PHASE4":25616,"NA":25618},{"trials":25592,"activeCount":101},[],{"trials":25594,"activeCount":101},[25595,25599],{"nctId":19275,"briefTitle":19276,"status":107,"phases":25596,"primaryCompletion":4445,"completion":4445,"start":8681,"enrollment":5901,"conditions":25597,"interventions":25598},[89],[21],[11967,11969,19280],{"nctId":25600,"briefTitle":25601,"status":107,"phases":25602,"primaryCompletion":3146,"completion":3146,"start":3213,"enrollment":931,"conditions":25603,"interventions":25604},"NCT01612143","A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers",[89],[21],[19280,19280],{"trials":25606,"activeCount":101},[25607],{"nctId":25608,"briefTitle":25609,"status":107,"phases":25610,"primaryCompletion":4445,"completion":4445,"start":5891,"enrollment":25611,"conditions":25612,"interventions":25613},"NCT01903954","A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C",[90],283,[27],[17072,17976,19280],{"trials":25615,"activeCount":101},[],{"trials":25617,"activeCount":101},[],{"trials":25619,"activeCount":101},[],{"intervention":4037,"totalTrials":706,"cells":25621},{"EARLY_PHASE1":25622,"PHASE1":25624,"PHASE2":25638,"PHASE3":25644,"PHASE4":25646,"NA":25648},{"trials":25623,"activeCount":101},[],{"trials":25625,"activeCount":101},[25626,25630],{"nctId":4028,"briefTitle":4029,"status":107,"phases":25627,"primaryCompletion":4031,"completion":4031,"start":4032,"enrollment":4033,"conditions":25628,"interventions":25629},[89],[4035],[1029,4037,1015],{"nctId":25631,"briefTitle":25632,"status":107,"phases":25633,"primaryCompletion":25634,"completion":720,"start":25635,"enrollment":3044,"conditions":25636,"interventions":25637},"NCT01688206","A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2016-12-02","2012-10-31",[1241],[3636,4037],{"trials":25639,"activeCount":101},[25640],{"nctId":4264,"briefTitle":4265,"status":130,"phases":25641,"primaryCompletion":3122,"completion":4267,"start":4268,"enrollment":4269,"conditions":25642,"interventions":25643},[90],[30],[1162,1015,4272,1165,4037],{"trials":25645,"activeCount":101},[],{"trials":25647,"activeCount":101},[],{"trials":25649,"activeCount":101},[],{"intervention":25651,"totalTrials":706,"cells":25652},"RO6889450",{"EARLY_PHASE1":25653,"PHASE1":25655,"PHASE2":25665,"PHASE3":25684,"PHASE4":25686,"NA":25688},{"trials":25654,"activeCount":101},[],{"trials":25656,"activeCount":101},[25657],{"nctId":25658,"briefTitle":25659,"status":107,"phases":25660,"primaryCompletion":25661,"completion":25661,"start":3123,"enrollment":25662,"conditions":25663,"interventions":25664},"NCT02699372","The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers",[89],"2017-04-14",164,[21],[25651],{"trials":25666,"activeCount":101},[25667,25676],{"nctId":25668,"briefTitle":25669,"status":130,"phases":25670,"primaryCompletion":25671,"completion":25671,"start":25672,"enrollment":414,"conditions":25673,"interventions":25675},"NCT03669640","A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms",[90],"2023-03-12","2018-12-04",[25674],"Schizophrenia, Schizoaffective Disorder",[25651],{"nctId":25677,"briefTitle":25678,"status":107,"phases":25679,"primaryCompletion":1269,"completion":1269,"start":25680,"enrollment":1376,"conditions":25681,"interventions":25682},"NCT04512066","A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder",[90],"2020-09-08",[25674],[25651,25683],"Risperidone",{"trials":25685,"activeCount":101},[],{"trials":25687,"activeCount":101},[],{"trials":25689,"activeCount":101},[],{"intervention":25691,"totalTrials":706,"cells":25692},"RO7017773",{"EARLY_PHASE1":25693,"PHASE1":25695,"PHASE2":25711,"PHASE3":25721,"PHASE4":25723,"NA":25725},{"trials":25694,"activeCount":101},[],{"trials":25696,"activeCount":101},[25697,25704],{"nctId":25698,"briefTitle":25699,"status":107,"phases":25700,"primaryCompletion":25701,"completion":25701,"start":5245,"enrollment":942,"conditions":25702,"interventions":25703},"NCT03507569","Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513",[89],"2018-06-22",[11768],[25691],{"nctId":25705,"briefTitle":25706,"status":107,"phases":25707,"primaryCompletion":25708,"completion":25708,"start":3276,"enrollment":13060,"conditions":25709,"interventions":25710},"NCT03774576","A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants",[89],"2019-03-14",[427],[25691,398],{"trials":25712,"activeCount":101},[25713],{"nctId":25714,"briefTitle":25715,"status":107,"phases":25716,"primaryCompletion":25717,"completion":25717,"start":1430,"enrollment":5376,"conditions":25718,"interventions":25720},"NCT04299464","A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)",[90],"2024-05-15",[25719],"Autism Spectrum Disorder (ASD)",[25691],{"trials":25722,"activeCount":101},[],{"trials":25724,"activeCount":101},[],{"trials":25726,"activeCount":101},[],{"intervention":1151,"totalTrials":706,"cells":25728},{"EARLY_PHASE1":25729,"PHASE1":25731,"PHASE2":25741,"PHASE3":25747,"PHASE4":25749,"NA":25751},{"trials":25730,"activeCount":101},[],{"trials":25732,"activeCount":101},[25733,25737],{"nctId":2519,"briefTitle":2520,"status":107,"phases":25734,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":25735,"interventions":25736},[89],[922],[1151,1018,1096],{"nctId":1144,"briefTitle":1145,"status":107,"phases":25738,"primaryCompletion":1147,"completion":1147,"start":394,"enrollment":1148,"conditions":25739,"interventions":25740},[89],[922],[68,1151],{"trials":25742,"activeCount":101},[25743],{"nctId":1308,"briefTitle":1309,"status":130,"phases":25744,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":25745,"interventions":25746},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"trials":25748,"activeCount":101},[],{"trials":25750,"activeCount":101},[],{"trials":25752,"activeCount":101},[],{"intervention":19506,"totalTrials":706,"cells":25754},{"EARLY_PHASE1":25755,"PHASE1":25757,"PHASE2":25759,"PHASE3":25773,"PHASE4":25775,"NA":25777},{"trials":25756,"activeCount":101},[],{"trials":25758,"activeCount":101},[],{"trials":25760,"activeCount":101},[25761,25765,25769],{"nctId":19501,"briefTitle":19502,"status":107,"phases":25762,"primaryCompletion":4513,"completion":4513,"start":6620,"enrollment":13060,"conditions":25763,"interventions":25764},[90],[36],[19506,13182],{"nctId":19508,"briefTitle":19509,"status":107,"phases":25766,"primaryCompletion":4113,"completion":4113,"start":6377,"enrollment":1415,"conditions":25767,"interventions":25768},[90],[36],[19506,13182],{"nctId":19528,"briefTitle":19529,"status":107,"phases":25770,"primaryCompletion":4198,"completion":4198,"start":8658,"enrollment":19531,"conditions":25771,"interventions":25772},[90],[36],[19506,13182],{"trials":25774,"activeCount":101},[],{"trials":25776,"activeCount":101},[],{"trials":25778,"activeCount":101},[],{"intervention":25348,"totalTrials":706,"cells":25780},{"EARLY_PHASE1":25781,"PHASE1":25783,"PHASE2":25796,"PHASE3":25802,"PHASE4":25804,"NA":25806},{"trials":25782,"activeCount":101},[],{"trials":25784,"activeCount":101},[25785,25792],{"nctId":25786,"briefTitle":25787,"status":107,"phases":25788,"primaryCompletion":3246,"completion":3246,"start":2830,"enrollment":8206,"conditions":25789,"interventions":25790},"NCT02019329","A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone",[89],[19752],[25791,25348],"RO5545965",{"nctId":25342,"briefTitle":25343,"status":107,"phases":25793,"primaryCompletion":132,"completion":132,"start":8681,"enrollment":425,"conditions":25794,"interventions":25795},[89],[21],[25316,25347,25348,25349],{"trials":25797,"activeCount":101},[25798],{"nctId":25677,"briefTitle":25678,"status":107,"phases":25799,"primaryCompletion":1269,"completion":1269,"start":25680,"enrollment":1376,"conditions":25800,"interventions":25801},[90],[25674],[25651,25683],{"trials":25803,"activeCount":101},[],{"trials":25805,"activeCount":101},[],{"trials":25807,"activeCount":101},[],{"intervention":25809,"totalTrials":706,"cells":25810},"RO7049665",{"EARLY_PHASE1":25811,"PHASE1":25813,"PHASE2":25830,"PHASE3":25840,"PHASE4":25842,"NA":25844},{"trials":25812,"activeCount":101},[],{"trials":25814,"activeCount":101},[25815,25823],{"nctId":25816,"briefTitle":25817,"status":130,"phases":25818,"primaryCompletion":25819,"completion":25819,"start":25820,"enrollment":909,"conditions":25821,"interventions":25822},"NCT03943550","Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)",[89],"2021-07-22","2019-05-13",[20387],[25809],{"nctId":25824,"briefTitle":25825,"status":107,"phases":25826,"primaryCompletion":25827,"completion":25827,"start":4885,"enrollment":1001,"conditions":25828,"interventions":25829},"NCT03221179","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers",[89],"2019-07-05",[427],[25809],{"trials":25831,"activeCount":101},[25832],{"nctId":25833,"briefTitle":25834,"status":130,"phases":25835,"primaryCompletion":2056,"completion":2056,"start":644,"enrollment":162,"conditions":25836,"interventions":25839},"NCT04790916","Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)",[90],[25837,25838],"Autoimmune Hepatitis","Autoimmune Chronic Hepatitis",[25809],{"trials":25841,"activeCount":101},[],{"trials":25843,"activeCount":101},[],{"trials":25845,"activeCount":101},[],{"intervention":25847,"totalTrials":162,"cells":25848},"Dual Integrin Antagonist",{"EARLY_PHASE1":25849,"PHASE1":25851,"PHASE2":25853,"PHASE3":25869,"PHASE4":25871,"NA":25873},{"trials":25850,"activeCount":101},[],{"trials":25852,"activeCount":101},[],{"trials":25854,"activeCount":101},[25855,25863],{"nctId":25856,"briefTitle":25857,"status":107,"phases":25858,"primaryCompletion":25859,"completion":25859,"start":25860,"conditions":25861,"interventions":25862},"NCT00048009","Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids",[90],"2004-02-02","2002-10-25",[17203],[25847],{"nctId":25864,"briefTitle":25865,"status":107,"phases":25866,"primaryCompletion":25859,"completion":25859,"start":25860,"conditions":25867,"interventions":25868},"NCT00048022","Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma",[90],[17203],[25847],{"trials":25870,"activeCount":101},[],{"trials":25872,"activeCount":101},[],{"trials":25874,"activeCount":101},[],{"intervention":1017,"totalTrials":162,"cells":25876},{"EARLY_PHASE1":25877,"PHASE1":25879,"PHASE2":25885,"PHASE3":25891,"PHASE4":25893,"NA":25895},{"trials":25878,"activeCount":101},[],{"trials":25880,"activeCount":101},[25881],{"nctId":1006,"briefTitle":1007,"status":107,"phases":25882,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":25883,"interventions":25884},[89],[1013],[68,1015,1016,1017,1018,1019],{"trials":25886,"activeCount":101},[25887],{"nctId":1277,"briefTitle":1278,"status":107,"phases":25888,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":25889,"interventions":25890},[89,90],[1285],[1287,1017,1288,68,988,1289],{"trials":25892,"activeCount":101},[],{"trials":25894,"activeCount":101},[],{"trials":25896,"activeCount":101},[],{"intervention":17693,"totalTrials":162,"cells":25898},{"EARLY_PHASE1":25899,"PHASE1":25901,"PHASE2":25909,"PHASE3":25915,"PHASE4":25917,"NA":25919},{"trials":25900,"activeCount":101},[],{"trials":25902,"activeCount":101},[25903],{"nctId":25904,"briefTitle":25905,"status":107,"phases":25906,"primaryCompletion":11550,"completion":11550,"start":3212,"enrollment":123,"conditions":25907,"interventions":25908},"NCT02015715","A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants",[89],[21],[17693],{"trials":25910,"activeCount":101},[25911],{"nctId":17686,"briefTitle":17687,"status":107,"phases":25912,"primaryCompletion":17689,"completion":17689,"start":17690,"enrollment":5013,"conditions":25913,"interventions":25914},[90],[11790],[17609,17693,17694],{"trials":25916,"activeCount":101},[],{"trials":25918,"activeCount":101},[],{"trials":25920,"activeCount":101},[],{"intervention":20202,"totalTrials":162,"cells":25922},{"EARLY_PHASE1":25923,"PHASE1":25925,"PHASE2":25931,"PHASE3":25937,"PHASE4":25939,"NA":25941},{"trials":25924,"activeCount":101},[],{"trials":25926,"activeCount":101},[25927],{"nctId":20242,"briefTitle":20243,"status":107,"phases":25928,"primaryCompletion":2601,"completion":2601,"start":132,"enrollment":3190,"conditions":25929,"interventions":25930},[89],[20237],[20247,20248,20249,20202,10088],{"trials":25932,"activeCount":101},[25933],{"nctId":20196,"briefTitle":20197,"status":130,"phases":25934,"primaryCompletion":19699,"completion":19699,"start":20199,"enrollment":425,"conditions":25935,"interventions":25936},[89,90],[933],[1500,10088,20202],{"trials":25938,"activeCount":101},[],{"trials":25940,"activeCount":101},[],{"trials":25942,"activeCount":101},[],{"intervention":17019,"totalTrials":162,"cells":25944},{"EARLY_PHASE1":25945,"PHASE1":25947,"PHASE2":25949,"PHASE3":25959,"PHASE4":25961,"NA":25963},{"trials":25946,"activeCount":101},[],{"trials":25948,"activeCount":101},[],{"trials":25950,"activeCount":101},[25951,25955],{"nctId":17014,"briefTitle":17015,"status":107,"phases":25952,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":549,"conditions":25953,"interventions":25954},[90],[27],[16996,17011,17019,17019,17019,17019],{"nctId":19380,"briefTitle":19381,"status":107,"phases":25956,"primaryCompletion":2956,"completion":2956,"start":3213,"enrollment":1283,"conditions":25957,"interventions":25958},[90],[27],[17034,17019,19385,17976,11969],{"trials":25960,"activeCount":101},[],{"trials":25962,"activeCount":101},[],{"trials":25964,"activeCount":101},[],{"intervention":5422,"totalTrials":162,"cells":25966},{"EARLY_PHASE1":25967,"PHASE1":25969,"PHASE2":25975,"PHASE3":25981,"PHASE4":25983,"NA":25985},{"trials":25968,"activeCount":101},[],{"trials":25970,"activeCount":101},[25971],{"nctId":14680,"briefTitle":14681,"status":107,"phases":25972,"primaryCompletion":2602,"completion":2602,"start":2905,"enrollment":14683,"conditions":25973,"interventions":25974},[89],[1241],[5422,1138,977,14686],{"trials":25976,"activeCount":101},[25977],{"nctId":5414,"briefTitle":5415,"status":130,"phases":25978,"primaryCompletion":5417,"completion":5417,"start":5418,"enrollment":709,"conditions":25979,"interventions":25980},[89,90],[5420],[990,1106,5422],{"trials":25982,"activeCount":101},[],{"trials":25984,"activeCount":101},[],{"trials":25986,"activeCount":101},[],{"intervention":11872,"totalTrials":162,"cells":25988},{"EARLY_PHASE1":25989,"PHASE1":25991,"PHASE2":26000,"PHASE3":26006,"PHASE4":26008,"NA":26010},{"trials":25990,"activeCount":101},[],{"trials":25992,"activeCount":101},[25993],{"nctId":25994,"briefTitle":25995,"status":107,"phases":25996,"primaryCompletion":25997,"completion":25997,"start":734,"enrollment":8322,"conditions":25998,"interventions":25999},"NCT04557150","A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r\u002Fr MM)",[89],"2026-03-17",[1305],[11872],{"trials":26001,"activeCount":101},[26002],{"nctId":11865,"briefTitle":11866,"status":107,"phases":26003,"primaryCompletion":7385,"completion":7385,"start":11868,"enrollment":8583,"conditions":26004,"interventions":26005},[89,90],[11870],[11872,9422,9322],{"trials":26007,"activeCount":101},[],{"trials":26009,"activeCount":101},[],{"trials":26011,"activeCount":101},[],{"intervention":1320,"totalTrials":162,"cells":26013},{"EARLY_PHASE1":26014,"PHASE1":26016,"PHASE2":26018,"PHASE3":26028,"PHASE4":26030,"NA":26032},{"trials":26015,"activeCount":101},[],{"trials":26017,"activeCount":101},[],{"trials":26019,"activeCount":101},[26020,26024],{"nctId":1308,"briefTitle":1309,"status":130,"phases":26021,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":26022,"interventions":26023},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"nctId":1588,"briefTitle":1589,"status":107,"phases":26025,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":26026,"interventions":26027},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"trials":26029,"activeCount":101},[],{"trials":26031,"activeCount":101},[],{"trials":26033,"activeCount":101},[],{"intervention":19793,"totalTrials":162,"cells":26035},{"EARLY_PHASE1":26036,"PHASE1":26038,"PHASE2":26044,"PHASE3":26050,"PHASE4":26052,"NA":26054},{"trials":26037,"activeCount":101},[],{"trials":26039,"activeCount":101},[26040],{"nctId":19748,"briefTitle":19749,"status":107,"phases":26041,"primaryCompletion":4682,"completion":4682,"start":5181,"enrollment":1174,"conditions":26042,"interventions":26043},[89],[19752],[19708,19754],{"trials":26045,"activeCount":101},[26046],{"nctId":19787,"briefTitle":19788,"status":107,"phases":26047,"primaryCompletion":6578,"completion":6578,"start":4198,"enrollment":19790,"conditions":26048,"interventions":26049},[90],[19752],[19708,19708,19708,19793],{"trials":26051,"activeCount":101},[],{"trials":26053,"activeCount":101},[],{"trials":26055,"activeCount":101},[],{"intervention":10994,"totalTrials":162,"cells":26057},{"EARLY_PHASE1":26058,"PHASE1":26060,"PHASE2":26072,"PHASE3":26078,"PHASE4":26080,"NA":26082},{"trials":26059,"activeCount":101},[],{"trials":26061,"activeCount":101},[26062],{"nctId":26063,"briefTitle":26064,"status":107,"phases":26065,"primaryCompletion":26066,"completion":26066,"start":26067,"enrollment":19,"conditions":26068,"interventions":26071},"NCT03708328","A Dose Escalation and Expansion Study of Lomvastomig, a PD-1\u002FTIM-3 Bispecific Antibody, in Participants With Advanced and\u002For Metastatic Solid Tumors",[89],"2024-07-09","2018-10-15",[922,1477,1432,26069,26070],"Small Cell Lung Cancer (SCLC)","Esophageal Squamous Cell Carcinoma (ESCC)",[10994],{"trials":26073,"activeCount":101},[26074],{"nctId":10987,"briefTitle":10988,"status":107,"phases":26075,"primaryCompletion":10990,"completion":10990,"start":3749,"enrollment":4079,"conditions":26076,"interventions":26077},[90],[10992],[10994,1445,1287],{"trials":26079,"activeCount":101},[],{"trials":26081,"activeCount":101},[],{"trials":26083,"activeCount":101},[],{"intervention":4131,"totalTrials":162,"cells":26085},{"EARLY_PHASE1":26086,"PHASE1":26088,"PHASE2":26090,"PHASE3":26100,"PHASE4":26102,"NA":26104},{"trials":26087,"activeCount":101},[],{"trials":26089,"activeCount":101},[],{"trials":26091,"activeCount":101},[26092,26096],{"nctId":4124,"briefTitle":4125,"status":107,"phases":26093,"primaryCompletion":2856,"completion":4127,"start":4128,"enrollment":1080,"conditions":26094,"interventions":26095},[90],[30],[1597,1015,4131,1165],{"nctId":8998,"briefTitle":8999,"status":107,"phases":26097,"primaryCompletion":5418,"completion":5418,"start":3007,"enrollment":1548,"conditions":26098,"interventions":26099},[90],[1735],[4244,1165,4272,4131,1597],{"trials":26101,"activeCount":101},[],{"trials":26103,"activeCount":101},[],{"trials":26105,"activeCount":101},[],{"intervention":4141,"totalTrials":162,"cells":26107},{"EARLY_PHASE1":26108,"PHASE1":26110,"PHASE2":26112,"PHASE3":26128,"PHASE4":26130,"NA":26132},{"trials":26109,"activeCount":101},[],{"trials":26111,"activeCount":101},[],{"trials":26113,"activeCount":101},[26114,26124],{"nctId":26115,"briefTitle":26116,"status":107,"phases":26117,"primaryCompletion":26118,"completion":2197,"start":26119,"enrollment":26120,"conditions":26121,"interventions":26123},"NCT02458638","A Study of Atezolizumab in Advanced Solid Tumors",[90],"2018-04-04","2015-07-16",474,[26122],"Tumors",[4141],{"nctId":4133,"briefTitle":4134,"status":107,"phases":26125,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":26126,"interventions":26127},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"trials":26129,"activeCount":101},[],{"trials":26131,"activeCount":101},[],{"trials":26133,"activeCount":101},[],{"intervention":13175,"totalTrials":162,"cells":26135},{"EARLY_PHASE1":26136,"PHASE1":26138,"PHASE2":26140,"PHASE3":26151,"PHASE4":26153,"NA":26155},{"trials":26137,"activeCount":101},[],{"trials":26139,"activeCount":101},[],{"trials":26141,"activeCount":101},[26142,26146],{"nctId":13168,"briefTitle":13169,"status":107,"phases":26143,"primaryCompletion":13171,"completion":13171,"start":122,"enrollment":13172,"conditions":26144,"interventions":26145},[90],[36],[13175,1576],{"nctId":26147,"briefTitle":13169,"status":107,"phases":26148,"primaryCompletion":9771,"completion":9771,"start":4563,"enrollment":3167,"conditions":26149,"interventions":26150},"NCT00111670",[90],[36],[13175],{"trials":26152,"activeCount":101},[],{"trials":26154,"activeCount":101},[],{"trials":26156,"activeCount":101},[],{"intervention":26158,"totalTrials":162,"cells":26159},"RO4917523 0.5 mg",{"EARLY_PHASE1":26160,"PHASE1":26162,"PHASE2":26164,"PHASE3":26180,"PHASE4":26182,"NA":26184},{"trials":26161,"activeCount":101},[],{"trials":26163,"activeCount":101},[],{"trials":26165,"activeCount":101},[26166,26174],{"nctId":26167,"briefTitle":26168,"status":107,"phases":26169,"primaryCompletion":2684,"completion":2684,"start":6315,"enrollment":26170,"conditions":26171,"interventions":26172},"NCT01437657","MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy",[90],319,[25206],[26158,26173],"RO4917523 1.5 mg",{"nctId":26175,"briefTitle":26176,"status":107,"phases":26177,"primaryCompletion":11437,"completion":11437,"start":2801,"enrollment":5821,"conditions":26178,"interventions":26179},"NCT01517698","A Study of RO4917523 in Patients With Fragile X Syndrome",[90],[24808],[26158,26173],{"trials":26181,"activeCount":101},[],{"trials":26183,"activeCount":101},[],{"trials":26185,"activeCount":101},[],{"intervention":26173,"totalTrials":162,"cells":26187},{"EARLY_PHASE1":26188,"PHASE1":26190,"PHASE2":26192,"PHASE3":26202,"PHASE4":26204,"NA":26206},{"trials":26189,"activeCount":101},[],{"trials":26191,"activeCount":101},[],{"trials":26193,"activeCount":101},[26194,26198],{"nctId":26167,"briefTitle":26168,"status":107,"phases":26195,"primaryCompletion":2684,"completion":2684,"start":6315,"enrollment":26170,"conditions":26196,"interventions":26197},[90],[25206],[26158,26173],{"nctId":26175,"briefTitle":26176,"status":107,"phases":26199,"primaryCompletion":11437,"completion":11437,"start":2801,"enrollment":5821,"conditions":26200,"interventions":26201},[90],[24808],[26158,26173],{"trials":26203,"activeCount":101},[],{"trials":26205,"activeCount":101},[],{"trials":26207,"activeCount":101},[],{"intervention":26209,"totalTrials":162,"cells":26210},"beta-lactam",{"EARLY_PHASE1":26211,"PHASE1":26213,"PHASE2":26215,"PHASE3":26233,"PHASE4":26235,"NA":26237},{"trials":26212,"activeCount":101},[],{"trials":26214,"activeCount":101},[],{"trials":26216,"activeCount":101},[26217,26225],{"nctId":26218,"briefTitle":26219,"status":107,"phases":26220,"primaryCompletion":16669,"completion":16669,"start":8659,"enrollment":17952,"conditions":26221,"interventions":26223},"NCT00111644","A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia",[90],[26222],"Pneumonia, Bacterial",[26224,26209,26209],"Ceftriaxone",{"nctId":26226,"briefTitle":26227,"status":107,"phases":26228,"primaryCompletion":2965,"completion":2965,"start":5469,"enrollment":6307,"conditions":26229,"interventions":26231},"NCT00303589","A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections",[90],[26230],"Soft Tissue Infections",[26232,26209,26209],"Standard care",{"trials":26234,"activeCount":101},[],{"trials":26236,"activeCount":101},[],{"trials":26238,"activeCount":101},[],{"intervention":3636,"totalTrials":162,"cells":26240},{"EARLY_PHASE1":26241,"PHASE1":26243,"PHASE2":26249,"PHASE3":26255,"PHASE4":26257,"NA":26259},{"trials":26242,"activeCount":101},[],{"trials":26244,"activeCount":101},[26245],{"nctId":25631,"briefTitle":25632,"status":107,"phases":26246,"primaryCompletion":25634,"completion":720,"start":25635,"enrollment":3044,"conditions":26247,"interventions":26248},[89],[1241],[3636,4037],{"trials":26250,"activeCount":101},[26251],{"nctId":3628,"briefTitle":3629,"status":107,"phases":26252,"primaryCompletion":3631,"completion":3632,"start":3633,"enrollment":1058,"conditions":26253,"interventions":26254},[89,90],[1038],[3636,1018,1785,1359],{"trials":26256,"activeCount":101},[],{"trials":26258,"activeCount":101},[],{"trials":26260,"activeCount":101},[],{"intervention":26262,"totalTrials":162,"cells":26263},"Mericitabine",{"EARLY_PHASE1":26264,"PHASE1":26266,"PHASE2":26268,"PHASE3":26283,"PHASE4":26285,"NA":26287},{"trials":26265,"activeCount":101},[],{"trials":26267,"activeCount":101},[],{"trials":26269,"activeCount":101},[26270,26279],{"nctId":26271,"briefTitle":26272,"status":107,"phases":26273,"primaryCompletion":8079,"completion":8079,"start":2914,"enrollment":920,"conditions":26274,"interventions":26276},"NCT01482390","A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a \u002F Ribavirin in Participants With Chronic Hepatitis C",[90],[26275],"Hepatitis C",[17366,26262,26277,26278],"Peginterferon Alfa-2a","Telaprevir",{"nctId":17052,"briefTitle":17053,"status":107,"phases":26280,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":26281,"interventions":26282},[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],{"trials":26284,"activeCount":101},[],{"trials":26286,"activeCount":101},[],{"trials":26288,"activeCount":101},[],{"intervention":4184,"totalTrials":162,"cells":26290},{"EARLY_PHASE1":26291,"PHASE1":26293,"PHASE2":26295,"PHASE3":26305,"PHASE4":26307,"NA":26309},{"trials":26292,"activeCount":101},[],{"trials":26294,"activeCount":101},[],{"trials":26296,"activeCount":101},[26297,26301],{"nctId":4177,"briefTitle":4178,"status":107,"phases":26298,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":26299,"interventions":26300},[90],[18],[4184,1015,4185,1597,992,1106,947],{"nctId":8303,"briefTitle":8304,"status":107,"phases":26302,"primaryCompletion":8306,"completion":444,"start":8307,"enrollment":8308,"conditions":26303,"interventions":26304},[90],[18],[1221,1222,4184,8311],{"trials":26306,"activeCount":101},[],{"trials":26308,"activeCount":101},[],{"trials":26310,"activeCount":101},[],{"intervention":25259,"totalTrials":162,"cells":26312},{"EARLY_PHASE1":26313,"PHASE1":26315,"PHASE2":26325,"PHASE3":26331,"PHASE4":26333,"NA":26335},{"trials":26314,"activeCount":101},[],{"trials":26316,"activeCount":101},[26317],{"nctId":26318,"briefTitle":26319,"status":107,"phases":26320,"completion":5181,"start":2932,"enrollment":721,"conditions":26321,"interventions":26322},"NCT01196065","A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine",[89],[21],[26323,26324],"RO5313534","memantine",{"trials":26326,"activeCount":101},[26327],{"nctId":25251,"briefTitle":25252,"status":107,"phases":26328,"primaryCompletion":25254,"completion":25254,"start":25255,"enrollment":1133,"conditions":26329,"interventions":26330},[90],[14384],[25215,25258,25259,25260,25261],{"trials":26332,"activeCount":101},[],{"trials":26334,"activeCount":101},[],{"trials":26336,"activeCount":101},[],{"intervention":529,"totalTrials":162,"cells":26338},{"EARLY_PHASE1":26339,"PHASE1":26341,"PHASE2":26343,"PHASE3":26353,"PHASE4":26355,"NA":26357},{"trials":26340,"activeCount":101},[],{"trials":26342,"activeCount":101},[],{"trials":26344,"activeCount":101},[26345,26349],{"nctId":519,"briefTitle":520,"status":107,"phases":26346,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":26347,"interventions":26348},[90],[526],[509,528,529],{"nctId":531,"briefTitle":532,"status":107,"phases":26350,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":26351,"interventions":26352},[90],[539,540],[509,528,529],{"trials":26354,"activeCount":101},[],{"trials":26356,"activeCount":101},[],{"trials":26358,"activeCount":101},[],{"intervention":26360,"totalTrials":162,"cells":26361},"RO6807952",{"EARLY_PHASE1":26362,"PHASE1":26364,"PHASE2":26372,"PHASE3":26381,"PHASE4":26383,"NA":26385},{"trials":26363,"activeCount":101},[],{"trials":26365,"activeCount":101},[26366],{"nctId":26367,"briefTitle":26368,"status":107,"phases":26369,"primaryCompletion":3189,"completion":3189,"start":14712,"enrollment":909,"conditions":26370,"interventions":26371},"NCT01358929","A Study of RO6807952 in Patients With Diabetes Mellitus Type 2",[89],[36],[26360],{"trials":26373,"activeCount":101},[26374],{"nctId":26375,"briefTitle":26376,"status":130,"phases":26377,"primaryCompletion":3103,"completion":3103,"start":2685,"enrollment":162,"conditions":26378,"interventions":26379},"NCT01516476","Study of RO6807952 in Patients With Diabetes Mellitus Type 2",[90],[36],[26360,26360,26380],"liraglutide",{"trials":26382,"activeCount":101},[],{"trials":26384,"activeCount":101},[],{"trials":26386,"activeCount":101},[],{"intervention":26323,"totalTrials":162,"cells":26388},{"EARLY_PHASE1":26389,"PHASE1":26391,"PHASE2":26397,"PHASE3":26405,"PHASE4":26407,"NA":26409},{"trials":26390,"activeCount":101},[],{"trials":26392,"activeCount":101},[26393],{"nctId":26318,"briefTitle":26319,"status":107,"phases":26394,"completion":5181,"start":2932,"enrollment":721,"conditions":26395,"interventions":26396},[89],[21],[26323,26324],{"trials":26398,"activeCount":101},[26399],{"nctId":26400,"briefTitle":26401,"status":107,"phases":26402,"primaryCompletion":5181,"completion":5181,"start":9596,"enrollment":6208,"conditions":26403,"interventions":26404},"NCT00884507","A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease",[90],[14384],[26323,26323,26323],{"trials":26406,"activeCount":101},[],{"trials":26408,"activeCount":101},[],{"trials":26410,"activeCount":101},[],{"intervention":26412,"totalTrials":162,"cells":26413},"RO5459072",{"EARLY_PHASE1":26414,"PHASE1":26416,"PHASE2":26427,"PHASE3":26436,"PHASE4":26438,"NA":26440},{"trials":26415,"activeCount":101},[],{"trials":26417,"activeCount":101},[26418],{"nctId":26419,"briefTitle":26420,"status":107,"phases":26421,"primaryCompletion":26422,"completion":26422,"start":26423,"enrollment":8583,"conditions":26424,"interventions":26426},"NCT02679014","A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease",[89],"2016-08-28","2016-03-06",[26425],"Celiac Disease",[26412],{"trials":26428,"activeCount":101},[26429],{"nctId":26430,"briefTitle":26431,"status":107,"phases":26432,"primaryCompletion":4885,"completion":4885,"start":2865,"enrollment":817,"conditions":26433,"interventions":26435},"NCT02701985","A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome",[90],[26434],"Sjogren's Syndrome",[26412],{"trials":26437,"activeCount":101},[],{"trials":26439,"activeCount":101},[],{"trials":26441,"activeCount":101},[],{"intervention":26443,"totalTrials":162,"cells":26444},"RO5186582",{"EARLY_PHASE1":26445,"PHASE1":26447,"PHASE2":26457,"PHASE3":26466,"PHASE4":26468,"NA":26470},{"trials":26446,"activeCount":101},[],{"trials":26448,"activeCount":101},[26449],{"nctId":26450,"briefTitle":26451,"status":107,"phases":26452,"primaryCompletion":11550,"completion":11550,"start":5418,"enrollment":709,"conditions":26453,"interventions":26454},"NCT02254759","A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants",[89],[21],[26455,26456,26443],"Midazolam, IV","Midazolam,",{"trials":26458,"activeCount":101},[26459],{"nctId":26460,"briefTitle":26461,"status":130,"phases":26462,"primaryCompletion":4960,"completion":4960,"start":26463,"enrollment":909,"conditions":26464,"interventions":26465},"NCT02484703","A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age",[90],"2015-10-28",[25039],[26443],{"trials":26467,"activeCount":101},[],{"trials":26469,"activeCount":101},[],{"trials":26471,"activeCount":101},[],{"intervention":1501,"totalTrials":162,"cells":26473},{"EARLY_PHASE1":26474,"PHASE1":26476,"PHASE2":26478,"PHASE3":26488,"PHASE4":26490,"NA":26492},{"trials":26475,"activeCount":101},[],{"trials":26477,"activeCount":101},[],{"trials":26479,"activeCount":101},[26480,26484],{"nctId":1490,"briefTitle":1491,"status":130,"phases":26481,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":26482,"interventions":26483},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"nctId":1504,"briefTitle":1505,"status":107,"phases":26485,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":26486,"interventions":26487},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"trials":26489,"activeCount":101},[],{"trials":26491,"activeCount":101},[],{"trials":26493,"activeCount":101},[],{"intervention":15431,"totalTrials":162,"cells":26495},{"EARLY_PHASE1":26496,"PHASE1":26498,"PHASE2":26504,"PHASE3":26510,"PHASE4":26512,"NA":26514},{"trials":26497,"activeCount":101},[],{"trials":26499,"activeCount":101},[26500],{"nctId":15426,"briefTitle":15427,"status":107,"phases":26501,"completion":4314,"start":5271,"enrollment":1174,"conditions":26502,"interventions":26503},[89],[15],[15431,5838,5894,5894],{"trials":26505,"activeCount":101},[26506],{"nctId":5802,"briefTitle":5803,"status":107,"phases":26507,"primaryCompletion":2948,"completion":2948,"start":5805,"enrollment":5806,"conditions":26508,"interventions":26509},[90],[15],[1359,2824,274,5809],{"trials":26511,"activeCount":101},[],{"trials":26513,"activeCount":101},[],{"trials":26515,"activeCount":101},[],{"intervention":26517,"totalTrials":162,"cells":26518},"Nucleos",{"EARLY_PHASE1":26519,"PHASE1":26521,"PHASE2":26523,"PHASE3":26544,"PHASE4":26546,"NA":26548},{"trials":26520,"activeCount":101},[],{"trials":26522,"activeCount":101},[],{"trials":26524,"activeCount":101},[26525,26532],{"nctId":26526,"briefTitle":26527,"status":107,"phases":26528,"primaryCompletion":2684,"completion":11550,"start":4249,"enrollment":537,"conditions":26529,"interventions":26530},"NCT01706575","A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression",[90],[11790],[26531,26517],"Pegylated Interferon (Peginterferon) Alfa-2a",{"nctId":26533,"briefTitle":26534,"status":107,"phases":26535,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":26537,"interventions":26538},"NCT04225715","A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B",[90],"2020-07-05",[11790],[26517,26539,26540,26541,26542,26543],"CpAM","TLR7","siRNA","PEG-IFN","PD-L1 LNA",{"trials":26545,"activeCount":101},[],{"trials":26547,"activeCount":101},[],{"trials":26549,"activeCount":101},[],{"intervention":1515,"totalTrials":162,"cells":26551},{"EARLY_PHASE1":26552,"PHASE1":26554,"PHASE2":26556,"PHASE3":26566,"PHASE4":26568,"NA":26570},{"trials":26553,"activeCount":101},[],{"trials":26555,"activeCount":101},[],{"trials":26557,"activeCount":101},[26558,26562],{"nctId":1504,"briefTitle":1505,"status":107,"phases":26559,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":26560,"interventions":26561},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"nctId":1588,"briefTitle":1589,"status":107,"phases":26563,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":26564,"interventions":26565},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"trials":26567,"activeCount":101},[],{"trials":26569,"activeCount":101},[],{"trials":26571,"activeCount":101},[],{"intervention":26573,"totalTrials":162,"cells":26574},"Ro 205-2349",{"EARLY_PHASE1":26575,"PHASE1":26577,"PHASE2":26579,"PHASE3":26596,"PHASE4":26598,"NA":26600},{"trials":26576,"activeCount":101},[],{"trials":26578,"activeCount":101},[],{"trials":26580,"activeCount":101},[26581,26589],{"nctId":26582,"briefTitle":26583,"status":107,"phases":26584,"primaryCompletion":17084,"completion":17084,"start":26585,"conditions":26586,"interventions":26588},"NCT00057317","Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus",[90],"2001-12",[26587],"Diabetes",[26573],{"nctId":26590,"briefTitle":26591,"status":107,"phases":26592,"primaryCompletion":8605,"completion":8605,"start":22664,"enrollment":4079,"conditions":26593,"interventions":26594},"NCT00057304","Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus",[90],[26587],[26595],"RO 205-2349",{"trials":26597,"activeCount":101},[],{"trials":26599,"activeCount":101},[],{"trials":26601,"activeCount":101},[],{"intervention":26603,"totalTrials":162,"cells":26604},"fotemustine",{"EARLY_PHASE1":26605,"PHASE1":26607,"PHASE2":26609,"PHASE3":26623,"PHASE4":26625,"NA":26627},{"trials":26606,"activeCount":101},[],{"trials":26608,"activeCount":101},[],{"trials":26610,"activeCount":101},[26611,26617],{"nctId":26612,"briefTitle":26613,"status":107,"phases":26614,"primaryCompletion":3212,"completion":3212,"start":2685,"enrollment":1352,"conditions":26615,"interventions":26616},"NCT01474239","A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma",[90],[16614],[5275,26603],{"nctId":26618,"briefTitle":26619,"status":107,"phases":26620,"primaryCompletion":4488,"completion":4488,"start":14454,"enrollment":2375,"conditions":26621,"interventions":26622},"NCT01069627","A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma",[90],[1261],[5275,26603],{"trials":26624,"activeCount":101},[],{"trials":26626,"activeCount":101},[],{"trials":26628,"activeCount":101},[],{"intervention":16488,"totalTrials":162,"cells":26630},{"EARLY_PHASE1":26631,"PHASE1":26633,"PHASE2":26641,"PHASE3":26647,"PHASE4":26649,"NA":26651},{"trials":26632,"activeCount":101},[],{"trials":26634,"activeCount":101},[26635],{"nctId":26636,"briefTitle":26637,"status":107,"phases":26638,"enrollment":425,"conditions":26639,"interventions":26640},"NCT00002096","A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine",[89],[17753,33],[16478,16488,17773],{"trials":26642,"activeCount":101},[26643],{"nctId":16481,"briefTitle":16482,"status":107,"phases":26644,"enrollment":1026,"conditions":26645,"interventions":26646},[90],[33],[16450,16486,16487,16478,16479,16488],{"trials":26648,"activeCount":101},[],{"trials":26650,"activeCount":101},[],{"trials":26652,"activeCount":101},[],{"intervention":26654,"totalTrials":162,"cells":26655},"Ruxolitinib",{"EARLY_PHASE1":26656,"PHASE1":26658,"PHASE2":26668,"PHASE3":26680,"PHASE4":26682,"NA":26684},{"trials":26657,"activeCount":101},[],{"trials":26659,"activeCount":101},[26660],{"nctId":26661,"briefTitle":26662,"status":107,"phases":26663,"primaryCompletion":21060,"completion":26664,"start":4032,"enrollment":462,"conditions":26665,"interventions":26667},"NCT02593760","A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)",[89],"2017-07-12",[26666],"Myelofibrosis",[26654,1770],{"trials":26669,"activeCount":101},[26670],{"nctId":26671,"briefTitle":26672,"status":107,"phases":26673,"primaryCompletion":6251,"completion":6251,"start":10461,"enrollment":26674,"conditions":26675,"interventions":26678},"NCT01981850","A Phase 2 Study of RO7490677 In Participants With Myelofibrosis",[90],125,[26676,20185,26677],"Primary Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis",[26679,26654],"RO7490677",{"trials":26681,"activeCount":101},[],{"trials":26683,"activeCount":101},[],{"trials":26685,"activeCount":101},[],{"intervention":26687,"totalTrials":162,"cells":26688},"interferon alfa-2a",{"EARLY_PHASE1":26689,"PHASE1":26691,"PHASE2":26693,"PHASE3":26709,"PHASE4":26711,"NA":26713},{"trials":26690,"activeCount":101},[],{"trials":26692,"activeCount":101},[],{"trials":26694,"activeCount":101},[26695,26701],{"nctId":26696,"briefTitle":26697,"status":107,"phases":26698,"primaryCompletion":2768,"completion":2768,"start":4562,"enrollment":11543,"conditions":26699,"interventions":26700},"NCT00796757","A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).",[90],[4692],[5275,26687],{"nctId":26702,"briefTitle":26703,"status":107,"phases":26704,"primaryCompletion":4555,"completion":4555,"start":3692,"enrollment":97,"conditions":26705,"interventions":26706},"NCT00520403","A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.",[90],[4692],[5275,26707,26708],"Interferon alfa-2a","Vinblastine",{"trials":26710,"activeCount":101},[],{"trials":26712,"activeCount":101},[],{"trials":26714,"activeCount":101},[],{"intervention":4070,"totalTrials":350,"cells":26716},{"EARLY_PHASE1":26717,"PHASE1":26719,"PHASE2":26721,"PHASE3":26727,"PHASE4":26729,"NA":26731},{"trials":26718,"activeCount":101},[],{"trials":26720,"activeCount":101},[],{"trials":26722,"activeCount":101},[26723],{"nctId":4061,"briefTitle":4062,"status":107,"phases":26724,"primaryCompletion":2089,"completion":4064,"start":4065,"enrollment":4066,"conditions":26725,"interventions":26726},[90],[4068],[1015,4070,4071,4072],{"trials":26728,"activeCount":101},[],{"trials":26730,"activeCount":101},[],{"trials":26732,"activeCount":101},[],{"intervention":4072,"totalTrials":350,"cells":26734},{"EARLY_PHASE1":26735,"PHASE1":26737,"PHASE2":26739,"PHASE3":26745,"PHASE4":26747,"NA":26749},{"trials":26736,"activeCount":101},[],{"trials":26738,"activeCount":101},[],{"trials":26740,"activeCount":101},[26741],{"nctId":4061,"briefTitle":4062,"status":107,"phases":26742,"primaryCompletion":2089,"completion":4064,"start":4065,"enrollment":4066,"conditions":26743,"interventions":26744},[90],[4068],[1015,4070,4071,4072],{"trials":26746,"activeCount":101},[],{"trials":26748,"activeCount":101},[],{"trials":26750,"activeCount":101},[],{"intervention":6567,"totalTrials":350,"cells":26752},{"EARLY_PHASE1":26753,"PHASE1":26755,"PHASE2":26757,"PHASE3":26763,"PHASE4":26765,"NA":26767},{"trials":26754,"activeCount":101},[],{"trials":26756,"activeCount":101},[],{"trials":26758,"activeCount":101},[26759],{"nctId":6558,"briefTitle":6559,"status":130,"phases":26760,"primaryCompletion":6561,"completion":6561,"start":6562,"enrollment":6563,"conditions":26761,"interventions":26762},[90],[6565],[6567,4219,1163,1983],{"trials":26764,"activeCount":101},[],{"trials":26766,"activeCount":101},[],{"trials":26768,"activeCount":101},[],{"intervention":1288,"totalTrials":350,"cells":26770},{"EARLY_PHASE1":26771,"PHASE1":26773,"PHASE2":26775,"PHASE3":26781,"PHASE4":26783,"NA":26785},{"trials":26772,"activeCount":101},[],{"trials":26774,"activeCount":101},[],{"trials":26776,"activeCount":101},[26777],{"nctId":1277,"briefTitle":1278,"status":107,"phases":26778,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":26779,"interventions":26780},[89,90],[1285],[1287,1017,1288,68,988,1289],{"trials":26782,"activeCount":101},[],{"trials":26784,"activeCount":101},[],{"trials":26786,"activeCount":101},[],{"intervention":1289,"totalTrials":350,"cells":26788},{"EARLY_PHASE1":26789,"PHASE1":26791,"PHASE2":26793,"PHASE3":26799,"PHASE4":26801,"NA":26803},{"trials":26790,"activeCount":101},[],{"trials":26792,"activeCount":101},[],{"trials":26794,"activeCount":101},[26795],{"nctId":1277,"briefTitle":1278,"status":107,"phases":26796,"primaryCompletion":1280,"completion":1281,"start":1282,"enrollment":1283,"conditions":26797,"interventions":26798},[89,90],[1285],[1287,1017,1288,68,988,1289],{"trials":26800,"activeCount":101},[],{"trials":26802,"activeCount":101},[],{"trials":26804,"activeCount":101},[],{"intervention":26806,"totalTrials":350,"cells":26807},"P38 Inhibitor (4) 150mg",{"EARLY_PHASE1":26808,"PHASE1":26810,"PHASE2":26812,"PHASE3":26824,"PHASE4":26826,"NA":26828},{"trials":26809,"activeCount":101},[],{"trials":26811,"activeCount":101},[],{"trials":26813,"activeCount":101},[26814],{"nctId":26815,"briefTitle":26816,"status":107,"phases":26817,"primaryCompletion":4198,"completion":4198,"start":13164,"enrollment":25121,"conditions":26818,"interventions":26819},"NCT00316771","A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy",[90],[15],[26806,26820,26821,26822,26823],"P38 Inhibitor (4) 25mg","P38 Inhibitor (4) 300mg","P38 Inhibitor (4) 50mg","P38 Inhibitor (4) 75mg",{"trials":26825,"activeCount":101},[],{"trials":26827,"activeCount":101},[],{"trials":26829,"activeCount":101},[],{"intervention":26820,"totalTrials":350,"cells":26831},{"EARLY_PHASE1":26832,"PHASE1":26834,"PHASE2":26836,"PHASE3":26842,"PHASE4":26844,"NA":26846},{"trials":26833,"activeCount":101},[],{"trials":26835,"activeCount":101},[],{"trials":26837,"activeCount":101},[26838],{"nctId":26815,"briefTitle":26816,"status":107,"phases":26839,"primaryCompletion":4198,"completion":4198,"start":13164,"enrollment":25121,"conditions":26840,"interventions":26841},[90],[15],[26806,26820,26821,26822,26823],{"trials":26843,"activeCount":101},[],{"trials":26845,"activeCount":101},[],{"trials":26847,"activeCount":101},[],{"intervention":26821,"totalTrials":350,"cells":26849},{"EARLY_PHASE1":26850,"PHASE1":26852,"PHASE2":26854,"PHASE3":26860,"PHASE4":26862,"NA":26864},{"trials":26851,"activeCount":101},[],{"trials":26853,"activeCount":101},[],{"trials":26855,"activeCount":101},[26856],{"nctId":26815,"briefTitle":26816,"status":107,"phases":26857,"primaryCompletion":4198,"completion":4198,"start":13164,"enrollment":25121,"conditions":26858,"interventions":26859},[90],[15],[26806,26820,26821,26822,26823],{"trials":26861,"activeCount":101},[],{"trials":26863,"activeCount":101},[],{"trials":26865,"activeCount":101},[],{"intervention":26822,"totalTrials":350,"cells":26867},{"EARLY_PHASE1":26868,"PHASE1":26870,"PHASE2":26872,"PHASE3":26878,"PHASE4":26880,"NA":26882},{"trials":26869,"activeCount":101},[],{"trials":26871,"activeCount":101},[],{"trials":26873,"activeCount":101},[26874],{"nctId":26815,"briefTitle":26816,"status":107,"phases":26875,"primaryCompletion":4198,"completion":4198,"start":13164,"enrollment":25121,"conditions":26876,"interventions":26877},[90],[15],[26806,26820,26821,26822,26823],{"trials":26879,"activeCount":101},[],{"trials":26881,"activeCount":101},[],{"trials":26883,"activeCount":101},[],{"intervention":26823,"totalTrials":350,"cells":26885},{"EARLY_PHASE1":26886,"PHASE1":26888,"PHASE2":26890,"PHASE3":26896,"PHASE4":26898,"NA":26900},{"trials":26887,"activeCount":101},[],{"trials":26889,"activeCount":101},[],{"trials":26891,"activeCount":101},[26892],{"nctId":26815,"briefTitle":26816,"status":107,"phases":26893,"primaryCompletion":4198,"completion":4198,"start":13164,"enrollment":25121,"conditions":26894,"interventions":26895},[90],[15],[26806,26820,26821,26822,26823],{"trials":26897,"activeCount":101},[],{"trials":26899,"activeCount":101},[],{"trials":26901,"activeCount":101},[],{"intervention":4090,"totalTrials":350,"cells":26903},{"EARLY_PHASE1":26904,"PHASE1":26906,"PHASE2":26908,"PHASE3":26914,"PHASE4":26916,"NA":26918},{"trials":26905,"activeCount":101},[],{"trials":26907,"activeCount":101},[],{"trials":26909,"activeCount":101},[26910],{"nctId":4083,"briefTitle":4084,"status":107,"phases":26911,"primaryCompletion":2792,"completion":2792,"start":4086,"enrollment":1272,"conditions":26912,"interventions":26913},[90],[18],[4089,4090,992,1106,1015],{"trials":26915,"activeCount":101},[],{"trials":26917,"activeCount":101},[],{"trials":26919,"activeCount":101},[],{"intervention":26921,"totalTrials":350,"cells":26922},"TRO40303",{"EARLY_PHASE1":26923,"PHASE1":26925,"PHASE2":26927,"PHASE3":26936,"PHASE4":26938,"NA":26940},{"trials":26924,"activeCount":101},[],{"trials":26926,"activeCount":101},[],{"trials":26928,"activeCount":101},[26929],{"nctId":26930,"briefTitle":26931,"status":107,"phases":26932,"primaryCompletion":2684,"completion":2684,"start":6315,"enrollment":4489,"conditions":26933,"interventions":26935},"NCT01374321","Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction",[90],[26934],"Acute Myocardial Infarctus",[26921],{"trials":26937,"activeCount":101},[],{"trials":26939,"activeCount":101},[],{"trials":26941,"activeCount":101},[],{"intervention":17443,"totalTrials":350,"cells":26943},{"EARLY_PHASE1":26944,"PHASE1":26946,"PHASE2":26948,"PHASE3":26954,"PHASE4":26956,"NA":26958},{"trials":26945,"activeCount":101},[],{"trials":26947,"activeCount":101},[],{"trials":26949,"activeCount":101},[26950],{"nctId":17437,"briefTitle":17438,"status":107,"phases":26951,"start":17440,"enrollment":4683,"conditions":26952,"interventions":26953},[90],[33],[17428,11782,17443,17444,16518],{"trials":26955,"activeCount":101},[],{"trials":26957,"activeCount":101},[],{"trials":26959,"activeCount":101},[],{"intervention":17444,"totalTrials":350,"cells":26961},{"EARLY_PHASE1":26962,"PHASE1":26964,"PHASE2":26966,"PHASE3":26972,"PHASE4":26974,"NA":26976},{"trials":26963,"activeCount":101},[],{"trials":26965,"activeCount":101},[],{"trials":26967,"activeCount":101},[26968],{"nctId":17437,"briefTitle":17438,"status":107,"phases":26969,"start":17440,"enrollment":4683,"conditions":26970,"interventions":26971},[90],[33],[17428,11782,17443,17444,16518],{"trials":26973,"activeCount":101},[],{"trials":26975,"activeCount":101},[],{"trials":26977,"activeCount":101},[],{"intervention":17012,"totalTrials":350,"cells":26979},{"EARLY_PHASE1":26980,"PHASE1":26982,"PHASE2":26984,"PHASE3":26990,"PHASE4":26992,"NA":26994},{"trials":26981,"activeCount":101},[],{"trials":26983,"activeCount":101},[],{"trials":26985,"activeCount":101},[26986],{"nctId":17005,"briefTitle":17006,"status":107,"phases":26987,"primaryCompletion":4206,"completion":4206,"start":4513,"enrollment":17008,"conditions":26988,"interventions":26989},[90],[27],[16996,17011,17011,17012,17012,17012],{"trials":26991,"activeCount":101},[],{"trials":26993,"activeCount":101},[],{"trials":26995,"activeCount":101},[],{"intervention":3599,"totalTrials":350,"cells":26997},{"EARLY_PHASE1":26998,"PHASE1":27000,"PHASE2":27002,"PHASE3":27008,"PHASE4":27010,"NA":27012},{"trials":26999,"activeCount":101},[],{"trials":27001,"activeCount":101},[],{"trials":27003,"activeCount":101},[27004],{"nctId":3589,"briefTitle":3590,"status":107,"phases":27005,"primaryCompletion":3592,"completion":3593,"start":3594,"enrollment":3595,"conditions":27006,"interventions":27007},[90],[3597],[3599,1018,274,1357],{"trials":27009,"activeCount":101},[],{"trials":27011,"activeCount":101},[],{"trials":27013,"activeCount":101},[],{"intervention":3609,"totalTrials":350,"cells":27015},{"EARLY_PHASE1":27016,"PHASE1":27018,"PHASE2":27020,"PHASE3":27026,"PHASE4":27028,"NA":27030},{"trials":27017,"activeCount":101},[],{"trials":27019,"activeCount":101},[],{"trials":27021,"activeCount":101},[27022],{"nctId":3601,"briefTitle":3602,"status":107,"phases":27023,"primaryCompletion":3604,"completion":3605,"start":1214,"enrollment":2492,"conditions":27024,"interventions":27025},[89,90],[3607],[3609,2644,1018],{"trials":27027,"activeCount":101},[],{"trials":27029,"activeCount":101},[],{"trials":27031,"activeCount":101},[],{"intervention":16231,"totalTrials":350,"cells":27033},{"EARLY_PHASE1":27034,"PHASE1":27036,"PHASE2":27038,"PHASE3":27044,"PHASE4":27046,"NA":27048},{"trials":27035,"activeCount":101},[],{"trials":27037,"activeCount":101},[],{"trials":27039,"activeCount":101},[27040],{"nctId":16225,"briefTitle":16226,"status":107,"phases":27041,"primaryCompletion":7152,"completion":7152,"start":2965,"enrollment":16228,"conditions":27042,"interventions":27043},[90],[975],[16231,5384],{"trials":27045,"activeCount":101},[],{"trials":27047,"activeCount":101},[],{"trials":27049,"activeCount":101},[],{"intervention":27051,"totalTrials":350,"cells":27052},"RAR Gamma",{"EARLY_PHASE1":27053,"PHASE1":27055,"PHASE2":27057,"PHASE3":27067,"PHASE4":27069,"NA":27071},{"trials":27054,"activeCount":101},[],{"trials":27056,"activeCount":101},[],{"trials":27058,"activeCount":101},[27059],{"nctId":27060,"briefTitle":27061,"status":107,"phases":27062,"primaryCompletion":3104,"completion":3104,"start":16669,"enrollment":27063,"conditions":27064,"interventions":27066},"NCT00413205","TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)",[90],491,[27065],"Emphysema",[27051],{"trials":27068,"activeCount":101},[],{"trials":27070,"activeCount":101},[],{"trials":27072,"activeCount":101},[],{"intervention":8269,"totalTrials":350,"cells":27074},{"EARLY_PHASE1":27075,"PHASE1":27077,"PHASE2":27079,"PHASE3":27085,"PHASE4":27087,"NA":27089},{"trials":27076,"activeCount":101},[],{"trials":27078,"activeCount":101},[],{"trials":27080,"activeCount":101},[27081],{"nctId":8264,"briefTitle":8265,"status":107,"phases":27082,"primaryCompletion":5181,"completion":2801,"start":4113,"enrollment":2429,"conditions":27083,"interventions":27084},[90],[18],[8269,1222,947],{"trials":27086,"activeCount":101},[],{"trials":27088,"activeCount":101},[],{"trials":27090,"activeCount":101},[],{"intervention":2654,"totalTrials":350,"cells":27092},{"EARLY_PHASE1":27093,"PHASE1":27095,"PHASE2":27097,"PHASE3":27103,"PHASE4":27105,"NA":27107},{"trials":27094,"activeCount":101},[],{"trials":27096,"activeCount":101},[],{"trials":27098,"activeCount":101},[27099],{"nctId":2646,"briefTitle":2647,"status":107,"phases":27100,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":291,"conditions":27101,"interventions":27102},[89,90],[2652],[2654,2655,1785,1096],{"trials":27104,"activeCount":101},[],{"trials":27106,"activeCount":101},[],{"trials":27108,"activeCount":101},[],{"intervention":2655,"totalTrials":350,"cells":27110},{"EARLY_PHASE1":27111,"PHASE1":27113,"PHASE2":27115,"PHASE3":27121,"PHASE4":27123,"NA":27125},{"trials":27112,"activeCount":101},[],{"trials":27114,"activeCount":101},[],{"trials":27116,"activeCount":101},[27117],{"nctId":2646,"briefTitle":2647,"status":107,"phases":27118,"primaryCompletion":2649,"completion":2649,"start":2650,"enrollment":291,"conditions":27119,"interventions":27120},[89,90],[2652],[2654,2655,1785,1096],{"trials":27122,"activeCount":101},[],{"trials":27124,"activeCount":101},[],{"trials":27126,"activeCount":101},[],{"intervention":1318,"totalTrials":350,"cells":27128},{"EARLY_PHASE1":27129,"PHASE1":27131,"PHASE2":27133,"PHASE3":27139,"PHASE4":27141,"NA":27143},{"trials":27130,"activeCount":101},[],{"trials":27132,"activeCount":101},[],{"trials":27134,"activeCount":101},[27135],{"nctId":1308,"briefTitle":1309,"status":130,"phases":27136,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":27137,"interventions":27138},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"trials":27140,"activeCount":101},[],{"trials":27142,"activeCount":101},[],{"trials":27144,"activeCount":101},[],{"intervention":1322,"totalTrials":350,"cells":27146},{"EARLY_PHASE1":27147,"PHASE1":27149,"PHASE2":27151,"PHASE3":27157,"PHASE4":27159,"NA":27161},{"trials":27148,"activeCount":101},[],{"trials":27150,"activeCount":101},[],{"trials":27152,"activeCount":101},[27153],{"nctId":1308,"briefTitle":1309,"status":130,"phases":27154,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":27155,"interventions":27156},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"trials":27158,"activeCount":101},[],{"trials":27160,"activeCount":101},[],{"trials":27162,"activeCount":101},[],{"intervention":1323,"totalTrials":350,"cells":27164},{"EARLY_PHASE1":27165,"PHASE1":27167,"PHASE2":27169,"PHASE3":27175,"PHASE4":27177,"NA":27179},{"trials":27166,"activeCount":101},[],{"trials":27168,"activeCount":101},[],{"trials":27170,"activeCount":101},[27171],{"nctId":1308,"briefTitle":1309,"status":130,"phases":27172,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":27173,"interventions":27174},[89,90],[1316],[68,1084,1151,947,1318,1319,990,1163,1320,1096,946,1015,1321,1322,988,1323,1324],{"trials":27176,"activeCount":101},[],{"trials":27178,"activeCount":101},[],{"trials":27180,"activeCount":101},[],{"intervention":1334,"totalTrials":350,"cells":27182},{"EARLY_PHASE1":27183,"PHASE1":27185,"PHASE2":27187,"PHASE3":27193,"PHASE4":27195,"NA":27197},{"trials":27184,"activeCount":101},[],{"trials":27186,"activeCount":101},[],{"trials":27188,"activeCount":101},[27189],{"nctId":1326,"briefTitle":1327,"status":130,"phases":27190,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":306,"conditions":27191,"interventions":27192},[89,90],[1332],[1334,988,68],{"trials":27194,"activeCount":101},[],{"trials":27196,"activeCount":101},[],{"trials":27198,"activeCount":101},[],{"intervention":27200,"totalTrials":350,"cells":27201},"Sildenafil",{"EARLY_PHASE1":27202,"PHASE1":27204,"PHASE2":27206,"PHASE3":27216,"PHASE4":27218,"NA":27220},{"trials":27203,"activeCount":101},[],{"trials":27205,"activeCount":101},[],{"trials":27207,"activeCount":101},[27208],{"nctId":27209,"briefTitle":27210,"status":107,"phases":27211,"primaryCompletion":4884,"completion":27212,"start":27213,"enrollment":7619,"conditions":27214,"interventions":27215},"NCT02951429","Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension",[90],"2020-08-22","2016-12-31",[18883],[18885,27200],{"trials":27217,"activeCount":101},[],{"trials":27219,"activeCount":101},[],{"trials":27221,"activeCount":101},[],{"intervention":15820,"totalTrials":350,"cells":27223},{"EARLY_PHASE1":27224,"PHASE1":27226,"PHASE2":27228,"PHASE3":27234,"PHASE4":27236,"NA":27238},{"trials":27225,"activeCount":101},[],{"trials":27227,"activeCount":101},[],{"trials":27229,"activeCount":101},[27230],{"nctId":15815,"briefTitle":15816,"status":107,"phases":27231,"primaryCompletion":8826,"completion":8826,"start":8658,"enrollment":2743,"conditions":27232,"interventions":27233},[90],[30],[5275,15820,5381,5384],{"trials":27235,"activeCount":101},[],{"trials":27237,"activeCount":101},[],{"trials":27239,"activeCount":101},[],{"intervention":20882,"totalTrials":350,"cells":27241},{"EARLY_PHASE1":27242,"PHASE1":27244,"PHASE2":27246,"PHASE3":27252,"PHASE4":27254,"NA":27256},{"trials":27243,"activeCount":101},[],{"trials":27245,"activeCount":101},[],{"trials":27247,"activeCount":101},[27248],{"nctId":20874,"briefTitle":20875,"status":107,"phases":27249,"primaryCompletion":20877,"completion":20877,"start":20878,"enrollment":559,"conditions":27250,"interventions":27251},[90],[20880],[20855,20882],{"trials":27253,"activeCount":101},[],{"trials":27255,"activeCount":101},[],{"trials":27257,"activeCount":101},[],{"intervention":27259,"totalTrials":350,"cells":27260},"RG7314",{"EARLY_PHASE1":27261,"PHASE1":27263,"PHASE2":27265,"PHASE3":27274,"PHASE4":27276,"NA":27278},{"trials":27262,"activeCount":101},[],{"trials":27264,"activeCount":101},[],{"trials":27266,"activeCount":101},[27267],{"nctId":27268,"briefTitle":27269,"status":107,"phases":27270,"primaryCompletion":27271,"completion":27271,"start":2684,"enrollment":5304,"conditions":27272,"interventions":27273},"NCT01793441","A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)",[90],"2016-09",[11768],[27259],{"trials":27275,"activeCount":101},[],{"trials":27277,"activeCount":101},[],{"trials":27279,"activeCount":101},[],{"intervention":27281,"totalTrials":350,"cells":27282},"RO5036505",{"EARLY_PHASE1":27283,"PHASE1":27285,"PHASE2":27287,"PHASE3":27295,"PHASE4":27297,"NA":27299},{"trials":27284,"activeCount":101},[],{"trials":27286,"activeCount":101},[],{"trials":27288,"activeCount":101},[27289],{"nctId":27290,"briefTitle":27291,"status":343,"phases":27292,"completion":7152,"start":6004,"enrollment":101,"conditions":27293,"interventions":27294},"NCT00967590","A Study of RO5036505 in Patients With Moderate to Severe Asthma",[90],[17203],[27281],{"trials":27296,"activeCount":101},[],{"trials":27298,"activeCount":101},[],{"trials":27300,"activeCount":101},[],{"intervention":21411,"totalTrials":350,"cells":27302},{"EARLY_PHASE1":27303,"PHASE1":27305,"PHASE2":27307,"PHASE3":27313,"PHASE4":27315,"NA":27317},{"trials":27304,"activeCount":101},[],{"trials":27306,"activeCount":101},[],{"trials":27308,"activeCount":101},[27309],{"nctId":21406,"briefTitle":21407,"status":107,"phases":27310,"primaryCompletion":2685,"completion":2685,"start":4315,"enrollment":984,"conditions":27311,"interventions":27312},[90],[1241],[5275,9036,21411,9083],{"trials":27314,"activeCount":101},[],{"trials":27316,"activeCount":101},[],{"trials":27318,"activeCount":101},[],{"intervention":27320,"totalTrials":350,"cells":27321},"Alogabat",{"EARLY_PHASE1":27322,"PHASE1":27324,"PHASE2":27326,"PHASE3":27337,"PHASE4":27339,"NA":27341},{"trials":27323,"activeCount":101},[],{"trials":27325,"activeCount":101},[],{"trials":27327,"activeCount":101},[27328],{"nctId":27329,"briefTitle":27330,"status":107,"phases":27331,"primaryCompletion":27332,"completion":27332,"start":27333,"enrollment":123,"conditions":27334,"interventions":27336},"NCT05630066","A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.",[90],"2025-12-02","2023-07-27",[27335],"Angelman Syndrome",[27320],{"trials":27338,"activeCount":101},[],{"trials":27340,"activeCount":101},[],{"trials":27342,"activeCount":101},[],{"intervention":6063,"totalTrials":350,"cells":27344},{"EARLY_PHASE1":27345,"PHASE1":27347,"PHASE2":27349,"PHASE3":27355,"PHASE4":27357,"NA":27359},{"trials":27346,"activeCount":101},[],{"trials":27348,"activeCount":101},[],{"trials":27350,"activeCount":101},[27351],{"nctId":6058,"briefTitle":6059,"status":130,"phases":27352,"primaryCompletion":3246,"completion":3246,"start":4409,"enrollment":306,"conditions":27353,"interventions":27354},[90],[3826],[992,3482,6063,1359],{"trials":27356,"activeCount":101},[],{"trials":27358,"activeCount":101},[],{"trials":27360,"activeCount":101},[],{"intervention":26224,"totalTrials":350,"cells":27362},{"EARLY_PHASE1":27363,"PHASE1":27365,"PHASE2":27367,"PHASE3":27373,"PHASE4":27375,"NA":27377},{"trials":27364,"activeCount":101},[],{"trials":27366,"activeCount":101},[],{"trials":27368,"activeCount":101},[27369],{"nctId":26218,"briefTitle":26219,"status":107,"phases":27370,"primaryCompletion":16669,"completion":16669,"start":8659,"enrollment":17952,"conditions":27371,"interventions":27372},[90],[26222],[26224,26209,26209],{"trials":27374,"activeCount":101},[],{"trials":27376,"activeCount":101},[],{"trials":27378,"activeCount":101},[],{"intervention":4142,"totalTrials":350,"cells":27380},{"EARLY_PHASE1":27381,"PHASE1":27383,"PHASE2":27385,"PHASE3":27391,"PHASE4":27393,"NA":27395},{"trials":27382,"activeCount":101},[],{"trials":27384,"activeCount":101},[],{"trials":27386,"activeCount":101},[27387],{"nctId":4133,"briefTitle":4134,"status":107,"phases":27388,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":27389,"interventions":27390},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"trials":27392,"activeCount":101},[],{"trials":27394,"activeCount":101},[],{"trials":27396,"activeCount":101},[],{"intervention":4143,"totalTrials":350,"cells":27398},{"EARLY_PHASE1":27399,"PHASE1":27401,"PHASE2":27403,"PHASE3":27409,"PHASE4":27411,"NA":27413},{"trials":27400,"activeCount":101},[],{"trials":27402,"activeCount":101},[],{"trials":27404,"activeCount":101},[27405],{"nctId":4133,"briefTitle":4134,"status":107,"phases":27406,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":27407,"interventions":27408},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"trials":27410,"activeCount":101},[],{"trials":27412,"activeCount":101},[],{"trials":27414,"activeCount":101},[],{"intervention":4144,"totalTrials":350,"cells":27416},{"EARLY_PHASE1":27417,"PHASE1":27419,"PHASE2":27421,"PHASE3":27427,"PHASE4":27429,"NA":27431},{"trials":27418,"activeCount":101},[],{"trials":27420,"activeCount":101},[],{"trials":27422,"activeCount":101},[27423],{"nctId":4133,"briefTitle":4134,"status":107,"phases":27424,"primaryCompletion":367,"completion":367,"start":4136,"enrollment":4137,"conditions":27425,"interventions":27426},[89,90],[4139],[4141,1015,4142,4143,1573,946,4144,1420],{"trials":27428,"activeCount":101},[],{"trials":27430,"activeCount":101},[],{"trials":27432,"activeCount":101},[],{"intervention":7933,"totalTrials":350,"cells":27434},{"EARLY_PHASE1":27435,"PHASE1":27437,"PHASE2":27439,"PHASE3":27445,"PHASE4":27447,"NA":27449},{"trials":27436,"activeCount":101},[],{"trials":27438,"activeCount":101},[],{"trials":27440,"activeCount":101},[27441],{"nctId":7927,"briefTitle":7928,"status":107,"phases":27442,"primaryCompletion":6004,"completion":6004,"start":7930,"enrollment":1047,"conditions":27443,"interventions":27444},[89,90],[18],[6647,4503,7933],{"trials":27446,"activeCount":101},[],{"trials":27448,"activeCount":101},[],{"trials":27450,"activeCount":101},[],{"intervention":21205,"totalTrials":350,"cells":27452},{"EARLY_PHASE1":27453,"PHASE1":27455,"PHASE2":27457,"PHASE3":27463,"PHASE4":27465,"NA":27467},{"trials":27454,"activeCount":101},[],{"trials":27456,"activeCount":101},[],{"trials":27458,"activeCount":101},[27459],{"nctId":21196,"briefTitle":21197,"status":107,"phases":27460,"primaryCompletion":21199,"completion":21200,"start":21201,"enrollment":3923,"conditions":27461,"interventions":27462},[90],[21203],[21205,8162,8164],{"trials":27464,"activeCount":101},[],{"trials":27466,"activeCount":101},[],{"trials":27468,"activeCount":101},[],{"intervention":27470,"totalTrials":350,"cells":27471},"GC33",{"EARLY_PHASE1":27472,"PHASE1":27474,"PHASE2":27476,"PHASE3":27486,"PHASE4":27488,"NA":27490},{"trials":27473,"activeCount":101},[],{"trials":27475,"activeCount":101},[],{"trials":27477,"activeCount":101},[27478],{"nctId":27479,"briefTitle":27480,"status":107,"phases":27481,"primaryCompletion":27482,"completion":27482,"start":27483,"enrollment":5821,"conditions":27484,"interventions":27485},"NCT01507168","A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma",[90],"2015-08-20","2012-02-02",[1443],[27470],{"trials":27487,"activeCount":101},[],{"trials":27489,"activeCount":101},[],{"trials":27491,"activeCount":101},[],{"intervention":4175,"totalTrials":350,"cells":27493},{"EARLY_PHASE1":27494,"PHASE1":27496,"PHASE2":27498,"PHASE3":27504,"PHASE4":27506,"NA":27508},{"trials":27495,"activeCount":101},[],{"trials":27497,"activeCount":101},[],{"trials":27499,"activeCount":101},[27500],{"nctId":4168,"briefTitle":4169,"status":107,"phases":27501,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":806,"conditions":27502,"interventions":27503},[90],[18],[1015,947,1222,4175],{"trials":27505,"activeCount":101},[],{"trials":27507,"activeCount":101},[],{"trials":27509,"activeCount":101},[],{"intervention":27511,"totalTrials":350,"cells":27512},"Induction- PF-06480605 50 mg SC Q4W",{"EARLY_PHASE1":27513,"PHASE1":27515,"PHASE2":27517,"PHASE3":27532,"PHASE4":27534,"NA":27536},{"trials":27514,"activeCount":101},[],{"trials":27516,"activeCount":101},[],{"trials":27518,"activeCount":101},[27519],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27522,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27524,"interventions":27526},"NCT04090411","A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis",[90],246,[27525],"Moderate to Severe Ulcerative Colitis",[27511,27527,27528,27529,27530,27531],"Induction- PF-06480605 150 mg SC Q4W","Induction- PF-06480605 450 mg SC Q4W","Chronic- PF-06480605 50 mg SC Q4W","Chronic- PF-06480605 150 mg SC Q4W","Chronic- PF-06480605 450 mg SC Q4W",{"trials":27533,"activeCount":101},[],{"trials":27535,"activeCount":101},[],{"trials":27537,"activeCount":101},[],{"intervention":27527,"totalTrials":350,"cells":27539},{"EARLY_PHASE1":27540,"PHASE1":27542,"PHASE2":27544,"PHASE3":27550,"PHASE4":27552,"NA":27554},{"trials":27541,"activeCount":101},[],{"trials":27543,"activeCount":101},[],{"trials":27545,"activeCount":101},[27546],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27547,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27548,"interventions":27549},[90],[27525],[27511,27527,27528,27529,27530,27531],{"trials":27551,"activeCount":101},[],{"trials":27553,"activeCount":101},[],{"trials":27555,"activeCount":101},[],{"intervention":27528,"totalTrials":350,"cells":27557},{"EARLY_PHASE1":27558,"PHASE1":27560,"PHASE2":27562,"PHASE3":27568,"PHASE4":27570,"NA":27572},{"trials":27559,"activeCount":101},[],{"trials":27561,"activeCount":101},[],{"trials":27563,"activeCount":101},[27564],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27565,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27566,"interventions":27567},[90],[27525],[27511,27527,27528,27529,27530,27531],{"trials":27569,"activeCount":101},[],{"trials":27571,"activeCount":101},[],{"trials":27573,"activeCount":101},[],{"intervention":27529,"totalTrials":350,"cells":27575},{"EARLY_PHASE1":27576,"PHASE1":27578,"PHASE2":27580,"PHASE3":27586,"PHASE4":27588,"NA":27590},{"trials":27577,"activeCount":101},[],{"trials":27579,"activeCount":101},[],{"trials":27581,"activeCount":101},[27582],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27583,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27584,"interventions":27585},[90],[27525],[27511,27527,27528,27529,27530,27531],{"trials":27587,"activeCount":101},[],{"trials":27589,"activeCount":101},[],{"trials":27591,"activeCount":101},[],{"intervention":27530,"totalTrials":350,"cells":27593},{"EARLY_PHASE1":27594,"PHASE1":27596,"PHASE2":27598,"PHASE3":27604,"PHASE4":27606,"NA":27608},{"trials":27595,"activeCount":101},[],{"trials":27597,"activeCount":101},[],{"trials":27599,"activeCount":101},[27600],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27601,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27602,"interventions":27603},[90],[27525],[27511,27527,27528,27529,27530,27531],{"trials":27605,"activeCount":101},[],{"trials":27607,"activeCount":101},[],{"trials":27609,"activeCount":101},[],{"intervention":27531,"totalTrials":350,"cells":27611},{"EARLY_PHASE1":27612,"PHASE1":27614,"PHASE2":27616,"PHASE3":27622,"PHASE4":27624,"NA":27626},{"trials":27613,"activeCount":101},[],{"trials":27615,"activeCount":101},[],{"trials":27617,"activeCount":101},[27618],{"nctId":27520,"briefTitle":27521,"status":107,"phases":27619,"primaryCompletion":2399,"completion":2399,"start":20330,"enrollment":27523,"conditions":27620,"interventions":27621},[90],[27525],[27511,27527,27528,27529,27530,27531],{"trials":27623,"activeCount":101},[],{"trials":27625,"activeCount":101},[],{"trials":27627,"activeCount":101},[],{"intervention":4185,"totalTrials":350,"cells":27629},{"EARLY_PHASE1":27630,"PHASE1":27632,"PHASE2":27634,"PHASE3":27640,"PHASE4":27642,"NA":27644},{"trials":27631,"activeCount":101},[],{"trials":27633,"activeCount":101},[],{"trials":27635,"activeCount":101},[27636],{"nctId":4177,"briefTitle":4178,"status":107,"phases":27637,"primaryCompletion":4180,"completion":4180,"start":4181,"enrollment":2839,"conditions":27638,"interventions":27639},[90],[18],[4184,1015,4185,1597,992,1106,947],{"trials":27641,"activeCount":101},[],{"trials":27643,"activeCount":101},[],{"trials":27645,"activeCount":101},[],{"intervention":25258,"totalTrials":350,"cells":27647},{"EARLY_PHASE1":27648,"PHASE1":27650,"PHASE2":27652,"PHASE3":27658,"PHASE4":27660,"NA":27662},{"trials":27649,"activeCount":101},[],{"trials":27651,"activeCount":101},[],{"trials":27653,"activeCount":101},[27654],{"nctId":25251,"briefTitle":25252,"status":107,"phases":27655,"primaryCompletion":25254,"completion":25254,"start":25255,"enrollment":1133,"conditions":27656,"interventions":27657},[90],[14384],[25215,25258,25259,25260,25261],{"trials":27659,"activeCount":101},[],{"trials":27661,"activeCount":101},[],{"trials":27663,"activeCount":101},[],{"intervention":25260,"totalTrials":350,"cells":27665},{"EARLY_PHASE1":27666,"PHASE1":27668,"PHASE2":27670,"PHASE3":27676,"PHASE4":27678,"NA":27680},{"trials":27667,"activeCount":101},[],{"trials":27669,"activeCount":101},[],{"trials":27671,"activeCount":101},[27672],{"nctId":25251,"briefTitle":25252,"status":107,"phases":27673,"primaryCompletion":25254,"completion":25254,"start":25255,"enrollment":1133,"conditions":27674,"interventions":27675},[90],[14384],[25215,25258,25259,25260,25261],{"trials":27677,"activeCount":101},[],{"trials":27679,"activeCount":101},[],{"trials":27681,"activeCount":101},[],{"intervention":25261,"totalTrials":350,"cells":27683},{"EARLY_PHASE1":27684,"PHASE1":27686,"PHASE2":27688,"PHASE3":27694,"PHASE4":27696,"NA":27698},{"trials":27685,"activeCount":101},[],{"trials":27687,"activeCount":101},[],{"trials":27689,"activeCount":101},[27690],{"nctId":25251,"briefTitle":25252,"status":107,"phases":27691,"primaryCompletion":25254,"completion":25254,"start":25255,"enrollment":1133,"conditions":27692,"interventions":27693},[90],[14384],[25215,25258,25259,25260,25261],{"trials":27695,"activeCount":101},[],{"trials":27697,"activeCount":101},[],{"trials":27699,"activeCount":101},[],{"intervention":1434,"totalTrials":350,"cells":27701},{"EARLY_PHASE1":27702,"PHASE1":27704,"PHASE2":27706,"PHASE3":27712,"PHASE4":27714,"NA":27716},{"trials":27703,"activeCount":101},[],{"trials":27705,"activeCount":101},[],{"trials":27707,"activeCount":101},[27708],{"nctId":1426,"briefTitle":1427,"status":343,"phases":27709,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":101,"conditions":27710,"interventions":27711},[90],[1432],[68,1434],{"trials":27713,"activeCount":101},[],{"trials":27715,"activeCount":101},[],{"trials":27717,"activeCount":101},[],{"intervention":26380,"totalTrials":350,"cells":27719},{"EARLY_PHASE1":27720,"PHASE1":27722,"PHASE2":27724,"PHASE3":27730,"PHASE4":27732,"NA":27734},{"trials":27721,"activeCount":101},[],{"trials":27723,"activeCount":101},[],{"trials":27725,"activeCount":101},[27726],{"nctId":26375,"briefTitle":26376,"status":130,"phases":27727,"primaryCompletion":3103,"completion":3103,"start":2685,"enrollment":162,"conditions":27728,"interventions":27729},[90],[36],[26360,26360,26380],{"trials":27731,"activeCount":101},[],{"trials":27733,"activeCount":101},[],{"trials":27735,"activeCount":101},[],{"intervention":27737,"totalTrials":350,"cells":27738},"A4I Antagonist",{"EARLY_PHASE1":27739,"PHASE1":27741,"PHASE2":27743,"PHASE3":27751,"PHASE4":27753,"NA":27755},{"trials":27740,"activeCount":101},[],{"trials":27742,"activeCount":101},[],{"trials":27744,"activeCount":101},[27745],{"nctId":27746,"briefTitle":27747,"status":343,"phases":27748,"start":2965,"enrollment":101,"conditions":27749,"interventions":27750},"NCT00104143","A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.",[90],[147],[27737],{"trials":27752,"activeCount":101},[],{"trials":27754,"activeCount":101},[],{"trials":27756,"activeCount":101},[],{"intervention":5657,"totalTrials":350,"cells":27758},{"EARLY_PHASE1":27759,"PHASE1":27761,"PHASE2":27763,"PHASE3":27769,"PHASE4":27771,"NA":27773},{"trials":27760,"activeCount":101},[],{"trials":27762,"activeCount":101},[],{"trials":27764,"activeCount":101},[27765],{"nctId":5649,"briefTitle":5650,"status":107,"phases":27766,"primaryCompletion":5652,"completion":2363,"start":5653,"enrollment":11,"conditions":27767,"interventions":27768},[90],[5655],[63,5657,1421],{"trials":27770,"activeCount":101},[],{"trials":27772,"activeCount":101},[],{"trials":27774,"activeCount":101},[],{"intervention":14457,"totalTrials":350,"cells":27776},{"EARLY_PHASE1":27777,"PHASE1":27779,"PHASE2":27781,"PHASE3":27787,"PHASE4":27789,"NA":27791},{"trials":27778,"activeCount":101},[],{"trials":27780,"activeCount":101},[],{"trials":27782,"activeCount":101},[27783],{"nctId":14451,"briefTitle":14452,"status":107,"phases":27784,"primaryCompletion":4113,"completion":4113,"start":14454,"enrollment":909,"conditions":27785,"interventions":27786},[90],[5846],[5848,14457,11717,14458],{"trials":27788,"activeCount":101},[],{"trials":27790,"activeCount":101},[],{"trials":27792,"activeCount":101},[],{"intervention":10089,"totalTrials":350,"cells":27794},{"EARLY_PHASE1":27795,"PHASE1":27797,"PHASE2":27799,"PHASE3":27805,"PHASE4":27807,"NA":27809},{"trials":27796,"activeCount":101},[],{"trials":27798,"activeCount":101},[],{"trials":27800,"activeCount":101},[27801],{"nctId":10078,"briefTitle":10079,"status":130,"phases":27802,"primaryCompletion":10081,"completion":10081,"start":10082,"enrollment":2492,"conditions":27803,"interventions":27804},[89,90],[10084,10085,10086,922],[1500,1073,992,6713,3482,10088,10089],{"trials":27806,"activeCount":101},[],{"trials":27808,"activeCount":101},[],{"trials":27810,"activeCount":101},[],{"intervention":26232,"totalTrials":350,"cells":27812},{"EARLY_PHASE1":27813,"PHASE1":27815,"PHASE2":27817,"PHASE3":27823,"PHASE4":27825,"NA":27827},{"trials":27814,"activeCount":101},[],{"trials":27816,"activeCount":101},[],{"trials":27818,"activeCount":101},[27819],{"nctId":26226,"briefTitle":26227,"status":107,"phases":27820,"primaryCompletion":2965,"completion":2965,"start":5469,"enrollment":6307,"conditions":27821,"interventions":27822},[90],[26230],[26232,26209,26209],{"trials":27824,"activeCount":101},[],{"trials":27826,"activeCount":101},[],{"trials":27828,"activeCount":101},[],{"intervention":27830,"totalTrials":350,"cells":27831},"Metronidazole Actavis",{"EARLY_PHASE1":27832,"PHASE1":27834,"PHASE2":27836,"PHASE3":27844,"PHASE4":27846,"NA":27848},{"trials":27833,"activeCount":101},[],{"trials":27835,"activeCount":101},[],{"trials":27837,"activeCount":101},[27838],{"nctId":27839,"briefTitle":27840,"status":107,"phases":27841,"primaryCompletion":3325,"completion":3325,"start":4086,"enrollment":1705,"conditions":27842,"interventions":27843},"NCT00642473","A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash",[90],[2257],[977,27830],{"trials":27845,"activeCount":101},[],{"trials":27847,"activeCount":101},[],{"trials":27849,"activeCount":101},[],{"intervention":25301,"totalTrials":350,"cells":27851},{"EARLY_PHASE1":27852,"PHASE1":27854,"PHASE2":27856,"PHASE3":27862,"PHASE4":27864,"NA":27866},{"trials":27853,"activeCount":101},[],{"trials":27855,"activeCount":101},[],{"trials":27857,"activeCount":101},[27858],{"nctId":25296,"briefTitle":25297,"status":107,"phases":27859,"primaryCompletion":5271,"completion":5271,"start":4322,"enrollment":1283,"conditions":27860,"interventions":27861},[90],[36],[25301,25301,19325,19325],{"trials":27863,"activeCount":101},[],{"trials":27865,"activeCount":101},[],{"trials":27867,"activeCount":101},[],{"intervention":27869,"totalTrials":350,"cells":27870},"Experimental",{"EARLY_PHASE1":27871,"PHASE1":27873,"PHASE2":27875,"PHASE3":27884,"PHASE4":27886,"NA":27888},{"trials":27872,"activeCount":101},[],{"trials":27874,"activeCount":101},[],{"trials":27876,"activeCount":101},[27877],{"nctId":27878,"briefTitle":27879,"status":107,"phases":27880,"primaryCompletion":4562,"completion":4562,"start":6620,"enrollment":6188,"conditions":27881,"interventions":27883},"NCT00496457","Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy",[90],[27882],"Diabetic Neuropathy",[27869],{"trials":27885,"activeCount":101},[],{"trials":27887,"activeCount":101},[],{"trials":27889,"activeCount":101},[],{"intervention":19385,"totalTrials":350,"cells":27891},{"EARLY_PHASE1":27892,"PHASE1":27894,"PHASE2":27896,"PHASE3":27902,"PHASE4":27904,"NA":27906},{"trials":27893,"activeCount":101},[],{"trials":27895,"activeCount":101},[],{"trials":27897,"activeCount":101},[27898],{"nctId":19380,"briefTitle":19381,"status":107,"phases":27899,"primaryCompletion":2956,"completion":2956,"start":3213,"enrollment":1283,"conditions":27900,"interventions":27901},[90],[27],[17034,17019,19385,17976,11969],{"trials":27903,"activeCount":101},[],{"trials":27905,"activeCount":101},[],{"trials":27907,"activeCount":101},[],{"intervention":27909,"totalTrials":350,"cells":27910},"ANA598",{"EARLY_PHASE1":27911,"PHASE1":27913,"PHASE2":27915,"PHASE3":27925,"PHASE4":27927,"NA":27929},{"trials":27912,"activeCount":101},[],{"trials":27914,"activeCount":101},[],{"trials":27916,"activeCount":101},[27917],{"nctId":27918,"briefTitle":27919,"status":107,"phases":27920,"primaryCompletion":8826,"completion":9079,"start":6004,"enrollment":8990,"conditions":27921,"interventions":27923},"NCT00978497","Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",[90],[27922],"HCV Infection",[27909,27909,27924,17366],"Peginterferon",{"trials":27926,"activeCount":101},[],{"trials":27928,"activeCount":101},[],{"trials":27930,"activeCount":101},[],{"intervention":27924,"totalTrials":350,"cells":27932},{"EARLY_PHASE1":27933,"PHASE1":27935,"PHASE2":27937,"PHASE3":27943,"PHASE4":27945,"NA":27947},{"trials":27934,"activeCount":101},[],{"trials":27936,"activeCount":101},[],{"trials":27938,"activeCount":101},[27939],{"nctId":27918,"briefTitle":27919,"status":107,"phases":27940,"primaryCompletion":8826,"completion":9079,"start":6004,"enrollment":8990,"conditions":27941,"interventions":27942},[90],[27922],[27909,27909,27924,17366],{"trials":27944,"activeCount":101},[],{"trials":27946,"activeCount":101},[],{"trials":27948,"activeCount":101},[],{"intervention":1498,"totalTrials":350,"cells":27950},{"EARLY_PHASE1":27951,"PHASE1":27953,"PHASE2":27955,"PHASE3":27961,"PHASE4":27963,"NA":27965},{"trials":27952,"activeCount":101},[],{"trials":27954,"activeCount":101},[],{"trials":27956,"activeCount":101},[27957],{"nctId":1490,"briefTitle":1491,"status":130,"phases":27958,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":27959,"interventions":27960},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"trials":27962,"activeCount":101},[],{"trials":27964,"activeCount":101},[],{"trials":27966,"activeCount":101},[],{"intervention":1499,"totalTrials":350,"cells":27968},{"EARLY_PHASE1":27969,"PHASE1":27971,"PHASE2":27973,"PHASE3":27979,"PHASE4":27981,"NA":27983},{"trials":27970,"activeCount":101},[],{"trials":27972,"activeCount":101},[],{"trials":27974,"activeCount":101},[27975],{"nctId":1490,"briefTitle":1491,"status":130,"phases":27976,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":27977,"interventions":27978},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"trials":27980,"activeCount":101},[],{"trials":27982,"activeCount":101},[],{"trials":27984,"activeCount":101},[],{"intervention":1502,"totalTrials":350,"cells":27986},{"EARLY_PHASE1":27987,"PHASE1":27989,"PHASE2":27991,"PHASE3":27997,"PHASE4":27999,"NA":28001},{"trials":27988,"activeCount":101},[],{"trials":27990,"activeCount":101},[],{"trials":27992,"activeCount":101},[27993],{"nctId":1490,"briefTitle":1491,"status":130,"phases":27994,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1036,"conditions":27995,"interventions":27996},[89,90],[30],[1497,68,1498,1015,1499,1029,1500,1501,1502],{"trials":27998,"activeCount":101},[],{"trials":28000,"activeCount":101},[],{"trials":28002,"activeCount":101},[],{"intervention":28004,"totalTrials":350,"cells":28005},"AT-527",{"EARLY_PHASE1":28006,"PHASE1":28008,"PHASE2":28010,"PHASE3":28020,"PHASE4":28022,"NA":28024},{"trials":28007,"activeCount":101},[],{"trials":28009,"activeCount":101},[],{"trials":28011,"activeCount":101},[28012],{"nctId":28013,"briefTitle":28014,"status":107,"phases":28015,"primaryCompletion":1404,"completion":28016,"start":28017,"enrollment":5376,"conditions":28018,"interventions":28019},"NCT04709835","Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19",[90],"2021-10-13","2021-02-03",[2476],[28004],{"trials":28021,"activeCount":101},[],{"trials":28023,"activeCount":101},[],{"trials":28025,"activeCount":101},[],{"intervention":17042,"totalTrials":350,"cells":28027},{"EARLY_PHASE1":28028,"PHASE1":28030,"PHASE2":28032,"PHASE3":28038,"PHASE4":28040,"NA":28042},{"trials":28029,"activeCount":101},[],{"trials":28031,"activeCount":101},[],{"trials":28033,"activeCount":101},[28034],{"nctId":17036,"briefTitle":17037,"status":107,"phases":28035,"primaryCompletion":3085,"completion":3085,"start":6277,"enrollment":15475,"conditions":28036,"interventions":28037},[90],[27],[16996,17041,17042,17043],{"trials":28039,"activeCount":101},[],{"trials":28041,"activeCount":101},[],{"trials":28043,"activeCount":101},[],{"intervention":17043,"totalTrials":350,"cells":28045},{"EARLY_PHASE1":28046,"PHASE1":28048,"PHASE2":28050,"PHASE3":28056,"PHASE4":28058,"NA":28060},{"trials":28047,"activeCount":101},[],{"trials":28049,"activeCount":101},[],{"trials":28051,"activeCount":101},[28052],{"nctId":17036,"briefTitle":17037,"status":107,"phases":28053,"primaryCompletion":3085,"completion":3085,"start":6277,"enrollment":15475,"conditions":28054,"interventions":28055},[90],[27],[16996,17041,17042,17043],{"trials":28057,"activeCount":101},[],{"trials":28059,"activeCount":101},[],{"trials":28061,"activeCount":101},[],{"intervention":19392,"totalTrials":350,"cells":28063},{"EARLY_PHASE1":28064,"PHASE1":28066,"PHASE2":28068,"PHASE3":28074,"PHASE4":28076,"NA":28078},{"trials":28065,"activeCount":101},[],{"trials":28067,"activeCount":101},[],{"trials":28069,"activeCount":101},[28070],{"nctId":19387,"briefTitle":19388,"status":107,"phases":28071,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":28072,"interventions":28073},[90],[27],[19392,17034,11967,17072,17976,11969],{"trials":28075,"activeCount":101},[],{"trials":28077,"activeCount":101},[],{"trials":28079,"activeCount":101},[],{"intervention":9133,"totalTrials":350,"cells":28081},{"EARLY_PHASE1":28082,"PHASE1":28084,"PHASE2":28086,"PHASE3":28092,"PHASE4":28094,"NA":28096},{"trials":28083,"activeCount":101},[],{"trials":28085,"activeCount":101},[],{"trials":28087,"activeCount":101},[28088],{"nctId":9123,"briefTitle":9124,"status":107,"phases":28089,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":28090,"interventions":28091},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"trials":28093,"activeCount":101},[],{"trials":28095,"activeCount":101},[],{"trials":28097,"activeCount":101},[],{"intervention":9134,"totalTrials":350,"cells":28099},{"EARLY_PHASE1":28100,"PHASE1":28102,"PHASE2":28104,"PHASE3":28110,"PHASE4":28112,"NA":28114},{"trials":28101,"activeCount":101},[],{"trials":28103,"activeCount":101},[],{"trials":28105,"activeCount":101},[28106],{"nctId":9123,"briefTitle":9124,"status":107,"phases":28107,"primaryCompletion":9126,"completion":9127,"start":9128,"enrollment":37,"conditions":28108,"interventions":28109},[90],[3644],[9131,9132,9131,992,991,1358,1357,9133,9134],{"trials":28111,"activeCount":101},[],{"trials":28113,"activeCount":101},[],{"trials":28115,"activeCount":101},[],{"intervention":4209,"totalTrials":350,"cells":28117},{"EARLY_PHASE1":28118,"PHASE1":28120,"PHASE2":28122,"PHASE3":28128,"PHASE4":28130,"NA":28132},{"trials":28119,"activeCount":101},[],{"trials":28121,"activeCount":101},[],{"trials":28123,"activeCount":101},[28124],{"nctId":4203,"briefTitle":4204,"status":107,"phases":28125,"primaryCompletion":4206,"completion":4206,"start":121,"enrollment":4159,"conditions":28126,"interventions":28127},[90],[975],[977,1015,4209],{"trials":28129,"activeCount":101},[],{"trials":28131,"activeCount":101},[],{"trials":28133,"activeCount":101},[],{"intervention":8311,"totalTrials":350,"cells":28135},{"EARLY_PHASE1":28136,"PHASE1":28138,"PHASE2":28140,"PHASE3":28146,"PHASE4":28148,"NA":28150},{"trials":28137,"activeCount":101},[],{"trials":28139,"activeCount":101},[],{"trials":28141,"activeCount":101},[28142],{"nctId":8303,"briefTitle":8304,"status":107,"phases":28143,"primaryCompletion":8306,"completion":444,"start":8307,"enrollment":8308,"conditions":28144,"interventions":28145},[90],[18],[1221,1222,4184,8311],{"trials":28147,"activeCount":101},[],{"trials":28149,"activeCount":101},[],{"trials":28151,"activeCount":101},[],{"intervention":7268,"totalTrials":350,"cells":28153},{"EARLY_PHASE1":28154,"PHASE1":28156,"PHASE2":28158,"PHASE3":28164,"PHASE4":28166,"NA":28168},{"trials":28155,"activeCount":101},[],{"trials":28157,"activeCount":101},[],{"trials":28159,"activeCount":101},[28160],{"nctId":7259,"briefTitle":7260,"status":343,"phases":28161,"primaryCompletion":7262,"completion":7263,"start":7264,"enrollment":101,"conditions":28162,"interventions":28163},[90],[7266],[58,7268],{"trials":28165,"activeCount":101},[],{"trials":28167,"activeCount":101},[],{"trials":28169,"activeCount":101},[],{"intervention":1514,"totalTrials":350,"cells":28171},{"EARLY_PHASE1":28172,"PHASE1":28174,"PHASE2":28176,"PHASE3":28182,"PHASE4":28184,"NA":28186},{"trials":28173,"activeCount":101},[],{"trials":28175,"activeCount":101},[],{"trials":28177,"activeCount":101},[28178],{"nctId":1504,"briefTitle":1505,"status":107,"phases":28179,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":28180,"interventions":28181},[89,90],[1511],[1107,1163,1165,1164,1513,68,1084,1514,1515,1029,1015,1051,1501,988,1096],{"trials":28183,"activeCount":101},[],{"trials":28185,"activeCount":101},[],{"trials":28187,"activeCount":101},[],{"intervention":17138,"totalTrials":350,"cells":28189},{"EARLY_PHASE1":28190,"PHASE1":28192,"PHASE2":28194,"PHASE3":28200,"PHASE4":28202,"NA":28204},{"trials":28191,"activeCount":101},[],{"trials":28193,"activeCount":101},[],{"trials":28195,"activeCount":101},[28196],{"nctId":17132,"briefTitle":17133,"status":107,"phases":28197,"primaryCompletion":4315,"completion":4315,"start":17135,"enrollment":11473,"conditions":28198,"interventions":28199},[89,90],[18],[17138,7139],{"trials":28201,"activeCount":101},[],{"trials":28203,"activeCount":101},[],{"trials":28205,"activeCount":101},[],{"intervention":1526,"totalTrials":350,"cells":28207},{"EARLY_PHASE1":28208,"PHASE1":28210,"PHASE2":28212,"PHASE3":28218,"PHASE4":28220,"NA":28222},{"trials":28209,"activeCount":101},[],{"trials":28211,"activeCount":101},[],{"trials":28213,"activeCount":101},[28214],{"nctId":1517,"briefTitle":1518,"status":107,"phases":28215,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":28216,"interventions":28217},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"trials":28219,"activeCount":101},[],{"trials":28221,"activeCount":101},[],{"trials":28223,"activeCount":101},[],{"intervention":1527,"totalTrials":350,"cells":28225},{"EARLY_PHASE1":28226,"PHASE1":28228,"PHASE2":28230,"PHASE3":28236,"PHASE4":28238,"NA":28240},{"trials":28227,"activeCount":101},[],{"trials":28229,"activeCount":101},[],{"trials":28231,"activeCount":101},[28232],{"nctId":1517,"briefTitle":1518,"status":107,"phases":28233,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":28234,"interventions":28235},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"trials":28237,"activeCount":101},[],{"trials":28239,"activeCount":101},[],{"trials":28241,"activeCount":101},[],{"intervention":1528,"totalTrials":350,"cells":28243},{"EARLY_PHASE1":28244,"PHASE1":28246,"PHASE2":28248,"PHASE3":28254,"PHASE4":28256,"NA":28258},{"trials":28245,"activeCount":101},[],{"trials":28247,"activeCount":101},[],{"trials":28249,"activeCount":101},[28250],{"nctId":1517,"briefTitle":1518,"status":107,"phases":28251,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":28252,"interventions":28253},[90],[30],[1138,1526,1527,68,1479,1015,1222,1221,1084,1528,1166],{"trials":28255,"activeCount":101},[],{"trials":28257,"activeCount":101},[],{"trials":28259,"activeCount":101},[],{"intervention":21535,"totalTrials":350,"cells":28261},{"EARLY_PHASE1":28262,"PHASE1":28264,"PHASE2":28266,"PHASE3":28272,"PHASE4":28274,"NA":28276},{"trials":28263,"activeCount":101},[],{"trials":28265,"activeCount":101},[],{"trials":28267,"activeCount":101},[28268],{"nctId":21530,"briefTitle":21531,"status":107,"phases":28269,"primaryCompletion":3146,"completion":3146,"start":4233,"enrollment":13839,"conditions":28270,"interventions":28271},[90],[19752],[21521,21521,21535],{"trials":28273,"activeCount":101},[],{"trials":28275,"activeCount":101},[],{"trials":28277,"activeCount":101},[],{"intervention":15863,"totalTrials":350,"cells":28279},{"EARLY_PHASE1":28280,"PHASE1":28282,"PHASE2":28284,"PHASE3":28290,"PHASE4":28292,"NA":28294},{"trials":28281,"activeCount":101},[],{"trials":28283,"activeCount":101},[],{"trials":28285,"activeCount":101},[28286],{"nctId":15856,"briefTitle":15857,"status":107,"phases":28287,"primaryCompletion":15859,"completion":15859,"start":15860,"enrollment":395,"conditions":28288,"interventions":28289},[90],[18],[15863,5381,5390],{"trials":28291,"activeCount":101},[],{"trials":28293,"activeCount":101},[],{"trials":28295,"activeCount":101},[],{"intervention":8325,"totalTrials":350,"cells":28297},{"EARLY_PHASE1":28298,"PHASE1":28300,"PHASE2":28302,"PHASE3":28308,"PHASE4":28310,"NA":28312},{"trials":28299,"activeCount":101},[],{"trials":28301,"activeCount":101},[],{"trials":28303,"activeCount":101},[28304],{"nctId":8317,"briefTitle":8318,"status":107,"phases":28305,"primaryCompletion":8320,"completion":8321,"start":3084,"enrollment":8322,"conditions":28306,"interventions":28307},[90],[18],[1221,1222,8325,947,8326],{"trials":28309,"activeCount":101},[],{"trials":28311,"activeCount":101},[],{"trials":28313,"activeCount":101},[],{"intervention":8326,"totalTrials":350,"cells":28315},{"EARLY_PHASE1":28316,"PHASE1":28318,"PHASE2":28320,"PHASE3":28326,"PHASE4":28328,"NA":28330},{"trials":28317,"activeCount":101},[],{"trials":28319,"activeCount":101},[],{"trials":28321,"activeCount":101},[28322],{"nctId":8317,"briefTitle":8318,"status":107,"phases":28323,"primaryCompletion":8320,"completion":8321,"start":3084,"enrollment":8322,"conditions":28324,"interventions":28325},[90],[18],[1221,1222,8325,947,8326],{"trials":28327,"activeCount":101},[],{"trials":28329,"activeCount":101},[],{"trials":28331,"activeCount":101},[],{"intervention":1541,"totalTrials":350,"cells":28333},{"EARLY_PHASE1":28334,"PHASE1":28336,"PHASE2":28338,"PHASE3":28344,"PHASE4":28346,"NA":28348},{"trials":28335,"activeCount":101},[],{"trials":28337,"activeCount":101},[],{"trials":28339,"activeCount":101},[28340],{"nctId":1530,"briefTitle":1531,"status":107,"phases":28341,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":28342,"interventions":28343},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"trials":28345,"activeCount":101},[],{"trials":28347,"activeCount":101},[],{"trials":28349,"activeCount":101},[],{"intervention":1542,"totalTrials":350,"cells":28351},{"EARLY_PHASE1":28352,"PHASE1":28354,"PHASE2":28356,"PHASE3":28362,"PHASE4":28364,"NA":28366},{"trials":28353,"activeCount":101},[],{"trials":28355,"activeCount":101},[],{"trials":28357,"activeCount":101},[28358],{"nctId":1530,"briefTitle":1531,"status":107,"phases":28359,"primaryCompletion":1533,"completion":1534,"start":1535,"enrollment":1536,"conditions":28360,"interventions":28361},[89,90],[1538,1539],[68,1541,1085,1542,988,1321,1096,1167,1163],{"trials":28363,"activeCount":101},[],{"trials":28365,"activeCount":101},[],{"trials":28367,"activeCount":101},[],{"intervention":28369,"totalTrials":350,"cells":28370},"First line chemotherapy",{"EARLY_PHASE1":28371,"PHASE1":28373,"PHASE2":28375,"PHASE3":28386,"PHASE4":28388,"NA":28390},{"trials":28372,"activeCount":101},[],{"trials":28374,"activeCount":101},[],{"trials":28376,"activeCount":101},[28377],{"nctId":28378,"briefTitle":28379,"status":107,"phases":28380,"primaryCompletion":28381,"completion":28381,"start":28382,"enrollment":123,"conditions":28383,"interventions":28385},"NCT00472420","A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.",[90],"2011-05-25","2007-06-27",[28384],"Mantle Cell Lymphoma",[5837,28369],{"trials":28387,"activeCount":101},[],{"trials":28389,"activeCount":101},[],{"trials":28391,"activeCount":101},[],{"intervention":28393,"totalTrials":350,"cells":28394},"Taspoglutide 20mg",{"EARLY_PHASE1":28395,"PHASE1":28397,"PHASE2":28399,"PHASE3":28409,"PHASE4":28411,"NA":28413},{"trials":28396,"activeCount":101},[],{"trials":28398,"activeCount":101},[],{"trials":28400,"activeCount":101},[28401],{"nctId":28402,"briefTitle":28403,"status":107,"phases":28404,"primaryCompletion":121,"completion":121,"start":8484,"enrollment":2857,"conditions":28405,"interventions":28406},"NCT00460941","A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.",[90],[36],[28393,28407,28408],"Taspoglutide 20mg-30mg","Taspoglutide 20mg-40mg",{"trials":28410,"activeCount":101},[],{"trials":28412,"activeCount":101},[],{"trials":28414,"activeCount":101},[],{"intervention":28407,"totalTrials":350,"cells":28416},{"EARLY_PHASE1":28417,"PHASE1":28419,"PHASE2":28421,"PHASE3":28427,"PHASE4":28429,"NA":28431},{"trials":28418,"activeCount":101},[],{"trials":28420,"activeCount":101},[],{"trials":28422,"activeCount":101},[28423],{"nctId":28402,"briefTitle":28403,"status":107,"phases":28424,"primaryCompletion":121,"completion":121,"start":8484,"enrollment":2857,"conditions":28425,"interventions":28426},[90],[36],[28393,28407,28408],{"trials":28428,"activeCount":101},[],{"trials":28430,"activeCount":101},[],{"trials":28432,"activeCount":101},[],{"intervention":28408,"totalTrials":350,"cells":28434},{"EARLY_PHASE1":28435,"PHASE1":28437,"PHASE2":28439,"PHASE3":28445,"PHASE4":28447,"NA":28449},{"trials":28436,"activeCount":101},[],{"trials":28438,"activeCount":101},[],{"trials":28440,"activeCount":101},[28441],{"nctId":28402,"briefTitle":28403,"status":107,"phases":28442,"primaryCompletion":121,"completion":121,"start":8484,"enrollment":2857,"conditions":28443,"interventions":28444},[90],[36],[28393,28407,28408],{"trials":28446,"activeCount":101},[],{"trials":28448,"activeCount":101},[],{"trials":28450,"activeCount":101},[],{"intervention":28452,"totalTrials":350,"cells":28453},"Ro 24-7429",{"EARLY_PHASE1":28454,"PHASE1":28456,"PHASE2":28458,"PHASE3":28467,"PHASE4":28469,"NA":28471},{"trials":28455,"activeCount":101},[],{"trials":28457,"activeCount":101},[],{"trials":28459,"activeCount":101},[28460],{"nctId":28461,"briefTitle":28462,"status":107,"phases":28463,"conditions":28464,"interventions":28466},"NCT00002314","A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma",[90],[28465,33],"Sarcoma, Kaposi",[28452],{"trials":28468,"activeCount":101},[],{"trials":28470,"activeCount":101},[],{"trials":28472,"activeCount":101},[],{"intervention":28474,"totalTrials":350,"cells":28475},"Tiragolumab and Atezolizumab IV FDC",{"EARLY_PHASE1":28476,"PHASE1":28478,"PHASE2":28480,"PHASE3":28491,"PHASE4":28493,"NA":28495},{"trials":28477,"activeCount":101},[],{"trials":28479,"activeCount":101},[],{"trials":28481,"activeCount":101},[28482],{"nctId":28483,"briefTitle":28484,"status":107,"phases":28485,"primaryCompletion":28486,"completion":28486,"start":28487,"enrollment":17519,"conditions":28488,"interventions":28490},"NCT05661578","A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors",[90],"2025-12-26","2023-05-04",[28489],"PD-L1-selected Solid Tumors",[28474],{"trials":28492,"activeCount":101},[],{"trials":28494,"activeCount":101},[],{"trials":28496,"activeCount":101},[],{"intervention":26539,"totalTrials":350,"cells":28498},{"EARLY_PHASE1":28499,"PHASE1":28501,"PHASE2":28503,"PHASE3":28509,"PHASE4":28511,"NA":28513},{"trials":28500,"activeCount":101},[],{"trials":28502,"activeCount":101},[],{"trials":28504,"activeCount":101},[28505],{"nctId":26533,"briefTitle":26534,"status":107,"phases":28506,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":28507,"interventions":28508},[90],[11790],[26517,26539,26540,26541,26542,26543],{"trials":28510,"activeCount":101},[],{"trials":28512,"activeCount":101},[],{"trials":28514,"activeCount":101},[],{"intervention":26540,"totalTrials":350,"cells":28516},{"EARLY_PHASE1":28517,"PHASE1":28519,"PHASE2":28521,"PHASE3":28527,"PHASE4":28529,"NA":28531},{"trials":28518,"activeCount":101},[],{"trials":28520,"activeCount":101},[],{"trials":28522,"activeCount":101},[28523],{"nctId":26533,"briefTitle":26534,"status":107,"phases":28524,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":28525,"interventions":28526},[90],[11790],[26517,26539,26540,26541,26542,26543],{"trials":28528,"activeCount":101},[],{"trials":28530,"activeCount":101},[],{"trials":28532,"activeCount":101},[],{"intervention":26541,"totalTrials":350,"cells":28534},{"EARLY_PHASE1":28535,"PHASE1":28537,"PHASE2":28539,"PHASE3":28545,"PHASE4":28547,"NA":28549},{"trials":28536,"activeCount":101},[],{"trials":28538,"activeCount":101},[],{"trials":28540,"activeCount":101},[28541],{"nctId":26533,"briefTitle":26534,"status":107,"phases":28542,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":28543,"interventions":28544},[90],[11790],[26517,26539,26540,26541,26542,26543],{"trials":28546,"activeCount":101},[],{"trials":28548,"activeCount":101},[],{"trials":28550,"activeCount":101},[],{"intervention":26542,"totalTrials":350,"cells":28552},{"EARLY_PHASE1":28553,"PHASE1":28555,"PHASE2":28557,"PHASE3":28563,"PHASE4":28565,"NA":28567},{"trials":28554,"activeCount":101},[],{"trials":28556,"activeCount":101},[],{"trials":28558,"activeCount":101},[28559],{"nctId":26533,"briefTitle":26534,"status":107,"phases":28560,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":28561,"interventions":28562},[90],[11790],[26517,26539,26540,26541,26542,26543],{"trials":28564,"activeCount":101},[],{"trials":28566,"activeCount":101},[],{"trials":28568,"activeCount":101},[],{"intervention":26543,"totalTrials":350,"cells":28570},{"EARLY_PHASE1":28571,"PHASE1":28573,"PHASE2":28575,"PHASE3":28581,"PHASE4":28583,"NA":28585},{"trials":28572,"activeCount":101},[],{"trials":28574,"activeCount":101},[],{"trials":28576,"activeCount":101},[28577],{"nctId":26533,"briefTitle":26534,"status":107,"phases":28578,"primaryCompletion":2306,"completion":2306,"start":26536,"enrollment":6005,"conditions":28579,"interventions":28580},[90],[11790],[26517,26539,26540,26541,26542,26543],{"trials":28582,"activeCount":101},[],{"trials":28584,"activeCount":101},[],{"trials":28586,"activeCount":101},[],{"intervention":28588,"totalTrials":350,"cells":28589},"RO4929097",{"EARLY_PHASE1":28590,"PHASE1":28592,"PHASE2":28594,"PHASE3":28602,"PHASE4":28604,"NA":28606},{"trials":28591,"activeCount":101},[],{"trials":28593,"activeCount":101},[],{"trials":28595,"activeCount":101},[28596],{"nctId":28597,"briefTitle":28598,"status":107,"phases":28599,"primaryCompletion":7152,"completion":7152,"start":4206,"enrollment":4548,"conditions":28600,"interventions":28601},"NCT01070927","An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer",[90],[2257],[28588,28588],{"trials":28603,"activeCount":101},[],{"trials":28605,"activeCount":101},[],{"trials":28607,"activeCount":101},[],{"intervention":1560,"totalTrials":350,"cells":28609},{"EARLY_PHASE1":28610,"PHASE1":28612,"PHASE2":28614,"PHASE3":28620,"PHASE4":28622,"NA":28624},{"trials":28611,"activeCount":101},[],{"trials":28613,"activeCount":101},[],{"trials":28615,"activeCount":101},[28616],{"nctId":1553,"briefTitle":1554,"status":107,"phases":28617,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1296,"conditions":28618,"interventions":28619},[90],[922],[1084,68,1560],{"trials":28621,"activeCount":101},[],{"trials":28623,"activeCount":101},[],{"trials":28625,"activeCount":101},[],{"intervention":28627,"totalTrials":350,"cells":28628},"Anti-TNF-alpha",{"EARLY_PHASE1":28629,"PHASE1":28631,"PHASE2":28633,"PHASE3":28643,"PHASE4":28645,"NA":28647},{"trials":28630,"activeCount":101},[],{"trials":28632,"activeCount":101},[],{"trials":28634,"activeCount":101},[28635],{"nctId":28636,"briefTitle":28637,"status":130,"phases":28638,"primaryCompletion":28639,"completion":28639,"start":5503,"enrollment":4564,"conditions":28640,"interventions":28641},"NCT03001219","A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy",[90],"2018-11-06",[15],[28627,2824,28642],"RO7123520",{"trials":28644,"activeCount":101},[],{"trials":28646,"activeCount":101},[],{"trials":28648,"activeCount":101},[],{"intervention":28642,"totalTrials":350,"cells":28650},{"EARLY_PHASE1":28651,"PHASE1":28653,"PHASE2":28655,"PHASE3":28661,"PHASE4":28663,"NA":28665},{"trials":28652,"activeCount":101},[],{"trials":28654,"activeCount":101},[],{"trials":28656,"activeCount":101},[28657],{"nctId":28636,"briefTitle":28637,"status":130,"phases":28658,"primaryCompletion":28639,"completion":28639,"start":5503,"enrollment":4564,"conditions":28659,"interventions":28660},[90],[15],[28627,2824,28642],{"trials":28662,"activeCount":101},[],{"trials":28664,"activeCount":101},[],{"trials":28666,"activeCount":101},[],{"intervention":9145,"totalTrials":350,"cells":28668},{"EARLY_PHASE1":28669,"PHASE1":28671,"PHASE2":28673,"PHASE3":28679,"PHASE4":28681,"NA":28683},{"trials":28670,"activeCount":101},[],{"trials":28672,"activeCount":101},[],{"trials":28674,"activeCount":101},[28675],{"nctId":9140,"briefTitle":9141,"status":107,"phases":28676,"primaryCompletion":2963,"completion":2963,"start":6673,"enrollment":462,"conditions":28677,"interventions":28678},[90],[1206],[5914,1357,9145],{"trials":28680,"activeCount":101},[],{"trials":28682,"activeCount":101},[],{"trials":28684,"activeCount":101},[],{"intervention":28686,"totalTrials":350,"cells":28687},"danoprevir + ritonavir",{"EARLY_PHASE1":28688,"PHASE1":28690,"PHASE2":28692,"PHASE3":28700,"PHASE4":28702,"NA":28704},{"trials":28689,"activeCount":101},[],{"trials":28691,"activeCount":101},[],{"trials":28693,"activeCount":101},[28694],{"nctId":28695,"briefTitle":28696,"status":107,"phases":28697,"primaryCompletion":3006,"completion":3006,"start":3029,"enrollment":34,"conditions":28698,"interventions":28699},"NCT01749150","A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis",[90],[27],[28686,28686,17072,17072,17976,17976],{"trials":28701,"activeCount":101},[],{"trials":28703,"activeCount":101},[],{"trials":28705,"activeCount":101},[],{"intervention":1598,"totalTrials":350,"cells":28707},{"EARLY_PHASE1":28708,"PHASE1":28710,"PHASE2":28712,"PHASE3":28718,"PHASE4":28720,"NA":28722},{"trials":28709,"activeCount":101},[],{"trials":28711,"activeCount":101},[],{"trials":28713,"activeCount":101},[28714],{"nctId":1588,"briefTitle":1589,"status":107,"phases":28715,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":28716,"interventions":28717},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"trials":28719,"activeCount":101},[],{"trials":28721,"activeCount":101},[],{"trials":28723,"activeCount":101},[],{"intervention":1599,"totalTrials":350,"cells":28725},{"EARLY_PHASE1":28726,"PHASE1":28728,"PHASE2":28730,"PHASE3":28736,"PHASE4":28738,"NA":28740},{"trials":28727,"activeCount":101},[],{"trials":28729,"activeCount":101},[],{"trials":28731,"activeCount":101},[28732],{"nctId":1588,"briefTitle":1589,"status":107,"phases":28733,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":28734,"interventions":28735},[89,90],[1595],[1597,1164,1165,68,1084,1598,1106,1599,1515,1320,68,1084,1167,988,1597],{"trials":28737,"activeCount":101},[],{"trials":28739,"activeCount":101},[],{"trials":28741,"activeCount":101},[],{"intervention":28743,"totalTrials":350,"cells":28744},"RO4876904",{"EARLY_PHASE1":28745,"PHASE1":28747,"PHASE2":28749,"PHASE3":28758,"PHASE4":28760,"NA":28762},{"trials":28746,"activeCount":101},[],{"trials":28748,"activeCount":101},[],{"trials":28750,"activeCount":101},[28751],{"nctId":28752,"briefTitle":28753,"status":107,"phases":28754,"primaryCompletion":4582,"completion":4582,"start":4315,"enrollment":28755,"conditions":28756,"interventions":28757},"NCT00502710","A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.",[90],289,[36],[28743],{"trials":28759,"activeCount":101},[],{"trials":28761,"activeCount":101},[],{"trials":28763,"activeCount":101},[],{"intervention":28765,"totalTrials":350,"cells":28766},"Tociliuzumab",{"EARLY_PHASE1":28767,"PHASE1":28769,"PHASE2":28771,"PHASE3":28780,"PHASE4":28782,"NA":28784},{"trials":28768,"activeCount":101},[],{"trials":28770,"activeCount":101},[],{"trials":28772,"activeCount":101},[28773],{"nctId":28774,"briefTitle":28775,"status":107,"phases":28776,"primaryCompletion":2639,"completion":2639,"start":28777,"enrollment":8990,"conditions":28778,"interventions":28779},"NCT04363736","A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia",[90],"2020-05-05",[3068],[28765],{"trials":28781,"activeCount":101},[],{"trials":28783,"activeCount":101},[],{"trials":28785,"activeCount":101},[],{"intervention":1608,"totalTrials":350,"cells":28787},{"EARLY_PHASE1":28788,"PHASE1":28790,"PHASE2":28792,"PHASE3":28798,"PHASE4":28800,"NA":28802},{"trials":28789,"activeCount":101},[],{"trials":28791,"activeCount":101},[],{"trials":28793,"activeCount":101},[28794],{"nctId":1601,"briefTitle":1602,"status":130,"phases":28795,"primaryCompletion":1604,"completion":1604,"start":1605,"enrollment":425,"conditions":28796,"interventions":28797},[89,90],[1539],[68,1608],{"trials":28799,"activeCount":101},[],{"trials":28801,"activeCount":101},[],{"trials":28803,"activeCount":101},[],{"intervention":28805,"totalTrials":350,"cells":28806},"Carboplatin-based chemotherapy",{"EARLY_PHASE1":28807,"PHASE1":28809,"PHASE2":28811,"PHASE3":28819,"PHASE4":28821,"NA":28823},{"trials":28808,"activeCount":101},[],{"trials":28810,"activeCount":101},[],{"trials":28812,"activeCount":101},[28813],{"nctId":28814,"briefTitle":28815,"status":107,"phases":28816,"primaryCompletion":3146,"completion":3146,"start":4113,"enrollment":3856,"conditions":28817,"interventions":28818},"NCT00700180","A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.",[90],[975],[5275,5275,28805],{"trials":28820,"activeCount":101},[],{"trials":28822,"activeCount":101},[],{"trials":28824,"activeCount":101},[],{"intervention":20024,"totalTrials":350,"cells":28826},{"EARLY_PHASE1":28827,"PHASE1":28829,"PHASE2":28831,"PHASE3":28837,"PHASE4":28839,"NA":28841},{"trials":28828,"activeCount":101},[],{"trials":28830,"activeCount":101},[],{"trials":28832,"activeCount":101},[28833],{"nctId":20017,"briefTitle":20018,"status":107,"phases":28834,"primaryCompletion":20020,"completion":20020,"start":20021,"enrollment":786,"conditions":28835,"interventions":28836},[90],[3925],[19991,20024],{"trials":28838,"activeCount":101},[],{"trials":28840,"activeCount":101},[],{"trials":28842,"activeCount":101},[],{"intervention":28844,"totalTrials":350,"cells":28845},"N-acetylcysteine",{"EARLY_PHASE1":28846,"PHASE1":28848,"PHASE2":28850,"PHASE3":28858,"PHASE4":28860,"NA":28862},{"trials":28847,"activeCount":101},[],{"trials":28849,"activeCount":101},[],{"trials":28851,"activeCount":101},[28852],{"nctId":28853,"briefTitle":28854,"status":107,"phases":28855,"primaryCompletion":3006,"completion":3006,"start":6157,"enrollment":1548,"conditions":28856,"interventions":28857},"NCT02707640","A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)",[90],[18883],[28844,18885],{"trials":28859,"activeCount":101},[],{"trials":28861,"activeCount":101},[],{"trials":28863,"activeCount":101},[],{"intervention":28865,"totalTrials":350,"cells":28866},"P38 Inhibitor",{"EARLY_PHASE1":28867,"PHASE1":28869,"PHASE2":28871,"PHASE3":28879,"PHASE4":28881,"NA":28883},{"trials":28868,"activeCount":101},[],{"trials":28870,"activeCount":101},[],{"trials":28872,"activeCount":101},[28873],{"nctId":28874,"briefTitle":28875,"status":107,"phases":28876,"primaryCompletion":4513,"completion":4513,"start":8810,"enrollment":1583,"conditions":28877,"interventions":28878},"NCT00303563","A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis",[90],[15],[28865,28865,28865],{"trials":28880,"activeCount":101},[],{"trials":28882,"activeCount":101},[],{"trials":28884,"activeCount":101},[],{"intervention":28886,"totalTrials":350,"cells":28887},"MSTT1041A",{"EARLY_PHASE1":28888,"PHASE1":28890,"PHASE2":28892,"PHASE3":28904,"PHASE4":28906,"NA":28908},{"trials":28889,"activeCount":101},[],{"trials":28891,"activeCount":101},[],{"trials":28893,"activeCount":101},[28894],{"nctId":28895,"briefTitle":28896,"status":107,"phases":28897,"primaryCompletion":28898,"completion":28899,"start":28900,"enrollment":28901,"conditions":28902,"interventions":28903},"NCT02918019","A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma",[90],"2019-04-05","2019-07-26","2016-09-20",517,[17203],[28886],{"trials":28905,"activeCount":101},[],{"trials":28907,"activeCount":101},[],{"trials":28909,"activeCount":101},[],{"intervention":17513,"totalTrials":350,"cells":28911},{"EARLY_PHASE1":28912,"PHASE1":28914,"PHASE2":28916,"PHASE3":28922,"PHASE4":28924,"NA":28926},{"trials":28913,"activeCount":101},[],{"trials":28915,"activeCount":101},[],{"trials":28917,"activeCount":101},[28918],{"nctId":17508,"briefTitle":17509,"status":107,"phases":28919,"primaryCompletion":8320,"completion":8320,"start":121,"enrollment":1174,"conditions":28920,"interventions":28921},[90],[33],[17499,17513],{"trials":28923,"activeCount":101},[],{"trials":28925,"activeCount":101},[],{"trials":28927,"activeCount":101},[],{"intervention":28929,"totalTrials":350,"cells":28930},"RO5217790",{"EARLY_PHASE1":28931,"PHASE1":28933,"PHASE2":28935,"PHASE3":28945,"PHASE4":28947,"NA":28949},{"trials":28932,"activeCount":101},[],{"trials":28934,"activeCount":101},[],{"trials":28936,"activeCount":101},[28937],{"nctId":28938,"briefTitle":28939,"status":107,"phases":28940,"primaryCompletion":2684,"completion":2684,"start":5271,"enrollment":28941,"conditions":28942,"interventions":28944},"NCT01022346","A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection",[90],206,[28943],"Cervical Intraepithelial Neoplasia",[28929],{"trials":28946,"activeCount":101},[],{"trials":28948,"activeCount":101},[],{"trials":28950,"activeCount":101},[],{"intervention":26679,"totalTrials":350,"cells":28952},{"EARLY_PHASE1":28953,"PHASE1":28955,"PHASE2":28957,"PHASE3":28963,"PHASE4":28965,"NA":28967},{"trials":28954,"activeCount":101},[],{"trials":28956,"activeCount":101},[],{"trials":28958,"activeCount":101},[28959],{"nctId":26671,"briefTitle":26672,"status":107,"phases":28960,"primaryCompletion":6251,"completion":6251,"start":10461,"enrollment":26674,"conditions":28961,"interventions":28962},[90],[26676,20185,26677],[26679,26654],{"trials":28964,"activeCount":101},[],{"trials":28966,"activeCount":101},[],{"trials":28968,"activeCount":101},[],{"intervention":28970,"totalTrials":350,"cells":28971},"Investigator's choice of anti-cancer treatment",{"EARLY_PHASE1":28972,"PHASE1":28974,"PHASE2":28976,"PHASE3":28986,"PHASE4":28988,"NA":28990},{"trials":28973,"activeCount":101},[],{"trials":28975,"activeCount":101},[],{"trials":28977,"activeCount":101},[28978],{"nctId":28979,"briefTitle":28980,"status":107,"phases":28981,"primaryCompletion":28982,"completion":28982,"start":28983,"enrollment":1272,"conditions":28984,"interventions":28985},"NCT03558490","A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment",[90],"2019-04-19","2018-06-12",[18],[28970],{"trials":28987,"activeCount":101},[],{"trials":28989,"activeCount":101},[],{"trials":28991,"activeCount":101},[],{"intervention":6663,"totalTrials":350,"cells":28993},{"EARLY_PHASE1":28994,"PHASE1":28996,"PHASE2":28998,"PHASE3":29004,"PHASE4":29006,"NA":29008},{"trials":28995,"activeCount":101},[],{"trials":28997,"activeCount":101},[],{"trials":28999,"activeCount":101},[29000],{"nctId":6657,"briefTitle":6658,"status":107,"phases":29001,"primaryCompletion":2768,"completion":2768,"start":4281,"enrollment":6660,"conditions":29002,"interventions":29003},[90],[6622],[6663,6664,1163],{"trials":29005,"activeCount":101},[],{"trials":29007,"activeCount":101},[],{"trials":29009,"activeCount":101},[],{"intervention":6664,"totalTrials":350,"cells":29011},{"EARLY_PHASE1":29012,"PHASE1":29014,"PHASE2":29016,"PHASE3":29022,"PHASE4":29024,"NA":29026},{"trials":29013,"activeCount":101},[],{"trials":29015,"activeCount":101},[],{"trials":29017,"activeCount":101},[29018],{"nctId":6657,"briefTitle":6658,"status":107,"phases":29019,"primaryCompletion":2768,"completion":2768,"start":4281,"enrollment":6660,"conditions":29020,"interventions":29021},[90],[6622],[6663,6664,1163],{"trials":29023,"activeCount":101},[],{"trials":29025,"activeCount":101},[],{"trials":29027,"activeCount":101},[],{"intervention":29029,"totalTrials":350,"cells":29030},"Second line chemotherapy",{"EARLY_PHASE1":29031,"PHASE1":29033,"PHASE2":29035,"PHASE3":29043,"PHASE4":29045,"NA":29047},{"trials":29032,"activeCount":101},[],{"trials":29034,"activeCount":101},[],{"trials":29036,"activeCount":101},[29037],{"nctId":29038,"briefTitle":29039,"status":107,"phases":29040,"primaryCompletion":9079,"completion":9079,"start":7096,"enrollment":22,"conditions":29041,"interventions":29042},"NCT00444587","A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.",[90],[18],[29029,5390],{"trials":29044,"activeCount":101},[],{"trials":29046,"activeCount":101},[],{"trials":29048,"activeCount":101},[],{"intervention":29050,"totalTrials":350,"cells":29051},"PEGASYS [peginterferon alfa-2a]",{"EARLY_PHASE1":29052,"PHASE1":29054,"PHASE2":29056,"PHASE3":29066,"PHASE4":29068,"NA":29070},{"trials":29053,"activeCount":101},[],{"trials":29055,"activeCount":101},[],{"trials":29057,"activeCount":101},[29058],{"nctId":29059,"briefTitle":29060,"status":107,"phases":29061,"primaryCompletion":29062,"completion":29062,"start":29063,"enrollment":3939,"conditions":29064,"interventions":29065},"NCT00442572","SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).",[90],"2012-04-23","2006-07-03",[11790],[29050],{"trials":29067,"activeCount":101},[],{"trials":29069,"activeCount":101},[],{"trials":29071,"activeCount":101},[],{"intervention":29073,"totalTrials":350,"cells":29074},"RG7774",{"EARLY_PHASE1":29075,"PHASE1":29077,"PHASE2":29079,"PHASE3":29088,"PHASE4":29090,"NA":29092},{"trials":29076,"activeCount":101},[],{"trials":29078,"activeCount":101},[],{"trials":29080,"activeCount":101},[29081],{"nctId":29082,"briefTitle":29083,"status":107,"phases":29084,"primaryCompletion":1329,"completion":1329,"start":29085,"enrollment":1103,"conditions":29086,"interventions":29087},"NCT04265261","A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy",[90],"2020-06-05",[12207],[29073],{"trials":29089,"activeCount":101},[],{"trials":29091,"activeCount":101},[],{"trials":29093,"activeCount":101},[],{"intervention":19953,"totalTrials":350,"cells":29095},{"EARLY_PHASE1":29096,"PHASE1":29098,"PHASE2":29100,"PHASE3":29106,"PHASE4":29108,"NA":29110},{"trials":29097,"activeCount":101},[],{"trials":29099,"activeCount":101},[],{"trials":29101,"activeCount":101},[29102],{"nctId":19946,"briefTitle":19947,"status":107,"phases":29103,"primaryCompletion":4282,"completion":4282,"start":4323,"enrollment":19949,"conditions":29104,"interventions":29105},[90],[19951],[19953,19944,19944,19944],{"trials":29107,"activeCount":101},[],{"trials":29109,"activeCount":101},[],{"trials":29111,"activeCount":101},[],{"intervention":20032,"totalTrials":350,"cells":29113},{"EARLY_PHASE1":29114,"PHASE1":29116,"PHASE2":29118,"PHASE3":29124,"PHASE4":29126,"NA":29128},{"trials":29115,"activeCount":101},[],{"trials":29117,"activeCount":101},[],{"trials":29119,"activeCount":101},[29120],{"nctId":20026,"briefTitle":20027,"status":107,"phases":29121,"primaryCompletion":20029,"completion":20029,"start":2947,"enrollment":2878,"conditions":29122,"interventions":29123},[90],[3925],[19991,20032],{"trials":29125,"activeCount":101},[],{"trials":29127,"activeCount":101},[],{"trials":29129,"activeCount":101},[],{"intervention":20041,"totalTrials":350,"cells":29131},{"EARLY_PHASE1":29132,"PHASE1":29134,"PHASE2":29136,"PHASE3":29142,"PHASE4":29144,"NA":29146},{"trials":29133,"activeCount":101},[],{"trials":29135,"activeCount":101},[],{"trials":29137,"activeCount":101},[29138],{"nctId":20034,"briefTitle":20035,"status":107,"phases":29139,"primaryCompletion":20037,"completion":20037,"start":20038,"enrollment":17519,"conditions":29140,"interventions":29141},[90],[17203],[19991,20041,20042],{"trials":29143,"activeCount":101},[],{"trials":29145,"activeCount":101},[],{"trials":29147,"activeCount":101},[],{"intervention":20042,"totalTrials":350,"cells":29149},{"EARLY_PHASE1":29150,"PHASE1":29152,"PHASE2":29154,"PHASE3":29160,"PHASE4":29162,"NA":29164},{"trials":29151,"activeCount":101},[],{"trials":29153,"activeCount":101},[],{"trials":29155,"activeCount":101},[29156],{"nctId":20034,"briefTitle":20035,"status":107,"phases":29157,"primaryCompletion":20037,"completion":20037,"start":20038,"enrollment":17519,"conditions":29158,"interventions":29159},[90],[17203],[19991,20041,20042],{"trials":29161,"activeCount":101},[],{"trials":29163,"activeCount":101},[],{"trials":29165,"activeCount":101},[],{"intervention":29167,"totalTrials":350,"cells":29168},"RG3421 120mg",{"EARLY_PHASE1":29169,"PHASE1":29171,"PHASE2":29173,"PHASE3":29182,"PHASE4":29184,"NA":29186},{"trials":29170,"activeCount":101},[],{"trials":29172,"activeCount":101},[],{"trials":29174,"activeCount":101},[29175],{"nctId":29176,"briefTitle":29177,"status":107,"phases":29178,"primaryCompletion":6004,"completion":6004,"start":4315,"enrollment":3497,"conditions":29179,"interventions":29180},"NCT00504270","A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.",[90],[19121],[29167,29181],"RG3421 20mg",{"trials":29183,"activeCount":101},[],{"trials":29185,"activeCount":101},[],{"trials":29187,"activeCount":101},[],{"intervention":29181,"totalTrials":350,"cells":29189},{"EARLY_PHASE1":29190,"PHASE1":29192,"PHASE2":29194,"PHASE3":29200,"PHASE4":29202,"NA":29204},{"trials":29191,"activeCount":101},[],{"trials":29193,"activeCount":101},[],{"trials":29195,"activeCount":101},[29196],{"nctId":29176,"briefTitle":29177,"status":107,"phases":29197,"primaryCompletion":6004,"completion":6004,"start":4315,"enrollment":3497,"conditions":29198,"interventions":29199},[90],[19121],[29167,29181],{"trials":29201,"activeCount":101},[],{"trials":29203,"activeCount":101},[],{"trials":29205,"activeCount":101},[],{"intervention":29207,"totalTrials":350,"cells":29208},"Trastuzumab emtansine [Kadcyla] 3.0 mg\u002Fkg",{"EARLY_PHASE1":29209,"PHASE1":29211,"PHASE2":29213,"PHASE3":29223,"PHASE4":29225,"NA":29227},{"trials":29210,"activeCount":101},[],{"trials":29212,"activeCount":101},[],{"trials":29214,"activeCount":101},[29215],{"nctId":29216,"briefTitle":29217,"status":107,"phases":29218,"primaryCompletion":9079,"completion":9079,"start":9596,"enrollment":6514,"conditions":29219,"interventions":29220},"NCT00875979","A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab",[89,90],[1569],[29207,29221,29222],"Trastuzumab emtansine [Kadcyla] 3.6 mg\u002Fkg","Pertuzumab 420 mg",{"trials":29224,"activeCount":101},[],{"trials":29226,"activeCount":101},[],{"trials":29228,"activeCount":101},[],{"intervention":29221,"totalTrials":350,"cells":29230},{"EARLY_PHASE1":29231,"PHASE1":29233,"PHASE2":29235,"PHASE3":29241,"PHASE4":29243,"NA":29245},{"trials":29232,"activeCount":101},[],{"trials":29234,"activeCount":101},[],{"trials":29236,"activeCount":101},[29237],{"nctId":29216,"briefTitle":29217,"status":107,"phases":29238,"primaryCompletion":9079,"completion":9079,"start":9596,"enrollment":6514,"conditions":29239,"interventions":29240},[89,90],[1569],[29207,29221,29222],{"trials":29242,"activeCount":101},[],{"trials":29244,"activeCount":101},[],{"trials":29246,"activeCount":101},[],{"intervention":29222,"totalTrials":350,"cells":29248},{"EARLY_PHASE1":29249,"PHASE1":29251,"PHASE2":29253,"PHASE3":29259,"PHASE4":29261,"NA":29263},{"trials":29250,"activeCount":101},[],{"trials":29252,"activeCount":101},[],{"trials":29254,"activeCount":101},[29255],{"nctId":29216,"briefTitle":29217,"status":107,"phases":29256,"primaryCompletion":9079,"completion":9079,"start":9596,"enrollment":6514,"conditions":29257,"interventions":29258},[89,90],[1569],[29207,29221,29222],{"trials":29260,"activeCount":101},[],{"trials":29262,"activeCount":101},[],{"trials":29264,"activeCount":101},[],{"intervention":14590,"totalTrials":350,"cells":29266},{"EARLY_PHASE1":29267,"PHASE1":29269,"PHASE2":29271,"PHASE3":29277,"PHASE4":29279,"NA":29281},{"trials":29268,"activeCount":101},[],{"trials":29270,"activeCount":101},[],{"trials":29272,"activeCount":101},[29273],{"nctId":14585,"briefTitle":14586,"status":130,"phases":29274,"primaryCompletion":4454,"completion":4454,"start":2684,"enrollment":162,"conditions":29275,"interventions":29276},[90],[18],[14590,14591,1572],{"trials":29278,"activeCount":101},[],{"trials":29280,"activeCount":101},[],{"trials":29282,"activeCount":101},[],{"intervention":14591,"totalTrials":350,"cells":29284},{"EARLY_PHASE1":29285,"PHASE1":29287,"PHASE2":29289,"PHASE3":29295,"PHASE4":29297,"NA":29299},{"trials":29286,"activeCount":101},[],{"trials":29288,"activeCount":101},[],{"trials":29290,"activeCount":101},[29291],{"nctId":14585,"briefTitle":14586,"status":130,"phases":29292,"primaryCompletion":4454,"completion":4454,"start":2684,"enrollment":162,"conditions":29293,"interventions":29294},[90],[18],[14590,14591,1572],{"trials":29296,"activeCount":101},[],{"trials":29298,"activeCount":101},[],{"trials":29300,"activeCount":101},[],{"intervention":1771,"totalTrials":350,"cells":29302},{"EARLY_PHASE1":29303,"PHASE1":29305,"PHASE2":29307,"PHASE3":29313,"PHASE4":29315,"NA":29317},{"trials":29304,"activeCount":101},[],{"trials":29306,"activeCount":101},[],{"trials":29308,"activeCount":101},[29309],{"nctId":1760,"briefTitle":1761,"status":107,"phases":29310,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":29311,"interventions":29312},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":29314,"activeCount":101},[],{"trials":29316,"activeCount":101},[],{"trials":29318,"activeCount":101},[],{"intervention":1772,"totalTrials":350,"cells":29320},{"EARLY_PHASE1":29321,"PHASE1":29323,"PHASE2":29325,"PHASE3":29331,"PHASE4":29333,"NA":29335},{"trials":29322,"activeCount":101},[],{"trials":29324,"activeCount":101},[],{"trials":29326,"activeCount":101},[29327],{"nctId":1760,"briefTitle":1761,"status":107,"phases":29328,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":29329,"interventions":29330},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":29332,"activeCount":101},[],{"trials":29334,"activeCount":101},[],{"trials":29336,"activeCount":101},[],{"intervention":1773,"totalTrials":350,"cells":29338},{"EARLY_PHASE1":29339,"PHASE1":29341,"PHASE2":29343,"PHASE3":29349,"PHASE4":29351,"NA":29353},{"trials":29340,"activeCount":101},[],{"trials":29342,"activeCount":101},[],{"trials":29344,"activeCount":101},[29345],{"nctId":1760,"briefTitle":1761,"status":107,"phases":29346,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":29347,"interventions":29348},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"trials":29350,"activeCount":101},[],{"trials":29352,"activeCount":101},[],{"trials":29354,"activeCount":101},[],{"intervention":17059,"totalTrials":350,"cells":29356},{"EARLY_PHASE1":29357,"PHASE1":29359,"PHASE2":29361,"PHASE3":29367,"PHASE4":29369,"NA":29371},{"trials":29358,"activeCount":101},[],{"trials":29360,"activeCount":101},[],{"trials":29362,"activeCount":101},[29363],{"nctId":17052,"briefTitle":17053,"status":107,"phases":29364,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":29365,"interventions":29366},[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],{"trials":29368,"activeCount":101},[],{"trials":29370,"activeCount":101},[],{"trials":29372,"activeCount":101},[],{"intervention":17060,"totalTrials":350,"cells":29374},{"EARLY_PHASE1":29375,"PHASE1":29377,"PHASE2":29379,"PHASE3":29385,"PHASE4":29387,"NA":29389},{"trials":29376,"activeCount":101},[],{"trials":29378,"activeCount":101},[],{"trials":29380,"activeCount":101},[29381],{"nctId":17052,"briefTitle":17053,"status":107,"phases":29382,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":29383,"interventions":29384},[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],{"trials":29386,"activeCount":101},[],{"trials":29388,"activeCount":101},[],{"trials":29390,"activeCount":101},[],{"intervention":17522,"totalTrials":350,"cells":29392},{"EARLY_PHASE1":29393,"PHASE1":29395,"PHASE2":29397,"PHASE3":29403,"PHASE4":29405,"NA":29407},{"trials":29394,"activeCount":101},[],{"trials":29396,"activeCount":101},[],{"trials":29398,"activeCount":101},[29399],{"nctId":17515,"briefTitle":17516,"status":107,"phases":29400,"primaryCompletion":8751,"completion":8751,"start":17518,"enrollment":17519,"conditions":29401,"interventions":29402},[90],[33],[17522,17499,17499],{"trials":29404,"activeCount":101},[],{"trials":29406,"activeCount":101},[],{"trials":29408,"activeCount":101},[],{"intervention":26708,"totalTrials":350,"cells":29410},{"EARLY_PHASE1":29411,"PHASE1":29413,"PHASE2":29415,"PHASE3":29421,"PHASE4":29423,"NA":29425},{"trials":29412,"activeCount":101},[],{"trials":29414,"activeCount":101},[],{"trials":29416,"activeCount":101},[29417],{"nctId":26702,"briefTitle":26703,"status":107,"phases":29418,"primaryCompletion":4555,"completion":4555,"start":3692,"enrollment":97,"conditions":29419,"interventions":29420},[90],[4692],[5275,26707,26708],{"trials":29422,"activeCount":101},[],{"trials":29424,"activeCount":101},[],{"trials":29426,"activeCount":101},[],{"intervention":398,"totalTrials":4548,"cells":29428},{"EARLY_PHASE1":29429,"PHASE1":29431,"PHASE2":29461,"PHASE3":29463,"PHASE4":29465,"NA":29467},{"trials":29430,"activeCount":101},[],{"trials":29432,"activeCount":101},[29433,29437,29441,29445,29449,29453,29457],{"nctId":20299,"briefTitle":20300,"status":107,"phases":29434,"primaryCompletion":20302,"completion":20302,"start":1765,"enrollment":2619,"conditions":29435,"interventions":29436},[89],[427],[20292,398],{"nctId":25705,"briefTitle":25706,"status":107,"phases":29438,"primaryCompletion":25708,"completion":25708,"start":3276,"enrollment":13060,"conditions":29439,"interventions":29440},[89],[427],[25691,398],{"nctId":25329,"briefTitle":25330,"status":107,"phases":29442,"primaryCompletion":3212,"completion":3212,"start":4454,"enrollment":496,"conditions":29443,"interventions":29444},[89],[21],[25316,25334,25058],{"nctId":7525,"briefTitle":7526,"status":107,"phases":29446,"primaryCompletion":7528,"completion":7528,"start":7529,"enrollment":2619,"conditions":29447,"interventions":29448},[89],[427],[946,398],{"nctId":390,"briefTitle":391,"status":107,"phases":29450,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":29451,"interventions":29452},[89],[386],[398,77],{"nctId":12914,"briefTitle":12915,"status":107,"phases":29454,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1058,"conditions":29455,"interventions":29456},[89],[7754],[12889,398,12921,11717],{"nctId":25052,"briefTitle":25053,"status":107,"phases":29458,"primaryCompletion":2792,"completion":2792,"start":2947,"enrollment":709,"conditions":29459,"interventions":29460},[89],[25056],[13150,25058],{"trials":29462,"activeCount":101},[],{"trials":29464,"activeCount":101},[],{"trials":29466,"activeCount":101},[],{"trials":29468,"activeCount":101},[],{"intervention":10618,"totalTrials":942,"cells":29470},{"EARLY_PHASE1":29471,"PHASE1":29473,"PHASE2":29513,"PHASE3":29515,"PHASE4":29517,"NA":29519},{"trials":29472,"activeCount":101},[],{"trials":29474,"activeCount":101},[29475,29479,29485,29493,29499,29506],{"nctId":10613,"briefTitle":10614,"status":107,"phases":29476,"primaryCompletion":10332,"completion":10332,"start":2801,"enrollment":145,"conditions":29477,"interventions":29478},[89],[4856],[10618,10619],{"nctId":29480,"briefTitle":29481,"status":107,"phases":29482,"primaryCompletion":2964,"completion":2964,"start":4409,"enrollment":2375,"conditions":29483,"interventions":29484},"NCT01143740","A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery",[89],[4856],[10618],{"nctId":29486,"briefTitle":29487,"status":107,"phases":29488,"primaryCompletion":11854,"completion":11854,"start":29489,"enrollment":2563,"conditions":29490,"interventions":29492},"NCT01677780","An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies",[89],"2012-11-28",[29491],"Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute",[10618],{"nctId":29494,"briefTitle":29495,"status":107,"phases":29496,"primaryCompletion":4445,"completion":4445,"start":7152,"enrollment":537,"conditions":29497,"interventions":29498},"NCT01164033","A Study of RO5045337 in Patients With Solid Tumors",[89],[1241],[10618],{"nctId":29500,"briefTitle":29501,"status":107,"phases":29502,"primaryCompletion":8681,"completion":8681,"start":4281,"enrollment":5355,"conditions":29503,"interventions":29505},"NCT00623870","A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.",[89],[29504],"Hematologic Neoplasms",[10618],{"nctId":29507,"briefTitle":29508,"status":107,"phases":29509,"primaryCompletion":8681,"completion":8681,"start":4513,"enrollment":29510,"conditions":29511,"interventions":29512},"NCT00559533","A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors",[89],106,[1241],[10618],{"trials":29514,"activeCount":101},[],{"trials":29516,"activeCount":101},[],{"trials":29518,"activeCount":101},[],{"trials":29520,"activeCount":101},[],{"intervention":25791,"totalTrials":2631,"cells":29522},{"EARLY_PHASE1":29523,"PHASE1":29525,"PHASE2":29556,"PHASE3":29558,"PHASE4":29560,"NA":29562},{"trials":29524,"activeCount":101},[],{"trials":29526,"activeCount":101},[29527,29533,29539,29546,29550],{"nctId":29528,"briefTitle":29529,"status":107,"phases":29530,"primaryCompletion":3674,"completion":3674,"start":2809,"enrollment":2532,"conditions":29531,"interventions":29532},"NCT01711801","A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers",[89],[21],[25791,25791],{"nctId":29534,"briefTitle":29535,"status":107,"phases":29536,"primaryCompletion":2830,"completion":2830,"start":10332,"enrollment":4886,"conditions":29537,"interventions":29538},"NCT01864226","A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers",[89],[21],[25791],{"nctId":29540,"briefTitle":29541,"status":107,"phases":29542,"primaryCompletion":8769,"completion":8769,"start":29543,"enrollment":395,"conditions":29544,"interventions":29545},"NCT02824055","A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics",[89],"2016-06-27",[19752],[25791],{"nctId":25786,"briefTitle":25787,"status":107,"phases":29547,"primaryCompletion":3246,"completion":3246,"start":2830,"enrollment":8206,"conditions":29548,"interventions":29549},[89],[19752],[25791,25348],{"nctId":29551,"briefTitle":29552,"status":107,"phases":29553,"primaryCompletion":2956,"completion":2956,"start":6157,"enrollment":1796,"conditions":29554,"interventions":29555},"NCT01923025","A PET Study With RO5545965 in Healthy Male Volunteers",[89],[19752],[25791],{"trials":29557,"activeCount":101},[],{"trials":29559,"activeCount":101},[],{"trials":29561,"activeCount":101},[],{"trials":29563,"activeCount":101},[],{"intervention":1063,"totalTrials":2631,"cells":29565},{"EARLY_PHASE1":29566,"PHASE1":29568,"PHASE2":29598,"PHASE3":29600,"PHASE4":29602,"NA":29604},{"trials":29567,"activeCount":101},[],{"trials":29569,"activeCount":101},[29570,29579,29583,29587,29594],{"nctId":29571,"briefTitle":29572,"status":107,"phases":29573,"primaryCompletion":29574,"completion":29574,"start":29575,"enrollment":973,"conditions":29576,"interventions":29578},"NCT01987362","A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies",[89],"2017-10-11","2013-10-16",[29577],"Solid Tumors, Advanced Solid Tumors",[1063],{"nctId":11851,"briefTitle":11852,"status":107,"phases":29580,"primaryCompletion":9623,"completion":9623,"start":11854,"enrollment":425,"conditions":29581,"interventions":29582},[89],[1305],[1063,11857],{"nctId":1053,"briefTitle":1054,"status":130,"phases":29584,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":29585,"interventions":29586},[89],[1060,1061],[68,1063],{"nctId":29588,"briefTitle":29589,"status":107,"phases":29590,"primaryCompletion":29591,"completion":29591,"start":20038,"enrollment":316,"conditions":29592,"interventions":29593},"NCT02308761","A Study of RO6870810\u002FTEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome",[89],"2017-08-09",[933,1206],[1063],{"nctId":6009,"briefTitle":6010,"status":107,"phases":29595,"primaryCompletion":1890,"completion":1890,"start":6012,"enrollment":6013,"conditions":29596,"interventions":29597},[89],[2652,6015],[1063,1073,1359],{"trials":29599,"activeCount":101},[],{"trials":29601,"activeCount":101},[],{"trials":29603,"activeCount":101},[],{"trials":29605,"activeCount":101},[],{"intervention":11483,"totalTrials":5110,"cells":29607},{"EARLY_PHASE1":29608,"PHASE1":29610,"PHASE2":29628,"PHASE3":29630,"PHASE4":29632,"NA":29634},{"trials":29609,"activeCount":101},[],{"trials":29611,"activeCount":101},[29612,29616,29620,29624],{"nctId":19227,"briefTitle":19228,"status":107,"phases":29613,"primaryCompletion":7152,"completion":7152,"start":7095,"enrollment":5901,"conditions":29614,"interventions":29615},[89],[21],[11967,11483,11969],{"nctId":11478,"briefTitle":11479,"status":343,"phases":29617,"primaryCompletion":4454,"completion":4454,"start":4454,"enrollment":101,"conditions":29618,"interventions":29619},[89],[11439],[11483,10466],{"nctId":25228,"briefTitle":25229,"status":107,"phases":29621,"primaryCompletion":2948,"completion":2948,"start":3007,"enrollment":1705,"conditions":29622,"interventions":29623},[89],[21],[25215,11483],{"nctId":19320,"briefTitle":19321,"status":107,"phases":29625,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":1115,"conditions":29626,"interventions":29627},[89],[21],[19325,19255,11483,19326,11969],{"trials":29629,"activeCount":101},[],{"trials":29631,"activeCount":101},[],{"trials":29633,"activeCount":101},[],{"trials":29635,"activeCount":101},[],{"intervention":11792,"totalTrials":706,"cells":29637},{"EARLY_PHASE1":29638,"PHASE1":29640,"PHASE2":29658,"PHASE3":29660,"PHASE4":29662,"NA":29664},{"trials":29639,"activeCount":101},[],{"trials":29641,"activeCount":101},[29642,29650,29654],{"nctId":29643,"briefTitle":29644,"status":107,"phases":29645,"primaryCompletion":2287,"completion":2287,"start":29646,"enrollment":5013,"conditions":29647,"interventions":29649},"NCT03570658","A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants",[89],"2018-08-24",[29648],"Hepatitis B Virus",[11792],{"nctId":14796,"briefTitle":14797,"status":107,"phases":29651,"primaryCompletion":3276,"completion":3276,"start":14799,"enrollment":5901,"conditions":29652,"interventions":29653},[89],[427],[11792,12903],{"nctId":11784,"briefTitle":11785,"status":107,"phases":29655,"primaryCompletion":1101,"completion":1101,"start":11787,"enrollment":11788,"conditions":29656,"interventions":29657},[89],[11790],[388,11792],{"trials":29659,"activeCount":101},[],{"trials":29661,"activeCount":101},[],{"trials":29663,"activeCount":101},[],{"trials":29665,"activeCount":101},[],{"intervention":29667,"totalTrials":706,"cells":29668},"Meropenem",{"EARLY_PHASE1":29669,"PHASE1":29671,"PHASE2":29700,"PHASE3":29702,"PHASE4":29704,"NA":29706},{"trials":29670,"activeCount":101},[],{"trials":29672,"activeCount":101},[29673,29683,29694],{"nctId":29674,"briefTitle":29675,"status":107,"phases":29676,"primaryCompletion":29677,"completion":29677,"start":3642,"enrollment":3939,"conditions":29678,"interventions":29680},"NCT03182504","A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants",[89],"2017-08-10",[29679],"Gram-negative Bacterial Infections",[29681,29682],"nacubactam","meropenem",{"nctId":29684,"briefTitle":29685,"status":107,"phases":29686,"primaryCompletion":29687,"completion":29688,"start":29689,"enrollment":2375,"conditions":29690,"interventions":29692},"NCT03174795","A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection",[89],"2017-12-04","2017-12-16","2017-07-11",[29691],"Urinary Tract Infections",[29693,29667],"RO7079901",{"nctId":29695,"briefTitle":29696,"status":107,"phases":29697,"primaryCompletion":190,"completion":190,"start":930,"enrollment":1204,"conditions":29698,"interventions":29699},"NCT02972255","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers",[89],[427],[29693,29667],{"trials":29701,"activeCount":101},[],{"trials":29703,"activeCount":101},[],{"trials":29705,"activeCount":101},[],{"trials":29707,"activeCount":101},[],{"intervention":29709,"totalTrials":706,"cells":29710},"Tamiflu",{"EARLY_PHASE1":29711,"PHASE1":29713,"PHASE2":29733,"PHASE3":29735,"PHASE4":29737,"NA":29739},{"trials":29712,"activeCount":101},[],{"trials":29714,"activeCount":101},[29715,29721,29727],{"nctId":29716,"briefTitle":29717,"status":130,"phases":29718,"primaryCompletion":4249,"completion":4249,"start":5891,"enrollment":1796,"conditions":29719,"interventions":29720},"NCT01053663","A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza",[89],[12770],[29709],{"nctId":29722,"briefTitle":29723,"status":107,"phases":29724,"primaryCompletion":3213,"completion":3213,"start":3175,"enrollment":721,"conditions":29725,"interventions":29726},"NCT01556633","A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance",[89],[21],[29709,29709],{"nctId":29728,"briefTitle":29729,"status":107,"phases":29730,"primaryCompletion":2793,"completion":2793,"start":5891,"enrollment":2694,"conditions":29731,"interventions":29732},"NCT00988325","A Pharmacokinetic\u002FPharmacodynamic (PK\u002FPD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to \u003C12 Months of Age With Confirmed Flu Infection",[89],[12770],[29709],{"trials":29734,"activeCount":101},[],{"trials":29736,"activeCount":101},[],{"trials":29738,"activeCount":101},[],{"trials":29740,"activeCount":101},[],{"intervention":19326,"totalTrials":706,"cells":29742},{"EARLY_PHASE1":29743,"PHASE1":29745,"PHASE2":29759,"PHASE3":29761,"PHASE4":29763,"NA":29765},{"trials":29744,"activeCount":101},[],{"trials":29746,"activeCount":101},[29747,29751,29755],{"nctId":20306,"briefTitle":20307,"status":107,"phases":29748,"primaryCompletion":20309,"completion":20310,"start":20311,"enrollment":721,"conditions":29749,"interventions":29750},[89],[427],[20292,20314],{"nctId":19466,"briefTitle":19467,"status":107,"phases":29752,"primaryCompletion":2948,"completion":2948,"start":15695,"enrollment":425,"conditions":29753,"interventions":29754},[89],[21],[13182,19326],{"nctId":19320,"briefTitle":19321,"status":107,"phases":29756,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":1115,"conditions":29757,"interventions":29758},[89],[21],[19325,19255,11483,19326,11969],{"trials":29760,"activeCount":101},[],{"trials":29762,"activeCount":101},[],{"trials":29764,"activeCount":101},[],{"trials":29766,"activeCount":101},[],{"intervention":29768,"totalTrials":706,"cells":29769},"RO5508887",{"EARLY_PHASE1":29770,"PHASE1":29772,"PHASE2":29792,"PHASE3":29794,"PHASE4":29796,"NA":29798},{"trials":29771,"activeCount":101},[],{"trials":29773,"activeCount":101},[29774,29780,29786],{"nctId":29775,"briefTitle":29776,"status":107,"phases":29777,"primaryCompletion":2905,"completion":2905,"start":3189,"enrollment":1001,"conditions":29778,"interventions":29779},"NCT01461967","A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers",[89],[21],[29768,29768],{"nctId":29781,"briefTitle":29782,"status":107,"phases":29783,"primaryCompletion":2809,"completion":2809,"start":2801,"enrollment":1733,"conditions":29784,"interventions":29785},"NCT01592331","A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers",[89],[21],[29768],{"nctId":29787,"briefTitle":29788,"status":107,"phases":29789,"primaryCompletion":3146,"completion":3146,"start":3007,"enrollment":1058,"conditions":29790,"interventions":29791},"NCT01664143","A Single-Center Study of RO5508887 in Healthy Volunteers",[89],[21],[29768],{"trials":29793,"activeCount":101},[],{"trials":29795,"activeCount":101},[],{"trials":29797,"activeCount":101},[],{"trials":29799,"activeCount":101},[],{"intervention":29693,"totalTrials":706,"cells":29801},{"EARLY_PHASE1":29802,"PHASE1":29804,"PHASE2":29821,"PHASE3":29823,"PHASE4":29825,"NA":29827},{"trials":29803,"activeCount":101},[],{"trials":29805,"activeCount":101},[29806,29813,29817],{"nctId":29807,"briefTitle":29808,"status":107,"phases":29809,"primaryCompletion":21487,"completion":21487,"start":16280,"enrollment":1174,"conditions":29810,"interventions":29812},"NCT02975388","A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901",[89],[29811],"Renal Impairment",[29693],{"nctId":29684,"briefTitle":29685,"status":107,"phases":29814,"primaryCompletion":29687,"completion":29688,"start":29689,"enrollment":2375,"conditions":29815,"interventions":29816},[89],[29691],[29693,29667],{"nctId":29695,"briefTitle":29696,"status":107,"phases":29818,"primaryCompletion":190,"completion":190,"start":930,"enrollment":1204,"conditions":29819,"interventions":29820},[89],[427],[29693,29667],{"trials":29822,"activeCount":101},[],{"trials":29824,"activeCount":101},[],{"trials":29826,"activeCount":101},[],{"trials":29828,"activeCount":101},[],{"intervention":19354,"totalTrials":706,"cells":29830},{"EARLY_PHASE1":29831,"PHASE1":29833,"PHASE2":29847,"PHASE3":29849,"PHASE4":29851,"NA":29853},{"trials":29832,"activeCount":101},[],{"trials":29834,"activeCount":101},[29835,29839,29843],{"nctId":19756,"briefTitle":19757,"status":107,"phases":29836,"primaryCompletion":4488,"completion":4488,"start":3308,"enrollment":1406,"conditions":29837,"interventions":29838},[89],[21],[19761,19761,19708,19708,19762],{"nctId":25234,"briefTitle":25235,"status":107,"phases":29840,"primaryCompletion":3246,"completion":3246,"start":11437,"enrollment":25237,"conditions":29841,"interventions":29842},[89],[21],[25215,25215,19354],{"nctId":19348,"briefTitle":19349,"status":107,"phases":29844,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":29845,"interventions":29846},[89],[21],[11967,11967,19353,19354,19355,11969,19356],{"trials":29848,"activeCount":101},[],{"trials":29850,"activeCount":101},[],{"trials":29852,"activeCount":101},[],{"trials":29854,"activeCount":101},[],{"intervention":11823,"totalTrials":162,"cells":29856},{"EARLY_PHASE1":29857,"PHASE1":29859,"PHASE2":29872,"PHASE3":29874,"PHASE4":29876,"NA":29878},{"trials":29858,"activeCount":101},[],{"trials":29860,"activeCount":101},[29861,29868],{"nctId":29862,"briefTitle":29863,"status":107,"phases":29864,"primaryCompletion":2932,"completion":2932,"start":3104,"enrollment":4548,"conditions":29865,"interventions":29867},"NCT01148758","A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer",[89],[29866],"Colorectal Cancer, Ovarian Cancer",[11823],{"nctId":11818,"briefTitle":11819,"status":107,"phases":29869,"primaryCompletion":3103,"completion":3103,"start":2964,"enrollment":942,"conditions":29870,"interventions":29871},[89],[1443],[11823,11823,5388],{"trials":29873,"activeCount":101},[],{"trials":29875,"activeCount":101},[],{"trials":29877,"activeCount":101},[],{"trials":29879,"activeCount":101},[],{"intervention":29881,"totalTrials":162,"cells":29882},"RG7625",{"EARLY_PHASE1":29883,"PHASE1":29885,"PHASE2":29899,"PHASE3":29901,"PHASE4":29903,"NA":29905},{"trials":29884,"activeCount":101},[],{"trials":29886,"activeCount":101},[29887,29893],{"nctId":29888,"briefTitle":29889,"status":107,"phases":29890,"primaryCompletion":4232,"completion":4232,"start":3324,"enrollment":510,"conditions":29891,"interventions":29892},"NCT02295332","A Study of RG7625 in Healthy Volunteers",[89],[21],[29881],{"nctId":29894,"briefTitle":29895,"status":107,"phases":29896,"primaryCompletion":3478,"completion":3478,"start":2955,"enrollment":395,"conditions":29897,"interventions":29898},"NCT02521610","A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers",[89],[21],[29881],{"trials":29900,"activeCount":101},[],{"trials":29902,"activeCount":101},[],{"trials":29904,"activeCount":101},[],{"trials":29906,"activeCount":101},[],{"intervention":29908,"totalTrials":162,"cells":29909},"RO7223280",{"EARLY_PHASE1":29910,"PHASE1":29912,"PHASE2":29930,"PHASE3":29932,"PHASE4":29934,"NA":29936},{"trials":29911,"activeCount":101},[],{"trials":29913,"activeCount":101},[29914,29921],{"nctId":29915,"briefTitle":29916,"status":107,"phases":29917,"primaryCompletion":29918,"completion":29918,"start":4527,"enrollment":4159,"conditions":29919,"interventions":29920},"NCT04605718","A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants",[89],"2023-03-09",[427],[29908],{"nctId":29922,"briefTitle":29923,"status":107,"phases":29924,"primaryCompletion":29925,"completion":29925,"start":29926,"enrollment":123,"conditions":29927,"interventions":29929},"NCT05614895","A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections",[89],"2024-01-13","2022-12-03",[29928],"Bacterial Infections",[29908,29908],{"trials":29931,"activeCount":101},[],{"trials":29933,"activeCount":101},[],{"trials":29935,"activeCount":101},[],{"trials":29937,"activeCount":101},[],{"intervention":4826,"totalTrials":162,"cells":29939},{"EARLY_PHASE1":29940,"PHASE1":29942,"PHASE2":29956,"PHASE3":29958,"PHASE4":29960,"NA":29962},{"trials":29941,"activeCount":101},[],{"trials":29943,"activeCount":101},[29944,29948],{"nctId":4821,"briefTitle":4822,"status":107,"phases":29945,"primaryCompletion":3197,"completion":3197,"start":3212,"enrollment":145,"conditions":29946,"interventions":29947},[89],[21],[43,4826],{"nctId":29949,"briefTitle":29950,"status":107,"phases":29951,"primaryCompletion":2800,"completion":2800,"start":6157,"enrollment":34,"conditions":29952,"interventions":29953},"NCT01901172","A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors",[89],[1241],[29954,29954,29954,29954,29955],"RO5503781","posaconazole",{"trials":29957,"activeCount":101},[],{"trials":29959,"activeCount":101},[],{"trials":29961,"activeCount":101},[],{"trials":29963,"activeCount":101},[],{"intervention":29965,"totalTrials":162,"cells":29966},"RO5424802",{"EARLY_PHASE1":29967,"PHASE1":29969,"PHASE2":29984,"PHASE3":29986,"PHASE4":29988,"NA":29990},{"trials":29968,"activeCount":101},[],{"trials":29970,"activeCount":101},[29971,29977],{"nctId":29972,"briefTitle":29973,"status":107,"phases":29974,"primaryCompletion":3212,"completion":3212,"start":2956,"enrollment":942,"conditions":29975,"interventions":29976},"NCT01981005","A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802",[89],[21],[29965],{"nctId":29978,"briefTitle":29979,"status":107,"phases":29980,"primaryCompletion":4454,"completion":4454,"start":4454,"enrollment":425,"conditions":29981,"interventions":29982},"NCT01940510","A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802",[89],[21],[29965,29983],"rifampin",{"trials":29985,"activeCount":101},[],{"trials":29987,"activeCount":101},[],{"trials":29989,"activeCount":101},[],{"trials":29991,"activeCount":101},[],{"intervention":15424,"totalTrials":162,"cells":29993},{"EARLY_PHASE1":29994,"PHASE1":29996,"PHASE2":30006,"PHASE3":30008,"PHASE4":30010,"NA":30012},{"trials":29995,"activeCount":101},[],{"trials":29997,"activeCount":101},[29998,30002],{"nctId":15419,"briefTitle":15420,"status":107,"phases":29999,"completion":4582,"enrollment":145,"conditions":30000,"interventions":30001},[89],[15],[5894,2824,15424],{"nctId":24960,"briefTitle":24961,"status":107,"phases":30003,"primaryCompletion":8484,"completion":8484,"start":5457,"enrollment":395,"conditions":30004,"interventions":30005},[89],[36],[13159,15424],{"trials":30007,"activeCount":101},[],{"trials":30009,"activeCount":101},[],{"trials":30011,"activeCount":101},[],{"trials":30013,"activeCount":101},[],{"intervention":957,"totalTrials":162,"cells":30015},{"EARLY_PHASE1":30016,"PHASE1":30018,"PHASE2":30032,"PHASE3":30034,"PHASE4":30036,"NA":30038},{"trials":30017,"activeCount":101},[],{"trials":30019,"activeCount":101},[30020,30028],{"nctId":30021,"briefTitle":30022,"status":343,"phases":30023,"primaryCompletion":9416,"completion":5322,"start":2126,"enrollment":101,"conditions":30024,"interventions":30026},"NCT06816017","A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)",[89],[30025],"Non-muscle Invasive Bladder Cancer",[957,30027],"BCG Medac Strain",{"nctId":949,"briefTitle":950,"status":130,"phases":30029,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":30030,"interventions":30031},[89],[922],[957,68],{"trials":30033,"activeCount":101},[],{"trials":30035,"activeCount":101},[],{"trials":30037,"activeCount":101},[],{"trials":30039,"activeCount":101},[],{"intervention":30041,"totalTrials":162,"cells":30042},"RO6799477",{"EARLY_PHASE1":30043,"PHASE1":30045,"PHASE2":30060,"PHASE3":30062,"PHASE4":30064,"NA":30066},{"trials":30044,"activeCount":101},[],{"trials":30046,"activeCount":101},[30047,30054],{"nctId":30048,"briefTitle":30049,"status":107,"phases":30050,"primaryCompletion":3324,"completion":3324,"start":3174,"enrollment":931,"conditions":30051,"interventions":30053},"NCT02164266","A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477",[89],[30052],"Healthy Volunteer, Type 2 Diabetes",[30041],{"nctId":30055,"briefTitle":30056,"status":107,"phases":30057,"primaryCompletion":4454,"completion":4454,"start":2515,"enrollment":11473,"conditions":30058,"interventions":30059},"NCT01893437","A Study of RO6799477 in Healthy Volunteers",[89],[21],[30041],{"trials":30061,"activeCount":101},[],{"trials":30063,"activeCount":101},[],{"trials":30065,"activeCount":101},[],{"trials":30067,"activeCount":101},[],{"intervention":8586,"totalTrials":162,"cells":30069},{"EARLY_PHASE1":30070,"PHASE1":30072,"PHASE2":30082,"PHASE3":30084,"PHASE4":30086,"NA":30088},{"trials":30071,"activeCount":101},[],{"trials":30073,"activeCount":101},[30074,30078],{"nctId":8580,"briefTitle":8581,"status":107,"phases":30075,"primaryCompletion":3030,"completion":3030,"start":8260,"enrollment":8583,"conditions":30076,"interventions":30077},[89],[1160],[1166,8586],{"nctId":9496,"briefTitle":9497,"status":107,"phases":30079,"primaryCompletion":8810,"completion":8810,"start":9499,"enrollment":8583,"conditions":30080,"interventions":30081},[89],[1160],[947,8586],{"trials":30083,"activeCount":101},[],{"trials":30085,"activeCount":101},[],{"trials":30087,"activeCount":101},[],{"trials":30089,"activeCount":101},[],{"intervention":19255,"totalTrials":162,"cells":30091},{"EARLY_PHASE1":30092,"PHASE1":30094,"PHASE2":30104,"PHASE3":30106,"PHASE4":30108,"NA":30110},{"trials":30093,"activeCount":101},[],{"trials":30095,"activeCount":101},[30096,30100],{"nctId":19250,"briefTitle":19251,"status":107,"phases":30097,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":931,"conditions":30098,"interventions":30099},[89],[21],[19255,11967,11969,19256],{"nctId":19320,"briefTitle":19321,"status":107,"phases":30101,"primaryCompletion":2685,"completion":2685,"start":3189,"enrollment":1115,"conditions":30102,"interventions":30103},[89],[21],[19325,19255,11483,19326,11969],{"trials":30105,"activeCount":101},[],{"trials":30107,"activeCount":101},[],{"trials":30109,"activeCount":101},[],{"trials":30111,"activeCount":101},[],{"intervention":1004,"totalTrials":162,"cells":30113},{"EARLY_PHASE1":30114,"PHASE1":30116,"PHASE2":30130,"PHASE3":30132,"PHASE4":30134,"NA":30136},{"trials":30115,"activeCount":101},[],{"trials":30117,"activeCount":101},[30118,30126],{"nctId":30119,"briefTitle":30120,"status":130,"phases":30121,"primaryCompletion":30122,"completion":30122,"start":30123,"enrollment":537,"conditions":30124,"interventions":30125},"NCT04158583","A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors",[89],"2022-07-21","2019-12-09",[922],[1004],{"nctId":996,"briefTitle":997,"status":130,"phases":30127,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":30128,"interventions":30129},[89],[922],[1004,68],{"trials":30131,"activeCount":101},[],{"trials":30133,"activeCount":101},[],{"trials":30135,"activeCount":101},[],{"trials":30137,"activeCount":101},[],{"intervention":30139,"totalTrials":162,"cells":30140},"RO7062931",{"EARLY_PHASE1":30141,"PHASE1":30143,"PHASE2":30161,"PHASE3":30163,"PHASE4":30165,"NA":30167},{"trials":30142,"activeCount":101},[],{"trials":30144,"activeCount":101},[30145,30154],{"nctId":30146,"briefTitle":30147,"status":107,"phases":30148,"primaryCompletion":30149,"completion":30149,"start":30150,"enrollment":1651,"conditions":30151,"interventions":30152},"NCT03038113","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B",[89],"2019-10-18","2017-02-06",[17356],[30139,30153],"Immune Modulator",{"nctId":30155,"briefTitle":30156,"status":107,"phases":30157,"primaryCompletion":25827,"completion":25827,"start":30158,"enrollment":2440,"conditions":30159,"interventions":30160},"NCT03505190","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.",[89],"2018-05-03",[7754],[30139],{"trials":30162,"activeCount":101},[],{"trials":30164,"activeCount":101},[],{"trials":30166,"activeCount":101},[],{"trials":30168,"activeCount":101},[],{"intervention":13143,"totalTrials":162,"cells":30170},{"EARLY_PHASE1":30171,"PHASE1":30173,"PHASE2":30185,"PHASE3":30187,"PHASE4":30189,"NA":30191},{"trials":30172,"activeCount":101},[],{"trials":30174,"activeCount":101},[30175,30181],{"nctId":30176,"briefTitle":30177,"status":107,"phases":30178,"primaryCompletion":9079,"completion":9079,"start":2769,"enrollment":8206,"conditions":30179,"interventions":30180},"NCT01017302","A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.",[89],[36],[13143,13143],{"nctId":13138,"briefTitle":13139,"status":107,"phases":30182,"primaryCompletion":2906,"completion":2906,"start":2963,"enrollment":3190,"conditions":30183,"interventions":30184},[89],[36],[13143,13143,13131],{"trials":30186,"activeCount":101},[],{"trials":30188,"activeCount":101},[],{"trials":30190,"activeCount":101},[],{"trials":30192,"activeCount":101},[],{"intervention":19727,"totalTrials":162,"cells":30194},{"EARLY_PHASE1":30195,"PHASE1":30197,"PHASE2":30207,"PHASE3":30209,"PHASE4":30211,"NA":30213},{"trials":30196,"activeCount":101},[],{"trials":30198,"activeCount":101},[30199,30203],{"nctId":19722,"briefTitle":19723,"status":107,"phases":30200,"primaryCompletion":4314,"completion":4314,"start":14712,"enrollment":721,"conditions":30201,"interventions":30202},[89],[21],[19708,19727],{"nctId":24782,"briefTitle":24783,"status":107,"phases":30204,"primaryCompletion":3146,"completion":3146,"start":3213,"enrollment":721,"conditions":30205,"interventions":30206},[89],[21],[24787,24749],{"trials":30208,"activeCount":101},[],{"trials":30210,"activeCount":101},[],{"trials":30212,"activeCount":101},[],{"trials":30214,"activeCount":101},[],{"intervention":29954,"totalTrials":162,"cells":30216},{"EARLY_PHASE1":30217,"PHASE1":30219,"PHASE2":30231,"PHASE3":30233,"PHASE4":30235,"NA":30237},{"trials":30218,"activeCount":101},[],{"trials":30220,"activeCount":101},[30221,30227],{"nctId":30222,"briefTitle":30223,"status":107,"phases":30224,"primaryCompletion":5364,"completion":5364,"start":2685,"enrollment":559,"conditions":30225,"interventions":30226},"NCT01462175","A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia",[89],[1241],[29954],{"nctId":29949,"briefTitle":29950,"status":107,"phases":30228,"primaryCompletion":2800,"completion":2800,"start":6157,"enrollment":34,"conditions":30229,"interventions":30230},[89],[1241],[29954,29954,29954,29954,29955],{"trials":30232,"activeCount":101},[],{"trials":30234,"activeCount":101},[],{"trials":30236,"activeCount":101},[],{"trials":30238,"activeCount":101},[],{"intervention":11476,"totalTrials":162,"cells":30240},{"EARLY_PHASE1":30241,"PHASE1":30243,"PHASE2":30253,"PHASE3":30255,"PHASE4":30257,"NA":30259},{"trials":30242,"activeCount":101},[],{"trials":30244,"activeCount":101},[30245,30249],{"nctId":11470,"briefTitle":11471,"status":107,"phases":30246,"primaryCompletion":3478,"completion":3478,"start":2515,"enrollment":11473,"conditions":30247,"interventions":30248},[89],[11439],[11476,1479],{"nctId":29978,"briefTitle":29979,"status":107,"phases":30250,"primaryCompletion":4454,"completion":4454,"start":4454,"enrollment":425,"conditions":30251,"interventions":30252},[89],[21],[29965,29983],{"trials":30254,"activeCount":101},[],{"trials":30256,"activeCount":101},[],{"trials":30258,"activeCount":101},[],{"trials":30260,"activeCount":101},[],{"intervention":1095,"totalTrials":162,"cells":30262},{"EARLY_PHASE1":30263,"PHASE1":30265,"PHASE2":30275,"PHASE3":30277,"PHASE4":30279,"NA":30281},{"trials":30264,"activeCount":101},[],{"trials":30266,"activeCount":101},[30267,30271],{"nctId":1087,"briefTitle":1088,"status":130,"phases":30268,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":1092,"conditions":30269,"interventions":30270},[89],[30],[1018,68,1095,1096],{"nctId":3570,"briefTitle":3571,"status":107,"phases":30272,"primaryCompletion":2219,"completion":2219,"start":3573,"enrollment":3574,"conditions":30273,"interventions":30274},[89],[1135],[3577,1095,1018],{"trials":30276,"activeCount":101},[],{"trials":30278,"activeCount":101},[],{"trials":30280,"activeCount":101},[],{"trials":30282,"activeCount":101},[],{"intervention":30284,"totalTrials":162,"cells":30285},"RO7020531",{"EARLY_PHASE1":30286,"PHASE1":30288,"PHASE2":30306,"PHASE3":30308,"PHASE4":30310,"NA":30312},{"trials":30287,"activeCount":101},[],{"trials":30289,"activeCount":101},[30290,30298],{"nctId":30291,"briefTitle":30292,"status":107,"phases":30293,"primaryCompletion":30294,"completion":30294,"start":30295,"enrollment":3923,"conditions":30296,"interventions":30297},"NCT02956850","A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531",[89],"2021-06-15","2016-12-12",[11790],[30284],{"nctId":30299,"briefTitle":30300,"status":107,"phases":30301,"primaryCompletion":30302,"completion":30302,"start":30303,"enrollment":31,"conditions":30304,"interventions":30305},"NCT03530917","A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.",[89],"2019-05-15","2018-05-15",[7754],[30284],{"trials":30307,"activeCount":101},[],{"trials":30309,"activeCount":101},[],{"trials":30311,"activeCount":101},[],{"trials":30313,"activeCount":101},[],{"intervention":30315,"totalTrials":162,"cells":30316},"RO7248824",{"EARLY_PHASE1":30317,"PHASE1":30319,"PHASE2":30336,"PHASE3":30338,"PHASE4":30340,"NA":30342},{"trials":30318,"activeCount":101},[],{"trials":30320,"activeCount":101},[30321,30328],{"nctId":30322,"briefTitle":30323,"status":107,"phases":30324,"primaryCompletion":1924,"completion":1924,"start":30325,"enrollment":8835,"conditions":30326,"interventions":30327},"NCT04428281","A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)",[89],"2020-08-19",[27335],[30315],{"nctId":30329,"briefTitle":30330,"status":107,"phases":30331,"primaryCompletion":30332,"completion":30332,"start":30333,"enrollment":3939,"conditions":30334,"interventions":30335},"NCT04863794","A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants",[89],"2022-08-01","2021-04-29",[27335],[30315],{"trials":30337,"activeCount":101},[],{"trials":30339,"activeCount":101},[],{"trials":30341,"activeCount":101},[],{"trials":30343,"activeCount":101},[],{"intervention":19314,"totalTrials":162,"cells":30345},{"EARLY_PHASE1":30346,"PHASE1":30348,"PHASE2":30358,"PHASE3":30360,"PHASE4":30362,"NA":30364},{"trials":30347,"activeCount":101},[],{"trials":30349,"activeCount":101},[30350,30354],{"nctId":24769,"briefTitle":24770,"status":107,"phases":30351,"primaryCompletion":8320,"completion":8320,"start":4206,"enrollment":97,"conditions":30352,"interventions":30353},[89],[21],[24749,19314,24774],{"nctId":19309,"briefTitle":19310,"status":107,"phases":30355,"primaryCompletion":3189,"completion":3189,"start":9079,"enrollment":2375,"conditions":30356,"interventions":30357},[89],[21],[11967,19314,11969],{"trials":30359,"activeCount":101},[],{"trials":30361,"activeCount":101},[],{"trials":30363,"activeCount":101},[],{"trials":30365,"activeCount":101},[],{"intervention":30367,"totalTrials":162,"cells":30368},"[18F]RO6958948",{"EARLY_PHASE1":30369,"PHASE1":30371,"PHASE2":30391,"PHASE3":30393,"PHASE4":30395,"NA":30397},{"trials":30370,"activeCount":101},[],{"trials":30372,"activeCount":101},[30373,30384],{"nctId":30374,"briefTitle":30375,"status":107,"phases":30376,"primaryCompletion":30377,"completion":30377,"start":30378,"enrollment":973,"conditions":30379,"interventions":30381},"NCT02187627","Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",[89],"2016-02-29","2014-08-31",[30380],"Alzheimer's Disease, Healthy Volunteer",[30382,30383,30367],"[11C]RO6924963","[11C]RO6931643",{"nctId":30385,"briefTitle":30386,"status":107,"phases":30387,"primaryCompletion":19609,"completion":19609,"start":30388,"enrollment":5110,"conditions":30389,"interventions":30390},"NCT02792179","Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants",[89],"2016-07-19",[14384],[30367],{"trials":30392,"activeCount":101},[],{"trials":30394,"activeCount":101},[],{"trials":30396,"activeCount":101},[],{"trials":30398,"activeCount":101},[],{"intervention":20256,"totalTrials":162,"cells":30400},{"EARLY_PHASE1":30401,"PHASE1":30403,"PHASE2":30415,"PHASE3":30417,"PHASE4":30419,"NA":30421},{"trials":30402,"activeCount":101},[],{"trials":30404,"activeCount":101},[30405,30411],{"nctId":30406,"briefTitle":30407,"status":107,"phases":30408,"primaryCompletion":3197,"completion":3197,"start":8320,"enrollment":2694,"conditions":30409,"interventions":30410},"NCT01358903","A Study of RO5429083 in Patients With Metastatic and\u002For Locally Advanced, CD44-Expressing, Malignant Solid Tumors",[89],[1241],[20256,20256],{"nctId":20251,"briefTitle":20252,"status":107,"phases":30412,"primaryCompletion":3006,"completion":3006,"start":15695,"enrollment":4886,"conditions":30413,"interventions":30414},[89],[20237],[20256,20240],{"trials":30416,"activeCount":101},[],{"trials":30418,"activeCount":101},[],{"trials":30420,"activeCount":101},[],{"trials":30422,"activeCount":101},[],{"intervention":4846,"totalTrials":162,"cells":30424},{"EARLY_PHASE1":30425,"PHASE1":30427,"PHASE2":30437,"PHASE3":30439,"PHASE4":30441,"NA":30443},{"trials":30426,"activeCount":101},[],{"trials":30428,"activeCount":101},[30429,30433],{"nctId":4841,"briefTitle":4842,"status":107,"phases":30430,"primaryCompletion":3197,"completion":3197,"start":3212,"enrollment":1733,"conditions":30431,"interventions":30432},[89],[21],[43,4846],{"nctId":20334,"briefTitle":20335,"status":107,"phases":30434,"primaryCompletion":20337,"completion":20338,"start":20339,"enrollment":721,"conditions":30435,"interventions":30436},[89],[11768],[20292,4846],{"trials":30438,"activeCount":101},[],{"trials":30440,"activeCount":101},[],{"trials":30442,"activeCount":101},[],{"trials":30444,"activeCount":101},[],{"intervention":19484,"totalTrials":162,"cells":30446},{"EARLY_PHASE1":30447,"PHASE1":30449,"PHASE2":30459,"PHASE3":30461,"PHASE4":30463,"NA":30465},{"trials":30448,"activeCount":101},[],{"trials":30450,"activeCount":101},[30451,30455],{"nctId":19479,"briefTitle":19480,"status":107,"phases":30452,"primaryCompletion":4249,"completion":4249,"start":2809,"enrollment":496,"conditions":30453,"interventions":30454},[89],[21],[13182,19484],{"nctId":11501,"briefTitle":11502,"status":107,"phases":30456,"primaryCompletion":3174,"completion":3174,"start":2515,"enrollment":1174,"conditions":30457,"interventions":30458},[89],[11439],[11506,1479],{"trials":30460,"activeCount":101},[],{"trials":30462,"activeCount":101},[],{"trials":30464,"activeCount":101},[],{"trials":30466,"activeCount":101},[],{"intervention":30468,"totalTrials":162,"cells":30469},"RO5428029",{"EARLY_PHASE1":30470,"PHASE1":30472,"PHASE2":30487,"PHASE3":30489,"PHASE4":30491,"NA":30493},{"trials":30471,"activeCount":101},[],{"trials":30473,"activeCount":101},[30474,30480],{"nctId":30475,"briefTitle":30476,"status":107,"phases":30477,"primaryCompletion":8320,"completion":8320,"start":2931,"enrollment":709,"conditions":30478,"interventions":30479},"NCT01345942","A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers",[89],[21],[30468],{"nctId":30481,"briefTitle":30482,"status":107,"phases":30483,"primaryCompletion":2905,"completion":2905,"start":8320,"enrollment":1733,"conditions":30484,"interventions":30486},"NCT01371162","A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C",[89],[30485],"Hepatitis C, Chronic, Healthy Volunteer",[30468],{"trials":30488,"activeCount":101},[],{"trials":30490,"activeCount":101},[],{"trials":30492,"activeCount":101},[],{"trials":30494,"activeCount":101},[],{"intervention":913,"totalTrials":350,"cells":30496},{"EARLY_PHASE1":30497,"PHASE1":30499,"PHASE2":30505,"PHASE3":30507,"PHASE4":30509,"NA":30511},{"trials":30498,"activeCount":101},[],{"trials":30500,"activeCount":101},[30501],{"nctId":904,"briefTitle":905,"status":107,"phases":30502,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":30503,"interventions":30504},[89],[911],[68,913],{"trials":30506,"activeCount":101},[],{"trials":30508,"activeCount":101},[],{"trials":30510,"activeCount":101},[],{"trials":30512,"activeCount":101},[],{"intervention":7882,"totalTrials":350,"cells":30514},{"EARLY_PHASE1":30515,"PHASE1":30517,"PHASE2":30523,"PHASE3":30525,"PHASE4":30527,"NA":30529},{"trials":30516,"activeCount":101},[],{"trials":30518,"activeCount":101},[30519],{"nctId":7875,"briefTitle":7876,"status":107,"phases":30520,"primaryCompletion":7878,"completion":7878,"start":6237,"enrollment":7879,"conditions":30521,"interventions":30522},[89],[5357],[1106,7882],{"trials":30524,"activeCount":101},[],{"trials":30526,"activeCount":101},[],{"trials":30528,"activeCount":101},[],{"trials":30530,"activeCount":101},[],{"intervention":30532,"totalTrials":350,"cells":30533},"RO6870868",{"EARLY_PHASE1":30534,"PHASE1":30536,"PHASE2":30544,"PHASE3":30546,"PHASE4":30548,"NA":30550},{"trials":30535,"activeCount":101},[],{"trials":30537,"activeCount":101},[30538],{"nctId":30539,"briefTitle":30540,"status":107,"phases":30541,"primaryCompletion":3197,"completion":3197,"start":6157,"enrollment":336,"conditions":30542,"interventions":30543},"NCT01911611","A Study of RO6870868 in Healthy Volunteers",[89],[21],[30532],{"trials":30545,"activeCount":101},[],{"trials":30547,"activeCount":101},[],{"trials":30549,"activeCount":101},[],{"trials":30551,"activeCount":101},[],{"intervention":11968,"totalTrials":350,"cells":30553},{"EARLY_PHASE1":30554,"PHASE1":30556,"PHASE2":30562,"PHASE3":30564,"PHASE4":30566,"NA":30568},{"trials":30555,"activeCount":101},[],{"trials":30557,"activeCount":101},[30558],{"nctId":11962,"briefTitle":11963,"status":107,"phases":30559,"primaryCompletion":3189,"completion":3189,"start":4314,"enrollment":8206,"conditions":30560,"interventions":30561},[89],[21],[11967,418,11968,11969],{"trials":30563,"activeCount":101},[],{"trials":30565,"activeCount":101},[],{"trials":30567,"activeCount":101},[],{"trials":30569,"activeCount":101},[],{"intervention":30571,"totalTrials":350,"cells":30572},"RO7020322",{"EARLY_PHASE1":30573,"PHASE1":30575,"PHASE2":30584,"PHASE3":30586,"PHASE4":30588,"NA":30590},{"trials":30574,"activeCount":101},[],{"trials":30576,"activeCount":101},[30577],{"nctId":30578,"briefTitle":30579,"status":130,"phases":30580,"primaryCompletion":11935,"completion":11935,"start":30581,"enrollment":1001,"conditions":30582,"interventions":30583},"NCT02604355","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients",[89],"2015-11-28",[11790],[30571],{"trials":30585,"activeCount":101},[],{"trials":30587,"activeCount":101},[],{"trials":30589,"activeCount":101},[],{"trials":30591,"activeCount":101},[],{"intervention":24761,"totalTrials":350,"cells":30593},{"EARLY_PHASE1":30594,"PHASE1":30596,"PHASE2":30602,"PHASE3":30604,"PHASE4":30606,"NA":30608},{"trials":30595,"activeCount":101},[],{"trials":30597,"activeCount":101},[30598],{"nctId":24756,"briefTitle":24757,"status":107,"phases":30599,"primaryCompletion":4454,"completion":4454,"start":2905,"enrollment":1272,"conditions":30600,"interventions":30601},[89],[21],[24749,24761],{"trials":30603,"activeCount":101},[],{"trials":30605,"activeCount":101},[],{"trials":30607,"activeCount":101},[],{"trials":30609,"activeCount":101},[],{"intervention":30611,"totalTrials":350,"cells":30612},"RLY-1971",{"EARLY_PHASE1":30613,"PHASE1":30615,"PHASE2":30625,"PHASE3":30627,"PHASE4":30629,"NA":30631},{"trials":30614,"activeCount":101},[],{"trials":30616,"activeCount":101},[30617],{"nctId":30618,"briefTitle":30619,"status":107,"phases":30620,"primaryCompletion":30621,"completion":30621,"start":1925,"enrollment":1272,"conditions":30622,"interventions":30624},"NCT04252339","RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors",[89],"2022-11-22",[30623],"Solid Tumor, Unspecified, Adult",[30611],{"trials":30626,"activeCount":101},[],{"trials":30628,"activeCount":101},[],{"trials":30630,"activeCount":101},[],{"trials":30632,"activeCount":101},[],{"intervention":20239,"totalTrials":350,"cells":30634},{"EARLY_PHASE1":30635,"PHASE1":30637,"PHASE2":30643,"PHASE3":30645,"PHASE4":30647,"NA":30649},{"trials":30636,"activeCount":101},[],{"trials":30638,"activeCount":101},[30639],{"nctId":20233,"briefTitle":20234,"status":107,"phases":30640,"primaryCompletion":4454,"completion":4454,"start":3007,"enrollment":1385,"conditions":30641,"interventions":30642},[89],[20237],[20239,20239,20240,20240],{"trials":30644,"activeCount":101},[],{"trials":30646,"activeCount":101},[],{"trials":30648,"activeCount":101},[],{"trials":30650,"activeCount":101},[],{"intervention":30652,"totalTrials":350,"cells":30653},"RO5469754",{"EARLY_PHASE1":30654,"PHASE1":30656,"PHASE2":30665,"PHASE3":30667,"PHASE4":30669,"NA":30671},{"trials":30655,"activeCount":101},[],{"trials":30657,"activeCount":101},[30658],{"nctId":30659,"briefTitle":30660,"status":107,"phases":30661,"primaryCompletion":10419,"completion":10419,"start":30662,"enrollment":1058,"conditions":30663,"interventions":30664},"NCT01620931","A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers",[89],"2011-11-07",[21],[30652],{"trials":30666,"activeCount":101},[],{"trials":30668,"activeCount":101},[],{"trials":30670,"activeCount":101},[],{"trials":30672,"activeCount":101},[],{"intervention":30674,"totalTrials":350,"cells":30675},"RO5267683",{"EARLY_PHASE1":30676,"PHASE1":30678,"PHASE2":30686,"PHASE3":30688,"PHASE4":30690,"NA":30692},{"trials":30677,"activeCount":101},[],{"trials":30679,"activeCount":101},[30680],{"nctId":30681,"briefTitle":30682,"status":107,"phases":30683,"primaryCompletion":3213,"completion":3213,"start":9079,"enrollment":2492,"conditions":30684,"interventions":30685},"NCT01398241","A Study of RO5267683 in Healthy Subjects",[89],[21],[30674],{"trials":30687,"activeCount":101},[],{"trials":30689,"activeCount":101},[],{"trials":30691,"activeCount":101},[],{"trials":30693,"activeCount":101},[],{"intervention":25179,"totalTrials":350,"cells":30695},{"EARLY_PHASE1":30696,"PHASE1":30698,"PHASE2":30704,"PHASE3":30706,"PHASE4":30708,"NA":30710},{"trials":30697,"activeCount":101},[],{"trials":30699,"activeCount":101},[30700],{"nctId":25174,"briefTitle":25175,"status":107,"phases":30701,"primaryCompletion":3189,"completion":3189,"start":2931,"enrollment":8206,"conditions":30702,"interventions":30703},[89],[21],[25167,25179],{"trials":30705,"activeCount":101},[],{"trials":30707,"activeCount":101},[],{"trials":30709,"activeCount":101},[],{"trials":30711,"activeCount":101},[],{"intervention":30713,"totalTrials":350,"cells":30714},"RO7017773 Phase I",{"EARLY_PHASE1":30715,"PHASE1":30717,"PHASE2":30729,"PHASE3":30731,"PHASE4":30733,"NA":30735},{"trials":30716,"activeCount":101},[],{"trials":30718,"activeCount":101},[30719],{"nctId":30720,"briefTitle":30721,"status":107,"phases":30722,"primaryCompletion":30723,"completion":30723,"start":30724,"enrollment":425,"conditions":30725,"interventions":30726},"NCT03847987","A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants",[89],"2019-04-22","2019-03-12",[427],[30713,30727,30728],"RO7017773 Phase II Tablet Unflavored","RO7017773 Phase II Tablet Sweetened\u002FFlavored",{"trials":30730,"activeCount":101},[],{"trials":30732,"activeCount":101},[],{"trials":30734,"activeCount":101},[],{"trials":30736,"activeCount":101},[],{"intervention":30727,"totalTrials":350,"cells":30738},{"EARLY_PHASE1":30739,"PHASE1":30741,"PHASE2":30747,"PHASE3":30749,"PHASE4":30751,"NA":30753},{"trials":30740,"activeCount":101},[],{"trials":30742,"activeCount":101},[30743],{"nctId":30720,"briefTitle":30721,"status":107,"phases":30744,"primaryCompletion":30723,"completion":30723,"start":30724,"enrollment":425,"conditions":30745,"interventions":30746},[89],[427],[30713,30727,30728],{"trials":30748,"activeCount":101},[],{"trials":30750,"activeCount":101},[],{"trials":30752,"activeCount":101},[],{"trials":30754,"activeCount":101},[],{"intervention":30728,"totalTrials":350,"cells":30756},{"EARLY_PHASE1":30757,"PHASE1":30759,"PHASE2":30765,"PHASE3":30767,"PHASE4":30769,"NA":30771},{"trials":30758,"activeCount":101},[],{"trials":30760,"activeCount":101},[30761],{"nctId":30720,"briefTitle":30721,"status":107,"phases":30762,"primaryCompletion":30723,"completion":30723,"start":30724,"enrollment":425,"conditions":30763,"interventions":30764},[89],[427],[30713,30727,30728],{"trials":30766,"activeCount":101},[],{"trials":30768,"activeCount":101},[],{"trials":30770,"activeCount":101},[],{"trials":30772,"activeCount":101},[],{"intervention":2381,"totalTrials":350,"cells":30774},{"EARLY_PHASE1":30775,"PHASE1":30777,"PHASE2":30783,"PHASE3":30785,"PHASE4":30787,"NA":30789},{"trials":30776,"activeCount":101},[],{"trials":30778,"activeCount":101},[30779],{"nctId":2370,"briefTitle":2371,"status":107,"phases":30780,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":30781,"interventions":30782},[89],[2377,2378,2379],[2381,1096,1018,2382],{"trials":30784,"activeCount":101},[],{"trials":30786,"activeCount":101},[],{"trials":30788,"activeCount":101},[],{"trials":30790,"activeCount":101},[],{"intervention":30792,"totalTrials":350,"cells":30793},"RO4989991",{"EARLY_PHASE1":30794,"PHASE1":30796,"PHASE2":30804,"PHASE3":30806,"PHASE4":30808,"NA":30810},{"trials":30795,"activeCount":101},[],{"trials":30797,"activeCount":101},[30798],{"nctId":30799,"briefTitle":30800,"status":107,"phases":30801,"primaryCompletion":4233,"completion":4233,"start":7095,"enrollment":425,"conditions":30802,"interventions":30803},"NCT01152619","A Study of RO4989991 in Patients With Allergic Rhinitis",[89],[17203],[30792],{"trials":30805,"activeCount":101},[],{"trials":30807,"activeCount":101},[],{"trials":30809,"activeCount":101},[],{"trials":30811,"activeCount":101},[],{"intervention":11428,"totalTrials":350,"cells":30813},{"EARLY_PHASE1":30814,"PHASE1":30816,"PHASE2":30822,"PHASE3":30824,"PHASE4":30826,"NA":30828},{"trials":30815,"activeCount":101},[],{"trials":30817,"activeCount":101},[30818],{"nctId":11419,"briefTitle":11420,"status":107,"phases":30819,"primaryCompletion":11422,"completion":11423,"start":11424,"enrollment":942,"conditions":30820,"interventions":30821},[89],[11426],[1479,11428],{"trials":30823,"activeCount":101},[],{"trials":30825,"activeCount":101},[],{"trials":30827,"activeCount":101},[],{"trials":30829,"activeCount":101},[],{"intervention":20247,"totalTrials":350,"cells":30831},{"EARLY_PHASE1":30832,"PHASE1":30834,"PHASE2":30840,"PHASE3":30842,"PHASE4":30844,"NA":30846},{"trials":30833,"activeCount":101},[],{"trials":30835,"activeCount":101},[30836],{"nctId":20242,"briefTitle":20243,"status":107,"phases":30837,"primaryCompletion":2601,"completion":2601,"start":132,"enrollment":3190,"conditions":30838,"interventions":30839},[89],[20237],[20247,20248,20249,20202,10088],{"trials":30841,"activeCount":101},[],{"trials":30843,"activeCount":101},[],{"trials":30845,"activeCount":101},[],{"trials":30847,"activeCount":101},[],{"intervention":20248,"totalTrials":350,"cells":30849},{"EARLY_PHASE1":30850,"PHASE1":30852,"PHASE2":30858,"PHASE3":30860,"PHASE4":30862,"NA":30864},{"trials":30851,"activeCount":101},[],{"trials":30853,"activeCount":101},[30854],{"nctId":20242,"briefTitle":20243,"status":107,"phases":30855,"primaryCompletion":2601,"completion":2601,"start":132,"enrollment":3190,"conditions":30856,"interventions":30857},[89],[20237],[20247,20248,20249,20202,10088],{"trials":30859,"activeCount":101},[],{"trials":30861,"activeCount":101},[],{"trials":30863,"activeCount":101},[],{"trials":30865,"activeCount":101},[],{"intervention":20249,"totalTrials":350,"cells":30867},{"EARLY_PHASE1":30868,"PHASE1":30870,"PHASE2":30876,"PHASE3":30878,"PHASE4":30880,"NA":30882},{"trials":30869,"activeCount":101},[],{"trials":30871,"activeCount":101},[30872],{"nctId":20242,"briefTitle":20243,"status":107,"phases":30873,"primaryCompletion":2601,"completion":2601,"start":132,"enrollment":3190,"conditions":30874,"interventions":30875},[89],[20237],[20247,20248,20249,20202,10088],{"trials":30877,"activeCount":101},[],{"trials":30879,"activeCount":101},[],{"trials":30881,"activeCount":101},[],{"trials":30883,"activeCount":101},[],{"intervention":924,"totalTrials":350,"cells":30885},{"EARLY_PHASE1":30886,"PHASE1":30888,"PHASE2":30894,"PHASE3":30896,"PHASE4":30898,"NA":30900},{"trials":30887,"activeCount":101},[],{"trials":30889,"activeCount":101},[30890],{"nctId":915,"briefTitle":916,"status":107,"phases":30891,"primaryCompletion":918,"completion":918,"start":919,"enrollment":920,"conditions":30892,"interventions":30893},[89],[922],[924,68],{"trials":30895,"activeCount":101},[],{"trials":30897,"activeCount":101},[],{"trials":30899,"activeCount":101},[],{"trials":30901,"activeCount":101},[],{"intervention":30903,"totalTrials":350,"cells":30904},"RO7239958",{"EARLY_PHASE1":30905,"PHASE1":30907,"PHASE2":30917,"PHASE3":30919,"PHASE4":30921,"NA":30923},{"trials":30906,"activeCount":101},[],{"trials":30908,"activeCount":101},[30909],{"nctId":30910,"briefTitle":30911,"status":130,"phases":30912,"primaryCompletion":20441,"completion":20441,"start":30913,"enrollment":786,"conditions":30914,"interventions":30916},"NCT03762681","A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection",[89],"2018-12-14",[30915],"Hepatitis B Virus Infection",[30903],{"trials":30918,"activeCount":101},[],{"trials":30920,"activeCount":101},[],{"trials":30922,"activeCount":101},[],{"trials":30924,"activeCount":101},[],{"intervention":20163,"totalTrials":350,"cells":30926},{"EARLY_PHASE1":30927,"PHASE1":30929,"PHASE2":30935,"PHASE3":30937,"PHASE4":30939,"NA":30941},{"trials":30928,"activeCount":101},[],{"trials":30930,"activeCount":101},[30931],{"nctId":20156,"briefTitle":20157,"status":107,"phases":30932,"primaryCompletion":20159,"completion":20159,"start":20160,"enrollment":306,"conditions":30933,"interventions":30934},[89],[922],[1500,20163,20164],{"trials":30936,"activeCount":101},[],{"trials":30938,"activeCount":101},[],{"trials":30940,"activeCount":101},[],{"trials":30942,"activeCount":101},[],{"intervention":20164,"totalTrials":350,"cells":30944},{"EARLY_PHASE1":30945,"PHASE1":30947,"PHASE2":30953,"PHASE3":30955,"PHASE4":30957,"NA":30959},{"trials":30946,"activeCount":101},[],{"trials":30948,"activeCount":101},[30949],{"nctId":20156,"briefTitle":20157,"status":107,"phases":30950,"primaryCompletion":20159,"completion":20159,"start":20160,"enrollment":306,"conditions":30951,"interventions":30952},[89],[922],[1500,20163,20164],{"trials":30954,"activeCount":101},[],{"trials":30956,"activeCount":101},[],{"trials":30958,"activeCount":101},[],{"trials":30960,"activeCount":101},[],{"intervention":30962,"totalTrials":350,"cells":30963},"RO5028442",{"EARLY_PHASE1":30964,"PHASE1":30966,"PHASE2":30974,"PHASE3":30976,"PHASE4":30978,"NA":30980},{"trials":30965,"activeCount":101},[],{"trials":30967,"activeCount":101},[30968],{"nctId":30969,"briefTitle":30970,"status":107,"phases":30971,"primaryCompletion":3674,"completion":3674,"start":2905,"enrollment":8583,"conditions":30972,"interventions":30973},"NCT01474278","A Study of RO5028442 in Adult Male High-Functioning Autistic Patients",[89],[11767],[30962],{"trials":30975,"activeCount":101},[],{"trials":30977,"activeCount":101},[],{"trials":30979,"activeCount":101},[],{"trials":30981,"activeCount":101},[],{"intervention":30027,"totalTrials":350,"cells":30983},{"EARLY_PHASE1":30984,"PHASE1":30986,"PHASE2":30992,"PHASE3":30994,"PHASE4":30996,"NA":30998},{"trials":30985,"activeCount":101},[],{"trials":30987,"activeCount":101},[30988],{"nctId":30021,"briefTitle":30022,"status":343,"phases":30989,"primaryCompletion":9416,"completion":5322,"start":2126,"enrollment":101,"conditions":30990,"interventions":30991},[89],[30025],[957,30027],{"trials":30993,"activeCount":101},[],{"trials":30995,"activeCount":101},[],{"trials":30997,"activeCount":101},[],{"trials":30999,"activeCount":101},[],{"intervention":29681,"totalTrials":350,"cells":31001},{"EARLY_PHASE1":31002,"PHASE1":31004,"PHASE2":31010,"PHASE3":31012,"PHASE4":31014,"NA":31016},{"trials":31003,"activeCount":101},[],{"trials":31005,"activeCount":101},[31006],{"nctId":29674,"briefTitle":29675,"status":107,"phases":31007,"primaryCompletion":29677,"completion":29677,"start":3642,"enrollment":3939,"conditions":31008,"interventions":31009},[89],[29679],[29681,29682],{"trials":31011,"activeCount":101},[],{"trials":31013,"activeCount":101},[],{"trials":31015,"activeCount":101},[],{"trials":31017,"activeCount":101},[],{"intervention":3500,"totalTrials":350,"cells":31019},{"EARLY_PHASE1":31020,"PHASE1":31022,"PHASE2":31028,"PHASE3":31030,"PHASE4":31032,"NA":31034},{"trials":31021,"activeCount":101},[],{"trials":31023,"activeCount":101},[31024],{"nctId":3492,"briefTitle":3493,"status":107,"phases":31025,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":3497,"conditions":31026,"interventions":31027},[89],[125],[3500,1359,1018],{"trials":31029,"activeCount":101},[],{"trials":31031,"activeCount":101},[],{"trials":31033,"activeCount":101},[],{"trials":31035,"activeCount":101},[],{"intervention":14686,"totalTrials":350,"cells":31037},{"EARLY_PHASE1":31038,"PHASE1":31040,"PHASE2":31046,"PHASE3":31048,"PHASE4":31050,"NA":31052},{"trials":31039,"activeCount":101},[],{"trials":31041,"activeCount":101},[31042],{"nctId":14680,"briefTitle":14681,"status":107,"phases":31043,"primaryCompletion":2602,"completion":2602,"start":2905,"enrollment":14683,"conditions":31044,"interventions":31045},[89],[1241],[5422,1138,977,14686],{"trials":31047,"activeCount":101},[],{"trials":31049,"activeCount":101},[],{"trials":31051,"activeCount":101},[],{"trials":31053,"activeCount":101},[],{"intervention":19256,"totalTrials":350,"cells":31055},{"EARLY_PHASE1":31056,"PHASE1":31058,"PHASE2":31064,"PHASE3":31066,"PHASE4":31068,"NA":31070},{"trials":31057,"activeCount":101},[],{"trials":31059,"activeCount":101},[31060],{"nctId":19250,"briefTitle":19251,"status":107,"phases":31061,"primaryCompletion":3213,"completion":3213,"start":2801,"enrollment":931,"conditions":31062,"interventions":31063},[89],[21],[19255,11967,11969,19256],{"trials":31065,"activeCount":101},[],{"trials":31067,"activeCount":101},[],{"trials":31069,"activeCount":101},[],{"trials":31071,"activeCount":101},[],{"intervention":31073,"totalTrials":350,"cells":31074},"peginterferon alfa 2a [Pegasys]",{"EARLY_PHASE1":31075,"PHASE1":31077,"PHASE2":31085,"PHASE3":31087,"PHASE4":31089,"NA":31091},{"trials":31076,"activeCount":101},[],{"trials":31078,"activeCount":101},[31079],{"nctId":31080,"briefTitle":31081,"status":107,"phases":31082,"primaryCompletion":2793,"completion":2793,"start":2964,"enrollment":5013,"conditions":31083,"interventions":31084},"NCT01337375","A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy",[89],[27],[31073,17072,17072,17072],{"trials":31086,"activeCount":101},[],{"trials":31088,"activeCount":101},[],{"trials":31090,"activeCount":101},[],{"trials":31092,"activeCount":101},[],{"intervention":935,"totalTrials":350,"cells":31094},{"EARLY_PHASE1":31095,"PHASE1":31097,"PHASE2":31103,"PHASE3":31105,"PHASE4":31107,"NA":31109},{"trials":31096,"activeCount":101},[],{"trials":31098,"activeCount":101},[31099],{"nctId":926,"briefTitle":927,"status":107,"phases":31100,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":31101,"interventions":31102},[89],[933],[68,935],{"trials":31104,"activeCount":101},[],{"trials":31106,"activeCount":101},[],{"trials":31108,"activeCount":101},[],{"trials":31110,"activeCount":101},[],{"intervention":31112,"totalTrials":350,"cells":31113},"RO5212054",{"EARLY_PHASE1":31114,"PHASE1":31116,"PHASE2":31126,"PHASE3":31128,"PHASE4":31130,"NA":31132},{"trials":31115,"activeCount":101},[],{"trials":31117,"activeCount":101},[31118],{"nctId":31119,"briefTitle":31120,"status":107,"phases":31121,"primaryCompletion":31122,"completion":20774,"start":31123,"enrollment":909,"conditions":31124,"interventions":31125},"NCT01143753","A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors",[89],"2012-06-30","2010-07-27",[1241],[31112],{"trials":31127,"activeCount":101},[],{"trials":31129,"activeCount":101},[],{"trials":31131,"activeCount":101},[],{"trials":31133,"activeCount":101},[],{"intervention":19720,"totalTrials":350,"cells":31135},{"EARLY_PHASE1":31136,"PHASE1":31138,"PHASE2":31144,"PHASE3":31146,"PHASE4":31148,"NA":31150},{"trials":31137,"activeCount":101},[],{"trials":31139,"activeCount":101},[31140],{"nctId":19715,"briefTitle":19716,"status":107,"phases":31141,"primaryCompletion":8681,"completion":8681,"start":15695,"enrollment":721,"conditions":31142,"interventions":31143},[89],[21],[19708,19708,19720],{"trials":31145,"activeCount":101},[],{"trials":31147,"activeCount":101},[],{"trials":31149,"activeCount":101},[],{"trials":31151,"activeCount":101},[],{"intervention":31153,"totalTrials":350,"cells":31154},"ribavirin [Vilona]",{"EARLY_PHASE1":31155,"PHASE1":31157,"PHASE2":31165,"PHASE3":31167,"PHASE4":31169,"NA":31171},{"trials":31156,"activeCount":101},[],{"trials":31158,"activeCount":101},[31159],{"nctId":31160,"briefTitle":31161,"status":107,"phases":31162,"primaryCompletion":6315,"completion":6315,"start":8320,"enrollment":931,"conditions":31163,"interventions":31164},"NCT01615393","A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers",[89],[21],[17976,31153],{"trials":31166,"activeCount":101},[],{"trials":31168,"activeCount":101},[],{"trials":31170,"activeCount":101},[],{"trials":31172,"activeCount":101},[],{"intervention":30153,"totalTrials":350,"cells":31174},{"EARLY_PHASE1":31175,"PHASE1":31177,"PHASE2":31183,"PHASE3":31185,"PHASE4":31187,"NA":31189},{"trials":31176,"activeCount":101},[],{"trials":31178,"activeCount":101},[31179],{"nctId":30146,"briefTitle":30147,"status":107,"phases":31180,"primaryCompletion":30149,"completion":30149,"start":30150,"enrollment":1651,"conditions":31181,"interventions":31182},[89],[17356],[30139,30153],{"trials":31184,"activeCount":101},[],{"trials":31186,"activeCount":101},[],{"trials":31188,"activeCount":101},[],{"trials":31190,"activeCount":101},[],{"intervention":31192,"totalTrials":350,"cells":31193},"RO7303359",{"EARLY_PHASE1":31194,"PHASE1":31196,"PHASE2":31205,"PHASE3":31207,"PHASE4":31209,"NA":31211},{"trials":31195,"activeCount":101},[],{"trials":31197,"activeCount":101},[31198],{"nctId":31199,"briefTitle":31200,"status":107,"phases":31201,"primaryCompletion":7580,"completion":7580,"start":31202,"enrollment":15799,"conditions":31203,"interventions":31204},"NCT04615325","A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration",[89],"2020-12-08",[15187],[31192],{"trials":31206,"activeCount":101},[],{"trials":31208,"activeCount":101},[],{"trials":31210,"activeCount":101},[],{"trials":31212,"activeCount":101},[],{"intervention":31214,"totalTrials":350,"cells":31215},"PEG-IFN alfa-2a BA-free formulation",{"EARLY_PHASE1":31216,"PHASE1":31218,"PHASE2":31229,"PHASE3":31231,"PHASE4":31233,"NA":31235},{"trials":31217,"activeCount":101},[],{"trials":31219,"activeCount":101},[31220],{"nctId":31221,"briefTitle":31222,"status":107,"phases":31223,"primaryCompletion":3051,"completion":3051,"start":31224,"enrollment":31225,"conditions":31226,"interventions":31227},"NCT02573025","A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration",[89],"2015-09-17",277,[427],[31214,31228],"PEG-IFN alfa-2a market formulation",{"trials":31230,"activeCount":101},[],{"trials":31232,"activeCount":101},[],{"trials":31234,"activeCount":101},[],{"trials":31236,"activeCount":101},[],{"intervention":31228,"totalTrials":350,"cells":31238},{"EARLY_PHASE1":31239,"PHASE1":31241,"PHASE2":31247,"PHASE3":31249,"PHASE4":31251,"NA":31253},{"trials":31240,"activeCount":101},[],{"trials":31242,"activeCount":101},[31243],{"nctId":31221,"briefTitle":31222,"status":107,"phases":31244,"primaryCompletion":3051,"completion":3051,"start":31224,"enrollment":31225,"conditions":31245,"interventions":31246},[89],[427],[31214,31228],{"trials":31248,"activeCount":101},[],{"trials":31250,"activeCount":101},[],{"trials":31252,"activeCount":101},[],{"trials":31254,"activeCount":101},[],{"intervention":11441,"totalTrials":350,"cells":31256},{"EARLY_PHASE1":31257,"PHASE1":31259,"PHASE2":31265,"PHASE3":31267,"PHASE4":31269,"NA":31271},{"trials":31258,"activeCount":101},[],{"trials":31260,"activeCount":101},[31261],{"nctId":11434,"briefTitle":11435,"status":107,"phases":31262,"primaryCompletion":11437,"completion":11437,"start":2684,"enrollment":162,"conditions":31263,"interventions":31264},[89],[11439],[11441,10466],{"trials":31266,"activeCount":101},[],{"trials":31268,"activeCount":101},[],{"trials":31270,"activeCount":101},[],{"trials":31272,"activeCount":101},[],{"intervention":31274,"totalTrials":350,"cells":31275},"RO6885247",{"EARLY_PHASE1":31276,"PHASE1":31278,"PHASE2":31286,"PHASE3":31288,"PHASE4":31290,"NA":31292},{"trials":31277,"activeCount":101},[],{"trials":31279,"activeCount":101},[31280],{"nctId":31281,"briefTitle":31282,"status":130,"phases":31283,"primaryCompletion":2792,"completion":2792,"start":11550,"enrollment":1796,"conditions":31284,"interventions":31285},"NCT02240355","A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)",[89],[406],[31274],{"trials":31287,"activeCount":101},[],{"trials":31289,"activeCount":101},[],{"trials":31291,"activeCount":101},[],{"trials":31293,"activeCount":101},[],{"intervention":31295,"totalTrials":350,"cells":31296},"Ralmitaront",{"EARLY_PHASE1":31297,"PHASE1":31299,"PHASE2":31308,"PHASE3":31310,"PHASE4":31312,"NA":31314},{"trials":31298,"activeCount":101},[],{"trials":31300,"activeCount":101},[31301],{"nctId":31302,"briefTitle":31303,"status":107,"phases":31304,"primaryCompletion":31305,"completion":31305,"start":14799,"enrollment":384,"conditions":31306,"interventions":31307},"NCT06880328","18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia",[89],"2019-09-04",[19752],[31295],{"trials":31309,"activeCount":101},[],{"trials":31311,"activeCount":101},[],{"trials":31313,"activeCount":101},[],{"trials":31315,"activeCount":101},[],{"intervention":31317,"totalTrials":350,"cells":31318},"balapiravir [RO4588161]",{"EARLY_PHASE1":31319,"PHASE1":31321,"PHASE2":31330,"PHASE3":31332,"PHASE4":31334,"NA":31336},{"trials":31320,"activeCount":101},[],{"trials":31322,"activeCount":101},[31323],{"nctId":31324,"briefTitle":31325,"status":107,"phases":31326,"primaryCompletion":14712,"completion":14712,"start":7095,"enrollment":17519,"conditions":31327,"interventions":31329},"NCT01096576","A Study of Balapiravir in Patients With Dengue Virus Infection",[89],[31328],"Dengue",[31317],{"trials":31331,"activeCount":101},[],{"trials":31333,"activeCount":101},[],{"trials":31335,"activeCount":101},[],{"trials":31337,"activeCount":101},[],{"intervention":2421,"totalTrials":350,"cells":31339},{"EARLY_PHASE1":31340,"PHASE1":31342,"PHASE2":31348,"PHASE3":31350,"PHASE4":31352,"NA":31354},{"trials":31341,"activeCount":101},[],{"trials":31343,"activeCount":101},[31344],{"nctId":2414,"briefTitle":2415,"status":130,"phases":31345,"primaryCompletion":2417,"completion":2417,"start":2418,"enrollment":316,"conditions":31346,"interventions":31347},[89],[922],[2421,1018,1096],{"trials":31349,"activeCount":101},[],{"trials":31351,"activeCount":101},[],{"trials":31353,"activeCount":101},[],{"trials":31355,"activeCount":101},[],{"intervention":966,"totalTrials":350,"cells":31357},{"EARLY_PHASE1":31358,"PHASE1":31360,"PHASE2":31366,"PHASE3":31368,"PHASE4":31370,"NA":31372},{"trials":31359,"activeCount":101},[],{"trials":31361,"activeCount":101},[31362],{"nctId":959,"briefTitle":960,"status":107,"phases":31363,"primaryCompletion":962,"completion":962,"start":963,"enrollment":31,"conditions":31364,"interventions":31365},[89],[922],[68,966],{"trials":31367,"activeCount":101},[],{"trials":31369,"activeCount":101},[],{"trials":31371,"activeCount":101},[],{"trials":31373,"activeCount":101},[],{"intervention":31375,"totalTrials":350,"cells":31376},"RO5458640",{"EARLY_PHASE1":31377,"PHASE1":31379,"PHASE2":31387,"PHASE3":31389,"PHASE4":31391,"NA":31393},{"trials":31378,"activeCount":101},[],{"trials":31380,"activeCount":101},[31381],{"nctId":31382,"briefTitle":31383,"status":107,"phases":31384,"primaryCompletion":3674,"completion":3674,"start":4314,"enrollment":3574,"conditions":31385,"interventions":31386},"NCT01383733","A Study of RO5458640 in Patients With Advanced Solid Tumors",[89],[1241],[31375],{"trials":31388,"activeCount":101},[],{"trials":31390,"activeCount":101},[],{"trials":31392,"activeCount":101},[],{"trials":31394,"activeCount":101},[],{"intervention":31396,"totalTrials":350,"cells":31397},"RO6895882",{"EARLY_PHASE1":31398,"PHASE1":31400,"PHASE2":31409,"PHASE3":31411,"PHASE4":31413,"NA":31415},{"trials":31399,"activeCount":101},[],{"trials":31401,"activeCount":101},[31402],{"nctId":31403,"briefTitle":31404,"status":107,"phases":31405,"primaryCompletion":19629,"completion":19629,"start":31406,"enrollment":1283,"conditions":31407,"interventions":31408},"NCT02004106","A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and\u002For Metastatic Solid Tumors",[89],"2013-12-31",[1241],[31396],{"trials":31410,"activeCount":101},[],{"trials":31412,"activeCount":101},[],{"trials":31414,"activeCount":101},[],{"trials":31416,"activeCount":101},[],{"intervention":31418,"totalTrials":350,"cells":31419},"[12C] RO7049389",{"EARLY_PHASE1":31420,"PHASE1":31422,"PHASE2":31432,"PHASE3":31434,"PHASE4":31436,"NA":31438},{"trials":31421,"activeCount":101},[],{"trials":31423,"activeCount":101},[31424],{"nctId":31425,"briefTitle":31426,"status":107,"phases":31427,"primaryCompletion":1045,"completion":1045,"start":1430,"enrollment":2289,"conditions":31428,"interventions":31429},"NCT04729309","Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers",[89],[427],[31418,31430,31431],"[13C] RO7049389","[14C] RO7049389",{"trials":31433,"activeCount":101},[],{"trials":31435,"activeCount":101},[],{"trials":31437,"activeCount":101},[],{"trials":31439,"activeCount":101},[],{"intervention":31430,"totalTrials":350,"cells":31441},{"EARLY_PHASE1":31442,"PHASE1":31444,"PHASE2":31450,"PHASE3":31452,"PHASE4":31454,"NA":31456},{"trials":31443,"activeCount":101},[],{"trials":31445,"activeCount":101},[31446],{"nctId":31425,"briefTitle":31426,"status":107,"phases":31447,"primaryCompletion":1045,"completion":1045,"start":1430,"enrollment":2289,"conditions":31448,"interventions":31449},[89],[427],[31418,31430,31431],{"trials":31451,"activeCount":101},[],{"trials":31453,"activeCount":101},[],{"trials":31455,"activeCount":101},[],{"trials":31457,"activeCount":101},[],{"intervention":31431,"totalTrials":350,"cells":31459},{"EARLY_PHASE1":31460,"PHASE1":31462,"PHASE2":31468,"PHASE3":31470,"PHASE4":31472,"NA":31474},{"trials":31461,"activeCount":101},[],{"trials":31463,"activeCount":101},[31464],{"nctId":31425,"briefTitle":31426,"status":107,"phases":31465,"primaryCompletion":1045,"completion":1045,"start":1430,"enrollment":2289,"conditions":31466,"interventions":31467},[89],[427],[31418,31430,31431],{"trials":31469,"activeCount":101},[],{"trials":31471,"activeCount":101},[],{"trials":31473,"activeCount":101},[],{"trials":31475,"activeCount":101},[],{"intervention":19734,"totalTrials":350,"cells":31477},{"EARLY_PHASE1":31478,"PHASE1":31480,"PHASE2":31486,"PHASE3":31488,"PHASE4":31490,"NA":31492},{"trials":31479,"activeCount":101},[],{"trials":31481,"activeCount":101},[31482],{"nctId":19729,"briefTitle":19730,"status":107,"phases":31483,"primaryCompletion":2801,"completion":2801,"start":6315,"enrollment":7619,"conditions":31484,"interventions":31485},[89],[21],[19708,19734],{"trials":31487,"activeCount":101},[],{"trials":31489,"activeCount":101},[],{"trials":31491,"activeCount":101},[],{"trials":31493,"activeCount":101},[],{"intervention":19450,"totalTrials":350,"cells":31495},{"EARLY_PHASE1":31496,"PHASE1":31498,"PHASE2":31504,"PHASE3":31506,"PHASE4":31508,"NA":31510},{"trials":31497,"activeCount":101},[],{"trials":31499,"activeCount":101},[31500],{"nctId":19445,"briefTitle":19446,"status":107,"phases":31501,"primaryCompletion":2906,"completion":2906,"start":7095,"enrollment":4886,"conditions":31502,"interventions":31503},[89],[21],[13182,19450],{"trials":31505,"activeCount":101},[],{"trials":31507,"activeCount":101},[],{"trials":31509,"activeCount":101},[],{"trials":31511,"activeCount":101},[],{"intervention":993,"totalTrials":350,"cells":31513},{"EARLY_PHASE1":31514,"PHASE1":31516,"PHASE2":31522,"PHASE3":31524,"PHASE4":31526,"NA":31528},{"trials":31515,"activeCount":101},[],{"trials":31517,"activeCount":101},[31518],{"nctId":979,"briefTitle":980,"status":107,"phases":31519,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":31520,"interventions":31521},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"trials":31523,"activeCount":101},[],{"trials":31525,"activeCount":101},[],{"trials":31527,"activeCount":101},[],{"trials":31529,"activeCount":101},[],{"intervention":994,"totalTrials":350,"cells":31531},{"EARLY_PHASE1":31532,"PHASE1":31534,"PHASE2":31540,"PHASE3":31542,"PHASE4":31544,"NA":31546},{"trials":31533,"activeCount":101},[],{"trials":31535,"activeCount":101},[31536],{"nctId":979,"briefTitle":980,"status":107,"phases":31537,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":31538,"interventions":31539},[89],[986],[988,68,989,988,68,989,990,991,992,993,994],{"trials":31541,"activeCount":101},[],{"trials":31543,"activeCount":101},[],{"trials":31545,"activeCount":101},[],{"trials":31547,"activeCount":101},[],{"intervention":31549,"totalTrials":350,"cells":31550},"BMS-986089",{"EARLY_PHASE1":31551,"PHASE1":31553,"PHASE2":31562,"PHASE3":31564,"PHASE4":31566,"NA":31568},{"trials":31552,"activeCount":101},[],{"trials":31554,"activeCount":101},[31555],{"nctId":31556,"briefTitle":31557,"status":107,"phases":31558,"primaryCompletion":30377,"completion":30377,"start":4268,"enrollment":1026,"conditions":31559,"interventions":31561},"NCT02145234","Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects",[89],[31560],"Healthy Adults",[31549],{"trials":31563,"activeCount":101},[],{"trials":31565,"activeCount":101},[],{"trials":31567,"activeCount":101},[],{"trials":31569,"activeCount":101},[],{"intervention":2444,"totalTrials":350,"cells":31571},{"EARLY_PHASE1":31572,"PHASE1":31574,"PHASE2":31580,"PHASE3":31582,"PHASE4":31584,"NA":31586},{"trials":31573,"activeCount":101},[],{"trials":31575,"activeCount":101},[31576],{"nctId":2435,"briefTitle":2436,"status":107,"phases":31577,"primaryCompletion":2438,"completion":2438,"start":2439,"enrollment":2440,"conditions":31578,"interventions":31579},[89],[1071,2442],[2444,1096],{"trials":31581,"activeCount":101},[],{"trials":31583,"activeCount":101},[],{"trials":31585,"activeCount":101},[],{"trials":31587,"activeCount":101},[],{"intervention":31589,"totalTrials":350,"cells":31590},"RO5271983 - MAD",{"EARLY_PHASE1":31591,"PHASE1":31593,"PHASE2":31602,"PHASE3":31604,"PHASE4":31606,"NA":31608},{"trials":31592,"activeCount":101},[],{"trials":31594,"activeCount":101},[31595],{"nctId":31596,"briefTitle":31597,"status":107,"phases":31598,"primaryCompletion":6315,"completion":6315,"start":2932,"enrollment":2365,"conditions":31599,"interventions":31600},"NCT01209221","A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers",[89],[21],[31589,31601],"RO5271983 - SAD",{"trials":31603,"activeCount":101},[],{"trials":31605,"activeCount":101},[],{"trials":31607,"activeCount":101},[],{"trials":31609,"activeCount":101},[],{"intervention":31601,"totalTrials":350,"cells":31611},{"EARLY_PHASE1":31612,"PHASE1":31614,"PHASE2":31620,"PHASE3":31622,"PHASE4":31624,"NA":31626},{"trials":31613,"activeCount":101},[],{"trials":31615,"activeCount":101},[31616],{"nctId":31596,"briefTitle":31597,"status":107,"phases":31617,"primaryCompletion":6315,"completion":6315,"start":2932,"enrollment":2365,"conditions":31618,"interventions":31619},[89],[21],[31589,31601],{"trials":31621,"activeCount":101},[],{"trials":31623,"activeCount":101},[],{"trials":31625,"activeCount":101},[],{"trials":31627,"activeCount":101},[],{"intervention":31629,"totalTrials":350,"cells":31630},"GDC-0853",{"EARLY_PHASE1":31631,"PHASE1":31633,"PHASE2":31641,"PHASE3":31643,"PHASE4":31645,"NA":31647},{"trials":31632,"activeCount":101},[],{"trials":31634,"activeCount":101},[31635],{"nctId":31636,"briefTitle":31637,"status":107,"phases":31638,"primaryCompletion":29591,"completion":29591,"start":9718,"enrollment":8206,"conditions":31639,"interventions":31640},"NCT03188783","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants",[89],[21],[31629],{"trials":31642,"activeCount":101},[],{"trials":31644,"activeCount":101},[],{"trials":31646,"activeCount":101},[],{"trials":31648,"activeCount":101},[],{"intervention":31650,"totalTrials":350,"cells":31651},"0.01% RO7058584",{"EARLY_PHASE1":31652,"PHASE1":31654,"PHASE2":31669,"PHASE3":31671,"PHASE4":31673,"NA":31675},{"trials":31653,"activeCount":101},[],{"trials":31655,"activeCount":101},[31656],{"nctId":31657,"briefTitle":31658,"status":107,"phases":31659,"primaryCompletion":743,"completion":31660,"start":31661,"enrollment":11473,"conditions":31662,"interventions":31665},"NCT03293992","A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",[89],"2017-12-21","2017-10-10",[31663,31664],"Glaucoma, Open-angle","Ocular Hypertension",[31650,31666,31667,31668],"0.1% RO7058584","1% RO7058584","Latanoprost 0.005%",{"trials":31670,"activeCount":101},[],{"trials":31672,"activeCount":101},[],{"trials":31674,"activeCount":101},[],{"trials":31676,"activeCount":101},[],{"intervention":31666,"totalTrials":350,"cells":31678},{"EARLY_PHASE1":31679,"PHASE1":31681,"PHASE2":31687,"PHASE3":31689,"PHASE4":31691,"NA":31693},{"trials":31680,"activeCount":101},[],{"trials":31682,"activeCount":101},[31683],{"nctId":31657,"briefTitle":31658,"status":107,"phases":31684,"primaryCompletion":743,"completion":31660,"start":31661,"enrollment":11473,"conditions":31685,"interventions":31686},[89],[31663,31664],[31650,31666,31667,31668],{"trials":31688,"activeCount":101},[],{"trials":31690,"activeCount":101},[],{"trials":31692,"activeCount":101},[],{"trials":31694,"activeCount":101},[],{"intervention":31667,"totalTrials":350,"cells":31696},{"EARLY_PHASE1":31697,"PHASE1":31699,"PHASE2":31705,"PHASE3":31707,"PHASE4":31709,"NA":31711},{"trials":31698,"activeCount":101},[],{"trials":31700,"activeCount":101},[31701],{"nctId":31657,"briefTitle":31658,"status":107,"phases":31702,"primaryCompletion":743,"completion":31660,"start":31661,"enrollment":11473,"conditions":31703,"interventions":31704},[89],[31663,31664],[31650,31666,31667,31668],{"trials":31706,"activeCount":101},[],{"trials":31708,"activeCount":101},[],{"trials":31710,"activeCount":101},[],{"trials":31712,"activeCount":101},[],{"intervention":31668,"totalTrials":350,"cells":31714},{"EARLY_PHASE1":31715,"PHASE1":31717,"PHASE2":31723,"PHASE3":31725,"PHASE4":31727,"NA":31729},{"trials":31716,"activeCount":101},[],{"trials":31718,"activeCount":101},[31719],{"nctId":31657,"briefTitle":31658,"status":107,"phases":31720,"primaryCompletion":743,"completion":31660,"start":31661,"enrollment":11473,"conditions":31721,"interventions":31722},[89],[31663,31664],[31650,31666,31667,31668],{"trials":31724,"activeCount":101},[],{"trials":31726,"activeCount":101},[],{"trials":31728,"activeCount":101},[],{"trials":31730,"activeCount":101},[],{"intervention":25281,"totalTrials":350,"cells":31732},{"EARLY_PHASE1":31733,"PHASE1":31735,"PHASE2":31741,"PHASE3":31743,"PHASE4":31745,"NA":31747},{"trials":31734,"activeCount":101},[],{"trials":31736,"activeCount":101},[31737],{"nctId":25275,"briefTitle":25276,"status":107,"phases":31738,"primaryCompletion":2560,"completion":2560,"start":25278,"enrollment":909,"conditions":31739,"interventions":31740},[89],[20786],[25281,19325],{"trials":31742,"activeCount":101},[],{"trials":31744,"activeCount":101},[],{"trials":31746,"activeCount":101},[],{"trials":31748,"activeCount":101},[],{"intervention":6529,"totalTrials":350,"cells":31750},{"EARLY_PHASE1":31751,"PHASE1":31753,"PHASE2":31759,"PHASE3":31761,"PHASE4":31763,"NA":31765},{"trials":31752,"activeCount":101},[],{"trials":31754,"activeCount":101},[31755],{"nctId":6524,"briefTitle":6525,"status":130,"phases":31756,"primaryCompletion":2955,"completion":2955,"start":3324,"enrollment":2619,"conditions":31757,"interventions":31758},[89],[1883],[6529,6529,5186,6530],{"trials":31760,"activeCount":101},[],{"trials":31762,"activeCount":101},[],{"trials":31764,"activeCount":101},[],{"trials":31766,"activeCount":101},[],{"intervention":1016,"totalTrials":350,"cells":31768},{"EARLY_PHASE1":31769,"PHASE1":31771,"PHASE2":31777,"PHASE3":31779,"PHASE4":31781,"NA":31783},{"trials":31770,"activeCount":101},[],{"trials":31772,"activeCount":101},[31773],{"nctId":1006,"briefTitle":1007,"status":107,"phases":31774,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":31775,"interventions":31776},[89],[1013],[68,1015,1016,1017,1018,1019],{"trials":31778,"activeCount":101},[],{"trials":31780,"activeCount":101},[],{"trials":31782,"activeCount":101},[],{"trials":31784,"activeCount":101},[],{"intervention":1019,"totalTrials":350,"cells":31786},{"EARLY_PHASE1":31787,"PHASE1":31789,"PHASE2":31795,"PHASE3":31797,"PHASE4":31799,"NA":31801},{"trials":31788,"activeCount":101},[],{"trials":31790,"activeCount":101},[31791],{"nctId":1006,"briefTitle":1007,"status":107,"phases":31792,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":31793,"interventions":31794},[89],[1013],[68,1015,1016,1017,1018,1019],{"trials":31796,"activeCount":101},[],{"trials":31798,"activeCount":101},[],{"trials":31800,"activeCount":101},[],{"trials":31802,"activeCount":101},[],{"intervention":2455,"totalTrials":350,"cells":31804},{"EARLY_PHASE1":31805,"PHASE1":31807,"PHASE2":31813,"PHASE3":31815,"PHASE4":31817,"NA":31819},{"trials":31806,"activeCount":101},[],{"trials":31808,"activeCount":101},[31809],{"nctId":2446,"briefTitle":2447,"status":107,"phases":31810,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":786,"conditions":31811,"interventions":31812},[89],[1443,1397,2452,2453],[2455,1096],{"trials":31814,"activeCount":101},[],{"trials":31816,"activeCount":101},[],{"trials":31818,"activeCount":101},[],{"trials":31820,"activeCount":101},[],{"intervention":17879,"totalTrials":350,"cells":31822},{"EARLY_PHASE1":31823,"PHASE1":31825,"PHASE2":31831,"PHASE3":31833,"PHASE4":31835,"NA":31837},{"trials":31824,"activeCount":101},[],{"trials":31826,"activeCount":101},[31827],{"nctId":17874,"briefTitle":17875,"status":107,"phases":31828,"primaryCompletion":6578,"completion":6578,"start":5271,"enrollment":425,"conditions":31829,"interventions":31830},[89],[21],[17867,17879],{"trials":31832,"activeCount":101},[],{"trials":31834,"activeCount":101},[],{"trials":31836,"activeCount":101},[],{"trials":31838,"activeCount":101},[],{"intervention":1040,"totalTrials":350,"cells":31840},{"EARLY_PHASE1":31841,"PHASE1":31843,"PHASE2":31849,"PHASE3":31851,"PHASE4":31853,"NA":31855},{"trials":31842,"activeCount":101},[],{"trials":31844,"activeCount":101},[31845],{"nctId":1031,"briefTitle":1032,"status":107,"phases":31846,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":31847,"interventions":31848},[89],[1038],[68,1018,1040],{"trials":31850,"activeCount":101},[],{"trials":31852,"activeCount":101},[],{"trials":31854,"activeCount":101},[],{"trials":31856,"activeCount":101},[],{"intervention":3533,"totalTrials":350,"cells":31858},{"EARLY_PHASE1":31859,"PHASE1":31861,"PHASE2":31867,"PHASE3":31869,"PHASE4":31871,"NA":31873},{"trials":31860,"activeCount":101},[],{"trials":31862,"activeCount":101},[31863],{"nctId":3526,"briefTitle":3527,"status":107,"phases":31864,"primaryCompletion":3529,"completion":3529,"start":1373,"enrollment":425,"conditions":31865,"interventions":31866},[89],[3531],[1018,3533],{"trials":31868,"activeCount":101},[],{"trials":31870,"activeCount":101},[],{"trials":31872,"activeCount":101},[],{"trials":31874,"activeCount":101},[],{"intervention":19458,"totalTrials":350,"cells":31876},{"EARLY_PHASE1":31877,"PHASE1":31879,"PHASE2":31885,"PHASE3":31887,"PHASE4":31889,"NA":31891},{"trials":31878,"activeCount":101},[],{"trials":31880,"activeCount":101},[31881],{"nctId":19452,"briefTitle":19453,"status":107,"phases":31882,"primaryCompletion":4249,"completion":4249,"start":3007,"enrollment":5901,"conditions":31883,"interventions":31884},[89],[21],[19457,19458],{"trials":31886,"activeCount":101},[],{"trials":31888,"activeCount":101},[],{"trials":31890,"activeCount":101},[],{"trials":31892,"activeCount":101},[],{"intervention":31894,"totalTrials":350,"cells":31895},"RO7565020",{"EARLY_PHASE1":31896,"PHASE1":31898,"PHASE2":31908,"PHASE3":31910,"PHASE4":31912,"NA":31914},{"trials":31897,"activeCount":101},[],{"trials":31899,"activeCount":101},[31900],{"nctId":31901,"briefTitle":31902,"status":130,"phases":31903,"primaryCompletion":7233,"completion":7233,"start":31904,"enrollment":336,"conditions":31905,"interventions":31906},"NCT05763576","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection",[89],"2023-04-28",[17356],[31894,31907],"Nucleos(t)ide analogue (NUC) treatment",{"trials":31909,"activeCount":101},[],{"trials":31911,"activeCount":101},[],{"trials":31913,"activeCount":101},[],{"trials":31915,"activeCount":101},[],{"intervention":31907,"totalTrials":350,"cells":31917},{"EARLY_PHASE1":31918,"PHASE1":31920,"PHASE2":31926,"PHASE3":31928,"PHASE4":31930,"NA":31932},{"trials":31919,"activeCount":101},[],{"trials":31921,"activeCount":101},[31922],{"nctId":31901,"briefTitle":31902,"status":130,"phases":31923,"primaryCompletion":7233,"completion":7233,"start":31904,"enrollment":336,"conditions":31924,"interventions":31925},[89],[17356],[31894,31907],{"trials":31927,"activeCount":101},[],{"trials":31929,"activeCount":101},[],{"trials":31931,"activeCount":101},[],{"trials":31933,"activeCount":101},[],{"intervention":24971,"totalTrials":350,"cells":31935},{"EARLY_PHASE1":31936,"PHASE1":31938,"PHASE2":31944,"PHASE3":31946,"PHASE4":31948,"NA":31950},{"trials":31937,"activeCount":101},[],{"trials":31939,"activeCount":101},[31940],{"nctId":24966,"briefTitle":24967,"status":107,"phases":31941,"primaryCompletion":4315,"completion":4315,"start":13171,"enrollment":5901,"conditions":31942,"interventions":31943},[89],[36],[13159,24971],{"trials":31945,"activeCount":101},[],{"trials":31947,"activeCount":101},[],{"trials":31949,"activeCount":101},[],{"trials":31951,"activeCount":101},[],{"intervention":14576,"totalTrials":350,"cells":31953},{"EARLY_PHASE1":31954,"PHASE1":31956,"PHASE2":31962,"PHASE3":31964,"PHASE4":31966,"NA":31968},{"trials":31955,"activeCount":101},[],{"trials":31957,"activeCount":101},[31958],{"nctId":14569,"briefTitle":14570,"status":107,"phases":31959,"primaryCompletion":5891,"completion":5891,"start":14572,"enrollment":2289,"conditions":31960,"interventions":31961},[89],[14574],[14576,14577],{"trials":31963,"activeCount":101},[],{"trials":31965,"activeCount":101},[],{"trials":31967,"activeCount":101},[],{"trials":31969,"activeCount":101},[],{"intervention":6804,"totalTrials":350,"cells":31971},{"EARLY_PHASE1":31972,"PHASE1":31974,"PHASE2":31980,"PHASE3":31982,"PHASE4":31984,"NA":31986},{"trials":31973,"activeCount":101},[],{"trials":31975,"activeCount":101},[31976],{"nctId":6796,"briefTitle":6797,"status":107,"phases":31977,"primaryCompletion":6799,"completion":6799,"start":6800,"enrollment":2619,"conditions":31978,"interventions":31979},[89],[6802],[1695,6804],{"trials":31981,"activeCount":101},[],{"trials":31983,"activeCount":101},[],{"trials":31985,"activeCount":101},[],{"trials":31987,"activeCount":101},[],{"intervention":11773,"totalTrials":350,"cells":31989},{"EARLY_PHASE1":31990,"PHASE1":31992,"PHASE2":31998,"PHASE3":32000,"PHASE4":32002,"NA":32004},{"trials":31991,"activeCount":101},[],{"trials":31993,"activeCount":101},[31994],{"nctId":11761,"briefTitle":11762,"status":107,"phases":31995,"primaryCompletion":11764,"completion":11764,"start":11765,"enrollment":736,"conditions":31996,"interventions":31997},[89],[11767,11768,11769,11770,11771],[11773,388],{"trials":31999,"activeCount":101},[],{"trials":32001,"activeCount":101},[],{"trials":32003,"activeCount":101},[],{"trials":32005,"activeCount":101},[],{"intervention":5359,"totalTrials":350,"cells":32007},{"EARLY_PHASE1":32008,"PHASE1":32010,"PHASE2":32016,"PHASE3":32018,"PHASE4":32020,"NA":32022},{"trials":32009,"activeCount":101},[],{"trials":32011,"activeCount":101},[32012],{"nctId":5350,"briefTitle":5351,"status":107,"phases":32013,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":32014,"interventions":32015},[89],[5357],[5359,1423,990],{"trials":32017,"activeCount":101},[],{"trials":32019,"activeCount":101},[],{"trials":32021,"activeCount":101},[],{"trials":32023,"activeCount":101},[],{"intervention":7611,"totalTrials":350,"cells":32025},{"EARLY_PHASE1":32026,"PHASE1":32028,"PHASE2":32034,"PHASE3":32036,"PHASE4":32038,"NA":32040},{"trials":32027,"activeCount":101},[],{"trials":32029,"activeCount":101},[32030],{"nctId":7604,"briefTitle":7605,"status":107,"phases":32031,"primaryCompletion":7607,"completion":7607,"start":2417,"enrollment":755,"conditions":32032,"interventions":32033},[89],[551,7609],[7611,528],{"trials":32035,"activeCount":101},[],{"trials":32037,"activeCount":101},[],{"trials":32039,"activeCount":101},[],{"trials":32041,"activeCount":101},[],{"intervention":19909,"totalTrials":350,"cells":32043},{"EARLY_PHASE1":32044,"PHASE1":32046,"PHASE2":32052,"PHASE3":32054,"PHASE4":32056,"NA":32058},{"trials":32045,"activeCount":101},[],{"trials":32047,"activeCount":101},[32048],{"nctId":19904,"briefTitle":19905,"status":107,"phases":32049,"primaryCompletion":4314,"completion":4314,"start":8320,"enrollment":425,"conditions":32050,"interventions":32051},[89],[21],[19909,19897],{"trials":32053,"activeCount":101},[],{"trials":32055,"activeCount":101},[],{"trials":32057,"activeCount":101},[],{"trials":32059,"activeCount":101},[],{"intervention":1108,"totalTrials":350,"cells":32061},{"EARLY_PHASE1":32062,"PHASE1":32064,"PHASE2":32070,"PHASE3":32072,"PHASE4":32074,"NA":32076},{"trials":32063,"activeCount":101},[],{"trials":32065,"activeCount":101},[32066],{"nctId":1098,"briefTitle":1099,"status":107,"phases":32067,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":32068,"interventions":32069},[89],[18],[946,1106,68,1107,1108],{"trials":32071,"activeCount":101},[],{"trials":32073,"activeCount":101},[],{"trials":32075,"activeCount":101},[],{"trials":32077,"activeCount":101},[],{"intervention":26455,"totalTrials":350,"cells":32079},{"EARLY_PHASE1":32080,"PHASE1":32082,"PHASE2":32088,"PHASE3":32090,"PHASE4":32092,"NA":32094},{"trials":32081,"activeCount":101},[],{"trials":32083,"activeCount":101},[32084],{"nctId":26450,"briefTitle":26451,"status":107,"phases":32085,"primaryCompletion":11550,"completion":11550,"start":5418,"enrollment":709,"conditions":32086,"interventions":32087},[89],[21],[26455,26456,26443],{"trials":32089,"activeCount":101},[],{"trials":32091,"activeCount":101},[],{"trials":32093,"activeCount":101},[],{"trials":32095,"activeCount":101},[],{"intervention":26456,"totalTrials":350,"cells":32097},{"EARLY_PHASE1":32098,"PHASE1":32100,"PHASE2":32106,"PHASE3":32108,"PHASE4":32110,"NA":32112},{"trials":32099,"activeCount":101},[],{"trials":32101,"activeCount":101},[32102],{"nctId":26450,"briefTitle":26451,"status":107,"phases":32103,"primaryCompletion":11550,"completion":11550,"start":5418,"enrollment":709,"conditions":32104,"interventions":32105},[89],[21],[26455,26456,26443],{"trials":32107,"activeCount":101},[],{"trials":32109,"activeCount":101},[],{"trials":32111,"activeCount":101},[],{"trials":32113,"activeCount":101},[],{"intervention":11490,"totalTrials":350,"cells":32115},{"EARLY_PHASE1":32116,"PHASE1":32118,"PHASE2":32124,"PHASE3":32126,"PHASE4":32128,"NA":32130},{"trials":32117,"activeCount":101},[],{"trials":32119,"activeCount":101},[32120],{"nctId":11485,"briefTitle":11486,"status":107,"phases":32121,"primaryCompletion":3174,"completion":3174,"start":6157,"enrollment":1796,"conditions":32122,"interventions":32123},[89],[11439],[11490,10466],{"trials":32125,"activeCount":101},[],{"trials":32127,"activeCount":101},[],{"trials":32129,"activeCount":101},[],{"trials":32131,"activeCount":101},[],{"intervention":32133,"totalTrials":350,"cells":32134},"RG1511",{"EARLY_PHASE1":32135,"PHASE1":32137,"PHASE2":32145,"PHASE3":32147,"PHASE4":32149,"NA":32151},{"trials":32136,"activeCount":101},[],{"trials":32138,"activeCount":101},[32139],{"nctId":32140,"briefTitle":32141,"status":107,"phases":32142,"primaryCompletion":3325,"completion":3325,"start":3692,"enrollment":2440,"conditions":32143,"interventions":32144},"NCT00517465","A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.",[89],[36],[32133],{"trials":32146,"activeCount":101},[],{"trials":32148,"activeCount":101},[],{"trials":32150,"activeCount":101},[],{"trials":32152,"activeCount":101},[],{"intervention":32154,"totalTrials":350,"cells":32155},"RO6806127",{"EARLY_PHASE1":32156,"PHASE1":32158,"PHASE2":32166,"PHASE3":32168,"PHASE4":32170,"NA":32172},{"trials":32157,"activeCount":101},[],{"trials":32159,"activeCount":101},[32160],{"nctId":32161,"briefTitle":32162,"status":107,"phases":32163,"primaryCompletion":6195,"completion":6195,"start":5364,"enrollment":15799,"conditions":32164,"interventions":32165},"NCT02196636","A Phase 1 Study of RO6806127 in Healthy Male Volunteers",[89],[21],[32154],{"trials":32167,"activeCount":101},[],{"trials":32169,"activeCount":101},[],{"trials":32171,"activeCount":101},[],{"trials":32173,"activeCount":101},[],{"intervention":25033,"totalTrials":350,"cells":32175},{"EARLY_PHASE1":32176,"PHASE1":32178,"PHASE2":32184,"PHASE3":32186,"PHASE4":32188,"NA":32190},{"trials":32177,"activeCount":101},[],{"trials":32179,"activeCount":101},[32180],{"nctId":25028,"briefTitle":25029,"status":107,"phases":32181,"primaryCompletion":3246,"completion":3246,"start":3246,"enrollment":5901,"conditions":32182,"interventions":32183},[89],[21],[25033,13150],{"trials":32185,"activeCount":101},[],{"trials":32187,"activeCount":101},[],{"trials":32189,"activeCount":101},[],{"trials":32191,"activeCount":101},[],{"intervention":7894,"totalTrials":350,"cells":32193},{"EARLY_PHASE1":32194,"PHASE1":32196,"PHASE2":32202,"PHASE3":32204,"PHASE4":32206,"NA":32208},{"trials":32195,"activeCount":101},[],{"trials":32197,"activeCount":101},[32198],{"nctId":7888,"briefTitle":7889,"status":107,"phases":32199,"primaryCompletion":7891,"completion":7891,"start":1375,"enrollment":3497,"conditions":32200,"interventions":32201},[89],[18],[1106,1221,7894],{"trials":32203,"activeCount":101},[],{"trials":32205,"activeCount":101},[],{"trials":32207,"activeCount":101},[],{"trials":32209,"activeCount":101},[],{"intervention":24774,"totalTrials":350,"cells":32211},{"EARLY_PHASE1":32212,"PHASE1":32214,"PHASE2":32220,"PHASE3":32222,"PHASE4":32224,"NA":32226},{"trials":32213,"activeCount":101},[],{"trials":32215,"activeCount":101},[32216],{"nctId":24769,"briefTitle":24770,"status":107,"phases":32217,"primaryCompletion":8320,"completion":8320,"start":4206,"enrollment":97,"conditions":32218,"interventions":32219},[89],[21],[24749,19314,24774],{"trials":32221,"activeCount":101},[],{"trials":32223,"activeCount":101},[],{"trials":32225,"activeCount":101},[],{"trials":32227,"activeCount":101},[],{"intervention":19287,"totalTrials":350,"cells":32229},{"EARLY_PHASE1":32230,"PHASE1":32232,"PHASE2":32238,"PHASE3":32240,"PHASE4":32242,"NA":32244},{"trials":32231,"activeCount":101},[],{"trials":32233,"activeCount":101},[32234],{"nctId":19282,"briefTitle":19283,"status":107,"phases":32235,"primaryCompletion":3175,"completion":3175,"start":2768,"enrollment":931,"conditions":32236,"interventions":32237},[89],[21],[11967,19287,11969],{"trials":32239,"activeCount":101},[],{"trials":32241,"activeCount":101},[],{"trials":32243,"activeCount":101},[],{"trials":32245,"activeCount":101},[],{"intervention":32247,"totalTrials":350,"cells":32248},"tocilizumab [RoActemra\u002FActemra] Syringe",{"EARLY_PHASE1":32249,"PHASE1":32251,"PHASE2":32261,"PHASE3":32263,"PHASE4":32265,"NA":32267},{"trials":32250,"activeCount":101},[],{"trials":32252,"activeCount":101},[32253],{"nctId":32254,"briefTitle":32255,"status":107,"phases":32256,"primaryCompletion":2685,"completion":2685,"start":4314,"enrollment":32257,"conditions":32258,"interventions":32259},"NCT01418989","A Study of Administration of RoActemra\u002FActemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers",[89],239,[21],[32247,32260],"tocilizumab [RoActemra\u002FActemra] auto-injector",{"trials":32262,"activeCount":101},[],{"trials":32264,"activeCount":101},[],{"trials":32266,"activeCount":101},[],{"trials":32268,"activeCount":101},[],{"intervention":32260,"totalTrials":350,"cells":32270},{"EARLY_PHASE1":32271,"PHASE1":32273,"PHASE2":32279,"PHASE3":32281,"PHASE4":32283,"NA":32285},{"trials":32272,"activeCount":101},[],{"trials":32274,"activeCount":101},[32275],{"nctId":32254,"briefTitle":32255,"status":107,"phases":32276,"primaryCompletion":2685,"completion":2685,"start":4314,"enrollment":32257,"conditions":32277,"interventions":32278},[89],[21],[32247,32260],{"trials":32280,"activeCount":101},[],{"trials":32282,"activeCount":101},[],{"trials":32284,"activeCount":101},[],{"trials":32286,"activeCount":101},[],{"intervention":32288,"totalTrials":350,"cells":32289},"RG7314 RD + AVP SD",{"EARLY_PHASE1":32290,"PHASE1":32292,"PHASE2":32300,"PHASE3":32302,"PHASE4":32304,"NA":32306},{"trials":32291,"activeCount":101},[],{"trials":32293,"activeCount":101},[32294],{"nctId":32295,"briefTitle":32296,"status":107,"phases":32297,"primaryCompletion":8341,"completion":8341,"start":5364,"enrollment":8206,"conditions":32298,"interventions":32299},"NCT02205073","A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism",[89],[21],[32288],{"trials":32301,"activeCount":101},[],{"trials":32303,"activeCount":101},[],{"trials":32305,"activeCount":101},[],{"trials":32307,"activeCount":101},[],{"intervention":2535,"totalTrials":350,"cells":32309},{"EARLY_PHASE1":32310,"PHASE1":32312,"PHASE2":32318,"PHASE3":32320,"PHASE4":32322,"NA":32324},{"trials":32311,"activeCount":101},[],{"trials":32313,"activeCount":101},[32314],{"nctId":2528,"briefTitle":2529,"status":130,"phases":32315,"primaryCompletion":2531,"completion":2531,"start":62,"enrollment":2532,"conditions":32316,"interventions":32317},[89],[1196],[2535,1784,1018,1096],{"trials":32319,"activeCount":101},[],{"trials":32321,"activeCount":101},[],{"trials":32323,"activeCount":101},[],{"trials":32325,"activeCount":101},[],{"intervention":19762,"totalTrials":350,"cells":32327},{"EARLY_PHASE1":32328,"PHASE1":32330,"PHASE2":32336,"PHASE3":32338,"PHASE4":32340,"NA":32342},{"trials":32329,"activeCount":101},[],{"trials":32331,"activeCount":101},[32332],{"nctId":19756,"briefTitle":19757,"status":107,"phases":32333,"primaryCompletion":4488,"completion":4488,"start":3308,"enrollment":1406,"conditions":32334,"interventions":32335},[89],[21],[19761,19761,19708,19708,19762],{"trials":32337,"activeCount":101},[],{"trials":32339,"activeCount":101},[],{"trials":32341,"activeCount":101},[],{"trials":32343,"activeCount":101},[],{"intervention":32345,"totalTrials":350,"cells":32346},"[^14C]-Risdiplam",{"EARLY_PHASE1":32347,"PHASE1":32349,"PHASE2":32358,"PHASE3":32360,"PHASE4":32362,"NA":32364},{"trials":32348,"activeCount":101},[],{"trials":32350,"activeCount":101},[32351],{"nctId":32352,"briefTitle":32353,"status":107,"phases":32354,"primaryCompletion":32355,"completion":32355,"start":1899,"enrollment":942,"conditions":32356,"interventions":32357},"NCT03036501","A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants",[89],"2017-02-28",[21466],[32345],{"trials":32359,"activeCount":101},[],{"trials":32361,"activeCount":101},[],{"trials":32363,"activeCount":101},[],{"trials":32365,"activeCount":101},[],{"intervention":32367,"totalTrials":350,"cells":32368},"RO4987655",{"EARLY_PHASE1":32369,"PHASE1":32371,"PHASE2":32379,"PHASE3":32381,"PHASE4":32383,"NA":32385},{"trials":32370,"activeCount":101},[],{"trials":32372,"activeCount":101},[32373],{"nctId":32374,"briefTitle":32375,"status":107,"phases":32376,"primaryCompletion":3324,"completion":3324,"start":3308,"enrollment":14683,"conditions":32377,"interventions":32378},"NCT00817518","A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors",[89],[1241],[32367,32367],{"trials":32380,"activeCount":101},[],{"trials":32382,"activeCount":101},[],{"trials":32384,"activeCount":101},[],{"trials":32386,"activeCount":101},[],{"intervention":32388,"totalTrials":350,"cells":32389},"Oral Balovaptan",{"EARLY_PHASE1":32390,"PHASE1":32392,"PHASE2":32404,"PHASE3":32406,"PHASE4":32408,"NA":32410},{"trials":32391,"activeCount":101},[],{"trials":32393,"activeCount":101},[32394],{"nctId":32395,"briefTitle":32396,"status":107,"phases":32397,"primaryCompletion":32398,"completion":32399,"start":32400,"enrollment":721,"conditions":32401,"interventions":32402},"NCT03764449","A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers",[89],"2019-03-04","2019-03-15","2019-01-10",[427],[32388,32403],"IV Balovaptan",{"trials":32405,"activeCount":101},[],{"trials":32407,"activeCount":101},[],{"trials":32409,"activeCount":101},[],{"trials":32411,"activeCount":101},[],{"intervention":32403,"totalTrials":350,"cells":32413},{"EARLY_PHASE1":32414,"PHASE1":32416,"PHASE2":32422,"PHASE3":32424,"PHASE4":32426,"NA":32428},{"trials":32415,"activeCount":101},[],{"trials":32417,"activeCount":101},[32418],{"nctId":32395,"briefTitle":32396,"status":107,"phases":32419,"primaryCompletion":32398,"completion":32399,"start":32400,"enrollment":721,"conditions":32420,"interventions":32421},[89],[427],[32388,32403],{"trials":32423,"activeCount":101},[],{"trials":32425,"activeCount":101},[],{"trials":32427,"activeCount":101},[],{"trials":32429,"activeCount":101},[],{"intervention":32431,"totalTrials":350,"cells":32432},"Renodapt",{"EARLY_PHASE1":32433,"PHASE1":32435,"PHASE2":32446,"PHASE3":32448,"PHASE4":32450,"NA":32452},{"trials":32434,"activeCount":101},[],{"trials":32436,"activeCount":101},[32437],{"nctId":32438,"briefTitle":32439,"status":107,"phases":32440,"primaryCompletion":8934,"completion":8934,"start":6343,"enrollment":8206,"conditions":32441,"interventions":32442},"NCT02981290","Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants",[89],[427],[32431,32443,32444,32445],"Mycept","Cellmune","CellCept",{"trials":32447,"activeCount":101},[],{"trials":32449,"activeCount":101},[],{"trials":32451,"activeCount":101},[],{"trials":32453,"activeCount":101},[],{"intervention":32443,"totalTrials":350,"cells":32455},{"EARLY_PHASE1":32456,"PHASE1":32458,"PHASE2":32464,"PHASE3":32466,"PHASE4":32468,"NA":32470},{"trials":32457,"activeCount":101},[],{"trials":32459,"activeCount":101},[32460],{"nctId":32438,"briefTitle":32439,"status":107,"phases":32461,"primaryCompletion":8934,"completion":8934,"start":6343,"enrollment":8206,"conditions":32462,"interventions":32463},[89],[427],[32431,32443,32444,32445],{"trials":32465,"activeCount":101},[],{"trials":32467,"activeCount":101},[],{"trials":32469,"activeCount":101},[],{"trials":32471,"activeCount":101},[],{"intervention":32444,"totalTrials":350,"cells":32473},{"EARLY_PHASE1":32474,"PHASE1":32476,"PHASE2":32482,"PHASE3":32484,"PHASE4":32486,"NA":32488},{"trials":32475,"activeCount":101},[],{"trials":32477,"activeCount":101},[32478],{"nctId":32438,"briefTitle":32439,"status":107,"phases":32479,"primaryCompletion":8934,"completion":8934,"start":6343,"enrollment":8206,"conditions":32480,"interventions":32481},[89],[427],[32431,32443,32444,32445],{"trials":32483,"activeCount":101},[],{"trials":32485,"activeCount":101},[],{"trials":32487,"activeCount":101},[],{"trials":32489,"activeCount":101},[],{"intervention":32445,"totalTrials":350,"cells":32491},{"EARLY_PHASE1":32492,"PHASE1":32494,"PHASE2":32500,"PHASE3":32502,"PHASE4":32504,"NA":32506},{"trials":32493,"activeCount":101},[],{"trials":32495,"activeCount":101},[32496],{"nctId":32438,"briefTitle":32439,"status":107,"phases":32497,"primaryCompletion":8934,"completion":8934,"start":6343,"enrollment":8206,"conditions":32498,"interventions":32499},[89],[427],[32431,32443,32444,32445],{"trials":32501,"activeCount":101},[],{"trials":32503,"activeCount":101},[],{"trials":32505,"activeCount":101},[],{"trials":32507,"activeCount":101},[],{"intervention":32509,"totalTrials":350,"cells":32510},"RO5303253",{"EARLY_PHASE1":32511,"PHASE1":32513,"PHASE2":32521,"PHASE3":32523,"PHASE4":32525,"NA":32527},{"trials":32512,"activeCount":101},[],{"trials":32514,"activeCount":101},[32515],{"nctId":32516,"briefTitle":32517,"status":107,"phases":32518,"primaryCompletion":2906,"completion":2906,"start":8826,"enrollment":2365,"conditions":32519,"interventions":32520},"NCT01181024","A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1",[89],[30485],[32509,32509,32509],{"trials":32522,"activeCount":101},[],{"trials":32524,"activeCount":101},[],{"trials":32526,"activeCount":101},[],{"trials":32528,"activeCount":101},[],{"intervention":19477,"totalTrials":350,"cells":32530},{"EARLY_PHASE1":32531,"PHASE1":32533,"PHASE2":32539,"PHASE3":32541,"PHASE4":32543,"NA":32545},{"trials":32532,"activeCount":101},[],{"trials":32534,"activeCount":101},[32535],{"nctId":19472,"briefTitle":19473,"status":107,"phases":32536,"primaryCompletion":2809,"completion":2809,"start":9079,"enrollment":786,"conditions":32537,"interventions":32538},[89],[36],[13182,19477],{"trials":32540,"activeCount":101},[],{"trials":32542,"activeCount":101},[],{"trials":32544,"activeCount":101},[],{"trials":32546,"activeCount":101},[],{"intervention":24979,"totalTrials":350,"cells":32548},{"EARLY_PHASE1":32549,"PHASE1":32551,"PHASE2":32557,"PHASE3":32559,"PHASE4":32561,"NA":32563},{"trials":32550,"activeCount":101},[],{"trials":32552,"activeCount":101},[32553],{"nctId":24973,"briefTitle":24974,"status":130,"phases":32554,"primaryCompletion":6377,"completion":6377,"start":7096,"enrollment":162,"conditions":32555,"interventions":32556},[89],[24977],[13159,24979],{"trials":32558,"activeCount":101},[],{"trials":32560,"activeCount":101},[],{"trials":32562,"activeCount":101},[],{"trials":32564,"activeCount":101},[],{"intervention":32566,"totalTrials":350,"cells":32567},"RG1530",{"EARLY_PHASE1":32568,"PHASE1":32570,"PHASE2":32578,"PHASE3":32580,"PHASE4":32582,"NA":32584},{"trials":32569,"activeCount":101},[],{"trials":32571,"activeCount":101},[32572],{"nctId":32573,"briefTitle":32574,"status":107,"phases":32575,"primaryCompletion":3479,"completion":3479,"start":133,"enrollment":123,"conditions":32576,"interventions":32577},"NCT00493155","A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.",[89],[1241],[32566],{"trials":32579,"activeCount":101},[],{"trials":32581,"activeCount":101},[],{"trials":32583,"activeCount":101},[],{"trials":32585,"activeCount":101},[],{"intervention":32587,"totalTrials":350,"cells":32588},"Paclitaxel + Carboplatin + CP-870,893",{"EARLY_PHASE1":32589,"PHASE1":32591,"PHASE2":32599,"PHASE3":32601,"PHASE4":32603,"NA":32605},{"trials":32590,"activeCount":101},[],{"trials":32592,"activeCount":101},[32593],{"nctId":32594,"briefTitle":32595,"status":107,"phases":32596,"primaryCompletion":4488,"completion":4488,"start":5820,"enrollment":1705,"conditions":32597,"interventions":32598},"NCT00607048","Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors",[89],[1241],[32587,32587],{"trials":32600,"activeCount":101},[],{"trials":32602,"activeCount":101},[],{"trials":32604,"activeCount":101},[],{"trials":32606,"activeCount":101},[],{"intervention":19769,"totalTrials":350,"cells":32608},{"EARLY_PHASE1":32609,"PHASE1":32611,"PHASE2":32617,"PHASE3":32619,"PHASE4":32621,"NA":32623},{"trials":32610,"activeCount":101},[],{"trials":32612,"activeCount":101},[32613],{"nctId":19764,"briefTitle":19765,"status":107,"phases":32614,"primaryCompletion":3103,"completion":3103,"start":6315,"enrollment":5901,"conditions":32615,"interventions":32616},[89],[21],[19708,19769],{"trials":32618,"activeCount":101},[],{"trials":32620,"activeCount":101},[],{"trials":32622,"activeCount":101},[],{"trials":32624,"activeCount":101},[],{"intervention":32626,"totalTrials":350,"cells":32627},"RO7486967",{"EARLY_PHASE1":32628,"PHASE1":32630,"PHASE2":32641,"PHASE3":32643,"PHASE4":32645,"NA":32647},{"trials":32629,"activeCount":101},[],{"trials":32631,"activeCount":101},[32632],{"nctId":32633,"briefTitle":32634,"status":107,"phases":32635,"primaryCompletion":32636,"completion":32636,"start":32637,"enrollment":336,"conditions":32638,"interventions":32640},"NCT05924243","A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.",[89],"2024-07-18","2022-09-22",[32639],"Parkinson Disease",[32626],{"trials":32642,"activeCount":101},[],{"trials":32644,"activeCount":101},[],{"trials":32646,"activeCount":101},[],{"trials":32648,"activeCount":101},[],{"intervention":2554,"totalTrials":350,"cells":32650},{"EARLY_PHASE1":32651,"PHASE1":32653,"PHASE2":32659,"PHASE3":32661,"PHASE4":32663,"NA":32665},{"trials":32652,"activeCount":101},[],{"trials":32654,"activeCount":101},[32655],{"nctId":2546,"briefTitle":2547,"status":130,"phases":32656,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":706,"conditions":32657,"interventions":32658},[89],[1049,1684,1511,30,2552],[2554,2555],{"trials":32660,"activeCount":101},[],{"trials":32662,"activeCount":101},[],{"trials":32664,"activeCount":101},[],{"trials":32666,"activeCount":101},[],{"intervention":25334,"totalTrials":350,"cells":32668},{"EARLY_PHASE1":32669,"PHASE1":32671,"PHASE2":32677,"PHASE3":32679,"PHASE4":32681,"NA":32683},{"trials":32670,"activeCount":101},[],{"trials":32672,"activeCount":101},[32673],{"nctId":25329,"briefTitle":25330,"status":107,"phases":32674,"primaryCompletion":3212,"completion":3212,"start":4454,"enrollment":496,"conditions":32675,"interventions":32676},[89],[21],[25316,25334,25058],{"trials":32678,"activeCount":101},[],{"trials":32680,"activeCount":101},[],{"trials":32682,"activeCount":101},[],{"trials":32684,"activeCount":101},[],{"intervention":30382,"totalTrials":350,"cells":32686},{"EARLY_PHASE1":32687,"PHASE1":32689,"PHASE2":32695,"PHASE3":32697,"PHASE4":32699,"NA":32701},{"trials":32688,"activeCount":101},[],{"trials":32690,"activeCount":101},[32691],{"nctId":30374,"briefTitle":30375,"status":107,"phases":32692,"primaryCompletion":30377,"completion":30377,"start":30378,"enrollment":973,"conditions":32693,"interventions":32694},[89],[30380],[30382,30383,30367],{"trials":32696,"activeCount":101},[],{"trials":32698,"activeCount":101},[],{"trials":32700,"activeCount":101},[],{"trials":32702,"activeCount":101},[],{"intervention":30383,"totalTrials":350,"cells":32704},{"EARLY_PHASE1":32705,"PHASE1":32707,"PHASE2":32713,"PHASE3":32715,"PHASE4":32717,"NA":32719},{"trials":32706,"activeCount":101},[],{"trials":32708,"activeCount":101},[32709],{"nctId":30374,"briefTitle":30375,"status":107,"phases":32710,"primaryCompletion":30377,"completion":30377,"start":30378,"enrollment":973,"conditions":32711,"interventions":32712},[89],[30380],[30382,30383,30367],{"trials":32714,"activeCount":101},[],{"trials":32716,"activeCount":101},[],{"trials":32718,"activeCount":101},[],{"trials":32720,"activeCount":101},[],{"intervention":11938,"totalTrials":350,"cells":32722},{"EARLY_PHASE1":32723,"PHASE1":32725,"PHASE2":32731,"PHASE3":32733,"PHASE4":32735,"NA":32737},{"trials":32724,"activeCount":101},[],{"trials":32726,"activeCount":101},[32727],{"nctId":11931,"briefTitle":11932,"status":107,"phases":32728,"primaryCompletion":11934,"completion":11934,"start":11935,"enrollment":2492,"conditions":32729,"interventions":32730},[89],[1241],[1126,11938],{"trials":32732,"activeCount":101},[],{"trials":32734,"activeCount":101},[],{"trials":32736,"activeCount":101},[],{"trials":32738,"activeCount":101},[],{"intervention":32740,"totalTrials":350,"cells":32741},"RG4733",{"EARLY_PHASE1":32742,"PHASE1":32744,"PHASE2":32752,"PHASE3":32754,"PHASE4":32756,"NA":32758},{"trials":32743,"activeCount":101},[],{"trials":32745,"activeCount":101},[32746],{"nctId":32747,"briefTitle":32748,"status":107,"phases":32749,"primaryCompletion":7152,"completion":7152,"start":5820,"enrollment":1283,"conditions":32750,"interventions":32751},"NCT00532090","A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.",[89],[1241],[32740,32740,32740],{"trials":32753,"activeCount":101},[],{"trials":32755,"activeCount":101},[],{"trials":32757,"activeCount":101},[],{"trials":32759,"activeCount":101},[],{"intervention":32761,"totalTrials":350,"cells":32762},"Fixed-Dose Combination of Pertuzumab and Trastuzumab SC",{"EARLY_PHASE1":32763,"PHASE1":32765,"PHASE2":32777,"PHASE3":32779,"PHASE4":32781,"NA":32783},{"trials":32764,"activeCount":101},[],{"trials":32766,"activeCount":101},[32767],{"nctId":32768,"briefTitle":32769,"status":107,"phases":32770,"primaryCompletion":32771,"completion":32772,"start":32773,"enrollment":3214,"conditions":32774,"interventions":32776},"NCT05275010","A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System",[89],"2023-05-14","2023-10-03","2022-05-30",[32775],"Healthy Male Subjects",[32761],{"trials":32778,"activeCount":101},[],{"trials":32780,"activeCount":101},[],{"trials":32782,"activeCount":101},[],{"trials":32784,"activeCount":101},[],{"intervention":19307,"totalTrials":350,"cells":32786},{"EARLY_PHASE1":32787,"PHASE1":32789,"PHASE2":32795,"PHASE3":32797,"PHASE4":32799,"NA":32801},{"trials":32788,"activeCount":101},[],{"trials":32790,"activeCount":101},[32791],{"nctId":19302,"briefTitle":19303,"status":107,"phases":32792,"primaryCompletion":3213,"completion":3213,"start":3103,"enrollment":145,"conditions":32793,"interventions":32794},[89],[33],[19307,11969,19294],{"trials":32796,"activeCount":101},[],{"trials":32798,"activeCount":101},[],{"trials":32800,"activeCount":101},[],{"trials":32802,"activeCount":101},[],{"intervention":32804,"totalTrials":350,"cells":32805},"RO7033877 + Bronchoscopy",{"EARLY_PHASE1":32806,"PHASE1":32808,"PHASE2":32816,"PHASE3":32818,"PHASE4":32820,"NA":32822},{"trials":32807,"activeCount":101},[],{"trials":32809,"activeCount":101},[32810],{"nctId":32811,"briefTitle":32812,"status":107,"phases":32813,"primaryCompletion":3182,"completion":3182,"start":3174,"enrollment":8206,"conditions":32814,"interventions":32815},"NCT02165293","A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers",[89],[21],[32804],{"trials":32817,"activeCount":101},[],{"trials":32819,"activeCount":101},[],{"trials":32821,"activeCount":101},[],{"trials":32823,"activeCount":101},[],{"intervention":25186,"totalTrials":350,"cells":32825},{"EARLY_PHASE1":32826,"PHASE1":32828,"PHASE2":32834,"PHASE3":32836,"PHASE4":32838,"NA":32840},{"trials":32827,"activeCount":101},[],{"trials":32829,"activeCount":101},[32830],{"nctId":25181,"briefTitle":25182,"status":107,"phases":32831,"primaryCompletion":2768,"completion":2768,"start":9079,"enrollment":316,"conditions":32832,"interventions":32833},[89],[21],[25167,25186],{"trials":32835,"activeCount":101},[],{"trials":32837,"activeCount":101},[],{"trials":32839,"activeCount":101},[],{"trials":32841,"activeCount":101},[],{"intervention":32843,"totalTrials":350,"cells":32844},"Ro542-4802\u002FF03",{"EARLY_PHASE1":32845,"PHASE1":32847,"PHASE2":32858,"PHASE3":32860,"PHASE4":32862,"NA":32864},{"trials":32846,"activeCount":101},[],{"trials":32848,"activeCount":101},[32849],{"nctId":32850,"briefTitle":32851,"status":107,"phases":32852,"primaryCompletion":3182,"completion":3182,"start":4682,"enrollment":8990,"conditions":32853,"interventions":32854},"NCT02074553","A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers",[89],[21],[32843,32855,32856,32857],"Ro542-4802\u002FF07","Ro542-4802\u002FF08","Ro542-4802\u002FF14",{"trials":32859,"activeCount":101},[],{"trials":32861,"activeCount":101},[],{"trials":32863,"activeCount":101},[],{"trials":32865,"activeCount":101},[],{"intervention":32855,"totalTrials":350,"cells":32867},{"EARLY_PHASE1":32868,"PHASE1":32870,"PHASE2":32876,"PHASE3":32878,"PHASE4":32880,"NA":32882},{"trials":32869,"activeCount":101},[],{"trials":32871,"activeCount":101},[32872],{"nctId":32850,"briefTitle":32851,"status":107,"phases":32873,"primaryCompletion":3182,"completion":3182,"start":4682,"enrollment":8990,"conditions":32874,"interventions":32875},[89],[21],[32843,32855,32856,32857],{"trials":32877,"activeCount":101},[],{"trials":32879,"activeCount":101},[],{"trials":32881,"activeCount":101},[],{"trials":32883,"activeCount":101},[],{"intervention":32856,"totalTrials":350,"cells":32885},{"EARLY_PHASE1":32886,"PHASE1":32888,"PHASE2":32894,"PHASE3":32896,"PHASE4":32898,"NA":32900},{"trials":32887,"activeCount":101},[],{"trials":32889,"activeCount":101},[32890],{"nctId":32850,"briefTitle":32851,"status":107,"phases":32891,"primaryCompletion":3182,"completion":3182,"start":4682,"enrollment":8990,"conditions":32892,"interventions":32893},[89],[21],[32843,32855,32856,32857],{"trials":32895,"activeCount":101},[],{"trials":32897,"activeCount":101},[],{"trials":32899,"activeCount":101},[],{"trials":32901,"activeCount":101},[],{"intervention":32857,"totalTrials":350,"cells":32903},{"EARLY_PHASE1":32904,"PHASE1":32906,"PHASE2":32912,"PHASE3":32914,"PHASE4":32916,"NA":32918},{"trials":32905,"activeCount":101},[],{"trials":32907,"activeCount":101},[32908],{"nctId":32850,"briefTitle":32851,"status":107,"phases":32909,"primaryCompletion":3182,"completion":3182,"start":4682,"enrollment":8990,"conditions":32910,"interventions":32911},[89],[21],[32843,32855,32856,32857],{"trials":32913,"activeCount":101},[],{"trials":32915,"activeCount":101},[],{"trials":32917,"activeCount":101},[],{"trials":32919,"activeCount":101},[],{"intervention":32921,"totalTrials":350,"cells":32922},"RO5126766",{"EARLY_PHASE1":32923,"PHASE1":32925,"PHASE2":32933,"PHASE3":32935,"PHASE4":32937,"NA":32939},{"trials":32924,"activeCount":101},[],{"trials":32926,"activeCount":101},[32927],{"nctId":32928,"briefTitle":32929,"status":107,"phases":32930,"primaryCompletion":3189,"completion":3189,"start":8688,"enrollment":973,"conditions":32931,"interventions":32932},"NCT00773526","A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.",[89],[1241],[32921],{"trials":32934,"activeCount":101},[],{"trials":32936,"activeCount":101},[],{"trials":32938,"activeCount":101},[],{"trials":32940,"activeCount":101},[],{"intervention":15803,"totalTrials":350,"cells":32942},{"EARLY_PHASE1":32943,"PHASE1":32945,"PHASE2":32951,"PHASE3":32953,"PHASE4":32955,"NA":32957},{"trials":32944,"activeCount":101},[],{"trials":32946,"activeCount":101},[32947],{"nctId":15796,"briefTitle":15797,"status":107,"phases":32948,"primaryCompletion":2809,"completion":2809,"start":2801,"enrollment":15799,"conditions":32949,"interventions":32950},[89],[15801],[15803,5381,5381],{"trials":32952,"activeCount":101},[],{"trials":32954,"activeCount":101},[],{"trials":32956,"activeCount":101},[],{"trials":32958,"activeCount":101},[],{"intervention":8893,"totalTrials":350,"cells":32960},{"EARLY_PHASE1":32961,"PHASE1":32963,"PHASE2":32969,"PHASE3":32971,"PHASE4":32973,"NA":32975},{"trials":32962,"activeCount":101},[],{"trials":32964,"activeCount":101},[32965],{"nctId":8888,"briefTitle":8889,"status":107,"phases":32966,"primaryCompletion":6277,"completion":4582,"start":4323,"enrollment":1058,"conditions":32967,"interventions":32968},[89],[30],[8893,1165,5381],{"trials":32970,"activeCount":101},[],{"trials":32972,"activeCount":101},[],{"trials":32974,"activeCount":101},[],{"trials":32976,"activeCount":101},[],{"intervention":32978,"totalTrials":350,"cells":32979},"RG1671",{"EARLY_PHASE1":32980,"PHASE1":32982,"PHASE2":32990,"PHASE3":32992,"PHASE4":32994,"NA":32996},{"trials":32981,"activeCount":101},[],{"trials":32983,"activeCount":101},[32984],{"nctId":32985,"briefTitle":32986,"status":107,"phases":32987,"primaryCompletion":4488,"completion":4488,"start":2965,"enrollment":1385,"conditions":32988,"interventions":32989},"NCT00517816","A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.",[89],[17203],[32978],{"trials":32991,"activeCount":101},[],{"trials":32993,"activeCount":101},[],{"trials":32995,"activeCount":101},[],{"trials":32997,"activeCount":101},[],{"intervention":32999,"totalTrials":350,"cells":33000},"RO7070179",{"EARLY_PHASE1":33001,"PHASE1":33003,"PHASE2":33013,"PHASE3":33015,"PHASE4":33017,"NA":33019},{"trials":33002,"activeCount":101},[],{"trials":33004,"activeCount":101},[33005],{"nctId":33006,"briefTitle":33007,"status":107,"phases":33008,"primaryCompletion":33009,"completion":33009,"start":33010,"enrollment":1796,"conditions":33011,"interventions":33012},"NCT02564614","A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",[89],"2018-01-22","2016-05-02",[1443],[32999],{"trials":33014,"activeCount":101},[],{"trials":33016,"activeCount":101},[],{"trials":33018,"activeCount":101},[],{"trials":33020,"activeCount":101},[],{"intervention":33022,"totalTrials":350,"cells":33023},"RXDX-107",{"EARLY_PHASE1":33024,"PHASE1":33026,"PHASE2":33034,"PHASE3":33036,"PHASE4":33038,"NA":33040},{"trials":33025,"activeCount":101},[],{"trials":33027,"activeCount":101},[33028],{"nctId":33029,"briefTitle":33030,"status":130,"phases":33031,"primaryCompletion":27271,"completion":27271,"start":2808,"enrollment":31,"conditions":33032,"interventions":33033},"NCT02548390","Study of Intravenous RXDX-107 in Patients With Solid Tumors",[89],[1160],[33022],{"trials":33035,"activeCount":101},[],{"trials":33037,"activeCount":101},[],{"trials":33039,"activeCount":101},[],{"trials":33041,"activeCount":101},[],{"intervention":2575,"totalTrials":350,"cells":33043},{"EARLY_PHASE1":33044,"PHASE1":33046,"PHASE2":33052,"PHASE3":33054,"PHASE4":33056,"NA":33058},{"trials":33045,"activeCount":101},[],{"trials":33047,"activeCount":101},[33048],{"nctId":2567,"briefTitle":2568,"status":107,"phases":33049,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":33050,"interventions":33051},[89],[933],[2575,2575,1096,2576,2577,2578,2579],{"trials":33053,"activeCount":101},[],{"trials":33055,"activeCount":101},[],{"trials":33057,"activeCount":101},[],{"trials":33059,"activeCount":101},[],{"intervention":2576,"totalTrials":350,"cells":33061},{"EARLY_PHASE1":33062,"PHASE1":33064,"PHASE2":33070,"PHASE3":33072,"PHASE4":33074,"NA":33076},{"trials":33063,"activeCount":101},[],{"trials":33065,"activeCount":101},[33066],{"nctId":2567,"briefTitle":2568,"status":107,"phases":33067,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":33068,"interventions":33069},[89],[933],[2575,2575,1096,2576,2577,2578,2579],{"trials":33071,"activeCount":101},[],{"trials":33073,"activeCount":101},[],{"trials":33075,"activeCount":101},[],{"trials":33077,"activeCount":101},[],{"intervention":2578,"totalTrials":350,"cells":33079},{"EARLY_PHASE1":33080,"PHASE1":33082,"PHASE2":33088,"PHASE3":33090,"PHASE4":33092,"NA":33094},{"trials":33081,"activeCount":101},[],{"trials":33083,"activeCount":101},[33084],{"nctId":2567,"briefTitle":2568,"status":107,"phases":33085,"primaryCompletion":2570,"completion":2570,"start":2571,"enrollment":2572,"conditions":33086,"interventions":33087},[89],[933],[2575,2575,1096,2576,2577,2578,2579],{"trials":33089,"activeCount":101},[],{"trials":33091,"activeCount":101},[],{"trials":33093,"activeCount":101},[],{"trials":33095,"activeCount":101},[],{"intervention":33097,"totalTrials":350,"cells":33098},"RO6874813",{"EARLY_PHASE1":33099,"PHASE1":33101,"PHASE2":33110,"PHASE3":33112,"PHASE4":33114,"NA":33116},{"trials":33100,"activeCount":101},[],{"trials":33102,"activeCount":101},[33103],{"nctId":33104,"briefTitle":33105,"status":107,"phases":33106,"primaryCompletion":20012,"completion":20012,"start":33107,"enrollment":1239,"conditions":33108,"interventions":33109},"NCT02558140","A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2015-10-11",[1241],[33097,33097],{"trials":33111,"activeCount":101},[],{"trials":33113,"activeCount":101},[],{"trials":33115,"activeCount":101},[],{"trials":33117,"activeCount":101},[],{"intervention":33119,"totalTrials":350,"cells":33120},"Part 1: SAD RO7033877",{"EARLY_PHASE1":33121,"PHASE1":33123,"PHASE2":33136,"PHASE3":33138,"PHASE4":33140,"NA":33142},{"trials":33122,"activeCount":101},[],{"trials":33124,"activeCount":101},[33125],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33128,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33129,"interventions":33130},"NCT02165332","A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval",[89],[21],[33119,33131,33132,33133,33134,33135],"Part 1: SAD placebo","Part 2: Treatment A, RO7033877","Part 2: Treatment B, RO7033877","Part 2: Treatment C, moxifloxacin","Part 2: Treatment D, RO7033877 and moxifloxacin placebo",{"trials":33137,"activeCount":101},[],{"trials":33139,"activeCount":101},[],{"trials":33141,"activeCount":101},[],{"trials":33143,"activeCount":101},[],{"intervention":33131,"totalTrials":350,"cells":33145},{"EARLY_PHASE1":33146,"PHASE1":33148,"PHASE2":33154,"PHASE3":33156,"PHASE4":33158,"NA":33160},{"trials":33147,"activeCount":101},[],{"trials":33149,"activeCount":101},[33150],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33151,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33152,"interventions":33153},[89],[21],[33119,33131,33132,33133,33134,33135],{"trials":33155,"activeCount":101},[],{"trials":33157,"activeCount":101},[],{"trials":33159,"activeCount":101},[],{"trials":33161,"activeCount":101},[],{"intervention":33132,"totalTrials":350,"cells":33163},{"EARLY_PHASE1":33164,"PHASE1":33166,"PHASE2":33172,"PHASE3":33174,"PHASE4":33176,"NA":33178},{"trials":33165,"activeCount":101},[],{"trials":33167,"activeCount":101},[33168],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33169,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33170,"interventions":33171},[89],[21],[33119,33131,33132,33133,33134,33135],{"trials":33173,"activeCount":101},[],{"trials":33175,"activeCount":101},[],{"trials":33177,"activeCount":101},[],{"trials":33179,"activeCount":101},[],{"intervention":33133,"totalTrials":350,"cells":33181},{"EARLY_PHASE1":33182,"PHASE1":33184,"PHASE2":33190,"PHASE3":33192,"PHASE4":33194,"NA":33196},{"trials":33183,"activeCount":101},[],{"trials":33185,"activeCount":101},[33186],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33187,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33188,"interventions":33189},[89],[21],[33119,33131,33132,33133,33134,33135],{"trials":33191,"activeCount":101},[],{"trials":33193,"activeCount":101},[],{"trials":33195,"activeCount":101},[],{"trials":33197,"activeCount":101},[],{"intervention":33134,"totalTrials":350,"cells":33199},{"EARLY_PHASE1":33200,"PHASE1":33202,"PHASE2":33208,"PHASE3":33210,"PHASE4":33212,"NA":33214},{"trials":33201,"activeCount":101},[],{"trials":33203,"activeCount":101},[33204],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33205,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33206,"interventions":33207},[89],[21],[33119,33131,33132,33133,33134,33135],{"trials":33209,"activeCount":101},[],{"trials":33211,"activeCount":101},[],{"trials":33213,"activeCount":101},[],{"trials":33215,"activeCount":101},[],{"intervention":33135,"totalTrials":350,"cells":33217},{"EARLY_PHASE1":33218,"PHASE1":33220,"PHASE2":33226,"PHASE3":33228,"PHASE4":33230,"NA":33232},{"trials":33219,"activeCount":101},[],{"trials":33221,"activeCount":101},[33222],{"nctId":33126,"briefTitle":33127,"status":107,"phases":33223,"primaryCompletion":11550,"completion":11550,"start":5364,"enrollment":17519,"conditions":33224,"interventions":33225},[89],[21],[33119,33131,33132,33133,33134,33135],{"trials":33227,"activeCount":101},[],{"trials":33229,"activeCount":101},[],{"trials":33231,"activeCount":101},[],{"trials":33233,"activeCount":101},[],{"intervention":33235,"totalTrials":350,"cells":33236},"RO5310074",{"EARLY_PHASE1":33237,"PHASE1":33239,"PHASE2":33248,"PHASE3":33250,"PHASE4":33252,"NA":33254},{"trials":33238,"activeCount":101},[],{"trials":33240,"activeCount":101},[33241],{"nctId":33242,"briefTitle":33243,"status":107,"phases":33244,"primaryCompletion":2768,"completion":2768,"start":4233,"enrollment":8583,"conditions":33245,"interventions":33247},"NCT01199809","A Study of RO5310074 in Patients With Psoriatic Arthritis",[89],[33246],"Arthritis, Psoriatic",[33235],{"trials":33249,"activeCount":101},[],{"trials":33251,"activeCount":101},[],{"trials":33253,"activeCount":101},[],{"trials":33255,"activeCount":101},[],{"intervention":33257,"totalTrials":350,"cells":33258},"Balovaptan therapeutic dose Treatment A",{"EARLY_PHASE1":33259,"PHASE1":33261,"PHASE2":33275,"PHASE3":33277,"PHASE4":33279,"NA":33281},{"trials":33260,"activeCount":101},[],{"trials":33262,"activeCount":101},[33263],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33266,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33268,"interventions":33269},"NCT03808298","Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects",[89],"2019-07-13",[427],[33257,33270,33271,33272,33273,33274],"Balovaptan supra-therapeutic dose Treatment B","Active control [moxifloxacin] on Day 2 Treatment C","Active control [Moxifloxacin] on Day 15 Treatment D","Moxifloxacin Treatment C","Moxifloxacin Treatment D",{"trials":33276,"activeCount":101},[],{"trials":33278,"activeCount":101},[],{"trials":33280,"activeCount":101},[],{"trials":33282,"activeCount":101},[],{"intervention":33270,"totalTrials":350,"cells":33284},{"EARLY_PHASE1":33285,"PHASE1":33287,"PHASE2":33293,"PHASE3":33295,"PHASE4":33297,"NA":33299},{"trials":33286,"activeCount":101},[],{"trials":33288,"activeCount":101},[33289],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33290,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33291,"interventions":33292},[89],[427],[33257,33270,33271,33272,33273,33274],{"trials":33294,"activeCount":101},[],{"trials":33296,"activeCount":101},[],{"trials":33298,"activeCount":101},[],{"trials":33300,"activeCount":101},[],{"intervention":33271,"totalTrials":350,"cells":33302},{"EARLY_PHASE1":33303,"PHASE1":33305,"PHASE2":33311,"PHASE3":33313,"PHASE4":33315,"NA":33317},{"trials":33304,"activeCount":101},[],{"trials":33306,"activeCount":101},[33307],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33308,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33309,"interventions":33310},[89],[427],[33257,33270,33271,33272,33273,33274],{"trials":33312,"activeCount":101},[],{"trials":33314,"activeCount":101},[],{"trials":33316,"activeCount":101},[],{"trials":33318,"activeCount":101},[],{"intervention":33272,"totalTrials":350,"cells":33320},{"EARLY_PHASE1":33321,"PHASE1":33323,"PHASE2":33329,"PHASE3":33331,"PHASE4":33333,"NA":33335},{"trials":33322,"activeCount":101},[],{"trials":33324,"activeCount":101},[33325],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33326,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33327,"interventions":33328},[89],[427],[33257,33270,33271,33272,33273,33274],{"trials":33330,"activeCount":101},[],{"trials":33332,"activeCount":101},[],{"trials":33334,"activeCount":101},[],{"trials":33336,"activeCount":101},[],{"intervention":33273,"totalTrials":350,"cells":33338},{"EARLY_PHASE1":33339,"PHASE1":33341,"PHASE2":33347,"PHASE3":33349,"PHASE4":33351,"NA":33353},{"trials":33340,"activeCount":101},[],{"trials":33342,"activeCount":101},[33343],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33344,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33345,"interventions":33346},[89],[427],[33257,33270,33271,33272,33273,33274],{"trials":33348,"activeCount":101},[],{"trials":33350,"activeCount":101},[],{"trials":33352,"activeCount":101},[],{"trials":33354,"activeCount":101},[],{"intervention":33274,"totalTrials":350,"cells":33356},{"EARLY_PHASE1":33357,"PHASE1":33359,"PHASE2":33365,"PHASE3":33367,"PHASE4":33369,"NA":33371},{"trials":33358,"activeCount":101},[],{"trials":33360,"activeCount":101},[33361],{"nctId":33264,"briefTitle":33265,"status":107,"phases":33362,"primaryCompletion":4618,"completion":33267,"start":2313,"enrollment":2999,"conditions":33363,"interventions":33364},[89],[427],[33257,33270,33271,33272,33273,33274],{"trials":33366,"activeCount":101},[],{"trials":33368,"activeCount":101},[],{"trials":33370,"activeCount":101},[],{"trials":33372,"activeCount":101},[],{"intervention":33374,"totalTrials":350,"cells":33375},"ANA598 200 mg bid or placebo",{"EARLY_PHASE1":33376,"PHASE1":33378,"PHASE2":33389,"PHASE3":33391,"PHASE4":33393,"NA":33395},{"trials":33377,"activeCount":101},[],{"trials":33379,"activeCount":101},[33380],{"nctId":33381,"briefTitle":33382,"status":107,"phases":33383,"primaryCompletion":3325,"completion":3325,"start":8934,"enrollment":384,"conditions":33384,"interventions":33386},"NCT00782353","Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection",[89],[33385],"Chronic Hepatitis C",[33374,33387,33388],"ANA598 400 mg bid or placebo","ANA598 800 mg bid or placebo",{"trials":33390,"activeCount":101},[],{"trials":33392,"activeCount":101},[],{"trials":33394,"activeCount":101},[],{"trials":33396,"activeCount":101},[],{"intervention":33387,"totalTrials":350,"cells":33398},{"EARLY_PHASE1":33399,"PHASE1":33401,"PHASE2":33407,"PHASE3":33409,"PHASE4":33411,"NA":33413},{"trials":33400,"activeCount":101},[],{"trials":33402,"activeCount":101},[33403],{"nctId":33381,"briefTitle":33382,"status":107,"phases":33404,"primaryCompletion":3325,"completion":3325,"start":8934,"enrollment":384,"conditions":33405,"interventions":33406},[89],[33385],[33374,33387,33388],{"trials":33408,"activeCount":101},[],{"trials":33410,"activeCount":101},[],{"trials":33412,"activeCount":101},[],{"trials":33414,"activeCount":101},[],{"intervention":33388,"totalTrials":350,"cells":33416},{"EARLY_PHASE1":33417,"PHASE1":33419,"PHASE2":33425,"PHASE3":33427,"PHASE4":33429,"NA":33431},{"trials":33418,"activeCount":101},[],{"trials":33420,"activeCount":101},[33421],{"nctId":33381,"briefTitle":33382,"status":107,"phases":33422,"primaryCompletion":3325,"completion":3325,"start":8934,"enrollment":384,"conditions":33423,"interventions":33424},[89],[33385],[33374,33387,33388],{"trials":33426,"activeCount":101},[],{"trials":33428,"activeCount":101},[],{"trials":33430,"activeCount":101},[],{"trials":33432,"activeCount":101},[],{"intervention":11781,"totalTrials":350,"cells":33434},{"EARLY_PHASE1":33435,"PHASE1":33437,"PHASE2":33443,"PHASE3":33445,"PHASE4":33447,"NA":33449},{"trials":33436,"activeCount":101},[],{"trials":33438,"activeCount":101},[33439],{"nctId":11775,"briefTitle":11776,"status":130,"phases":33440,"primaryCompletion":11778,"completion":11778,"start":10316,"enrollment":1847,"conditions":33441,"interventions":33442},[89],[21],[11781,388,11782],{"trials":33444,"activeCount":101},[],{"trials":33446,"activeCount":101},[],{"trials":33448,"activeCount":101},[],{"trials":33450,"activeCount":101},[],{"intervention":11499,"totalTrials":350,"cells":33452},{"EARLY_PHASE1":33453,"PHASE1":33455,"PHASE2":33461,"PHASE3":33463,"PHASE4":33465,"NA":33467},{"trials":33454,"activeCount":101},[],{"trials":33456,"activeCount":101},[33457],{"nctId":11492,"briefTitle":11493,"status":107,"phases":33458,"primaryCompletion":11495,"completion":11495,"start":11496,"enrollment":5901,"conditions":33459,"interventions":33460},[89],[11439],[11499,1479],{"trials":33462,"activeCount":101},[],{"trials":33464,"activeCount":101},[],{"trials":33466,"activeCount":101},[],{"trials":33468,"activeCount":101},[],{"intervention":33470,"totalTrials":350,"cells":33471},"ANA773",{"EARLY_PHASE1":33472,"PHASE1":33474,"PHASE2":33482,"PHASE3":33484,"PHASE4":33486,"NA":33488},{"trials":33473,"activeCount":101},[],{"trials":33475,"activeCount":101},[33476],{"nctId":33477,"briefTitle":33478,"status":107,"phases":33479,"primaryCompletion":5271,"completion":5271,"start":14572,"enrollment":817,"conditions":33480,"interventions":33481},"NCT01211626","Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)",[89],[27922],[33470],{"trials":33483,"activeCount":101},[],{"trials":33485,"activeCount":101},[],{"trials":33487,"activeCount":101},[],{"trials":33489,"activeCount":101},[],{"intervention":19497,"totalTrials":350,"cells":33491},{"EARLY_PHASE1":33492,"PHASE1":33494,"PHASE2":33500,"PHASE3":33502,"PHASE4":33504,"NA":33506},{"trials":33493,"activeCount":101},[],{"trials":33495,"activeCount":101},[33496],{"nctId":19492,"briefTitle":19493,"status":107,"phases":33497,"completion":3189,"start":4409,"enrollment":4886,"conditions":33498,"interventions":33499},[89],[21],[13182,19497],{"trials":33501,"activeCount":101},[],{"trials":33503,"activeCount":101},[],{"trials":33505,"activeCount":101},[],{"trials":33507,"activeCount":101},[],{"intervention":33509,"totalTrials":350,"cells":33510},"Basimglurant",{"EARLY_PHASE1":33511,"PHASE1":33513,"PHASE2":33522,"PHASE3":33524,"PHASE4":33526,"NA":33528},{"trials":33512,"activeCount":101},[],{"trials":33514,"activeCount":101},[33515],{"nctId":33516,"briefTitle":33517,"status":107,"phases":33518,"primaryCompletion":2808,"completion":2808,"start":4232,"enrollment":1272,"conditions":33519,"interventions":33521},"NCT02433093","A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)",[89],[33520],"Major Depressive Disorder, Healthy Volunteer",[33509],{"trials":33523,"activeCount":101},[],{"trials":33525,"activeCount":101},[],{"trials":33527,"activeCount":101},[],{"trials":33529,"activeCount":101},[],{"intervention":33531,"totalTrials":350,"cells":33532},"inclacumab",{"EARLY_PHASE1":33533,"PHASE1":33535,"PHASE2":33543,"PHASE3":33545,"PHASE4":33547,"NA":33549},{"trials":33534,"activeCount":101},[],{"trials":33536,"activeCount":101},[33537],{"nctId":33538,"briefTitle":33539,"status":107,"phases":33540,"primaryCompletion":4682,"completion":4682,"start":10332,"enrollment":447,"conditions":33541,"interventions":33542},"NCT01815827","A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers",[89],[21],[33531],{"trials":33544,"activeCount":101},[],{"trials":33546,"activeCount":101},[],{"trials":33548,"activeCount":101},[],{"trials":33550,"activeCount":101},[],{"intervention":1208,"totalTrials":350,"cells":33552},{"EARLY_PHASE1":33553,"PHASE1":33555,"PHASE2":33561,"PHASE3":33563,"PHASE4":33565,"NA":33567},{"trials":33554,"activeCount":101},[],{"trials":33556,"activeCount":101},[33557],{"nctId":1199,"briefTitle":1200,"status":107,"phases":33558,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":33559,"interventions":33560},[89],[1206],[68,1208],{"trials":33562,"activeCount":101},[],{"trials":33564,"activeCount":101},[],{"trials":33566,"activeCount":101},[],{"trials":33568,"activeCount":101},[],{"intervention":33570,"totalTrials":350,"cells":33571},"RO5323441 + bevacizumab [Avastin]",{"EARLY_PHASE1":33572,"PHASE1":33574,"PHASE2":33582,"PHASE3":33584,"PHASE4":33586,"NA":33588},{"trials":33573,"activeCount":101},[],{"trials":33575,"activeCount":101},[33576],{"nctId":33577,"briefTitle":33578,"status":107,"phases":33579,"primaryCompletion":132,"completion":132,"start":2931,"enrollment":2289,"conditions":33580,"interventions":33581},"NCT01308684","A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma",[89],[16614],[33570,5275],{"trials":33583,"activeCount":101},[],{"trials":33585,"activeCount":101},[],{"trials":33587,"activeCount":101},[],{"trials":33589,"activeCount":101},[],{"intervention":12921,"totalTrials":350,"cells":33591},{"EARLY_PHASE1":33592,"PHASE1":33594,"PHASE2":33600,"PHASE3":33602,"PHASE4":33604,"NA":33606},{"trials":33593,"activeCount":101},[],{"trials":33595,"activeCount":101},[33596],{"nctId":12914,"briefTitle":12915,"status":107,"phases":33597,"primaryCompletion":12917,"completion":12917,"start":12918,"enrollment":1058,"conditions":33598,"interventions":33599},[89],[7754],[12889,398,12921,11717],{"trials":33601,"activeCount":101},[],{"trials":33603,"activeCount":101},[],{"trials":33605,"activeCount":101},[],{"trials":33607,"activeCount":101},[],{"intervention":33609,"totalTrials":350,"cells":33610},"RO7051790",{"EARLY_PHASE1":33611,"PHASE1":33613,"PHASE2":33622,"PHASE3":33624,"PHASE4":33626,"NA":33628},{"trials":33612,"activeCount":101},[],{"trials":33614,"activeCount":101},[33615],{"nctId":33616,"briefTitle":33617,"status":107,"phases":33618,"primaryCompletion":33619,"completion":33619,"start":16280,"enrollment":5901,"conditions":33620,"interventions":33621},"NCT02913443","A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)",[89],"2017-10-24",[1071],[33609],{"trials":33623,"activeCount":101},[],{"trials":33625,"activeCount":101},[],{"trials":33627,"activeCount":101},[],{"trials":33629,"activeCount":101},[],{"intervention":33631,"totalTrials":350,"cells":33632},"RO4917838 and Rosuvastatin",{"EARLY_PHASE1":33633,"PHASE1":33635,"PHASE2":33643,"PHASE3":33645,"PHASE4":33647,"NA":33649},{"trials":33634,"activeCount":101},[],{"trials":33636,"activeCount":101},[33637],{"nctId":33638,"briefTitle":33639,"status":107,"phases":33640,"primaryCompletion":2932,"completion":2932,"start":7152,"enrollment":5901,"conditions":33641,"interventions":33642},"NCT01183585","A Study of RO4917838 With Rosuvastatin in Healthy Volunteers",[89],[21],[33631],{"trials":33644,"activeCount":101},[],{"trials":33646,"activeCount":101},[],{"trials":33648,"activeCount":101},[],{"trials":33650,"activeCount":101},[],{"intervention":33652,"totalTrials":350,"cells":33653},"[ 14C]-labeled RO7269162",{"EARLY_PHASE1":33654,"PHASE1":33656,"PHASE2":33666,"PHASE3":33668,"PHASE4":33670,"NA":33672},{"trials":33655,"activeCount":101},[],{"trials":33657,"activeCount":101},[33658],{"nctId":33659,"briefTitle":33660,"status":107,"phases":33661,"primaryCompletion":33662,"completion":33662,"start":33663,"enrollment":306,"conditions":33664,"interventions":33665},"NCT06733298","A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants",[89],"2025-01-29","2025-01-08",[427],[33652],{"trials":33667,"activeCount":101},[],{"trials":33669,"activeCount":101},[],{"trials":33671,"activeCount":101},[],{"trials":33673,"activeCount":101},[],{"intervention":19333,"totalTrials":350,"cells":33675},{"EARLY_PHASE1":33676,"PHASE1":33678,"PHASE2":33684,"PHASE3":33686,"PHASE4":33688,"NA":33690},{"trials":33677,"activeCount":101},[],{"trials":33679,"activeCount":101},[33680],{"nctId":19328,"briefTitle":19329,"status":107,"phases":33681,"primaryCompletion":3175,"completion":3175,"start":3103,"enrollment":2375,"conditions":33682,"interventions":33683},[89],[21],[11967,19333,11969],{"trials":33685,"activeCount":101},[],{"trials":33687,"activeCount":101},[],{"trials":33689,"activeCount":101},[],{"trials":33691,"activeCount":101},[],{"intervention":5380,"totalTrials":350,"cells":33693},{"EARLY_PHASE1":33694,"PHASE1":33696,"PHASE2":33702,"PHASE3":33704,"PHASE4":33706,"NA":33708},{"trials":33695,"activeCount":101},[],{"trials":33697,"activeCount":101},[33698],{"nctId":5373,"briefTitle":5374,"status":130,"phases":33699,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":33700,"interventions":33701},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":33703,"activeCount":101},[],{"trials":33705,"activeCount":101},[],{"trials":33707,"activeCount":101},[],{"trials":33709,"activeCount":101},[],{"intervention":5387,"totalTrials":350,"cells":33711},{"EARLY_PHASE1":33712,"PHASE1":33714,"PHASE2":33720,"PHASE3":33722,"PHASE4":33724,"NA":33726},{"trials":33713,"activeCount":101},[],{"trials":33715,"activeCount":101},[33716],{"nctId":5373,"briefTitle":5374,"status":130,"phases":33717,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":33718,"interventions":33719},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":33721,"activeCount":101},[],{"trials":33723,"activeCount":101},[],{"trials":33725,"activeCount":101},[],{"trials":33727,"activeCount":101},[],{"intervention":1232,"totalTrials":350,"cells":33729},{"EARLY_PHASE1":33730,"PHASE1":33732,"PHASE2":33738,"PHASE3":33740,"PHASE4":33742,"NA":33744},{"trials":33731,"activeCount":101},[],{"trials":33733,"activeCount":101},[33734],{"nctId":1225,"briefTitle":1226,"status":130,"phases":33735,"primaryCompletion":1228,"completion":1228,"start":1229,"enrollment":372,"conditions":33736,"interventions":33737},[89],[933],[68,1232],{"trials":33739,"activeCount":101},[],{"trials":33741,"activeCount":101},[],{"trials":33743,"activeCount":101},[],{"trials":33745,"activeCount":101},[],{"intervention":33747,"totalTrials":350,"cells":33748},"RO6839921",{"EARLY_PHASE1":33749,"PHASE1":33751,"PHASE2":33762,"PHASE3":33764,"PHASE4":33766,"NA":33768},{"trials":33750,"activeCount":101},[],{"trials":33752,"activeCount":101},[33753],{"nctId":33754,"briefTitle":33755,"status":107,"phases":33756,"primaryCompletion":33757,"completion":33757,"start":33758,"enrollment":4683,"conditions":33759,"interventions":33761},"NCT02098967","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",[89],"2018-05-07","2014-04-21",[33760],"Neoplasms, Myelogenous Leukemia, Acute",[33747,33747,33747],{"trials":33763,"activeCount":101},[],{"trials":33765,"activeCount":101},[],{"trials":33767,"activeCount":101},[],{"trials":33769,"activeCount":101},[],{"intervention":2612,"totalTrials":350,"cells":33771},{"EARLY_PHASE1":33772,"PHASE1":33774,"PHASE2":33780,"PHASE3":33782,"PHASE4":33784,"NA":33786},{"trials":33773,"activeCount":101},[],{"trials":33775,"activeCount":101},[33776],{"nctId":2606,"briefTitle":2607,"status":130,"phases":33777,"primaryCompletion":592,"completion":592,"start":2609,"enrollment":145,"conditions":33778,"interventions":33779},[89],[922],[2612,1096],{"trials":33781,"activeCount":101},[],{"trials":33783,"activeCount":101},[],{"trials":33785,"activeCount":101},[],{"trials":33787,"activeCount":101},[],{"intervention":33789,"totalTrials":350,"cells":33790},"4 mg\u002Fkg Onartuzumab",{"EARLY_PHASE1":33791,"PHASE1":33793,"PHASE2":33805,"PHASE3":33807,"PHASE4":33809,"NA":33811},{"trials":33792,"activeCount":101},[],{"trials":33794,"activeCount":101},[33795],{"nctId":33796,"briefTitle":33797,"status":107,"phases":33798,"primaryCompletion":33799,"completion":33799,"start":33800,"enrollment":1184,"conditions":33801,"interventions":33802},"NCT02031731","The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2014-04-14","2014-01-13",[1241],[33789,33803,33804],"15 mg\u002Fkg Onartuzumab","30 mg\u002Fkg Onartuzumab",{"trials":33806,"activeCount":101},[],{"trials":33808,"activeCount":101},[],{"trials":33810,"activeCount":101},[],{"trials":33812,"activeCount":101},[],{"intervention":33803,"totalTrials":350,"cells":33814},{"EARLY_PHASE1":33815,"PHASE1":33817,"PHASE2":33823,"PHASE3":33825,"PHASE4":33827,"NA":33829},{"trials":33816,"activeCount":101},[],{"trials":33818,"activeCount":101},[33819],{"nctId":33796,"briefTitle":33797,"status":107,"phases":33820,"primaryCompletion":33799,"completion":33799,"start":33800,"enrollment":1184,"conditions":33821,"interventions":33822},[89],[1241],[33789,33803,33804],{"trials":33824,"activeCount":101},[],{"trials":33826,"activeCount":101},[],{"trials":33828,"activeCount":101},[],{"trials":33830,"activeCount":101},[],{"intervention":33804,"totalTrials":350,"cells":33832},{"EARLY_PHASE1":33833,"PHASE1":33835,"PHASE2":33841,"PHASE3":33843,"PHASE4":33845,"NA":33847},{"trials":33834,"activeCount":101},[],{"trials":33836,"activeCount":101},[33837],{"nctId":33796,"briefTitle":33797,"status":107,"phases":33838,"primaryCompletion":33799,"completion":33799,"start":33800,"enrollment":1184,"conditions":33839,"interventions":33840},[89],[1241],[33789,33803,33804],{"trials":33842,"activeCount":101},[],{"trials":33844,"activeCount":101},[],{"trials":33846,"activeCount":101},[],{"trials":33848,"activeCount":101},[],{"intervention":33850,"totalTrials":350,"cells":33851},"RG547",{"EARLY_PHASE1":33852,"PHASE1":33854,"PHASE2":33862,"PHASE3":33864,"PHASE4":33866,"NA":33868},{"trials":33853,"activeCount":101},[],{"trials":33855,"activeCount":101},[33856],{"nctId":33857,"briefTitle":33858,"status":107,"phases":33859,"primaryCompletion":8688,"completion":8688,"start":122,"enrollment":1724,"conditions":33860,"interventions":33861},"NCT00400296","A Study of R547 in Patients With Advanced Solid Tumors.",[89],[1241],[33850],{"trials":33863,"activeCount":101},[],{"trials":33865,"activeCount":101},[],{"trials":33867,"activeCount":101},[],{"trials":33869,"activeCount":101},[],{"intervention":3577,"totalTrials":350,"cells":33871},{"EARLY_PHASE1":33872,"PHASE1":33874,"PHASE2":33880,"PHASE3":33882,"PHASE4":33884,"NA":33886},{"trials":33873,"activeCount":101},[],{"trials":33875,"activeCount":101},[33876],{"nctId":3570,"briefTitle":3571,"status":107,"phases":33877,"primaryCompletion":2219,"completion":2219,"start":3573,"enrollment":3574,"conditions":33878,"interventions":33879},[89],[1135],[3577,1095,1018],{"trials":33881,"activeCount":101},[],{"trials":33883,"activeCount":101},[],{"trials":33885,"activeCount":101},[],{"trials":33887,"activeCount":101},[],{"intervention":25106,"totalTrials":350,"cells":33889},{"EARLY_PHASE1":33890,"PHASE1":33892,"PHASE2":33898,"PHASE3":33900,"PHASE4":33902,"NA":33904},{"trials":33891,"activeCount":101},[],{"trials":33893,"activeCount":101},[33894],{"nctId":25100,"briefTitle":25101,"status":107,"phases":33895,"primaryCompletion":25103,"completion":25103,"start":2916,"enrollment":97,"conditions":33896,"interventions":33897},[89],[1261],[25106,25075],{"trials":33899,"activeCount":101},[],{"trials":33901,"activeCount":101},[],{"trials":33903,"activeCount":101},[],{"trials":33905,"activeCount":101},[],{"intervention":24800,"totalTrials":350,"cells":33907},{"EARLY_PHASE1":33908,"PHASE1":33910,"PHASE2":33916,"PHASE3":33918,"PHASE4":33920,"NA":33922},{"trials":33909,"activeCount":101},[],{"trials":33911,"activeCount":101},[33912],{"nctId":24795,"briefTitle":24796,"status":107,"phases":33913,"primaryCompletion":3146,"completion":3146,"start":3007,"enrollment":721,"conditions":33914,"interventions":33915},[89],[21],[24800,24749],{"trials":33917,"activeCount":101},[],{"trials":33919,"activeCount":101},[],{"trials":33921,"activeCount":101},[],{"trials":33923,"activeCount":101},[],{"intervention":25347,"totalTrials":350,"cells":33925},{"EARLY_PHASE1":33926,"PHASE1":33928,"PHASE2":33934,"PHASE3":33936,"PHASE4":33938,"NA":33940},{"trials":33927,"activeCount":101},[],{"trials":33929,"activeCount":101},[33930],{"nctId":25342,"briefTitle":25343,"status":107,"phases":33931,"primaryCompletion":132,"completion":132,"start":8681,"enrollment":425,"conditions":33932,"interventions":33933},[89],[21],[25316,25347,25348,25349],{"trials":33935,"activeCount":101},[],{"trials":33937,"activeCount":101},[],{"trials":33939,"activeCount":101},[],{"trials":33941,"activeCount":101},[],{"intervention":25349,"totalTrials":350,"cells":33943},{"EARLY_PHASE1":33944,"PHASE1":33946,"PHASE2":33952,"PHASE3":33954,"PHASE4":33956,"NA":33958},{"trials":33945,"activeCount":101},[],{"trials":33947,"activeCount":101},[33948],{"nctId":25342,"briefTitle":25343,"status":107,"phases":33949,"primaryCompletion":132,"completion":132,"start":8681,"enrollment":425,"conditions":33950,"interventions":33951},[89],[21],[25316,25347,25348,25349],{"trials":33953,"activeCount":101},[],{"trials":33955,"activeCount":101},[],{"trials":33957,"activeCount":101},[],{"trials":33959,"activeCount":101},[],{"intervention":19346,"totalTrials":350,"cells":33961},{"EARLY_PHASE1":33962,"PHASE1":33964,"PHASE2":33970,"PHASE3":33972,"PHASE4":33974,"NA":33976},{"trials":33963,"activeCount":101},[],{"trials":33965,"activeCount":101},[33966],{"nctId":19341,"briefTitle":19342,"status":107,"phases":33967,"primaryCompletion":4314,"completion":4314,"start":8320,"enrollment":5901,"conditions":33968,"interventions":33969},[89],[21],[11967,19346,11969],{"trials":33971,"activeCount":101},[],{"trials":33973,"activeCount":101},[],{"trials":33975,"activeCount":101},[],{"trials":33977,"activeCount":101},[],{"intervention":33979,"totalTrials":350,"cells":33980},"RO6867461",{"EARLY_PHASE1":33981,"PHASE1":33983,"PHASE2":33991,"PHASE3":33993,"PHASE4":33995,"NA":33997},{"trials":33982,"activeCount":101},[],{"trials":33984,"activeCount":101},[33985],{"nctId":33986,"briefTitle":33987,"status":107,"phases":33988,"primaryCompletion":3006,"completion":3006,"start":3212,"enrollment":425,"conditions":33989,"interventions":33990},"NCT01941082","A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration",[89],[7621],[33979],{"trials":33992,"activeCount":101},[],{"trials":33994,"activeCount":101},[],{"trials":33996,"activeCount":101},[],{"trials":33998,"activeCount":101},[],{"intervention":34000,"totalTrials":350,"cells":34001},"RO7428731",{"EARLY_PHASE1":34002,"PHASE1":34004,"PHASE2":34014,"PHASE3":34016,"PHASE4":34018,"NA":34020},{"trials":34003,"activeCount":101},[],{"trials":34005,"activeCount":101},[34006],{"nctId":34007,"briefTitle":34008,"status":107,"phases":34009,"primaryCompletion":34010,"completion":34010,"start":34011,"enrollment":1058,"conditions":34012,"interventions":34013},"NCT05187624","A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma",[89],"2025-05-14","2022-04-05",[4068],[34000],{"trials":34015,"activeCount":101},[],{"trials":34017,"activeCount":101},[],{"trials":34019,"activeCount":101},[],{"trials":34021,"activeCount":101},[],{"intervention":24924,"totalTrials":350,"cells":34023},{"EARLY_PHASE1":34024,"PHASE1":34026,"PHASE2":34032,"PHASE3":34034,"PHASE4":34036,"NA":34038},{"trials":34025,"activeCount":101},[],{"trials":34027,"activeCount":101},[34028],{"nctId":24919,"briefTitle":24920,"status":130,"phases":34029,"primaryCompletion":10332,"completion":10332,"start":3084,"enrollment":2563,"conditions":34030,"interventions":34031},[89],[1241],[24924,5379],{"trials":34033,"activeCount":101},[],{"trials":34035,"activeCount":101},[],{"trials":34037,"activeCount":101},[],{"trials":34039,"activeCount":101},[],{"intervention":34041,"totalTrials":350,"cells":34042},"R7103",{"EARLY_PHASE1":34043,"PHASE1":34045,"PHASE2":34054,"PHASE3":34056,"PHASE4":34058,"NA":34060},{"trials":34044,"activeCount":101},[],{"trials":34046,"activeCount":101},[34047],{"nctId":34048,"briefTitle":34049,"status":343,"phases":34050,"primaryCompletion":2769,"completion":2769,"start":3022,"enrollment":101,"conditions":34051,"interventions":34053},"NCT01009424","A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease",[89],[34052],"COPD",[34041],{"trials":34055,"activeCount":101},[],{"trials":34057,"activeCount":101},[],{"trials":34059,"activeCount":101},[],{"trials":34061,"activeCount":101},[],{"intervention":25247,"totalTrials":350,"cells":34063},{"EARLY_PHASE1":34064,"PHASE1":34066,"PHASE2":34072,"PHASE3":34074,"PHASE4":34076,"NA":34078},{"trials":34065,"activeCount":101},[],{"trials":34067,"activeCount":101},[34068],{"nctId":25241,"briefTitle":25242,"status":107,"phases":34069,"primaryCompletion":4445,"completion":4445,"start":3146,"enrollment":510,"conditions":34070,"interventions":34071},[89],[25245],[25247,25215,25215],{"trials":34073,"activeCount":101},[],{"trials":34075,"activeCount":101},[],{"trials":34077,"activeCount":101},[],{"trials":34079,"activeCount":101},[],{"intervention":34081,"totalTrials":350,"cells":34082},"RO6836191",{"EARLY_PHASE1":34083,"PHASE1":34085,"PHASE2":34094,"PHASE3":34096,"PHASE4":34098,"NA":34100},{"trials":34084,"activeCount":101},[],{"trials":34086,"activeCount":101},[34087],{"nctId":34088,"briefTitle":34089,"status":107,"phases":34090,"primaryCompletion":3174,"completion":3174,"start":2956,"enrollment":736,"conditions":34091,"interventions":34093},"NCT01995383","A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.",[89],[34092],"Atherosclerosis",[34081,34081,34081],{"trials":34095,"activeCount":101},[],{"trials":34097,"activeCount":101},[],{"trials":34099,"activeCount":101},[],{"trials":34101,"activeCount":101},[],{"intervention":34103,"totalTrials":350,"cells":34104},"CMS",{"EARLY_PHASE1":34105,"PHASE1":34107,"PHASE2":34117,"PHASE3":34119,"PHASE4":34121,"NA":34123},{"trials":34106,"activeCount":101},[],{"trials":34108,"activeCount":101},[34109],{"nctId":34110,"briefTitle":34111,"status":107,"phases":34112,"primaryCompletion":4473,"completion":4473,"start":5364,"enrollment":496,"conditions":34113,"interventions":34114},"NCT02156323","A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)",[89],[21],[34103,34115,34116],"RO7033877","RO7033877 + CMS",{"trials":34118,"activeCount":101},[],{"trials":34120,"activeCount":101},[],{"trials":34122,"activeCount":101},[],{"trials":34124,"activeCount":101},[],{"intervention":34115,"totalTrials":350,"cells":34126},{"EARLY_PHASE1":34127,"PHASE1":34129,"PHASE2":34135,"PHASE3":34137,"PHASE4":34139,"NA":34141},{"trials":34128,"activeCount":101},[],{"trials":34130,"activeCount":101},[34131],{"nctId":34110,"briefTitle":34111,"status":107,"phases":34132,"primaryCompletion":4473,"completion":4473,"start":5364,"enrollment":496,"conditions":34133,"interventions":34134},[89],[21],[34103,34115,34116],{"trials":34136,"activeCount":101},[],{"trials":34138,"activeCount":101},[],{"trials":34140,"activeCount":101},[],{"trials":34142,"activeCount":101},[],{"intervention":34116,"totalTrials":350,"cells":34144},{"EARLY_PHASE1":34145,"PHASE1":34147,"PHASE2":34153,"PHASE3":34155,"PHASE4":34157,"NA":34159},{"trials":34146,"activeCount":101},[],{"trials":34148,"activeCount":101},[34149],{"nctId":34110,"briefTitle":34111,"status":107,"phases":34150,"primaryCompletion":4473,"completion":4473,"start":5364,"enrollment":496,"conditions":34151,"interventions":34152},[89],[21],[34103,34115,34116],{"trials":34154,"activeCount":101},[],{"trials":34156,"activeCount":101},[],{"trials":34158,"activeCount":101},[],{"trials":34160,"activeCount":101},[],{"intervention":34162,"totalTrials":350,"cells":34163},"RO6926496",{"EARLY_PHASE1":34164,"PHASE1":34166,"PHASE2":34174,"PHASE3":34176,"PHASE4":34178,"NA":34180},{"trials":34165,"activeCount":101},[],{"trials":34167,"activeCount":101},[34168],{"nctId":34169,"briefTitle":34170,"status":107,"phases":34171,"primaryCompletion":8341,"completion":8341,"start":6195,"enrollment":123,"conditions":34172,"interventions":34173},"NCT02281786","A Study of RO6926496 in Healthy Volunteers",[89],[21],[34162],{"trials":34175,"activeCount":101},[],{"trials":34177,"activeCount":101},[],{"trials":34179,"activeCount":101},[],{"trials":34181,"activeCount":101},[],{"intervention":19353,"totalTrials":350,"cells":34183},{"EARLY_PHASE1":34184,"PHASE1":34186,"PHASE2":34192,"PHASE3":34194,"PHASE4":34196,"NA":34198},{"trials":34185,"activeCount":101},[],{"trials":34187,"activeCount":101},[34188],{"nctId":19348,"briefTitle":19349,"status":107,"phases":34189,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":34190,"interventions":34191},[89],[21],[11967,11967,19353,19354,19355,11969,19356],{"trials":34193,"activeCount":101},[],{"trials":34195,"activeCount":101},[],{"trials":34197,"activeCount":101},[],{"trials":34199,"activeCount":101},[],{"intervention":19355,"totalTrials":350,"cells":34201},{"EARLY_PHASE1":34202,"PHASE1":34204,"PHASE2":34210,"PHASE3":34212,"PHASE4":34214,"NA":34216},{"trials":34203,"activeCount":101},[],{"trials":34205,"activeCount":101},[34206],{"nctId":19348,"briefTitle":19349,"status":107,"phases":34207,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":34208,"interventions":34209},[89],[21],[11967,11967,19353,19354,19355,11969,19356],{"trials":34211,"activeCount":101},[],{"trials":34213,"activeCount":101},[],{"trials":34215,"activeCount":101},[],{"trials":34217,"activeCount":101},[],{"intervention":19356,"totalTrials":350,"cells":34219},{"EARLY_PHASE1":34220,"PHASE1":34222,"PHASE2":34228,"PHASE3":34230,"PHASE4":34232,"NA":34234},{"trials":34221,"activeCount":101},[],{"trials":34223,"activeCount":101},[34224],{"nctId":19348,"briefTitle":19349,"status":107,"phases":34225,"primaryCompletion":2685,"completion":2685,"start":9079,"enrollment":973,"conditions":34226,"interventions":34227},[89],[21],[11967,11967,19353,19354,19355,11969,19356],{"trials":34229,"activeCount":101},[],{"trials":34231,"activeCount":101},[],{"trials":34233,"activeCount":101},[],{"trials":34235,"activeCount":101},[],{"intervention":34237,"totalTrials":350,"cells":34238},"RXDX-106",{"EARLY_PHASE1":34239,"PHASE1":34250,"PHASE2":34252,"PHASE3":34254,"PHASE4":34256,"NA":34258},{"trials":34240,"activeCount":101},[34241],{"nctId":34242,"briefTitle":34243,"status":130,"phases":34244,"primaryCompletion":34245,"completion":34245,"start":34246,"enrollment":350,"conditions":34247,"interventions":34249},"NCT03454243","Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors",[88],"2018-06-05","2018-02-15",[34248],"Advanced or Metastatic Solid Tumors",[34237],{"trials":34251,"activeCount":101},[],{"trials":34253,"activeCount":101},[],{"trials":34255,"activeCount":101},[],{"trials":34257,"activeCount":101},[],{"trials":34259,"activeCount":101},[],{"intervention":5275,"totalTrials":3574,"cells":34261},{"EARLY_PHASE1":34262,"PHASE1":34264,"PHASE2":34286,"PHASE3":34418,"PHASE4":34471,"NA":34489},{"trials":34263,"activeCount":101},[],{"trials":34265,"activeCount":101},[34266,34270,34274,34278,34282],{"nctId":15783,"briefTitle":15784,"status":107,"phases":34267,"primaryCompletion":3212,"completion":3212,"start":3308,"enrollment":8206,"conditions":34268,"interventions":34269},[89],[6622],[5275,5381,5384],{"nctId":7020,"briefTitle":7021,"status":107,"phases":34271,"primaryCompletion":2906,"completion":2906,"start":4562,"enrollment":942,"conditions":34272,"interventions":34273},[89],[2257],[5275,5185,7025],{"nctId":7027,"briefTitle":7028,"status":107,"phases":34275,"primaryCompletion":6578,"completion":6578,"start":4322,"enrollment":350,"conditions":34276,"interventions":34277},[89],[2257],[5275,5185,5385],{"nctId":33577,"briefTitle":33578,"status":107,"phases":34279,"primaryCompletion":132,"completion":132,"start":2931,"enrollment":2289,"conditions":34280,"interventions":34281},[89],[16614],[33570,5275],{"nctId":5373,"briefTitle":5374,"status":130,"phases":34283,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":34284,"interventions":34285},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":34287,"activeCount":101},[34288,34294,34298,34302,34306,34310,34314,34318,34322,34326,34330,34334,34338,34342,34346,34350,34354,34358,34362,34366,34370,34374,34378,34382,34386,34390,34394,34398,34402,34406,34410,34414],{"nctId":34289,"briefTitle":34290,"status":107,"phases":34291,"primaryCompletion":3104,"completion":3104,"start":4563,"enrollment":3574,"conditions":34292,"interventions":34293},"NCT01181609","A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum",[90],[30],[5275],{"nctId":6575,"briefTitle":6576,"status":107,"phases":34295,"primaryCompletion":5364,"completion":5364,"start":6578,"enrollment":6110,"conditions":34296,"interventions":34297},[90],[2257],[5275,5185,5186,5186],{"nctId":20817,"briefTitle":20818,"status":130,"phases":34299,"primaryCompletion":2769,"completion":2769,"start":6620,"enrollment":706,"conditions":34300,"interventions":34301},[90],[2257],[9587,5275],{"nctId":15815,"briefTitle":15816,"status":107,"phases":34303,"primaryCompletion":8826,"completion":8826,"start":8658,"enrollment":2743,"conditions":34304,"interventions":34305},[90],[30],[5275,15820,5381,5384],{"nctId":21406,"briefTitle":21407,"status":107,"phases":34307,"primaryCompletion":2685,"completion":2685,"start":4315,"enrollment":984,"conditions":34308,"interventions":34309},[90],[1241],[5275,9036,21411,9083],{"nctId":20567,"briefTitle":20568,"status":107,"phases":34311,"primaryCompletion":3007,"completion":3007,"start":4409,"enrollment":8206,"conditions":34312,"interventions":34313},[90],[16614],[5275,5389],{"nctId":14720,"briefTitle":14721,"status":343,"phases":34315,"primaryCompletion":3213,"completion":3213,"start":4513,"enrollment":101,"conditions":34316,"interventions":34317},[90],[30],[5275,4577,1164,9036,1138],{"nctId":15834,"briefTitle":15835,"status":107,"phases":34319,"primaryCompletion":2847,"completion":2847,"start":4562,"enrollment":736,"conditions":34320,"interventions":34321},[90],[18],[5275,5381,5390],{"nctId":9543,"briefTitle":9544,"status":130,"phases":34323,"primaryCompletion":2963,"completion":2963,"start":5820,"enrollment":145,"conditions":34324,"interventions":34325},[90],[18],[5275,947,9083],{"nctId":5440,"briefTitle":5441,"status":107,"phases":34327,"primaryCompletion":2809,"completion":2809,"start":4322,"enrollment":1352,"conditions":34328,"interventions":34329},[90],[975],[5275,5367,5384,4503],{"nctId":15846,"briefTitle":15847,"status":107,"phases":34331,"primaryCompletion":4198,"completion":4198,"start":122,"enrollment":909,"conditions":34332,"interventions":34333},[90],[4121],[5275,5381],{"nctId":8931,"briefTitle":8932,"status":107,"phases":34335,"primaryCompletion":4454,"completion":4454,"start":8934,"enrollment":920,"conditions":34336,"interventions":34337},[90],[30],[1162,1162,1162,4577,1164,1164,1165,5275],{"nctId":8938,"briefTitle":8939,"status":130,"phases":34339,"primaryCompletion":3325,"completion":3325,"start":4281,"enrollment":2440,"conditions":34340,"interventions":34341},[90],[30],[5381,5381,5275,4104,4102],{"nctId":18181,"briefTitle":18182,"status":130,"phases":34343,"primaryCompletion":4086,"completion":4086,"start":5457,"enrollment":15799,"conditions":34344,"interventions":34345},[90],[975],[5275,18172],{"nctId":8944,"briefTitle":8945,"status":107,"phases":34347,"primaryCompletion":2685,"completion":2685,"start":3085,"enrollment":909,"conditions":34348,"interventions":34349},[90],[30],[5275,5381,4104],{"nctId":8950,"briefTitle":8951,"status":107,"phases":34351,"primaryCompletion":3103,"completion":3103,"start":4488,"enrollment":817,"conditions":34352,"interventions":34353},[90],[30],[8955,8956,5275,5381,4104],{"nctId":20823,"briefTitle":20824,"status":107,"phases":34355,"primaryCompletion":8826,"completion":5418,"start":8934,"enrollment":973,"conditions":34356,"interventions":34357},[90],[18],[9587,5275,5390],{"nctId":15877,"briefTitle":15878,"status":107,"phases":34359,"primaryCompletion":7152,"completion":7152,"start":13164,"enrollment":1385,"conditions":34360,"interventions":34361},[90],[30],[5275,5381,5275,4089,8956],{"nctId":26612,"briefTitle":26613,"status":107,"phases":34363,"primaryCompletion":3212,"completion":3212,"start":2685,"enrollment":1352,"conditions":34364,"interventions":34365},[90],[16614],[5275,26603],{"nctId":16610,"briefTitle":16611,"status":107,"phases":34367,"primaryCompletion":3182,"completion":3182,"start":4409,"enrollment":3015,"conditions":34368,"interventions":34369},[90],[16614],[5275,4102,5389],{"nctId":28814,"briefTitle":28815,"status":107,"phases":34371,"primaryCompletion":3146,"completion":3146,"start":4113,"enrollment":3856,"conditions":34372,"interventions":34373},[90],[975],[5275,5275,28805],{"nctId":8974,"briefTitle":8975,"status":107,"phases":34375,"primaryCompletion":7095,"completion":7095,"start":8977,"enrollment":37,"conditions":34376,"interventions":34377},[90],[30],[5275,5381,4104],{"nctId":9563,"briefTitle":9564,"status":107,"phases":34379,"primaryCompletion":4582,"completion":4582,"start":4446,"enrollment":5901,"conditions":34380,"interventions":34381},[90],[18],[5275,5383,5381],{"nctId":20829,"briefTitle":20830,"status":107,"phases":34383,"primaryCompletion":20832,"completion":20833,"start":20834,"enrollment":5458,"conditions":34384,"interventions":34385},[90],[4856],[9587,5275],{"nctId":8678,"briefTitle":8679,"status":107,"phases":34387,"primaryCompletion":8681,"completion":8681,"start":4563,"enrollment":2933,"conditions":34388,"interventions":34389},[90],[30],[8105,1166,4577],{"nctId":8987,"briefTitle":8988,"status":107,"phases":34391,"primaryCompletion":4682,"completion":4682,"start":2963,"enrollment":8990,"conditions":34392,"interventions":34393},[90],[30],[1162,5275,4102,8956,4104],{"nctId":26618,"briefTitle":26619,"status":107,"phases":34395,"primaryCompletion":4488,"completion":4488,"start":14454,"enrollment":2375,"conditions":34396,"interventions":34397},[90],[1261],[5275,26603],{"nctId":9582,"briefTitle":9583,"status":107,"phases":34399,"primaryCompletion":2932,"completion":2932,"start":4513,"enrollment":3665,"conditions":34400,"interventions":34401},[90],[18],[5275,947,9587],{"nctId":9593,"briefTitle":9594,"status":130,"phases":34403,"primaryCompletion":2931,"completion":2931,"start":9596,"enrollment":2289,"conditions":34404,"interventions":34405},[90],[18],[5275,5381,5383],{"nctId":26696,"briefTitle":26697,"status":107,"phases":34407,"primaryCompletion":2768,"completion":2768,"start":4562,"enrollment":11543,"conditions":34408,"interventions":34409},[90],[4692],[5275,26687],{"nctId":9600,"briefTitle":9601,"status":343,"phases":34411,"primaryCompletion":6157,"completion":6157,"start":2964,"enrollment":101,"conditions":34412,"interventions":34413},[90],[18],[5275,5381,5383,5390],{"nctId":26702,"briefTitle":26703,"status":107,"phases":34415,"primaryCompletion":4555,"completion":4555,"start":3692,"enrollment":97,"conditions":34416,"interventions":34417},[90],[4692],[5275,26707,26708],{"trials":34419,"activeCount":101},[34420,34424,34428,34432,34439,34443,34447,34451,34455,34459,34463,34467],{"nctId":15933,"briefTitle":15934,"status":107,"phases":34421,"primaryCompletion":3174,"completion":3174,"start":4488,"enrollment":1376,"conditions":34422,"interventions":34423},[91],[18],[5275,5381],{"nctId":6699,"briefTitle":6700,"status":107,"phases":34425,"primaryCompletion":4233,"completion":4233,"start":6702,"enrollment":1523,"conditions":34426,"interventions":34427},[91],[2257],[1167,1163,5275,5275],{"nctId":9641,"briefTitle":9642,"status":107,"phases":34429,"primaryCompletion":3246,"completion":3246,"start":6277,"enrollment":9644,"conditions":34430,"interventions":34431},[91],[18],[5275,947,7139],{"nctId":34433,"briefTitle":34434,"status":107,"phases":34435,"primaryCompletion":8934,"completion":8934,"start":4323,"enrollment":34436,"conditions":34437,"interventions":34438},"NCT01214720","A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer",[91],607,[6622],[5275],{"nctId":12164,"briefTitle":12165,"status":107,"phases":34440,"primaryCompletion":132,"completion":132,"start":6277,"enrollment":12167,"conditions":34441,"interventions":34442},[91],[18],[5275,12153],{"nctId":23491,"briefTitle":23492,"status":107,"phases":34444,"primaryCompletion":4113,"completion":4113,"start":11713,"enrollment":3066,"conditions":34445,"interventions":34446},[91],[4692],[8105,23480],{"nctId":8097,"briefTitle":8098,"status":107,"phases":34448,"primaryCompletion":4712,"completion":8100,"start":8101,"enrollment":8102,"conditions":34449,"interventions":34450},[91],[1569],[8105,1106],{"nctId":14609,"briefTitle":14610,"status":107,"phases":34452,"primaryCompletion":3212,"completion":4473,"start":4233,"enrollment":14612,"conditions":34453,"interventions":34454},[91],[18],[5275,1572],{"nctId":14732,"briefTitle":14733,"status":343,"phases":34456,"primaryCompletion":2947,"completion":2947,"start":8320,"enrollment":101,"conditions":34457,"interventions":34458},[91],[30],[5275,5382,5386],{"nctId":23794,"briefTitle":23795,"status":107,"phases":34460,"primaryCompletion":8688,"completion":8688,"start":5457,"enrollment":17519,"conditions":34461,"interventions":34462},[91],[30],[5275,23783,5275,23799],{"nctId":5268,"briefTitle":5269,"status":107,"phases":34464,"primaryCompletion":2931,"completion":2931,"start":5271,"enrollment":5272,"conditions":34465,"interventions":34466},[91],[2257],[5275,5185,5187],{"nctId":13257,"briefTitle":13258,"status":107,"phases":34468,"primaryCompletion":4474,"completion":4474,"start":4315,"enrollment":1593,"conditions":34469,"interventions":34470},[91],[30],[5275,4102,8956,8955],{"trials":34472,"activeCount":101},[34473,34477,34481,34485],{"nctId":8197,"briefTitle":8198,"status":343,"phases":34474,"primaryCompletion":2948,"completion":2948,"start":2906,"enrollment":101,"conditions":34475,"interventions":34476},[92],[18],[5275,4503],{"nctId":18191,"briefTitle":18192,"status":107,"phases":34478,"primaryCompletion":2963,"completion":2963,"start":5457,"enrollment":18194,"conditions":34479,"interventions":34480},[92],[2257],[18172,8105],{"nctId":9760,"briefTitle":9761,"status":343,"phases":34482,"primaryCompletion":2956,"completion":2956,"start":4206,"enrollment":101,"conditions":34483,"interventions":34484},[92],[18],[5275,5383],{"nctId":9076,"briefTitle":9077,"status":107,"phases":34486,"primaryCompletion":9079,"completion":9079,"start":4086,"enrollment":9080,"conditions":34487,"interventions":34488},[92],[30],[5275,1165,9083],{"trials":34490,"activeCount":101},[34491],{"nctId":34492,"briefTitle":34493,"status":107,"phases":34494,"primaryCompletion":10332,"completion":10332,"start":4206,"enrollment":4713,"conditions":34495,"interventions":34496},"NCT01089413","Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)",[],[30],[5275],{"intervention":2824,"totalTrials":123,"cells":34498},{"EARLY_PHASE1":34499,"PHASE1":34501,"PHASE2":34511,"PHASE3":34535,"PHASE4":34649,"NA":34718},{"trials":34500,"activeCount":101},[],{"trials":34502,"activeCount":101},[34503,34507],{"nctId":15419,"briefTitle":15420,"status":107,"phases":34504,"completion":4582,"enrollment":145,"conditions":34505,"interventions":34506},[89],[15],[5894,2824,15424],{"nctId":15426,"briefTitle":15427,"status":107,"phases":34508,"completion":4314,"start":5271,"enrollment":1174,"conditions":34509,"interventions":34510},[89],[15],[15431,5838,5894,5894],{"trials":34512,"activeCount":101},[34513,34517,34523,34527,34531],{"nctId":20268,"briefTitle":20269,"status":130,"phases":34514,"primaryCompletion":3325,"completion":3325,"start":3692,"enrollment":2631,"conditions":34515,"interventions":34516},[90],[1038],[5837,2824,10088],{"nctId":34518,"briefTitle":34519,"status":130,"phases":34520,"primaryCompletion":4409,"completion":4409,"start":8977,"enrollment":706,"conditions":34521,"interventions":34522},"NCT00422942","A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)",[90],[15],[5837,2824],{"nctId":28636,"briefTitle":28637,"status":130,"phases":34524,"primaryCompletion":28639,"completion":28639,"start":5503,"enrollment":4564,"conditions":34525,"interventions":34526},[90],[15],[28627,2824,28642],{"nctId":6131,"briefTitle":6132,"status":107,"phases":34528,"primaryCompletion":5805,"completion":6134,"start":6135,"enrollment":6136,"conditions":34529,"interventions":34530},[90],[15],[992,2824,1359],{"nctId":5802,"briefTitle":5803,"status":107,"phases":34532,"primaryCompletion":2948,"completion":2948,"start":5805,"enrollment":5806,"conditions":34533,"interventions":34534},[90],[15],[1359,2824,274,5809],{"trials":34536,"activeCount":101},[34537,34541,34545,34549,34553,34557,34561,34565,34569,34573,34577,34581,34585,34589,34593,34597,34601,34605,34609,34613,34617,34621,34627,34631,34635,34639,34643],{"nctId":15463,"briefTitle":15464,"status":107,"phases":34538,"primaryCompletion":5820,"completion":5820,"start":122,"enrollment":15466,"conditions":34539,"interventions":34540},[91],[15],[2824,5894,5894],{"nctId":15470,"briefTitle":15471,"status":107,"phases":34542,"primaryCompletion":15473,"completion":15473,"start":15474,"enrollment":15475,"conditions":34543,"interventions":34544},[91],[15],[5894,2824],{"nctId":2813,"briefTitle":2814,"status":107,"phases":34546,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":1847,"conditions":34547,"interventions":34548},[91],[15],[2820,2821,2822,2823,2824,2825,1096],{"nctId":2834,"briefTitle":2835,"status":107,"phases":34550,"primaryCompletion":2837,"completion":2837,"start":2838,"enrollment":2839,"conditions":34551,"interventions":34552},[91],[15],[2842,1096,2824],{"nctId":2844,"briefTitle":2845,"status":107,"phases":34554,"primaryCompletion":2847,"completion":2847,"start":2830,"enrollment":1103,"conditions":34555,"interventions":34556},[91],[15],[1096,2824,2850],{"nctId":5817,"briefTitle":5818,"status":107,"phases":34558,"primaryCompletion":3084,"completion":4445,"start":5820,"enrollment":5821,"conditions":34559,"interventions":34560},[91],[15],[1359,274,2824,5824],{"nctId":2852,"briefTitle":2853,"status":107,"phases":34562,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":34563,"interventions":34564},[91],[15],[1096,2824,2842],{"nctId":15498,"briefTitle":15499,"status":107,"phases":34566,"primaryCompletion":4682,"completion":4682,"start":2768,"enrollment":1080,"conditions":34567,"interventions":34568},[91],[15],[5838,5838,5894],{"nctId":15504,"briefTitle":15505,"status":107,"phases":34570,"primaryCompletion":3007,"completion":3007,"start":2964,"enrollment":6013,"conditions":34571,"interventions":34572},[91],[15],[5894,5838],{"nctId":15510,"briefTitle":15511,"status":107,"phases":34574,"primaryCompletion":6620,"completion":3007,"start":8689,"enrollment":15513,"conditions":34575,"interventions":34576},[91],[15],[5894,2824],{"nctId":5830,"briefTitle":5831,"status":107,"phases":34578,"primaryCompletion":5833,"completion":5833,"start":5834,"enrollment":2619,"conditions":34579,"interventions":34580},[91],[15],[5837,5838,5839],{"nctId":15517,"briefTitle":15518,"status":107,"phases":34582,"primaryCompletion":7152,"completion":4249,"start":3325,"enrollment":15520,"conditions":34583,"interventions":34584},[91],[15],[5894,5838],{"nctId":15524,"briefTitle":15525,"status":107,"phases":34586,"primaryCompletion":2948,"completion":2948,"start":4233,"enrollment":3286,"conditions":34587,"interventions":34588},[91],[15],[5838,5894],{"nctId":2893,"briefTitle":2894,"status":107,"phases":34590,"primaryCompletion":2896,"completion":2896,"start":2897,"enrollment":2898,"conditions":34591,"interventions":34592},[91],[15],[1096,2824],{"nctId":15587,"briefTitle":15588,"status":107,"phases":34594,"primaryCompletion":6004,"completion":3246,"start":4281,"enrollment":15590,"conditions":34595,"interventions":34596},[91],[2367],[5894,3035,5838,14484],{"nctId":2970,"briefTitle":2971,"status":107,"phases":34598,"primaryCompletion":2973,"completion":2974,"start":2975,"enrollment":2976,"conditions":34599,"interventions":34600},[91],[15],[1096,2824],{"nctId":15607,"briefTitle":15608,"status":107,"phases":34602,"primaryCompletion":2792,"completion":5417,"start":2684,"enrollment":7923,"conditions":34603,"interventions":34604},[91],[15],[15612,5838,5894,5894,5894],{"nctId":2988,"briefTitle":2989,"status":107,"phases":34606,"primaryCompletion":393,"completion":393,"start":2991,"enrollment":1395,"conditions":34607,"interventions":34608},[91],[15],[1096,2870,2994,2824],{"nctId":15614,"briefTitle":15615,"status":107,"phases":34610,"primaryCompletion":4513,"completion":4513,"start":4323,"enrollment":15617,"conditions":34611,"interventions":34612},[91],[15],[2824,5894],{"nctId":15636,"briefTitle":15637,"status":107,"phases":34614,"primaryCompletion":3182,"completion":3182,"start":4206,"enrollment":15639,"conditions":34615,"interventions":34616},[91],[15],[5838,5894],{"nctId":3038,"briefTitle":3039,"status":107,"phases":34618,"primaryCompletion":3041,"completion":3042,"start":3043,"enrollment":3044,"conditions":34619,"interventions":34620},[91],[15],[1096,2824],{"nctId":34622,"briefTitle":34623,"status":107,"phases":34624,"primaryCompletion":4562,"completion":4562,"start":4446,"enrollment":27523,"conditions":34625,"interventions":34626},"NCT00502996","A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.",[91],[15],[2824,5837],{"nctId":3048,"briefTitle":3049,"status":107,"phases":34628,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":3054,"conditions":34629,"interventions":34630},[91],[2508],[1096,1357,3057,3058,3059,2824],{"nctId":24372,"briefTitle":24373,"status":107,"phases":34632,"primaryCompletion":8689,"completion":3007,"start":14446,"enrollment":24375,"conditions":34633,"interventions":34634},[91],[15],[24361,2824],{"nctId":15677,"briefTitle":15678,"status":107,"phases":34636,"completion":2965,"enrollment":15680,"conditions":34637,"interventions":34638},[91],[15],[5894,5894,2824],{"nctId":15684,"briefTitle":15685,"status":107,"phases":34640,"primaryCompletion":2809,"completion":2809,"start":3479,"enrollment":9685,"conditions":34641,"interventions":34642},[91],[15],[5894,5838],{"nctId":34644,"briefTitle":34645,"status":107,"phases":34646,"primaryCompletion":10332,"completion":10332,"start":11713,"enrollment":1509,"conditions":34647,"interventions":34648},"NCT02097745","A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies",[91],[15],[5838,5837],{"trials":34650,"activeCount":101},[34651,34657,34661,34665,34669,34677,34683,34687,34694,34698,34704,34708,34712],{"nctId":34652,"briefTitle":34653,"status":107,"phases":34654,"primaryCompletion":4555,"completion":4555,"start":4315,"enrollment":1058,"conditions":34655,"interventions":34656},"NCT00504777","A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.",[92],[15],[5837,2824],{"nctId":6374,"briefTitle":6375,"status":107,"phases":34658,"primaryCompletion":4488,"completion":4488,"start":6377,"enrollment":931,"conditions":34659,"interventions":34660},[92],[15],[3677,2824,6380],{"nctId":15692,"briefTitle":15693,"status":130,"phases":34662,"primaryCompletion":15695,"completion":15695,"start":2931,"enrollment":1036,"conditions":34663,"interventions":34664},[92],[15],[5894,15698,5838,15699],{"nctId":5870,"briefTitle":5871,"status":107,"phases":34666,"primaryCompletion":5873,"completion":5873,"start":3823,"enrollment":4637,"conditions":34667,"interventions":34668},[92],[15],[3677,5838,5839,5876,5877],{"nctId":34670,"briefTitle":34671,"status":107,"phases":34672,"primaryCompletion":34673,"completion":34673,"start":34674,"enrollment":462,"conditions":34675,"interventions":34676},"NCT00502853","A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.",[92],"2010-07-23","2007-10-25",[15],[5837,2824],{"nctId":34678,"briefTitle":34679,"status":107,"phases":34680,"primaryCompletion":3022,"completion":3022,"start":16669,"enrollment":2375,"conditions":34681,"interventions":34682},"NCT00424502","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.",[92],[15],[5837,2824],{"nctId":15724,"briefTitle":15725,"status":343,"phases":34684,"primaryCompletion":2800,"completion":2800,"start":10332,"enrollment":101,"conditions":34685,"interventions":34686},[92],[15],[5838,5894],{"nctId":34688,"briefTitle":34689,"status":130,"phases":34690,"primaryCompletion":4409,"completion":4409,"start":8826,"enrollment":162,"conditions":34691,"interventions":34692},"NCT01117129","A Study of Efficacy of Rituximab [Mabthera\u002FRituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)",[92],[15],[5837,5838,34693],"rituximab [Mabthera\u002FRituxan]",{"nctId":3143,"briefTitle":3144,"status":130,"phases":34695,"primaryCompletion":3006,"completion":3006,"start":3146,"enrollment":3147,"conditions":34696,"interventions":34697},[92],[15],[2824,1096,2824],{"nctId":34699,"briefTitle":34700,"status":107,"phases":34701,"primaryCompletion":5181,"completion":5181,"start":4513,"enrollment":336,"conditions":34702,"interventions":34703},"NCT00576433","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.",[92],[15],[2824,5837],{"nctId":15762,"briefTitle":15763,"status":107,"phases":34705,"primaryCompletion":15740,"completion":15740,"start":3189,"enrollment":15765,"conditions":34706,"interventions":34707},[92],[15],[5838,5838,5894],{"nctId":5896,"briefTitle":5897,"status":107,"phases":34709,"primaryCompletion":5899,"completion":5899,"start":5900,"enrollment":5901,"conditions":34710,"interventions":34711},[92],[15],[5837,5838,5839],{"nctId":34713,"briefTitle":34714,"status":107,"phases":34715,"primaryCompletion":5181,"completion":5181,"start":2965,"enrollment":2619,"conditions":34716,"interventions":34717},"NCT00934648","A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate",[92],[15],[5837,5838],{"trials":34719,"activeCount":101},[34720],{"nctId":3163,"briefTitle":3164,"status":107,"phases":34721,"primaryCompletion":3166,"completion":3166,"start":1214,"enrollment":3167,"conditions":34722,"interventions":34723},[],[15],[2824,1096],{"intervention":17072,"totalTrials":909,"cells":34725},{"EARLY_PHASE1":34726,"PHASE1":34728,"PHASE2":34748,"PHASE3":34774,"PHASE4":34805,"NA":34957},{"trials":34727,"activeCount":101},[],{"trials":34729,"activeCount":101},[34730,34736,34740,34744],{"nctId":34731,"briefTitle":34732,"status":107,"phases":34733,"primaryCompletion":4445,"completion":4445,"start":6004,"enrollment":1174,"conditions":34734,"interventions":34735},"NCT00962975","A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies",[89],[11790],[17072],{"nctId":31080,"briefTitle":31081,"status":107,"phases":34737,"primaryCompletion":2793,"completion":2793,"start":2964,"enrollment":5013,"conditions":34738,"interventions":34739},[89],[27],[31073,17072,17072,17072],{"nctId":19258,"briefTitle":19259,"status":107,"phases":34741,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":2572,"conditions":34742,"interventions":34743},[89],[27],[11967,17072,19263,11969],{"nctId":21300,"briefTitle":21301,"status":107,"phases":34745,"primaryCompletion":2768,"completion":2768,"start":5271,"enrollment":1184,"conditions":34746,"interventions":34747},[89],[11790],[17072,21293],{"trials":34749,"activeCount":101},[34750,34754,34758,34762,34766,34770],{"nctId":19360,"briefTitle":19361,"status":343,"phases":34751,"primaryCompletion":3197,"completion":3197,"start":3007,"enrollment":101,"conditions":34752,"interventions":34753},[90],[27],[17034,17034,11967,17072,17976,11969],{"nctId":25608,"briefTitle":25609,"status":107,"phases":34755,"primaryCompletion":4445,"completion":4445,"start":5891,"enrollment":25611,"conditions":34756,"interventions":34757},[90],[27],[17072,17976,19280],{"nctId":19387,"briefTitle":19388,"status":107,"phases":34759,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":34760,"interventions":34761},[90],[27],[19392,17034,11967,17072,17976,11969],{"nctId":24874,"briefTitle":24875,"status":107,"phases":34763,"primaryCompletion":2793,"completion":2793,"start":6578,"enrollment":4489,"conditions":34764,"interventions":34765},[90],[27],[17034,24879,17072],{"nctId":28695,"briefTitle":28696,"status":107,"phases":34767,"primaryCompletion":3006,"completion":3006,"start":3029,"enrollment":34,"conditions":34768,"interventions":34769},[90],[27],[28686,28686,17072,17072,17976,17976],{"nctId":19398,"briefTitle":19399,"status":107,"phases":34771,"primaryCompletion":2684,"completion":2684,"start":2793,"enrollment":1385,"conditions":34772,"interventions":34773},[90],[27],[17034,11967,17072,19263,11969],{"trials":34775,"activeCount":101},[34776,34785,34791,34795,34801],{"nctId":34777,"briefTitle":34778,"status":107,"phases":34779,"primaryCompletion":34780,"completion":34781,"start":34782,"enrollment":18451,"conditions":34783,"interventions":34784},"NCT01519960","A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B",[91],"2015-07-09","2021-10-18","2012-07-11",[11790],[17072,17072],{"nctId":34786,"briefTitle":34787,"status":107,"phases":34788,"primaryCompletion":6004,"completion":6004,"start":4323,"enrollment":510,"conditions":34789,"interventions":34790},"NCT01237496","Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253",[91],[11790],[17072],{"nctId":21314,"briefTitle":21315,"status":107,"phases":34792,"primaryCompletion":14644,"completion":14644,"start":21317,"enrollment":37,"conditions":34793,"interventions":34794},[91],[21319],[17072,21293],{"nctId":34796,"briefTitle":34797,"status":343,"phases":34798,"primaryCompletion":2769,"completion":2769,"start":2769,"enrollment":101,"conditions":34799,"interventions":34800},"NCT01296971","A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)",[91],[27],[17072,17976,17976],{"nctId":18210,"briefTitle":18211,"status":107,"phases":34802,"primaryCompletion":2931,"completion":2931,"start":3085,"enrollment":462,"conditions":34803,"interventions":34804},[91],[11790],[18215,17072],{"trials":34806,"activeCount":101},[34807,34811,34815,34819,34827,34833,34837,34841,34848,34852,34858,34864,34871,34880,34886,34892,34899,34903,34907,34914,34918,34922,34929,34933,34940,34944,34950],{"nctId":18083,"briefTitle":18084,"status":107,"phases":34808,"primaryCompletion":3674,"completion":3674,"start":8826,"enrollment":16020,"conditions":34809,"interventions":34810},[92],[11790],[17724,18088,18088,18088],{"nctId":17704,"briefTitle":17705,"status":107,"phases":34812,"primaryCompletion":2905,"completion":2905,"start":4322,"enrollment":2708,"conditions":34813,"interventions":34814},[92],[11790],[17709,17709,17072],{"nctId":17711,"briefTitle":17712,"status":107,"phases":34816,"primaryCompletion":3022,"completion":3022,"start":6673,"enrollment":14666,"conditions":34817,"interventions":34818},[92],[11790],[17609,17609,17072,17072],{"nctId":34820,"briefTitle":34821,"status":107,"phases":34822,"primaryCompletion":3213,"completion":3213,"start":34823,"enrollment":34824,"conditions":34825,"interventions":34826},"NCT00922779","A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C",[92],"2002-06",6661,[27],[17072,19263],{"nctId":34828,"briefTitle":34829,"status":107,"phases":34830,"primaryCompletion":14572,"completion":14572,"start":133,"enrollment":2839,"conditions":34831,"interventions":34832},"NCT01519921","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.",[92],[11790],[17072],{"nctId":18448,"briefTitle":18449,"status":107,"phases":34834,"primaryCompletion":3174,"completion":3174,"start":15695,"enrollment":18451,"conditions":34835,"interventions":34836},[92],[27],[17057,17072,17072,18435,18435],{"nctId":17066,"briefTitle":17067,"status":107,"phases":34838,"primaryCompletion":10332,"completion":10332,"start":2769,"enrollment":2572,"conditions":34839,"interventions":34840},[92],[27],[17071,17072],{"nctId":34842,"briefTitle":34843,"status":107,"phases":34844,"primaryCompletion":6343,"completion":6343,"start":14446,"enrollment":34845,"conditions":34846,"interventions":34847},"NCT01258101","A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3",[92],395,[27],[17072,17072,19263,19263],{"nctId":17074,"briefTitle":17075,"status":107,"phases":34849,"primaryCompletion":3084,"completion":3084,"start":6306,"enrollment":17077,"conditions":34850,"interventions":34851},[92],[27],[16996,16996,17072,17072],{"nctId":34853,"briefTitle":34854,"status":107,"phases":34855,"primaryCompletion":8320,"completion":8320,"start":4315,"enrollment":11473,"conditions":34856,"interventions":34857},"NCT00474955","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.",[92],[27],[17072],{"nctId":34859,"briefTitle":34860,"status":107,"phases":34861,"primaryCompletion":2830,"completion":2830,"start":3103,"enrollment":1184,"conditions":34862,"interventions":34863},"NCT01585324","A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)",[92],[27],[17072,17976],{"nctId":34865,"briefTitle":34866,"status":107,"phases":34867,"primaryCompletion":13171,"completion":13171,"start":34868,"enrollment":123,"conditions":34869,"interventions":34870},"NCT00087594","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.",[92],"2003-11",[27],[17072,19263],{"nctId":34872,"briefTitle":34873,"status":107,"phases":34874,"primaryCompletion":4455,"completion":8810,"start":8260,"enrollment":34875,"conditions":34876,"interventions":34877},"NCT00087607","Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).",[92],385,[27],[17366,34878,17366,34879],"Peginterferon alfa-2b","Peginterferon alfa-2a [Pegasys]",{"nctId":34881,"briefTitle":34882,"status":107,"phases":34883,"primaryCompletion":3022,"completion":3022,"start":5457,"enrollment":5901,"conditions":34884,"interventions":34885},"NCT00487747","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.",[92],[11790],[17072],{"nctId":34887,"briefTitle":34888,"status":107,"phases":34889,"primaryCompletion":9596,"completion":9596,"start":8977,"enrollment":2572,"conditions":34890,"interventions":34891},"NCT01787279","An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B",[92],[11790],[34879],{"nctId":34893,"briefTitle":34894,"status":107,"phases":34895,"primaryCompletion":11550,"completion":11550,"start":4322,"enrollment":34896,"conditions":34897,"interventions":34898},"NCT00927082","A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B",[92],383,[11790],[17072],{"nctId":17081,"briefTitle":17082,"status":107,"phases":34900,"primaryCompletion":4455,"completion":4455,"start":17084,"enrollment":17085,"conditions":34901,"interventions":34902},[92],[27],[16996,16996,17072,17072],{"nctId":17717,"briefTitle":17718,"status":107,"phases":34904,"primaryCompletion":17720,"completion":17720,"start":17721,"enrollment":571,"conditions":34905,"interventions":34906},[92],[11790],[17724,17609,17072],{"nctId":34908,"briefTitle":34909,"status":107,"phases":34910,"primaryCompletion":4455,"completion":4455,"start":34911,"enrollment":2999,"conditions":34912,"interventions":34913},"NCT00087568","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin",[92],"2003-01",[27],[17366,17072],{"nctId":17089,"briefTitle":17090,"status":107,"phases":34915,"primaryCompletion":8934,"completion":8934,"start":8811,"enrollment":17092,"conditions":34916,"interventions":34917},[92],[27],[17072,16996],{"nctId":17726,"briefTitle":17727,"status":343,"phases":34919,"primaryCompletion":11550,"completion":11550,"start":17729,"enrollment":101,"conditions":34920,"interventions":34921},[92],[11790],[17709,17072,17072],{"nctId":34923,"briefTitle":34924,"status":107,"phases":34925,"primaryCompletion":3096,"completion":3096,"start":34926,"enrollment":281,"conditions":34927,"interventions":34928},"NCT01429792","A Study Evaluating Slow Response\u002FNon-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)",[92],"2008-09-25",[27],[17072,17976],{"nctId":17096,"briefTitle":17097,"status":107,"phases":34930,"primaryCompletion":2932,"completion":2932,"start":16669,"enrollment":5376,"conditions":34931,"interventions":34932},[92],[27],[16996,16996,17072,17072],{"nctId":34934,"briefTitle":34935,"status":107,"phases":34936,"primaryCompletion":4474,"completion":4474,"start":7096,"enrollment":34937,"conditions":34938,"interventions":34939},"NCT00435825","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).",[92],551,[11790],[17072],{"nctId":17971,"briefTitle":17972,"status":107,"phases":34941,"primaryCompletion":4474,"completion":4474,"start":121,"enrollment":1259,"conditions":34942,"interventions":34943},[92],[27],[17072,17976,17977],{"nctId":34945,"briefTitle":34946,"status":107,"phases":34947,"primaryCompletion":9771,"completion":9771,"start":22664,"enrollment":13060,"conditions":34948,"interventions":34949},"NCT00475072","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.",[92],[27],[17072,19263],{"nctId":34951,"briefTitle":34952,"status":107,"phases":34953,"primaryCompletion":4281,"completion":4281,"start":11320,"enrollment":34954,"conditions":34955,"interventions":34956},"NCT00087646","REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))\u002FRibavirin Combination Therapy",[92],948,[27],[17366,17366,17072,17072,17072,17072],{"trials":34958,"activeCount":101},[34959,34967,34974],{"nctId":34960,"briefTitle":34961,"status":107,"phases":34962,"primaryCompletion":2964,"completion":2931,"start":2965,"enrollment":34963,"conditions":34964,"interventions":34965},"NCT01066793","PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",[],2343,[27],[34879,34966],"Peginterferon alfa-2b [PegIntron®]",{"nctId":34968,"briefTitle":34969,"status":107,"phases":34970,"primaryCompletion":9079,"completion":9079,"start":121,"enrollment":34971,"conditions":34972,"interventions":34973},"NCT01066819","PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b",[],1656,[27],[34879,34966],{"nctId":34975,"briefTitle":34976,"status":107,"phases":34977,"primaryCompletion":5181,"completion":5181,"start":8688,"enrollment":34978,"conditions":34979,"interventions":34980},"NCT00700401","POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).",[],262,[27],[17072,17976],{"intervention":17366,"totalTrials":6013,"cells":34982},{"EARLY_PHASE1":34983,"PHASE1":34985,"PHASE2":34991,"PHASE3":35015,"PHASE4":35045,"NA":35133},{"trials":34984,"activeCount":101},[],{"trials":34986,"activeCount":101},[34987],{"nctId":19258,"briefTitle":19259,"status":107,"phases":34988,"primaryCompletion":3103,"completion":3103,"start":5271,"enrollment":2572,"conditions":34989,"interventions":34990},[89],[27],[11967,17072,19263,11969],{"trials":34992,"activeCount":101},[34993,34997,35001,35005,35011],{"nctId":26271,"briefTitle":26272,"status":107,"phases":34994,"primaryCompletion":8079,"completion":8079,"start":2914,"enrollment":920,"conditions":34995,"interventions":34996},[90],[26275],[17366,26262,26277,26278],{"nctId":21595,"briefTitle":21596,"status":107,"phases":34998,"primaryCompletion":8826,"completion":8826,"start":8484,"enrollment":4683,"conditions":34999,"interventions":35000},[90],[27],[21586,17366],{"nctId":27918,"briefTitle":27919,"status":107,"phases":35002,"primaryCompletion":8826,"completion":9079,"start":6004,"enrollment":8990,"conditions":35003,"interventions":35004},[90],[27922],[27909,27909,27924,17366],{"nctId":35006,"briefTitle":35007,"status":107,"phases":35008,"primaryCompletion":9596,"completion":9596,"start":18285,"enrollment":709,"conditions":35009,"interventions":35010},"NCT02731131","A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)",[90],[21319],[8692,17366],{"nctId":19398,"briefTitle":19399,"status":107,"phases":35012,"primaryCompletion":2684,"completion":2684,"start":2793,"enrollment":1385,"conditions":35013,"interventions":35014},[90],[27],[17034,11967,17072,19263,11969],{"trials":35016,"activeCount":101},[35017,35021,35025,35032,35038],{"nctId":21824,"briefTitle":21825,"status":107,"phases":35018,"primaryCompletion":3175,"completion":3175,"start":4322,"enrollment":1184,"conditions":35019,"interventions":35020},[91],[27],[21813,17366],{"nctId":21830,"briefTitle":21831,"status":107,"phases":35022,"primaryCompletion":3104,"completion":3104,"start":6377,"enrollment":20945,"conditions":35023,"interventions":35024},[91],[27],[21835,17366],{"nctId":35026,"briefTitle":35027,"status":130,"phases":35028,"primaryCompletion":14572,"completion":14572,"start":4563,"enrollment":145,"conditions":35029,"interventions":35030},"NCT02791256","A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6",[91],[27],[17366,35031],"peginterferon alfa-2a",{"nctId":35033,"briefTitle":35034,"status":107,"phases":35035,"primaryCompletion":3189,"completion":3189,"start":11320,"enrollment":1536,"conditions":35036,"interventions":35037},"NCT01853254","A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials",[91],[27],[8692,17366],{"nctId":35039,"briefTitle":35040,"status":107,"phases":35041,"primaryCompletion":2801,"completion":2801,"start":14572,"enrollment":35042,"conditions":35043,"interventions":35044},"NCT00623428","A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response",[91],235,[27],[35031,17366],{"trials":35046,"activeCount":101},[35047,35051,35058,35062,35066,35070,35074,35081,35087,35091,35100,35104,35111,35119,35125,35129],{"nctId":34820,"briefTitle":34821,"status":107,"phases":35048,"primaryCompletion":3213,"completion":3213,"start":34823,"enrollment":34824,"conditions":35049,"interventions":35050},[92],[27],[17072,19263],{"nctId":35052,"briefTitle":35053,"status":107,"phases":35054,"primaryCompletion":2956,"completion":2956,"start":14446,"enrollment":35055,"conditions":35056,"interventions":35057},"NCT02641379","A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)",[92],737,[27],[8692,17366],{"nctId":34842,"briefTitle":34843,"status":107,"phases":35059,"primaryCompletion":6343,"completion":6343,"start":14446,"enrollment":34845,"conditions":35060,"interventions":35061},[92],[27],[17072,17072,19263,19263],{"nctId":17361,"briefTitle":17362,"status":107,"phases":35063,"primaryCompletion":2685,"completion":2685,"start":4198,"enrollment":4079,"conditions":35064,"interventions":35065},[92],[24],[17011,17366,16992],{"nctId":34865,"briefTitle":34866,"status":107,"phases":35067,"primaryCompletion":13171,"completion":13171,"start":34868,"enrollment":123,"conditions":35068,"interventions":35069},[92],[27],[17072,19263],{"nctId":34872,"briefTitle":34873,"status":107,"phases":35071,"primaryCompletion":4455,"completion":8810,"start":8260,"enrollment":34875,"conditions":35072,"interventions":35073},[92],[27],[17366,34878,17366,34879],{"nctId":35075,"briefTitle":35076,"status":107,"phases":35077,"primaryCompletion":3692,"completion":3692,"start":8811,"enrollment":35078,"conditions":35079,"interventions":35080},"NCT00107653","Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.",[92],569,[27],[17366,8692,17366,8692],{"nctId":35082,"briefTitle":35083,"status":107,"phases":35084,"primaryCompletion":4322,"completion":4322,"start":8751,"enrollment":10420,"conditions":35085,"interventions":35086},"NCT00353418","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection",[92],[27],[8692,17366,17366],{"nctId":34908,"briefTitle":34909,"status":107,"phases":35088,"primaryCompletion":4455,"completion":4455,"start":34911,"enrollment":2999,"conditions":35089,"interventions":35090},[92],[27],[17366,17072],{"nctId":35092,"briefTitle":35093,"status":107,"phases":35094,"primaryCompletion":35095,"completion":35095,"start":35096,"enrollment":35097,"conditions":35098,"interventions":35099},"NCT00800748","A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C",[92],"2009-01-09","2006-02-01",372,[27],[8692,17366],{"nctId":18938,"briefTitle":18939,"status":107,"phases":35101,"primaryCompletion":4281,"completion":4281,"start":11300,"enrollment":11722,"conditions":35102,"interventions":35103},[92],[27],[18925,17366],{"nctId":35105,"briefTitle":35106,"status":107,"phases":35107,"primaryCompletion":4322,"completion":4322,"start":6506,"enrollment":35108,"conditions":35109,"interventions":35110},"NCT00394277","A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C",[92],1175,[27],[35031,17366,35031,17366],{"nctId":35112,"briefTitle":35113,"status":107,"phases":35114,"primaryCompletion":3325,"completion":3325,"start":6134,"enrollment":35115,"conditions":35116,"interventions":35117},"NCT00192647","A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection",[92],896,[27],[35118,17366],"PEG-IFN alfa-2a",{"nctId":35120,"briefTitle":35121,"status":107,"phases":35122,"primaryCompletion":3692,"completion":3692,"start":9499,"enrollment":6629,"conditions":35123,"interventions":35124},"NCT02864199","A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment",[92],[27],[8692,17366],{"nctId":34945,"briefTitle":34946,"status":107,"phases":35126,"primaryCompletion":9771,"completion":9771,"start":22664,"enrollment":13060,"conditions":35127,"interventions":35128},[92],[27],[17072,19263],{"nctId":34951,"briefTitle":34952,"status":107,"phases":35130,"primaryCompletion":4281,"completion":4281,"start":11320,"enrollment":34954,"conditions":35131,"interventions":35132},[92],[27],[17366,17366,17072,17072,17072,17072],{"trials":35134,"activeCount":101},[35135,35143,35151,35159,35167,35173,35181,35188,35195,35202,35211,35220],{"nctId":35136,"briefTitle":35137,"status":107,"phases":35138,"primaryCompletion":2684,"completion":2684,"start":121,"enrollment":35139,"conditions":35140,"interventions":35141},"NCT02106156","Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)",[],10228,[33385],[35142,17366],"Pegylated interferon alfa-2a",{"nctId":35144,"briefTitle":35145,"status":130,"phases":35146,"primaryCompletion":2947,"completion":2947,"start":15740,"enrollment":8583,"conditions":35147,"interventions":35148},"NCT02118597","An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients",[],[27],[35149,35150,26531,17366],"Boceprevir","Simeprevir",{"nctId":35152,"briefTitle":35153,"status":107,"phases":35154,"primaryCompletion":8681,"completion":10332,"start":4206,"enrollment":2057,"conditions":35155,"interventions":35156},"NCT01280656","A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)",[],[27],[35157,26277,35158,17366],"Conventional Interferon","Peginterferon Alfa-2b",{"nctId":35160,"briefTitle":35161,"status":107,"phases":35162,"primaryCompletion":35163,"completion":35163,"start":35164,"enrollment":17008,"conditions":35165,"interventions":35166},"NCT01659567","A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C",[],"2015-10-20","2011-04-06",[27],[22297,17366],{"nctId":35168,"briefTitle":35169,"status":107,"phases":35170,"primaryCompletion":4314,"completion":4314,"start":6506,"enrollment":22,"conditions":35171,"interventions":35172},"NCT02726022","A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels",[],[27],[8692,17366],{"nctId":35174,"briefTitle":35175,"status":130,"phases":35176,"primaryCompletion":2800,"completion":2800,"start":8681,"enrollment":35177,"conditions":35178,"interventions":35179},"NCT01798576","An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure",[],282,[27],[35180,17366],"Pegylated Interferon alfa-2a",{"nctId":35182,"briefTitle":35183,"status":107,"phases":35184,"primaryCompletion":3197,"completion":3197,"start":9596,"enrollment":35185,"conditions":35186,"interventions":35187},"NCT02557646","An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C",[],697,[27],[8692,17366],{"nctId":35189,"briefTitle":35190,"status":107,"phases":35191,"primaryCompletion":8934,"completion":8934,"start":8810,"enrollment":34875,"conditions":35192,"interventions":35193},"NCT02850289","APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin",[],[27],[35194,17366],"Pegylated interferon (PEG-INF) alfa-2a",{"nctId":35196,"briefTitle":35197,"status":107,"phases":35198,"primaryCompletion":3324,"completion":3324,"start":8688,"enrollment":35199,"conditions":35200,"interventions":35201},"NCT02515279","An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria",[],463,[26275],[8692,17366],{"nctId":35203,"briefTitle":35204,"status":107,"phases":35205,"primaryCompletion":35206,"completion":35206,"start":35207,"enrollment":35208,"conditions":35209,"interventions":35210},"NCT01609049","An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis",[],"2015-06-22","2011-12-07",1496,[27],[8692,17366],{"nctId":35212,"briefTitle":35213,"status":107,"phases":35214,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":35215,"conditions":35216,"interventions":35217},"NCT01447446","An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C",[],4442,[27],[35218,35219,17366,35149,26278],"Peg-IFN Alfa-2a","Peg-IFN Alfa-2b",{"nctId":35221,"briefTitle":35222,"status":107,"phases":35223,"primaryCompletion":5364,"completion":5364,"start":3325,"enrollment":2940,"conditions":35224,"interventions":35225},"NCT02556307","A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients",[],[27],[8692,17366],{"intervention":977,"totalTrials":395,"cells":35227},{"EARLY_PHASE1":35228,"PHASE1":35230,"PHASE2":35244,"PHASE3":35323,"PHASE4":35363,"NA":35382},{"trials":35229,"activeCount":101},[],{"trials":35231,"activeCount":101},[35232,35236,35240],{"nctId":14680,"briefTitle":14681,"status":107,"phases":35233,"primaryCompletion":2602,"completion":2602,"start":2905,"enrollment":14683,"conditions":35234,"interventions":35235},[89],[1241],[5422,1138,977,14686],{"nctId":968,"briefTitle":969,"status":107,"phases":35237,"primaryCompletion":971,"completion":971,"start":972,"enrollment":973,"conditions":35238,"interventions":35239},[89],[975],[43,68,977],{"nctId":11269,"briefTitle":11270,"status":107,"phases":35241,"primaryCompletion":4562,"completion":4562,"start":6277,"enrollment":510,"conditions":35242,"interventions":35243},[89],[975],[977,1221],{"trials":35245,"activeCount":101},[35246,35250,35254,35258,35262,35271,35278,35282,35291,35298,35305,35311,35315,35319],{"nctId":6586,"briefTitle":6587,"status":107,"phases":35247,"primaryCompletion":2906,"completion":4474,"start":3085,"enrollment":2375,"conditions":35248,"interventions":35249},[90],[6590],[977,1163],{"nctId":27839,"briefTitle":27840,"status":107,"phases":35251,"primaryCompletion":3325,"completion":3325,"start":4086,"enrollment":1705,"conditions":35252,"interventions":35253},[90],[2257],[977,27830],{"nctId":4195,"briefTitle":4196,"status":107,"phases":35255,"primaryCompletion":2932,"completion":2932,"start":4198,"enrollment":1115,"conditions":35256,"interventions":35257},[90],[4121],[4100,4201],{"nctId":4203,"briefTitle":4204,"status":107,"phases":35259,"primaryCompletion":4206,"completion":4206,"start":121,"enrollment":4159,"conditions":35260,"interventions":35261},[90],[975],[977,1015,4209],{"nctId":35263,"briefTitle":35264,"status":107,"phases":35265,"primaryCompletion":35266,"completion":35267,"start":35268,"enrollment":37,"conditions":35269,"interventions":35270},"NCT01378962","A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)",[90],"2013-06-30","2017-01-31","2011-03-31",[2257],[4201],{"nctId":35272,"briefTitle":35273,"status":107,"phases":35274,"primaryCompletion":2792,"completion":2792,"start":8320,"enrollment":145,"conditions":35275,"interventions":35277},"NCT01153984","A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations",[90],[35276],"Carcinoma，Non-Small-Cell Lung",[977],{"nctId":6617,"briefTitle":6618,"status":107,"phases":35279,"primaryCompletion":5181,"completion":5181,"start":6620,"enrollment":1249,"conditions":35280,"interventions":35281},[90],[6622],[977,1163],{"nctId":35283,"briefTitle":35284,"status":107,"phases":35285,"primaryCompletion":35286,"completion":35287,"start":35288,"enrollment":8,"conditions":35289,"interventions":35290},"NCT01310036","A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations",[90],"2014-02-14","2016-12-30","2011-04-30",[2257],[977],{"nctId":35292,"briefTitle":35293,"status":107,"phases":35294,"primaryCompletion":2963,"completion":2963,"start":4323,"enrollment":35295,"conditions":35296,"interventions":35297},"NCT02774278","A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)",[90],264,[2257],[977],{"nctId":35299,"briefTitle":35300,"status":107,"phases":35301,"primaryCompletion":4474,"completion":4473,"start":14572,"enrollment":35302,"conditions":35303,"interventions":35304},"NCT00674973","A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer",[90],207,[6622],[977],{"nctId":35306,"briefTitle":35307,"status":107,"phases":35308,"primaryCompletion":6487,"completion":6487,"start":35268,"enrollment":1184,"conditions":35309,"interventions":35310},"NCT01260181","A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations",[90],[2257],[977],{"nctId":6670,"briefTitle":6671,"status":107,"phases":35312,"primaryCompletion":3479,"completion":3479,"start":6673,"enrollment":510,"conditions":35313,"interventions":35314},[90],[2257],[977,1163],{"nctId":1760,"briefTitle":1761,"status":107,"phases":35316,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":35317,"interventions":35318},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"nctId":4923,"briefTitle":4924,"status":107,"phases":35320,"primaryCompletion":4901,"completion":4926,"start":4927,"enrollment":897,"conditions":35321,"interventions":35322},[89,90],[4929],[977,43],{"trials":35324,"activeCount":101},[35325,35329,35333,35337,35343,35347,35351,35355],{"nctId":6687,"briefTitle":6688,"status":107,"phases":35326,"primaryCompletion":6690,"completion":6690,"start":6691,"enrollment":920,"conditions":35327,"interventions":35328},[91],[6622],[977,1163],{"nctId":14595,"briefTitle":14596,"status":107,"phases":35330,"primaryCompletion":3007,"completion":11437,"start":2964,"enrollment":7879,"conditions":35331,"interventions":35332},[91],[975],[977,1572],{"nctId":4384,"briefTitle":4385,"status":107,"phases":35334,"primaryCompletion":4387,"completion":4387,"start":4388,"enrollment":4389,"conditions":35335,"interventions":35336},[91],[2257],[1015,947,977,1319],{"nctId":35338,"briefTitle":35339,"status":130,"phases":35340,"primaryCompletion":2769,"completion":2769,"start":8658,"enrollment":4033,"conditions":35341,"interventions":35342},"NCT00412217","A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer",[91],[14704],[977],{"nctId":4430,"briefTitle":4431,"status":107,"phases":35344,"primaryCompletion":4433,"completion":4433,"start":4434,"enrollment":709,"conditions":35345,"interventions":35346},[91],[1160],[4244,1015,977],{"nctId":20490,"briefTitle":20491,"status":107,"phases":35348,"primaryCompletion":3006,"completion":3006,"start":3212,"enrollment":462,"conditions":35349,"interventions":35350},[91],[2257],[4201,20495],{"nctId":23469,"briefTitle":23470,"status":107,"phases":35352,"primaryCompletion":2847,"completion":8321,"start":3189,"enrollment":23472,"conditions":35353,"interventions":35354},[91],[2257],[977,23458],{"nctId":35356,"briefTitle":35357,"status":107,"phases":35358,"primaryCompletion":35359,"completion":35359,"start":35360,"enrollment":16507,"conditions":35361,"interventions":35362},"NCT01667562","A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],"2017-09-07","2012-01-20",[975],[977],{"trials":35364,"activeCount":101},[35365,35372,35376],{"nctId":35366,"briefTitle":35367,"status":107,"phases":35368,"primaryCompletion":4322,"completion":4322,"start":7054,"enrollment":35369,"conditions":35370,"interventions":35371},"NCT00949910","An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",[92],6586,[975],[977],{"nctId":14629,"briefTitle":14630,"status":107,"phases":35373,"primaryCompletion":3324,"completion":3324,"start":2830,"enrollment":909,"conditions":35374,"interventions":35375},[92],[1316],[977,1572],{"nctId":35377,"briefTitle":35378,"status":107,"phases":35379,"primaryCompletion":2684,"completion":2684,"start":2964,"enrollment":1115,"conditions":35380,"interventions":35381},"NCT01230710","A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression",[92],[975],[977],{"trials":35383,"activeCount":101},[35384,35392,35396,35402,35408],{"nctId":35385,"briefTitle":35386,"status":107,"phases":35387,"primaryCompletion":15695,"completion":15695,"start":4582,"enrollment":35388,"conditions":35389,"interventions":35391},"NCT01161173","An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer",[],347,[35390],"Nonsquamous Nonsmall Cell Neoplasm of Lung",[977],{"nctId":6782,"briefTitle":6783,"status":107,"phases":35393,"primaryCompletion":6785,"completion":6785,"start":6786,"enrollment":5768,"conditions":35394,"interventions":35395},[],[6622],[4201,5186],{"nctId":35397,"briefTitle":35398,"status":107,"phases":35399,"primaryCompletion":6157,"completion":6157,"start":3189,"enrollment":2999,"conditions":35400,"interventions":35401},"NCT01664533","An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy",[],[2257],[977],{"nctId":35403,"briefTitle":35404,"status":107,"phases":35405,"primaryCompletion":11550,"completion":11550,"start":4113,"enrollment":3880,"conditions":35406,"interventions":35407},"NCT02595450","A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer",[],[975],[977],{"nctId":35409,"briefTitle":35410,"status":130,"phases":35411,"primaryCompletion":3182,"completion":3182,"start":4445,"enrollment":395,"conditions":35412,"interventions":35413},"NCT01990261","A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment",[],[2257],[977],{"intervention":5837,"totalTrials":8206,"cells":35415},{"EARLY_PHASE1":35416,"PHASE1":35418,"PHASE2":35420,"PHASE3":35476,"PHASE4":35534,"NA":35576},{"trials":35417,"activeCount":101},[],{"trials":35419,"activeCount":101},[],{"trials":35421,"activeCount":101},[35422,35428,35434,35438,35442,35446,35450,35457,35461,35469],{"nctId":35423,"briefTitle":35424,"status":107,"phases":35425,"primaryCompletion":15950,"completion":15950,"start":15951,"enrollment":931,"conditions":35426,"interventions":35427},"NCT01388959","A Study of MabThera\u002FRituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma",[90],[125],[5837],{"nctId":35429,"briefTitle":35430,"status":107,"phases":35431,"primaryCompletion":9079,"completion":9079,"start":6620,"enrollment":3190,"conditions":35432,"interventions":35433},"NCT00475423","A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.",[90],[6346],[5837],{"nctId":20268,"briefTitle":20269,"status":130,"phases":35435,"primaryCompletion":3325,"completion":3325,"start":3692,"enrollment":2631,"conditions":35436,"interventions":35437},[90],[1038],[5837,2824,10088],{"nctId":15442,"briefTitle":15443,"status":130,"phases":35439,"primaryCompletion":3674,"completion":3674,"start":3325,"enrollment":425,"conditions":35440,"interventions":35441},[90],[15],[5837,5894],{"nctId":34518,"briefTitle":34519,"status":130,"phases":35443,"primaryCompletion":4409,"completion":4409,"start":8977,"enrollment":706,"conditions":35444,"interventions":35445},[90],[15],[5837,2824],{"nctId":28378,"briefTitle":28379,"status":107,"phases":35447,"primaryCompletion":28381,"completion":28381,"start":28382,"enrollment":123,"conditions":35448,"interventions":35449},[90],[28384],[5837,28369],{"nctId":35451,"briefTitle":35452,"status":107,"phases":35453,"primaryCompletion":4086,"completion":4086,"start":35454,"enrollment":2492,"conditions":35455,"interventions":35456},"NCT01998893","A Study of MabThera\u002FRituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma",[90],"1997-01",[125],[5837],{"nctId":10115,"briefTitle":10116,"status":107,"phases":35458,"primaryCompletion":10118,"completion":10118,"start":10119,"enrollment":1385,"conditions":35459,"interventions":35460},[90],[3741],[5837,10122,10123],{"nctId":35462,"briefTitle":35463,"status":107,"phases":35464,"primaryCompletion":35465,"completion":35465,"start":35466,"enrollment":8990,"conditions":35467,"interventions":35468},"NCT00738374","A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.",[90],"2013-01-14","2008-11-03",[3741],[5837,3743],{"nctId":35470,"briefTitle":35471,"status":107,"phases":35472,"primaryCompletion":4446,"completion":4446,"start":35473,"enrollment":123,"conditions":35474,"interventions":35475},"NCT01392716","A Study of MabThera\u002FRituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma",[90],"1997-10",[125],[5837],{"trials":35477,"activeCount":101},[35478,35487,35491,35499,35503,35507,35516,35520,35524,35530],{"nctId":35479,"briefTitle":35480,"status":107,"phases":35481,"primaryCompletion":35482,"completion":35482,"start":35483,"enrollment":11607,"conditions":35484,"interventions":35485},"NCT00503425","A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and\u002For Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.",[91],"2013-05-26","2005-06-30",[15],[35486],"Rituximab [MabThera\u002FRituxan]",{"nctId":5830,"briefTitle":5831,"status":107,"phases":35488,"primaryCompletion":5833,"completion":5833,"start":5834,"enrollment":2619,"conditions":35489,"interventions":35490},[91],[15],[5837,5838,5839],{"nctId":35492,"briefTitle":35493,"status":107,"phases":35494,"primaryCompletion":240,"completion":240,"start":35495,"enrollment":35496,"conditions":35497,"interventions":35498},"NCT00502840","A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.",[91],"2007-07-23",193,[15],[5837],{"nctId":15573,"briefTitle":15574,"status":107,"phases":35500,"primaryCompletion":4682,"completion":4682,"start":2964,"enrollment":15576,"conditions":35501,"interventions":35502},[91],[15],[5837,5894,5894],{"nctId":34622,"briefTitle":34623,"status":107,"phases":35504,"primaryCompletion":4562,"completion":4562,"start":4446,"enrollment":27523,"conditions":35505,"interventions":35506},[91],[15],[2824,5837],{"nctId":35508,"briefTitle":35509,"status":107,"phases":35510,"primaryCompletion":35511,"completion":35511,"start":35512,"enrollment":35513,"conditions":35514,"interventions":35515},"NCT01144364","A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)",[91],"2011-07-21","2004-01-19",234,[125],[34693],{"nctId":20844,"briefTitle":20845,"status":107,"phases":35517,"primaryCompletion":4322,"completion":4322,"start":20847,"enrollment":157,"conditions":35518,"interventions":35519},[91],[125],[5837,9587],{"nctId":22175,"briefTitle":22176,"status":107,"phases":35521,"primaryCompletion":22178,"completion":8127,"start":22179,"enrollment":5293,"conditions":35522,"interventions":35523},[91],[3644],[4539,5837,5837],{"nctId":35525,"briefTitle":35526,"status":107,"phases":35527,"primaryCompletion":3674,"completion":3674,"start":4446,"enrollment":871,"conditions":35528,"interventions":35529},"NCT00422383","A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)",[91],[15],[5837,5837,5837],{"nctId":34644,"briefTitle":34645,"status":107,"phases":35531,"primaryCompletion":10332,"completion":10332,"start":11713,"enrollment":1509,"conditions":35532,"interventions":35533},[91],[15],[5838,5837],{"trials":35535,"activeCount":101},[35536,35540,35544,35548,35552,35556,35560,35564,35568],{"nctId":34652,"briefTitle":34653,"status":107,"phases":35537,"primaryCompletion":4555,"completion":4555,"start":4315,"enrollment":1058,"conditions":35538,"interventions":35539},[92],[15],[5837,2824],{"nctId":11681,"briefTitle":11682,"status":107,"phases":35541,"primaryCompletion":3197,"completion":3197,"start":4555,"enrollment":11684,"conditions":35542,"interventions":35543},[92],[3741],[3668,3743,5837],{"nctId":34670,"briefTitle":34671,"status":107,"phases":35545,"primaryCompletion":34673,"completion":34673,"start":34674,"enrollment":462,"conditions":35546,"interventions":35547},[92],[15],[5837,2824],{"nctId":34678,"briefTitle":34679,"status":107,"phases":35549,"primaryCompletion":3022,"completion":3022,"start":16669,"enrollment":2375,"conditions":35550,"interventions":35551},[92],[15],[5837,2824],{"nctId":34688,"briefTitle":34689,"status":130,"phases":35553,"primaryCompletion":4409,"completion":4409,"start":8826,"enrollment":162,"conditions":35554,"interventions":35555},[92],[15],[5837,5838,34693],{"nctId":34699,"briefTitle":34700,"status":107,"phases":35557,"primaryCompletion":5181,"completion":5181,"start":4513,"enrollment":336,"conditions":35558,"interventions":35559},[92],[15],[2824,5837],{"nctId":5896,"briefTitle":5897,"status":107,"phases":35561,"primaryCompletion":5899,"completion":5899,"start":5900,"enrollment":5901,"conditions":35562,"interventions":35563},[92],[15],[5837,5838,5839],{"nctId":34713,"briefTitle":34714,"status":107,"phases":35565,"primaryCompletion":5181,"completion":5181,"start":2965,"enrollment":2619,"conditions":35566,"interventions":35567},[92],[15],[5837,5838],{"nctId":35569,"briefTitle":35570,"status":107,"phases":35571,"primaryCompletion":35572,"completion":35572,"start":35573,"enrollment":16714,"conditions":35574,"interventions":35575},"NCT00430352","MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.",[92],"2011-05-26","2006-09-04",[125],[5837],{"trials":35577,"activeCount":101},[35578,35585,35589],{"nctId":35579,"briefTitle":35580,"status":107,"phases":35581,"primaryCompletion":8320,"completion":8320,"start":6004,"enrollment":35582,"conditions":35583,"interventions":35584},"NCT01072240","An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia",[],92,[3741],[34693],{"nctId":14663,"briefTitle":14664,"status":107,"phases":35586,"primaryCompletion":4682,"completion":4682,"start":2906,"enrollment":14666,"conditions":35587,"interventions":35588},[],[3741],[1572,5837],{"nctId":35590,"briefTitle":35591,"status":107,"phases":35592,"primaryCompletion":2905,"completion":2905,"start":6004,"enrollment":3214,"conditions":35593,"interventions":35594},"NCT01075477","An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)",[],[15],[34693],{"intervention":8692,"totalTrials":1174,"cells":35596},{"EARLY_PHASE1":35597,"PHASE1":35599,"PHASE2":35601,"PHASE3":35615,"PHASE4":35642,"NA":35702},{"trials":35598,"activeCount":101},[],{"trials":35600,"activeCount":101},[],{"trials":35602,"activeCount":101},[35603,35607,35611],{"nctId":26271,"briefTitle":26272,"status":107,"phases":35604,"primaryCompletion":8079,"completion":8079,"start":2914,"enrollment":920,"conditions":35605,"interventions":35606},[90],[26275],[17366,26262,26277,26278],{"nctId":35006,"briefTitle":35007,"status":107,"phases":35608,"primaryCompletion":9596,"completion":9596,"start":18285,"enrollment":709,"conditions":35609,"interventions":35610},[90],[21319],[8692,17366],{"nctId":8685,"briefTitle":8686,"status":107,"phases":35612,"primaryCompletion":8688,"completion":8688,"start":8689,"enrollment":721,"conditions":35613,"interventions":35614},[90],[1443],[1166,8692],{"trials":35616,"activeCount":101},[35617,35621,35625,35629,35636],{"nctId":35026,"briefTitle":35027,"status":130,"phases":35618,"primaryCompletion":14572,"completion":14572,"start":4563,"enrollment":145,"conditions":35619,"interventions":35620},[91],[27],[17366,35031],{"nctId":35033,"briefTitle":35034,"status":107,"phases":35622,"primaryCompletion":3189,"completion":3189,"start":11320,"enrollment":1536,"conditions":35623,"interventions":35624},[91],[27],[8692,17366],{"nctId":35039,"briefTitle":35040,"status":107,"phases":35626,"primaryCompletion":2801,"completion":2801,"start":14572,"enrollment":35042,"conditions":35627,"interventions":35628},[91],[27],[35031,17366],{"nctId":35630,"briefTitle":35631,"status":107,"phases":35632,"primaryCompletion":5181,"completion":5181,"start":11320,"enrollment":2440,"conditions":35633,"interventions":35635},"NCT02736721","Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)",[91],[35634],"Myelogenous Leukemia, Chronic",[8692],{"nctId":35637,"briefTitle":35638,"status":107,"phases":35639,"primaryCompletion":6673,"completion":6673,"start":11713,"enrollment":6432,"conditions":35640,"interventions":35641},"NCT02806505","HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)",[91],[27],[8692],{"trials":35643,"activeCount":101},[35644,35650,35654,35660,35664,35668,35674,35678,35682,35688,35692,35698],{"nctId":35645,"briefTitle":35646,"status":107,"phases":35647,"primaryCompletion":8681,"completion":8681,"start":4233,"enrollment":14873,"conditions":35648,"interventions":35649},"NCT01447420","A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)",[92],[27],[35031,17976],{"nctId":35052,"briefTitle":35053,"status":107,"phases":35651,"primaryCompletion":2956,"completion":2956,"start":14446,"enrollment":35055,"conditions":35652,"interventions":35653},[92],[27],[8692,17366],{"nctId":35655,"briefTitle":35656,"status":107,"phases":35657,"primaryCompletion":6506,"completion":6506,"start":7054,"enrollment":336,"conditions":35658,"interventions":35659},"NCT02570191","A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)",[92],[11790],[8692],{"nctId":35075,"briefTitle":35076,"status":107,"phases":35661,"primaryCompletion":3692,"completion":3692,"start":8811,"enrollment":35078,"conditions":35662,"interventions":35663},[92],[27],[17366,8692,17366,8692],{"nctId":35082,"briefTitle":35083,"status":107,"phases":35665,"primaryCompletion":4322,"completion":4322,"start":8751,"enrollment":10420,"conditions":35666,"interventions":35667},[92],[27],[8692,17366,17366],{"nctId":35669,"briefTitle":35670,"status":107,"phases":35671,"primaryCompletion":13164,"completion":13164,"start":34868,"enrollment":16964,"conditions":35672,"interventions":35673},"NCT02604823","A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)",[92],[11790],[8692],{"nctId":35092,"briefTitle":35093,"status":107,"phases":35675,"primaryCompletion":35095,"completion":35095,"start":35096,"enrollment":35097,"conditions":35676,"interventions":35677},[92],[27],[8692,17366],{"nctId":35105,"briefTitle":35106,"status":107,"phases":35679,"primaryCompletion":4322,"completion":4322,"start":6506,"enrollment":35108,"conditions":35680,"interventions":35681},[92],[27],[35031,17366,35031,17366],{"nctId":35683,"briefTitle":35684,"status":107,"phases":35685,"primaryCompletion":6343,"completion":6343,"start":8977,"enrollment":425,"conditions":35686,"interventions":35687},"NCT02791269","A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program",[92],[11790],[8692],{"nctId":17622,"briefTitle":17623,"status":107,"phases":35689,"primaryCompletion":4322,"completion":4322,"start":133,"enrollment":17625,"conditions":35690,"interventions":35691},[92],[11790],[17628,16486,8692],{"nctId":35693,"briefTitle":35694,"status":107,"phases":35695,"primaryCompletion":3104,"completion":3104,"start":7096,"enrollment":6013,"conditions":35696,"interventions":35697},"NCT00436163","A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B",[92],[11790],[8692],{"nctId":35120,"briefTitle":35121,"status":107,"phases":35699,"primaryCompletion":3692,"completion":3692,"start":9499,"enrollment":6629,"conditions":35700,"interventions":35701},[92],[27],[8692,17366],{"trials":35703,"activeCount":101},[35704,35708,35712,35716,35723,35730,35734,35738,35742],{"nctId":35152,"briefTitle":35153,"status":107,"phases":35705,"primaryCompletion":8681,"completion":10332,"start":4206,"enrollment":2057,"conditions":35706,"interventions":35707},[],[27],[35157,26277,35158,17366],{"nctId":35168,"briefTitle":35169,"status":107,"phases":35709,"primaryCompletion":4314,"completion":4314,"start":6506,"enrollment":22,"conditions":35710,"interventions":35711},[],[27],[8692,17366],{"nctId":35182,"briefTitle":35183,"status":107,"phases":35713,"primaryCompletion":3197,"completion":3197,"start":9596,"enrollment":35185,"conditions":35714,"interventions":35715},[],[27],[8692,17366],{"nctId":35717,"briefTitle":35718,"status":107,"phases":35719,"primaryCompletion":4314,"completion":4314,"start":6377,"enrollment":35720,"conditions":35721,"interventions":35722},"NCT01070550","PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)",[],4680,[27],[8692],{"nctId":35724,"briefTitle":35725,"status":107,"phases":35726,"primaryCompletion":35727,"completion":35727,"start":1035,"enrollment":37,"conditions":35728,"interventions":35729},"NCT02201407","An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study",[],"2017-04-10",[11790],[8692],{"nctId":35196,"briefTitle":35197,"status":107,"phases":35731,"primaryCompletion":3324,"completion":3324,"start":8688,"enrollment":35199,"conditions":35732,"interventions":35733},[],[26275],[8692,17366],{"nctId":35203,"briefTitle":35204,"status":107,"phases":35735,"primaryCompletion":35206,"completion":35206,"start":35207,"enrollment":35208,"conditions":35736,"interventions":35737},[],[27],[8692,17366],{"nctId":35221,"briefTitle":35222,"status":107,"phases":35739,"primaryCompletion":5364,"completion":5364,"start":3325,"enrollment":2940,"conditions":35740,"interventions":35741},[],[27],[8692,17366],{"nctId":35743,"briefTitle":35744,"status":107,"phases":35745,"primaryCompletion":20442,"completion":20442,"start":35746,"enrollment":35747,"conditions":35748,"interventions":35749},"NCT01667432","An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B",[],"2011-07-08",141,[11790],[8692],{"intervention":16968,"totalTrials":11473,"cells":35751},{"EARLY_PHASE1":35752,"PHASE1":35754,"PHASE2":35756,"PHASE3":35772,"PHASE4":35876,"NA":35898},{"trials":35753,"activeCount":101},[],{"trials":35755,"activeCount":101},[],{"trials":35757,"activeCount":101},[35758,35765],{"nctId":35759,"briefTitle":35760,"status":107,"phases":35761,"primaryCompletion":4528,"completion":4528,"start":4700,"enrollment":13493,"conditions":35762,"interventions":35764},"NCT01194154","A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)",[90],[35763],"Kidney Disease, Chronic",[16968],{"nctId":35766,"briefTitle":35767,"status":107,"phases":35768,"primaryCompletion":5417,"completion":5417,"start":6343,"enrollment":17519,"conditions":35769,"interventions":35771},"NCT00717366","Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis",[90],[35770],"Renal Anemia",[16930],{"trials":35773,"activeCount":101},[35774,35778,35784,35790,35794,35798,35804,35810,35814,35820,35824,35830,35834,35840,35846,35852,35858,35864,35868],{"nctId":21376,"briefTitle":21377,"status":107,"phases":35775,"primaryCompletion":3030,"completion":3030,"start":8605,"enrollment":5293,"conditions":35776,"interventions":35777},[91],[24],[16050,16958,16958],{"nctId":35779,"briefTitle":35780,"status":107,"phases":35781,"primaryCompletion":7095,"completion":7095,"start":6343,"enrollment":4637,"conditions":35782,"interventions":35783},"NCT00699348","A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia",[91],[24],[16968],{"nctId":35785,"briefTitle":35786,"status":130,"phases":35787,"primaryCompletion":3084,"completion":3084,"start":6377,"enrollment":1174,"conditions":35788,"interventions":35789},"NCT00517881","Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia",[91],[24],[16968],{"nctId":17642,"briefTitle":17643,"status":107,"phases":35791,"primaryCompletion":4206,"completion":4206,"start":121,"enrollment":1891,"conditions":35792,"interventions":35793},[91],[24],[16958,16097],{"nctId":16924,"briefTitle":16925,"status":107,"phases":35795,"primaryCompletion":2769,"completion":2769,"start":8811,"enrollment":16927,"conditions":35796,"interventions":35797},[91],[24],[16930,16097,16023,16000],{"nctId":35799,"briefTitle":35800,"status":107,"phases":35801,"primaryCompletion":4409,"completion":4409,"start":121,"enrollment":16,"conditions":35802,"interventions":35803},"NCT00559637","A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis",[91],[24],[16968],{"nctId":35805,"briefTitle":35806,"status":107,"phases":35807,"primaryCompletion":17779,"completion":17779,"start":3041,"enrollment":1036,"conditions":35808,"interventions":35809},"NCT00737477","A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis",[91],[24],[16968],{"nctId":16943,"briefTitle":16944,"status":107,"phases":35811,"primaryCompletion":4314,"completion":4314,"start":3085,"enrollment":16946,"conditions":35812,"interventions":35813},[91],[24],[16949,16950,16951],{"nctId":35815,"briefTitle":35816,"status":107,"phases":35817,"primaryCompletion":5181,"completion":5181,"start":3085,"enrollment":4159,"conditions":35818,"interventions":35819},"NCT00660023","A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis",[91],[24],[16968],{"nctId":16953,"briefTitle":16954,"status":130,"phases":35821,"primaryCompletion":4086,"completion":4086,"start":8484,"enrollment":2389,"conditions":35822,"interventions":35823},[91],[24],[16958,16959,16065],{"nctId":35825,"briefTitle":35826,"status":107,"phases":35827,"primaryCompletion":4555,"completion":4555,"start":4113,"enrollment":1026,"conditions":35828,"interventions":35829},"NCT00773968","A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia",[91],[24],[16930],{"nctId":16961,"briefTitle":16962,"status":107,"phases":35831,"primaryCompletion":3022,"completion":3022,"start":4513,"enrollment":16964,"conditions":35832,"interventions":35833},[91],[16966],[16968,16000],{"nctId":35835,"briefTitle":35836,"status":107,"phases":35837,"primaryCompletion":7152,"completion":7152,"start":14572,"enrollment":7408,"conditions":35838,"interventions":35839},"NCT00642967","A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis",[91],[24],[16949],{"nctId":35841,"briefTitle":35842,"status":107,"phases":35843,"primaryCompletion":3022,"completion":3022,"start":2965,"enrollment":1239,"conditions":35844,"interventions":35845},"NCT00545571","MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia",[91],[24],[16968],{"nctId":35847,"briefTitle":35848,"status":343,"phases":35849,"completion":3022,"start":2965,"enrollment":101,"conditions":35850,"interventions":35851},"NCT00560547","A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.",[91],[24],[16958],{"nctId":35853,"briefTitle":35854,"status":107,"phases":35855,"primaryCompletion":6004,"completion":6004,"start":121,"enrollment":8,"conditions":35856,"interventions":35857},"NCT00550680","A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia",[91],[16983],[16968],{"nctId":35859,"briefTitle":35860,"status":130,"phases":35861,"primaryCompletion":14712,"completion":14712,"start":4086,"enrollment":6013,"conditions":35862,"interventions":35863},"NCT00462384","A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.",[91],[24],[16949],{"nctId":17660,"briefTitle":17661,"status":130,"phases":35865,"primaryCompletion":4513,"completion":4513,"start":7096,"enrollment":6507,"conditions":35866,"interventions":35867},[91],[24],[16958,16097],{"nctId":35869,"briefTitle":35870,"status":107,"phases":35871,"primaryCompletion":35872,"completion":35872,"start":35873,"enrollment":3044,"conditions":35874,"interventions":35875},"NCT00661505","A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia",[91],"2010-06-22","2008-05-14",[24],[16958],{"trials":35877,"activeCount":101},[35878,35885,35894],{"nctId":35879,"briefTitle":35880,"status":107,"phases":35881,"primaryCompletion":3738,"completion":3738,"start":35882,"enrollment":384,"conditions":35883,"interventions":35884},"NCT00642668","A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia",[92],"2008-06-30",[24],[16958],{"nctId":35886,"briefTitle":35887,"status":107,"phases":35888,"primaryCompletion":35889,"completion":35889,"start":35890,"enrollment":1296,"conditions":35891,"interventions":35893},"NCT01519947","A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis",[92],"2015-05-30","2012-05-30",[35892],"Anemia, Kidney Disease, Chronic",[16968],{"nctId":16976,"briefTitle":16977,"status":107,"phases":35895,"primaryCompletion":16979,"completion":16979,"start":16980,"enrollment":16981,"conditions":35896,"interventions":35897},[92],[16983],[16951,16985,16950,16958],{"trials":35899,"activeCount":101},[35900,35909,35916],{"nctId":35901,"briefTitle":35902,"status":107,"phases":35903,"primaryCompletion":35904,"completion":35904,"start":35905,"enrollment":34937,"conditions":35906,"interventions":35908},"NCT01756612","A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)",[],"2015-03-25","2012-11-21",[35907],"Renal Anemia of Chronic Kidney Disease",[16930],{"nctId":35910,"briefTitle":35911,"status":107,"phases":35912,"primaryCompletion":3213,"completion":3213,"start":2769,"enrollment":4269,"conditions":35913,"interventions":35915},"NCT02238080","An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis",[],[35914],"Chronic Kidney Diseases",[16930],{"nctId":35917,"briefTitle":35918,"status":107,"phases":35919,"primaryCompletion":4712,"completion":4712,"start":15562,"enrollment":35920,"conditions":35921,"interventions":35922},"NCT02547454","An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)",[],393,[35763],[16968],{"intervention":16023,"totalTrials":721,"cells":35924},{"EARLY_PHASE1":35925,"PHASE1":35927,"PHASE2":35929,"PHASE3":35939,"PHASE4":35970,"NA":36020},{"trials":35926,"activeCount":101},[],{"trials":35928,"activeCount":101},[],{"trials":35930,"activeCount":101},[35931],{"nctId":35932,"briefTitle":35933,"status":107,"phases":35934,"primaryCompletion":35935,"completion":35935,"start":35936,"enrollment":2708,"conditions":35937,"interventions":35938},"NCT02761642","A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy",[90],"2007-03-31","2004-02-29",[24],[16950],{"trials":35940,"activeCount":101},[35941,35945,35951,35955,35959,35963],{"nctId":16017,"briefTitle":16018,"status":107,"phases":35942,"primaryCompletion":3104,"completion":3104,"start":6620,"enrollment":16020,"conditions":35943,"interventions":35944},[91],[24],[16023,15973],{"nctId":35946,"briefTitle":35947,"status":107,"phases":35948,"primaryCompletion":121,"completion":121,"start":133,"enrollment":3190,"conditions":35949,"interventions":35950},"NCT02827266","A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis",[91],[24],[16023],{"nctId":16924,"briefTitle":16925,"status":107,"phases":35952,"primaryCompletion":2769,"completion":2769,"start":8811,"enrollment":16927,"conditions":35953,"interventions":35954},[91],[24],[16930,16097,16023,16000],{"nctId":16031,"briefTitle":16032,"status":107,"phases":35956,"primaryCompletion":4474,"completion":4474,"start":4488,"enrollment":6005,"conditions":35957,"interventions":35958},[91],[24],[16036,15973],{"nctId":16943,"briefTitle":16944,"status":107,"phases":35960,"primaryCompletion":4314,"completion":4314,"start":3085,"enrollment":16946,"conditions":35961,"interventions":35962},[91],[24],[16949,16950,16951],{"nctId":35964,"briefTitle":35965,"status":107,"phases":35966,"primaryCompletion":4323,"completion":4323,"start":35967,"enrollment":13516,"conditions":35968,"interventions":35969},"NCT00354341","(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy",[91],"2002-09",[24],[16023],{"trials":35971,"activeCount":101},[35972,35978,35984,35990,35996,36000,36006,36014],{"nctId":35973,"briefTitle":35974,"status":107,"phases":35975,"primaryCompletion":3030,"completion":3030,"start":11713,"enrollment":496,"conditions":35976,"interventions":35977},"NCT02554942","A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors",[92],[24],[16023],{"nctId":35979,"briefTitle":35980,"status":107,"phases":35981,"primaryCompletion":8751,"completion":8751,"start":6702,"enrollment":3574,"conditions":35982,"interventions":35983},"NCT02564094","A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies",[92],[24],[16023],{"nctId":35985,"briefTitle":35986,"status":107,"phases":35987,"primaryCompletion":9771,"completion":9771,"start":8811,"enrollment":1724,"conditions":35988,"interventions":35989},"NCT02569515","A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia",[92],[24],[16950],{"nctId":35991,"briefTitle":35992,"status":130,"phases":35993,"primaryCompletion":2965,"completion":2965,"start":6277,"enrollment":5110,"conditions":35994,"interventions":35995},"NCT02608060","A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B",[92],[24],[16950],{"nctId":16976,"briefTitle":16977,"status":107,"phases":35997,"primaryCompletion":16979,"completion":16979,"start":16980,"enrollment":16981,"conditions":35998,"interventions":35999},[92],[16983],[16951,16985,16950,16958],{"nctId":36001,"briefTitle":36002,"status":107,"phases":36003,"primaryCompletion":8681,"completion":8681,"start":16669,"enrollment":2733,"conditions":36004,"interventions":36005},"NCT00776425","A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies",[92],[24],[16023],{"nctId":36007,"briefTitle":36008,"status":107,"phases":36009,"primaryCompletion":36010,"completion":36010,"start":36011,"enrollment":1847,"conditions":36012,"interventions":36013},"NCT02145026","A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)",[92],"2019-04-09","2014-08-06",[1206],[16023],{"nctId":36015,"briefTitle":36016,"status":130,"phases":36017,"primaryCompletion":2769,"completion":2769,"start":8810,"enrollment":462,"conditions":36018,"interventions":36019},"NCT02624141","A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy",[92],[24],[16950],{"trials":36021,"activeCount":101},[36022],{"nctId":36023,"briefTitle":36024,"status":107,"phases":36025,"primaryCompletion":3022,"completion":3022,"start":4198,"enrollment":36026,"conditions":36027,"interventions":36028},"NCT01809314","An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy",[],1167,[24],[16023],{"intervention":18860,"totalTrials":721,"cells":36030},{"EARLY_PHASE1":36031,"PHASE1":36033,"PHASE2":36035,"PHASE3":36037,"PHASE4":36074,"NA":36130},{"trials":36032,"activeCount":101},[],{"trials":36034,"activeCount":101},[],{"trials":36036,"activeCount":101},[],{"trials":36038,"activeCount":101},[36039,36048,36054,36061,36068],{"nctId":36040,"briefTitle":36041,"status":107,"phases":36042,"primaryCompletion":4410,"completion":4410,"start":36043,"enrollment":36044,"conditions":36045,"interventions":36046},"NCT00048061","MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis",[91],"2002-04",1609,[16765],[36047,36047,36047,36047],"Ibandronate [Bonviva\u002FBoniva]",{"nctId":36049,"briefTitle":36050,"status":107,"phases":36051,"primaryCompletion":5364,"completion":5364,"start":14712,"enrollment":2440,"conditions":36052,"interventions":36053},"NCT01290094","A Study of Bonviva\u002FBoniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis",[91],[16765],[18860],{"nctId":36055,"briefTitle":36056,"status":107,"phases":36057,"primaryCompletion":122,"completion":122,"start":34823,"enrollment":36058,"conditions":36059,"interventions":36060},"NCT00048074","DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis",[91],1395,[16765],[18860,18860,18860],{"nctId":36062,"briefTitle":36063,"status":107,"phases":36064,"primaryCompletion":2932,"completion":2932,"enrollment":2839,"conditions":36065,"interventions":36067},"NCT00545207","A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.",[91],[36066],"Post-Menopausal Osteopenia",[18860],{"nctId":36069,"briefTitle":36070,"status":107,"phases":36071,"primaryCompletion":2769,"completion":2769,"start":6377,"enrollment":4683,"conditions":36072,"interventions":36073},"NCT00493623","BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.",[91],[16750],[18860],{"trials":36075,"activeCount":101},[36076,36083,36090,36096,36100,36106,36113,36120,36124],{"nctId":36077,"briefTitle":36078,"status":107,"phases":36079,"primaryCompletion":8826,"completion":8826,"start":4315,"enrollment":36080,"conditions":36081,"interventions":36082},"NCT00503113","A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.",[92],801,[16679],[18860,18860,16744],{"nctId":36084,"briefTitle":36085,"status":107,"phases":36086,"primaryCompletion":8688,"completion":8688,"start":8811,"enrollment":36087,"conditions":36088,"interventions":36089},"NCT00551174","A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment",[92],781,[16679],[18860,18860],{"nctId":36091,"briefTitle":36092,"status":107,"phases":36093,"primaryCompletion":5820,"completion":4281,"start":17135,"enrollment":4671,"conditions":36094,"interventions":36095},"NCT00081653","A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva",[92],[16679],[18860,18860],{"nctId":18855,"briefTitle":18856,"status":107,"phases":36097,"primaryCompletion":6377,"completion":6377,"start":4446,"enrollment":6514,"conditions":36098,"interventions":36099},[92],[16765],[18842,18860],{"nctId":36101,"briefTitle":36102,"status":107,"phases":36103,"primaryCompletion":4513,"completion":4513,"start":5469,"enrollment":3923,"conditions":36104,"interventions":36105},"NCT00129623","A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia",[92],[36066],[18860],{"nctId":36107,"briefTitle":36108,"status":107,"phases":36109,"primaryCompletion":14572,"completion":14572,"start":5457,"enrollment":36110,"conditions":36111,"interventions":36112},"NCT00545090","ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.",[92],561,[16765],[18860],{"nctId":36114,"briefTitle":36115,"status":107,"phases":36116,"primaryCompletion":3085,"completion":3085,"start":4455,"enrollment":36117,"conditions":36118,"interventions":36119},"NCT00545909","BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis",[92],585,[16716],[18860,18860],{"nctId":19095,"briefTitle":19096,"status":107,"phases":36121,"primaryCompletion":3085,"completion":3085,"start":4282,"enrollment":19098,"conditions":36122,"interventions":36123},[92],[16765],[19082,18860],{"nctId":36125,"briefTitle":36126,"status":107,"phases":36127,"primaryCompletion":3325,"completion":3325,"start":9771,"enrollment":9720,"conditions":36128,"interventions":36129},"NCT00545480","SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.",[92],[16765],[18860,18860],{"trials":36131,"activeCount":101},[36132,36140],{"nctId":36133,"briefTitle":36134,"status":107,"phases":36135,"primaryCompletion":2905,"completion":2905,"start":8826,"enrollment":36136,"conditions":36137,"interventions":36138},"NCT01128257","A Study of Ibandronate [Bonviva\u002FBoniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis",[],6054,[16716],[36139,18860],"alendronate",{"nctId":36141,"briefTitle":36142,"status":6886,"phases":36143,"primaryCompletion":4474,"completion":4474,"start":6377,"conditions":36144,"interventions":36145},"NCT00493532","A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.",[],[16716],[18860],{"intervention":17976,"totalTrials":2619,"cells":36147},{"EARLY_PHASE1":36148,"PHASE1":36150,"PHASE2":36162,"PHASE3":36188,"PHASE4":36194,"NA":36216},{"trials":36149,"activeCount":101},[],{"trials":36151,"activeCount":101},[36152,36156],{"nctId":31160,"briefTitle":31161,"status":107,"phases":36153,"primaryCompletion":6315,"completion":6315,"start":8320,"enrollment":931,"conditions":36154,"interventions":36155},[89],[21],[17976,31153],{"nctId":36157,"briefTitle":36158,"status":107,"phases":36159,"primaryCompletion":2948,"completion":2948,"start":3146,"enrollment":931,"conditions":36160,"interventions":36161},"NCT01697436","A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets",[89],[21],[17976,17976,17976,17976],{"trials":36163,"activeCount":101},[36164,36168,36172,36176,36180,36184],{"nctId":19360,"briefTitle":19361,"status":343,"phases":36165,"primaryCompletion":3197,"completion":3197,"start":3007,"enrollment":101,"conditions":36166,"interventions":36167},[90],[27],[17034,17034,11967,17072,17976,11969],{"nctId":25608,"briefTitle":25609,"status":107,"phases":36169,"primaryCompletion":4445,"completion":4445,"start":5891,"enrollment":25611,"conditions":36170,"interventions":36171},[90],[27],[17072,17976,19280],{"nctId":19380,"briefTitle":19381,"status":107,"phases":36173,"primaryCompletion":2956,"completion":2956,"start":3213,"enrollment":1283,"conditions":36174,"interventions":36175},[90],[27],[17034,17019,19385,17976,11969],{"nctId":19387,"briefTitle":19388,"status":107,"phases":36177,"primaryCompletion":2809,"completion":2809,"start":4233,"enrollment":13516,"conditions":36178,"interventions":36179},[90],[27],[19392,17034,11967,17072,17976,11969],{"nctId":24874,"briefTitle":24875,"status":107,"phases":36181,"primaryCompletion":2793,"completion":2793,"start":6578,"enrollment":4489,"conditions":36182,"interventions":36183},[90],[27],[17034,24879,17072],{"nctId":28695,"briefTitle":28696,"status":107,"phases":36185,"primaryCompletion":3006,"completion":3006,"start":3029,"enrollment":34,"conditions":36186,"interventions":36187},[90],[27],[28686,28686,17072,17072,17976,17976],{"trials":36189,"activeCount":101},[36190],{"nctId":34796,"briefTitle":34797,"status":343,"phases":36191,"primaryCompletion":2769,"completion":2769,"start":2769,"enrollment":101,"conditions":36192,"interventions":36193},[91],[27],[17072,17976,17976],{"trials":36195,"activeCount":101},[36196,36200,36204,36208,36212],{"nctId":35645,"briefTitle":35646,"status":107,"phases":36197,"primaryCompletion":8681,"completion":8681,"start":4233,"enrollment":14873,"conditions":36198,"interventions":36199},[92],[27],[35031,17976],{"nctId":18546,"briefTitle":18547,"status":107,"phases":36201,"primaryCompletion":5469,"completion":5469,"start":8260,"enrollment":291,"conditions":36202,"interventions":36203},[92],[27],[17976,17976,18533,18533],{"nctId":34859,"briefTitle":34860,"status":107,"phases":36205,"primaryCompletion":2830,"completion":2830,"start":3103,"enrollment":1184,"conditions":36206,"interventions":36207},[92],[27],[17072,17976],{"nctId":34923,"briefTitle":34924,"status":107,"phases":36209,"primaryCompletion":3096,"completion":3096,"start":34926,"enrollment":281,"conditions":36210,"interventions":36211},[92],[27],[17072,17976],{"nctId":17971,"briefTitle":17972,"status":107,"phases":36213,"primaryCompletion":4474,"completion":4474,"start":121,"enrollment":1259,"conditions":36214,"interventions":36215},[92],[27],[17072,17976,17977],{"trials":36217,"activeCount":101},[36218],{"nctId":34975,"briefTitle":34976,"status":107,"phases":36219,"primaryCompletion":5181,"completion":5181,"start":8688,"enrollment":34978,"conditions":36220,"interventions":36221},[],[27],[17072,17976],{"intervention":17773,"totalTrials":13060,"cells":36223},{"EARLY_PHASE1":36224,"PHASE1":36226,"PHASE2":36232,"PHASE3":36234,"PHASE4":36248,"NA":36254},{"trials":36225,"activeCount":101},[],{"trials":36227,"activeCount":101},[36228],{"nctId":26636,"briefTitle":26637,"status":107,"phases":36229,"enrollment":425,"conditions":36230,"interventions":36231},[89],[17753,33],[16478,16488,17773],{"trials":36233,"activeCount":101},[],{"trials":36235,"activeCount":101},[36236,36244],{"nctId":36237,"briefTitle":36238,"status":107,"phases":36239,"primaryCompletion":36240,"completion":36240,"start":35454,"conditions":36241,"interventions":36243},"NCT00002377","A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes",[91],"2002-12",[36242,33],"Cytomegalovirus Retinitis",[24169,17773],{"nctId":24164,"briefTitle":24165,"status":107,"phases":36245,"primaryCompletion":8341,"completion":8341,"start":4282,"enrollment":3880,"conditions":36246,"interventions":36247},[91],[17753],[24153,24169,17773],{"trials":36249,"activeCount":101},[36250],{"nctId":17768,"briefTitle":17769,"status":107,"phases":36251,"primaryCompletion":3085,"completion":3085,"start":15950,"enrollment":3414,"conditions":36252,"interventions":36253},[92],[17753],[17773,17735],{"trials":36255,"activeCount":101},[36256,36262,36268,36274,36281,36288,36294,36300,36306,36312],{"nctId":36257,"briefTitle":36258,"status":107,"phases":36259,"enrollment":2839,"conditions":36260,"interventions":36261},"NCT00002257","A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS",[93],[36242,33],[17773],{"nctId":36263,"briefTitle":36264,"status":107,"phases":36265,"enrollment":2349,"conditions":36266,"interventions":36267},"NCT00002095","A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus",[93],[17753,33],[17773],{"nctId":36269,"briefTitle":36270,"status":107,"phases":36271,"enrollment":2375,"conditions":36272,"interventions":36273},"NCT00002251","A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir",[93],[17753,33],[17773],{"nctId":36275,"briefTitle":36276,"status":107,"phases":36277,"conditions":36278,"interventions":36279},"NCT00002299","The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS",[93],[36242,33],[36280,17773],"Interferon beta-1b",{"nctId":36282,"briefTitle":36283,"status":107,"phases":36284,"conditions":36285,"interventions":36287},"NCT00002273","A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS",[93],[36286,33],"Colitis",[17773],{"nctId":36289,"briefTitle":36290,"status":107,"phases":36291,"conditions":36292,"interventions":36293},"NCT00002024","Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections",[93],[17753,33],[17773],{"nctId":36295,"briefTitle":36296,"status":107,"phases":36297,"conditions":36298,"interventions":36299},"NCT00002025","Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient",[93],[17753,36242,33],[17773],{"nctId":36301,"briefTitle":36302,"status":107,"phases":36303,"conditions":36304,"interventions":36305},"NCT00002135","An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access",[93],[36242,33],[17773],{"nctId":36307,"briefTitle":36308,"status":107,"phases":36309,"enrollment":1847,"conditions":36310,"interventions":36311},"NCT00002034","A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS",[93],[36242,33],[16478,17773],{"nctId":36313,"briefTitle":36314,"status":107,"phases":36315,"enrollment":8322,"conditions":36316,"interventions":36317},"NCT00002247","A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy",[93],[36242,33],[17773],{"intervention":5390,"totalTrials":13060,"cells":36319},{"EARLY_PHASE1":36320,"PHASE1":36322,"PHASE2":36334,"PHASE3":36370,"PHASE4":36380,"NA":36388},{"trials":36321,"activeCount":101},[],{"trials":36323,"activeCount":101},[36324,36330],{"nctId":36325,"briefTitle":36326,"status":107,"phases":36327,"primaryCompletion":3103,"completion":3103,"start":14712,"enrollment":1651,"conditions":36328,"interventions":36329},"NCT01344863","A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe",[89],[21],[5390,5390],{"nctId":5373,"briefTitle":5374,"status":130,"phases":36331,"primaryCompletion":2948,"completion":2948,"start":3479,"enrollment":5376,"conditions":36332,"interventions":36333},[89],[1241],[5379,5380,5275,5381,5367,5382,5383,5384,5385,5186,4102,5386,4503,5387,5388,5389,5390],{"trials":36335,"activeCount":101},[36336,36340,36346,36350,36354,36358,36362,36366],{"nctId":15828,"briefTitle":15829,"status":130,"phases":36337,"primaryCompletion":2948,"completion":2948,"start":2905,"enrollment":5110,"conditions":36338,"interventions":36339},[90],[18],[5381,5390],{"nctId":36341,"briefTitle":36342,"status":130,"phases":36343,"primaryCompletion":3213,"completion":3213,"start":3189,"enrollment":706,"conditions":36344,"interventions":36345},"NCT01363986","A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer",[90],[18],[5390],{"nctId":15834,"briefTitle":15835,"status":107,"phases":36347,"primaryCompletion":2847,"completion":2847,"start":4562,"enrollment":736,"conditions":36348,"interventions":36349},[90],[18],[5275,5381,5390],{"nctId":15856,"briefTitle":15857,"status":107,"phases":36351,"primaryCompletion":15859,"completion":15859,"start":15860,"enrollment":395,"conditions":36352,"interventions":36353},[90],[18],[15863,5381,5390],{"nctId":20823,"briefTitle":20824,"status":107,"phases":36355,"primaryCompletion":8826,"completion":5418,"start":8934,"enrollment":973,"conditions":36356,"interventions":36357},[90],[18],[9587,5275,5390],{"nctId":8966,"briefTitle":8967,"status":107,"phases":36359,"primaryCompletion":3174,"completion":3174,"start":7095,"enrollment":1058,"conditions":36360,"interventions":36361},[90],[1735],[8971,1165,8972],{"nctId":29038,"briefTitle":29039,"status":107,"phases":36363,"primaryCompletion":9079,"completion":9079,"start":7096,"enrollment":22,"conditions":36364,"interventions":36365},[90],[18],[29029,5390],{"nctId":9600,"briefTitle":9601,"status":343,"phases":36367,"primaryCompletion":6157,"completion":6157,"start":2964,"enrollment":101,"conditions":36368,"interventions":36369},[90],[18],[5275,5381,5383,5390],{"trials":36371,"activeCount":101},[36372,36376],{"nctId":9680,"briefTitle":9681,"status":107,"phases":36373,"primaryCompletion":9683,"completion":9683,"start":9684,"enrollment":9685,"conditions":36374,"interventions":36375},[91],[18],[947,9688,5390],{"nctId":8123,"briefTitle":8124,"status":107,"phases":36377,"primaryCompletion":8126,"completion":8127,"start":8128,"enrollment":8129,"conditions":36378,"interventions":36379},[91],[18],[5383,4503,5472,8132,5390,8133],{"trials":36381,"activeCount":101},[36382],{"nctId":36383,"briefTitle":36384,"status":130,"phases":36385,"primaryCompletion":6195,"completion":6195,"start":8320,"enrollment":5110,"conditions":36386,"interventions":36387},"NCT01260194","A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer",[92],[1735],[5390],{"trials":36389,"activeCount":101},[36390],{"nctId":36391,"briefTitle":36392,"status":107,"phases":36393,"primaryCompletion":36394,"completion":36394,"start":36395,"enrollment":36396,"conditions":36397,"interventions":36398},"NCT01152606","A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin",[],"2016-05-31","2007-08-30",3942,[18],[5390],{"intervention":12796,"totalTrials":709,"cells":36400},{"EARLY_PHASE1":36401,"PHASE1":36403,"PHASE2":36425,"PHASE3":36427,"PHASE4":36456,"NA":36475},{"trials":36402,"activeCount":101},[],{"trials":36404,"activeCount":101},[36405,36412,36418],{"nctId":36406,"briefTitle":36407,"status":107,"phases":36408,"primaryCompletion":36409,"completion":36409,"start":1341,"enrollment":2375,"conditions":36410,"interventions":36411},"NCT01715909","A Pharmacokinetic\u002FPharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection",[89],"2018-06-17",[12770],[12796],{"nctId":36413,"briefTitle":36414,"status":107,"phases":36415,"primaryCompletion":3104,"completion":3104,"start":2769,"enrollment":559,"conditions":36416,"interventions":36417},"NCT02717754","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants",[89],[21],[12796],{"nctId":36419,"briefTitle":36420,"status":107,"phases":36421,"primaryCompletion":34823,"completion":34823,"start":15886,"enrollment":425,"conditions":36422,"interventions":36424},"NCT02617784","A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)",[89],[36423],"End Stage Renal Disease",[12796],{"trials":36426,"activeCount":101},[],{"trials":36428,"activeCount":101},[36429,36433,36442,36448,36452],{"nctId":22683,"briefTitle":22684,"status":107,"phases":36430,"primaryCompletion":3146,"completion":3146,"start":4206,"enrollment":22686,"conditions":36431,"interventions":36432},[91],[12770],[22672,12796],{"nctId":36434,"briefTitle":36435,"status":107,"phases":36436,"primaryCompletion":20774,"completion":20774,"start":36437,"enrollment":1148,"conditions":36438,"interventions":36440},"NCT00545532","A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.",[91],"2008-02-04",[36439],"Influenza, Human",[36441],"oseltamivir",{"nctId":36443,"briefTitle":36444,"status":107,"phases":36445,"primaryCompletion":2906,"completion":2906,"start":5271,"enrollment":15799,"conditions":36446,"interventions":36447},"NCT00949533","A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza",[91],[12770],[12796],{"nctId":12790,"briefTitle":12791,"status":107,"phases":36449,"primaryCompletion":2263,"completion":2263,"start":12793,"enrollment":1847,"conditions":36450,"interventions":36451},[91],[12770],[12752,12796],{"nctId":12798,"briefTitle":12799,"status":107,"phases":36453,"primaryCompletion":12801,"completion":12801,"start":12802,"enrollment":12803,"conditions":36454,"interventions":36455},[91],[12770],[12752,12796],{"trials":36457,"activeCount":101},[36458,36462,36468],{"nctId":18661,"briefTitle":18662,"status":107,"phases":36459,"primaryCompletion":6343,"completion":6343,"start":4086,"enrollment":2375,"conditions":36460,"interventions":36461},[92],[18665],[12796,18648],{"nctId":36463,"briefTitle":36464,"status":130,"phases":36465,"primaryCompletion":2906,"completion":2906,"start":3084,"enrollment":3247,"conditions":36466,"interventions":36467},"NCT01032837","A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain",[92],[12770],[12796,12796],{"nctId":36469,"briefTitle":36470,"status":107,"phases":36471,"primaryCompletion":4281,"completion":4281,"start":16669,"enrollment":36472,"conditions":36473,"interventions":36474},"NCT00412737","A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants",[92],477,[12770],[12796],{"trials":36476,"activeCount":101},[36477],{"nctId":36478,"briefTitle":36479,"status":107,"phases":36480,"primaryCompletion":3478,"completion":3478,"start":3308,"enrollment":36481,"conditions":36482,"interventions":36483},"NCT00884117","Influenza Resistance Information Study",[],4561,[12770],[12796],{"intervention":18885,"totalTrials":2563,"cells":36485},{"EARLY_PHASE1":36486,"PHASE1":36488,"PHASE2":36503,"PHASE3":36528,"PHASE4":36536,"NA":36542},{"trials":36487,"activeCount":101},[],{"trials":36489,"activeCount":101},[36490,36497],{"nctId":36491,"briefTitle":36492,"status":107,"phases":36493,"primaryCompletion":2229,"completion":2229,"start":36494,"enrollment":3939,"conditions":36495,"interventions":36496},"NCT02648048","A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis",[89],"2016-01-15",[18883],[18885,1770],{"nctId":36498,"briefTitle":36499,"status":107,"phases":36500,"primaryCompletion":2955,"completion":2955,"start":2955,"enrollment":4886,"conditions":36501,"interventions":36502},"NCT02525484","A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants",[89],[21],[18885],{"trials":36504,"activeCount":101},[36505,36509,36520,36524],{"nctId":27209,"briefTitle":27210,"status":107,"phases":36506,"primaryCompletion":4884,"completion":27212,"start":27213,"enrollment":7619,"conditions":36507,"interventions":36508},[90],[18883],[18885,27200],{"nctId":36510,"briefTitle":36511,"status":107,"phases":36512,"primaryCompletion":36513,"completion":36514,"start":36515,"enrollment":36516,"conditions":36517,"interventions":36519},"NCT03099187","A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease",[90],"2018-11-21","2020-01-10","2017-05-15",253,[36518],"Lung Diseases, Interstitial",[18885],{"nctId":20008,"briefTitle":20009,"status":107,"phases":36521,"primaryCompletion":20011,"completion":20012,"start":20013,"enrollment":6425,"conditions":36522,"interventions":36523},[90],[18883],[19991,18885],{"nctId":28853,"briefTitle":28854,"status":107,"phases":36525,"primaryCompletion":3006,"completion":3006,"start":6157,"enrollment":1548,"conditions":36526,"interventions":36527},[90],[18883],[28844,18885],{"trials":36529,"activeCount":101},[36530],{"nctId":36531,"briefTitle":36532,"status":107,"phases":36533,"primaryCompletion":1213,"completion":1213,"start":3254,"enrollment":336,"conditions":36534,"interventions":36535},"NCT03208933","Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).",[91],[18883],[18885],{"trials":36537,"activeCount":101},[36538],{"nctId":18877,"briefTitle":18878,"status":107,"phases":36539,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":25,"conditions":36540,"interventions":36541},[92],[18883],[18864,18885],{"trials":36543,"activeCount":101},[36544,36551,36559],{"nctId":36545,"briefTitle":36546,"status":107,"phases":36547,"primaryCompletion":36548,"completion":36548,"start":3174,"enrollment":709,"conditions":36549,"interventions":36550},"NCT02622477","Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)",[],"2016-12",[18883],[18885],{"nctId":36552,"briefTitle":36553,"status":107,"phases":36554,"primaryCompletion":4571,"completion":4571,"start":36555,"enrollment":36556,"conditions":36557,"interventions":36558},"NCT02699879","Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)",[],"2012-02-16",1009,[18883],[18885],{"nctId":36560,"briefTitle":36561,"status":107,"phases":36562,"primaryCompletion":36514,"completion":36514,"start":36563,"enrollment":3247,"conditions":36564,"interventions":36565},"NCT03115619","Quality of Life Study in Participants With IPF Under Pirfenidone Treatment",[],"2017-04-18",[18883],[18885],{"intervention":2496,"totalTrials":2563,"cells":36567},{"EARLY_PHASE1":36568,"PHASE1":36570,"PHASE2":36576,"PHASE3":36586,"PHASE4":36608,"NA":36618},{"trials":36569,"activeCount":101},[],{"trials":36571,"activeCount":101},[36572],{"nctId":2487,"briefTitle":2488,"status":130,"phases":36573,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":2492,"conditions":36574,"interventions":36575},[89],[2494],[2496,1018,1096],{"trials":36577,"activeCount":101},[36578,36582],{"nctId":6077,"briefTitle":6078,"status":107,"phases":36579,"primaryCompletion":2793,"completion":2793,"start":5820,"enrollment":1847,"conditions":36580,"interventions":36581},[90],[3741],[1359,2496],{"nctId":35462,"briefTitle":35463,"status":107,"phases":36583,"primaryCompletion":35465,"completion":35465,"start":35466,"enrollment":8990,"conditions":36584,"interventions":36585},[90],[3741],[5837,3743],{"trials":36587,"activeCount":101},[36588,36592,36596,36600,36604],{"nctId":3733,"briefTitle":3734,"status":107,"phases":36589,"primaryCompletion":3736,"completion":3737,"start":3738,"enrollment":3739,"conditions":36590,"interventions":36591},[91],[3741],[3669,3677,3743],{"nctId":3757,"briefTitle":3758,"status":107,"phases":36593,"primaryCompletion":3760,"completion":1439,"start":3761,"enrollment":3762,"conditions":36594,"interventions":36595},[91],[3741],[2496,1073,1018],{"nctId":3787,"briefTitle":3788,"status":107,"phases":36597,"primaryCompletion":3790,"completion":3737,"start":3791,"enrollment":3739,"conditions":36598,"interventions":36599},[91],[3741],[3669,3677,3743],{"nctId":3833,"briefTitle":3834,"status":107,"phases":36601,"primaryCompletion":3836,"completion":3737,"start":3837,"enrollment":3739,"conditions":36602,"interventions":36603},[91],[3741],[3669,3677,3743],{"nctId":3841,"briefTitle":3842,"status":107,"phases":36605,"primaryCompletion":3844,"completion":3845,"start":3846,"enrollment":3847,"conditions":36606,"interventions":36607},[91],[2431],[1356,2496,992,3482,1018],{"trials":36609,"activeCount":101},[36610,36614],{"nctId":11681,"briefTitle":11682,"status":107,"phases":36611,"primaryCompletion":3197,"completion":3197,"start":4555,"enrollment":11684,"conditions":36612,"interventions":36613},[92],[3741],[3668,3743,5837],{"nctId":6390,"briefTitle":6391,"status":130,"phases":36615,"primaryCompletion":6393,"completion":6393,"start":6394,"enrollment":316,"conditions":36616,"interventions":36617},[92],[3741],[2496,992,3482,1359],{"trials":36619,"activeCount":101},[36620],{"nctId":3884,"briefTitle":3885,"status":107,"phases":36621,"primaryCompletion":3887,"completion":3887,"start":3888,"enrollment":37,"conditions":36622,"interventions":36623},[],[2431],[2496,1018],{"intervention":1770,"totalTrials":462,"cells":36625},{"EARLY_PHASE1":36626,"PHASE1":36628,"PHASE2":36638,"PHASE3":36680,"PHASE4":36682,"NA":36684},{"trials":36627,"activeCount":101},[],{"trials":36629,"activeCount":101},[36630,36634],{"nctId":36491,"briefTitle":36492,"status":107,"phases":36631,"primaryCompletion":2229,"completion":2229,"start":36494,"enrollment":3939,"conditions":36632,"interventions":36633},[89],[18883],[18885,1770],{"nctId":26661,"briefTitle":26662,"status":107,"phases":36635,"primaryCompletion":21060,"completion":26664,"start":4032,"enrollment":462,"conditions":36636,"interventions":36637},[89],[26666],[26654,1770],{"trials":36639,"activeCount":101},[36640,36649,36656,36660,36669,36673],{"nctId":36641,"briefTitle":36642,"status":130,"phases":36643,"primaryCompletion":36644,"completion":36644,"start":36645,"enrollment":5901,"conditions":36646,"interventions":36648},"NCT01898598","A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma",[90],"2016-01-26","2014-01-23",[36647],"Basal Cell Carcinoma",[1770],{"nctId":36650,"briefTitle":36651,"status":107,"phases":36652,"primaryCompletion":4434,"completion":19629,"start":36653,"enrollment":549,"conditions":36654,"interventions":36655},"NCT01815840","A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas",[90],"2013-04-30",[36647],[1770],{"nctId":20274,"briefTitle":20275,"status":130,"phases":36657,"primaryCompletion":11550,"completion":11550,"start":2684,"enrollment":2492,"conditions":36658,"interventions":36659},[90],[20278],[20240,20280],{"nctId":36661,"briefTitle":36662,"status":107,"phases":36663,"primaryCompletion":36664,"completion":36664,"start":36665,"enrollment":36666,"conditions":36667,"interventions":36668},"NCT01367665","STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma",[90],"2017-06-14","2011-07-01",1232,[36647],[20280],{"nctId":1760,"briefTitle":1761,"status":107,"phases":36670,"primaryCompletion":1763,"completion":1764,"start":1765,"enrollment":1766,"conditions":36671,"interventions":36672},[90],[1768],[43,1770,946,1423,977,1015,1479,1084,1771,1221,68,990,1106,1167,1163,1695,1772,1773],{"nctId":36674,"briefTitle":36675,"status":343,"phases":36676,"primaryCompletion":36677,"completion":36677,"start":5418,"enrollment":101,"conditions":36678,"interventions":36679},"NCT02168530","A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)",[90],"2017-01",[18883],[20280],{"trials":36681,"activeCount":101},[],{"trials":36683,"activeCount":101},[],{"trials":36685,"activeCount":101},[36686,36694],{"nctId":36687,"briefTitle":36688,"status":107,"phases":36689,"primaryCompletion":36690,"completion":36690,"start":31224,"enrollment":6514,"conditions":36691,"interventions":36693},"NCT02674009","Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)",[],"2019-03-31",[36692],"Carcinoma, Basal Cell",[1770],{"nctId":36695,"briefTitle":36696,"status":107,"phases":36697,"primaryCompletion":30325,"completion":30325,"start":36698,"enrollment":37,"conditions":36699,"interventions":36700},"NCT02371967","A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)",[],"2015-04-08",[36647],[1770],{"intervention":16478,"totalTrials":462,"cells":36702},{"EARLY_PHASE1":36703,"PHASE1":36705,"PHASE2":36711,"PHASE3":36725,"PHASE4":36746,"NA":36748},{"trials":36704,"activeCount":101},[],{"trials":36706,"activeCount":101},[36707],{"nctId":26636,"briefTitle":26637,"status":107,"phases":36708,"enrollment":425,"conditions":36709,"interventions":36710},[89],[17753,33],[16478,16488,17773],{"trials":36712,"activeCount":101},[36713,36717,36721],{"nctId":16472,"briefTitle":16473,"status":107,"phases":36714,"primaryCompletion":16475,"enrollment":4811,"conditions":36715,"interventions":36716},[90],[33],[16450,16478,16479],{"nctId":16481,"briefTitle":16482,"status":107,"phases":36718,"enrollment":1026,"conditions":36719,"interventions":36720},[90],[33],[16450,16486,16487,16478,16479,16488],{"nctId":16496,"briefTitle":16497,"status":107,"phases":36722,"enrollment":1184,"conditions":36723,"interventions":36724},[90],[33],[16450,16486,16478],{"trials":36726,"activeCount":101},[36727,36731,36735,36742],{"nctId":16534,"briefTitle":16535,"status":107,"phases":36728,"enrollment":16537,"conditions":36729,"interventions":36730},[91],[33],[16450,16478,16479],{"nctId":16547,"briefTitle":16548,"status":107,"phases":36732,"enrollment":16550,"conditions":36733,"interventions":36734},[91],[33],[11782,16468,16450,16510,16486,16487,16478],{"nctId":36736,"briefTitle":36737,"status":107,"phases":36738,"enrollment":36739,"conditions":36740,"interventions":36741},"NCT00002117","A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection",[91],528,[33],[16478,16479],{"nctId":16554,"briefTitle":16555,"status":107,"phases":36743,"enrollment":931,"conditions":36744,"interventions":36745},[91],[33],[16450,16486,16478],{"trials":36747,"activeCount":101},[],{"trials":36749,"activeCount":101},[36750,36756],{"nctId":36751,"briefTitle":36752,"status":107,"phases":36753,"conditions":36754,"interventions":36755},"NCT00002081","Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease",[93],[33],[16478,16479],{"nctId":36307,"briefTitle":36308,"status":107,"phases":36757,"enrollment":1847,"conditions":36758,"interventions":36759},[93],[36242,33],[16478,17773],{"intervention":16479,"totalTrials":462,"cells":36761},{"EARLY_PHASE1":36762,"PHASE1":36764,"PHASE2":36766,"PHASE3":36786,"PHASE4":36796,"NA":36798},{"trials":36763,"activeCount":101},[],{"trials":36765,"activeCount":101},[],{"trials":36767,"activeCount":101},[36768,36772,36778,36782],{"nctId":16472,"briefTitle":16473,"status":107,"phases":36769,"primaryCompletion":16475,"enrollment":4811,"conditions":36770,"interventions":36771},[90],[33],[16450,16478,16479],{"nctId":36773,"briefTitle":36774,"status":107,"phases":36775,"conditions":36776,"interventions":36777},"NCT00002265","An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492",[90],[33],[16479],{"nctId":16481,"briefTitle":16482,"status":107,"phases":36779,"enrollment":1026,"conditions":36780,"interventions":36781},[90],[33],[16450,16486,16487,16478,16479,16488],{"nctId":16490,"briefTitle":16491,"status":107,"phases":36783,"enrollment":11202,"conditions":36784,"interventions":36785},[90],[33],[16450,16479],{"trials":36787,"activeCount":101},[36788,36792],{"nctId":16534,"briefTitle":16535,"status":107,"phases":36789,"enrollment":16537,"conditions":36790,"interventions":36791},[91],[33],[16450,16478,16479],{"nctId":36736,"briefTitle":36737,"status":107,"phases":36793,"enrollment":36739,"conditions":36794,"interventions":36795},[91],[33],[16478,16479],{"trials":36797,"activeCount":101},[],{"trials":36799,"activeCount":101},[36800,36806,36812,36818],{"nctId":36801,"briefTitle":36802,"status":107,"phases":36803,"enrollment":3996,"conditions":36804,"interventions":36805},"NCT00002118","An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies",[93],[33],[16479],{"nctId":36807,"briefTitle":36808,"status":107,"phases":36809,"conditions":36810,"interventions":36811},"NCT00002256","Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.",[93],[33],[16479],{"nctId":36813,"briefTitle":36814,"status":107,"phases":36815,"conditions":36816,"interventions":36817},"NCT00002279","A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)",[93],[33],[16479],{"nctId":36751,"briefTitle":36752,"status":107,"phases":36819,"conditions":36820,"interventions":36821},[93],[33],[16478,16479],{"intervention":16992,"totalTrials":306,"cells":36823},{"EARLY_PHASE1":36824,"PHASE1":36826,"PHASE2":36828,"PHASE3":36830,"PHASE4":36840,"NA":36868},{"trials":36825,"activeCount":101},[],{"trials":36827,"activeCount":101},[],{"trials":36829,"activeCount":101},[],{"trials":36831,"activeCount":101},[36832],{"nctId":36833,"briefTitle":36834,"status":107,"phases":36835,"primaryCompletion":8811,"completion":4410,"start":36836,"enrollment":36837,"conditions":36838,"interventions":36839},"NCT00321919","A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia",[91],"2000-07",605,[24],[16992,16992],{"trials":36841,"activeCount":101},[36842,36848,36852,36858,36862],{"nctId":36843,"briefTitle":36844,"status":130,"phases":36845,"conditions":36846,"interventions":36847},"NCT00440063","A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.",[92],[24],[16992],{"nctId":17361,"briefTitle":17362,"status":107,"phases":36849,"primaryCompletion":2685,"completion":2685,"start":4198,"enrollment":4079,"conditions":36850,"interventions":36851},[92],[24],[17011,17366,16992],{"nctId":36853,"briefTitle":36854,"status":107,"phases":36855,"completion":4198,"enrollment":37,"conditions":36856,"interventions":36857},"NCT00413101","A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.",[92],[24],[16992],{"nctId":16987,"briefTitle":16988,"status":107,"phases":36859,"primaryCompletion":6377,"completion":6377,"start":6277,"enrollment":123,"conditions":36860,"interventions":36861},[92],[24],[16065,16992],{"nctId":36863,"briefTitle":36864,"status":107,"phases":36865,"completion":4582,"enrollment":2743,"conditions":36866,"interventions":36867},"NCT00437723","A Study of NeoRecormon in Patients With Chronic Kidney Disease.",[92],[24],[16992],{"trials":36869,"activeCount":101},[36870,36876],{"nctId":36871,"briefTitle":36872,"status":107,"phases":36873,"primaryCompletion":3213,"completion":3213,"start":4562,"enrollment":680,"conditions":36874,"interventions":36875},"NCT01105494","An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia",[],[24],[16992],{"nctId":36877,"briefTitle":36878,"status":107,"phases":36879,"primaryCompletion":4474,"completion":4474,"start":4206,"enrollment":36880,"conditions":36881,"interventions":36883},"NCT01168349","An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)",[],1060,[36882],"Anemia, Neoplasms",[16992],{"intervention":2382,"totalTrials":942,"cells":36885},{"EARLY_PHASE1":36886,"PHASE1":36888,"PHASE2":36894,"PHASE3":36896,"PHASE4":36906,"NA":36916},{"trials":36887,"activeCount":101},[],{"trials":36889,"activeCount":101},[36890],{"nctId":2370,"briefTitle":2371,"status":107,"phases":36891,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":36892,"interventions":36893},[89],[2377,2378,2379],[2381,1096,1018,2382],{"trials":36895,"activeCount":101},[],{"trials":36897,"activeCount":101},[36898,36902],{"nctId":20404,"briefTitle":20405,"status":107,"phases":36899,"primaryCompletion":17165,"completion":20407,"start":20408,"enrollment":2323,"conditions":36900,"interventions":36901},[91],[20387],[2382,20375],{"nctId":20412,"briefTitle":20405,"status":107,"phases":36903,"primaryCompletion":20414,"completion":20415,"start":20416,"enrollment":2323,"conditions":36904,"interventions":36905},[91],[20387],[2382,20375],{"trials":36907,"activeCount":101},[36908,36912],{"nctId":15692,"briefTitle":15693,"status":130,"phases":36909,"primaryCompletion":15695,"completion":15695,"start":2931,"enrollment":1036,"conditions":36910,"interventions":36911},[92],[15],[5894,15698,5838,15699],{"nctId":3100,"briefTitle":3101,"status":107,"phases":36913,"primaryCompletion":3103,"completion":3103,"start":3104,"enrollment":3105,"conditions":36914,"interventions":36915},[92],[15],[1096,2382],{"trials":36917,"activeCount":101},[36918],{"nctId":6442,"briefTitle":6443,"status":107,"phases":36919,"primaryCompletion":3324,"completion":3324,"start":2685,"enrollment":2743,"conditions":36920,"interventions":36921},[],[15],[1359,2382,3159,6447],{"intervention":24169,"totalTrials":942,"cells":36923},{"EARLY_PHASE1":36924,"PHASE1":36926,"PHASE2":36928,"PHASE3":36930,"PHASE4":36956,"NA":36965},{"trials":36925,"activeCount":101},[],{"trials":36927,"activeCount":101},[],{"trials":36929,"activeCount":101},[],{"trials":36931,"activeCount":101},[36932,36939,36943,36952],{"nctId":36933,"briefTitle":36934,"status":36935,"phases":36936,"enrollment":211,"conditions":36937,"interventions":36938},"NCT00017784","Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection","UNKNOWN",[91],[36242,33],[24169],{"nctId":36237,"briefTitle":36238,"status":107,"phases":36940,"primaryCompletion":36240,"completion":36240,"start":35454,"conditions":36941,"interventions":36942},[91],[36242,33],[24169,17773],{"nctId":36944,"briefTitle":36945,"status":107,"phases":36946,"primaryCompletion":36947,"completion":36948,"start":36949,"enrollment":3105,"conditions":36950,"interventions":36951},"NCT00294515","IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients",[91],"2008-08-31","2009-08-31","2006-03-31",[17753],[24169,24169],{"nctId":24164,"briefTitle":24165,"status":107,"phases":36953,"primaryCompletion":8341,"completion":8341,"start":4282,"enrollment":3880,"conditions":36954,"interventions":36955},[91],[17753],[24153,24169,17773],{"trials":36957,"activeCount":101},[36958],{"nctId":36959,"briefTitle":36960,"status":107,"phases":36961,"primaryCompletion":20057,"completion":35287,"start":36962,"enrollment":2572,"conditions":36963,"interventions":36964},"NCT01663740","A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls",[92],"2012-01-30",[17753],[24169],{"trials":36966,"activeCount":101},[36967],{"nctId":36968,"briefTitle":36969,"status":107,"phases":36970,"enrollment":2708,"conditions":36971,"interventions":36972},"NCT00002222","A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS",[93],[36242,33],[24169],{"intervention":22297,"totalTrials":2631,"cells":36974},{"EARLY_PHASE1":36975,"PHASE1":36977,"PHASE2":36979,"PHASE3":36981,"PHASE4":36991,"NA":36993},{"trials":36976,"activeCount":101},[],{"trials":36978,"activeCount":101},[],{"trials":36980,"activeCount":101},[],{"trials":36982,"activeCount":101},[36983,36987],{"nctId":22291,"briefTitle":22292,"status":107,"phases":36984,"primaryCompletion":121,"completion":121,"start":8260,"enrollment":1796,"conditions":36985,"interventions":36986},[90,91],[22295,1261,1049],[22297,22280],{"nctId":17602,"briefTitle":17603,"status":107,"phases":36988,"primaryCompletion":3413,"completion":3413,"start":17605,"enrollment":447,"conditions":36989,"interventions":36990},[91],[17607],[17609,16486,17610],{"trials":36992,"activeCount":101},[],{"trials":36994,"activeCount":101},[36995,36999,37003],{"nctId":35136,"briefTitle":35137,"status":107,"phases":36996,"primaryCompletion":2684,"completion":2684,"start":121,"enrollment":35139,"conditions":36997,"interventions":36998},[],[33385],[35142,17366],{"nctId":35160,"briefTitle":35161,"status":107,"phases":37000,"primaryCompletion":35163,"completion":35163,"start":35164,"enrollment":17008,"conditions":37001,"interventions":37002},[],[27],[22297,17366],{"nctId":35174,"briefTitle":35175,"status":130,"phases":37004,"primaryCompletion":2800,"completion":2800,"start":8681,"enrollment":35177,"conditions":37005,"interventions":37006},[],[27],[35180,17366],{"intervention":9083,"totalTrials":2631,"cells":37008},{"EARLY_PHASE1":37009,"PHASE1":37011,"PHASE2":37013,"PHASE3":37027,"PHASE4":37029,"NA":37035},{"trials":37010,"activeCount":101},[],{"trials":37012,"activeCount":101},[],{"trials":37014,"activeCount":101},[37015,37019,37023],{"nctId":21406,"briefTitle":21407,"status":107,"phases":37016,"primaryCompletion":2685,"completion":2685,"start":4315,"enrollment":984,"conditions":37017,"interventions":37018},[90],[1241],[5275,9036,21411,9083],{"nctId":17118,"briefTitle":17119,"status":107,"phases":37020,"primaryCompletion":4455,"completion":121,"start":17121,"enrollment":8322,"conditions":37021,"interventions":37022},[90],[18],[9083,15945,7139],{"nctId":9543,"briefTitle":9544,"status":130,"phases":37024,"primaryCompletion":2963,"completion":2963,"start":5820,"enrollment":145,"conditions":37025,"interventions":37026},[90],[18],[5275,947,9083],{"trials":37028,"activeCount":101},[],{"trials":37030,"activeCount":101},[37031],{"nctId":9076,"briefTitle":9077,"status":107,"phases":37032,"primaryCompletion":9079,"completion":9079,"start":4086,"enrollment":9080,"conditions":37033,"interventions":37034},[92],[30],[5275,1165,9083],{"trials":37036,"activeCount":101},[37037],{"nctId":9768,"briefTitle":9769,"status":107,"phases":37038,"primaryCompletion":2963,"completion":2963,"start":9771,"enrollment":9772,"conditions":37039,"interventions":37040},[],[9774],[947,9083],{"intervention":35149,"totalTrials":5110,"cells":37042},{"EARLY_PHASE1":37043,"PHASE1":37045,"PHASE2":37047,"PHASE3":37053,"PHASE4":37055,"NA":37061},{"trials":37044,"activeCount":101},[],{"trials":37046,"activeCount":101},[],{"trials":37048,"activeCount":101},[37049],{"nctId":17052,"briefTitle":17053,"status":107,"phases":37050,"primaryCompletion":2830,"completion":2830,"start":2685,"enrollment":1724,"conditions":37051,"interventions":37052},[90],[27],[16996,16996,17011,17011,17057,17057,17058,17059,17060,17057],{"trials":37054,"activeCount":101},[],{"trials":37056,"activeCount":101},[37057],{"nctId":18448,"briefTitle":18449,"status":107,"phases":37058,"primaryCompletion":3174,"completion":3174,"start":15695,"enrollment":18451,"conditions":37059,"interventions":37060},[92],[27],[17057,17072,17072,18435,18435],{"trials":37062,"activeCount":101},[37063,37067],{"nctId":35144,"briefTitle":35145,"status":130,"phases":37064,"primaryCompletion":2947,"completion":2947,"start":15740,"enrollment":8583,"conditions":37065,"interventions":37066},[],[27],[35149,35150,26531,17366],{"nctId":35212,"briefTitle":35213,"status":107,"phases":37068,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":35215,"conditions":37069,"interventions":37070},[],[27],[35218,35219,17366,35149,26278],{"intervention":16937,"totalTrials":5110,"cells":37072},{"EARLY_PHASE1":37073,"PHASE1":37075,"PHASE2":37077,"PHASE3":37088,"PHASE4":37094,"NA":37096},{"trials":37074,"activeCount":101},[],{"trials":37076,"activeCount":101},[],{"trials":37078,"activeCount":101},[37079],{"nctId":37080,"briefTitle":37081,"status":107,"phases":37082,"primaryCompletion":37083,"completion":37083,"start":37084,"enrollment":931,"conditions":37085,"interventions":37087},"NCT03552393","Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.",[90],"2021-07-19","2018-08-03",[24,37086],"Renal Insufficiency, Chronic",[16937],{"trials":37089,"activeCount":101},[37090],{"nctId":16932,"briefTitle":16933,"status":107,"phases":37091,"primaryCompletion":7152,"completion":7152,"start":3692,"enrollment":1148,"conditions":37092,"interventions":37093},[91],[24],[16937,16000],{"trials":37095,"activeCount":101},[],{"trials":37097,"activeCount":101},[37098,37105],{"nctId":37099,"briefTitle":37100,"status":107,"phases":37101,"primaryCompletion":6786,"completion":6786,"start":37102,"enrollment":2289,"conditions":37103,"interventions":37104},"NCT01417377","An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)",[],"2010-05-31",[24],[16937],{"nctId":37106,"briefTitle":37107,"status":107,"phases":37108,"primaryCompletion":15695,"completion":15695,"start":6004,"enrollment":37109,"conditions":37110,"interventions":37111},"NCT02263833","An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice",[],748,[35763],[16937],{"intervention":16744,"totalTrials":706,"cells":37113},{"EARLY_PHASE1":37114,"PHASE1":37116,"PHASE2":37118,"PHASE3":37120,"PHASE4":37122,"NA":37132},{"trials":37115,"activeCount":101},[],{"trials":37117,"activeCount":101},[],{"trials":37119,"activeCount":101},[],{"trials":37121,"activeCount":101},[],{"trials":37123,"activeCount":101},[37124,37128],{"nctId":36077,"briefTitle":36078,"status":107,"phases":37125,"primaryCompletion":8826,"completion":8826,"start":4315,"enrollment":36080,"conditions":37126,"interventions":37127},[92],[16679],[18860,18860,16744],{"nctId":16739,"briefTitle":16740,"status":107,"phases":37129,"primaryCompletion":122,"completion":122,"start":8605,"enrollment":1509,"conditions":37130,"interventions":37131},[92],[16716],[16744,16655],{"trials":37133,"activeCount":101},[37134],{"nctId":36133,"briefTitle":36134,"status":107,"phases":37135,"primaryCompletion":2905,"completion":2905,"start":8826,"enrollment":36136,"conditions":37136,"interventions":37137},[],[16716],[36139,18860],{"intervention":2842,"totalTrials":706,"cells":37139},{"EARLY_PHASE1":37140,"PHASE1":37142,"PHASE2":37144,"PHASE3":37146,"PHASE4":37156,"NA":37158},{"trials":37141,"activeCount":101},[],{"trials":37143,"activeCount":101},[],{"trials":37145,"activeCount":101},[],{"trials":37147,"activeCount":101},[37148,37152],{"nctId":2834,"briefTitle":2835,"status":107,"phases":37149,"primaryCompletion":2837,"completion":2837,"start":2838,"enrollment":2839,"conditions":37150,"interventions":37151},[91],[15],[2842,1096,2824],{"nctId":2852,"briefTitle":2853,"status":107,"phases":37153,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":37154,"interventions":37155},[91],[15],[1096,2824,2842],{"trials":37157,"activeCount":101},[],{"trials":37159,"activeCount":101},[37160],{"nctId":37161,"briefTitle":37162,"status":107,"phases":37163,"primaryCompletion":2948,"completion":2948,"start":37164,"enrollment":37165,"conditions":37166,"interventions":37167},"NCT02784808","Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)",[],"2000-01",4557,[2367],[37168,2842],"Biological DMARDs",{"intervention":37170,"totalTrials":706,"cells":37171},"Peg-IFN alfa-2a",{"EARLY_PHASE1":37172,"PHASE1":37174,"PHASE2":37176,"PHASE3":37178,"PHASE4":37180,"NA":37186},{"trials":37173,"activeCount":101},[],{"trials":37175,"activeCount":101},[],{"trials":37177,"activeCount":101},[],{"trials":37179,"activeCount":101},[],{"trials":37181,"activeCount":101},[37182],{"nctId":35112,"briefTitle":35113,"status":107,"phases":37183,"primaryCompletion":3325,"completion":3325,"start":6134,"enrollment":35115,"conditions":37184,"interventions":37185},[92],[27],[35118,17366],{"trials":37187,"activeCount":101},[37188,37196],{"nctId":37189,"briefTitle":37190,"status":107,"phases":37191,"primaryCompletion":37192,"completion":37192,"start":11447,"enrollment":37193,"conditions":37194,"interventions":37195},"NCT01855997","A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside\u002FNucleotide Analogue",[],"2014-11-28",1669,[11790],[37170],{"nctId":35212,"briefTitle":35213,"status":107,"phases":37197,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":35215,"conditions":37198,"interventions":37199},[],[27],[35218,35219,17366,35149,26278],{"intervention":26531,"totalTrials":162,"cells":37201},{"EARLY_PHASE1":37202,"PHASE1":37204,"PHASE2":37206,"PHASE3":37212,"PHASE4":37214,"NA":37216},{"trials":37203,"activeCount":101},[],{"trials":37205,"activeCount":101},[],{"trials":37207,"activeCount":101},[37208],{"nctId":26526,"briefTitle":26527,"status":107,"phases":37209,"primaryCompletion":2684,"completion":11550,"start":4249,"enrollment":537,"conditions":37210,"interventions":37211},[90],[11790],[26531,26517],{"trials":37213,"activeCount":101},[],{"trials":37215,"activeCount":101},[],{"trials":37217,"activeCount":101},[37218],{"nctId":35144,"briefTitle":35145,"status":130,"phases":37219,"primaryCompletion":2947,"completion":2947,"start":15740,"enrollment":8583,"conditions":37220,"interventions":37221},[],[27],[35149,35150,26531,17366],{"intervention":37223,"totalTrials":162,"cells":37224},"Methoxy polyethylene glycol epoetin beta",{"EARLY_PHASE1":37225,"PHASE1":37227,"PHASE2":37229,"PHASE3":37231,"PHASE4":37233,"NA":37235},{"trials":37226,"activeCount":101},[],{"trials":37228,"activeCount":101},[],{"trials":37230,"activeCount":101},[],{"trials":37232,"activeCount":101},[],{"trials":37234,"activeCount":101},[],{"trials":37236,"activeCount":101},[37237,37243],{"nctId":37238,"briefTitle":37239,"status":107,"phases":37240,"primaryCompletion":3285,"completion":3285,"start":36948,"enrollment":1215,"conditions":37241,"interventions":37242},"NCT01940484","An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis",[],[24],[37223],{"nctId":37244,"briefTitle":37245,"status":107,"phases":37246,"primaryCompletion":37247,"completion":37247,"start":37248,"enrollment":5304,"conditions":37249,"interventions":37250},"NCT02596945","Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis",[],"2011-02-28","2009-07-31",[29811,35907],[37223],{"intervention":35158,"totalTrials":162,"cells":37252},{"EARLY_PHASE1":37253,"PHASE1":37255,"PHASE2":37257,"PHASE3":37259,"PHASE4":37261,"NA":37267},{"trials":37254,"activeCount":101},[],{"trials":37256,"activeCount":101},[],{"trials":37258,"activeCount":101},[],{"trials":37260,"activeCount":101},[],{"trials":37262,"activeCount":101},[37263],{"nctId":34872,"briefTitle":34873,"status":107,"phases":37264,"primaryCompletion":4455,"completion":8810,"start":8260,"enrollment":34875,"conditions":37265,"interventions":37266},[92],[27],[17366,34878,17366,34879],{"trials":37268,"activeCount":101},[37269],{"nctId":35152,"briefTitle":35153,"status":107,"phases":37270,"primaryCompletion":8681,"completion":10332,"start":4206,"enrollment":2057,"conditions":37271,"interventions":37272},[],[27],[35157,26277,35158,17366],{"intervention":6447,"totalTrials":162,"cells":37274},{"EARLY_PHASE1":37275,"PHASE1":37277,"PHASE2":37279,"PHASE3":37281,"PHASE4":37287,"NA":37289},{"trials":37276,"activeCount":101},[],{"trials":37278,"activeCount":101},[],{"trials":37280,"activeCount":101},[],{"trials":37282,"activeCount":101},[37283],{"nctId":20395,"briefTitle":20396,"status":107,"phases":37284,"primaryCompletion":20398,"completion":20398,"start":20399,"enrollment":20400,"conditions":37285,"interventions":37286},[91],[20387],[20375,6447],{"trials":37288,"activeCount":101},[],{"trials":37290,"activeCount":101},[37291],{"nctId":6442,"briefTitle":6443,"status":107,"phases":37292,"primaryCompletion":3324,"completion":3324,"start":2685,"enrollment":2743,"conditions":37293,"interventions":37294},[],[15],[1359,2382,3159,6447],{"intervention":3159,"totalTrials":162,"cells":37296},{"EARLY_PHASE1":37297,"PHASE1":37299,"PHASE2":37301,"PHASE3":37303,"PHASE4":37305,"NA":37311},{"trials":37298,"activeCount":101},[],{"trials":37300,"activeCount":101},[],{"trials":37302,"activeCount":101},[],{"trials":37304,"activeCount":101},[],{"trials":37306,"activeCount":101},[37307],{"nctId":3151,"briefTitle":3152,"status":107,"phases":37308,"primaryCompletion":3154,"completion":3154,"start":3155,"enrollment":3156,"conditions":37309,"interventions":37310},[92],[15],[3159,1096],{"trials":37312,"activeCount":101},[37313],{"nctId":6442,"briefTitle":6443,"status":107,"phases":37314,"primaryCompletion":3324,"completion":3324,"start":2685,"enrollment":2743,"conditions":37315,"interventions":37316},[],[15],[1359,2382,3159,6447],{"intervention":37318,"totalTrials":162,"cells":37319},"RXDX-105",{"EARLY_PHASE1":37320,"PHASE1":37322,"PHASE2":37333,"PHASE3":37335,"PHASE4":37337,"NA":37339},{"trials":37321,"activeCount":101},[],{"trials":37323,"activeCount":101},[37324],{"nctId":37325,"briefTitle":37326,"status":107,"phases":37327,"primaryCompletion":37328,"completion":37329,"start":10332,"enrollment":37330,"conditions":37331,"interventions":37332},"NCT01877811","Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors",[89],"2018-12","2019-02",143,[922],[37318],{"trials":37334,"activeCount":101},[],{"trials":37336,"activeCount":101},[],{"trials":37338,"activeCount":101},[],{"trials":37340,"activeCount":101},[37341],{"nctId":37342,"briefTitle":37343,"status":6886,"phases":37344,"conditions":37345,"interventions":37347},"NCT03052569","Expanded Access to RXDX-105 for Cancers With RET Alterations",[],[37346],"Cancers With RET Alterations",[37318],{"intervention":37349,"totalTrials":162,"cells":37350},"C.E.R.A.",{"EARLY_PHASE1":37351,"PHASE1":37353,"PHASE2":37355,"PHASE3":37365,"PHASE4":37367,"NA":37369},{"trials":37352,"activeCount":101},[],{"trials":37354,"activeCount":101},[],{"trials":37356,"activeCount":101},[37357],{"nctId":37358,"briefTitle":37359,"status":107,"phases":37360,"primaryCompletion":37361,"completion":37361,"start":37362,"conditions":37363,"interventions":37364},"NCT00360347","A Study of Mircera in Anemic Patients With Multiple Myeloma",[89,90],"2003-04-29","2001-11-29",[24],[37349],{"trials":37366,"activeCount":101},[],{"trials":37368,"activeCount":101},[],{"trials":37370,"activeCount":101},[37371],{"nctId":37372,"briefTitle":37373,"status":107,"phases":37374,"primaryCompletion":2956,"completion":2956,"start":9079,"enrollment":37375,"conditions":37376,"interventions":37377},"NCT01695746","An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia",[],108,[24],[37349],{"intervention":26278,"totalTrials":162,"cells":37379},{"EARLY_PHASE1":37380,"PHASE1":37382,"PHASE2":37384,"PHASE3":37390,"PHASE4":37392,"NA":37394},{"trials":37381,"activeCount":101},[],{"trials":37383,"activeCount":101},[],{"trials":37385,"activeCount":101},[37386],{"nctId":26271,"briefTitle":26272,"status":107,"phases":37387,"primaryCompletion":8079,"completion":8079,"start":2914,"enrollment":920,"conditions":37388,"interventions":37389},[90],[26275],[17366,26262,26277,26278],{"trials":37391,"activeCount":101},[],{"trials":37393,"activeCount":101},[],{"trials":37395,"activeCount":101},[37396],{"nctId":35212,"briefTitle":35213,"status":107,"phases":37397,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":35215,"conditions":37398,"interventions":37399},[],[27],[35218,35219,17366,35149,26278],{"intervention":3116,"totalTrials":162,"cells":37401},{"EARLY_PHASE1":37402,"PHASE1":37404,"PHASE2":37406,"PHASE3":37408,"PHASE4":37410,"NA":37416},{"trials":37403,"activeCount":101},[],{"trials":37405,"activeCount":101},[],{"trials":37407,"activeCount":101},[],{"trials":37409,"activeCount":101},[],{"trials":37411,"activeCount":101},[37412],{"nctId":3109,"briefTitle":3110,"status":107,"phases":37413,"primaryCompletion":3112,"completion":3113,"start":754,"enrollment":447,"conditions":37414,"interventions":37415},[92],[2367],[1096,3116,3117,2891],{"trials":37417,"activeCount":101},[37418],{"nctId":3290,"briefTitle":3291,"status":107,"phases":37419,"primaryCompletion":3293,"completion":3293,"start":3294,"enrollment":3295,"conditions":37420,"interventions":37421},[],[15],[1096,3116],{"intervention":37423,"totalTrials":162,"cells":37424},"Guaifenesin",{"EARLY_PHASE1":37425,"PHASE1":37427,"PHASE2":37429,"PHASE3":37431,"PHASE4":37433,"NA":37435},{"trials":37426,"activeCount":101},[],{"trials":37428,"activeCount":101},[],{"trials":37430,"activeCount":101},[],{"trials":37432,"activeCount":101},[],{"trials":37434,"activeCount":101},[],{"trials":37436,"activeCount":101},[37437,37448],{"nctId":37438,"briefTitle":37439,"status":107,"phases":37440,"primaryCompletion":37441,"completion":37441,"start":37442,"enrollment":973,"conditions":37443,"interventions":37445},"NCT02902640","A Non-Interventional Safety Study of Balsamic Bactrim",[],"2017-07-31","2016-11-15",[37444],"Bronchitis",[37423,37446,37447],"Sulfamethoxazole","Trimethoprim",{"nctId":37449,"briefTitle":37450,"status":107,"phases":37451,"primaryCompletion":6012,"completion":6012,"start":37452,"enrollment":1115,"conditions":37453,"interventions":37454},"NCT02879981","A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis",[],"2016-11-10",[37444],[37423,37446,37447],{"intervention":37446,"totalTrials":162,"cells":37456},{"EARLY_PHASE1":37457,"PHASE1":37459,"PHASE2":37461,"PHASE3":37463,"PHASE4":37465,"NA":37467},{"trials":37458,"activeCount":101},[],{"trials":37460,"activeCount":101},[],{"trials":37462,"activeCount":101},[],{"trials":37464,"activeCount":101},[],{"trials":37466,"activeCount":101},[],{"trials":37468,"activeCount":101},[37469,37473],{"nctId":37438,"briefTitle":37439,"status":107,"phases":37470,"primaryCompletion":37441,"completion":37441,"start":37442,"enrollment":973,"conditions":37471,"interventions":37472},[],[37444],[37423,37446,37447],{"nctId":37449,"briefTitle":37450,"status":107,"phases":37474,"primaryCompletion":6012,"completion":6012,"start":37452,"enrollment":1115,"conditions":37475,"interventions":37476},[],[37444],[37423,37446,37447],{"intervention":37447,"totalTrials":162,"cells":37478},{"EARLY_PHASE1":37479,"PHASE1":37481,"PHASE2":37483,"PHASE3":37485,"PHASE4":37487,"NA":37489},{"trials":37480,"activeCount":101},[],{"trials":37482,"activeCount":101},[],{"trials":37484,"activeCount":101},[],{"trials":37486,"activeCount":101},[],{"trials":37488,"activeCount":101},[],{"trials":37490,"activeCount":101},[37491,37495],{"nctId":37438,"briefTitle":37439,"status":107,"phases":37492,"primaryCompletion":37441,"completion":37441,"start":37442,"enrollment":973,"conditions":37493,"interventions":37494},[],[37444],[37423,37446,37447],{"nctId":37449,"briefTitle":37450,"status":107,"phases":37496,"primaryCompletion":6012,"completion":6012,"start":37452,"enrollment":1115,"conditions":37497,"interventions":37498},[],[37444],[37423,37446,37447],{"intervention":34966,"totalTrials":162,"cells":37500},{"EARLY_PHASE1":37501,"PHASE1":37503,"PHASE2":37505,"PHASE3":37507,"PHASE4":37509,"NA":37511},{"trials":37502,"activeCount":101},[],{"trials":37504,"activeCount":101},[],{"trials":37506,"activeCount":101},[],{"trials":37508,"activeCount":101},[],{"trials":37510,"activeCount":101},[],{"trials":37512,"activeCount":101},[37513,37517],{"nctId":34960,"briefTitle":34961,"status":107,"phases":37514,"primaryCompletion":2964,"completion":2931,"start":2965,"enrollment":34963,"conditions":37515,"interventions":37516},[],[27],[34879,34966],{"nctId":34968,"briefTitle":34969,"status":107,"phases":37518,"primaryCompletion":9079,"completion":9079,"start":121,"enrollment":34971,"conditions":37519,"interventions":37520},[],[27],[34879,34966],{"intervention":37522,"totalTrials":350,"cells":37523},"Erlotinib 150 mg",{"EARLY_PHASE1":37524,"PHASE1":37526,"PHASE2":37528,"PHASE3":37530,"PHASE4":37532,"NA":37534},{"trials":37525,"activeCount":101},[],{"trials":37527,"activeCount":101},[],{"trials":37529,"activeCount":101},[],{"trials":37531,"activeCount":101},[],{"trials":37533,"activeCount":101},[],{"trials":37535,"activeCount":101},[37536],{"nctId":37537,"briefTitle":37538,"status":107,"phases":37539,"primaryCompletion":8321,"completion":8321,"start":4445,"enrollment":31,"conditions":37540,"interventions":37541},"NCT01836133","An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)",[],[2257],[37522],{"intervention":35150,"totalTrials":350,"cells":37543},{"EARLY_PHASE1":37544,"PHASE1":37546,"PHASE2":37548,"PHASE3":37550,"PHASE4":37552,"NA":37554},{"trials":37545,"activeCount":101},[],{"trials":37547,"activeCount":101},[],{"trials":37549,"activeCount":101},[],{"trials":37551,"activeCount":101},[],{"trials":37553,"activeCount":101},[],{"trials":37555,"activeCount":101},[37556],{"nctId":35144,"briefTitle":35145,"status":130,"phases":37557,"primaryCompletion":2947,"completion":2947,"start":15740,"enrollment":8583,"conditions":37558,"interventions":37559},[],[27],[35149,35150,26531,17366],{"intervention":35157,"totalTrials":350,"cells":37561},{"EARLY_PHASE1":37562,"PHASE1":37564,"PHASE2":37566,"PHASE3":37568,"PHASE4":37570,"NA":37572},{"trials":37563,"activeCount":101},[],{"trials":37565,"activeCount":101},[],{"trials":37567,"activeCount":101},[],{"trials":37569,"activeCount":101},[],{"trials":37571,"activeCount":101},[],{"trials":37573,"activeCount":101},[37574],{"nctId":35152,"briefTitle":35153,"status":107,"phases":37575,"primaryCompletion":8681,"completion":10332,"start":4206,"enrollment":2057,"conditions":37576,"interventions":37577},[],[27],[35157,26277,35158,17366],{"intervention":37579,"totalTrials":350,"cells":37580},"Concomitant Bevacizumab",{"EARLY_PHASE1":37581,"PHASE1":37583,"PHASE2":37585,"PHASE3":37587,"PHASE4":37589,"NA":37591},{"trials":37582,"activeCount":101},[],{"trials":37584,"activeCount":101},[],{"trials":37586,"activeCount":101},[],{"trials":37588,"activeCount":101},[],{"trials":37590,"activeCount":101},[],{"trials":37592,"activeCount":101},[37593],{"nctId":37594,"briefTitle":37595,"status":107,"phases":37596,"primaryCompletion":2809,"completion":2809,"start":4281,"enrollment":37597,"conditions":37598,"interventions":37599},"NCT02612077","Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)",[],765,[1135],[37579],{"intervention":37601,"totalTrials":350,"cells":37602},"ESA",{"EARLY_PHASE1":37603,"PHASE1":37605,"PHASE2":37607,"PHASE3":37609,"PHASE4":37611,"NA":37613},{"trials":37604,"activeCount":101},[],{"trials":37606,"activeCount":101},[],{"trials":37608,"activeCount":101},[],{"trials":37610,"activeCount":101},[],{"trials":37612,"activeCount":101},[],{"trials":37614,"activeCount":101},[37615],{"nctId":37616,"briefTitle":37617,"status":107,"phases":37618,"primaryCompletion":6157,"completion":6157,"start":3189,"enrollment":14916,"conditions":37619,"interventions":37620},"NCT02238067","Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis",[],[35914],[37601],{"intervention":36280,"totalTrials":350,"cells":37622},{"EARLY_PHASE1":37623,"PHASE1":37625,"PHASE2":37627,"PHASE3":37629,"PHASE4":37631,"NA":37633},{"trials":37624,"activeCount":101},[],{"trials":37626,"activeCount":101},[],{"trials":37628,"activeCount":101},[],{"trials":37630,"activeCount":101},[],{"trials":37632,"activeCount":101},[],{"trials":37634,"activeCount":101},[37635],{"nctId":36275,"briefTitle":36276,"status":107,"phases":37636,"conditions":37637,"interventions":37638},[93],[36242,33],[36280,17773],{"intervention":3240,"totalTrials":350,"cells":37640},{"EARLY_PHASE1":37641,"PHASE1":37643,"PHASE2":37645,"PHASE3":37647,"PHASE4":37649,"NA":37651},{"trials":37642,"activeCount":101},[],{"trials":37644,"activeCount":101},[],{"trials":37646,"activeCount":101},[],{"trials":37648,"activeCount":101},[],{"trials":37650,"activeCount":101},[],{"trials":37652,"activeCount":101},[37653],{"nctId":3233,"briefTitle":3234,"status":107,"phases":37654,"primaryCompletion":3236,"completion":3236,"start":3236,"enrollment":3237,"conditions":37655,"interventions":37656},[],[15],[3240,1096],{"intervention":35194,"totalTrials":350,"cells":37658},{"EARLY_PHASE1":37659,"PHASE1":37661,"PHASE2":37663,"PHASE3":37665,"PHASE4":37667,"NA":37669},{"trials":37660,"activeCount":101},[],{"trials":37662,"activeCount":101},[],{"trials":37664,"activeCount":101},[],{"trials":37666,"activeCount":101},[],{"trials":37668,"activeCount":101},[],{"trials":37670,"activeCount":101},[37671],{"nctId":35189,"briefTitle":35190,"status":107,"phases":37672,"primaryCompletion":8934,"completion":8934,"start":8810,"enrollment":34875,"conditions":37673,"interventions":37674},[],[27],[35194,17366],{"intervention":37168,"totalTrials":350,"cells":37676},{"EARLY_PHASE1":37677,"PHASE1":37679,"PHASE2":37681,"PHASE3":37683,"PHASE4":37685,"NA":37687},{"trials":37678,"activeCount":101},[],{"trials":37680,"activeCount":101},[],{"trials":37682,"activeCount":101},[],{"trials":37684,"activeCount":101},[],{"trials":37686,"activeCount":101},[],{"trials":37688,"activeCount":101},[37689],{"nctId":37161,"briefTitle":37162,"status":107,"phases":37690,"primaryCompletion":2948,"completion":2948,"start":37164,"enrollment":37165,"conditions":37691,"interventions":37692},[],[2367],[37168,2842],{"intervention":37694,"totalTrials":350,"cells":37695},"Pegylated Interferon Alfa",{"EARLY_PHASE1":37696,"PHASE1":37698,"PHASE2":37700,"PHASE3":37702,"PHASE4":37704,"NA":37706},{"trials":37697,"activeCount":101},[],{"trials":37699,"activeCount":101},[],{"trials":37701,"activeCount":101},[],{"trials":37703,"activeCount":101},[],{"trials":37705,"activeCount":101},[],{"trials":37707,"activeCount":101},[37708],{"nctId":37709,"briefTitle":37710,"status":107,"phases":37711,"primaryCompletion":37712,"completion":37712,"start":37713,"enrollment":37714,"conditions":37715,"interventions":37716},"NCT01730508","An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B",[],"2017-06-25","2012-11-20",978,[11790],[37694],{"intervention":4674,"totalTrials":350,"cells":37718},{"EARLY_PHASE1":37719,"PHASE1":37721,"PHASE2":37723,"PHASE3":37725,"PHASE4":37727,"NA":37729},{"trials":37720,"activeCount":101},[],{"trials":37722,"activeCount":101},[],{"trials":37724,"activeCount":101},[],{"trials":37726,"activeCount":101},[],{"trials":37728,"activeCount":101},[],{"trials":37730,"activeCount":101},[37731],{"nctId":4666,"briefTitle":4667,"status":107,"phases":37732,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":37733,"interventions":37734},[],[30],[1015,4674,4675,1166,4676,4677],{"intervention":4675,"totalTrials":350,"cells":37736},{"EARLY_PHASE1":37737,"PHASE1":37739,"PHASE2":37741,"PHASE3":37743,"PHASE4":37745,"NA":37747},{"trials":37738,"activeCount":101},[],{"trials":37740,"activeCount":101},[],{"trials":37742,"activeCount":101},[],{"trials":37744,"activeCount":101},[],{"trials":37746,"activeCount":101},[],{"trials":37748,"activeCount":101},[37749],{"nctId":4666,"briefTitle":4667,"status":107,"phases":37750,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":37751,"interventions":37752},[],[30],[1015,4674,4675,1166,4676,4677],{"intervention":4676,"totalTrials":350,"cells":37754},{"EARLY_PHASE1":37755,"PHASE1":37757,"PHASE2":37759,"PHASE3":37761,"PHASE4":37763,"NA":37765},{"trials":37756,"activeCount":101},[],{"trials":37758,"activeCount":101},[],{"trials":37760,"activeCount":101},[],{"trials":37762,"activeCount":101},[],{"trials":37764,"activeCount":101},[],{"trials":37766,"activeCount":101},[37767],{"nctId":4666,"briefTitle":4667,"status":107,"phases":37768,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":37769,"interventions":37770},[],[30],[1015,4674,4675,1166,4676,4677],{"intervention":4677,"totalTrials":350,"cells":37772},{"EARLY_PHASE1":37773,"PHASE1":37775,"PHASE2":37777,"PHASE3":37779,"PHASE4":37781,"NA":37783},{"trials":37774,"activeCount":101},[],{"trials":37776,"activeCount":101},[],{"trials":37778,"activeCount":101},[],{"trials":37780,"activeCount":101},[],{"trials":37782,"activeCount":101},[],{"trials":37784,"activeCount":101},[37785],{"nctId":4666,"briefTitle":4667,"status":107,"phases":37786,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":37787,"interventions":37788},[],[30],[1015,4674,4675,1166,4676,4677],{"intervention":37790,"totalTrials":350,"cells":37791},"Standard of Care for Haemophilia A",{"EARLY_PHASE1":37792,"PHASE1":37794,"PHASE2":37796,"PHASE3":37798,"PHASE4":37800,"NA":37802},{"trials":37793,"activeCount":101},[],{"trials":37795,"activeCount":101},[],{"trials":37797,"activeCount":101},[],{"trials":37799,"activeCount":101},[],{"trials":37801,"activeCount":101},[],{"trials":37803,"activeCount":101},[37804],{"nctId":37805,"briefTitle":37806,"status":107,"phases":37807,"primaryCompletion":37808,"completion":37808,"start":21199,"enrollment":6344,"conditions":37809,"interventions":37812},"NCT04165135","An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment",[],"2022-04-28",[37810,768,37811],"Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor","Haemophilia A",[37790],{"intervention":37814,"totalTrials":350,"cells":37815},"methoxy polyethylene glycol-ep [Mircera]",{"EARLY_PHASE1":37816,"PHASE1":37818,"PHASE2":37820,"PHASE3":37822,"PHASE4":37824,"NA":37826},{"trials":37817,"activeCount":101},[],{"trials":37819,"activeCount":101},[],{"trials":37821,"activeCount":101},[],{"trials":37823,"activeCount":101},[],{"trials":37825,"activeCount":101},[],{"trials":37827,"activeCount":101},[37828],{"nctId":37829,"briefTitle":37830,"status":107,"phases":37831,"primaryCompletion":132,"completion":132,"start":4555,"enrollment":37832,"conditions":37833,"interventions":37834},"NCT01051323","An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia",[],1580,[24],[37814],{"intervention":14561,"totalTrials":350,"cells":37836},{"EARLY_PHASE1":37837,"PHASE1":37839,"PHASE2":37841,"PHASE3":37843,"PHASE4":37845,"NA":37847},{"trials":37838,"activeCount":101},[],{"trials":37840,"activeCount":101},[],{"trials":37842,"activeCount":101},[],{"trials":37844,"activeCount":101},[],{"trials":37846,"activeCount":101},[],{"trials":37848,"activeCount":101},[37849],{"nctId":14556,"briefTitle":14557,"status":107,"phases":37850,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":4573,"conditions":37851,"interventions":37852},[],[5846],[3707,14561],{"intervention":4694,"totalTrials":350,"cells":37854},{"EARLY_PHASE1":37855,"PHASE1":37857,"PHASE2":37859,"PHASE3":37861,"PHASE4":37863,"NA":37865},{"trials":37856,"activeCount":101},[],{"trials":37858,"activeCount":101},[],{"trials":37860,"activeCount":101},[],{"trials":37862,"activeCount":101},[],{"trials":37864,"activeCount":101},[],{"trials":37866,"activeCount":101},[37867],{"nctId":4687,"briefTitle":4688,"status":107,"phases":37868,"primaryCompletion":3182,"completion":3182,"start":121,"enrollment":4690,"conditions":37869,"interventions":37870},[],[4692],[1015,4694],{"intervention":37872,"totalTrials":350,"cells":37873},"Methoxy-polyethyleneglycol epoetin beta",{"EARLY_PHASE1":37874,"PHASE1":37876,"PHASE2":37878,"PHASE3":37880,"PHASE4":37882,"NA":37884},{"trials":37875,"activeCount":101},[],{"trials":37877,"activeCount":101},[],{"trials":37879,"activeCount":101},[],{"trials":37881,"activeCount":101},[],{"trials":37883,"activeCount":101},[],{"trials":37885,"activeCount":101},[37886],{"nctId":37887,"briefTitle":37888,"status":107,"phases":37889,"primaryCompletion":2914,"completion":2914,"start":37890,"enrollment":37891,"conditions":37892,"interventions":37894},"NCT02538107","An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant",[],"2007-09-30",290,[37893],"Anemia, Kidney Transplantation",[37872],{"intervention":6500,"totalTrials":350,"cells":37896},{"EARLY_PHASE1":37897,"PHASE1":37899,"PHASE2":37901,"PHASE3":37903,"PHASE4":37905,"NA":37907},{"trials":37898,"activeCount":101},[],{"trials":37900,"activeCount":101},[],{"trials":37902,"activeCount":101},[],{"trials":37904,"activeCount":101},[],{"trials":37906,"activeCount":101},[],{"trials":37908,"activeCount":101},[37909],{"nctId":6494,"briefTitle":6495,"status":107,"phases":37910,"primaryCompletion":5891,"completion":5891,"start":2923,"enrollment":5458,"conditions":37911,"interventions":37912},[],[6498],[992,6500,6501,1357,1359],{"intervention":6501,"totalTrials":350,"cells":37914},{"EARLY_PHASE1":37915,"PHASE1":37917,"PHASE2":37919,"PHASE3":37921,"PHASE4":37923,"NA":37925},{"trials":37916,"activeCount":101},[],{"trials":37918,"activeCount":101},[],{"trials":37920,"activeCount":101},[],{"trials":37922,"activeCount":101},[],{"trials":37924,"activeCount":101},[],{"trials":37926,"activeCount":101},[37927],{"nctId":6494,"briefTitle":6495,"status":107,"phases":37928,"primaryCompletion":5891,"completion":5891,"start":2923,"enrollment":5458,"conditions":37929,"interventions":37930},[],[6498],[992,6500,6501,1357,1359],{"intervention":12849,"totalTrials":350,"cells":37932},{"EARLY_PHASE1":37933,"PHASE1":37935,"PHASE2":37937,"PHASE3":37939,"PHASE4":37941,"NA":37943},{"trials":37934,"activeCount":101},[],{"trials":37936,"activeCount":101},[],{"trials":37938,"activeCount":101},[],{"trials":37940,"activeCount":101},[],{"trials":37942,"activeCount":101},[],{"trials":37944,"activeCount":101},[37945],{"nctId":12843,"briefTitle":12844,"status":107,"phases":37946,"primaryCompletion":12846,"completion":12846,"start":6358,"enrollment":11,"conditions":37947,"interventions":37948},[],[723],[824,12849],{"intervention":37950,"totalTrials":350,"cells":37951},"MabThera",{"EARLY_PHASE1":37952,"PHASE1":37954,"PHASE2":37956,"PHASE3":37958,"PHASE4":37960,"NA":37962},{"trials":37953,"activeCount":101},[],{"trials":37955,"activeCount":101},[],{"trials":37957,"activeCount":101},[],{"trials":37959,"activeCount":101},[],{"trials":37961,"activeCount":101},[],{"trials":37963,"activeCount":101},[37964],{"nctId":37965,"briefTitle":37966,"status":107,"phases":37967,"primaryCompletion":37968,"completion":37968,"start":546,"enrollment":37969,"conditions":37970,"interventions":37971},"NCT03289182","An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)",[],"2020-10-27",701,[1196,6112],[37950],{"intervention":35219,"totalTrials":350,"cells":37973},{"EARLY_PHASE1":37974,"PHASE1":37976,"PHASE2":37978,"PHASE3":37980,"PHASE4":37982,"NA":37984},{"trials":37975,"activeCount":101},[],{"trials":37977,"activeCount":101},[],{"trials":37979,"activeCount":101},[],{"trials":37981,"activeCount":101},[],{"trials":37983,"activeCount":101},[],{"trials":37985,"activeCount":101},[37986],{"nctId":35212,"briefTitle":35213,"status":107,"phases":37987,"primaryCompletion":2792,"completion":2792,"start":3189,"enrollment":35215,"conditions":37988,"interventions":37989},[],[27],[35218,35219,17366,35149,26278],{"intervention":37991,"totalTrials":350,"cells":37992},"TNF inhibitor\u002FTCZ",{"EARLY_PHASE1":37993,"PHASE1":37995,"PHASE2":37997,"PHASE3":37999,"PHASE4":38001,"NA":38003},{"trials":37994,"activeCount":101},[],{"trials":37996,"activeCount":101},[],{"trials":37998,"activeCount":101},[],{"trials":38000,"activeCount":101},[],{"trials":38002,"activeCount":101},[],{"trials":38004,"activeCount":101},[38005],{"nctId":38006,"briefTitle":38007,"status":107,"phases":38008,"primaryCompletion":1862,"completion":1862,"start":3651,"enrollment":2708,"conditions":38009,"interventions":38010},"NCT02679001","A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.",[],[15],[37991],{"intervention":3319,"totalTrials":350,"cells":38012},{"EARLY_PHASE1":38013,"PHASE1":38015,"PHASE2":38017,"PHASE3":38019,"PHASE4":38021,"NA":38023},{"trials":38014,"activeCount":101},[],{"trials":38016,"activeCount":101},[],{"trials":38018,"activeCount":101},[],{"trials":38020,"activeCount":101},[],{"trials":38022,"activeCount":101},[],{"trials":38024,"activeCount":101},[38025],{"nctId":3312,"briefTitle":3313,"status":107,"phases":38026,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":1891,"conditions":38027,"interventions":38028},[],[15],[1096,3319],{"intervention":14660,"totalTrials":350,"cells":38030},{"EARLY_PHASE1":38031,"PHASE1":38033,"PHASE2":38035,"PHASE3":38037,"PHASE4":38039,"NA":38041},{"trials":38032,"activeCount":101},[],{"trials":38034,"activeCount":101},[],{"trials":38036,"activeCount":101},[],{"trials":38038,"activeCount":101},[],{"trials":38040,"activeCount":101},[],{"trials":38042,"activeCount":101},[38043],{"nctId":14652,"briefTitle":14653,"status":107,"phases":38044,"primaryCompletion":14655,"completion":14656,"start":14655,"enrollment":14657,"conditions":38045,"interventions":38046},[],[30],[14660,14661,1572],{"intervention":14661,"totalTrials":350,"cells":38048},{"EARLY_PHASE1":38049,"PHASE1":38051,"PHASE2":38053,"PHASE3":38055,"PHASE4":38057,"NA":38059},{"trials":38050,"activeCount":101},[],{"trials":38052,"activeCount":101},[],{"trials":38054,"activeCount":101},[],{"trials":38056,"activeCount":101},[],{"trials":38058,"activeCount":101},[],{"trials":38060,"activeCount":101},[38061],{"nctId":14652,"briefTitle":14653,"status":107,"phases":38062,"primaryCompletion":14655,"completion":14656,"start":14655,"enrollment":14657,"conditions":38063,"interventions":38064},[],[30],[14660,14661,1572]]